[
    {
        "instruction":"已知信息：\n'在药品杂质检查中，用古蔡氏检碑法(Gutzeit'sarsenictestmethod)时，金属锌与盐酸作用产生新生态的氢，与试品中的微量碑盐反应生成具有挥发性的碑化氢，遇澳化汞试纸所产 生的黄色至棕色的斑点。'可被翻译为：In the examination of drug impurities, the Gutzeit'sarsenictestmethod is used to produce new ecological hydrogen by the interaction of metal zinc with hydrochloric acid, which reacts with trace salt in the test to produce volatile stele hydrogen, and meets the yellow to brown spots produced by the mercury test paper.\n'无机化学与生物化学的交叉学科，主要研究含金属的生物分子（如金属酶）、金属与生物分子的相互作用（如金属离子通道、金属药物）等。'可被翻译为：The interdisciplinary study of metal-containing biomolecules (e.g., metalloenzymes) and metal-biomolecular interactions (e.g., metal ion channels, metal drugs).\n'能与金属离子形成络合离子的化合物。'可被翻译为：A compound capable of forming a complex ion with a metal ion.\n'以2,4,6-三硝基间苯二酚镉为主要有效成分的收敛药物。此药物由2,4,6-三硝基间苯二酚与金属镉离子（Cd2+）合成而得。'可被翻译为：An astringent drug with cadmium 2,4, 6-trinitroresorcinol as the main active ingredient. This drug is synthesized by 2,4, 6-trinitroresorcinol and cadmium metal ion (Cd2+).\n\n根据上述已知信息，请将'在实验条件下能与硫代乙酰胺或硫化钠作用显色的金属杂质。如银、铅、汞、铜、镉、秘、睇、锡、碑、锌、钻与镖等。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Metallic impurities capable of acting with thioacetamide or sodium sulfide to produce color under experimental conditions. Such as silver, lead, mercury, copper, cadmium, secret, tin, tablets, zinc, diamonds, darts, etc."
    },
    {
        "instruction":"已知信息：\n'十三、推进医疗服务精细化监管'可被翻译为：13. Promoting fine-grained supervision of medical services\n'为贯彻落实党中央、国务院关于深化医药卫生体制改革的决策部署，推动各地加大力度持续深化医疗、医保、医药联动改革，2019年11月29日，经国务院同意，国务院深化医药卫生体制改革领导小组发布《关于以药品集中采购和使用为突破口 进一步深化医药卫生体制改革的若干政策措施》。通知指出要促进医疗、医保、医药联动，放大改革效应，更好推动解决群众看病就医问题。'可被翻译为：On November 29, 2019, approved by the State Council, the Leading Group for Deepening the Reform of the Medical and Health System Issued the Notice on Several Policies and Measures to Further Deepen the Reform of the Medical and Health System with Centralized Procurement &Use of Drugs as a Breakthrough in order to implement the decisions and plans of the CPC central Committee and the State Council on deepening the reform of the medical and health care systems and promote the interlocked reform of healthcare, health insurance, and pharmaceuticals. The Notice pointed out that it is necessary to promote the interlocked reform of healthcare, health insurance, and pharmaceuticals, magnify the effects of reform, and better address the problems complicating medical services to the people, the following policies and measures shall be implemented, covering 15 aspects:\n'为落实《国务院办公厅关于印发进一步深化“互联网+政务服务”推进政务服务“一网、一门、一次”改革实施方案的通知和《国务院办公厅关于加快推进政务服务“跨省通办”的指导意见》有关要求，国家药监局已开通药品注册事项网上申报功能，并于2021年1月1日正式上线运行。'可被翻译为：As per the requirements of the Notice of the General Office of the State Council on the Issuance of Implementation Program for Furtherance of the 'Internet + Government Affairs Service' and the 'One Network, One Door, One Time (One Network Online Service, One Door Offline Service and One Time On-Site Service)' Reform and the Guiding Opinions of the General Office of the State Council on Accelerating 'Cross provincial Handling' of Government Affairs Services, the NMPA has enabled and officially launched on January 1, 2021 the online application module for drug registration affairs.\n'国家药监局关于发布医疗器械分类目录动态调整工作程序的公告'可被翻译为：NMPA Announcement on Issuing the Working Procedures for Dynamic Adjustment of Classification Catalogue for Medical Devices\n\n根据上述已知信息，请将'七、推进医疗服务价格动态调整等联动改革'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"7. Promoting interlocked reforms such as the dynamic adjustment of medical service prices"
    },
    {
        "instruction":"已知信息：\n'为规范化妆品生产质量管理，根据《化妆品监督管理条例》《化妆品生产经营监督管理办法》等法律、法规和规章，国家药监局组织制定了《化妆品生产质量管理规范》（以下简称《规范》），并于1月6日发布，自2022年7月1日起施行。'可被翻译为：In order to regulate the production quality management of cosmetics, according to the Regulations for the Supervision and Administration of Cosmetics, Provisions for the Supervision and Administration of Cosmetics Manufacture and Distribution and other laws, regulations and rules, NMPA organized to formulate the Good Manufacturing Practice for Cosmetics (hereinafter referred to as the GMP), which was issued on January 6, and shall enter into force as of July 1, 2022.\n'为贯彻落实《化妆品监督管理条例》，规范和指导化妆品分类工作，国家药监局制定了《化妆品分类规则和分类目录》，于2021年4月8日予以公布，自2021年5月1日起施行。'可被翻译为：In order to fully implement the Regulations on the Supervision and Administration of Cosmetics and standardize and guide the classification of cosmetics, the NMPA has formulated the Classification Rules and Classification Catalogue of Cosmetics, which was issued on April 8 and shall take effect as of May 1, 2021.\n'国家药监局关于发布《化妆品不良反应监测管理办法》的公告'可被翻译为：NMPA Announcement on Issuing the Provisions for the Administration of Adverse Reaction Monitoring of Cosmetics\n'为贯彻落实《化妆品监督管理条例》，规范和指导化妆品功效宣称评价工作，国家药监局组织起草了《化妆品功效宣称评价规范》，于2021年4月8日予以公布，自2021年5月1日起施行。'可被翻译为：In order to fully implement the Regulations on the Supervision and Administration of Cosmetics and standardize and guide the evaluation of efficacy claims of cosmetics, the NMPA has organized to formulate the Standard for the Evaluation of Efficacy Claims Cosmetics, which was issued on April 8 and shall take effect as of May 1, 2021.\n\n根据上述已知信息，请将'为规范化妆品不良反应监测工作，根据《化妆品监督管理条例》《化妆品生产经营监督管理办法》等法规、规章，国家药监局组织制定了《化妆品不良反应监测管理办法》，于2022年2月15日予以公布，自2022年10月1日起施行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to regulate the ADR monitoring for cosmetics, according to the Regulations on Supervision and Administration of Cosmetics and the Provisions for Supervision and Administration of Cosmetic Manufacturing and Distribution, the NMPA formulated the Provisions for the Administration of Adverse Reaction Monitoring of Cosmetics, which was issued on February 15, 2022 and will come into force on October 1, 2022."
    },
    {
        "instruction":"已知信息：\n'如果在混悬剂中因加入电解质使微粒表面的&电位升高，静电排斥力阻碍了微粒之间的碰撞聚集，絮凝状态消失，所加入的电解质称为反絮凝剂。'可被翻译为：If the electrolyte is added to the suspension to increase the potential of the particle surface, the electrostatic repulsion hinders the collision between the particles and the aggregation, the flocculation state disappears, the added electrolyte is called the deflocculant.\n'混悬剂中如果加入适量的电解质，可使J电位降低到适当的程度，即使微粒间的排斥力稍低于吸引力，此时微粒聚集成疏松的絮状聚集体，经振摇可恢复成均匀的混悬剂，所加电解质称为絮凝剂。'可被翻译为：If the appropriate amount of electrolyte is added to the suspension, the J potential can be reduced to an appropriate degree, even if the repulsive force between the particles is slightly lower than the attractive force, at this time the particles gather into a loose flocculent aggregate, which can be restored to a uniform suspension by shaking, the added electrolyte is called a flocculant.\n'混悬剂中加入适量的电解质调节自电位，可使微粒间的排斥力稍低于吸引力，形成疏松的絮状聚集体，经振摇恢复成均匀的混悬剂的现象。'可被翻译为：Adding an appropriate amount of electrolyte to the suspension to adjust the self-potential can make the repulsive force between the particles slightly lower than the attractive force, forming a loose flocculent aggregate, which is restored to a uniform suspension by shaking.\n'具有相似性质微粒间相互聚集的现象。是与粒子混合相反的过程。'可被翻译为：The aggregation of particles having similar properties. It is the opposite of the mixing of particles.\n\n根据上述已知信息，请将'在混悬体系中加入电解质使微粒表面J电位升高，这时静电排斥力的增大阻碍了微粒间的碰撞聚集，使得絮凝现象减少的过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The addition of electrolyte in the suspension system increases the J potential of the surface of the particles, and the increase of electrostatic repulsion hinders the collision and aggregation of the particles, making the process of reducing the flocculation phenomenon."
    },
    {
        "instruction":"已知信息：\n'1.每批药品均应当有留样；如果一批药品分成数次进行包装，则每次包装至少应当保留一件最小市售包装的成品。'可被翻译为：1) There should be reference samples for each batch. Where a batch is packaged into several distinct packaging operations, at least one reference sample should be taken from each individual packaging operation.\n'（七）物料和最终包装的成品应当有足够的留样，以备必要的检查或检验；除最终包装容器过大的成品外，成品的留样包装应当与最终包装相同。'可被翻译为：7. Sufficient reference samples of starting materials and finished products are retained to permit future inspection and testing of the product when necessary, and that the finished product is retained in its final package unless exceptionally large packages are produced.\n'(viii)根据附录19保留足够的原材料和产品留样，以便必要时产品检查，并且样品应保留在最终包装相同的包装中。'可被翻译为：(viii) Sufficient reference samples of starting materials and products are retained in accordance with Annex 19 to permit future examination of the product if necessary and that the sample is retained in the final pack.\n'（三）产品规格和包装形式；'可被翻译为：3. The strength, dosage form and package type;\n\n根据上述已知信息，请将'2.留样的包装形式应当与药品市售包装形式相同，原料药的留样如无法采用市售包装形式的，可采用模拟包装。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2) The package of reference samples should be identical to the products in the market. If the package of reference samples of active pharmaceutical ingredients (API) cannot be the same as the form in the market, a simulated package may be adopted."
    },
    {
        "instruction":"已知信息：\n'（四）有与生产的化妆品品种、数量和生产许可项目等相适应的技术人员；'可被翻译为：(4) having technicians who are suited to the varieties, quantity and manufacturing licensed items, etc. of the cosmetics manufactured;\n'（二）有与生产的化妆品品种、数量和生产许可项目等相适应的生产场地，且与有毒、有害场所以及其他污染源保持规定的距离；'可被翻译为：(2) having the manufacturing premises that are appropriate to the varieties, quantity and manufacturing licensed items, etc. of the cosmetics produced, and being kept prescribed distance from toxic and hazardous premises and other sources of pollution;\n'（五）有与生产的化妆品品种、数量相适应，能对生产的化妆品进行检验的检验人员和检验设备；'可被翻译为：(5) having the staff members and equipment that are appropriate to the varieties and quantity of the cosmetics produced and that can perform inspection of the cosmetics produced;\n'第四十六条 为降低污染和交叉污染的风险，厂房、生产设施和设备应当根据所生产药品的特性、工艺流程及相应洁净度级别要求合理设计、布局和使用，并符合下列要求：'可被翻译为：Article 46: In order to minimize the risks of contamination and cross-contamination, premises, facilities and equipment should be designed, laid out and used appropriately in accordance with the properties of the manufactured product and its process, as well as the corresponding cleanliness level, and the following requirements should be met:\n\n根据上述已知信息，请将'（三）有与生产的化妆品品种、数量和生产许可项目等相适应的生产设施设备且布局合理，空气净化、水处理等设施设备符合规定要求；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) having the manufacturing facilities and equipment that are appropriate to the varieties, quantity and manufacturing licensed items, etc. of the cosmetics produced, and having a reasonable layout thereof, and the air purification, water treatment facilities and equipment, etc. that meet the specified requirements;"
    },
    {
        "instruction":"已知信息：\n'将药物与辅料制成的小块状或条状供植入体内的无菌固体制剂。'可被翻译为：A sterile solid preparation in which a drug and excipient are inserted into the body in small chunks or strips.\n'药物与辅料混匀后，经制粒或不经制粒，再用压片机压制而成的片剂。'可被翻译为：A tablet made of a drug mixed with excipients, granulated or ungranulated, and pressed by a tablet press.\n'草药剂型是由草药生产的草药产品的物理形式(液体、固体、半固体)，有或没有赋形剂，在特定配方中(如煎剂、片剂和软膏)。它们由草药原料(如干根或新鲜果汁)或草药制剂(如提取物)制成。'可被翻译为：Herbal dosage forms are the physical form (liquid, solid, semi-solid) of herbal products produced from herbs, with or without excipients, in a particular formulation (such as decoctions, tablets and ointments). They are produced either from herbal materials (such as dried roots or fresh juices) or herbal preparations (such as extracts).\n'由单体经聚合而成的产物。包括由一种单体聚合而成的均聚物，和由两种或两种以上不同单体聚合而成的共聚物两大类。'可被翻译为：A product formed by polymerization of monomers. Includes homopolymers polymerized from one monomer, and copolymers polymerized from two or more different monomers.\n\n根据上述已知信息，请将'由药物与赋形剂或单独由药物经热融压制而成的一种供腔道或皮下植入的无菌固体控释制剂。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A sterile solid controlled release preparation made by heat melting of a drug with an excipient or a drug alone for endovascular or subcutaneous implantation."
    },
    {
        "instruction":"已知信息：\n'第九条 国家鼓励体外诊断试剂的研究与创新，对创新体外诊断试剂实行特别审批，促进体外诊断试剂新技术的推广与应用，推动医疗器械产业的发展。'可被翻译为：Article 9 The State encourages the research and innovation of in-vitro diagnostic reagents, implements special review for innovative medical devices, accelerates the popularization and application for new technologies of in-vitro diagnostic reagents and promotes the development of medical device industry.\n'无需进行临床试验的体外诊断试剂，申请人或者备案人应当通过对涵盖预期用途及干扰因素的临床样本的评估、综合文献资料等非临床试验的方式对体外诊断试剂的临床性能进行评价。申请人或者备案人应当保证评价所用的临床样本具有可追溯性。'可被翻译为：For the clinical trial of in-vitro diagnostic reagents are not required, the applicant shall evaluate the clinical performance of in-vitro diagnostic reagents through non-clinical trial methods such as evaluation on the clinical samples covering intended use and interference factors as well as comprehensive literatures. The applicant or filing entity shall ensure that the clinical samples for evaluation are traceable.\n'（一）申请人对拟上市销售体外诊断试剂的安全性、有效性进行的研究及其结果无法证明产品安全、有效的；'可被翻译为：(I) The research conducted by the applicant and its result cannot prove the safety and effectiveness of the in-vitro diagnostic reagent to be sold on the market.\n'第三十条 办理第一类体外诊断试剂备案，不需进行临床试验。申请第二类、第三类体外诊断试剂注册，应当进行临床试验。'可被翻译为：Article 30 For filing of a class I in-vitro diagnostic reagent, clinical trial is not required. For application for registration of a class II or class III in-vitro diagnostic reagent, clinical trial shall be conducted; however,\n\n根据上述已知信息，请将'体外诊断试剂临床试验（包括与已上市产品进行的比较研究试验）是指在相应的临床环境中，对体外诊断试剂的临床性能进行的系统性研究。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The clinical trial of in-vitro diagnostic reagents (including the comparative study made with the marketed products) refers to the systematic study on the clinical performance of in-vitro diagnostic reagents in the corresponding clinical environment."
    },
    {
        "instruction":"已知信息：\n'第二十一条 医疗器械生产企业对召回医疗器械的处理应当有详细的记录，并向医疗器械生产企业所在地省、自治区、直辖市食品药品监督管理部门报告，记录应当保存至医疗器械注册证失效后5年，第一类医疗器械召回的处理记录应当保存5年。对通过警示、检查、修理、重新标签、修改并完善说明书、软件更新、替换、销毁等方式能够消除产品缺陷的，可以在产品所在地完成上述行为。需要销毁的，应当在食品药品监督管理部门监督下销毁。'可被翻译为：Article 21 The medical device manufacturer shall keep detailed records on the handling of recalled medical devices, and report to the food and drug regulatory department of the province, autonomous region or municipality directly under the Central Government where the medical device manufacturer is located. The records shall be kept up to 5 years after the expiration of the Medical Device Registration Certificate, and the handling records of the recall of Class I medical devices shall be kept for 5 years. Where product defects can be eliminated by warning, checking, repairing, relabeling, modifying and improving the instructions for use, software upgrade, replacement, and destruction, the above actions may be completed at the location of the product. The medical devices that need to be destroyed shall be destroyed under the supervision of the food and drug regulatory department.\n'第三条 本办法所称药品召回，是指药品生产企业（包括进口药品的境外制药厂商，下同）按照规定的程序收回已上市销售的存在安全隐患的药品。'可被翻译为：Article 3 Recall of drugs mentioned in these Provisions refers to recall of drugs with safety hazards on the market by drug manufacturers (including overseas manufacturers of imported drugs, the same below) in accordance with prescribed procedures.\n'第六条 医疗器械生产企业应当按照本办法的规定建立健全医疗器械召回管理制度，收集医疗器械安全相关信息，对可能的缺陷产品进行调查、评估，及时召回缺陷产品。'可被翻译为：Article 6 The medical device manufacturers shall establish and improve the medical device recall management system in accordance with these Provisions, collect the information related to medical device safety, investigate and assess possible defective products, and recall defective products in a timely manner.\n'第四条 本办法所称存在缺陷的医疗器械产品包括：'可被翻译为：Article 4 The defective medical device products mentioned in these Provisions include:\n\n根据上述已知信息，请将'第三条 本办法所称医疗器械召回，是指医疗器械生产企业按照规定的程序对其已上市销售的某一类别、型号或者批次的存在缺陷的医疗器械产品，采取警示、检查、修理、重新标签、修改并完善说明书、软件更新、替换、收回、销毁等方式进行处理的行为。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 3 The recall of medical devices in these Provisions refers to the handling acts of medical device manufacturers to the defective medical device products of a certain category, model or batch which have gone to the market through warning, checking, repair, relabeling, modifying and improving the instructions for use, software upgrade, replacement, withdrawal, destruction in accordance with the prescribed procedures."
    },
    {
        "instruction":"已知信息：\n'在无菌性测试中所用的每种培养基（THIO和SCD）管在整个检测时间段内均需 直接暴露于测试环境中（例如，层流罩）。或者，实验室可使用节b中详细说明 的琼脂沉淀板。'可被翻译为：Tubes of each medium (THIO and SCD) used in the sterility analysis are exposed to the immediate environment of the test (e.g., laminar flow hood) for the duration of the test. Alternatively, a laboratory may use agar settling plates as detailed in section b.\n'化验员在结束无菌性检测之后，退出无菌洁净室之前，必须对人员进行监测。化 验员应使用通用培养基接触碟，对其洁净室服装的无菌条件进行监测，确保遵守 了无菌技术。'可被翻译为：Personnel monitoring must be performed after analysts conclude sterility testing and prior to exiting the aseptic clean room. The analyst shall use general media touch plates to monitor the sterile condition of their clean room attire and to ensure aseptic techniques were followed.\n'生长培养基和其它检测溶液'可被翻译为：E. Growth Media and Additional Test Solutions\n'应对 A 级和 B 级区的人员进行微生物监测。当操作属于手动操作时（例如无菌配制或灌装），风险的增加应引起对洁净服微生物监测的重视，并在 CCS 中进行论证。'可被翻译为：Microbial  monitoring  of personnel  in  the  grade  A  and  grade  B  areas  should  be  performed.  Where operations are manual in nature (e.g. aseptic compounding or filling), the increased risk should lead to enhanced emphasis placed on microbial monitoring of gowns and justified within the CCS.\n\n根据上述已知信息，请将'可以在实验室工作台上进行检测，不需要设置洁净间或层流罩。但是，在使用通用生长培养基和检测微生物时要重视遵守无菌操作技术，防止交叉污染。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Testing can be performed on a laboratory benchtop and does not require setup in a clean room or a laminar flow hood. However, it is important to exercise aseptic technique when working with general growth media and test organisms to prevent cross contamination."
    },
    {
        "instruction":"已知信息：\n'第一百一十六条 违反本办法第二十八条、第三十三条规定，申办者有下列情形之一的，责令限期改正；逾期不改正的，处一万元以上三万元以下罚款：'可被翻译为：Article 116 In any of the following circumstances in violation of Articles 28 and 33 of these Provisions, the sponsor shall be ordered to make corrections; where corrections are not made within the specified timeline, the sponsor shall be imposed a fine of not less than RMB 10,000 but not more than RMB 30,000.\n'第七十二条 药品监督管理部门有下列行为之一的，对直接负责的主管人员和其他直接责任人员按照《药品管理法》第一百四十九条的规定给予处罚：'可被翻译为：Article 72 Where a drug regulatory department has committed any of the following behaviors, the executives directly responsible and other persons directly responsible shall be punished according to provisions in Article 149 of the Drug Administration Law:\n'第七十八条  有下列情形之一的，由药品监督管理部门依职责给予警告，并处1万元以上5万元以下罚款：'可被翻译为：Article 78 In one of the following circumstances, the drug regulatory department shall give warning according to its duties, and impose a fine of more than 10,000 yuan and less than 50,000 yuan:\n'第五十五条 有下列情形之一的，不予延续注册：'可被翻译为：Article 55 The registration renewal shall not be approved in any of the following circumstances:\n\n根据上述已知信息，请将'第六十八条 有下列情形之一的，按照《药品管理法》第一百一十五条给予处罚：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 68 In case of any following circumstances, penalties shall be imposed in accordance with Article 115 under the Drug Administration Law:"
    },
    {
        "instruction":"已知信息：\n'下面列出的分析用所有物品要单独控制。试验中使用的每种培养基都测试了每个高 压灭菌器中的一个设备。因此，对于在THIO和SCD中测试的样品，在每个培养基 中检测来自每个灭菌器（烘箱或高压灭菌器）装载的一个物品，测试中使用的每个 镊子、注射器等总共进行两个控制。'可被翻译为：All equipment items used in the analysis listed below will be controlled individually. One item from each autoclave lot of equipment is tested in each medium used in the test. Therefore, for a sample tested in THIO and SCD, one item from each sterilizer load (oven or autoclave) is tested in each medium giving a total of two controls for each forceps, syringe, etc., used in the test.\n'采用与样本相同的条件培养所有阴性控制样本，如系统控制样、培养基控制样。'可被翻译为：8. Incubate all negative controls, such as system controls, media controls, under the same conditions as the sample.\n'2.确保在产品放行前完成对批记录的审核；'可被翻译为：2) To ensure that the batch records are reviewed before product release;\n'原辅料控制——包括过程控制'可被翻译为：Raw material controls - including in-process controls\n\n根据上述已知信息，请将'或者，完成对这些材料的控制，作为每个歧管的“系统控制”的一部分。这还将 包括薄膜切割器和其他接触产品但无法单独控制的物品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Alternatively, controls for these materials are accomplished as part of the \"system control\" for each manifold. This will also include membrane cutters, and other items that contact the product but cannot be individually controlled."
    },
    {
        "instruction":"已知信息：\n'亚基'可被翻译为：subunit\n'蛋白质在二级结构基础上，由氨基酸残基侧链的相互作用，使多肽链进一步盘旋和折叠，导致整个分子形成很不规则的特定构象。'可被翻译为：On the basis of the secondary structure of protein, the interaction of the side chain of amino acid residues makes the polypeptide chain further spiral and fold, resulting in the formation of a very irregular specific conformation of the entire molecule.\n'具有相同化学结构的分子间的无序排列。'可被翻译为：Disordered arrangement of molecules having the same chemical structure.\n'由一种单体聚合得到的聚合物。即聚合物中含一种单体形成的不同结构的单体单元。'可被翻译为：A polymer obtained by polymerization of a single monomer. That is, a monomer unit in a polymer containing a monomer of different structures.\n\n根据上述已知信息，请将'蛋白质分子由多个具有三级结构亚基聚集形成的稳定构象。亚基间的聚合主要靠静电荷，并须在空间结构上互补。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A protein molecule is a stable conformation formed by the aggregation of multiple subunits with tertiary structure. The aggregation of subunits depends mainly on electrostatic charge and must be complementary in spatial structure."
    },
    {
        "instruction":"已知信息：\n'第五十八条 承担备案管理工作的药品监督管理部门发现已备案化妆品、化妆品新原料的备案资料不符合要求的，应当责令限期改正，其中，与化妆品、化妆品新原料安全性有关的备案资料不符合要求的，可以同时责令暂停销售、使用。'可被翻译为：Article 58 If the filing drug regulatory department finds that the dossiers of filed cosmetics or new cosmetic ingredients do not meet the requirements, the filing management department shall order that correction be made within a specified timeline; where the data filed that relate to the safety of cosmetics and new cosmetic ingredients do not meet the requirements, the filing management department may at the same time order suspension of their sales and use.\n'第九条 药品监督管理部门应当自化妆品、化妆品新原料准予注册、完成备案之日起5个工作日内，向社会公布化妆品、化妆品新原料注册和备案管理有关信息，供社会公众查询。'可被翻译为：Article 9 The drug regulatory department under the State Council shall release the information on registration and filing of cosmetics and new cosmetic ingredients to the public for reference within 5 working days since the date when the registration is approved or the filing is filed.\n'化妆品、化妆品新原料备案人未按照本办法规定更新普通化妆品、化妆品新原料备案信息的，由承担备案管理工作的药品监督管理部门责令改正，给予警告，处5000元以上3万元以下罚款。'可被翻译为：If the filing person of cosmetics and new cosmetics ingredients fails to update the filing information of general cosmetics and new cosmetics ingredients in accordance with the requirements of these Provisions, the drug regulatory department responsible for the filing administration shall order corrections, give warnings, and impose a fine of no less than 5,000 yuan but no more than 30,000 yuan.\n'化妆品、化妆品新原料注册人、备案人按照规定通过化妆品、化妆品新原料注册备案信息服务平台（以下简称信息服务平台）申请注册、进行备案。'可被翻译为：Registrants and filing persons of cosmetics and new cosmetic ingredients shall apply for registration and filing through the information service platform of registration and filing for cosmetics and new cosmetic ingredients (hereinafter referred to as the information service platform) in accordance with regulations.\n\n根据上述已知信息，请将'已进行备案但备案信息尚未向社会公布的化妆品、化妆品新原料，承担备案管理工作的药品监督管理部门发现备案资料不符合要求的，可以责令备案人改正并在符合要求后向社会公布备案信息。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For cosmetics and new cosmetic ingredients that have been filed but the filing dossiers has not yet been released to the public, if the filing drug regulatory department finds that the filing dossiers do not meet the requirements, they may order the filing person to make corrections and release the information to the public when the requirements are met."
    },
    {
        "instruction":"已知信息：\n'薄层色谱或纸色谱展开方式之一。根据展开剂的走向可分为双向展开法和同向多次展开法等。'可被翻译为：One of the development methods of thin layer chromatography or paper chromatography. According to the direction of the development agent can be divided into bidirectional development method and the same direction multiple development method.\n'在滤纸或薄层色谱板上用相同或不同溶剂两个方向展开的操作。这种方法适用于某些复杂混合物的分离。'可被翻译为：The operation of developing in two directions with the same or different solvents on filter paper or thin-layer chromatography plate. This method is suitable for the separation of certain complex mixtures.\n'双波长薄层扫描仪的一种扫描方式，展开后的薄层斑点经锯齿扫描能够消除斑点形状不规则引起的误差，从而获得满意的定量结果。'可被翻译为：A scanning method of dual-wavelength TLC scanner. The errors caused by irregular shape of the TLC spots can be eliminated by zigzag scanning, and satisfactory quantitative results can be obtained.\n'上行展开'可被翻译为：ascending development\n\n根据上述已知信息，请将'在一个薄层色谱板上，采用同样的展开剂，同一展开方向，同样展开距离，单向多次展开后样品斑点直径变小的现象。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"On a thin layer chromatography plate, using the same development agent, the same development direction, the same development distance, the phenomenon that the sample spot diameter becomes smaller after multiple unidirectional development."
    },
    {
        "instruction":"已知信息：\n'第十六条 申办者、临床试验机构和研究者不得夸大参与临床试验的补偿措施，误导受试者参与临床试验。'可被翻译为：Article 16 The sponsor, clinical trial institution and investigator shall not exaggerate the compensation measures for participation in the clinical trial, which may mislead the subjects into participating in the clinical trial.\n'（一）药物临床试验申请的研究资料不足以支持开展药物临床试验或者不能保障受试者安全的；'可被翻译为：(1) Study data in the drug clinical trial application are inadequate to support the conduct of drug clinical trials or cannot guarantee subjects’ safety;\n'(2) 受试者筛选应遵守临床试验方案规定的入选\/排除标准， 入组受试者应保留足够的支持性证据。'可被翻译为：(2) Subject screening complies with the inclusion\/exclusion criteria specified in clinical trial protocol and retain sufficient supporting evidence for the subjects enrolled.\n'(1) 临床试验源文件的管理符合医疗管理要求，源数据应满足临床试验数据质量通用标准(ALCOA+)。'可被翻译为：(1) The management of source files related to clinical trials shall meet the medical requirements, and the source data shall meet the common criteria for the quality of clinical trial data (ALCOA+).\n\n根据上述已知信息，请将'(1) 有源数据支持以证实所有受试者确实参与了临床试验。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) There shall be source data to confirm that all the subjects actually participate in the clinical trial."
    },
    {
        "instruction":"已知信息：\n'(1) 试验样品分析按照分析计划执行， 分析批中样品预处理的过程和检测方法与方法学验证一致， 血药浓度数据与申报资料一致。'可被翻译为：(1) The test sample analysis is conducted according to the analysis plan, the preprocessing and testing method of the samples in the analysis batch are consist with the method validation, and the plasma concentration data is consistent with that in the application dossier.\n'(3) 抽取工作站中的试验样品、随行标准曲线和 QC 样品以及方法学验证样品的部分电子图谱， 与申报资料一致。'可被翻译为：(3) Extract part of the electronic chromatograms of the test sample, accompanying standard curves and QC samples as well as method validation sample, which are consist with the application dossier.\n'(4) 所有在仪器中进样的样品均记录在原始记录中， 并对样品分析过程中出现的异常情况进行调查和分析， 与申报资料一致。'可被翻译为：(4) Samples introduced into all the instruments are recorded in the original records, and investigation and analysis are conducted for abnormal circumstances occurred during the process of sample analysis, consist with the application dossier.\n'(8) 试验样品重新分析的理由和报告值的选择符合标准操作规程或分析计划的规定。试验样品的初始值、重分析的原因、重复次数、重分析的结果、最终接受的值以及接受的理由记录，并与申报资料一致。'可被翻译为：(8) The reason for reanalysis of test samples and their reporting value selection comply with the standard operation procedures or provision of the analysis plan. The records of initial value, reason for reanalysis, number of repetition, results of reanalysis, the value finally accepted and reason for acceptance of the test sample are consist with those in the application dossier.\n\n根据上述已知信息，请将'(5) 试验样品分析过程中如有残留， 对试验样品浓度的影响进行评估并采取具体措施， 与申报资料一致。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(5) If there is residual during the process of test sample analysis, evaluate the impact on the concentration of the test sample and carry out specific measures, consist with the application dossier."
    },
    {
        "instruction":"已知信息：\n'鼓励研制创新 保障供应可及'可被翻译为：Encourage R&D to Ensure Accessible Supply\n'第一条 为了加强药品管理，保证药品质量，保障公众用药安全和合法权益，保护和促进公众健康，制定本法。'可被翻译为：Article 1 This Law is enacted to strengthen drug administration, ensure drug quality, protect drug safety and legitimate rights and interests of the public, and protect and promote public health.\n'全面贯彻落实“四个最严” 有效保障公众用药安全 新修订《药品管理法》审议通过'可被翻译为：Newly Revised Drug Administration Law Adopted After Deliberation —To Comprehensively Implement the Four Strictest Requirements and Effectively Protect Drug Safety for the Public\n'（七）沟通交流情况（省略）'可被翻译为：(VII) Communication and exchanges(omitted)\n\n根据上述已知信息，请将'三、鼓励创新与保障公众用药情况（省略）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"III. Encouraging innovation and safeguarding medication safety for the public (omitted)"
    },
    {
        "instruction":"已知信息：\n'将目的基因导入病变细胞或其他细胞，不去除异常基因，而是通过基因的非定点整合，使其表达产物补偿缺陷基因的功能或使原有的功能得以加强。目前基因治疗多采用此种方式。'可被翻译为：By introducing the target gene into the diseased cells or other cells, the abnormal gene is not removed, but through the non-site-specific integration of the gene, so that the expression products of the defective gene can compensate for the function of the original gene or strengthen the original function. At present, this method is commonly used in gene therapy.\n'控制一个或多个其他基因表达的基因。能编码蛋白质。在基因编码微小RNA情况下，也可作用在RNA水平上。'可被翻译为：A gene that controls the expression of one or more other genes. A gene that codes for proteins. In cases where genes encode micrornas, they also work at the RNA level.\n'启动基因、终止基因和一系列紧密连锁的结构基因的总称。'可被翻译为：A general term for starter genes, terminator genes, and a series of tightly linked structural genes.\n'对主基因进行检测中作为候选者的并具有已知生物学功能的基因。'可被翻译为：A gene with a known biological function that is a candidate in the detection of a major gene.\n\n根据上述已知信息，请将'维持细胞最低限度功能所不可少的基因。如编码组蛋白基因、编码核糖体蛋白基因、线粒体蛋白基因、糖酵解酶的基因等。这类基因在所有类型的细胞中都进行表达，因为这些基因的产物对于维持细胞的基本结构和代谢功能是必不可少的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Genes that are essential for a cell to function at a minimum level. Such as genes encoding histone proteins, genes encoding ribosomal proteins, mitochondrial protein genes, glycolytic enzymes, etc. Such genes are expressed in all types of cells because the products of these genes are essential for maintaining the basic structure and metabolic function of the cell."
    },
    {
        "instruction":"已知信息：\n'第十七条 临床试验前，申办者应当通过研究者和临床试验机构的医疗器械临床试验管理部门向伦理委员会提交下列文件：'可被翻译为：Article 17 Before the clinical trial, the sponsor shall submit the following materials to the ethics committee through the investigator and the medical device clinical trial management department of the clinical trial institution:\n'第四十三条 在临床试验过程中，申办者得到影响临床试验的重要信息时，应当及时对研究者手册以及相关文件进行修改，并通过临床试验机构的医疗器械临床试验管理部门提交伦理委员会审查同意。'可被翻译为：Article 43 In the course of the clinical trial, the sponsor shall make timely change to the investigator's brochure and related documents when obtaining important information that affects the clinical trial and submit it to the ethics committee for review and approval through the medical device clinical trial management department of the clinical trial institution.\n'第十八条 在临床试验过程中发生下列情况之一的，研究者应当及时向临床试验机构的医疗器械临床试验管理部门报告，并经其及时通报申办者、报告伦理委员会：'可被翻译为：Article 18 For any of the following circumstances during the clinical trial, the investigator shall report it to the medical device clinical trial management department of the clinical trial institution, which will inform the sponsor and ethics committee of the circumstance in time:\n'第七十一条 在临床试验中出现严重不良事件的，研究者应当立即对受试者采取适当的治疗措施，同时书面报告所属的临床试验机构医疗器械临床试验管理部门，并经其书面通知申办者。医疗器械临床试验管理部门应当在24小时内书面报告相应的伦理委员会以及临床试验机构所在地省、自治区、直辖市食品药品监督管理部门和卫生计生主管部门。对于死亡事件，临床试验机构和研究者应当向伦理委员会和申办者提供所需要的全部资料。'可被翻译为：Article 71 If any serious adverse event in the clinical trial occurs, the investigator shall immediately give appropriate treatment measures to the subjects, at the same time report in writing to the relevant medical device clinical trial management department of the clinical trial institution, and notify the sponsor through the department by a written notice. The medical device clinical trial management department shall report in writing to the corresponding ethics committee and the local food and drug administration department and the competent health and family planning department of the province, autonomous region or municipality where the clinical trial institution is located within 24 hours. For death events, the clinical trial institution and the investigator shall provide the ethics committee and the sponsor with all the information needed.\n\n根据上述已知信息，请将'第六十二条 临床试验前，临床试验机构的医疗器械临床试验管理部门应当配合申办者向伦理委员会提出申请，并按照规定递交相关文件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 62 Before the clinical trial, the medical device clinical trial management department of the clinical trial institution shall coordinate with the sponsor to submit the application to the ethics committee and submit relevant documents according to the regulations."
    },
    {
        "instruction":"已知信息：\n'验证批次：由接收方（RU）为了证明其生产所转移产品符合其预定质量标准的能力，或作为工艺性能确认一部分而生产的批次。'可被翻译为：Validation batches Those batches produced by the receiving unit (RU) to demonstrate its ability to manufacture the transferred product which complies with its predetermined specifications, or as part of process performance quanlification.\n'在给定的时间内，严格遵守已建立和验证的控制措施，按顺序生产同一产品的一系列批次。'可被翻译为：The manufacture of a series of batches of the same product in sequence in a given period of time with strict adherence to established and validated control measures.\n'与备案相关的申请人或生产商已上市销售至少5年且上一年生产了至少10个生产批次的多源产品，或者，如果上一年生产了少于10个批次，则在过去3年内生产了不少于25个批次的多源产品。'可被翻译为：A multisource product that has been marketed by the applicant or manufacturer associated with the dossier for at least five years and for which at least 10 production batches were produced over the previous year, or, if less than 10 batches were produced in the previous year, not less than 25 batches were produced in the previous three years.\n'阶段性生产：在给定的时间内，严格按照既定且经验证的控制措施生产多批次同一产品的生产方式。'可被翻译为：Campaign manufacture - A manufacture of a series of batches of the same product in sequence in a given period of time with strict adherence to established and validated control measures.\n\n根据上述已知信息，请将'1.在拟销售产品的常规生产过程中进行的验证。\n2.在特殊情况下，在用于销售的产品的常规生产期间进行验证，当由于只生产了有限数量的批次、不经常生产批次或由已修改的经过验证的工艺生产批次而无法获得复制生产运行的数据时。在对批次进行全面监控和测试的基础上，可以在验证工作完成之前对单个批次进行评估和放行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.Validation carried out during routine production of products intended for sale.\n2.Validation carried out during routine production of products intended for sale in exceptional circumstances when data from replicate production runs are unavailable because only a limited number of batches have been produced, batches are produced infrequently or batches are produced by a validated process that has been modified. Individual batches may be evaluated and released before completion of the validation exercise, based on thorough monitoring and testing of the batches."
    },
    {
        "instruction":"已知信息：\n'阶段性生产：在给定的时间内，严格按照既定且经验证的控制措施生产多批次同一产品的生产方式。'可被翻译为：Campaign manufacture - A manufacture of a series of batches of the same product in sequence in a given period of time with strict adherence to established and validated control measures.\n'第一百八十五条 应当建立划分产品生产批次的操作规程，生产批次的划分应当能够确保同一批次产品质量和特性的均一性。'可被翻译为：Article 185: Operation procedures should be established to differentiate production batches, and the differentiations of production batches should achieve homogenous quality and property of the product within the same batch.\n'1.在拟销售产品的常规生产过程中进行的验证。\n2.在特殊情况下，在用于销售的产品的常规生产期间进行验证，当由于只生产了有限数量的批次、不经常生产批次或由已修改的经过验证的工艺生产批次而无法获得复制生产运行的数据时。在对批次进行全面监控和测试的基础上，可以在验证工作完成之前对单个批次进行评估和放行。'可被翻译为：1.Validation carried out during routine production of products intended for sale.\n2.Validation carried out during routine production of products intended for sale in exceptional circumstances when data from replicate production runs are unavailable because only a limited number of batches have been produced, batches are produced infrequently or batches are produced by a validated process that has been modified. Individual batches may be evaluated and released before completion of the validation exercise, based on thorough monitoring and testing of the batches.\n'与备案相关的申请人或生产商已上市销售至少5年且上一年生产了至少10个生产批次的多源产品，或者，如果上一年生产了少于10个批次，则在过去3年内生产了不少于25个批次的多源产品。'可被翻译为：A multisource product that has been marketed by the applicant or manufacturer associated with the dossier for at least five years and for which at least 10 production batches were produced over the previous year, or, if less than 10 batches were produced in the previous year, not less than 25 batches were produced in the previous three years.\n\n根据上述已知信息，请将'在给定的时间内，严格遵守已建立和验证的控制措施，按顺序生产同一产品的一系列批次。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The manufacture of a series of batches of the same product in sequence in a given period of time with strict adherence to established and validated control measures."
    },
    {
        "instruction":"已知信息：\n'（五）可被人体吸收的医疗器械，按照第三类医疗器械管理。'可被翻译为：(5) An absorbable medical device shall be regarded as a class III medical device.\n'（十七）慢性创面'可被翻译为：(17) Chronic wound\n'（四）根据不同的结构特征、是否接触人体以及使用形式，医疗器械的使用状态或者其产生的影响包括以下情形：'可被翻译为：(4) The status of use or the effects generated of medical devices, according to their different structural characteristics, whether are in contact with human body and patterns of use, include:\n'无源接触人体器械：根据使用时限分为暂时使用、短期使用、长期使用；接触人体的部位分为皮肤或腔道（口）、创伤或组织、血液循环系统或中枢神经系统。'可被翻译为：Non-active body-contacting devices: temporarily used, the device used for short term and the device used for long term, according to service life. The positions in contact with human body include skin or orifice (stoma), trauma or tissue, blood circulation system or central nervous system.\n\n根据上述已知信息，请将'（七）医用敷料如果有以下情形，按照第三类医疗器械管理，包括：预期具有防组织或器官粘连功能，作为人工皮肤，接触真皮深层或其以下组织受损的创面，用于慢性创面，或者可被人体全部或部分吸收的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(7) In any of the following cases, medical dressings shall be regarded as a class III medical device: the medical dressing is intended to have a function to prevent tissue\/organ adhesion; is used as artificial skin; is to contact with the deep dermis or the injured trauma of tissue below dermis; is used to heal chronic wound, or may be wholly\/partially absorbed by human body."
    },
    {
        "instruction":"已知信息：\n'负责授权进口的国家机构(如贸易部或进出口部门)。'可被翻译为：The national agency responsible for authorizing imports (e.g. the ministry or department of trade or of imports and exports).\n'为落实国务院常务会议关于进出口环节监管证件实现网上申报、网上办理的工作要求，国家药监局整合开发了药品业务应用系统，用于进出口环节药品监管证件业务办理，包括药品出口销售证明、出口欧盟原料药证明文件、麻醉药品和精神药品进出口准许证、首次进口药材等事项。该系统同时具备麻醉药品和精神药品研制立项、中药提取物备案的网上申请与办理功能。'可被翻译为：In order to implement the requirements of the Executive meeting of The State Council on the implementation of online declaration and online processing of import and export regulatory documents, the State Food and Drug Administration has integrated and developed a drug business application system for the import and export process of drug regulatory documents. Including drug export sales certificates, export documents of EU raw material drugs, narcotics and psychotropic drugs import and export permits, first import of medicinal materials and other matters. The system also has the function of online application and management for the development of narcotic drugs and psychotropic drugs and the filing of traditional Chinese medicine extracts.\n'国家保护野生药材资源和中药品种，鼓励培育道地中药材。'可被翻译为：The State protects the resources of crude drugs and traditional Chinese medicines and encourages cultivation of traditional Chinese herbs.\n'办理首次进口药材备案的，除第一款规定资料外，还应当报送进口药材批件和进口药材补充申请批件（如有）复印件。'可被翻译为：For the filing of first importation of crude drugs, in addition to materials specified in the first paragraph, a copy of the approval document for importation of crude drugs and that for supplementary application for importation of crude drugs (if any) shall also be submitted.\n\n根据上述已知信息，请将'（六）进口药材涉及《濒危野生动植物种国际贸易公约》限制进出口的濒危野生动植物的，还应当提供国家濒危物种进出口管理机构核发的允许进出口证明书复印件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(VI) Where the importation of crude drugs involve the endangered species of wild fauna and flora that are restricted from export and import as specified in the Convention on International Trade in Endangered Species of Wild Fauna and Flora, a copy of the approval document for export and import issued by national authorities for the import and export management of endangered species shall also be provided."
    },
    {
        "instruction":"已知信息：\n'在有关国家或地区的药品管理机构注册过的任何药品中从未出现过的一种活性药物成分。在本指导原则中，一种已批准原料药的新的盐、酯或非共价结合的衍生物也认为是一种需进行稳定性试验的新分子实体。'可被翻译为：An active pharmaceutical substance not previously contained in any drug product registered with the national or regional authority concerned. A new salt, ester, or non-covalent-bond derivative of an approved drug substance is considered a new molecular entity for the purpose of stability testing under this guidance.\n'药物与适宜的辅料制成的具有一定粒度的干燥颗粒状制剂。'可被翻译为：A dry granular preparation with a certain particle size made of drugs and appropriate excipients.\n'1.药物起始原料是一种活性药物成分(API)或赋形剂，预定或指定用于药品生产。\n2.在药品生产中使用的具有一定质量的物质，但不包括包装材料。这包括活性药物成分(api)和药用辅料。'可被翻译为：1.A pharmaceutical starting material is an active pharmaceutical ingredient (API) or an excipient intended or designated for use in the production of a pharmaceutical product.\n2.Any substance of a defined quality used in the production of a pharmaceutical product, but excluding packaging materials. This includes active pharmaceutical ingredients (APIs) and pharmaceutical excipients.\n'药物与制剂稳定性研究的一种方法。依据阿伦尼乌斯（Arrhenius）公式可求出药物室温降解一定水平所需的时间，或室温贮藏一定时间后残余的药物水平。'可被翻译为：A method for studying the stability of drugs and preparations. The Arrhenius formula can be used to determine the time required for a drug to degrade to a certain level at room temperature, or the residual drug level after a certain period of storage at room temperature.\n\n根据上述已知信息，请将'一种药物的制剂形式，如片剂、胶囊剂、溶液剂、乳膏剂，它们以前未在地区或成员国注册过。通常是一种药物成份与辅料的组合，但不一定都是。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A pharmaceutical product type, for example, tablet, capsule, solution, cream, etc., which has not previously been registered in a region or Member State, and which contains a drug ingredient generally, but not necessarily, in association with excipients."
    },
    {
        "instruction":"已知信息：\n'经验证的封口温度、整个封口的封口温度均匀性、封口时间和压力的设置、维护和监测（如相关）。'可被翻译为：Setting, maintenance and monitoring of validated sealing temperatures, sealing temperatureuniformity across the seal, sealing times and pressures as relevant.\n'模具温度的设置、维护和监测，包括产品稳定性所需的冷却速率。'可被翻译为：Setting, maintenance and monitoring of mould temperatures, including rate of cooling where necessary  for product stability.\n'应通过适当的循环设计和控制（例如，设置正确的压力，加热和冷却速率以及装载模式），防止最终灭菌的非刚性容器（例如釆用吹灌封或者成型-灌装-密封技术生产的容器）的变形和损坏。'可被翻译为：Distortion and damage of non-rigid containers that are terminally sterilised, such as containers produced by\nBlow-Fill-Seal or Form-Fill-Seal technologies, should be prevented by appropriate cycle design and control (for\ninstance setting correct pressure, heating and cooling rates and loading patterns).\n'挤出参数的设置、维护和监测，包括温度、速度和型坯厚度的挤出机关键设置。'可被翻译为：Setting, maintenance and monitoring of extrusion parameters, including temperature, speed and extruder throat settings for parison thickness.\n\n根据上述已知信息，请将'经验证的成型温度（包括预热和冷却）、成型时间和压力的设置、维护和监测（如相关）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Setting, maintenance and monitoring of validated  forming temperatures (including preheating and cooling),forming times and pressures as relevant."
    },
    {
        "instruction":"已知信息：\n'第十三条 质量风险管理是在整个产品生命周期中采用前瞻或回顾的方式，对质量风险进行评估、控制、沟通、审核的系统过程。'可被翻译为：Article 13: Quality risk management is a systematic process for the assessment, control, communication and review of the risk to quality throughout the entire product life cycle. It can be applied both proactively and retrospectively.\n'对产品生命周期中药品质量风险进行评估、控制、沟通和回顾的系统过程。（ICHQ9）'可被翻译为：A systematic process for the assessment, control, communication, and review of risks to the quality of the drug product across the product lifecycle. (ICH Q9)\n'贯穿产品生命周期的对药品质量风险进行评估、控制、沟通和回顾分析的系统化过程。(ICH Q9)'可被翻译为：A systematic process for the assessment, control, communication and review of risks to the quality of the drug (medicinal) product across the product lifecycle. (ICH Q9)\n'质量风险管理应作为系统性流程执行，用于评估、控制、沟通和回顾风险。'可被翻译为：6.5. Quality risk management should be implemented as a systematic process for the assessment, control, communication and review of risks.\n\n根据上述已知信息，请将'第十条 企业应当采用前瞻或者回顾的方式，对药品流通过程中的质量风险进行评估、控制、沟通和审核。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 10 Enterprises shall assess, communicate, control the quality risks in the process of drug circulation in a prospective or retrospective manner."
    },
    {
        "instruction":"已知信息：\n'无菌测试：如果使用生物指示剂验证和监测灭菌周期，并且该批次通过其他质量 控制测试，则可使用该批次培养基。此外，如果可能，在同时进行其他操作之前， 将部分培养基在指定温度下培养14天。'可被翻译为：Sterility: The media batch may be used if the sterilization cycle is validated and monitored with the use of a biological indicator, and the batch passes other quality control testing. Also, if possible, prior to otherwise concurrently, incubate a portion of the media at the specified temperature for 14 days.\n'一个批次的待包装品或成品的所有生产记录。批生产记录能提供该批产品的生产历史，以及与质量有关的情况。'可被翻译为：All production records for a batch of goods to be packaged or finished. Batch production records provide the production history of the batch, as well as information related to quality.\n'跳过批次(定期)测试'可被翻译为：skip lot (periodic) testing\n'封闭式隔离器的设计通过工艺过程中充分保护暴露产品保证 A 级条件。在进行简单操作的封闭式隔离器中，气流可能不是完全单向的。然而，任何湍流不应增加暴露产品的污染风险。当生产线包含在封闭式隔离器中时，应通过关键区域的初始气流保护和工艺过程中暴露产品上方和周围的单向流吹扫保证 A 级条件。'可被翻译为：The design of closed isolators should ensure grade A conditions with adequate protection for exposed products during processing. Airflow may not be fully unidirectional in closed isolators where simple operations are conducted. However, any turbulent airflow should not increase risk of contamination of the exposed product.\nWhere processing lines are included in closed isolators, grade A conditions should be ensured with first air protection in the critical zone and unidirectional airflow that sweeps over and away from exposed products during processing.\n\n根据上述已知信息，请将'所有批次必须通过的关键质量测试，以提供充分的消费者保护。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The critical tests of quality that all lots must pass in order to provide adequate consumer protection."
    },
    {
        "instruction":"已知信息：\n'已知浓度的溶剂或溶剂混合物中的待测物，用于制备校正标样或QC样品。'可被翻译为：An analyte in a solvent or mixture of solvents at a known concentration, which is used to prepare calibration standards or QCs.\n'校正标样中待测物的高、低浓度区间（包括两端浓度）。'可被翻译为：The interval between the upper and lower concentration (amounts) of analyte in the calibration standards (including these concentrations)\n'加入已知量待测物的基质。校正标样被用于构建校正曲线。'可被翻译为：A matrix to which a known amount of analyte has been added or spiked. Calibration standards are used to construct calibration curves.\n'分析批中单个样品、QC和校正标样的所有数据的表格输出（例如，对于色谱法有保留时间、待测物和IS响应、浓度、稀释因子（如有）、采集时间；对于配体结合分析，有待测物响应、浓度、稀释因子）。'可被翻译为：Tabular output of all data from individual samples, QCs and calibration standards within the analytical run (e.g., for chromatography retention times, analyte and IS responses, concentrations, and dilution factors if any; for ligand binding assays analyte responses concentrations, dilution factors).\n\n根据上述已知信息，请将'待测物的结构类似物或稳定同位素标记化合物，其浓度已知且恒定地加入到校正标样、QC 样品和研究样品中，以促进目标待测物的定量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A structurally similar analogue or stable isotope labelled compound added to calibration standards, QCs and study samples at a known and constant concentration to facilitate quantification of the target analyte."
    },
    {
        "instruction":"已知信息：\n'（九）必要时应当将检验用实验动物在使用前进行检验或隔离检疫。饲养和管理应当符合相关的实验动物管理规定。动物应当有标识，并应当保存使用的历史记录。'可被翻译为：9. Animals used for testing should, where appropriate, be inspected and quarantined before use. They should be maintained and controlled in a manner that meets the regulations of lab animal management. They should be identified, and records should be maintained, showing the history of their use.\n'第二十三条 药物研究机构应当具有与试验研究项目相适应的人员、场地、设备、仪器和管理制度，并保证所有试验数据和资料的真实性；所用实验动物、试剂和原材料应当符合国家有关规定和要求。'可被翻译为：Article 23 The drug research institution shall have relevant staff, premises, equipment, instruments and management system, which are appropriate to the research project, and ensure the authenticity of all experimental data. Experimental animals, reagents and raw materials used in the study shall conform with the provisions of the State.\n'2.实验动物以外的其他实验系统'可被翻译为：2. Test systems other than laboratory animals\n'实验动物'可被翻译为：laboratory animals\n\n根据上述已知信息，请将'第六十七条 实验动物房应当与其他区域严格分开，其设计、建造应当符合国家有关规定，并设有独立的空气处理设施以及动物的专用通道。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 67: Experimental animal houses should be well isolated from other areas, and their design and construction should comply with relevant regulatory requirements. There should be dedicated air handling facilities and separate entrance for animal access."
    },
    {
        "instruction":"已知信息：\n'在开始样本检测序列之前，应根据USP<788>进行空白检测。环境空白必须符合USP<788>中所设定的要求方可开始样本检测。'可被翻译为：Prior to initiating the test sequence with a specimen, a blank determination is required and must be carried out according to USP<788> . The environmental blank must meet the requirements set forth in USP <788>in order to initiate testing of the specimen.\n'检测环境和环境空白'可被翻译为：Test Environment and Environmental Blank:\n'在完成检测之后，仪器会生成一份报告。该报告会有原始数据计数、计算结果和 检测样本是否符合USP中颗粒物检测限度的声明。'可被翻译为：Following the completion of the test the instrument will generate a report. The report will include the raw data counts, calculated values and state if the test specimen met the USP limits for the particular test performed.\n'检测程序'可被翻译为：Test Procedure\n\n根据上述已知信息，请将'在开始检测程序之前，必须根据ORA-LAB.019制备和检测一份环境空白。在得 到合格结果之后，可使用该仪器执行检测程序。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Prior to beginning a test procedure an environment blank must be prepared and tested according to ORA-LAB.019. After passing results have been obtained the instrument can now be used to perform the test procedure."
    },
    {
        "instruction":"已知信息：\n'第十四条 医疗器械生产企业按照本办法第十条、第十二条的要求进行调查评估后，确定医疗器械产品存在缺陷的，应当立即决定并实施召回，同时向社会发布产品召回信息。'可被翻译为：Article 14 After the medical device manufacturer carries out an investigation and assessment in accordance with the requirements of Articles 10 and 12 of these Provisions, if it is confirmed that the medical device product is defective, it shall immediately decide and implement a recall, and disclose the product recall information to the society.\n'医疗器械生产企业应当按照食品药品监督管理部门的要求进行召回，并按本办法第十四条第二款的规定向社会公布产品召回信息。'可被翻译为：The medical device manufacturer shall recall in accordance with the requirements of the food and drug regulatory department, and disclose the product recall information to the society in accordance with Paragraph 2, Article 14 of these Provisions.\n'（一）未按照本办法规定建立医疗器械召回管理制度的；'可被翻译为：(1) fail to establish a medical device recall management system in accordance with these Provisions;\n'（三）违反本办法第十八条、第二十三条、第二十七条第二款规定，未按照食品药品监督管理部门要求采取改正措施或者重新召回医疗器械的；'可被翻译为：(3) fail to take corrective measures or make another round of medical devices recall according to the requirements of the food and drug regulatory department, which violates Article 18, Article 23, and Paragraph 2 of Article 27 of these Provisions;\n\n根据上述已知信息，请将'（一）违反本办法第十四条规定，未按照要求及时向社会发布产品召回信息的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) fail to disclose the product recall information to the society in a timely manner as required, which violates Article 14 of these Provisions;"
    },
    {
        "instruction":"已知信息：\n'生产商应釆取所有必要的步骤和预防措施，保证其设施内生产的产品的无菌性。不应仅依靠任何终端工艺或成品检验来确保无菌性或其它质量要素。'可被翻译为：The manufacturer should take all steps and precautions necessary to assure the sterility of the products manufactured within its facilities. Sole reliance for sterility or other quality aspects should not be placed on any terminal process or finished product test.\n'在可能的情况下，成品应使用经验证且受控的灭菌工艺进行最终灭菌，因为这种灭菌工艺比经验证且受控的除菌过滤工艺和\/或无菌工艺的无菌保证程度更高。当产品不能经受最终灭菌时，应考虑使用无菌工艺后终端热处理，结合无菌工艺，以提供更好的无菌保证。'可被翻译为：Where possible, finished product should be terminally sterilised, using a validated and controlled sterilisation process, as this provides a greater assurance of sterility than a validated and controlled sterile filtration process and\/or aseptic processing. Where it is not possible for a product to undergo terminal sterilisation, consideration should be given to using post-aseptic processing terminal heat treatment, combined with aseptic process to give improved sterility assurance.\n'确保无菌工艺中密闭系统的所有产品接触表面的无菌性至关重要。无菌工艺中任何密闭系统的设计和选择 都应确保维持无菌性。最终除菌级过滤器之后，无菌设备（例如管道\/管道系统）与已灭菌产品通路的连接应设计成无菌连接（例如通过内在无菌连接装置）。'可被翻译为：It  is  critical  to  ensure  the  sterility  of  all  product  contact  surfaces  of closed  systems  used  for  aseptic processing. The design and selection of any closed system used for aseptic processing should ensure maintenance of sterility. Connection of sterile equipment (e.g. tubing\/pipework) to the sterilised product pathway after the final sterilising grade filter should be designed to be connected aseptically (e.g. by intrinsic sterile connection devices).\n'对于最终灭菌产品，最终灭菌工艺的验证应确保组件和成型容器之间的所有关键产品通路的无菌性，包括灭菌过程中未润湿的区域。'可被翻译为：For terminally sterilised products, the validation of terminal sterilisation processes should ensure the sterility of all critical product pathways between the component and moulded container, including areas that are not wetted during sterilisation.\n\n根据上述已知信息，请将'成品的无菌检验应仅被视为确保无菌性的一系列关键控制措施中的最后一步。成品无菌检验不能用于确保不符合设计、程序或验证参数的产品的无菌性。成品无菌检验方法应使用相关产品进行验证。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The sterility test applied to the finished product should only be regarded as the last in a series of critical control measures by which sterility is assured. It cannot be used to assure sterility of a product that does not meet its design, procedural or validation parameters. The test should be validated for the product concerned."
    },
    {
        "instruction":"已知信息：\n'社会各界高度关注我国常用药、急（抢）救药短缺问题，新修订《药品管理法》对“药品储备和供应”做出专章规定，明确国家实行药品储备制度、国家建立药品供求监测体系、国家实行短缺药品清单管理制度，国家实行短缺药品优先审评制度等，多部门共同加强药品供应保障工作。'可被翻译为：All sectors of the society pay close attention to the shortage of commonly used drugs and emergency (first aid) drugs in China.The newly revised DAL provides a special Chapter on Pharmaceutical Reserves and Supplies, clarifying the state's drug reserve system, drug supply & demand monitoring system, list management system and prioritized drug review system forshort-supplied drugs, involving multiple departments' synergy to strengthen drug supply security.\n'第九十七条 对短缺药品，国务院可以限制或者禁止出口。必要时，国务院有关部门可以采取组织生产、价格干预和扩大进口等措施，保障药品供应。'可被翻译为：Article 97 The State Council may restrict or prohibit exportation of drugs in shortage. Where necessary, the relevant State Council departments may adopt measures such as organizing the manufacturing, implementing price intervention, or expanding importation to secure drug supply.\n'第九十六条 国家鼓励短缺药品的研制和生产，对临床急需的短缺药品、防治重大传染病和罕见病等疾病的新药予以优先审评审批。'可被翻译为：Article 96 The State encourages the research, development, and manufacture of drugs in shortage, and implements priority review and approval for drugs in shortage in urgent clinical needs or new drugs for prevention and treatment of serious infectious diseases and rare diseases.\n'短缺药品'可被翻译为：drug shortages\n\n根据上述已知信息，请将'第九十四条 国家建立药品供求监测体系，及时收集和汇总分析短缺药品供求信息，对短缺药品实行预警，采取应对措施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 94 The State establishes a drug supply monitoring system to promptly gather, compile, and analyze the supply information of drugs in shortage, implement advance drug shortage warnings, and take countermeasures."
    },
    {
        "instruction":"已知信息：\n'为保证药品注册核查质量，统一核查范围和判定标准， 根据《中华人民共和国药品管理法》《药品注册管理办法》等 法律法规及相关指导原则，特制定《药品注册核查要点与判定原则(药理毒理学研究)(试行)》。'可被翻译为：In order to ensure the quality of drug registration inspection and to unify the scope of inspection and determination standards, in accordance with the Drug Administration Law of the People's Republic of China, Measures for Administration of Drug Registration and other laws and regulations and related guidelines, the Key Points and Determination Principles of Drug Registration Inspection (Pharmacological and Toxicological study) (Trial) is hereby formulated.\n'药品注册核查要点与判定原则(药物临床试验)(试行)'可被翻译为：Key Points and Determination Principles for Drug Registration Inspection(Drug Clinical Trials)(Trial)\n'3. 药品注册核查要点与判定原则（药物临床试验）（试行）'可被翻译为：3.《Key Points and Determination Principles for Drug Registration Inspection(Drug Clinical Trials)(Trial)》\n'药品注册核查要点与判定原则'可被翻译为：Key Points and Determination Principles of Drug Registration Inspection\n\n根据上述已知信息，请将'2. 药品注册核查要点与判定原则（药理毒理学研究）（试行）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2.《Key Points and Determination Principles of Drug Registration Inspection(Pharmacological and Toxicological Study)(Trial)》"
    },
    {
        "instruction":"已知信息：\n'1.这是一个不会对产品质量产生任何直接或间接影响的系统。这些系统仅根据GEP进行设计和调试。\n2.一个不会对产品质量产生任何直接或间接影响的系统。这些系统仅根据良好的工程实践进行设计和调试。'可被翻译为：1.This is a system that will not have any impact, either directly or indirectly, on product quality. These systems are designed and commissioned according to GEP only.\n2.A system that will not have any impact, either directly or indirectly, on product quality. These systems are designed and commissioned according to good engineering practice only.\n'1.描述必须控制在预定标准内的工艺步骤、工艺条件、测试要求或其他相关参数或项目，以确保原料药符合其规格。\n2.有可能对产品质量或性能产生重大影响的。'可被翻译为：1.Describes a process step, process condition, test requirement or other relevant parameter or item that must be controlled within predetermined criteria to ensure that the API meets its specification.\n2.Having the potential to impact on product quality or performance in a  significant way.\n'间接影响系统'可被翻译为：indirect impact system\n'对于无菌工艺，直接和间接接触产品的部件应进行灭菌。直接接触产品的部件是指产品通过的部件，例如灌装针或泵。间接接触产品的部件是不接触产品的设备部件，但可能与其它灭菌表面接触，其无菌性对整个产品的无菌性至关重要（例如胶塞桶和导槽等已灭菌物品，以及已灭菌组件）。'可被翻译为：For aseptic processes, direct and indirect product contact parts should be sterilised. Direct product contact parts are those that the product passes through, such as filling needles or pumps. Indirect product contact parts are equipment parts that do not contact the product, but may come into contact with other sterilised surfaces, the\nsterility of which is critical to the overall product sterility (e.g. sterilised items such as stopper bowls and guides, and sterilised components).\n\n根据上述已知信息，请将'系统内的加工参数或部件，其操作、接触、数据控制、报警或故障将对产品质量产生间接影响或无影响。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A processing parameter or component within a system where the operation, contact, data control, alarm or failure will have an indirect impact or no impact on the quality of the product."
    },
    {
        "instruction":"已知信息：\n'（一）主动申请注销的；'可被翻译为：(1) the cancellation is applied voluntarily;\n'（一）主动申请注销药品生产许可证的；'可被翻译为：(1) An application for the revocation of the Drug Manufacturing Certificate is voluntarily submitted;\n'第四十二条 已经注册的产品不再生产或者进口的，注册人应当主动申请注销注册证。'可被翻译为：Article 42 If the registered product is no longer produced or imported, the registrant shall take the initiative to apply for cancellation of the registration license.\n'化妆品生产企业申请注销生产许可时，原发证的药品监督管理部门发现注销可能影响案件查处的，可以暂停办理注销手续。'可被翻译为：When the cosmetics manufacturer applies for cancelling the cosmetics manufacturing license, if the drug regulatory department issued former license finds out that cancellation may affect investigation of cases, it may suspend handling of the cancellation procedures.\n\n根据上述已知信息，请将'（一）企业主动申请注销的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) The enterprise takes the initiative to apply for cancellation;"
    },
    {
        "instruction":"已知信息：\n'实验过程中测定温度按照预先设计的速率循序上升从而测定药物反应速度常数的方法。'可被翻译为：A method of determining the drug reaction rate constant by increasing the measured temperature at a predetermined rate during an experiment.\n'种物质按照规定的方法测定，由固相融化成液相时的温度。是物质的-项物理常数。'可被翻译为：The temperature at which a substance melts from a solid phase into a liquid phase, as determined by a prescribed method. Is the physical constant of a substance.\n'温度测定测试。'可被翻译为：Temperature measurement test.\n'使酶促反应速度最快的温度。'可被翻译为：The temperature that causes the fastest enzymatic reaction.\n\n根据上述已知信息，请将'在实验过程中保持测定温度不变，从而测定药物反应速度常数的方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A method of determining a drug reaction rate constant by keeping the measurement temperature constant during an experiment."
    },
    {
        "instruction":"已知信息：\n'物质从液态（液体或熔融体）或气态形成晶体的过程。'可被翻译为：The process by which a substance forms a crystal from a liquid (liquid or molten) or gaseous state.\n'某一药物的不同结晶形态。包括溶剂化或水合物（伪晶体及无定型）。'可被翻译为：Different crystalline forms of the same drug substance. These can include solvation or hydration products (also known as pseudo-polymorphs) and amorphous forms.\n'溶质从溶液里结晶析出时，晶体里结合着的一定数目的水分子。'可被翻译为：When a solute crystallizes out of a solution, a certain number of water molecules are bound to the crystal.\n'白色片状或斜方晶形结晶。不溶于水，溶于大多数香料。'可被翻译为：A white flake or rhombic crystal. Insoluble in water, soluble in most spices.\n\n根据上述已知信息，请将'将晶体溶于溶剂或熔融以后，又重新从溶液或熔体中结晶的过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process of re-crystallizing a crystal from a solution or melt after it is dissolved in a solvent or melted."
    },
    {
        "instruction":"已知信息：\n'RU应有能力接收准备转移的活动。'可被翻译为：12.4. The RU should be able to accommodate the intended activity.\n'小组成员应具备必要的资质和经验，可以管理转移方面的问题。'可被翻译为：5.7. The team members should have the necessary qualifications and experience to manage the particular aspects of the transfer.\n'技术转移应由来自双方（SU和RU）的负责人，和其它技术和质量监管部门的人进行管理。可指定一个技术转移小组，并书面说明其职责。'可被翻译为：5.6. The technology transfer should be managed by responsible persons from each site (the SU and RU) and any other units with the appropriate technical and quality oversight. A technology transfer team may be appointed with identified and documented responsibilities.\n'SU与RU应分别具备经过恰当设计、清楚规定和文件化的质量体系。'可被翻译为：6.1. The SU and RU should each have an appropriately designed, clearly defined and documented quality system.\n\n根据上述已知信息，请将'应由在GXP领域和准备转移的活动方面具备恰当资质和知识经验的人员组成小组进行评估。建议SU和RU质量部分参与该活动。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4.3. The assessment should be done by a team of appropriately qualified persons with knowledge and experience in the field of GxP and the activity to be transferred. It is recommended that the quality units of the SU and RU participate in this activity."
    },
    {
        "instruction":"已知信息：\n'第二十二条 口岸药品检验机构收到进口药材口岸检验通知书后，应当在2日内与进口单位商定现场抽样时间，按时到规定的存货地点进行现场抽样。现场抽样时，进口单位应当出示产地证明原件。'可被翻译为：Article 22 Drug control institutions of ports shall, within 2 days after receiving the notice for port testing for importation of crude drugs, negotiate with the importers on site sampling time, and carry out on-site sampling at the specified storage location on time. During on-site sampling, importers shall show the original certificate of the place of production.\n'对不予抽样的药品，口岸药品检验所应当在2日内，将《进口药品抽样记录单》送交所在地口岸药品监督管理局。'可被翻译为：As to drugs from which no sample shall be taken, the drug control institute of port shall within 2 days deliver the Record of Sampling for Import Drugs to the local drug regulatory department at ports of entry.\n'口岸药品检验所按照《进口药品口岸检验通知书》规定的抽样地点，抽取检验样品，进行质量检验，并将检验结果送交所在地口岸药品监督管理局。检验符合标准规定的，准予进口备案，由口岸药品监督管理局发出《进口药品通关单》；不符合标准规定的，不予进口备案，由口岸药品监督管理局发出《药品不予进口备案通知书》。'可被翻译为：A drug control institute of port shall take sample sat the sampling place specified in the Notice of Port Testing for Import Drugs, test the quality, and deliver the testing result to the local drug regulatory department at ports of entry. If the testing result is in conformity with relevant standards, the importation record filing shall be approved, and the drug regulatory department at ports of entry shall issue the Import Drug Note; if the testing result is not in conformity with relevant standards, the importation record filing shall not be approved, and the drug regulatory department at ports of entry shall issue the Notice of Non-Acceptance of Drug Import Filing.\n'第十五条 本办法第十条规定情形的药品，口岸药品监督管理局审查全部资料无误后，应当向负责检验的口岸药品检验所发出《进口药品口岸检验通知书》，附本办法第十三条规定的资料一份，同时向海关发出《进口药品抽样通知书》。有关口岸药品检验进入海关监管场所抽样的管理规定，由国家食品药品监督管理局与海关总署另行制定。'可被翻译为：Article 15 In the case of drugs as specified in Article 10 of the Provisions, drug regulatory department at ports of entry shall, if all the materials pass examination, issue a Notice of Port Testing for Import Drugs to the relevant drug control institute of port with one set of materials specified in Article 13 of the Provisions attached, and shall at the same time send a Notice of Sampling for Import Drugs to the customs. The rules for sampling by drug control institute of port within customs surveillance area shall be separately formulated by the State Food and Drug Administration and the General Administration of Customs.\n\n根据上述已知信息，请将'第二十三条 口岸药品检验所接到《进口药品口岸检验通知书》后，应当在2日内与进口单位联系，到规定的存货地点按照《进口药品抽样规定》进行现场抽样。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 23 Drug control institutes of port shall, within two days after receiving the Notice of Port Testing for Import Drugs, contact the importer, and carry out on-site sampling at the specified storage location in accordance with the Rules for Import Drugs Sampling."
    },
    {
        "instruction":"已知信息：\n'第七十一条 违反本办法规定，未依法办理第一类医疗器械变更备案或者第二类、第三类医疗器械注册登记事项变更的，按照《医疗器械监督管理条例》有关未备案的情形予以处罚。'可被翻译为：Article 71 Where, in violation of the Provisions, a change of filing for a class I medical device is not performed, or a registration alteration of registry items for a class II or class III medical device is not performed according to law, punishments shall be imposed according to the situation concerning fail in filing in the Regulations on Supervision and Administration of Medical Devices.\n'第八十二条 违反本办法规定，未依法办理体外诊断试剂注册许可事项变更的，按照《医疗器械监督管理条例》有关未取得医疗器械注册证的情形予以处罚。'可被翻译为：Article 82 Where, in violation of the Provisions, a registration alteration of permission items for an in-vitro diagnostic reagent is not performed according to law, punishments shall be imposed according to the situation concerning not obtaining a medical device registration certificate in the Regulations on Supervision and Administration of Medical Devices.\n'第七十二条 违反本办法规定，未依法办理医疗器械注册许可事项变更的，按照《医疗器械监督管理条例》有关未取得医疗器械注册证的情形予以处罚。'可被翻译为：Article 72 Where, in violation of the Provisions, a registration alteration of permission items for a medical device is not performed according to law, punishments shall be imposed according to the situation concerning not obtaining a medical device registration certificate in the Regulations on Supervision and Administration of Medical Devices.\n'第六条 第一类体外诊断试剂实行备案管理，第二类、第三类体外诊断试剂实行注册管理。'可被翻译为：Article 6 Class I in-vitro diagnostic reagents are subject to filing administration and class II and class III in-vitro diagnostic reagents are subject to registration administration.\n\n根据上述已知信息，请将'第八十一条 违反本办法规定，未依法办理第一类体外诊断试剂变更备案或者第二类、第三类体外诊断试剂注册登记事项变更的，按照《医疗器械监督管理条例》有关未备案的情形予以处罚。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 81 Where, in violation of the Provisions, a change of filing for a class I in-vitro diagnostic reagent is not performed, or a registration alteration of registry items for a class II or class III in-vitro diagnostic reagent is not performed according to law, punishments shall be imposed according to the situation concerning fail in filing in the Regulations on Supervision and Administration of Medical Devices."
    },
    {
        "instruction":"已知信息：\n'应对泵进行评估，以确保其正常工作。如果使用蠕动泵，测试完成后应松开泵管，以防止泵管不必要的磨损，这可能导致流量的变化。蠕动泵管应定期更换，以确保所有池体的流速保持一致。对于自动取样系统，还应检查样管对准，以确保所有样品完全收集到小瓶或试管中，无泄漏、样品捕获失败或因其他原因丢失样品。'可被翻译为：The pump should be evaluated to ensure it is working properly. If a peristaltic pump is used, the tubing should be unclamped once the test has completed to prevent unnecessary wear on the tubing, which may cause variation in the flow rate. Peristaltic pump tubing should be replaced at regular intervals to ensure the flow rate remains consistent across all the cells. For automated sampling systems, sample tube alignment should also be checked to ensure that all samples are entirely collected into the vials or test tubes, without leakage, failure to capture samples, or sample loss for other reasons.\n'粒子计数器，包括釆样管，应经确认。对于管径和弯曲半径，应考虑生产商建议的标准。除非另有正当理由，否则管长通常应不超过 1 米，并且应尽量减少弯曲。在测定房间级别时，应使用釆样管较短的便携式粒子计数器。在单向流系统中应使用等速釆样头。采样头应朝向适当并尽可能靠近关键位置，以确保样品具有代表性。'可被翻译为：Particle counters, including sampling tubing, should be qualified. The manufacturer's recommended specifications should be considered for tube diameter and bend radii. Tube length should typically be no longer than 1m unless justified and the number of bends should be minimized. Portable particle counters with a short\nlength of sample tubing should be used for classification purposes. Isokinetic sampling heads should be used in unidirectional airflow systems. They should be oriented appropriately and positioned as close as possible to the\ncritical location to ensure that samples are representative.\n'有关将产品涂抹在皮肤上的具体剂量技术，请参阅体外渗透试验，实验设计，剂量。将泵设置为用于测试的流量，并将流出样管(应全部相同长度)与第一组小瓶或试管对齐。'可被翻译为：For specific dosing techniques to apply the product to the skin, refer to the In Vitro Permeation Test, Experimental Design, Dose. Set the pump to the flow rate to be used for testing and align the outflow sample tubes (which should all be the same length) with the first set of vials or test tubes.\n'所有FDC系统应得到适当维护，并定期重新确认(如前所述)。相关的FDC系统(加热和温度调节、泵、管、机械取样系统等)和FDC系统的其他组件应保持清洁，并对其运行进行评估，以确保每个扩散池能够将皮肤表面温度保持在32±1°的目标范围内，将流量保持在规定的范围内，并在测试方法的规范范围内支持测试的性能。'可被翻译为：All FDC systems should be properly maintained and requalified on a regular basis (as described previously). The relevant FDC systems (heating and thermoregulation, pumps, tubes, mechanical sampling systems, etc.) and other components of the FDC system should be kept clean and their operation should be evaluated to ensure that each diffusion cell can maintain the skin surface temperature within the target range of 32 ± 1°, maintain the flow rate within the specified range, and support the performance of the test within the specifications of the test method.\n\n根据上述已知信息，请将'泵的流量应符合试验时使用的流量。对于每分钟微升范围内的流速，建议延长采样时间，以减少液滴粘附在样品线上的影响。如果使用自动化系统，应确保样品管线在小瓶上正确对齐。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The flow rate of the pump should be qualified for the rate used during testing. For flow rates in the microliters-per-minute range, it is recommended to extend the sampling time to reduce the effects of droplets adhering to the sample line. If an automated system is used it should be ensured that the sample lines are properly aligned over the vials."
    },
    {
        "instruction":"已知信息：\n'第一条 为规范药品注册核查(以下简称注册核查)工作行为，加强注册核查与审评工作的衔接，保证注册核查工作质量和效率，根据《药品注册管理办法》《药品生产监督管理办法》,制定本程序。'可被翻译为：Article 1 In order to standardize the work process of drug registration inspection (hereinafter referred to as registration inspection), strengthen the connection between registration inspection and evaluation, and ensure the quality and efficiency of registration inspection, the Procedures is formulated in accordance with the Drug Registration Regulation and Drug Manufacture Regulation.\n'第二十六条 核查中心实施注册核查前，根据《药品注册核查要点与判定原则》,基于风险原则，并结合药品审评中心提出的核查对象和核查关注点(如有),制定核查方案。核查方案内容包括：被核查单位基本情况、核查品种、核查目的、核查依据、现场核查时间、核查内容、核查组成员等。'可被翻译为：Article 26 Before CFDI implements registration inspection, it shall formulate an inspection protocol in accordance with the Key Points and Determination Principles of Drug Registration Inspection, based on the risk principle, and in combination with the inspection objects and inspection concerns (if any) proposed by CDE. The content of the inspection protocol includes: the basic information of the inspected institution, the type of inspection, the purpose of the inspection, the basis of the inspection, the time of the on-site inspection, the content of the inspection, the members of the inspection team, etc.\n'为保证药品注册核查质量，统一核查范围和判定标准， 根据《中华人民共和国药品管理法》《药品注册管理办法》等 法律法规及相关指导原则，特制定《药品注册核查要点与判定原则(药理毒理学研究)(试行)》。'可被翻译为：In order to ensure the quality of drug registration inspection and to unify the scope of inspection and determination standards, in accordance with the Drug Administration Law of the People's Republic of China, Measures for Administration of Drug Registration and other laws and regulations and related guidelines, the Key Points and Determination Principles of Drug Registration Inspection (Pharmacological and Toxicological study) (Trial) is hereby formulated.\n'为保证药品注册核查质量， 统一核查范围和判定标准， 根据《中华人民共和国药品管理法》《药品注册管理办法》和《药物临床试验质量管理规范》等法律法规及相关指导原则， 特制定《药品注册核查要点与判定原则(药物临床试验)(试行)》。'可被翻译为：In order to ensure the quality of drug registration inspection and unify the inspection scope and determination criteria, in accordance with the Drug Administration Law of the People’s Republic of China, the Provisions for Drug Registration, Good Clinical Practice and other laws and regulations as well as relevant guidelines, the Key Points and Determination Principles for Drug Registration Inspection (Drug Clinical Trials) (Trial) is hereby formulated.\n\n根据上述已知信息，请将'第十条 核查中心建立注册核查相关质量管理体系，制定注册核查的标准操作程序及相应的《药品注册核查要点与判定原则》,加强检查员队伍建设，建立注册核查检查员库，规范注册核查有关工作。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 10 CFDI shall establish a quality management system related to registration inspection, formulate standard operating procedures for registration inspection and the corresponding Key Points and Determination Principles of Drug Registration Inspection, strengthen the construction of the inspector team, establish a registration inspection inspector database, and regulate the related work of registration inspection."
    },
    {
        "instruction":"已知信息：\n'利用同位素标记的与未标记的抗原或抗体与抗体或抗原发生竞争性抑制反应来测定抗体或抗原含量的方法。'可被翻译为：A method of determining antibody or antigen content using a competitive inhibition reaction between an isotopically labeled antigen or antibody and an unlabeled antigen or antibody.\n'1.与致病性病原体抗原、抗体以及核酸等检测相关的试剂；'可被翻译为：1. Reagents related to the testing of antigen, antibody and nucleic acid, etc. for pathogen.\n'（一）药品生产场地管理文件以及变更材料；'可被翻译为：(1) site master files and the materials in connection with any change;\n'（一）产品所用原辅料的所有变更，尤其是来自新供应商的原辅料；'可被翻译为：1. All changes of starting materials used for the product, especially those materials from new suppliers;\n\n根据上述已知信息，请将'（一）抗原、抗体等主要材料供应商变更的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) Change of suppliers of main materials such as antigen and antibody, etc.."
    },
    {
        "instruction":"已知信息：\n'对受体有较强亲和力和较强的内在活性(a=l),能产生最大药理效应的药物。如肾上腺素等为完全激动药。药物和受体的相互作用不仅与药物对受体的亲和力有关，还与内在活性有关。内在活性是药物产生最大生物效应的能力。'可被翻译为：a drug that has a strong affinity for the receptor and a strong intrinsic activity (a=l) to produce the greatest pharmacological effect. Complete agonists, such as epinephrine. The drug and receptor interaction is not only related to the affinity of the drug to the receptor, but also to the intrinsic activity. Intrinsic activity is the ability of a drug to produce the maximum biological effect.\n'药物具有一定的亲和力，但内在活性低，单用时与受体结合后只能产生较弱的效应，即使浓度再增加也不能达到完全激动剂那样的最大效应的药物。'可被翻译为：The drug has a certain affinity, but the intrinsic activity is low, and can only produce a weak effect after binding to the receptor when used alone. Even if the concentration is increased, the maximum effect cannot be achieved as a full agonist.\n'能与受体结合，具有较强亲和力而无内在活性的药物。'可被翻译为：A drug that can bind to the receptor and has a strong affinity without intrinsic activity.\n'可直接或间接引起类似交感神经系统激动的药物。包括：①α受体激动药，可起到血管收缩和血压升高作用,如去甲肾上腺素;②β受体激动药，包括：β1受体激动药，可增加心率，β2受体激动药，可引起平滑肌舒张。'可被翻译为：Drugs that can directly or indirectly cause a similar sympathetic nervous system excitation. These include: ① alpha-receptor agonists, which can play a role in vasoconstriction and blood pressure increase, such as norepinephrine; ② beta agonists, including beta 1 agonists, which can increase heart rate, and beta 2 agonists, which can cause smooth muscle relaxation.\n\n根据上述已知信息，请将'以拮抗作用为主，还有一定内在活性，即激动受体的效应的药物。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The antagonistic action is mainly, and there is a certain intrinsic activity, that is, the effect of activating the receptor."
    },
    {
        "instruction":"已知信息：\n'第四十二条 化妆品集中交易市场开办者、展销会举办者应当建立保证化妆品质量安全的管理制度并有效实施，承担入场化妆品经营者管理责任，督促入场化妆品经营者依法履行义务，每年或者展销会期间至少组织开展一次化妆品质量安全知识培训。'可被翻译为：Article 42 The organizers of centralized trading market and expos shall establish a management system for ensuring quality and safety of cosmetics and make effective implementation, undertake the responsibility for managing the participating marketers of cosmetics, urge the participating marketers of cosmetics to perform their obligations according to law, and organize to carry out training on knowledge in quality and safety of cosmetics at least once a year or once during the trade fair period.\n'（三）有保证医疗器械质量的管理制度；'可被翻译为：(3) having the management systems to ensure the quality of the medical devices;\n'第一条 为了规范化妆品注册和备案行为，保证化妆品质量安全，根据《化妆品监督管理条例》，制定本办法。'可被翻译为：Article 1 These Provisions are formulated for the purpose of regulating registration and filing of cosmetics, while ensuring the quality and safety of cosmetics in accordance with the Regulations on Supervision and Administration of Cosmetics.\n'第一条 为了规范化妆品生产经营活动，加强化妆品监督管理，保证化妆品质量安全，根据《化妆品监督管理条例》，制定本办法。'可被翻译为：Article 1 These Provisions are formulated in accordance with the Regulations on Supervision and Administration of Cosmetics for the purpose of regulating manufacturing and marketing of cosmetics, strengthening supervision and administration of cosmetics, and ensuring quality and safety of cosmetics.\n\n根据上述已知信息，请将'（六）有保证化妆品质量安全的管理制度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(6) having a management system for guaranteeing the quality and safety of the cosmetics."
    },
    {
        "instruction":"已知信息：\n'一种液相色谱一质谱联用的接口。'可被翻译为：The utility model relates to a liquid chromatography-mass spectrometry interface.\n'质谱仪主体组成部分，将离子源中形成的离子按质荷比的差异进行分离并将这些微弱的离子流信号接收并放大后送至显示单元及计算机数据处理系统，得到被分析样品的质谱图及数据。'可被翻译为：The main part of the mass spectrometer is to separate the ions formed in the ion source according to the difference of the mass charge ratio, and receive and amplify the weak ion flow signal and send it to the display unit and computer data processing system to obtain the mass spectrum and data of the analyzed sample.\n'1975年由美国陶氏化学公司(DowChemical)的斯莫尔(Small),史蒂文斯(Stevens)和鲍曼(Bowman)发明的一种色谱技术。采用电导检测器的离子交换色谱，用于无机离子的分析，是一项新的液相色谱分析技术。已有多种分离方式和多种检测器可分为带有抑制柱的离子色谱(双柱离子色谱)和单柱离子色谱。'可被翻译为：A chromatographic technique invented in 1975 by Small, Stevens and Bowman of DowChemical in the United States. Ion exchange chromatography with conductance detectors, for the analysis of inorganic ions, is a new analytical technique for liquid chromatography. There are a variety of separation methods and a variety of detectors that can be divided into ion chromatography with suppression columns (double column ion chromatography) and single column ion chromatography.\n'以质谱图中指定质核比范围内最强峰为100%,其他离子峰对其归一化所得的强度。现在标准质谱图均以离子相对丰度值为纵坐标。'可被翻译为：The maximum peak is 100% in the range of the specified mass nucleus ratio in the mass spectrum, and the intensity obtained by the normalization of other ion peaks. Now the standard mass spectrometry is the relative abundance value of ions as the ordinate.\n\n根据上述已知信息，请将'一种高效液相色谱一质谱联用的仪器接口。属于大气压电离的范畴，包括电喷雾、离子的形成及离子的传递三个步骤。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An instrument interface for high performance liquid chromatography-mass spectrometry. It belongs to the category of atmospheric pressure ionization, including electrospray, ion formation and ion transfer three steps."
    },
    {
        "instruction":"已知信息：\n'与剂量和常规药理作用无关的不良反应。其发生与患者体质密切相关，难预测，发生率低。'可被翻译为：Adverse reactions independent of dose and routine pharmacological action. Its occurrence is closely related to the patient's constitution, difficult to predict, and the incidence is low.\n'又称\"剂量无关性不良反应\"。通常在长期用药后出现的不良反应。其特点是：难预测、非特异性、没有明确的时间关系、潜伏期长。'可被翻译为：It is also known as \"dose-independent adverse reactions\". An adverse reaction that usually occurs after prolonged use of medication. It is characterized by: difficult to predict, non-specific, no clear time relationship, long incubation period.\n'用药剂量过大或用药时间过长而引起的不良反应。'可被翻译为：Adverse reactions caused by excessive dosage or prolonged use of antibiotics.\n'药物治疗作用之后出现的不良反应，是治疗剂量下治疗作用本身带来的后果。'可被翻译为：The adverse reactions that occur after the therapeutic effect of drugs are the consequences of the therapeutic effect itself under the therapeutic dose.\n\n根据上述已知信息，请将'又称\"剂量相关性不良反应\"。与剂量密切相关的不良反应。可预测。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Also known as \"dose-related adverse reactions\". Adverse reactions that are closely related to dosage. Predictable."
    },
    {
        "instruction":"已知信息：\n'在一项研究或一组研究中，在人或动物暴露于某物质后任何生物学效应发生频率或严重程度显著增加的最低暴露量。'可被翻译为：The lowest dose of substance in a study or group of studies that produces biologically significant increases in frequency or severity of any effects in the exposed humans or animals.\n'在特定暴露条件下，通过实验或观察发现的可导致目标生物体的形态、功能、生长、发育、或寿命发生可区别于正常（对照）同种同株生物体的有害作用的最低物质（制剂）浓度或量。（IUPAC）'可被翻译为：Lowest-Observed-Adverse-Effect Level: Lowest concentration or amount of a substance (dose), found by experiment or observation, that causes an adverse effect on morphology, functional capacity, growth, development, or life span of a target organism distinguishable from normal (control) organisms of the same species and strain under defined conditions of exposure. (IUPAC)\n'某种物质导致有害作用发生，停止暴露于该物质时反应消失。'可被翻译为：The occurrence of harmful effects that are caused by a substance and which disappear after exposure to the substance ends.\n'在特定暴露条件下，通过实验或观察发现的不会导致目标生物体的形态、功能、生长、发育、或寿命发生可被观测到副作用的物质最大量或浓度。'可被翻译为：No-Observed-Adverse-Effect Level: Greatest concentration or amount of a substance, found by experiment or observation, that causes no detectable adverse alteration of morphology, functional \ncapacity, growth, development, or life span of the target organism under defined conditions of exposure.\n\n根据上述已知信息，请将'在特定环境下，某试剂的暴露量不足以导致不良反应的实际发生。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Practical certainty that adverse effects will not result from exposure to an agent under defined circumstances."
    },
    {
        "instruction":"已知信息：\n'（三）持有人药品注册证书、药品生产许可证等行政许可被依法吊销或者撤销的；'可被翻译为：(3) Where the MAH's Drug Approval License, Drug Manufacturing Certificate and other administrative licenses have been revoked or withdrawn in accordance with the law;\n'（四）药品生产许可证依法被吊销或者撤销的；'可被翻译为：(4) The Drug Manufacturing Certificate has been withdrawn or cancelled according to law;\n'（三）营业执照依法被吊销或者注销的；'可被翻译为：(3) The business license has been withdrawn or cancelled according to law;\n'（三）被药品监督管理部门依法作出吊销许可证、责令停产停业等处罚的；'可被翻译为：(3) those who receive the punishments such as revoking license or ordering suspension of manufacturing and operation, etc. from the drug regulatory department;\n\n根据上述已知信息，请将'（三）《药品生产许可证》被依法吊销或者缴销的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) the Drug Manufacturing Certificate is revoked or withdrawn by law;"
    },
    {
        "instruction":"已知信息：\n'国家药监局 海关总署关于增设长春空港口岸为药品进口口岸的公告'可被翻译为：Announcement of NMPA and General Administration of Customs on the Establishment of Changchun Airport as a Drug Import Port\n'国家药监局 海关总署关于增设无锡航空口岸、江阴港口岸为药品进口口岸的公告'可被翻译为：NMPA and General Administration of Customs issued the Announcement on the Setting up of Wuxi Airport and Jiangyin Port as Drug Import Ports\n'国家药监局关于印发国家药品监督管理局重点实验室管理办法的通知'可被翻译为：NMPA Issued the Administrative Measures for Key Laboratories of NMPA\n'2020年1月16日，国家药监局、海关总署和市场监管总局联合发布了《关于实施〈进口药材管理办法〉及有关事项的公告》，明确了关于首次进口药材的申请和审批、进口药材的备案和口岸检验问题。'可被翻译为：On January 16, 2020, the National Medical Products Administration, the General Administration of Customs and the State Administration for Market Regulation issued the Announcement on Implementing the Measures for the Administration of Imported Medicinal Materials and related matters to clarify issues pertaining to the application and approval of initial import, record filing and port inspection of imported medicinal materials.\n\n根据上述已知信息，请将'根据《药品进口规定》、《中国食品药品监督管理总局、海关总署关于印发新设立药品进口口岸原则和标准的通知》、《中国食品药品监督管理总局、海关总署关于印发新设立药品进口口岸评价考核方案的通知》，《国家药品监督管理局综合司关于印发《药品首次进口口岸评审标准》及其他有关规定的通知》经现场评审评估，国家药品监督管理局批准重庆市药品监督管理局关于增加化学品首次进口备案功能的申请，于2月2日发布本公告如下:'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"According to the Provisions for Drug Importation, the Notice of the China Food and Drug Administration and General Administration of Customs on Printing and Issuing Principles and Standards for the Newly Establishment of Drug Import Ports, the Notice of the China Food and Drug Administration and General Administration of Customs on Printing and Issuing the Evaluation and Assessment Scheme for the Newly Establishment of Drug Import Ports, the Notice of the Comprehensive Department of National Medical Products Administration on Printing and Issuing the Evaluation Criteria for the Ports for the First Drug Importation and other relevant regulations, upon the on-site evaluation and assessment, the NMPA has approved the application of the Chongqing Municipal Medical Products Administration for adding the filing function for the first importation of chemicals, and this Announcement was hereby issued on February 2 as follows:"
    },
    {
        "instruction":"已知信息：\n'(1) 试验样品和空白基质由专人管理。接收试验样品的房间具有足够的空间用于样品接收、清点和登记。核对运输、接收、清点、入库、储存、领取、使用、归还、销毁等原始记录，信息记录完整， 有明确的时间及操作人员签名。'可被翻译为：(1) The test sample and blank matrix are specially managed by the designated person, the room for receiving test samples has enough space for sample receipt, inventory and registration. Check the original records of transportation, receipt, inventory, stocking, storage, picking, weighing, use, return, and destruction, and the information and records are intact, with clear time and signature of the operator.\n'(3) 对照标准物质的状态和原包装标签上的信息与CoA或同等证明性文件的规定一致。'可被翻译为：(3) Status of the reference materials and information on the original packing label are consistent with the regulations specified in CoA or the equal supporting documents.\n'采用准确、可靠的方法或直接与一级标准物质相比较的方法，测量标准物质的特性量值，测量准确度满足需要的标准物质。在实验室中通常是指与一级标准物质比对后作为对照使用的工作对照品（标准品）。'可被翻译为：The characteristic quantity value of the standard substance shall be measured by accurate and reliable method or by method directly compared with the first class standard substance, and the standard substance whose measurement accuracy meets the needs shall be measured. In the laboratory, it usually refers to the working reference material (standard material) used as a control after comparison with the primary reference material.\n'4.待测样本接收、处理、检验检测、储存、归还( 如适用)、销毁等过程具有完整的记录。'可被翻译为：4. There are complete records for the process of receipt, processing, inspection and testing, storage, return (if applicable) and destruction of samples to be tested.\n\n根据上述已知信息，请将'(1) 对照标准物质由专人管理， 来源可靠且可追溯， 在分析证书(CoA) 或同等证明性文件规定的条件下储存和使用。核对运输、接收、储存、领取、称量、使用、归还、销毁等原始记录， 信息记录完整。对于不用于定量的对照标准物质， 提供能证明其适用性的文件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) The reference materials are specifically managed by the designated person, with reliable and traceable source, and are stored and used under the conditions specified by the Certificate of Analysis (CoA) or the equal supporting documents. Check the original records of transportation, receipt, storage, picking, weighing, use, return, and destruction, and the information and records are intact."
    },
    {
        "instruction":"已知信息：\n'《药品注册管理办法》已于2020年1月15日经国家市场监督管理总局2020年第1次局务会议审议通过，现予公布，自2020年7月1日起施行。'可被翻译为：The Provisions for Drug Registration, adopted at the first executive meeting of the State Administration for Market Regulation on January 15, 2020, is hereby promulgated and shall come into force as of July 1, 2020.\n'《生物制品批签发管理办法》已于2020年11月19日经国家市场监督管理总局2020年第11次局务会议审议通过，现予公布，自2021年3月1日起施行。'可被翻译为：Provisions for the Lot Release of Biological Products, deliberated and adopted at the 11th executive meeting in 2020 of State Administration for Market Regulation on November 19, 2020, is hereby promulgated and shall go into effect as of March 1, 2021.\n'《化妆品注册备案管理办法》已于2020年12月31日经国家市场监督管理总局2020年第14次局务会议审议通过，现予公布，自2021年5月1日起施行。'可被翻译为：The Provisions for Registration and Filing of Cosmetics adopted at the 14th Executive Meeting of the State Administration for Market Regulation on December 31, 2020 is hereby promulgated and shall go into effect as of May 1, 2021.\n'（2020年1月22日国家市场监督管理总局令第28号公布 自2020年7月1日起施行）'可被翻译为：(Promulgated by Decree No.28 of State Administration for Market Regulation on January 22, 2020)\n\n根据上述已知信息，请将'《药品生产监督管理办法》已于2020年1月15日经国家市场监督管理总局2020年第1次局务会议审议通过，现予公布，自2020年7月1日起施行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The Provisions for the Supervision and Administration of Drug Manufacturing, adopted at the first executive meeting of the State Administration for Market Regulation in 2020 held on January 15, 2020, is hereby promulgated and shall come into effect as of July 1, 2020."
    },
    {
        "instruction":"已知信息：\n'第十六条 本办法第十条规定情形以外的药品，口岸药品监督管理局审查全部资料无误后，准予进口备案，发出《进口药品通关单》。同时向负责检验的口岸药品检验所发出《进口药品口岸检验通知书》，附本办法第十三条规定的资料一份。'可被翻译为：Article 16 In the case of drugs other than those specified in Article 10 of the Provisions, a drug regulatory department at ports of entry shall, if all the materials pass examination, approve the importation record filing and issue the Import Drug Note. At the same time, it shall issue the Notice of Port Testing for Import Drugs to the relevant drug control institute of port with one set of the materials specified in Article 13 of the Provisions attached.\n'第十五条 本办法第十条规定情形的药品，口岸药品监督管理局审查全部资料无误后，应当向负责检验的口岸药品检验所发出《进口药品口岸检验通知书》，附本办法第十三条规定的资料一份，同时向海关发出《进口药品抽样通知书》。有关口岸药品检验进入海关监管场所抽样的管理规定，由国家食品药品监督管理局与海关总署另行制定。'可被翻译为：Article 15 In the case of drugs as specified in Article 10 of the Provisions, drug regulatory department at ports of entry shall, if all the materials pass examination, issue a Notice of Port Testing for Import Drugs to the relevant drug control institute of port with one set of materials specified in Article 13 of the Provisions attached, and shall at the same time send a Notice of Sampling for Import Drugs to the customs. The rules for sampling by drug control institute of port within customs surveillance area shall be separately formulated by the State Food and Drug Administration and the General Administration of Customs.\n'第二十条 口岸药品监督管理部门应当对备案资料的完整性、规范性进行形式审查，符合要求的，发给进口药品通关单，收回首次进口药材批件，同时向口岸药品检验机构发出进口药材口岸检验通知书，并附备案资料一份。'可被翻译为：Article 20 Drug regulatory departments of ports shall conduct a preliminary review on the completeness and normalization of filing materials. For those meeting the requirements, drug regulatory departments of ports shall issue the Drug Import Note, take back the approval document for first importation of crude drugs, and simultaneously issue the Notice for Port Testing for Importation of Crude Drugs to the drug control institutions of ports with a copy of filing materials attached.\n'第十七条 下列情形之一的进口药品，不予进口备案，由口岸药品监督管理局发出《药品不予进口备案通知书》；对麻醉药品、精神药品，口岸药品监督管理局不予发放《进口药品口岸检验通知书》：'可被翻译为：Article 17 Importation record filing of drugs to be imported shall not be approved in any of the following cases, and the drug regulatory department at ports of entry shall issue the Notice of Non-Acceptance of Drug Importation record filing; in the case of narcotic drugs and psychotropic substances, the drug regulatory department at ports of entry shall not issue the Notice of Port Testing for Import Drugs:\n\n根据上述已知信息，请将'对麻醉药品、精神药品，口岸药品监督管理局审查全部资料无误后，应当只向负责检验的口岸药品检验所发出《进口药品口岸检验通知书》，附本办法第十三条规定的资料一份，无需办理《进口药品通关单》。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In the case of narcotic drugs and psychotropic substances, a drug regulatory department at ports of entry shall, if all the materials pass examination, only issue a Notice of Port Testing for Import Drugs to the relevant drug control institute of port with one set of the materials specified in Article 13 of the Provisions attached, where no Import Drug Note is required."
    },
    {
        "instruction":"已知信息：\n'标准操作规程 （SOP）：经过批准的程序，给出执行操作的指令，不一定是某个具体的产品或物料，可能是更为通用的（例如设备的操作、维护和清洁、设施的验证和清洁、环境控制、取样和检查）。特定的标准操作规程可能会被用于补充产品专用的主生产文件和批生产文件'可被翻译为：standard operating procedure (SOP). An authorized written procedure giving instructions for performing operations, not necessarily specific to a given product or material , but of a more general nature (for example, operation of equipment, maintenance and cleaning, validation, cleaning of premises and environmental control, sampling and inspection). Certain standard operating procedures may be used to supplement product-specific master and batch production documentation.\n'第七十二条 应当建立设备使用、清洁、维护和维修的操作规程，并保存相应的操作记录。'可被翻译为：Article 72: Procedures for the use, cleaning, maintenance and repair of the equipment should be established, and their operation records should be retained.\n'（四）检验应当有书面操作规程，规定所用方法、仪器和设备，检验操作规程的内容应当与经确认或验证的检验方法一致。'可被翻译为：4. Written operation procedures for testing should be in place to specify testing methods, apparatus and instruments to be used, and the content of the procedures should be consistent with the verified or validated testing methods.\n'有效地实施和完成某一临床试验中每项工作所拟定的标准和详细的书面规程，或经批准用以指示操作的通用性文件或管理办法。'可被翻译为：3. The effective implementation and completion of standards and detailed written procedures for each element of a clinical trial, or of approved generic documents or administrative procedures for directing operations.\n\n根据上述已知信息，请将'经批准用来指导设备操作、维护与清洁、验证、环境控制、取样和检验等药品生产活动的通用性文件，也称标准操作规程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Approved documents to guide operations related to the manufacture of drugs, such as equipment operation, maintenance and cleaning, validation, environmental control, sampling, testing, and etc. Also refer to as standard operating procedure (SOP)."
    },
    {
        "instruction":"已知信息：\n'第二十九条 列入国家药品标准的药品名称为药品通用名称。已经作为药品通用名称的，该名称不得作为药品商标使用。'可被翻译为：Article 29 A drug name listed in the national drug standards is an adopted name in China and may not be used as a trademark.\n'申报药品拟使用的药品通用名称，已列入国家药品标准或者药品注册标准，药品审评中心在审评过程中认为需要核准药品通用名称的，应当通知药典委核准通用名称并提供相关资料，药典委核准后反馈药品审评中心。'可被翻译为：Where the adopted name to be used for a drug under application has been included in the national drug standards or drug registration specifications, and the CDE, during review, considers it necessary to examine and approve the adopted name, the CPC shall be notified to examine and approve the adopted name and relevant information shall be provided. After examination and approval, the CPC shall give feedback to the CDE.\n'第三十七条 申报药品拟使用的药品通用名称，未列入国家药品标准或者药品注册标准的，申请人应当在提出药品上市许可申请时同时提出通用名称核准申请。药品上市许可申请受理后，通用名称核准相关资料转药典委，药典委核准后反馈药品审评中心。'可被翻译为：Article 37 Where the adopted name to be used for a drug under application has not been included in the national drug standards or drug registration specifications, the applicant shall file the adopted name examination and approval application when submitting the drug marketing authorization application. After the drug marketing authorization application has been accepted, dossiers related to the adopted name examination and approval shall be forwarded to the CPC. After examination and approval, the CPC shall give feedback to the CDE.\n'向世界卫生组织申请，并获得核准的药品正式名称，全球通用的唯一性名称。'可被翻译为：Application to the World Health Organization and approval of the official name of the drug, universal unique name.\n\n根据上述已知信息，请将'列入国家药品标准的药品名称，为药品通用名称。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A drug name included in the national drug standard shall be the generic name of the drug."
    },
    {
        "instruction":"已知信息：\n'应有关于取消人员在洁净室工作或取消人员无监督进入洁净室资格的系统，基于的依据包括持续评估和\/或识别该人员监测计划的不良趋势和\/或参与的 APS 失败。一旦取消资格，应完成再培训和再次资质确认后才能允许该操作人员进一步参与无菌操作。对于进入 B 级洁净室或执行 A 级干预的操作人员，再次资质确认应包括是否参与成功的 APS。'可被翻译为：There should be systems in place for the disqualification of personnel from working in or given unsupervised entry into cleanrooms that is based on aspects including ongoing assessment and\/or identification of an adverse trend from the personnel monitoring programme and\/or after being implicated in a failed APS. Once disqualified, retraining and requalification should be completed before permitting the operator to have any further involvement in aseptic practices. For operators entering grade B cleanrooms or performing intervention into grade A, this requalification should include consideration of participation in a successful APS.\n'人员—无菌技术的培训程序、更衣程序、清洁和维护的人员进入 ISO 5 级区域的培训；手套和洁净服监测程序'可被翻译为：8. Personnel- training procedures for aseptic technique, gowning procedures, cleaning and maintenance personnel training for ISO 5 room entry; glove and garment monitoring procedures\n'未经资质确认的人员不应进入 B 级洁净室或 A 级（动态）。如果在例外情况下需要进入，生产商应制定书面程序，概述未经资质确认的人员被带入 B 级区和 A 级区的流程。生产商经批准的人员应在未经资质确认人员的活动期间对其进行监督，并应评估这些活动对该区域洁净度的影响。这些人员的进入应按照 PQS进行评估和记录。'可被翻译为：Unqualified personnel should not enter grade B cleanrooms or grade A in operation. If needed in exceptional\ncases, manufacturers should establish written procedures outlining the process by which unqualified personnel are\nbrought into the grade B and A areas. An authorized person from the manufacturer should supervise the\nunqualified personnel during their activities and should assess the impact of these activities on the cleanliness of\nthe area. Access by these persons should be assessed and recorded in accordance with the PQS.\n'进入 A 级和 B 级区的人员应接受无菌更衣和无菌行为的培训。应通过评估和至少每年定期再评估来确认符合无菌更衣程序，并应包括目检和微生物评估（使用戴手套的手指、前臂、胸部和头罩（口罩\/额头）等监测位置。预期限度参见 9.30 节）。对于正在或即将进行无菌操作的 A 级和 B 级区，无监督进入应仅限于经过适当资质确认、已通过更衣评估并参与过成功的 APS 的人员。'可被翻译为：The personnel accessing grade A and B areas should be trained for aseptic gowning and aseptic behaviours.\nCompliance with aseptic gowning procedures should be confirmed by assessment and periodic reassessment at\nleast annually, and should involve both visual and microbial assessment (using monitoring locations such as\ngloved fingers, forearms, chest and hood (facemask \/ forehead). See paragraph 9.30 for the expected limits). The\nunsupervised access to the grade A and grade B areas where aseptic operations are or will be conducted should be\nrestricted to appropriately qualified personnel, who have passed the gowning assessment and have participated in\na successful APS.\n\n根据上述已知信息，请将'所有人员，包括执行清洁、维护、监控以及进入洁净室的人员，均应定期接受无菌产品正确生产相关纪律的培训、更衣确认和评估。该培训应包括微生物学和卫生学的基本要素，特别关注洁净室实践、污染控制、无菌技术和无菌产品的保护（对于进入 B 级洁净室和\/或干预 A 级的操作人员）以及产品非无菌对患者的潜在安全性影响。培训水平应基于人员职能以及工作区域的关键程度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"All personnel including those performing cleaning, maintenance, monitoring and those that access cleanrooms\nshould receive regular training, gowning qualification and assessment in disciplines relevant to the correct manufacture of sterile products. This training should include the basic elements of microbiology and hygiene, with a specific focus on cleanroom practices, contamination control, aseptic techniques and the protection of sterile products (for those operators entering the grade B cleanrooms and\/or intervening into grade A) and the potential safety implications to the patient if the product is not sterile. The level of training should be based on the criticality of the function and area in which the personnel are working."
    },
    {
        "instruction":"已知信息：\n'工艺资格将实际的设施、公用设施、设备(每一个现在都是合格的)和经过培训的人员与商业制造工艺、控制程序和部件相结合，以生产商业批次;确认工艺设计，并证明商业制造工艺按预期执行。'可被翻译为：Process qualification combines the actual facility, utilities, equipment (each now qualified) and the trained personnel with the commercial manufacturing process, control procedures and components to produce commercial batches; confirms the process design and demonstrates that the commercial manufacturing process performs as expected.\n'测量样品从制造过程中转移，并可能返回到工艺流。'可被翻译为：Measurement where the sample is diverted from the manufacturing process, and may be returned to the process stream.\n'允许在经验证的工艺参数内操作。'可被翻译为：Allow operation within validated process parameters.\n'控制任何产品或工艺(包括产品或工艺知识)及其文件和专业知识转让的逻辑程序。技术转让可能涉及开发、制造或测试场所。'可被翻译为：A logical procedure that controls the transfer of any product or process, including product or process knowledge, together with its documentation and professional expertise. Technology transfer may involve development, manufacturing or testing sites.\n\n根据上述已知信息，请将'(ii)制造工艺的关键步骤和工艺重大变更应进行验证；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(ii) Critical steps of manufacturing processes and significant changes to the process are validated;"
    },
    {
        "instruction":"已知信息：\n'第八条 注册人、备案人在境外的，应当指定我国境内的企业法人作为境内责任人。境内责任人应当履行以下义务：'可被翻译为：Article 8 Overseas registrants and filing persons shall designate an enterprise legal person within the territory of China as the domestic responsible person. The domestic responsible person shall fulfill the following obligations:\n'前款所述医疗器械生产企业，是指境内医疗器械产品注册人或者备案人、进口医疗器械的境外制造厂商在中国境内指定的代理人。'可被翻译为：The medical device manufacturers mentioned in the preceding paragraph refer to the registrants or filing entities of the domestic medical device products, and the agents appointed by the overseas manufacturer of imported medical devices within the territory of China.\n'第十四条 境外申请人或者备案人应当通过其在中国境内设立的代表机构或者指定中国境内的企业法人作为代理人，配合境外申请人或者备案人开展相关工作。'可被翻译为：Article 14 An overseas applicant or filing entity shall conduct related work with the support of its representative office established in China or an enterprise legal person in China designated by it as its agent.\n'第十六条 境外申请人或者备案人应当通过其在中国境内设立的代表机构或者指定中国境内的企业法人作为代理人，配合境外申请人或者备案人开展相关工作。'可被翻译为：Article 16 An overseas applicant or filing entity shall conduct related work with the support of its representative office established in China or an enterprise legal person in China designated by it as its agent.\n\n根据上述已知信息，请将'第六十一条  进口医疗器械注册人、备案人应当指定我国境内企业法人作为代理人，代理人应当协助注册人、备案人履行医疗器械监督管理条例和本办法规定的义务。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 61 The registrant or filing entity of imported medical devices shall designate the domestic enterprise legal person as the agent, who shall assist the registrant or filing entity to fulfill the obligations prescribed in the Regulations on Supervision and Administration of Medical Devices and these Provisions."
    },
    {
        "instruction":"已知信息：\n'（八）企业产品抽检、监督检查、投诉举报等发现问题的整改落实情况；'可被翻译为：(8) rectification implementation condition of problems discovered from sample testing of the enterprise’s products, supervision and inspection, complaint report, etc.;\n'（二）药品生产企业接受监督检查及整改落实情况；'可被翻译为：(2) information on the inspections that have been made to the drug manufacturer and the conduction of corrective actions;\n'第五十八条  药品监督管理部门应当根据监督检查、产品抽检、不良事件监测、投诉举报、行政处罚等情况，定期开展风险会商研判，做好医疗器械质量安全隐患排查和防控处置工作。'可被翻译为：Article 58 The drug regulatory departments shall, in accordance with the conditions of supervision and inspection, sample testing of products, monitoring of adverse events, complaint reporting and administrative penalty, etc., carry out risk analysis and assessment through consultation regularly, and make proper investigation and prevention and control of potential medical device quality and safety hazards.\n'跟踪检查可以对企业提交的整改报告进行书面审查，也可以对企业的问题整改、责任落实、纠正预防措施等进行现场复查。'可被翻译为：Follow-up inspection could make written review of the rectification report submitted by the enterprise, or make on-site review of the enterprise’s rectification of problems, implementation of responsibilities, and corrective and preventive measures, etc.\n\n根据上述已知信息，请将'（六）企业产品抽检、监督检查、投诉举报等发现问题的整改落实情况；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(6) rectification implementation condition of problems discovered from sample testing of the enterprise’s products, supervision and inspection, complaint report, etc.;"
    },
    {
        "instruction":"已知信息：\n'或者在必要时，实施ORS实验室修订后的医疗器械内毒素萃取和分析。'可被翻译为：Alternatively, if deemed necessary, perform the ORS laboratory modified extraction and analysis of Endotoxin from Medical Devices:\n'ORS 实验室到要做的分析准备工作'可被翻译为：E. Analysis Preparation conducted by ORS laboratory\n'如果这样做会降低可用于无菌测试的单元数量，该数量低于USP要求或ORS法规要 求，当有可行的替代方案时，则不应该牺牲产品单元作为系统控制。如果使用产品 单元将会使得子样品减少至USP或ORS法规所要求数量以下，则分析实验室应尽可 能使用除样品之外的其他物料进行控制。'可被翻译为：When there are viable alternatives, a product unit should not be sacrificed for use as a system control if this will reduce the number of units available for sterility testing below USP requirements or ORS policy requirements, except as provided in the preceding paragraph. If using a product unit would reduce the subsamples examined below the number required by USP or ORS policy, the analyzing laboratory should prepare a control from other material than a unit of the sample product whenever possible.\n'ORS实验室起草了一份协作方法，用于从医疗器械中萃取内毒素，必要时可使用之。 应由责任实验室对最终版本的分析方法进行确认。方便起见，将ORS实验室方案总结 如下：'可被翻译为：A collaborated method prepared by an ORS laboratory is available for extraction of endotoxin from devices and may be used if necessary. Analytical verification of the final version should be conducted by the responsible laboratory. The ORS laboratory protocol is summarized below for convenience.\n\n根据上述已知信息，请将'本文件中的说明是 ORS 分析人员的指南。分析人员在执行与药品和医疗器械产品测试相关 的分析时，应使用在所有 ORS 实验室以及 PMM 中标准化和统一的程序和工作表（如有）。 当需要修改或有所偏离时，应根据实验室的质量管理体系完成文件记录。一般来说，这些变化应该源于诸如新产品、异常产品或特殊情况等情况。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The instructions in this document are guidelines for ORS analysts. When available, analysts should use procedures and worksheets that are standardized and harmonized across all ORS labs, along with the PMM, when performing analyses related to product testing of pharmaceuticals and medical devices. When changes or deviations are necessary, documentation should be completed per the laboratory’s Quality Management System. Generally, these changes should originate from situations such as new products, unusual products, or unique situations."
    },
    {
        "instruction":"已知信息：\n'从混合物中分离出某一组分。'可被翻译为：Separate a component from the mixture.\n'泾类基质'可被翻译为：hydrocarbon base\n'饱和'可被翻译为：saturation\n'芳香挥发性药物的饱和或近饱和水溶液。'可被翻译为：A saturated or nearly saturated aqueous solution of aromatic volatile drugs.\n\n根据上述已知信息，请将'从石油中得到的各种烽的混合物。其中大部分属于饱和泾。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A mixture of various polymers obtained from petroleum. Most of which belong to saturated Jing."
    },
    {
        "instruction":"已知信息：\n'在透析过程中通过半透膜的物质。常含有在溶液中容易扩散的物质。'可被翻译为：A substance that passes through a semi-permeable membrane during dialysis. Often containing a substance that diffuses easily in solution.\n'当溶液与纯溶剂（或两种浓度不同的溶液）在半透膜隔开的情况下，溶剂（或较稀溶液中的溶剂）通过半透膜向溶液（或较浓溶液）扩散的现象。'可被翻译为：The diffusion of a solvent (or a solvent in a dilute solution) through a semi-permeable membrane into a solution (or a concentrated solution) when the solution is separated from the pure solvent (or two solutions of different concentrations) by a semi-permeable membrane.\n'芳香挥发性药物的饱和或近饱和水溶液。'可被翻译为：A saturated or nearly saturated aqueous solution of aromatic volatile drugs.\n'从溶液或气相中被吸附至另一物质表面的物质。'可被翻译为：A substance adsorbed from a solution or gas phase to the surface of another substance.\n\n根据上述已知信息，请将'含有药物或芳香物质的浓糖水溶液。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An aqueous solution of concentrated sugar containing a medicinal or aromatic substance."
    },
    {
        "instruction":"已知信息：\n'接触碟限度适用于 A 级和 B 级区内的设备、房间和洁净服表面。C 级和 D 级区通常不需要进行常规工作服监测，具体取决于该区域的功能。'可被翻译为：(b) Contact plate limits apply to equipment, room and gown surfaces within the grade A and grade B areas. Routine\ngown monitoring is not normally required for grade C and D areas, depending on their function.\n'洁净区：一种有明确的粒子和微生物洁净度标准的区域，通常包含数个相连的洁净室。'可被翻译为：Clean area - An area with defined particle and microbiological cleanliness standards usually containing a number of joined cleanrooms.\n'洁净区与非洁净区之间、不同级别洁净区之间的压差应当不低于10帕斯卡。必要时，相同洁净度级别的不同功能区域（操作间）之间也应当保持适当的压差梯度。'可被翻译为：The air pressure differential between clean and non-clean areas, or between differently classified clean areas should not be less than 10Pa. When necessary, an appropriately-graded pressure differential should be maintained between rooms of different functions (operation rooms) with the same cleanliness level.\n'人员气锁：用于人员进入的洁净级别越来越高的区域（例如从 D 级区到 C 级区到 B 级区）。一般而言，洗手设施应仅设置在更衣室的第一阶段，且不能设置在直接进入 B 级区的更衣室中。'可被翻译为：Personnel airlocks: Areas of increasing cleanliness used for entry of personnel (e.g. from the grade D area to the grade C area to the grade B area). In general hand washing facilities should be provided only in the first stage of the changing room and not be present in changing rooms directly accessing the grade B area.\n\n根据上述已知信息，请将'口服液体和固体制剂、腔道用药（含直肠用药）、表皮外用药品等非无菌制剂生产的暴露工序区域及其直接接触药品的包装材料最终处理的暴露工序区域，应当参照“无菌药品”附录中D级洁净区的要求设置，企业可根据产品的标准和特性对该区域采取适当的微生物监控措施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The exposed processing areas for oral liquid and solid preparations, drugs applied through tract (including recta), epidermal products, and other non-sterile products, as well as the exposed processing areas for handling immediate packaging materials should be designed as Grade D according to requirements in Annex 1 of GMP for sterile products. The manufacturer may take appropriate measures to monitor the microorganism, in accordance with product specifications and property."
    },
    {
        "instruction":"已知信息：\n'第十八条 药品生产、经营企业和医疗机构应当建立并保存药品不良反应报告和监测档案。'可被翻译为：Article 18 Drug manufacturers, distributors and medical institutions shall establish and maintain archives for ADR reporting and monitoring.\n'（二）未按照规定每年对直接接触药品的工作人员进行健康检查并建立健康档案；'可被翻译为：(2) failing to carry out health examination of personnel in direct contact with drugs each year and establish health achieves; or\n'（四）未按照规定进行药品不良反应监测的；'可被翻译为：(4) the adverse drug reaction monitoring is not conducted in accordance with regulations;\n'（二）接收或者购进疫苗时未按照规定索取并保存相关证明文件、温度监测记录；'可被翻译为：(2) failing to obtain and keep relevant certification documents and temperature monitoring records when receiving or purchasing vaccines;\n\n根据上述已知信息，请将'（二）未建立和保存药品不良反应监测档案的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(II) Having not established and maintained achieves for ADR monitoring;"
    },
    {
        "instruction":"已知信息：\n'细菌产生对抗菌药物不敏感的现象，产生原因是细菌在自身生存过程中的一种特殊表现形式。根\n据发生原因，耐药性可分为固有耐药和获得性耐药。'可被翻译为：The phenomenon where bacteria develop insensitivity to antimicrobial drugs is known as antimicrobial resistance (AMR). The reasons behind this development are special manifestations in the bacteria's natural survival process. Antimicrobial resistance can be classified into intrinsic resistance and acquired resistance based on the cause.\n'细菌与抗生素短暂接触，当药物浓度下降至低于最低抑菌浓度或消除后，细菌的生长仍受到持续抑制的效应。'可被翻译为：Bacteria are in short contact with antibiotics, and when the drug concentration is reduced to below the minimum inhibitory concentration or after elimination, the growth of bacteria is still subjected to sustained inhibitory effects.\n'感染细菌、真菌、放线菌或螺旋体等微生物的细菌病毒的总称。'可被翻译为：A general term for bacterial viruses that infect microorganisms such as bacteria, fungi, actinomyces, or spirochaetes.\n'细菌产生的、存在于细菌菌体内的毒素。是主要的致热源。'可被翻译为：A toxin produced by bacteria and present in bacteria. It is a major source of heat.\n\n根据上述已知信息，请将'长期应用广谱抗生素后，使敏感细菌受到抑制，不敏感细菌趁机在体内大量繁殖所造成的多种以上的病原微生物感染。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"After long-term application of broad-spectrum antibiotics, the sensitive bacteria are inhibited, and the insensitive bacteria take the opportunity to multiply in the body, resulting in more than a variety of pathogenic microbial infection."
    },
    {
        "instruction":"已知信息：\n'2019年8月26日，经第十三届全国人大常委会第十二次会议修订通过，修订后的《中华人民共和国药品管理法》（以下称药品管理法）自2019年12月1日起施行。国家药监局正在抓紧开展配套规章、规范性文件和技术指南的制修订工作，并将按程序陆续发布。现就贯彻实施新修订的药品管理法有关事项公告如下：'可被翻译为：Revised and adopted by the Twelfth Session of the Standing Committee of the 13th National People's Congress on August 26,2019, the revised Drug Administration Law of the People's Republic of China(hereinafter referred to as DAL) shall be implemented as from December 1,2019. NMPA is stepping up work on the development, formulation and revision of supporting regulations, normative documents and technical guidelines, which will be released in accordance with procedures. We hereby announce the issues pertaining to the implementation of the newly revised DALas follows:\n'医疗器械违法行为发生在2021年6月1日以前的，适用修订前的《条例》，但依据新《条例》认为不违法或者处罚较轻的，适用新《条例》。违法行为发生在2021年6月1日以后的，适用新《条例》。'可被翻译为：Where an illegal act of medical device occurs before June 1, 2021, the Regulations before revision shall apply. However, if the act is not considered illegal or the punishment is relatively light according to the new Regulations, the new Regulations shall apply. Where an illegal act occurs after June 1, 2021, the new Regulations shall apply.\n'一、新《办法》发布后，与新《办法》相关的规范性文件、技术指导原则等（以下简称新《办法》及其相关文件）将按程序陆续发布。新《办法》及其相关文件已作出规定和要求的，从其规定；无新规定和要求的，按照现行的有关规定和要求执行。'可被翻译为：1. After the release of the new Provisions, the normative documents and technical guidelines related to the new Provisions (hereinafter collectively referred to as the new Provisions and related documents) will be issued as per procedures. New stipulations and requirements made in the new Provisions shall prevail; and otherwise, the existing relevant stipulations and requirements shall apply.\n'2020年3月31日，国家药监局发布了《关于实施新修订的<药品生产监督管理办法>有关事项的公告》（2020年 第47号），内容如下：'可被翻译为：On March 31, 2020, NMPA issued the Announcement on Issues Pertaining to the Implementation of the Newly Revised Provisions for the Supervision and Administration of Drug Production (No. 47 of 2020), which reads as follows:\n\n根据上述已知信息，请将'新修订的《医疗器械监督管理条例》（国务院令第739号，以下简称新《条例》），将于2021年6月1日起施行。国家药监局正在组织制修订配套规章、规范性文件和技术指导原则等，将按照程序陆续发布。现就贯彻实施新《条例》有关事项公告如下：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The revised Regulations for the Supervision and Administration of Medical Devices (State Council Order No. 739, hereinafter referred to as the Regulations) will be implemented as of June 1, 2021. NMPA is organizing the formulation and revision of supporting regulations, normative documents and technical guidances, which will be released one after another in accordance with procedures. The matters related to implementation of the new Regulations are hereby announced as follows:"
    },
    {
        "instruction":"已知信息：\n'《生物制品批签发管理办法》已于2020年11月19日经国家市场监督管理总局2020年第11次局务会议审议通过，现予公布，自2021年3月1日起施行。'可被翻译为：Provisions for the Lot Release of Biological Products, deliberated and adopted at the 11th executive meeting in 2020 of State Administration for Market Regulation on November 19, 2020, is hereby promulgated and shall go into effect as of March 1, 2021.\n'《药品注册管理办法》已于2020年1月15日经国家市场监督管理总局2020年第1次局务会议审议通过，现予公布，自2020年7月1日起施行。'可被翻译为：The Provisions for Drug Registration, adopted at the first executive meeting of the State Administration for Market Regulation on January 15, 2020, is hereby promulgated and shall come into force as of July 1, 2020.\n'《药品生产监督管理办法》已于2020年1月15日经国家市场监督管理总局2020年第1次局务会议审议通过，现予公布，自2020年7月1日起施行。'可被翻译为：The Provisions for the Supervision and Administration of Drug Manufacturing, adopted at the first executive meeting of the State Administration for Market Regulation in 2020 held on January 15, 2020, is hereby promulgated and shall come into effect as of July 1, 2020.\n'《医疗器械注册管理办法》已于2014年6月27日经国家食品药品监督管理总局局务会议审议通过，现予公布，自2014年10月1日起施行。'可被翻译为：The Provisions for Medical Device Registration, adopted at the executive meeting of China Food and Drug Administration on June 27, 2014, is hereby promulgated and shall be effective as of October 1, 2014.\n\n根据上述已知信息，请将'《化妆品注册备案管理办法》已于2020年12月31日经国家市场监督管理总局2020年第14次局务会议审议通过，现予公布，自2021年5月1日起施行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The Provisions for Registration and Filing of Cosmetics adopted at the 14th Executive Meeting of the State Administration for Market Regulation on December 31, 2020 is hereby promulgated and shall go into effect as of May 1, 2021."
    },
    {
        "instruction":"已知信息：\n'（三）三级召回：使用该医疗器械引起危害的可能性较小但仍需要召回的。'可被翻译为：(3) Class III recalls: the use of the medical device is less likely to cause hazard but the device still needs to be recalled.\n'（一）一级召回：使用该药品可能引起严重健康危害的;'可被翻译为：(Ⅰ)  Class 1 recall: Use of the drug may cause serious harms to health;\n'（二）二级召回：使用该药品可能引起暂时的或者可逆的健康危害的;'可被翻译为：(Ⅱ)  Class 2 recall: Use of the drug may cause temporary or reversible harms to health;\n'（一）一级召回：使用该医疗器械可能或者已经引起严重健康危害的；'可被翻译为：(1) Class I recalls: the use of the medical device may cause or has caused serious hazards to health;\n\n根据上述已知信息，请将'（三）三级召回：使用该药品一般不会引起健康危害，但由于其他原因需要收回的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(Ⅲ)  Class 3 recall: Use of the drug usually will not cause any harm to health, but the drug has to be recalled due to other reasons."
    },
    {
        "instruction":"已知信息：\n'发布本指南的法律背景：2001\/83\/EC号指令第47条——共同体人用药品规范，以及法规2019\/6——共同体兽用药品规范。本文件为欧盟指令（EU）2017\/1572中的人用药品、指令91\/412\/EEC中的兽用药品，委员会委托条例（EU）2017\/1569中的人用研究用药品提供了药品生产质量管理规范（GMP）原则和指南的技术指导，并补充了法规（EU）536\/2014临床研究中的检查安排。'可被翻译为：Legal context for publishing the detailed guidelines:Article 47 of Directive 2001\/83\/EC on the Community  code relating to medicinal products for human use and Regulation 2019\/6 on the Community code relating to veterinary medicinal products. This document provides technical guidance on the principles and guidelines of good manufacturing practice (GMP) for medicinal products as laid down in Commission Directive (EU) 2017\/1572 for medicinal products for human use,Directive 91\/412\/EEC for veterinary use,and Commission Delegated Regulation (EU)2017\/1569 for investigational medicinal products for human useand arrangements for inspections supplementing Regulation (EU)No536\/2014 on clinical trials.\n'第三十五条 临床试验用药物应当在符合《药品生产质量管理规范》的车间制备。制备过程应当严格执行《药品生产质量管理规范》的要求。'可被翻译为：Article 35 Drugs used for clinical trials shall be manufactured in facilities in compliance with the Good Manufacturing Practice for Pharmaceutical Products (GMP). The manufacturing process shall strictly meet the requirements of the GMP.\n'这是监管机构之间在人用或兽用医疗产品良好生产规范领域的一项不具约束力的非正式合作安排。'可被翻译为：This is a non-binding, informal cooperative arrangement between regulatory authorities in the field of good manufacturing practices of medical products for human or veterinary use.\n'药品生产质量管理规范'可被翻译为：GMP：Good Manufacturing Practice\n\n根据上述已知信息，请将'第4卷欧盟人用和兽用药品生产质量管理规范指南'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for\nHuman and Veterinary Use"
    },
    {
        "instruction":"已知信息：\n'药师应临床科室或医务部门的邀请，出于诊疗需要对患者的药物治疗方案进行优化和药学监护的\n药学服务。'可被翻译为：Pharmacists provide pharmaceutical services by optimizing medication treatment plans and offering pharmaceutical monitoring when invited by clinical departments or medical administrations for the purpose of patient care.\n'医疗机构在给患者提供诊疗服务同时，就给患者提供的合理、安全用药方案而加收的专业技术服务费用，也包含药品在用于患者前的运输储存等物耗成本。'可被翻译为：Medical institutions, while providing diagnosis and treatment services to patients, charge additional fees for professional and technical services to provide patients with reasonable and safe drug use plans, including the cost of material consumption such as transportation and storage of drugs before they are used in patients.\n'为保证用药安全有效，由药师建立的患者治疗或预防疾病进行药物治疗过程的记录。包括为影响患者预后结果的专业活动（方案制定，实施，疗效、不良反应观察，评价、调整，患者教育）等内容。有纸质和电子两种形式。'可被翻译为：A record established by a pharmacist of a patient's treatment or prevention of a disease in order to ensure the safety and effectiveness of a drug. It includes professional activities that affect the outcome of the patient's prognosis (protocol development, implementation, efficacy, adverse reaction observation, evaluation, adjustment, patient education). Available in both paper and electronic form.\n'多学科诊疗'可被翻译为：multi-disciplinary treatment（mdt）\n\n根据上述已知信息，请将'由多个专业的专家组成团队协作诊疗的工作模式，由来自不同学科的专家定期在一起通过会议的\n形式，全面考虑患者的具体情况，制定适合患者的诊疗方案，进而由某一科室或某几个科室联合执行\n诊疗方案。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A collaborative diagnostic and treatment model involves a team of experts from various professions. These experts, representing different disciplines, regularly convene through meetings to comprehensively consider the patient's specific situation. They collaboratively devise a tailored diagnostic and treatment plan. Subsequently, one or several departments jointly execute the implemented plan."
    },
    {
        "instruction":"已知信息：\n'第三条  医疗器械上市许可持有人（以下简称持有人），应当具有保证医疗器械安全有效的质量管理能力和相应责任能力，建立医疗器械不良事件监测体系，向医疗器械不良事件监测技术机构（以下简称监测机构）直接报告医疗器械不良事件。由持有人授权销售的经营企业、医疗器械使用单位应当向持有人和监测机构报告医疗器械不良事件。'可被翻译为：Article 3 Medical device marketing authorization holders (hereinafter referred to as MAHs) shall possess the capacities of quality management and corresponding responsibilities to ensure that the medical devices are safe and effective, establish medical device adverse event monitoring system and directly report medical device adverse events to medical device adverse event monitoring agencies (hereinafter referred to as monitoring agencies). Distributing enterprises and user facility of medical device authorized by MAHs shall report medical device adverse events to MAHs and monitoring agencies.\n'创新医疗器械持有人应当在首个注册周期内，每半年向国家监测机构提交产品不良事件监测分析评价汇总报告。国家监测机构发现医疗器械可能存在严重缺陷的信息，应当及时报国家药品监督管理局。'可被翻译为：MAHs of innovative medical devices shall, within the first registration cycle, submit analysis, evaluation and summary report of product adverse event monitoring to national monitoring agency every half a year. In case of identifying any possible serious defects of a medical device, national monitoring agency shall promptly report to National Medical Products Administration.\n'第十二条  国家监测机构负责接收持有人、经营企业及使用单位等报告的医疗器械不良事件信息，承担全国医疗器械不良事件监测和再评价的相关技术工作；负责全国医疗器械不良事件监测信息网络及数据库的建设、维护和信息管理，组织制定技术规范和指导原则，组织开展国家药品监督管理局批准注册的医疗器械不良事件相关信息的调查、评价和反馈，对市级以上地方药品监督管理部门批准注册或者备案的医疗器械不良事件信息进行汇总、分析和指导，开展全国范围内影响较大并造成严重伤害或者死亡以及其他严重后果的群体医疗器械不良事件的调查和评价。'可被翻译为：Article 12 National monitoring agencies shall be responsible for receiving medical device adverse events information reported by MAHs, distributing enterprises and user facility, assume relevant technical works related to medical device adverse event monitoring and re-evaluation nationwide; be responsible for the construction, maintenance and information management of national network and database of monitoring information of medical device adverse event, organize to develop technical specifications and guidelines, organize the investigation, evaluation and feedback of relevant adverse events information of the medical devices approved by the NMPA to be registered, summarize, analyze and guide relevant adverse events information of the medical devices approved by local drug regulatory departments above municipal level to be registered or filed, and investigate and evaluate group adverse events of medical device that have great influence nationwide and cause severe injuries or death and other serious consequences.\n'第十三条  省、自治区、直辖市药品监督管理部门指定的监测机构（以下简称省级监测机构）组织开展本行政区域内医疗器械不良事件监测和再评价相关技术工作；承担本行政区域内注册或者备案的医疗器械不良事件的调查、评价和反馈，对本行政区域内发生的群体医疗器械不良事件进行调查和评价。'可被翻译为：Article 13 The monitoring agencies designated by the drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government (hereinafter referred to as provincial monitoring agencies) shall organize the technical works related to medical device adverse event monitoring and re-evaluation within their respective administrative regions; assume the investigation, evaluation and feedback of adverse events of the medical devices registered or filed within their respective administrative regions, and investigate and evaluate group adverse events of medical device that occurs within their respective administrative regions.\n\n根据上述已知信息，请将'国家药品监督管理局指定的监测机构（以下简称国家监测机构）负责对收集到的医疗器械不良事件信息进行统一管理，并向相关监测机构、持有人、经营企业或者使用单位反馈医疗器械不良事件监测相关信息。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Monitoring agencies designated by the NMPA (hereinafter referred to as national monitoring agencies) shall be responsible for unified management of all the information of medical device adverse events collected and provide feedback of relevant monitoring information of medical device adverse events to relevant monitoring agencies, MAHs, distributing enterprises or user facilities."
    },
    {
        "instruction":"已知信息：\n'药物与油脂性或水溶性基质混合制成的均匀的半固体外用制剂。'可被翻译为：A uniform semi-solid preparation for external use made by mixing a drug with an oily or water-soluble substrate.\n'第一百八十六条 应当建立编制药品批号和确定生产日期的操作规程。每批药品均应当编制唯一的批号。除另有法定要求外，生产日期不得迟于产品成型或灌装（封）前经最后混合的操作开始日期，不得以产品包装日期作为生产日期。'可被翻译为：Article 186: Operation procedures should be established to determine the manufacturing date and batch number. Each batch of product should have a unique batch number. Unless stipulated in other regulations, the manufacturing date should be no later than the commencing date of the last blending operation for formulation or filling (sealing) of the product. The packaging date of the product should not be used as its manufacturing date.\n'同一原料(如来自同一批次)为均质原料，不同原料为非均质原料。'可被翻译为：A material is regarded as homogeneous when it is all of the same origin (e.g. from the same batch) and as non-homogeneous when it is of differing origins.\n'1.使用申请中规定的生产设施中的生产设备按生产规模生产的一批原料药或制剂。\n2.在申请中指定的生产设施中使用生产设备按生产规模生产的一批API或FPP。'可被翻译为：1.A batch of an active pharmaceutical ingredient or finished pharmaceutical product manufactured at production scale by using production equipment in a production facility as specified in the application.\n2.A batch of an API or FPP manufactured at production scale by using production equipment in a production facility as specified in the application.\n\n根据上述已知信息，请将'例如：口服或外用的固体、半固体制剂在成型或分装前使用同一台混合设备一次混合所生产的均质产品为一批；口服或外用的液体制剂以灌装（封）前经最后混合的药液所生产的均质产品为一批。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For example, the homogeneous product that solid or semi-solid preparations for oral or topical use are produced within the same blender by one blending prior to molding or filling should be regarded as one batch. The homogeneous product that liquid preparations for oral or topical use are produced by final mixing prior to filling (sealing) should be regarded as one batch."
    },
    {
        "instruction":"已知信息：\n'第一百一十三条 药品监督管理部门发现药品违法行为涉嫌犯罪的，应当及时将案件移送公安机关。'可被翻译为：Article 113 Upon discovery of illegal behaviors related to drugs which allegedly constitutes a criminal offense, the drug regulatory departments shall promptly forward the case to the public security authorities.\n'第三十二条 法律、行政法规对药品网络销售违法行为的处罚有规定的，依照其规定。药品监督管理部门发现药品网络销售违法行为涉嫌犯罪的，应当及时将案件移送公安机关。'可被翻译为：Article 32 Where laws and administrative regulations provide for the penalties for illegal acts of online drug sales, such provisions shall prevail. Upon discovery of illegal behaviors related to online drug sales which allegedly constitutes a criminal offense, the drug regulatory departments shall promptly forward the case to the public security authorities.\n'第七十九条 违反本法规定，构成犯罪的，依法从重追究刑事责任。'可被翻译为：Article 79 Illegal act that violates this Law and constitutes a crime shall be subject to severer criminal liabilities according to law.\n'公安机关、人民检察院、人民法院商请药品监督管理部门、生态环境主管部门等部门提供检验结论、认定意见以及对涉案药品进行无害化处理等协助的，有关部门应当及时提供，予以协助。'可被翻译为：Where the public security authorities, the People's Procuratorate and the People's Court seek assistance from the drug regulatory departments, the ecology and environment departments, etc., to provide inspection conclusion and confirmation opinion as well as decontamination of the involved drugs, the relevant departments shall promptly provide assistance.\n\n根据上述已知信息，请将'对依法不需要追究刑事责任或者免予刑事处罚，但应当追究行政责任的，公安机关、人民检察院、人民法院应当及时将案件移送药品监督管理部门。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where it is not necessary to pursue criminal liability in accordance with the law or criminal punishment is not required in accordance with the law, but it is necessary to pursue administrative liability, the public security authorities, the People's Procuratorate and the People's Court shall promptly forward the case to the drug regulatory departments."
    },
    {
        "instruction":"已知信息：\n'简称\"肌松药”。阻滞神经肌肉后膜的N胆碱受体，产生神经肌肉阻滞，使骨骼肌麻痹松弛的药物。根据作用机制不同而分为：①除极化型肌松药，如琥珀胆碱，其作用不能为抗胆碱酯酶药所对抗；②非除极化型肌松药，如筒箭毒碱，其肌松作用可为抗胆碱酯酶药所对抗。'可被翻译为：\"Muscle relaxants\" for short. A drug that blocks N choline receptors in the posterior neuromuscular membrane, producing a neuromuscular block that paralyses and relaxes skeletal muscles. According to the different mechanism of action, it can be divided into: (1) depolarizing muscle relaxants, such as succincholine, whose action cannot be opposed by anti-cholinesterase drugs; ② Non-depolarizing muscle relaxants, such as tubocurarine, whose muscle relaxants can be resisted by anti-cholinesterase drugs.\n'类似副交感神经系统激动的药物。引起胆碱受体激动，包括拟胆碱药和胆碱酯酶药抑制药，后者如新斯的明。'可被翻译为：Drugs that mimic parasympathetic nervous system excitation. Drugs that cause cholinergic receptor excitation, including cholinomimetic drugs and cholinesterase inhibitors, the latter being neostigmine.\n'神经节阻滞药'可被翻译为：neuroganglion blockers\n'抗胆碱药'可被翻译为：anticholinergics\n\n根据上述已知信息，请将'又称\"胆碱受体阻滞药”。能与乙酰胆碱或外源性拟胆碱药争夺胆碱受体从而产生抗胆碱作用的药物。可分为，①M-胆碱受体阻滞药；②N-胆碱受体阻滞药，包括骨骼肌松弛药和神经节阻滞药；③中枢性抗胆碱药等。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Also known as \"cholinergic blockers\". A drug that competes with acetylcholine or exogenous cholinomimetic drugs for cholinergic receptors to produce anticholinergic effects. They can be divided into: (1) M-cholinergic blockers; ② N-choline receptor blockers, including skeletal muscle relaxants and ganglion blockers; ③ central anticholinergics, etc."
    },
    {
        "instruction":"已知信息：\n'第六十七条 研究者负责招募受试者、与受试者或者其监护人谈话。研究者有责任向受试者说明试验用医疗器械以及临床试验有关的详细情况，告知受试者可能的受益和已知的、可以预见的风险，并取得受试者或者其监护人签字和注明日期的知情同意书。'可被翻译为：Article 67 The investigator is responsible for recruiting subjects and talking with them or the guardians. The investigator shall explain to the subjects the details of the investigational medical device and details about the clinical trial, inform the subjects of possible benefits and known and foreseeable risks, and obtain signed and dated informed consent forms from the subjects or the guardians.\n'第七十条 研究者负责作出与临床试验相关的医疗决定，在发生与临床试验相关的不良事件时，临床试验机构和研究者应当保证为受试者提供足够、及时的治疗和处理。当受试者出现并发疾病需要治疗和处理时，研究者应当及时告知受试者。'可被翻译为：Article 70 The investigator is responsible for making medical decisions related to the clinical trial. When any adverse event related to the clinical trial occurs, the clinical trial institution and the investigator shall ensure that the subjects are in a timely manner provided with adequate treatment and solution. When the subjects develop complications which require treatment, the investigator shall promptly inform the subjects of the situation.\n'第八十九条 试验用医疗器械的使用由临床试验机构和研究者负责，研究者应当保证所有试验用医疗器械仅用于该临床试验的受试者，在试验期间按照要求储存和保管试验用医疗器械，在临床试验后按照国家有关规定和与申办者的协议对试验用医疗器械进行处理。上述过程需由专人负责并记录。研究者不得把试验用医疗器械转交任何非临床试验参加者。'可被翻译为：Article 89 The use of investigational medical devices shall be in the charge of the clinical trial institution and the investigator. The investigator shall ensure that all investigational medical devices are used only for the subjects of the clinical trial, well stored and kept during the trial in accordance with relevant requirements, and properly handled after the clinical trial in accordance with relevant state regulations and the agreement with the sponsor. The above process shall be designated to and recorded by identified personnel. The investigator shall not hand over the investigational medical device to any non-clinical trial participants.\n'6.临床试验各环节参与人员具有能够承担临床试验工作相应的教育、培训和经验，并得到主要研究者的授权。'可被翻译为：6. The participants in all aspects of clinical trials shall be qualified in education, training and experience correspondingly to undertake the work of clinical trials, and shall be authorized by the principal investigator.\n\n根据上述已知信息，请将'第七十九条 研究者可以根据临床试验的需要，授权相应人员进行受试者招募、与受试者持续沟通、临床试验数据记录、试验用医疗器械管理等。研究者应当对其授权的人员进行相关的培训并形成相应的文件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 79 The investigator may, according to the needs of the clinical trial, authorize corresponding personnel to recruit subjects, communicate with the subjects, record the clinical data and manage the investigational medical device. The investigator shall carry out relevant training and form the corresponding document for the personnel authorized."
    },
    {
        "instruction":"已知信息：\n'第二十八条 批签发机构根据资料审核、样品检验或者现场检查等结果作出批签发结论。符合要求的，签发生物制品批签发证明，加盖批签发专用章，发给批签发申请人。'可被翻译为：Article 28 The lot release institution shall make decision on lot release based on dossier review, sample test or on-site inspection and other results. If the requirements are met, the institution shall issue a Certificate for Lot Release of Biological Products which is affixed with the special seal for lot release, and send it to the lot release applicant.\n'第二十九条    批签发机构根据资料审核、样品检验或者现场检查等结果作出批签发结论。符合要求的，签发生物制品批签发证明，加盖批签发专用章，发给批签发申请人。'可被翻译为：Article 29 The lot release institution shall make decision on lot release based on dossier review, sample testing or on-site inspection. If the requirements are met, the institution shall issue a Certificate for Lot Release of Biological Products which is affixed with the special seal for lot release, and send it to the lot release applicant.\n'第二十八条    批签发申请人申请撤回批签发的，应当说明理由，经批签发机构同意后方可撤回；批签发申请人应当向所在地省、自治区、直辖市药品监督管理部门报告批签发申请撤回情况。批签发机构已经确认资料审核提示缺陷、检验结果不符合规定的，批签发申请人不得撤回。'可被翻译为：Article 28 If the lot release applicant applies for withdrawal of its lot release application, it shall provide the explanation, and may withdraw the application only upon approval by the lot release institution; the lot release applicant shall report such withdrawal to the drug regulatory departments of provinces, autonomous regions or municipalities directly under the Central Government. If the lot release institution has confirmed through review that the dossiers show defects or the testing results do not comply with the requirements, the application shall not be withdrawn by the lot release applicant.\n'第十四条    批签发申请人凭生物制品批签发申请表向省、自治区、直辖市药品监督管理部门或者其指定的抽样机构提出抽样申请，抽样人员在5日内组织现场抽样，并将所抽样品封存。批签发申请人将封存样品在规定条件下送至批签发机构办理批签发登记，同时提交批签发申请资料。'可被翻译为：Article 14 The lot release applicant shall propose a sampling application to the drug regulatory departments of provinces, autonomous regions or municipalities directly under the Central Government or the sampling institutions designated thereby by virtue of the Application Form for Lot Release of Biological Products; sampling personnel shall organize on-site sampling within 5 days, and seal the samples. The lot release applicant shall be responsible for delivering the sealed samples under the stipulated conditions to the lot release institution to handle registration for lot release, and shall submit lot release application dossiers at the same time.\n\n根据上述已知信息，请将'在批签发机构作出批签发合格结论前，批签发申请人应当将批签发申请资料补充完整并提交批签发机构。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Before the lot release institution makes any conclusion in lot release, the lot release applicant shall supplement the lot release application dossiers and submit them to the lot release institution."
    },
    {
        "instruction":"已知信息：\n'为规范儿童化妆品生产经营活动，加强儿童化妆品监督管理，保障儿童使用化妆品安全，依据《化妆品监督管理条例》等法律法规，国家药监局组织制定了《儿童化妆品监督管理规定》（以下简称《规定》），于2021年10月8日予以公布，并就《规定》实施有关事宜公告如下：'可被翻译为：In order to regulate the production and distribution activities of children’s cosmetics, strengthen the supervision and administration of children's cosmetics and ensure the safety of children in the use of cosmetics, according to the Regulations for the Supervision and Administration of Cosmetics and other laws and regulations, the National Medical Products Administration has organized to formulate the Provisions for the Supervision and Administration of Children's Cosmetics(hereinafter referred to as the Provisions),which was issued on October 8. The issues related to the implementation of the Provisions are hereby announced as follows:\n'国家药监局关于发布《化妆品注册备案资料管理规定》的公告'可被翻译为：NMPA Announcement on Issuing the Rules for Registration and Notification Dossiers of Cosmetics\n'国家药监局关于发布《化妆品新原料注册备案资料管理规定》的公告'可被翻译为：NMPA Announcement on Issuing the Rules for Registration and Notification Dossiers of New Cosmetic Ingredients\n'国家药监局关于发布实施《化妆品标签管理办法》的公告'可被翻译为：NMPA Announcement on Issuance and Implementation of the Measures for the Administration of Cosmetics Labels\n\n根据上述已知信息，请将'国家药监局关于发布《儿童化妆品监督管理规定》的公告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Announcement on Issuing the Provisions for the Supervision and Administration of Children's Cosmetics"
    },
    {
        "instruction":"已知信息：\n'第一百三十六条 国家药品标准，是指国家食品药品监督管理局颁布的《中华人民共和国药典》、药品注册标准和其他药品标准，其内容包括质量指标、检验方法以及生产工艺等技术要求。'可被翻译为：Article 136 National drug standards refer to the Pharmacopoeia of the People's Republic of China, drug registration specifications, etc. published by the State Food and Drug Administration, including the technical requirements such as specifications, testing methods and manufacturing processes, etc.\n'（四）产品原液、半成品和成品的检验项目、检验方法和结果是否符合国家药品标准和药品注册标准的要求；'可被翻译为：(IV)  Whether the testing items, testing methods and results of bulk, final bulk and finished products meet the requirements stipulated by national drug standards and drug registration standards;\n'（四）产品原液、半成品和成品的检验项目、检验方法和结果是否符合药典和药品注册标准的要求；'可被翻译为：(IV) Whether the testing items, testing methods and results of bulk, final bulk and finished products meet the requirements stipulated by the ChP and the drug registration specifications;\n'2.出厂及货架期的中、英文药品标准，检验方法及相关检验方法的方法学验证资料（包括符合现行《中国药典》要求的无菌及微生物限度检查的验证资料），按照现行版《中国药典》格式整理的药品标准及起草说明。'可被翻译为：2.Drug substance release or shelf-life specifications in Chinese and English versions, test methods and relevant method validation data (including validation data for sterility and microbial limit tests in accordance with the current Chinese Pharmacopoeia), specifications and drafting instructions collated as per the format of the current Chinese Pharmacopoeia.\n\n根据上述已知信息，请将'第一百三十七条 药品注册标准的项目及其检验方法的设定，应当符合中国药典的基本要求、国家食品药品监督管理局发布的技术指导原则及国家药品标准编写原则。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 137 The establishment of items and the testing methods for drug registration specifications shall be in conformity with the basic requirements of the Chinese Pharmacopoeia, the technical guidelines and rules for compiling the national drug standards published by the State Food and Drug Administration."
    },
    {
        "instruction":"已知信息：\n'2021年5月1日前申请并取得注册的祛斑美白、防脱发化妆品，注册人应当在2023年5月1日前补充提交人体功效试验报告。'可被翻译为：For the cosmetics for spot correcting, whitening and preventing hair loss with the application submitted and registration completed prior to May 1, 2021, registration persons shall submit the human efficacy test report prior to May 1, 2023.\n'自2022年1月1日起，申请祛斑美白、防脱发化妆品注册时，注册申请人应当按照规定，提交符合要求的人体功效试验报告。'可被翻译为：As of January 1, 2022, for the registration application of cosmetics for spot correcting, whitening and preventing hair loss, registration persons shall submit the human efficacy test report conforming to the requirements in accordance with the Rules.\n'四、关于祛斑美白和防脱发化妆品功效评价检验报告'可被翻译为：IV. Efficacy evaluation and test report of cosmetics for spot correcting, whitening and preventing hair loss\n'自2022年1月1日起，通过原注册备案平台和新注册备案平台备案的普通化妆品，统一实施年度报告制度。备案人应当于每年1月1日至3月31日期间，通过新注册备案平台，提交备案时间满一年普通化妆品的年度报告。'可被翻译为：As of January 1, 2022, an annual reporting system shall be implemented for the general cosmetics filed notification through the original and new platforms. The notification persons shall submit the annual report of general cosmetics that have been filed notification for a full year through the new platform during each January 1 to March 31.\n\n根据上述已知信息，请将'2021年5月1日至12月31日期间申请并取得注册的祛斑美白、防脱发化妆品，注册人应当于2022年5月1日前补充提交符合要求的人体功效试验报告。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For the cosmetics for spot correcting, whitening and preventing hair loss with the application submitted and registration completed between May 1 and December 31, 2021, registration persons shall submit the human efficacy test report conforming to the requirements prior to May 1, 2022."
    },
    {
        "instruction":"已知信息：\n'（七）禁忌症、注意事项、警示以及提示的内容；'可被翻译为：(7) Contraindications, precautions, warnings and suggestive descriptions.\n'第十二条 重复使用的医疗器械应当在说明书中明确重复使用的处理过程，包括清洁、消毒、包装及灭菌的方法和重复使用的次数或者其他限制。'可被翻译为：Article 12 For reusable medical devices, treatment processes, including methods of cleaning, disinfection, packaging and sterilization, as well as times of reuse and other restrictions, shall be provided in instructions.\n'（二）药品说明书中涉及有效性内容以及增加安全性风险的其他内容的变更；'可被翻译为：(2) Changes in drug package inserts pertinent to efficacy information and to other information on increasing safety risks;\n'（八）必要的警示、注意事项；'可被翻译为：(8) Necessary warnings and precautions.\n\n根据上述已知信息，请将'第十一条 医疗器械说明书中有关注意事项、警示以及提示性内容主要包括：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 11 Precautions, warnings and suggestive descriptions in medical device instructions mainly include:"
    },
    {
        "instruction":"已知信息：\n'第一百七十六条 企业发现已售出药品有严重质量问题，应当及时采取措施追回药品并做好记录，同时向食品药品监督管理部门报告。'可被翻译为：Article 176 In case of identifying that a sold drug has serious quality issue, an enterprise shall immediately take measures to retrieve the drug, make records and report to the food and drug regulatory department.\n'第二百三十八条 应当对不符合质量标准的结果或重要的异常趋势进行调查。对任何已确认的不符合质量标准的结果或重大不良趋势，企业都应当考虑是否可能对已上市药品造成影响，必要时应当实施召回，调查结果以及采取的措施应当报告当地药品监督管理部门。'可被翻译为：Article 238: Out-of-specification results or significant atypical trends should be investigated. Any confirmed out-of-specification result, or significant negative trend, the manufacturer should consider the possible impact on the marketed products. If necessary, a recall should be carried out, and investigation result and actions taken should be reported to the local drug regulatory department.\n'第二百七十六条 应当定期回顾分析投诉记录，以便发现需要警觉、重复出现以及可能需要从市场召回药品的问题，并采取相应措施。'可被翻译为：Article 276: Complaint records should be reviewed regularly, in order to find problems which require attention, occur repeatedly, and possibly need a recall of drugs from the market. Actions should be taken accordingly.\n'第十条 药品生产企业应当建立健全药品质量保证体系和药品不良反应监测系统，收集、记录药品的质量问题与药品不良反应信息，并按规定及时向药品监督管理部门报告。'可被翻译为：Article 10 Drug manufacturers shall establish and improve the drug quality assurance system and adverse drug reaction monitoring system, collect and record information relating to drug quality problems and adverse drug reactions and report the results to the drug regulatory department promptly as required.\n\n根据上述已知信息，请将'第二百七十七条 企业出现生产失误、药品变质或其他重大质量问题，应当及时采取相应措施，必要时还应当向当地药品监督管理部门报告。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 277: The manufacturer should take actions timely for manufacturing failure, drug deterioration, or any other serious quality problems. If necessary, actions taken should be reported to the local drug regulatory department."
    },
    {
        "instruction":"已知信息：\n'国务院办公厅印发《关于建立职业化专业化药品检查员队伍的意见》'可被翻译为：General Office of the State Council Issued the Opinions on Establishing a Team of Professionalized & Specialized Drug Inspectors\n'第五十一条 药品监督管理部门应当建立健全职业化、专业化检查员制度，明确检查员的资格标准、检查职责、分级管理、能力培训、行为规范、绩效评价和退出程序等规定，提升检查员的专业素质和工作水平。检查员应当熟悉药品法律法规，具备药品专业知识。'可被翻译为：Article 51 The drug regulatory department shall establish and improve the system of professional and specialized inspectors by clarifying qualification criteria, inspection duties, hierarchical management, skill training, code of conduct, performance evaluation and withdrawal procedures, to enhance their professionalism and skill level. The inspectors shall be familiar with drug laws and regulations, and have professional knowledge in drugs.\n'近日，国务院办公厅印发《关于建立职业化专业化药品检查员队伍的意见》（以下简称《意见》）。'可被翻译为：Recently, the General Office of the State Council issued the Opinions on Establishing a Team of Professionalized & Specialized Drug Inspectors (hereinafter referred to as Opinions).\n'检查员应当熟悉医疗器械法律法规，具备医疗器械专业知识和检查技能。'可被翻译为：The inspectors shall be familiar with laws and regulations of medical devices, and have professional knowledge and inspection skills in terms of medical devices.\n\n根据上述已知信息，请将'第一百零四条 国家建立职业化、专业化药品检查员队伍。检查员应当熟悉药品法律法规，具备药品专业知识。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 104 The State establishes a professional and specialized team of drug inspectors who are familiar with drug laws and regulations and have professional knowledge of drugs."
    },
    {
        "instruction":"已知信息：\n'与药物具有相同的分子式，但其分子中原子的空间排列不同并且为不能重合的镜像的化合物。'可被翻译为：A compound with the same molecular formula as the drug substance that differs in the spatial arrangement of atoms within the molecule and is a non-superimposable mirror image.\n'与原料药有相同的分子式，在分子内部原子的空间排列不同，并且不与其镜象重叠的化合物。'可被翻译为：Compounds with the same molecular formula as the drug substance, which differ in the spatial arrangement of atoms within the molecule and are nonsuperimposable mirror images.\n'具有相同化学结构的分子间的无序排列。'可被翻译为：Disordered arrangement of molecules having the same chemical structure.\n'含有两个或两个以上多价原子的有机化合物，由于单键自由旋转导致分子中其他原子或基团在空间排列不同，分子的这种立体形象称为构象。'可被翻译为：Organic compounds containing two or more polyvalent atoms, because the free rotation of single bonds causes other atoms or groups in the molecule to be arranged differently in space, this stereoscopic image of the molecule is called conformation.\n\n根据上述已知信息，请将'具有相同分子式而分子中原子排列不同的化合物。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A compound having the same molecular formula but with a different arrangement of atoms."
    },
    {
        "instruction":"已知信息：\n'促生长试验；使用现行USP（表1，USP<71>）推荐的微生物菌株。不要使用从 原始主种子批次中传代五代以上的培养物。也可以使用所推荐微生物的商业制备 并标化的稳定悬浮培养物。繁殖体细菌或酵母的试验菌悬液应在2小时内使用， 如果在2-8ºC冷藏，则应在24小时内使用。在2-8ºC冷藏的孢子悬浮液（A巴 西芽孢杆菌，B枯草芽孢杆菌和C孢子芽孢杆菌）可保存至经过验证的时长。如 果使用商业制备的生物体，应遵守生产商的说明。此外，所制备的所有菌悬液和 孢子悬浮液浓度应≤100CFU。使用时必须核查所有细菌数量。'可被翻译为：Growth promotion test; follow the current USP using recommended strains of organisms (Table 1, USP<71> ). Do not use cultures that are more than five passages removed from the original master seed lot. Commercially prepared and standardized stable suspension cultures of the recommended organisms can also be used. Test strains suspensions of vegetative bacteria or yeast should be used within 2 hours, or within 24 hours if refrigerated between 2ºC and 8ºC. Spore suspensions (A. brasiliensis, B. subtilis, and C. sporogenes) refrigerated between 2ºC and 8ºC may be kept for a validated period of time. If using commercially prepared organisms, follow the manufacturer’s instructions. Additionally, all bacterial and spore suspensions should be prepared to yield ≤100CFU. All bacterial counts must be verified at time of use.\n'细菌和酵母菌悬液在收获后24小时内使用。霉菌悬液可在冷藏 (2-8° C) 下储存长达 7 天。'可被翻译为：Use bacterial and yeast suspensions within 24 hr. of harvest. The mold preparation may be stored under refrigeration (2-8° C) for up to 7 days.\n'如果2 小时内未使用，则将菌悬液冷藏在 2-8°C 下。'可被翻译为：Refrigerate the suspension if not used within 2 hours at 2-8° C.\n'出现厌氧生长的杆状菌（无论有无内生孢子），过氧化氢酶反应为阴性，则表明存在 梭状芽孢杆菌。应通过鉴别试验进行证实。应使用快速鉴定试剂盒或DNA测序将分 离物鉴定至属，如有可能，鉴定至种。如未观察到生长或确认性鉴别试验为阴性，则 产品符合试验要求。'可被翻译为：The occurrence of anaerobic growth of rods with or without endospores, giving a negative catalase reaction indicates the presence of Clostridia. This is confirmed by identification tests. Isolates should be identified to genus and, if possible, species using rapid identification kits or DNA sequencing. The product complies with the test if no growth is observed or if the confirmatory identification tests are negative.\n\n根据上述已知信息，请将'对于细菌和真菌，根据USP要求接种至检测容器。确保所用种子批培养物 不超过原始主种子批的五代。公司自己配制的繁殖性细菌和酵母测试菌悬 液应在2小时使用；如果冷藏在2-8 ºC ，则应在24小时内使用。孢子混悬 液（A巴西芽孢杆菌，B枯草芽孢杆菌和C孢子芽孢杆菌）可在2-8 ºC 制 备并保存最长达7天。此外，所有的细菌和孢子悬液应制备为≤100CFU。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For bacteria and fungi, incubate test vessels according to USP requirements. Ensure that seed-lot cultures used are not more than five passages removed from the original master seed-lot. For in-house prepared test strain suspensions of vegetative bacteria and yeast should be used within 2 hours, or within 24 hours if refrigerated between 2ºC and 8ºC. Spore suspensions (A. brasiliensis, B. subtilis, and C. sporogenes) can be prepared and maintained between 2ºC and 8ºC for up to seven days. Additionally, all bacterial and spore suspensions should be prepared to yield ≤100 CFU."
    },
    {
        "instruction":"已知信息：\n'第八条 有下列情形之一的，食品药品监督管理部门可以开展药品医疗器械飞行检查：'可被翻译为：Article 8 Where any of the following circumstances exists, the food and drug regulatory departments can conduct an unannounced inspection for drugs and medical devices:\n'经组织实施飞行检查的食品药品监督管理部门同意后，检查组方可结束检查。'可被翻译为：Article 22 The inspection team shall inform the organization being inspected of the\n'第三十一条 上级食品药品监督管理部门应当及时将其组织实施的飞行检查结果通报被检查单位所在地食品药品监督管理部门。'可被翻译为：Article 31 The food and drug regulatory department at higher level shall timely notify the results of an unannounced inspection organized by itself, to the local food and drug regulatory department.\n'第二十四条 检查组一般应当在检查结束后5个工作日内，将检查报告、检查记录、相关证据材料等报组织实施飞行检查的食品药品监督管理部门。必要时，可以抄送被检查单位所在地食品药品监督管理部门。'可被翻译为：Article 24 The inspection team shall generally submit the inspection report, records and relevant evidence materials, etc. to the food and drug regulatory department conducting the unannounced inspection within five working days after completing the inspection. When necessary, a copy thereof may be sent to the local food and drug regulatory department.\n\n根据上述已知信息，请将'第二十条 有下列情形之一的，检查组应当立即报组织实施飞行检查的食品药品监督管理部门及时作出决定：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 20 Where any of the following circumstances exist, the inspection team shall report promptly to the food and drug regulatory department organizing the unannounced inspection for its timely decisions:"
    },
    {
        "instruction":"已知信息：\n'（六）采用经过验证或已知有效的清洁和去污染操作规程进行设备清洁；必要时，应当对与物料直接接触的设备表面的残留物进行检测。'可被翻译为：6. Using cleaning and decontamination procedures that are validated or of known effectiveness; where appropriate, testing the residue on the surface direct contact with materials;\n'清洁：去除污染（如产品残留或消毒剂残留）的工艺。'可被翻译为：Cleaning - A process for removing contamination e.g. product residues or disinfectant residues.\n'洁净室的消毒尤为重要。应根据书面程序彻底清洁洁净室并消毒。消毒前应清洁以去除表面污染物，确保消毒有效。清洁程序应有效去除消毒剂残留。应使用一种以上的消毒剂，确保这些消毒剂有不同作用机制，其联合使用能有效杀灭细菌和真菌。消毒应包括定期使用杀孢子剂。应定期进行监测，以评估消毒程序的有效性，并检测微生物菌群类型的变化（例如，对目前使用的消毒方式产生抗性的微生物）。'可被翻译为：The disinfection of cleanrooms is particularly important. They should be cleaned and disinfected thoroughly in accordance with a written programme. For disinfection to be effective, prior cleaning to remove surface contamination should be performed. Cleaning programmes should effectively remove disinfectant residues. More than one type of disinfecting agent should be employed to ensure that where they have different modes of action,\ntheir combined usage is effective against bacteria and fungi. Disinfection should include the periodic use of a sporicidal agent. Monitoring should be undertaken regularly in order to assess the effectiveness of the disinfection programme and to detect changes in types of microbial flora (e.g. organisms resistant to the disinfection regime currently in use).\n'清洁和消毒'可被翻译为：Cleaning and disinfection\n\n根据上述已知信息，请将'应适当规定和控制去污染的方法（清洁和消毒，以及适用时生物材料的灭活）。消毒步骤之前的清洁非常重要：任何残留物可能会抑制去污染过程的有效性。还应提供证据证明使用的清洁和消毒剂不会对 RABS或隔离器内生产的产品产生不良影响。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Decontamination methods (cleaning and bio-decontamination, and where applicable inactivation for biological materials) should be appropriately defined and controlled. The cleaning process prior to the bio-decontamination step is essential; any residues that remain may inhibit the effectiveness of the decontamination process. Evidence should also be available to demonstrate that the cleaning and bio-decontamination agents used do not have adverse impact on the product produced within the RABS or isolator."
    },
    {
        "instruction":"已知信息：\n'第三十五条 本办法自2020年1月1日起施行。原国家食品药品监督管理局2005年11月24日公布的《进口药材管理办法（试行）》同时废止。'可被翻译为：Article 35 The Provisions shall come into force as of January 1, 2020. The Provisions for Medicinal Material Import (Interim) promulgated by the former China Food and Drug Administration on November 24, 2005, shall be repealed simultaneously.\n'二是落实“四个最严”要求，严格药材执 行标准。《办法》规定申请进口的药材应当符 合国家药品标准。同时，考虑维药、藏药等少 数民族药传统上多依赖进口药材，为保障少数 民族地区用药，规定少数民族地区进口当地习 用的少数民族药药材，尚无国家药品标准的， 应当符合相应的省、自治区药材标准。'可被翻译为：II. Implement the Four Strictest Requirements and strictly enforce the standards for medicinal materials. The Measures stipulates that the medicinal materials applied for import shall comply with the national drug standards. Meanwhile, considering that traditional medicines such as Uygur medicine and Tibetan medicine are traditionally more dependent on import, to protect drug use in ethnic minority areas, the Measures stipulates that: in ethnic minority areas, the import of locally customarily used ethnic medicines shall, in the absence of national drug standards, conform to the medicinal materials standards of the corresponding province or autonomous region.\n'为加强进口药材监督管理，保障进口药材 质量，2019年5月16日，国家市场监督管理总 局发布了修订后的《进口药材管理办法》（国 家市场监督管理总局令第9号，以下简称《办 法》）。'可被翻译为：To strengthen the administration and guarantee the quality of imported medicinal materials, on May 16, 2019, the State Administration for Market Regulation (SAMR) issued the revised Measures for the Administration of Imported Medicinal Materials (SAMR Order No. 9, hereinafter referred to as the Measures).\n'2020年1月16日，国家药监局、海关总署和市场监管总局联合发布了《关于实施〈进口药材管理办法〉及有关事项的公告》，明确了关于首次进口药材的申请和审批、进口药材的备案和口岸检验问题。'可被翻译为：On January 16, 2020, the National Medical Products Administration, the General Administration of Customs and the State Administration for Market Regulation issued the Announcement on Implementing the Measures for the Administration of Imported Medicinal Materials and related matters to clarify issues pertaining to the application and approval of initial import, record filing and port inspection of imported medicinal materials.\n\n根据上述已知信息，请将'《办法》经2019年4月28日国家市场监督 管理总局第8次局务会议审议通过，自2020年1 月1日起实施。原国家食品药品监督管理局2005 年11月24日公布的《进口药材管理办法（试 行）》同时废止。《办法》共7章35条，在进口 药材管理上，严格落实“四个最严”要求，严 格药材执行的标准，加强溯源管理。同时，落 实“放管服”改革要求，对首次进口和非首次 进口药材实施分类管理。重点内容包括：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The Measures has been adopted upon deliberation at the 8th SAMR Conference on April 28, 2019, and shall enter into force as from January 1, 2020. The Measures for the Administration of Imported Medicinal Materials (Interim), promulgated by the former State Food and Drug Administration on November 24, 2005, shall be repealed simultaneously. The current Measures consists of 35 Articles in 7 Chapters. Regarding the administration of imported medicinal materials, the Four Strictest requirements and the standards for medicinal materials are strictly enforced, and traceability management is reinforced. Furthermore, the Measures embodies the reform requirements of Streamlining Administration, Delegating More Powers to Lower-level Governments and Society, Improving Regulation and Optimizing Services, requiring classified management on initial import and non-initial import of medicinal materials. Highlights include:"
    },
    {
        "instruction":"已知信息：\n'（四）不配合药品监督管理部门和监测机构开展的医疗器械不良事件相关调查和采取的控制措施的。'可被翻译为：(IV) Failing to cooperate with drug regulatory departments and monitoring agencies in relevant investigation of medical device adverse events and control measures to be taken.\n'（三）不配合药品监督管理部门和监测机构开展的医疗器械不良事件相关调查和采取的控制措施的。'可被翻译为：(III) Failing to cooperate with drug regulatory departments and monitoring agencies in relevant investigation of medical device adverse events and control measures to be taken.\n'第六十八条  持有人未按照要求建立不良事件监测制度、开展不良事件监测和再评价相关工作、未按照本办法第四十八条规定及时采取有效风险控制措施、不配合药品监督管理部门开展的医疗器械不良事件相关调查和采取的控制措施的，药品监督管理部门可以要求其停产整改，必要时采取停止产品销售的控制措施。'可被翻译为：Article 68 Where MAHs fail to establish adverse event monitoring system and carry out adverse event monitoring and re-evaluation as required, fail to promptly take effective risk control measures in accordance with Article 48 of the Provisions, fail to cooperate with the drug regulatory departments in relevant investigation of medical device adverse events and control measures to be taken, the drug regulatory departments shall require them to stop production and make rectification, and take the control measure of stopping product sale when necessary.\n'（六）未配合持有人对医疗器械不良事件调查和评价的；'可被翻译为：(VI)  Failing to cooperate with MAHs in the investigation and evaluation of medical device adverse events;\n\n根据上述已知信息，请将'（四）不配合药品监督管理部门开展的医疗器械不良事件相关调查和采取的控制措施的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(IV) Failing to cooperate with the drug regulatory departments in relevant investigation of medical device adverse events and control measures to be taken;"
    },
    {
        "instruction":"已知信息：\n'第二百一十三条 包装期间，产品的中间控制检查应当至少包括下述内容：'可被翻译为：Article 213: In-process control of the product during packaging should include at least the following information:\n'第二百二十二条 取样应当至少符合以下要求：'可被翻译为：Article 222: Sampling should at least meet the following requirements:\n'第一百五十九条 与本规范有关的每项活动均应当有记录，以保证产品生产、质量控制和质量保证等活动可以追溯。记录应当留有填写数据的足够空格。记录应当及时填写，内容真实，字迹清晰、易读，不易擦除。'可被翻译为：Article 159: Records should be made at the time each activity related to the Provisions is taken and in such a way that activities concerning the manufacture, quality control and quality assurance of products are traceable. Sufficient space should be provided for data entering in the record. The record should be entered timely and truthfully, and the handwriting should be clear, legible and indelible.\n'第二百一十七条 质量控制实验室的人员、设施、设备应当与产品性质和生产规模相适应。'可被翻译为：Article 217: The personnel, facilities, and equipment in the quality control laboratories should be appropriate to the tasks imposed by the product nature and the scale of the manufacturing operations.\n\n根据上述已知信息，请将'第二百一十二条 包装材料上印刷或模压的内容应当清晰，不易褪色和擦除。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 212: Printed and embossed information on packaging materials should be distinct and resistant to fading or erasing."
    },
    {
        "instruction":"已知信息：\n'偏离行动限或警戒限的次数增加。'可被翻译为：Increasing numbers of excursions from action limits or alert levels.\n'偏离警戒限的异常情况应进行记录和审核，包括调查确定偏离是否为单个（独立）事件，或结果是否表明不良趋势或系统恶化。应对偏离行动限的每个异常情况进行调查，以确定可能的根本原因以及工艺用水对产品质量和生产工艺的任何潜在影响。'可被翻译为：Alert level excursions should be documented and reviewed, and include an investigation to determine whether the excursion is a single (isolated) event or if results are indicative of an adverse trend or system deterioration. Each action limit excursion should be investigated to determine the probable root causes and any\npotential impact on the quality of products and manufacturing processes as a result of the use of the water\n'预防性维护——按照确保没有额外污染风险的标准，对设备、公用设施和厂房进行维护（包括计划内和计划外维护）。'可被翻译为：Preventative maintenance - maintaining equipment, utilities and premises (planned and unplanned\nmaintenance) to a standard that will ensure there is no additional risk of contamination.\n'行动限'可被翻译为：action limit\n\n根据上述已知信息，请将'可能由共同原因引起的孤立的，有规律的偏离行动限的事件（例如，经常在计划内预防性维护后出现的单次偏离）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Regular but isolated excursion from action limits that may have a common cause, (e.g. single excursions that always follow planned preventative maintenance)."
    },
    {
        "instruction":"已知信息：\n'传送带速度或在灭菌区的滞留时间。'可被翻译为：Belt speed or dwell time within the sterilising zone.\n'人员气锁：用于人员进入的洁净级别越来越高的区域（例如从 D 级区到 C 级区到 B 级区）。一般而言，洗手设施应仅设置在更衣室的第一阶段，且不能设置在直接进入 B 级区的更衣室中。'可被翻译为：Personnel airlocks: Areas of increasing cleanliness used for entry of personnel (e.g. from the grade D area to the grade C area to the grade B area). In general hand washing facilities should be provided only in the first stage of the changing room and not be present in changing rooms directly accessing the grade B area.\n'A 级和 B 级区再确认的最长时间间隔为6个月。'可被翻译为：The maximum time interval for requalification of grade A & B areas, is 6 months.\n'屏障：一种通过将无菌工艺区（通常 A 级）与周围环境隔开，为无菌工艺区提供防护的物理隔断。此类系统经常部分或整体使用屏障技术，如 RABS 或隔离器。'可被翻译为：Barrier - A physical partition that affords aseptic processing area (usually grade A) protection by separating it from the background environment. Such systems frequently use in part or totally the Barrier Technologies known\nas RABS or isolators.\n\n根据上述已知信息，请将'除传送带本身能连续灭菌（如隧道式灭菌器）以外，传送带不得穿越 A 级或 B 级区与低级别工艺区的隔离墙。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A conveyor belt should not pass through a partition between a grade A or B area and a processing area of lower air cleanliness, unless the belt itself is continually sterilised (e.g. in a sterilising tunnel)."
    },
    {
        "instruction":"已知信息：\n'第十八条 开展疫苗临床试验，应当取得受试者的书面知情同意；受试者为无民事行为能力人的，应当取得其监护人的书面知情同意；受试者为限制民事行为能力人的，应当取得本人及其监护人的书面知情同意。'可被翻译为：Article 18 Written informed consent shall be obtained from subjects for vaccine clinical trials; where the subject is a person without capacity for civil conduct, the written informed consent shall be obtained from his\/her guardian; where the subject is a person with limited capacity for civil conduct, the written informed consent shall be obtained from the subject and his\/her guardian.\n'第六十七条 研究者负责招募受试者、与受试者或者其监护人谈话。研究者有责任向受试者说明试验用医疗器械以及临床试验有关的详细情况，告知受试者可能的受益和已知的、可以预见的风险，并取得受试者或者其监护人签字和注明日期的知情同意书。'可被翻译为：Article 67 The investigator is responsible for recruiting subjects and talking with them or the guardians. The investigator shall explain to the subjects the details of the investigational medical device and details about the clinical trial, inform the subjects of possible benefits and known and foreseeable risks, and obtain signed and dated informed consent forms from the subjects or the guardians.\n'第二十一条 实施药物临床试验，应当向受试者或者其监护人如实说明和解释临床试验的目的和风险等详细情况，取得受试者或者其监护人自愿签署的知情同意书，并采取有效措施保护受试者合法权益。'可被翻译为：Article 21 When conducting a drug clinical trial, details such as the clinical trial objective and risks shall be truthfully stated and explained to the trial subjects or their guardians, an informed consent letter signed voluntarily by the trial subject or their guardian shall be obtained, and effective measures shall be taken to protect the lawful rights and interests of the trial subjects.\n'（二）受试者或者其监护人均无阅读能力时，在知情过程中应当有1名见证人在场，经过详细解释知情同意书后，见证人阅读知情同意书与口头知情内容一致，由受试者或者其监护人口头同意后，见证人在知情同意书上签名并注明日期，见证人的签名与研究者的签名应当在同1天；'可被翻译为：(2) Where the subjects or their guardians have no reading ability, a witness shall be present in the informed process. After the detailed explanation of the informed consent form, the witness shall confirm if the literal expression of the informed consent form is consistent with the verbally informed content. After the subjects or their guardians show verbal consent, the witness shall sign and date the informed consent form, and the signature of the witness and the signature of the investigator shall be on the same day.\n\n根据上述已知信息，请将'第二十一条 在受试者参与临床试验前，研究者应当充分向受试者或者无民事行为能力人、限制民事行为能力人的监护人说明临床试验的详细情况，包括已知的、可以预见的风险和可能发生的不良事件等。经充分和详细解释后由受试者或者其监护人在知情同意书上签署姓名和日期，研究者也需在知情同意书上签署姓名和日期。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 21 Before a subject is to be involved in the clinical trial, the investigator shall adequately explain the details of the clinical trial to the subject or the guardians of the subject who is without capacity for civil conduct or with limited capacity for civil conduct, including known and foreseeable risks and possible adverse events. After a full and detailed explanation, the subject or the guardians shall sign and date the informed consent form, and the investigator shall also sign and date the informed consent form."
    },
    {
        "instruction":"已知信息：\n'国家药监局关于发布影像型超声诊断设备同品种临床评价技术审查指导原则等2项注册技术审查指导原则的通告'可被翻译为：NMPA Announcement on Issuing of Two Registration Technical Review Guidelines Including the Guidelines for Technical Review of Clinical Evaluation of Ultrasound Diagnostic Imaging Equipment Based on Predicate Products\n'国家药监局关于药械组合产品注册有关事宜的通告'可被翻译为：NMPA Notice on Matters Concerning the Registration of Drug-device Combination Products\n'国家药监局关于发布视力筛查仪和乳腺X射线系统2项注册技术审查指导原则的通告'可被翻译为：NMPA Announcement on Issuing 2 Guidance including the Technical Review Guidance for the Registration of Vision Screeners and Mammography Systems\n'国家药监局关于发布神经和心血管手术器械通用名称命名指导原则等2项指导原则的通告'可被翻译为：NMPA Announcement on Issuing 2 Guidance including the Guidance for Nomenclature of the Generic Names of Neurosurgical and Cardiovascular Surgical Devices\n\n根据上述已知信息，请将'国家药监局关于发布以医疗器械作用为主的药械组合产品等2项注册审查指导原则的通告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Announcement on Two Guidelines for Registration Review of Drug-Device Combination Products with Device Taking Primary Mode of Action"
    },
    {
        "instruction":"已知信息：\n'第一百四十九条 违反本法规定，药品监督管理等部门有下列行为之一的，对直接负责的主管人员和其他直接责任人员给予记过或者记大过处分；情节较重的，给予降级或者撤职处分；情节严重的，给予开除处分：'可被翻译为：Article 149 Where a drug regulatory department commits any of the following acts in violation of this Law, the persons directly in charge and other directly responsible persons shall be given a demerit or serious demerit. In relatively serious circumstances, they shall be demoted or removed and in serious circumstances, they shall be dismissed:\n'第一百四十八条 违反本法规定，县级以上地方人民政府有下列行为之一的，对直接负责的主管人员和其他直接责任人员给予记过或者记大过处分；情节严重的，给予降级、撤职或者开除处分：'可被翻译为：Article 148 Where a people's government at or above the county level commits any of the following acts in violation of this Law, the persons directly in charge and other directly responsible persons shall be given a demerit or serious demerit. In serious circumstances, such individuals shall be demoted, removed, or dismissed:\n'第八十四条 违反本法规定，批签发机构有下列情形之一的，由国务院药品监督管理部门责令改正，给予警告，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予警告直至降级处分：'可被翻译为：Article 84 Where a lot release institution has one of the following circumstances in violation of this Law, the drug regulatory department under the State Council shall order to make rectifications and give a warning to the said institution, and give warnings until downgrade as punishment to the principal, director in charge and other directly responsible personnel:\n'第九十四条 县级以上地方人民政府在疫苗监督管理工作中有下列情形之一的，对直接负责的主管人员和其他直接责任人员依法给予降级或者撤职处分；情节严重的，依法给予开除处分；造成严重后果的，其主要负责人应当引咎辞职：'可被翻译为：Article 94 Where local people's governments at or above the county level are under any of the following circumstances in vaccine administration, the executive in charge and other directly responsible personnel shall be given a downgrade or dismissal; and in serious circumstances, the executive in charge and other directly responsible personnel shall be given an expulsion; if it causes serious consequences, the principal shall resign to assume responsibility:\n\n根据上述已知信息，请将'第三十四条 食品药品监督管理部门及其工作人员不履行医疗器械监督管理职责或者滥用职权、玩忽职守，有下列情形之一的，由监察机关或者任免机关根据情节轻重，对直接负责的主管人员和其他直接责任人员给予批评教育，或者依法给予警告、记过或者记大过的处分；造成严重后果的，给予降级、撤职或者开除的处分：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 34 The food and drug regulatory departments and their personnel who fail to perform their responsibilities for medical device supervision and administration, or abuse their powers or neglect their duties, in any of the following circumstances, the supervisory authority or the appointment and dismissal authority shall, according to the seriousness of the circumstances, give criticism and education, or give warning, demerit or major demerit to the persons directly in charge and other directly responsible persons according to law; if serious consequences are caused, demotion, removal or dismissal shall be given:"
    },
    {
        "instruction":"已知信息：\n'已经备案的产品不再生产或者进口的，备案人应当及时报告承担备案管理工作的药品监督管理部门取消备案。'可被翻译为：If the products that have been filed are no longer produced or imported, the filing person shall promptly report to the drug regulatory department responsible for the filing administration for cancelling the filing.\n'第三十三条 化妆品注册申请人、备案人应当委托取得资质认定、满足化妆品注册和备案检验工作需要的检验机构，按照强制性国家标准、技术规范和注册备案检验规定的要求进行检验。'可被翻译为：Article 33 Cosmetic registrants and filing persons shall entrust a testing agency that has obtained qualification certifications and meets the needs for testing on cosmetic registration and filing to conduct testing according to mandatory national standards, technical specifications and testing requirements of registration and filing.\n'化妆品、化妆品新原料注册人、备案人申请注册或者进行备案时，应当遵守有关法律、行政法规、强制性国家标准和技术规范的要求，对所提交资料的真实性和科学性负责。'可被翻译为：Registrants and filing persons of cosmetics and new cosmetic ingredients shall comply with the requirements of relevant laws, administrative regulations, mandatory national standards and technical specifications when applying for registration or filing for filing, and shall be responsible for the authenticity and scientificalness of the submitted dossiers.\n'第三十条 化妆品注册人、备案人应当选择符合法律、行政法规、强制性国家标准和技术规范要求的原料用于化妆品生产，对其使用的化妆品原料安全性负责。化妆品注册人、备案人申请注册、进行备案时，应当通过信息服务平台明确原料来源和原料安全相关信息。'可被翻译为：Article 30 Cosmetic registrants and filing persons shall select ingredients that meet the requirements of laws, administrative regulations, mandatory national standards and technical specifications for cosmetic production, and shall be responsible for the safety of cosmetic ingredients they use. When applying for registration and filing for filing, the cosmetic registrant and filing person shall clarify the source of ingredients and relevant information on ingredient safety through the information service platform.\n\n根据上述已知信息，请将'第三十七条 普通化妆品的备案人应当每年向承担备案管理工作的药品监督管理部门报告生产、进口情况，以及符合法律法规、强制性国家标准、技术规范的情况。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 37 The filing person of general cosmetics shall report the production and import status, as well as the compliance with laws and regulations, compulsory national standards, and technical specifications to the drug regulatory department responsible for filing administration on a yearly basis."
    },
    {
        "instruction":"已知信息：\n'（二）特殊药品和疫苗类制品的样品检验：60日；同时进行样品检验和标准复核：90日。'可被翻译为：(2) sample testing of a controlled drug or vaccine: 60 days; sample testing and specifications verification: 90 days.\n'第五十二条 与国家药品标准收载的同品种药品使用的检验项目和检验方法一致的，可以不进行标准复核，只进行样品检验。其他情形应当进行标准复核和样品检验。'可被翻译为：Article 52 Where the testing items and methods are identical with those of the same variety of drugs included in the national drug standards, specification verification is not necessary and only sample testing is required. In other cases, both specification verification and sample testing shall be required.\n'（一）样品检验：30日；同时进行样品检验和标准复核：60日；'可被翻译为：(1) sample testing: 30 days; sample testing and specifications verification : 60 days; and\n'第一百二十八条 药品注册检验，包括样品检验和药品标准复核。'可被翻译为：Article 128 Testing for drug registration consists of sample testing and verification of specifications.\n\n根据上述已知信息，请将'特殊药品和疫苗类制品的样品检验和药品标准复核应当在90日内完成。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Sample testing and verification of specifications for controlled drugs or vaccines shall be completed within 90 days."
    },
    {
        "instruction":"已知信息：\n'第五条 被检查单位对食品药品监督管理部门组织实施的药品医疗器械飞行检查应当予以配合，不得拒绝、逃避或者阻碍。'可被翻译为：Article 5 The organization being inspected shall provide cooperation, and shall not refuse, delay, deny or limit the unannounced inspection of drugs and medical devices organized by the food and drug regulatory departments.\n'被检查单位有下列情形之一的，视为拒绝、逃避检查：'可被翻译为：Where any of the following circumstances exists, the organization being inspected shall be regarded as refusing, delaying and denying inspection:\n'（一）拖延、限制、拒绝检查人员进入被检查场所或者区域的，或者限制检查时间的；'可被翻译为：(i) Delaying, restricting and refusing the entering of the inspectors into the sites or areas being inspected, or limiting the inspection time and duration;\n'第九十九条 药品监督管理部门应当依照法律、法规的规定对药品研制、生产、经营和药品使用单位使用药品等活动进行监督检查，必要时可以对为药品研制、生产、经营、使用提供产品或者服务的单位和个人进行延伸检查，有关单位和个人应当予以配合，不得拒绝和隐瞒。'可被翻译为：Article 99 Drug regulatory departments shall, in accordance with the laws and regulations, supervise and inspect drug research and development, manufacturing, distribution, and use of drugs by institutions, and other activities, and where necessary, conduct extended inspection on institutions and individuals providing products or services for drug research and development, manufacture, distribution, and use. Relevant organizations and individuals shall cooperate and shall not refuse inspection or conceal information.\n\n根据上述已知信息，请将'第二十八条 食品药品监督管理部门有权在任何时间进入被检查单位研制、生产、经营、使用等场所进行检查，被检查单位不得拒绝、逃避。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 28 A food and drug regulatory department has the right to enter at any time into the sites of research and development, manufacture, sales or use and etc. of the organization being inspected to conduct the inspection, and the organization being inspected shall not refuse, delay or deny."
    },
    {
        "instruction":"已知信息：\n'治疗真性红细胞系细胞的肿瘤性增生所造成的红细胞增多症的药物。如羟基脲等。'可被翻译为：Drugs used to treat polycythemia caused by neoplastic hyperplasia of genuine erythrocytic cells. Such as hydroxyurea.\n'药物起作用的初始点。如细胞、蛋白质、受体、离子通道和基因等。'可被翻译为：The initial point at which a drug acts. Such as cells, proteins, receptors, ion channels, and genes.\n'由一个基因组，或一个细胞、组织表达的所有蛋白质。'可被翻译为：All the proteins expressed by a genome, or by a cell or tissue.\n'一种在性活动期间戴在阴茎上的医疗器械，目的是避孕和防止性传播疾病的传播。避孕套通常由天然胶乳制成，但也可能由合成材料制成，如聚氨酯。'可被翻译为：A medical device that is intended to be worn on the penis during sexual activity, for purposes of contraception and to prevent the spread of sexually transmitted infections. Condoms are usually made from natural rubber latex but may also be made from synthetic materials, such as polyurethane.\n\n根据上述已知信息，请将'由活生物体或细胞制成的药物（如治疗性蛋白质） 。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Drugs that are made by living organisms or cells (e.g., therapeutic proteins)."
    },
    {
        "instruction":"已知信息：\n'管碟法是最常使用的 USP<81>测试方法。管碟法使用固体培养基（琼脂）证明抗生素活性（即抑菌圈（ZOI））。该方法需要使用 5 点标准曲线【S1】-【S5】、中值标准品【S3】、供试抗生素\/未知样品【U3】、经过确认的接种物、不锈钢小管和含有生长琼脂的培养碟。参见图 1 中一次独立碟法测试及一式三份标准曲线和未知样品琼脂平板的放置示例。'可被翻译为：The Plate Method is the most commonly used USP <81> test. The Plate Method uses a solid \nmedium (agar) to demonstrate antibiotic activity (i.e. zones of inhibitions (ZOIs)). This method \nrequires the use of a five-point standard curve [S1] – [S5], median reference standard [S3], test \nantibiotic\/ unknown sample [U3], verified inoculum, stainless steel penicylinders and petri_x0002_plates containing growth agar. See Diagram 1 for an example of one independent test run for the \nPlate Method and placement of the standard curve and unknown sample onto triplicate agar \nplates.\n'在琼脂固化之后（单层或双层琼脂碟），使用小管分配器将不锈钢小管以等距直立方式放置到琼脂表面。每支小管应立即注入 2 种浓度的抗生素、稀释后的未知样品【U3】或中值标准品（S3）。另取相同体积的 2 种浓度抗生素注入另外小管中。详情参见图 2。'可被翻译为：Once the agar solidifies (either single layer or bi-layer agar plate), stainless steel penicylinders are applied to the agar surface using a penicylinder dispenser. Penicylinders are applied in an equidistant and upright fashion. Each penicylinder should be immediately dosed with two concentrations of antibiotic, the diluted unknown sample [U3] or the median reference standard(S3). Further, both antibiotics are dosed in equal volume into alternating penicylinders. See Diagram 2 for further details.\n'测试抗生素\/未知样品（【U3】）的计算效价必须为中值标准品（【S3】）的 80-125%'可被翻译为：The calculated potency of the test antibiotic\/unknown sample ([U3]) must be 80% to 125% of the median reference standard ([S3]);\n'未知样品【U3】的稀释方式应确保检测限在标准曲线线性范围内。例如，如果中值标准品【S3】的浓度为 10.0 µg\/mL，则未知样品 【U3】 也会稀释到 10.0 µg\/mL 的浓度。碟法一次独立测试中将一式三份标准曲线和未知样品放置到琼脂平板上的示例参见图 1。'可被翻译为：Diluting the unknown sample [U3] in this manner ensures a detection limit within the linear portion of the standard curve. For example, if the median reference standard [S3] has a \nconcentration of 10.0 ug\/mL, the unknown sample [U3] will also be diluted to a concentration \nof 10.0 ug\/mL. See Diagram 1 for an example of one independent test run for the Plate Method \nand placement of the standard curve and unknown sample onto triplicate agar plates.\n\n根据上述已知信息，请将'在加入抗生素之后，同时培养一次检测中制备的所有培养碟。在平板培养期间，抗生素会在琼脂中扩散，在小管周边底下形成清晰的圆圈，该圈称为抑菌圈（ZOI）。ZOI 显示的是稀释后的未知样品【U3】和中值标准品【S3】的抗生素活性。详情参见图 3。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"After dosing, all plates prepared in one independent test run are incubated at the same time. As \nthe plates incubate, the antibiotics diffuse through the agar, creating a zone of clearing below \nand around penicylinder perimeter; this clearing is referred to as the zone of inhibition (ZOI). \nThe ZOI demonstrates the antibiotic activity of the diluted unknown sample [U3] and the \nmedian reference standard [S3]. See Diagram 3 for further details."
    },
    {
        "instruction":"已知信息：\n'第八十九条 试验用医疗器械的使用由临床试验机构和研究者负责，研究者应当保证所有试验用医疗器械仅用于该临床试验的受试者，在试验期间按照要求储存和保管试验用医疗器械，在临床试验后按照国家有关规定和与申办者的协议对试验用医疗器械进行处理。上述过程需由专人负责并记录。研究者不得把试验用医疗器械转交任何非临床试验参加者。'可被翻译为：Article 89 The use of investigational medical devices shall be in the charge of the clinical trial institution and the investigator. The investigator shall ensure that all investigational medical devices are used only for the subjects of the clinical trial, well stored and kept during the trial in accordance with relevant requirements, and properly handled after the clinical trial in accordance with relevant state regulations and the agreement with the sponsor. The above process shall be designated to and recorded by identified personnel. The investigator shall not hand over the investigational medical device to any non-clinical trial participants.\n'第十条 临床试验前，申办者与临床试验机构和研究者应当就试验设计、试验质量控制、试验中的职责分工、申办者承担的临床试验相关费用以及试验中可能发生的伤害处理原则等达成书面协议。'可被翻译为：Article 10 Before the clinical trial, the sponsor, clinical trial institution and investigator shall reach a written agreement on the trial design, trial quality control, division of duties in the trial, relevant clinical trial cost borne by the sponsor, and treatment principle of possible injury in the trial.\n'第四十条 申办者应当根据试验用医疗器械的特性，在经资质认定的医疗器械临床试验机构中选择试验机构及其研究者。申办者在与临床试验机构签署临床试验协议前，应当向临床试验机构和研究者提供最新的研究者手册以及其他相关文件，以供其决定是否可以承担该项临床试验。'可被翻译为：Article 40 The sponsor shall, according to the characteristics of the investigational medical device, select the trial institutions and investigators among certified medical device clinical trial institutions. The sponsor shall provide the latest investigator's brochure and other relevant documents to the clinical trial institutions and investigators before signing the clinical trial protocol with the clinical trial institution, so that they can decide whether they are able to undertake the clinical trial.\n'伦理委员会中独立于研究者和申办者的委员有权发表意见并参与有关试验的表决。'可被翻译为：The members of the ethics committee who are independent of the investigator and sponsor are entitled to comment and participate in the voting of relevant trials.\n\n根据上述已知信息，请将'第四十五条 申办者对试验用医疗器械在临床试验中的安全性负责。当发现可能影响受试者安全或者试验实施可能改变伦理委员会对继续试验的批准情况时，申办者应当立即通知所有临床试验机构和研究者，并作出相应处理。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 45 The sponsor shall be responsible for the safety of investigational medical device in clinical trial. When finding it may affect the safety of the subjects or the implementation of the trial may change the approval of the ethics committee for the continuation of the trial, the sponsor shall immediately notify all clinical trial institutions and investigators and make corresponding handling."
    },
    {
        "instruction":"已知信息：\n'化妆品、化妆品新原料注册人未按照本办法的规定重新注册的，依照化妆品监督管理条例第五十九条的规定给予处罚；化妆品、化妆品新原料备案人未按照本办法的规定重新备案的，依照化妆品监督管理条例第六十一条第一款的规定给予处罚。'可被翻译为：If the registrant of cosmetics and new cosmetic ingredients fails to re-register in accordance with requirements of these Provisions, it shall be punished in accordance with Article 59 of the Regulations on Supervision and Administration of Cosmetics; if the filing person of cosmetics or new cosmetic ingredients fails to re-file the filing in accordance with requirements of these Provisions, fines shall be imposed as in the first paragraph of Article 61 of the Regulations on Supervision and Administration of Cosmetics.\n'第四十九条 已注册的第二类、第三类医疗器械，医疗器械注册证及其附件载明的内容发生变化，注册人应当向原注册部门申请注册变更，并按照相关要求提交申报资料。'可被翻译为：Article 49 For a registered class II or class III medical device, if the content of the medical device registration certificate and its attachment(s) has an alteration, the registrant shall apply to the original registration department for registration alteration and submit application materials according to relevant requirements.\n'化妆品、化妆品新原料注册人、备案人按照规定通过化妆品、化妆品新原料注册备案信息服务平台（以下简称信息服务平台）申请注册、进行备案。'可被翻译为：Registrants and filing persons of cosmetics and new cosmetic ingredients shall apply for registration and filing through the information service platform of registration and filing for cosmetics and new cosmetic ingredients (hereinafter referred to as the information service platform) in accordance with regulations.\n'第三十九条  新的强制性标准实施后，医疗器械注册人、备案人应当及时识别产品技术要求和强制性标准的差异，需要进行注册变更或者备案变更的，应当按照注册备案管理的规定办理相关手续。'可被翻译为：Article 39 Upon implementation of new mandatory standards, the registrant or filing entity of medical devices shall identify the differences between the technical specifications and the mandatory standards of the products. If it is necessary to make registration change or filing change, they shall handle relevant formalities according to stipulations on administration of registration and filing.\n\n根据上述已知信息，请将'第四十九条 化妆品注册证不得转让。因企业合并、分立等法定事由导致原注册人主体资格注销，将注册人变更为新设立的企业或者其他组织的，应当按照本办法的规定申请变更注册。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 49 The transfer of cosmetic registration license is prohibited. The change application of registration shall be followed in accordance with these Provisions, if the registrant is changed to a new company or another organization due to company merger or split causing the cancellation of the original registrant as an entity."
    },
    {
        "instruction":"已知信息：\n'在测试时使用与产品相似的物料。对照物料必须与测试产品有着相同的体 积和相似的包装。在许多情况下，过滤灭菌和高压灭菌的蛋白胨水（USP 流体 A）可用于此目的。'可被翻译为：Use a material similar to the product under test. The control material must be of the same volume, and similarly packaged as the test product. Filter- sterilized and autoclaved Peptone water (USP Fluid A) may be useful for this purpose in many cases.\n'使用与待测物特异性结合的试剂，对目标待测物进行分析的方法。使用标记的试剂检测待测物，例如酶、放射性同位素、荧光团或发色团。反应在微孔板、试管或光盘等中进行。'可被翻译为：A method to analyse an analyte of interest using reagents that specifically bind to the analyte. The analyte is detected using reagents labelled with e.g., an enzyme, radioisotope, fluorophore or chromophore. Reactions are carried out in microtitre plates, test tubes, disks, etc.\n'使用相似尺寸、形状、材质和相似包装的物料作为待测产品。尽可能复制相关的 和不寻常的特征，这些可能反映无菌测试的可信度。'可被翻译为：Use materials similar in size, shape, and texture, and similarly packaged as product under test. Replicate as nearly as possible pertinent, unusual features that may reflect on the credibility of the sterility test.\n'流动相携带待测组分在色谱柱内向前移动并流出色谱柱的过程。'可被翻译为：The process by which the mobile phase carries the components under test forward within and out of the column.\n\n根据上述已知信息，请将'使用针孔、阀门、连通器等相似的管子或其他容器作为待测产品。使用 USP 流体D冲洗内腔。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Use tubing or other containers similarly fitted with needles, valves, connectors, etc., as the product under test. Use USP Fluid D to flush lumens."
    },
    {
        "instruction":"已知信息：\n'微生物接种到液体培养基培养一段时间后，经微生物代谢合成菌体及分泌产物的液体。'可被翻译为：The liquid in which the microorganisms are inoculated into the liquid medium for a period of time and then metabolized to synthesize the bacteria and secrete the products.\n'能产生抗生素等次级代谢产物的微生物。'可被翻译为：Microorganisms that produce secondary metabolites such as antibiotics.\n'将次级代谢产物产生菌进行诱变处理或基因操作，筛选出阻断某种目的代谢产物合成能力的突变体。'可被翻译为：Secondary metabolite producing bacteria were mutagenically treated or genetically manipulated to screen out mutants that blocked the ability of metabolite synthesis for a certain purpose.\n'微生物生长过程中合成代谢产物的量逐渐增多，直至产物合成能力衰退的阶段。'可被翻译为：During microbial growth, the amount of anabolic products gradually increases until the stage of product synthesis decline.\n\n根据上述已知信息，请将'微生物包括细菌、真菌、藻类和原生动物合成并分泌到体外的一种代谢产物。其主要成分为蛋白质，通过破坏细胞或干扰细胞正常代谢对宿主产生损害。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A metabolite synthesized and secreted into the body by microorganisms including bacteria, fungi, algae and protozoa. Its main component is protein, which damages the host by destroying cells or interfering with normal cell metabolism."
    },
    {
        "instruction":"已知信息：\n'药师对患者提供合理用药指导、普及合理用药知识等药学服务的过程，以提高患者用药知识水平，\n提高用药依从性，降低用药错误发生率，保障医疗质量和医疗安全。'可被翻译为：The process of pharmacists providing patients with guidance on rational drug use, disseminating knowledge about appropriate medication practices, and offering pharmaceutical services aims to elevate patients' understanding of medications. This, in turn, enhances medication adherence, reduces the occurrence of medication errors, and safeguards the quality and safety of healthcare.\n'药师对医生和护士提出的用药建议，或对患者进行的用药教育，属于保障合理用药的药学专业技术服务。'可被翻译为：The drug use suggestions made by pharmacists to doctors and nurses, or drug use education to patients, belong to the pharmaceutical professional technical services to ensure rational drug use.\n'负责药品管理、药学专业技术服务和药事管理工作，开展以患者为中心，以合理用药为核心的临\n床药学工作，组织药师参与临床药物治疗，提供药学专业技术服务的部门。'可被翻译为：The department responsible for medication management, pharmaceutical technical services, and pharmaceutical management. It conducts clinical pharmacy work centered around patients and focused on rational drug use. This department organizes pharmacists' involvement in clinical drug therapy and provides pharmaceutical professional technical services.\n'医疗机构以患者为中心，以临床药学为基础，对临床用药全过程进行有效的组织实施与管理，促\n进临床科学、合理用药的药学技术服务和相关的药品管理工作。'可被翻译为：Healthcare institutions, with a patient-centered approach and clinical pharmacy as the foundation, efficiently organize, implement, and manage the entire process of clinical drug use. This aims to facilitate pharmaceutical technical services and related drug management activities that promote clinical scientific and rational drug use.\n\n根据上述已知信息，请将'临床药师在病区内对患者开展以合理用药为目的的查房过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Clinical pharmacists conduct ward rounds in the patient care area with the aim of promoting rational drug use."
    },
    {
        "instruction":"已知信息：\n'（一）原辅包的使用必须符合药用要求，主要是指原辅包的质量、安全及功能应该满足药品制剂的需要。原辅包与药品\/制剂关联审评审批由原辅包登记人在登记平台上登记，药品\/制剂注册申请人提交注册申请时与平台登记资料进行关联；因特殊原因无法在平台登记的原辅包，药品\/制剂注册申请人也可在药品\/制剂注册申请时，一并提供原辅包研究资料。'可被翻译为：(1) The use of AEP must comply with the medical requirements, mainly referring to the quality, safety and function of AEP should meet the needs of the pharmaceutical preparation. The review & approval of AEP and drug\/preparation associated registration shall be registered on the registration platform by AEP registrant, and the drug\/preparation registration applicant shall associate the data with the platform registration data when submitting the registration application; for AEPs that cannot be registered on the platform for special reasons, it is also possible for drug\/preparation registration applicants to provide the AEP research dossiers together with the application for drug\/preparation registration.\n'（二）原辅包登记人负责维护登记平台的登记信息，并对登记资料的真实性和完整性负责。境内原辅包供应商作为原辅包登记人应当对所持有的产品自行登记。境外原辅包供应商可由常驻中国代表机构或委托中国代理机构进行登记，登记资料应当为中文，境外原辅包供应商和代理机构共同对登记资料的真实性和完整性负责。'可被翻译为：(2) AEP registrant is responsible for maintaining the registration information of the registration platform, and for the authenticity and completeness of the registration information. AEP supplier, as AEP registrant, shall register the product voluntarily. The overseas AEP suppliers maybe registered by their resident representative offices in China, or entrusted Chinese agencies. The registration information shall be in Chinese, and the overseas AEP supplier and agency shall be jointly responsible for the authenticity and completeness of the registration information.\n'（三）药品制剂注册申请人申报药品注册申请时，需提供原辅包登记号和原辅包登记人的使用授权书。'可被翻译为：(3) When applying for registration of a drug\/preparation, the applicant must provide the AEP registration number and the authorization letter of AEP registrant.\n'（十二）药品\/制剂注册申请关联审评时，原辅包登记平台研究资料不能满足审评需要的，药审中心可以要求药品制剂注册申请人或原辅包登记人进行补充。补充资料的报送途径由药审中心在发补通知中明确。'可被翻译为：(12) Where the research materials of AEP registration platform cannot meet the needs in the associated review of application for registration of drug\/preparation, CDE may require the applicant or the original registrant to supplement dossiers. The means of submission of supplementary information shall be specified by CDE in the notice for supplementary information.\n\n根据上述已知信息，请将'（十六）原辅包发生变更时原辅包登记人应主动开展研究，并及时通知相关药品\/制剂生产企业（药品上市许可持有人），并及时更新登记资料，并在年报中体现。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(16) Where any change arises for AEP, the AEP registrant shall initiate research on its own initiative, and promptly notify the relevant drug\/preparation production enterprise (Drug Marketing Authorization Holders), update the registration information in a timely manner and specify it in the annual report."
    },
    {
        "instruction":"已知信息：\n'通常，需要在IVRT方法开发过程中对不同的接收介质进行评估（采用与待评估的接收液具有化学兼容性的同一种膜）；根据药物（通常是疏水性的）在接收液中的溶解性和稳定性，接收介质通常是水-醇二元混合体系。接收液取样频率通常是在6个小时的研究中，每小时至少取样一次。'可被翻译为：It is conventional to evaluate different receptor solutions during IVRT method development (all using the same membrane that has broad chemical compatibility with the receptor solutions evaluated); these receptor solutions are frequently binary hydro-alcoholic mixtures selected based upon the solubility and stability of the (frequently hydrophobic) drug in the receptor solution. The receptor solutions are conventionally sampled at least hourly across a 6-hour duration.\n'一般情况下，在IVRT方法开发中，（使用相同的接收介质）对不同的膜进行评估；通常采用合成膜过滤溶液中的微粒物质。在IVRT膜的选择中，可根据膜的有效孔径（如0.45μm），以及它们对药物的预期惰性。应在IVRT方法开发报告中，提供每种膜对化合物结合的信息和膜本身对IVRT方法中所选接收液的惰性（根据IVRT方法开发的前一阶段），以及在IVRT中所用的每种膜的药物释放线性和精密度信息，这些信息有助于解释IVRT方法中膜选择的合理性。'可被翻译为：It is conventional to evaluate different membranes during IVRT method development (all using the same receptor solution); these membranes are frequently synthetic membranes used for the filtration of particulate matter in solutions. IVRT membranes are selected based upon their effective pore size (e.g., 0.45 micrometers (μm)), as well as their expected inertness to binding the drug. Information should be provided in the IVRT method development report on each membrane’s binding to the drug and its chemical compatibility with relevant receptor solution(s) selected for the IVRT method (based on the preceding phase of IVRT method development), as well as information on the linearity and precision of the resulting release rate when each membrane is used in an IVRT, as this information can help to explain why a specific membrane is optimal for the IVRT method.\n'如适用，接收液中样品分析方法的验证应包括相关的稀释完整性确认，以及样品在最高相关温度的接收液中放置最长相关时间的稳定性评估；最高相关温度可以略高于IVRT膜表面温度，因为接收液的温度通常高于膜表面温度（例如，当膜表面温度为32℃时，接收液温度可能是34℃，因此，IVRT接收液的稳定性评估可以设定为34℃维持6小时；而在阴道凝胶制剂的IVRT研究中，温度会更高）。'可被翻译为：The validation of the receptor sample analytical method should include relevant qualifications of dilution integrity, if applicable, as well as stability assessments with the highest relevant temperature in the receptor solution for the longest relevant duration; the highest relevant temperature may be warmer than the IVRT membrane surface temperature because the temperature of the receptor solution is often higher than the temperature at the surface of the membrane (e.g., the temperature of the receptor solution may be 34°C when the temperature of membrane surface is 32°C, so stability assessments with the IVRT receptor solution may be performed at 34°C for 6 hours; the temperature would be higher for an IVRT with a vaginal gel, for example).\n'虽然在IVRT方法开发的探索性研究中，可以采用未验证的样品分析方法，但作为IVRT方法验证的一部分，在IVRT方法验证时，必须采用已验证的样品分析方法。已验证的IVRT方法应当使用已验证的接收液样品分析方法。因此，该部分讨论用于IVRT方法的样品分析方法。'可被翻译为：While exploratory studies performed during IVRT method development may use an unvalidated sample analytical method, it is essential that all studies conducted as part of the IVRT method validation use a validated sample analytical method. A validated IVRT method should use a validated receptor solution sample analytical method. Therefore, a discussion of the sample analytical method for the IVRT method is included in this guidance under this section.\n\n根据上述已知信息，请将'选择最佳接收液作为IVRT方法开发初始步骤的一个优点是，在使用接收液对不同膜评估前，可先采用选定的接收液对样品分析方法进行优化。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"One advantage of selecting an optimal receptor solution as an initial step in IVRT method development is that it allows for the sample analysis method to be optimized for the selected receptor solution sample matrix before proceeding to an evaluation of different membranes using that receptor solution."
    },
    {
        "instruction":"已知信息：\n'第六条  药品监督管理部门依法设置或者指定的医疗器械检查、检验、监测与评价等专业技术机构，按照职责分工承担相关技术工作并出具技术意见，为医疗器械经营监督管理提供技术支持。'可被翻译为：Article 6 The drug regulatory departments shall set or designate professional technical institutions for inspection, testing, monitoring, and reevaluation, etc. of medical devices according to law, to assume relevant technical work and issue technical opinions in accordance with division of responsibilities, and provide technical support for supervision and administration of medical device distribution.\n'药品监督管理部门依法设置或者指定的药品审评、检验、核查、监测与评价等专业技术机构，依职责承担相关技术工作并出具技术结论，为药品生产监督管理提供技术支撑。'可被翻译为：The professional technical institutions for drug review, testing, inspection, monitoring and evaluation set or designated by drug regulatory departments shall undertake the technical work and draw technical conclusions according to their duties, providing technical supports for the regulation of drug manufacture.\n'第十一条 药品监督管理部门设置或者指定的药品专业技术机构，承担依法实施药品监督管理所需的审评、检验、核查、监测与评价等工作。'可被翻译为：Article 11 The drug professional and technical institutions established or designated by drug regulatory departments shall perform review, testing, inspection, monitoring and assessment as required by the conduct of drug administration in accordance with the law.\n'省、自治区、直辖市药品监督管理部门设置或者指定的药品专业技术机构，承担依法实施药品监督管理所需的审评、检验、核查、监测与评价等工作。'可被翻译为：Specialized technical institutions for drugs set up or designated by drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government shall undertake the review, testing, inspection, monitoring and evaluation and other tasks required for drug supervision and administration in accordance with the law.\n\n根据上述已知信息，请将'第六条  药品监督管理部门依法设置或者指定的医疗器械审评、检查、检验、监测与评价等专业技术机构，按照职责分工承担相关技术工作，为医疗器械生产监督管理提供技术支撑。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 6 The drug regulatory department shall set or designate professional technical institutions for review, inspection, testing, monitoring and reevaluation, etc. of medical devices according to law, to assume relevant technical work in accordance with division of responsibilities, and to provide technical support for supervision and administration of medical device manufacturing."
    },
    {
        "instruction":"已知信息：\n'补料'可被翻译为：feeding\n'连续补料'可被翻译为：continuous feeding\n'补料分批发酵'可被翻译为：fed-batch fermentation\n'补料速率'可被翻译为：feed rate\n\n根据上述已知信息，请将'在发酵过程中一边补入新鲜料液，一边以相近的流速放料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The addition of fresh liquid at a similar flow rate during fermentation."
    },
    {
        "instruction":"已知信息：\n'第四十五条 医疗器械注册证遗失的，注册人应当立即在原发证机关指定的媒体上登载遗失声明。自登载遗失声明之日起满1个月后，向原发证机关申请补发，原发证机关在20个工作日内予以补发。'可被翻译为：Article 45 Where a medical device registration certificate is lost, the registrant shall publish a loss declaration immediately at the media specified by the original certificate-issuing authority, and apply after 1 month of declaration to the original certificate-issuing authority for re-issuing the certificate. The original certificate-issuing authority shall re-grant the medical device registration certificate within 20 workdays.\n'第二十一条 药品生产许可证遗失的，药品上市许可持有人、药品生产企业应当向原发证机关申请补发，原发证机关按照原核准事项在十日内补发药品生产许可证。许可证编号、有效期等与原许可证一致。'可被翻译为：Article 21 In the event that a drug MAH or manufacturer has lost the Drug Manufacturing Certificate, they may apply to the original issuing authority for a replacement of the Certificate. The original issuing authority shall issue the replacing Drug Manufacturing Certificate with the same previously authorized contents within 10 days. The information such as Certificate number and valid term specified on the replacing Certificate shall be the same as that specified on the original Certificate.\n'第十九条  医疗器械生产许可证遗失的，应当向原发证部门申请补发。原发证部门应当及时补发医疗器械生产许可证，补发的医疗器械生产许可证编号和有效期限与原许可证一致。'可被翻译为：Article 19 If the Medical Device Manufacturing License is lost, the applicant shall apply to the former license issuing department for re-issuance. The former license issuing department shall promptly re-issue the Medical Device Manufacturing License, and the number and valid term of the re-issued Medical Device Manufacturing License shall be consistent with those of the former license.\n'第十九条  医疗器械经营许可证遗失的，应当向原发证部门申请补发。原发证部门应当及时补发医疗器械经营许可证，补发的医疗器械经营许可证编号和有效期限与原许可证一致。'可被翻译为：Article 19 If the Medical Device Distribution License is lost, an application for re-issuance shall be made to the former license issuing department. The former license issuing department shall promptly re-issue the Medical Device Distribution License, and the number and valid term of the re-issued Medical Device Distribution License shall be consistent with those of the former license.\n\n根据上述已知信息，请将'第五十四条 医疗器械注册证遗失的，注册人应当立即在原发证机关指定的媒体上登载遗失声明。自登载遗失声明之日起满1个月后，向原发证机关申请补发，原发证机关在20个工作日内予以补发。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 54 Where a medical device registration certificate is lost, the registrant shall publish a loss declaration immediately at the media specified by the original certificate-issuing authority, and apply after 1 month of declaration to the original certificate-issuing authority for re-issuing the certificate. The original certificate-issuing authority shall re-issue the medical device registration certificate within 20 workdays."
    },
    {
        "instruction":"已知信息：\n'由于某种原因不能选用首选药用于治疗时，可供选用的药物品种。'可被翻译为：A variety of drugs that can be used for treatment when the preferred drug cannot be used for some reason.\n'治疗方案中，所用药物的品种、剂量、疗程等严重超过常规或通常需要的情况。均属不合理用药。'可被翻译为：The variety, dosage, duration, etc. of drugs used in a treatment plan seriously exceeds the routine or usual need. All are irrational drug use.\n'按正常用法、用量应用药物预防、诊断或治疗疾病过程中，发生于治疗目的无关的有害反应。'可被翻译为：According to the normal usage, dosage of the drug to prevent, diagnose or treat the disease process, occurred in the therapeutic purpose unrelated harmful reactions.\n'治疗方案欠缺或由于依从性的原因，导致用药剂量或疗程不足的现象。'可被翻译为：Insufficient dosage or duration of medication due to lack of treatment plan or due to compliance.\n\n根据上述已知信息，请将'药物治疗中所选用药品单次用量偏大或疗程偏长。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The drug used in drug therapy is too large or the course of treatment is too long."
    },
    {
        "instruction":"已知信息：\n'省、自治区、直辖市药品监督管理部门负责本行政区域医疗器械生产监督管理信息化建设和管理工作，按照国家药品监督管理局的要求统筹推进医疗器械生产监督管理信息共享。'可被翻译为：The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall be responsible for the construction and management of information technology for supervision and administration of medical device manufacturing within the administrative areas, and the coordination and promotion of information sharing on supervision and administration of medical device manufacturing as required by NMPA.\n'省、自治区、直辖市药品监督管理部门负责本行政区域的医疗器械经营监督管理工作。'可被翻译为：The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall be responsible for supervision and administration of medical device distribution within their administrative areas.\n'省、自治区、直辖市药品监督管理部门负责本行政区域第二类、第三类医疗器械生产监督管理，依法按照职责负责本行政区域第一类医疗器械生产监督管理，并加强对本行政区域第一类医疗器械生产监督管理工作的指导。'可被翻译为：The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall be responsible for supervision and administration of Class II and Class III medical device manufacturing within their administrative areas, be responsible for the supervision and administration of Class I medical device manufacturing within their administrative areas in accordance with their duties according to law, and strengthen guidance for the supervision and administration of Class I medical device manufacturing within their administrative areas.\n'第七条  国家药品监督管理局加强医疗器械经营监督管理信息化建设，提高在线政务服务水平。'可被翻译为：Article 7 NMPA shall strengthen the construction of information technology for supervision and administration of medical device distribution, and improve the level of online government services.\n\n根据上述已知信息，请将'省、自治区、直辖市药品监督管理部门负责本行政区域医疗器械经营监督管理信息化建设和管理工作，按照国家药品监督管理局要求统筹推进医疗器械经营监督管理信息共享。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall be responsible for the construction and management of information technology for supervision and administration of medical device distribution within the administrative areas, and the coordination and promotion of information sharing on supervision and administration of medical device distribution as required by NMPA."
    },
    {
        "instruction":"已知信息：\n'本节提供的程序信息可用于动力学分析方法。动力学色度和浊度试剂可通过商业化获取。 分析过程可作为试剂盒采购。控制标准内毒素、检测中所用LAL试剂和无热源水的 COA应保存。其它物料如无热源移液管、微量移液头、试管和96阱微生物碟可从不同 供应商处采购。实验室亦应保存显示这些物料无热源的COA。'可被翻译为：This section provides procedural information that can be applied to kinetic assays. The Kinetic Chromogenic and Turbidimetric reagents are commercially available. Assay may be purchased as a kit. A certificate of analysis should be maintained for the control standard endotoxin, Limulus Amebocyte Lysate (LAL), and pyrogen free water used in the assay. Other materials such as pyrogen free pipettes, micropipettor tips, test tubes, and 96- well microplates may be purchased from various vendors. Certificates of analysis indicating these materials are pyrogen-free should also be maintained by the laboratory.\n'移液管'可被翻译为：Pipettes\n'标准实验室玻璃仪器如烧杯、漏斗、烧瓶、圆颈培养瓶和1-2升的瓶子也是必须的。一 次性无菌设备，如试管 、培养皿和血清移液管，只要不影响效价检测的定量就可以一直 使用。其它设备包括不锈钢瓶、比色皿、血清移液管、单通道微量移液器、pH计、加热 板、可调温水浴锅、培养箱和手动\/自动平板计数器或紫外可见分光光度计。'可被翻译为：Standard laboratory glassware such as beakers, funnels, flasks, roux and 1-2 liter bottles are also required. Sterile and disposable equipment such as test tubes, petri-plates and serological pipettes may be used so long as the use of this equipment does not affect the quantitative aspect of potency testing. Additional equipment includes a stainless steel penicylinders, penicylinder dropper, cuvettes, pipettor and micropipette, pH meter, hot plate, adjustable- temperature water bath, incubator and a manual\/automatic plate reader or UV- VIS spectrophotometer.\n'红移'可被翻译为：red shift\n\n根据上述已知信息，请将'注：无热源移液管、微量移液头、试管和其它用品均有商业化产品可及。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NOTE: Pyrogen free pipettes, micropipettor tips, test tubes, and other accessories are commercially available."
    },
    {
        "instruction":"已知信息：\n'染色体数目与原来的染色体单倍体或二倍体不同；对于细胞系，其染色体数目与原型染色体不同。'可被翻译为：Chromosome numbers different from the original haploid or diploid set of chromosomes; for cell lines, chromosome numbers differe nt from the modal chromosome set.\n'染色体结构的损伤。表现为两个染色单体相同位点均出现断裂或断裂重组的改变。'可被翻译为：Damage to chromosome structure. Both chromatids appear to be broken or recombined at the same site.\n'位于同一染色体上彼此相邻近的一组相关基因。'可被翻译为：A group of related genes located in close proximity to each other on the same chromosome.\n'染色体畸变'可被翻译为：chromosome aberration\n\n根据上述已知信息，请将'染色体的一部分置换到不同染色体上，或同一染色体的不同位点上。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Part of a chromosome is replaced on a different chromosome, or at a different site on the same chromosome."
    },
    {
        "instruction":"已知信息：\n'有一些与 SUS 有关的特定风险，应作为 CCS 的一部分予以评估。这些风险包括但不限于：'可被翻译为：There are some specific risks associated with SUS which should be assessed as part of the CCS. These risks include but are not limited to:\n'质量风险管理应作为系统性流程执行，用于评估、控制、沟通和回顾风险。'可被翻译为：6.5. Quality risk management should be implemented as a systematic process for the assessment, control, communication and review of risks.\n'一个系统的信息组织过程，以支持风险管理过程中的风险决策。包括危害的识别和与 危害物质暴露相关的分析和风险评估。（ICH Q9）'可被翻译为：A systematic process of organizing information to support a risk decision to be made within a risk management process. It consists of the identification of hazards and the analysis and evaluation of risks associated with exposure to those hazards. (ICH Q9)\n'无菌工艺应被明确定义。无菌工艺相关风险以及任何相关要求应被识别、评估并适当控制。工厂的 CCS应明确规定这些控制的可接受标准、监测要求及其有效性审核。应描述并执行控制这些风险的方法和程序。可接受的残留风险应形成正式记录。'可被翻译为：The aseptic process should be clearly defined. The risks associated with the aseptic process, and any\nassociated requirements, should be identified, assessed and appropriately controlled. The site's CCS should clearly\ndefine the acceptance criteria for these controls, requirements for monitoring and the review of their effectiveness.\nMethods and procedures to control these risks should be described and implemented. Accepted residual risks\nshould be formally documented.\n\n根据上述已知信息，请将'在 CCS 的制定和维护中进行风险管理，来识别、评估、减少\/消除（如适用）和控制污染风险。风险管理应书面化，并应包括降低风险和接受剩余风险有关决策的理由。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Risk management is applied in the development and maintenance of the CCS, to identify, assess,\nreduce\/eliminate (where applicable) and control contamination risks. Risk management should be documented and should include the rationale for decisions taken in relation to risk reduction and acceptance of residual risk."
    },
    {
        "instruction":"已知信息：\n'二、增加吉林省药品监督管理局为口岸药品监督管理部门，由其承担长春空港口岸药品进口备案的具体工作。'可被翻译为：II. Jilin Medical Products Administration is added as the port drug regulatory authority, which shall undertake the specific drug import filing at Changchun AirPort.\n'国家药监局 海关总署关于增设无锡航空口岸、江阴港口岸为药品进口口岸的公告'可被翻译为：NMPA and General Administration of Customs issued the Announcement on the Setting up of Wuxi Airport and Jiangyin Port as Drug Import Ports\n'三、增加无锡市药品安全检验检测中心为口岸药品检验机构。自本公告发布之日起，无锡市药品安全检验检测中心开始承担无锡航空口岸、江阴港口岸的药品口岸检验工作。'可被翻译为：III. Wuxi Center for Drug Safety Inspection and Testing is added as the port drug inspection agency. As of the date of issuance of this Announcement, WuxiCenter for Drug Safety Inspection and Testing starts to undertake the drug port inspection at Wuxi Airport and Jiangyin Port.\n'根据《中华人民共和国药品管理法》，经国务院批准，同意增设无锡航空口岸、江阴港口岸为药品进口口岸。现将有关事宜公告如下：'可被翻译为：According to the Drug Administration Law of the People's Republic of China, upon the approval of the State Council, it is agreed to set up Wuxi Airport and Jiangyin Port as drug import ports. The relevant matters are announced as follows:\n\n根据上述已知信息，请将'二、增加无锡市市场监督管理局为口岸药品监督管理部门，由其承担无锡航空口岸、江阴港口岸药品进口备案的具体工作。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"II. Wuxi Administration of Market Regulation is added as the port drug regulatory authority, which shall undertake the specific drug import filing at Wuxi Airport and Jiangyin Port."
    },
    {
        "instruction":"已知信息：\n'在 FFS 确认过程中确定的控制措施应与 CCS 保持一致。应考虑的方面包括但不限于：'可被翻译为：The controls identified during qualification of FFS  should be in alignment with the CCS. Aspects to be considered include but are not limited to:\n'CCS 中要考虑的要素应包括（但不限于）:'可被翻译为：Elements to be considered within a CCS should include (but are not limited to):\n'BFS 的关键工艺参数应在设备确认过程中确定，包括但不限于：'可被翻译为：Critical  process  parameters  for  BFS  should  be  determined  during  equipment  qualification  and  should include, but are not limited to:\n'在验证过程中考虑并确定的过滤参数，包括但不限于：'可被翻译为：Filtration parameters that should be considered and established during validation should include, but are not limited to:\n\n根据上述已知信息，请将'BFS 确认过程中确定的控制措施应与工厂的 CCS 保持一致。应考虑的方面包括但不限于：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The controls identified during qualification of BFS should be in alignment with the site's CCS. Aspects to be considered include but are not limited to:"
    },
    {
        "instruction":"已知信息：\n'八、本通告自发布之日起实施，《关于药械组合产品注册有关事宜的通告》（原国家食品药品监督管理局通告2009年第16号）和《关于调整药械组合产品属性界定有关事项的通告》（国家药品监督管理局通告2019年第28号）同时废止。'可被翻译为：VIII. The Notice shall be implemented as of the date of issuance. The Notice on Matters Concerning the Registration of Drug-device Combination Products(Former CFDA Notice [2009] No. 16)and the Notice on Matters Concerning the Adjustment of Attribute Definition of Drug-device Combination Products(NMPA Notice [2019] No. 28) shall be simultaneously abolished.\n'为进一步规范药械组合产品属性界定工作，根据国家药品监督管理局事业单位“三定”规定，现就调整药械组合产品属性界定有关事项通告如下：'可被翻译为：To further standardize the definition of the attributes of Drug\/Device Combination Products, according to the Three- Determinations (of posts, duties and staffing) regulations for NMPA institutions, on May 31, 2019, NMPA announced the relevant matters as follows:\n'八、其他药械组合产品注册事项按照《关于药械组合产品注册有关事宜的通告》（国家食品药品监督管理局通告2009年第16号）的规定执行。'可被翻译为：VIII. Other registration issues of Drug\/ Device Combination Products shall be handled in accordance with the Announcement on Matters Concerning the Definition of the Attributes of Drug\/ Device Combination Products (SFDA Announcement No. 16 of 2009).\n'四、标管中心对受理的药械组合产品属性界定申请资料进行审查，按程序提出属性界定意见，在药械组合产品属性界定信息系统中告知申请人，并及时在其网站对外公布药械组合产品属性界定结果。'可被翻译为：IV. The CMDSM shall review the dossiers for accepted attribute definition application of drug-device combination products, propose opinions on attribute definition as per the procedure, inform the applicants in the Information System for Attribute Definition of Drug-Device Combination Products, and in a timely manner issue the attribute definition results of drug-device combination products to the public on website.\n\n根据上述已知信息，请将'关于调整药械组合产品属性界定有关事项的通告【废止】'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA issued the Announcement on Adjusting the Relevant Matters Concerning the Definition of the Attributes of Drug\/Device Combination Products"
    },
    {
        "instruction":"已知信息：\n'第五十六条 国家药品监督管理局和省、自治区、直辖市药品监督管理部门组织监督检查时，应当制定检查方案，明确检查标准，如实记录现场检查情况，需要抽样检验或者研究的，按照有关规定执行。检查结论应当清晰明确，检查发现的问题应当以书面形式告知被检查单位。需要整改的，应当提出整改内容及整改期限，必要时对整改后情况实施检查。'可被翻译为：Article 56 When organizing supervision and inspections, the NMPA and the drug regulatory authority of the province, autonomous region or municipality directly under the Central Government shall make inspection plans to clarify the inspection standards, record the on-site inspections truthfully, conduct the inspections in accordance with relevant rules when sample testing or study is required. The conclusion of the inspection shall be clear and unambiguous, and the problems found during the inspection shall be notified to the inspected company in written format. If corrective actions are required, the content and the deadline of corrective actions shall be proposed, and the situation after the remediation shall be inspected if necessary.\n'检查结束后10日内，核查中心应当组织对批签发机构提出的相关批次产品的质量风险进行技术评估，作出明确结论，形成现场检查报告送批签发机构并报食品药品监管总局。境外现场检查时限由食品药品监管总局根据具体情况确定。'可被翻译为：The CFDI shall, within 10 days upon completion of the inspection, organize the technical evaluation on the quality risks of relevant batches of products proposed by the lot release institution, make a clear conclusion, form an on-site inspection report and send it to the lot release institution and the CFDA. The CFDA will determine the time limit for on-site inspection overseas depending on specific conditions.\n'记录应当及时、准确、完整，客观真实反映现场检查情况。'可被翻译为：The records shall timely, accurately, completely, objectively and truthfully reflect the situation of the on-site inspection.\n'派出单位负责对现场检查结论进行综合研判。'可被翻译为：The dispatching unit is responsible for the comprehensive analysis and assessment of the on-site inspection conclusion.\n\n根据上述已知信息，请将'第五十八条 现场检查结束后，应当对现场检查情况进行分析汇总，并客观、公平、公正地对检查中发现的缺陷进行风险评定并作出现场检查结论。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 58 After the on-site inspection, the results shall be analyzed and summarized; risks of deficiencies found in the inspection shall be assessed objectively, fairly and impartially, and the on-site inspection conclusion shall be made."
    },
    {
        "instruction":"已知信息：\n'1.一种原料、中间产品或成品被另一种原料或产品污染。\n2.一种原料、中间产品或成品在生产过程中被另一种原料或产品污染。\n3.一种原料、中间产品或成品在生产过程中被另一种原料或产品污染。\n4.污染:一种材料或产品被另一种材料或产品污染\n5.在生产、储存、运输过程中，原料药、中间产品或药品成品被另一原料药或产品污染的。\n6.在生产、储存、运输过程中，原料药、中间产品、药品、医疗产品被其他原料药、产品污染的。'可被翻译为：1.Contamination of a starting material, intermediate product or finished product with another starting material or product.\n2.Contamination of a starting material, intermediate product or finished product with another starting material or product during production.\n3.Contamination of a starting material, intermediate product or finished product with another starting material or product during production.\n4.Contamination of a material or product with another material or product.\n5.Contamination of a starting material, intermediate product or finished pharmaceutical product with another starting material or product during production, storage and transportation.\n6.Contamination of a starting material, intermediate product or ﬁnished pharmaceutical product or medical product with another starting material or product, during production, storage and transportation.\n'不同原料、辅料及产品之间发生的相互污染。'可被翻译为：Contamination of raw materials and excipients (starting materials) or of a product with another material or product.\n'一种原料或制品污染了另一种原料或制品。'可被翻译为：Contamination of a material or product with another material or product.\n'是指预期产品或产品相关物质长时间放置和\/或受光、温度、pH、水的作用或与辅料、直接接触的容器\/密闭系统发生反应而产生的分子变异体。在生产和\/或贮藏过程中也可能发生这些变化(如脱酰胺、氧化、聚合、蛋白水解)。降解产物可能是产品相关物质,亦可能是产品相关杂。'可被翻译为：Molecular variants resulting from changes in the desired product or product-related substances brought about over time and\/or by the action of, e.g., light, temperature, pH, water, or by reaction with an excipient and\/or the immediate container\/closure system. Such changes may occur as a result of manufacture and\/or storage (e.g., deamidation, oxidation, aggregation, proteolysis). Degradation products may be either product-related substances, or product-related impurities.\n\n根据上述已知信息，请将'生产过程中原料、辅料、中间产品或成品之间，或与其他的原料或产品的不适当接触而产生的污染。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Pollution resulting from improper contact between raw materials, auxiliary materials, intermediate products or finished products, or with other raw materials or products in the production process."
    },
    {
        "instruction":"已知信息：\n'批生产： 已执行的批记录、放大信息、风险评估、关键工艺参数、中控标准、放大方案和报告、工艺验证'可被翻译为：Batch manufacturing: Master of executed batch record; Scale up information; Risk assessment; Critical process parameters; In-process control specification; Scale up protocol and report; Process validation\n'批准后变更管理方案'可被翻译为：pacmp\n'注册管理事项变更包括药品注册批准证明文件及其附件载明的技术内容和相应管理信息的变更，具体变更管理要求按照《药品注册管理办法》及相关技术指导原则的有关规定执行。'可被翻译为：The change of administrative items for registration includes the change of technical content and corresponding management information as specified in the drug registration approval documents and attachments thereof, and the specific change management requirements shall follow the Provisions for Drug Registration and relevant technical guidelines.\n'第十一条 持有人名称、生产企业名称、生产地址名称等变更，应当完成药品生产许可证相应事项变更后，向所在地省级药品监管部门就药品批准证明文件相应管理信息变更进行备案。'可被翻译为：Article 11 For changing the names of MAH, manufacturer, manufacturing site and so on, after the change of corresponding items in the Drug Manufacturing Certificate is completed, the change shall be filed to the local provincial drug regulatory department to change the corresponding management information of drug approval documents.\n\n根据上述已知信息，请将'其它文件： 拒收批准信息、生物批信息、中试批信息、变更历史和变更管理、保存时间方案和报告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Other documents: Rejected batch information; Bio-batch information; Pilot batch information; History of changes and change management; Hold time protocols and reports"
    },
    {
        "instruction":"已知信息：\n'第二十九条 疫苗批签发应当逐批进行资料审核和抽样检验。疫苗批签发检验项目和检验频次应当根据疫苗质量风险评估情况进行动态调整。'可被翻译为：Article 29 For lot release of vaccines, dossier review and sample testing shall be conducted lot by lot. The testing items and testing frequency for lot release of vaccines shall be dynamically adjusted according to the vaccine quality risk evaluation.\n'第十九条    疫苗批签发应当逐批进行资料审核和抽样检验，其他生物制品批签发可以采取资料审核的方式，也可以采取资料审核和样品检验相结合的方式进行，并可根据需要进行现场核实。对不同品种检验项目和检验比例，由中检院负责组织论证，并抄报国家药品监督管理局。批签发机构按照确定的检验要求进行检验。'可被翻译为：Article 19  For the lot release of vaccines, dossier review and sample testing shall be conducted lot by lot. For other biological products, lot release may be conducted by means of independent dossier review or by combining dossier review with sample testing, and on-site verification may be conducted as required. For the testing items and testing proportion for different varieties, the NIFDC shall organize the demonstration and submit a copy to the NMPA. Each lot release institution shall conduct test in accordance with the determined specifications.\n'第二十八条 预防、控制传染病疫情或者应对突发事件急需的疫苗，经国务院药品监督管理部门批准，免予批签发。'可被翻译为：Article 28 Vaccines urgently needed to prevent and control outbreaks of infectious diseases or emergencies may be exempted from lot release at the approval of the drug regulatory department under the State Council.\n'第十八条    预防、控制传染病疫情或者应对突发事件急需的疫苗，经国家药品监督管理局批准，免予批签发。'可被翻译为：Article 18 Vaccines, urgently needed to prevent and control outbreaks of infectious diseases or emergencies, may be exempted from lot release procedure after the approval of the NMPA.\n\n根据上述已知信息，请将'二是规范批签发管理要求，明确批签发豁免情形、检验项目和频次要求，强化生产工艺偏差管理。依照《疫苗管理法》规定，明确预防、控制传染病疫情或者应对突发事件急需的疫苗，经国家药监局批准，免予批签发。对疫苗产品和其他生物制品批签发方式、检验项目和频次分别作出细化规定，要求疫苗批签发应当逐批进行资料审核和抽样检验。规定在批签发申报时应当提交生产工艺偏差等有关资料，由批签发机构对相关资料进行审核、开展现场检查等。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2. Standardization of administrative requirements for lot release, clarifying the exemptions, inspection items and frequency requirements for lot release, and emphasizing control over production process deviations. According to the Vaccine Administration Law, vaccines that are urgently needed to prevent and control infectious diseases or respond to emergencies shall be exempted, with NMPA approval, from lot release. Detailed regulations have been made on the lot release methods, inspection items, and frequency for vaccines and other biological products, and it is required that the lot release of vaccines should be subject to dossier review and sampling inspection. It is stipulated that relevant dossiers such as production process deviation should be submitted while applying for lot release, to facilitate the competent agency's review and on-site inspections."
    },
    {
        "instruction":"已知信息：\n'第二百三十四条 持续稳定性考察的时间应当涵盖药品有效期，考察方案应当至少包括以下内容：'可被翻译为：Article 234: The protocol for an on-going stability program should extend to the end of the shelf life period and should at least include the following contents:\n'第三十九条 申请人完成临床试验后，应当向国家食品药品监督管理局提交临床试验总结报告、统计分析报告以及数据库。'可被翻译为：Article 39 After completion of a clinical trial, the applicant shall submit a clinical trial final report, a statistical analysis report and its database to the State Food and Drug Administration.\n'第二百三十五条 考察批次数和检验频次应当能够获得足够的数据，以供趋势分析。通常情况下，每种规格、每种内包装形式的药品，至少每年应当考察一个批次，除非当年没有生产。'可被翻译为：Article 235: The number of batches and frequency of testing should provide a sufficient amount of data to allow trend analysis. Unless otherwise justified, at least one batch per year of product manufactured in every strength and every primary packaging type, should be included in the stability program, unless none are produced during that year.\n'第二百三十七条 关键人员，尤其是质量受权人，应当了解持续稳定性考察的结果。当持续稳定性考察不在待包装产品和成品的生产企业进行时，则相关各方之间应当有书面协议，且均应当保存持续稳定性考察的结果以供药品监督管理部门审查。'可被翻译为：Article 237: Results of on-going stability studies should be made available to key personnel and, in particular, to the Authorized Person(s). Where on-going stability studies are carried out at a site other than the site of manufacture of the bulk or finished product, there should be a written agreement between the parties concerned. Results of on-going stability studies should be available at both sites for review by regulatory authority.\n\n根据上述已知信息，请将'第二百三十九条 应当根据所获得的全部数据资料，包括考察的阶段性结论，撰写总结报告并保存。应当定期审核总结报告。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 239: A summary of all the data generated, including any interim conclusions on the program, should be written and maintained. This summary should be subjected to periodic review."
    },
    {
        "instruction":"已知信息：\n'1.药物起始原料是一种活性药物成分(API)或赋形剂，预定或指定用于药品生产。\n2.在药品生产中使用的具有一定质量的物质，但不包括包装材料。这包括活性药物成分(api)和药用辅料。'可被翻译为：1.A pharmaceutical starting material is an active pharmaceutical ingredient (API) or an excipient intended or designated for use in the production of a pharmaceutical product.\n2.Any substance of a defined quality used in the production of a pharmaceutical product, but excluding packaging materials. This includes active pharmaceutical ingredients (APIs) and pharmaceutical excipients.\n'压力测试(有效药物成分(API))'可被翻译为：stress testing (of the active pharmaceutical ingredient (api))\n'在本章中，“药物”一词更一般地指活性成分，可能包括不被视为药物的活性成分(如防晒霜活性成分)。'可被翻译为：In this chapter, the term “drug” is utilized to refer more generally to active ingredients, potentially including active ingredients that may not be considered drugs (e.g., sunscreen active ingredients).\n'活性药物成分'可被翻译为：API active pharmaceutical ingredient\n\n根据上述已知信息，请将'生产、包装和标记活性药物成分(api)的公司。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A company that produces, packages and labels active pharmaceutical ingredients (APIs)."
    },
    {
        "instruction":"已知信息：\n'（一）存放于标志明显的专用场所，并有效隔离，不得销售；'可被翻译为：(I) Such drugs shall be stored in special places clearly marked and effectively isolated, and shall not be sold;\n'（一）按剂型、用途以及储存要求分类陈列，并设置醒目标志，类别标签字迹清晰、放置准确。'可被翻译为：(I) Adopting classified display according to the dosage form, indications and storage requirements, and setting up clear marks with legible labels and accurate placement;\n'第七十五条 收货人员对符合收货要求的药品，应当按品种特性要求放于相应待验区域，或者设置状态标志，通知验收。冷藏、冷冻药品应当在冷库内待验。'可被翻译为：Article 75 For drugs conforming to receipt requirements, the receiving personnel shall place them in the corresponding area for quarantine according to the characteristics and requirements of the varieties, or set status identification, and notify relevant personnel for acceptance inspection. The refrigerated and frozen drugs shall be placed in the freezer for quarantine.\n'（十）经营特殊管理的药品有符合国家规定的储存设施。'可被翻译为：(X) There shall be storage facilities conforming to national provisions for the drugs under special management.\n\n根据上述已知信息，请将'（十）经营非药品应当设置专区，与药品区域明显隔离，并有醒目标志。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(X) A special partition shall be set up for distributing non-drugs, which shall be clearly separated from the drug partition and provided with clear marks."
    },
    {
        "instruction":"已知信息：\n'（六）伤害发生的概率；'可被翻译为：(6) the probability of injury;\n'（四）危害的严重与紧急程度；'可被翻译为：(Ⅳ)  Severity and urgency of the harm;\n'严重伤害'可被翻译为：serious injury\n'2020年，国家药品不良反应监测中心收到的医疗器械不良事件报告中，伤害程度为死亡的报告218份，占报告总数的0.04%；伤害程度为严重伤害的报告32,874份，占报告总数的6.13%；伤害程度为其他的报告502,963份，占报告总数的93.83%。'可被翻译为：In 2020, among the medical device adverse event reports received by the National Center for ADR Monitoring, there were 218 (0.04%) reports of death, 32,874 (6.13%) reports of severe injury, and 502,963 (93.83%)reports of other injuries.\n\n根据上述已知信息，请将'1.危害发生的概率与危害严重程度的结合。\n2.伤害发生的概率和伤害的严重程度的组合(15)。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.Combination of the probability of occurrence of harm and severity of the harm.\n2.The combination of the probability of occurrence of harm and the severity of that harm (15)."
    },
    {
        "instruction":"已知信息：\n'境外生产药品的注册申请，药品注册申请受理后需要药品注册检验的，申请人应当按规定要求抽取样品，并将样品、检验所需资料及标准物质等送至中检院。'可被翻译为：For drugs manufactured overseas, where drug registration testing is necessary after the drug registration application is accepted, the applicant shall conduct sampling as required and send the samples, dossiers required for testing and reference standard to the NIFDC.\n'第五十五条 境内生产药品的注册申请，申请人在药品注册申请受理前提出药品注册检验的，向相关省、自治区、直辖市药品监督管理部门申请抽样，省、自治区、直辖市药品监督管理部门组织进行抽样并封签，由申请人将抽样单、样品、检验所需资料及标准物质等送至相应药品检验机构。'可被翻译为：Article 55 For drugs manufactured within the territory of the People’s Republic of China, where drug registration testing has been proposed before the drug registration application is accepted, the applicant can apply for sampling to the drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government, and the drug regulatory department shall organize to conduct the sampling and sealing. The applicant shall send the sampling form, samples, dossiers required for testing and reference standard to the corresponding drug testing institutions.\n'第五十六条 境内生产药品的注册申请，药品注册申请受理后需要药品注册检验的，药品审评中心应当在受理后四十日内向药品检验机构和申请人发出药品注册检验通知。申请人向相关省、自治区、直辖市药品监督管理部门申请抽样，省、自治区、直辖市药品监督管理部门组织进行抽样并封签，申请人应当在规定时限内将抽样单、样品、检验所需资料及标准物质等送至相应药品检验机构。'可被翻译为：Article 56 For drugs manufactured within the territory of the People's Republic of China, where drug registration testing is necessary after the drug registration application is accepted, the CDE shall, within 40 days after the acceptance, send the notice for drug registration testing to the drug testing institutions and the applicant. The applicant can apply for sampling to the drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government, and the drug regulatory department shall organize sampling and sealing. The applicant shall send the sampling form, samples, dossiers required for testing and reference standard to the corresponding drug testing institutions within the specified timeline.\n'第五十四条 申请人完成支持药品上市的药学相关研究，确定质量标准，并完成商业规模生产工艺验证后，可以在药品注册申请受理前向中检院或者省、自治区、直辖市药品监督管理部门提出药品注册检验；申请人未在药品注册申请受理前提出药品注册检验的，在药品注册申请受理后四十日内由药品审评中心启动药品注册检验。原则上申请人在药品注册申请受理前只能提出一次药品注册检验，不得同时向多个药品检验机构提出药品注册检验。'可被翻译为：Article 54 Having completed the relevant CMC study supporting drug marketing, the specifications establishment, and commercial-scale manufacturing process validation, the applicant may apply for drug registration testing to the NIFDC or the drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government before the drug registration application is accepted; Where the applicant does not propose drug registration testing before the drug registration application is accepted, the drug registration testing shall be initiated by the CDE within 40 days after accepting the drug registration application. In principle, the applicant can only propose drug registration testing once before the drug registration application is accepted, and may not propose drug registration testing to multiple drug testing institutions at the same time.\n\n根据上述已知信息，请将'境外生产药品的注册申请，申请人在药品注册申请受理前提出药品注册检验的，申请人应当按规定要求抽取样品，并将样品、检验所需资料及标准物质等送至中检院。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For drugs manufactured overseas, where drug registration testing has been proposed before the drug registration application is accepted, the applicant shall conduct sampling as required and send the samples, dossiers required for testing and reference standard to the NIFDC."
    },
    {
        "instruction":"已知信息：\n'（二）按照强制性标准以及经注册、备案的产品技术要求组织生产，实际生产与医疗器械注册备案、医疗器械生产许可备案等内容的一致情况；'可被翻译为：(2) organizing manufacturing in accordance with mandatory standards and registered or filed technical specifications for the products; consistency of  the actual manufacturing with the contents of medical device registration and filing, and medical device manufacturing licensing and filing, etc.;\n'医疗器械说明书和标签的内容应当与经注册或者备案的相关内容一致。'可被翻译为：Contents in the instructions and labels of medical devices shall be consistent with the relevant information in their registration or filing.\n'2020年3月17日，NMPA发布《2019年医疗器械注册年度报告》，内容包括医疗器械注册情况、医疗器械注册申请受理情况、医疗器械注册审批情况、创新医疗器械等产品注册审批情况、其他注册管理情况五个部分。'可被翻译为：On March 17, 2020, NMPA issued the 2019 Annual Report for Medical Device Registration, which covers five parts: medical device registration status, medical device registration application acceptance status, medical device registration approval status, innovative medical device registration approval status, and other registration management status.\n'（三）医疗器械注册人、备案人和受托生产企业名称、生产许可证编号或者备案编号。'可被翻译为：(3) name of the registrant, filing entity and contract manufacturer of the medical device, manufacturing license number or filing number.\n\n根据上述已知信息，请将'（一）实际生产与医疗器械注册备案、医疗器械生产许可备案等内容的一致情况；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) consistency of the actually manufactured products and the contents of medical device registration and filing, and medical device manufacturing licensing and filing, etc.;"
    },
    {
        "instruction":"已知信息：\n'第八十三条 违反本法规定，疫苗上市许可持有人有下列情形之一的，由省级以上人民政府药品监督管理部门责令改正，给予警告；拒不改正的，处二十万元以上五十万元以下的罚款；情节严重的，责令停产停业整顿，并处五十万元以上二百万元以下的罚款：'可被翻译为：Article 83 In cases where vaccine MAHs' violation of this Law involves any of the following circumstances, the drug regulatory departments of the people's governments at or above the provincial level shall order to make rectification and give a warning; and those who refuse to make rectification shall be subject to a fine of not less than RMB 200,000 yuan but not more than RMB 500,000 yuan; in serious circumstances, the offender shall be subject to an order to stop production for rectification and a fine of not less than RMB 500,000 yuan but not more than RMB 2,000,000 yuan:\n'第四十条 违反本办法第二十条、第二十二条、第二十三条的规定，第三方平台未履行资质审核、报告、停止提供网络交易平台服务等义务的，依照药品管理法第一百三十一条的规定处罚。'可被翻译为：Article 40 If the third-party platform violates the provisions of Article 20, Article 22 and Article 23 of these Provisions and fails to perform the obligations of qualification audit, reporting, suspension on providing online transaction platform services and other obligations, the punishments stipulated in Article 131 of the Drug Administration Law shall apply.\n'第六十六条  有下列情形之一的，责令限期改正，并处1万元以上5万元以下罚款；情节严重的，处5万元以上10万元以下罚款；造成危害后果的，处10万元以上20万元以下罚款：'可被翻译为：Article 66 For any of the following circumstances, rectification shall be ordered within prescribed time limit, and a fine of not less than 10,000 yuan and not more than 50,000 yuan shall be imposed; for serious circumstances, a fine of not less than 50,000 yuan and not more than 100,000 yuan shall be imposed; and for hazardous consequences, a fine of not less than 100,000 yuan and not more than 200,000 yuan shall be imposed:\n'违反本办法第九条第四款的规定，责令限期改正，处1万元以上3万元以下罚款；情节严重的，处3万元以上5万元以下罚款。'可被翻译为：In case of violation of the provisions of Paragraph 4, Article 9 of these Provisions, it shall be ordered to make correction within the time limit, and subject to a fine of not less than RMB 10,000 and not more than RMB 30,000; for severe circumstances, a fine of not less than RMB 30,000 and not more than RMB 50,000 shall be imposed.\n\n根据上述已知信息，请将'第一百三十一条 违反本法规定，药品网络交易第三方平台提供者未履行资质审核、报告、停止提供网络交易平台服务等义务的，责令改正，没收违法所得，并处二十万元以上二百万元以下的罚款；情节严重的，责令停业整顿，并处二百万元以上五百万元以下的罚款。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 131 Where a third party platform provider for online drug transactions fails to perform its obligations, such as examine qualifications, report incidents, and cease to provide online services in violation of this Law, the offender shall be ordered to make correction and subject to a confiscation of illegal income and a fine of not less than RMB 200,000 but not more than RMB 2,000,000. In serious circumstances, the offender shall be ordered to stop production for rectification and be subject a fine of not less than RMB 2,000,000 but not more than RMB 5,000,000."
    },
    {
        "instruction":"已知信息：\n'测量样品从制造过程中转移，并可能返回到工艺流。'可被翻译为：Measurement where the sample is diverted from the manufacturing process, and may be returned to the process stream.\n'第五十一条 传染病暴发、流行时，县级以上地方人民政府或者其卫生健康主管部门需要采取应急接种措施的，依照法律、行政法规的规定执行。'可被翻译为：Article 51 Where the local people's governments at or above the county level or their competent health departments need to take emergency immunization measures in the event of outbreak or prevalence of an infectious disease, laws and administrative regulations shall be followed.\n'质谱仪主体组成部分，将离子源中形成的离子按质荷比的差异进行分离并将这些微弱的离子流信号接收并放大后送至显示单元及计算机数据处理系统，得到被分析样品的质谱图及数据。'可被翻译为：The main part of the mass spectrometer is to separate the ions formed in the ion source according to the difference of the mass charge ratio, and receive and amplify the weak ion flow signal and send it to the display unit and computer data processing system to obtain the mass spectrum and data of the analyzed sample.\n'在超速离心机中，应用强大的离心力分离、制备、分析物质的方法。'可被翻译为：In the ultra-fast centrifuge, the powerful centrifugal force is applied to separate, prepare and analyze the material.\n\n根据上述已知信息，请将'在靠近工艺流的地方进行取样、分离和分析的测量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Measurement where the sample is removed, isolated from, and analysed in close proximity to the process stream."
    },
    {
        "instruction":"已知信息：\n'风险评估应基于科学知识与经验，包括对工艺和产品的科学知识与经验。'可被翻译为：6.7. The evaluation of the risk should be based on scientific knowledge and experience including that of the process and product.\n'第十四条  持有人应当对其上市的医疗器械进行持续研究，评估风险情况，承担医疗器械不良事件监测的责任，根据分析评价结果采取有效控制措施，并履行下列主要义务：'可被翻译为：Article 14 MAHs shall carry out continuous research on the medical devices already marketed, evaluate the risks, assume the responsibilities of medical device adverse event monitoring, take effective control measures based on the analysis and evaluation results, and fulfill the following main obligations:\n'1.在整个产品生命周期内对产品质量风险进行评估、控制、沟通和审查的系统过程。\n2.质量风险管理是对药品在整个生命周期内的质量风险进行评估、控制、沟通和评审的系统过程。'可被翻译为：1.A systematic process for the assessment, control, communication and review of risks to the quality of the product across the product’s life cycle.\n2.Quality risk management is a systematic process for the assessment, control, communication and review of risks to the quality of the pharmaceutical product throughout the product life- cycle.\n'（五）对已识别的风险未及时采取有效的风险控制措施，无法保证产品质量；'可被翻译为：(5) effective risk control measures have not been promptly taken for identified risks so that the product quality cannot be ensured;\n\n根据上述已知信息，请将'第十四条 应当根据科学知识及经验对质量风险进行评估，以保证产品质量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 14: The evaluation of the risk to quality is based on scientific knowledge and experience, to ensure the quality of products."
    },
    {
        "instruction":"已知信息：\n'第六条 进行医疗器械临床试验应当有充分的科学依据和明确的试验目的，并权衡对受试者和公众健康预期的受益以及风险，预期的受益应当超过可能出现的损害。'可被翻译为：Article 6 Medical device clinical trials shall have sufficient scientific basis and clear trial objectives and weight the expected benefits and risks that will pose to the subjects' and public's health and the expected benefits shall exceed the possible damage.\n'（六）预期受试者可能的受益和已知的、可以预见的风险以及可能发生的不良事件；'可被翻译为：(6) Expectation of possible benefits and known, foreseeable risks and possible adverse events;\n'（四）试验方案是否充分考虑了伦理原则，是否符合科学性，包括研究目的是否适当、受试者的权益是否得到保障、其他人员可能遭受风险的保护以及受试者入选的方法是否科学。'可被翻译为：(4) Whether the trial protocol fully considers the ethical principles and meets scientificity, including whether the purpose of the study is appropriate, whether the subjects' rights and interests are guaranteed, whether the protection of other persons who may suffer risk and the subject enrollment method are scientific.\n'第六十七条 研究者负责招募受试者、与受试者或者其监护人谈话。研究者有责任向受试者说明试验用医疗器械以及临床试验有关的详细情况，告知受试者可能的受益和已知的、可以预见的风险，并取得受试者或者其监护人签字和注明日期的知情同意书。'可被翻译为：Article 67 The investigator is responsible for recruiting subjects and talking with them or the guardians. The investigator shall explain to the subjects the details of the investigational medical device and details about the clinical trial, inform the subjects of possible benefits and known and foreseeable risks, and obtain signed and dated informed consent forms from the subjects or the guardians.\n\n根据上述已知信息，请将'（三）受试者可能遭受的风险程度与试验预期的受益相比是否合适。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) Whether the potential severity of risk that the subjects may suffer is appropriate compared to the expected benefits of the trial."
    },
    {
        "instruction":"已知信息：\n'第三十九条 应当根据厂房及生产防护措施综合考虑选址，厂房所处的环境应当能够最大限度地降低物料或产品遭受污染的风险。'可被翻译为：Article 39: Premises should be situated in an environment that, when considered together with measures to protect the manufacturing process, presents minimal risk of causing contamination of materials or products.\n'第五十三条 产尘操作间（如干燥物料或产品的取样、称量、混合、包装等操作间）应当保持相对负压或采取专门的措施，防止粉尘扩散、避免交叉污染并便于清洁。'可被翻译为：Article 53: Operation areas where dust is generated (e.g. during sampling, weighing, mixing and packaging of dry materials and products) should be kept under relatively negative pressure, and specific measures should be taken to avoid dust diffusion and cross-contamination, and to facilitate cleaning.\n'（二）安装确认应当证明厂房、设施、设备的建造和安装符合设计标准；'可被翻译为：2. Installation qualification is to verify that the premises, facilities and equipment have been built and installed in accordance with their design specifications;\n'防止污染，尤其是被任何杀虫剂或任何其它毒性物质污染，或其它药品与非药品化学物质的污染的控制'可被翻译为：v. Controls to prevent contamination, particularly with any pesticides or any other toxic materials, or other drug or non- drug chemicals\n\n根据上述已知信息，请将'第四十三条 厂房、设施的设计和安装应当能够有效防止昆虫或其它动物进入。应当采取必要的措施，避免所使用的灭鼠药、杀虫剂、烟熏剂等对设备、物料、产品造成污染。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 43: Premises and facilities should be designed and equipped so as to afford maximum protection against the entry of insects or other animals. Necessary measures should be taken to avoid the contamination to equipment, materials and products caused by raticide, insecticide, fumigation reagent, etc."
    },
    {
        "instruction":"已知信息：\n'进货查验记录应当保存至医疗器械有效期满后2年；没有有效期的，不得少于5年。植入类医疗器械进货查验记录应当永久保存。'可被翻译为：The inspection records of incoming goods shall be kept till 2 years after expiration of valid term of the medical device; if there is no valid term for such medical device, the records shall be kept for no less than 5 years. The inspection records of incoming implantable medical devices shall be kept permanently.\n'第六条 化妆品生产经营者应当依法建立进货查验记录、产品销售记录等制度，确保产品可追溯。'可被翻译为：Article 6 Manufacturers and marketers of cosmetics shall establish, in accordance with the law, documentation system for the check and test of purchases, and product sales record, and other systems, to ensure traceability of the products.\n'第三十二条 化妆品注册人、备案人、受托生产企业应当建立并执行原料以及直接接触化妆品的包装材料进货查验记录制度、产品销售记录制度。进货查验记录和产品销售记录应当真实、完整，保证可追溯，保存期限不得少于产品使用期限期满后1年；产品使用期限不足1年的，记录保存期限不得少于2年。'可被翻译为：Article 32 The registrant, the filing entity and the contract manufacturer of cosmetics shall establish and implement documentation system for the check and test of purchases and product sales record of raw materials and packaging materials contacted with cosmetics. The records of purchase check and test and product sales shall be authentic, complete and fully traceable, the preservation period shall be not less than one year after the expiration of the shelf life of the products; if the shelf life of a product is less than one year, the preservation period for the records shall be not less than two years.\n'第三十八条  从事第二类、第三类医疗器械批发业务以及第三类医疗器械零售业务的经营企业应当建立销售记录制度。销售记录信息应当真实、准确、完整和可追溯。销售记录包括：'可被翻译为：Article 38 The distributors engaging in wholesale of Class II and Class III medical devices and retail of Class III medical devices shall establish procedures for recording sales. The sales records shall be authentic, accurate, complete, and traceable. The sales records shall include:\n\n根据上述已知信息，请将'第三十二条  医疗器械经营企业应当建立进货查验记录制度，购进医疗器械时应当查验供货企业的资质，以及医疗器械注册证和备案信息、合格证明文件。进货查验记录应当真实、准确、完整和可追溯。进货查验记录包括：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 32 The medical device distributors shall establish procedures for inspecting and recording incoming goods, and when purchasing medical devices, it shall inspect qualifications of the supplier, the Medical Device Registration Certificate, the filing information and qualification certificates. The inspection records of incoming goods shall be authentic, accurate, complete, and traceable. The inspection records of incoming goods shall include:"
    },
    {
        "instruction":"已知信息：\n'采用准确、可靠的方法或直接与一级标准物质相比较的方法，测量标准物质的特性量值，测量准确度满足需要的标准物质。在实验室中通常是指与一级标准物质比对后作为对照使用的工作对照品（标准品）。'可被翻译为：The characteristic quantity value of the standard substance shall be measured by accurate and reliable method or by method directly compared with the first class standard substance, and the standard substance whose measurement accuracy meets the needs shall be measured. In the laboratory, it usually refers to the working reference material (standard material) used as a control after comparison with the primary reference material.\n'（三）企业如需自制工作标准品或对照品，应当建立工作标准品或对照品的质量标准以及制备、鉴别、检验、批准和贮存的操作规程，每批工作标准品或对照品应当用法定标准品或对照品进行标化，并确定有效期，还应当通过定期标化证明工作标准品或对照品的效价或含量在有效期内保持稳定。标化的过程和结果应当有相应的记录。'可被翻译为：3. Where in-house working standard substances or reference substances are to be self-prepared, the manufacturer should establish specifications of the working standards and operation procedures for the preparation, identification, testing, approval and storage. Each lot of in-house working standard substance or reference substance should be standardized against an official standard substance or reference substance, and shelf life established. In addition, the working standard substances or reference substances s should be standardized regularly to demonstrate that their potency or assay is stable within shelf life. The process and result of the standardization should be recorded.\n'通过与一级标准品的比对表明具有确定的质量和纯度的物质，作为日常实验室分析的标准品之用。'可被翻译为：A substance of established quality and purity, as shown by comparison to a primary reference standard, used as a reference standard for routine laboratory analysis.\n'第二百二十七条 标准品或对照品的管理应当至少符合以下要求：'可被翻译为：Article 227: The management of the standard substances or reference substances should meet at least the following requirements:\n\n根据上述已知信息，请将'以合理的测量范围，通过与对照品或可溯源标准的比对，证明来自于某一具体仪器或设备的结果符合特定的限度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The demonstration that a particular instrument or device produces results within specified limits by comparison with those produced by a reference or traceable standard over an appropriate range of measurements."
    },
    {
        "instruction":"已知信息：\n'配制记录、分发与返还记录等完整；'可被翻译为：Records of formulating, distribution, and return, etc. of the test\/control articles should be complete;\n'1.受试物\/对照品的接收、保存、分发、使用、留样、返还或废弃等应有完整记录且数量吻合；'可被翻译为：1. The receipt, storage, distribution, use, reserve samples, return or disposal of the test\/control articles should be recorded completely and their accountability should be maintained;\n'(1)研究所需实验系统的来源应清晰合规，应完整保存 实验系统购入(转入)、质量鉴定等相关证明性文件；应完整保留适用性评估资料。'可被翻译为：(1) The source of the test system used in the study should be clear and compliant with the related regulation, and the relevant supporting documentation for acquisition and characterization of the test system should be kept completely; documentation for assessing suitability of the test system should be kept completely.\n'2.应完整保留研究期间所使用仪器设备的使用、清洁、 保养、测试、校准、确认或验证、维修、异常情况处理、报废等记录；仪器设备使用记录的时间及内容应与研究对应一致；'可被翻译为：2. Records of use, cleaning, maintenance, testing, calibration, verification or validation, repair, handling of unexpected events and decommission of instruments and equipment used in the study during the study period should be retained completely; the testing time and items in the use records of instruments and equipment should be in line with that as required by the study;\n\n根据上述已知信息，请将'4.应完整保留研究所需毒麻药品、造模试剂(药品)等的配制、保存、使用、返还或废弃等记录。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4. Records of formulating, storage, use, return and disposal of narcotic drugs and modeling reagents (drugs) used in the study should be retained completely."
    },
    {
        "instruction":"已知信息：\n'能产生抗生素等次级代谢产物的微生物。'可被翻译为：Microorganisms that produce secondary metabolites such as antibiotics.\n'将次级代谢产物产生菌进行诱变处理或基因操作，筛选出阻断某种目的代谢产物合成能力的突变体。'可被翻译为：Secondary metabolite producing bacteria were mutagenically treated or genetically manipulated to screen out mutants that blocked the ability of metabolite synthesis for a certain purpose.\n'抗生素产生菌的菌体生长阶段。'可被翻译为：The somatic growth stage of antibiotic-producing bacteria.\n'次级代谢产物'可被翻译为：secondary metabolite\n\n根据上述已知信息，请将'抗生素产生菌快速生长结束之后的次级代谢产物形成期。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The phase of secondary metabolite formation after rapid growth of antibiotic-producing bacteria has ended."
    },
    {
        "instruction":"已知信息：\n'1.生产商根据预定的时间表对生产批次进行的研究，以监测、确认和延长活性药物成分的预计复测期(或保质期)，或确认或延长成品药品的保质期。\n2.生产商根据预定的时间表对生产批次进行的研究，以监测、确认和延长原料药的预计复测期(或保质期)，或确认或延长FPP的保质期。'可被翻译为：1.The study carried out by the manufacturer on production batches according to a predetermined schedule in order to monitor, confirm and extend the projected retest period (or shelf life) of the active harmaceutical ingredient, or confirm or extend the shelf life of the finished pharmaceutical product.\n2.The study carried out by the manufacturer on production batches according to a predetermined schedule in order to monitor, confirm and extend the projected re-test period (or shelf-life) of the API, or confirm or extend the shelf-life of the FPP.\n'按照呈报的稳定性方案对申报和\/或承诺的批次的样品进行的长期和加速（和中间）试验，以建立或确定原料药的再试验期或制剂的货架期。'可被翻译为：Long term and accelerated (and intermediate) studies undertaken on primary and\/or commitment batches according to a prescribed stability protocol to establish or confirm the re-test period of a drug substance or the shelf life of a drug product.\n'1.在预期市场中预期的储存条件下，在样品的预期保质期和储存期期间和之后，对活性药物成分或成品的物理、化学、生物、生物制药和微生物特性进行的实验。结果用于确定复测期或保质期，以确认预计的复测期和保质期，并推荐储存条件。\n2.在预期市场中预期的储存条件下，在样品的预期保质期和储存期期间和之后，对原料药或FPP的物理、化学、生物、生物制药和微生物特性进行实验。结果用于建立复测期或保质期，以确认预计的复测期和保质期，并推荐储存条件。'可被翻译为：1.Experiments on the physical, chemical, biological, biopharmaceutical and microbiological characteristics of an active pharmaceutical ingredient or finished pharmaceutical product, during and beyond the expected shelf life and storage periods of samples under the storage conditions expected in the intended market. The results are used to establish the retest period or the shelf life, to confirm the projected retest period and shelf life, and to recommend  storage conditions.\n2.Experiments on the physical, chemical, biological, biopharmaceutical and microbiological characteristics of an API or FPP, during and beyond the expected shelf-life and storage periods of samples under the storage conditions expected in the intended market. The results are used to establish the re-test period or the shelf-life, to confirm the projected re-test period and shelf-life, and to recommend storage conditions.\n'1.通过在监管申请中作出的承诺在批准后启动或完成稳定性研究的活性药物成分或成品的生产批次。\n2.通过在监管申请中做出的承诺，在批准后启动或完成稳定性研究的原料药或FPP的生产批次。'可被翻译为：1.Production batches of an active pharmaceutical ingredient or finished pharmaceutical product for which the stability studies are initiated or completed post-approval through a commitment made in a regulatory application.\n2.Production batches of an API or FPP for which the stability studies are initiated or completed post-approval through a commitment made in a regulatory application.\n\n根据上述已知信息，请将'1.根据规定的稳定性协议，对主要批次和\/或承诺批次进行长期和加速(和中间)研究，以确定或确认API或FPP的复测期(或保质期)。\n2.根据规定的稳定性方案对主要批次和\/或承诺批次进行的长期和加速(和中间)研究，以确定或确认活性药物成分的复测期(或保质期)或成品药品的保质期。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.Long-term and accelerated (and intermediate) studies undertaken on primary and\/or commitment batches according to a prescribed stability protocol to establish or confirm the re- test period (or shelf-life) of an API or the shelf-life of an FPP.\n2.Long-term and accelerated (and intermediate) studies undertaken on primary and\/or commitment batches according to a prescribed stability protocol to establish or confirm the retest period (or shelf life) of an active pharmaceutical ingredient or the shelf life of a finished pharmaceutical product."
    },
    {
        "instruction":"已知信息：\n'在色谱分析中，一种通过对照品和供试品色谱峰面积或峰高的比较进行定量的方法。'可被翻译为：In chromatographic analysis, a quantitative method is performed by comparing the chromatographic peak area or peak height of the reference and the test.\n'供试品溶液'可被翻译为：test solution\n'在两个不同的波长处测定供试品溶液和对照品溶液的吸光度，以两波长处吸光度的差值（A4）作为定量的依据来测定含量的方法。'可被翻译为：The absorbance of test solution and control solution is measured at two different wavelengths, and the difference of absorbance at two wavelengths (A4) is used as a quantitative basis to determine the content of the method.\n'(四)受试物\/对照品'可被翻译为：(IV) Test\/control articles\n\n根据上述已知信息，请将'进行色谱分析时，在供试品与对照品溶液中添加一定量参比物的定量方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When performing chromatographic analysis, a quantitative method of adding a certain amount of reference substance to the solution of the test product and the control product."
    },
    {
        "instruction":"已知信息：\n'在新药审批期间，其注册分类和技术要求不因国内药品生产企业申报的相同活性成份的制剂在我国获准上市而发生变化。'可被翻译为：In the process of the review and approval of a new drug, the registration classification and technical requirements thereof shall not be changed, even though the preparations of the same active ingredients applied for by domestic manufacturers are approved for marketing in China.\n'（七）药品上市申请审评审批期间，药品注册分类和技术要求不因相同活性成份的制剂在境内外获准上市而发生变化。药品注册分类在提出上市申请时确定。'可被翻译为：(7) During the review and approval of the drug marketing application, the drug registration classification and technical requirements shall not be changed because the preparation with the same active ingredients is approved to be marketed at home and abroad. Drug registration classification shall be determined when marketing authorization is applied.\n'（二）新药生产：150日；获准进入特殊审批程序的品种：120日；'可被翻译为：(2) new drug application for production: 150 days; any drug permitted to enter the special review and approval procedures: 120 days;\n'（一）新药临床试验：90日；获准进入特殊审批程序的品种：80日；'可被翻译为：(1) new drug application for clinical trial: 90 days; any drug permitted to enter the special review and approval procedures: 80 days;\n\n根据上述已知信息，请将'第四十八条 在新药审批期间，新药的注册分类和技术要求不因相同活性成份的制剂在国外获准上市而发生变化。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 48 In the process of the review and approval of a new drug, the registration classification and technical requirements thereof shall not be changed, even though the preparations of the same active ingredients are approved for marketing abroad."
    },
    {
        "instruction":"已知信息：\n'第三十条 化妆品注册人、备案人应当选择符合法律、行政法规、强制性国家标准和技术规范要求的原料用于化妆品生产，对其使用的化妆品原料安全性负责。化妆品注册人、备案人申请注册、进行备案时，应当通过信息服务平台明确原料来源和原料安全相关信息。'可被翻译为：Article 30 Cosmetic registrants and filing persons shall select ingredients that meet the requirements of laws, administrative regulations, mandatory national standards and technical specifications for cosmetic production, and shall be responsible for the safety of cosmetic ingredients they use. When applying for registration and filing for filing, the cosmetic registrant and filing person shall clarify the source of ingredients and relevant information on ingredient safety through the information service platform.\n'第二十九条 化妆品注册人、备案人应当依照法律、行政法规、强制性国家标准、技术规范和注册备案管理等规定，开展化妆品研制、安全评估、注册备案检验等工作，并按照化妆品注册备案资料规范要求提交注册备案资料。'可被翻译为：Article 29 The cosmetic registrant and filing person shall carry out cosmetic research and development, safety assessment, testing of registration and filing, etc. in accordance with laws, administrative regulations, mandatory national standards, technical specifications, and provisions for registration and filing administration etc., and submit registration and filing documents in accordance with the instructions for cosmetic registration and filing dossiers.\n'化妆品注册人、备案人使用化妆品新原料生产化妆品的，相关化妆品申请注册、办理备案时应当通过信息服务平台经化妆品新原料注册人、备案人关联确认。'可被翻译为：If cosmetic registrants and filing persons use new cosmetic ingredients to produce cosmetics, the relevant cosmetic registration application and filing shall be associated and confirmed by the registrant or filing person of the new cosmetic ingredient through the information service platform.\n'第七条 化妆品、化妆品新原料注册人、备案人依法履行产品注册、备案义务，对化妆品、化妆品新原料的质量安全负责。'可被翻译为：Article 7 The registrant and filing person of cosmetics and new cosmetic ingredients shall perform product registration and filing obligations in accordance with law and shall be responsible for the quality and safety of cosmetics and new cosmetic ingredients.\n\n根据上述已知信息，请将'化妆品、化妆品新原料注册人、备案人申请注册或者进行备案时，应当遵守有关法律、行政法规、强制性国家标准和技术规范的要求，对所提交资料的真实性和科学性负责。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Registrants and filing persons of cosmetics and new cosmetic ingredients shall comply with the requirements of relevant laws, administrative regulations, mandatory national standards and technical specifications when applying for registration or filing for filing, and shall be responsible for the authenticity and scientificalness of the submitted dossiers."
    },
    {
        "instruction":"已知信息：\n'第六十条 本程序自2022年1月1日起施行。'可被翻译为：Article 60 The Procedures shall come into force as of January 1, 2022.\n'第四十二条 本办法自2022年12月1日起施行。'可被翻译为：Article 42 These Provisions shall go into effect as of December 1, 2022.\n'第八十条  本办法自2019年1月1日起施行。'可被翻译为：Article 80  The Provisions shall be put into effect as of January 1, 2019.\n'第六十三条 本办法自2021年5月1日起施行。'可被翻译为：Article 63 These Provisions shall go into effect as of May 1, 2021.\n\n根据上述已知信息，请将'第六十六条 本办法自2022年1月1日起施行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 66 These Provisions shall be effective as of January 1, 2022."
    },
    {
        "instruction":"已知信息：\n'按照创新医疗器械特别审批程序审批的境内医疗器械申请注册时，样品委托其他企业生产的，应当委托具有相应生产范围的医疗器械生产企业；不属于按照创新医疗器械特别审批程序审批的境内医疗器械申请注册时，样品不得委托其他企业生产。'可被翻译为：Where applying for registration of a domestic medical device subject to the special review procedures for innovative medical devices and its sample production is entrusted to another enterprise, the applicant shall entrust a medical device manufacturer having corresponding production range. Where the domestic medical device applied for registration is not subject to the special review procedures for innovative medical devices, the sample production shall not be entrusted to another enterprise.\n'第八十七条 体外诊断试剂的应急审批和创新特别审批按照国家食品药品监督管理总局制定的医疗器械应急审批程序和创新医疗器械特别审批程序执行。'可被翻译为：Article 87 The emergency approval and the innovation special approval for in-vitro diagnostic reagents shall be executed according to emergency approval procedure for medical device and special approval procedure for innovative medical device formulated by China Food and Drug Administration.\n'第九条 国家鼓励体外诊断试剂的研究与创新，对创新体外诊断试剂实行特别审批，促进体外诊断试剂新技术的推广与应用，推动医疗器械产业的发展。'可被翻译为：Article 9 The State encourages the research and innovation of in-vitro diagnostic reagents, implements special review for innovative medical devices, accelerates the popularization and application for new technologies of in-vitro diagnostic reagents and promotes the development of medical device industry.\n'第七十九条 医疗器械应急审批程序和创新医疗器械特别审批程序由国家食品药品监督管理总局另行制定。'可被翻译为：Article 79 The emergency approval procedure for medical devices and the special approval procedure for innovative medical devices shall be separately formulated by China Food and Drug Administration.\n\n根据上述已知信息，请将'按照创新医疗器械特别审批程序审批的境内体外诊断试剂申请注册时，样品委托其他企业生产的，应当委托具有相应生产范围的医疗器械生产企业；不属于按照创新医疗器械特别审批程序审批的境内体外诊断试剂申请注册时，样品不得委托其他企业生产。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where applying for registration of a in-vitro diagnostic reagent subject to the special review procedures for innovative medical devices and its sample production is entrusted to another enterprise, the applicant shall entrust a medical device manufacturer having corresponding production range. Where the domestic medical device applied for registration is not subject to the special review procedures for innovative medical devices, the sample production shall not be entrusted to another enterprise."
    },
    {
        "instruction":"已知信息：\n'第十一条  国务院卫生行政部门和地方各级卫生行政部门负责医疗器械使用单位中与医疗器械不良事件监测相关的监督管理工作，督促医疗器械使用单位开展医疗器械不良事件监测相关工作并组织检查，加强医疗器械不良事件监测工作的考核，在职责范围内依法对医疗器械不良事件采取相关控制措施。'可被翻译为：Article 11 Health administrative departments of the State Council and health administrative departments at all levels shall be responsible for supervision and administration of user facility of medical device related to medical device adverse event monitoring, urge user facility of medical device to carry out relevant medical device adverse event monitoring work and organize inspection, strengthen  assessment of medical device adverse event monitoring, and take relevant control measures for medical device adverse events within their responsibility according to law.\n'上级卫生行政部门指导和监督下级卫生行政部门开展医疗器械不良事件监测相关的监督管理工作。'可被翻译为：Superior health administrative departments shall guide and supervise subordinate health administrative departments to carry out the supervision and administration related to medical device adverse event monitoring.\n'第九条  省、自治区、直辖市药品监督管理部门负责本行政区域内医疗器械不良事件监测和再评价的监督管理工作，会同同级卫生行政部门和相关部门组织开展本行政区域内发生的群体医疗器械不良事件的调查和处理，依法采取紧急控制措施。'可被翻译为：Article 9 The drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall be responsible for the supervision and administration of medical device adverse event monitoring and re-evaluation within their respective administrative regions, organize the investigation and handling of group adverse events of medical device that occurs within their respective administrative regions jointly with the health administrative departments at the same level and relevant authorities, and take emergency control measures according to law.\n'第十条  上级药品监督管理部门指导和监督下级药品监督管理部门开展医疗器械不良事件监测和再评价的监督管理工作。'可被翻译为：Article 10 Drug regulatory departments shall guide and supervise subordinate drug regulatory departments in conducting supervision and administration on medical device adverse event monitoring and re-evaluation.\n\n根据上述已知信息，请将'第六十三条  药品监督管理部门应当依据职责对持有人和经营企业开展医疗器械不良事件监测和再评价工作情况进行监督检查，会同同级卫生行政部门对医疗器械使用单位开展医疗器械不良事件监测情况进行监督检查。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 63 The drug regulatory departments shall, based on their responsibilities, supervise and inspect the medical device adverse event monitoring and re-evaluation carried out by MAHs and distributing enterprises, and supervise and inspect the medical device adverse event monitoring by user facility of medical device jointly with the health administrative departments at the same level."
    },
    {
        "instruction":"已知信息：\n'第二十七条 企业应当按照培训管理制度制定年度培训计划并开展培训，使相关人员能正确理解并履行职责。培训工作应当做好记录并建立档案。'可被翻译为：Article 27 Enterprises shall, in accordance with the training management system, formulate annual training plans and carry out training so that relevant personnel can correctly understand and perform their duties. Training shall be well documented and related archives shall be established.\n'第六条 药品生产、经营企业应当对其购销人员进行药品相关的法律、法规和专业知识培训，建立培训档案，培训档案中应当记录培训时间、地点、内容及接受培训的人员。'可被翻译为：Article 6    Drug manufacturers or distributors shall train their purchase and sales staff on drug related laws, regulations and professional knowledge, and establish training records including time, venue, content and trainees.\n'第二十八条  医疗器械注册人、备案人、受托生产企业应当开展医疗器械法律、法规、规章、标准以及质量管理等方面的培训，建立培训制度，制定培训计划，加强考核并做好培训记录。'可被翻译为：Article 28 The registrant, filing entity or contract manufacturer of medical devices shall carry out training in aspects such as laws, regulations, provisions, standards and quality management, etc. of medical devices, establish training system, formulate training plan, strengthen the assessment and keep proper training records.\n'第三十条 化妆品注册人、备案人、受托生产企业应当制定从业人员年度培训计划，开展化妆品法律、法规、规章、强制性国家标准、技术规范等知识培训，并建立培训档案。生产岗位操作人员、检验人员应当具有相应的知识和实际操作技能。'可被翻译为：Article 30 The registrant, the filing entity and the contract manufacturer of cosmetics shall formulate annual training plan for the employees, carry out training on laws, regulations, provisions, mandatory national standards, technical specifications, and other knowledge related with cosmetics, and establish training files. Operating and testing personnel for manufacturing should have corresponding knowledge and practical operation skills.\n\n根据上述已知信息，请将'第一百二十八条 企业应当按照培训管理制度制定年度培训计划并开展培训，使相关人员能正确理解并履行职责。培训工作应当做好记录并建立档案。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 128 Enterprises shall, in accordance with the training management system, formulate annual training plans and carry out training so that relevant personnel can correctly understand and perform their duties. Training shall be well documented and related archives shall be established."
    },
    {
        "instruction":"已知信息：\n'(2) 一个分析批中所有样品被处理和提取的顺序与进样顺序一致， 过程可溯源。如有分批处理的情况， 每个处理批应当包括低、中、高浓度质控样品， 并符合事先规定的接受标准。'可被翻译为：(2) All the samples in one analysis batch are processed and extracted in the same order with that of the introduction, and the process is traceable. In the case of batch processing, every processing batch shall contain quality control samples of low, medium and high concentration, and comply with the predefined acceptance criteria.\n'(4) 所有在仪器中进样的样品均记录在原始记录中， 并对样品分析过程中出现的异常情况进行调查和分析， 与申报资料一致。'可被翻译为：(4) Samples introduced into all the instruments are recorded in the original records, and investigation and analysis are conducted for abnormal circumstances occurred during the process of sample analysis, consist with the application dossier.\n'(1) 试验样品分析按照分析计划执行， 分析批中样品预处理的过程和检测方法与方法学验证一致， 血药浓度数据与申报资料一致。'可被翻译为：(1) The test sample analysis is conducted according to the analysis plan, the preprocessing and testing method of the samples in the analysis batch are consist with the method validation, and the plasma concentration data is consistent with that in the application dossier.\n'(5) 所有在仪器中进样的样品均记录在原始记录中， 并对方法学验证过程中出现的异常情况进行调查和分析， 与申报资料一致。'可被翻译为：(5) All samples introduced into the instruments are recorded in the original records, and investigation and analysis is conducted for abnormal circumstances occurred during the process of method validation, which are consist with those in the application dossier.\n\n根据上述已知信息，请将'(3) 一个分析批中所有样品有唯一性编号， 样品按照顺序连续不间断进样， 如中断， 在原始记录中记录中断原因， 与申报资料一致。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) Within one analysis batch, all samples have a unique identifier, and are introduced continuously in sequence, if there is interruption, the reason for interruption is recorded in the original records, consist with the application dossier."
    },
    {
        "instruction":"已知信息：\n'编码于DNA或RNA（一些病毒）核昔酸序列中的可遗传的生物信息。'可被翻译为：The heritable biological information encoded in the nucleotide sequence of DNA or RNA (some viruses).\n'一类20个以下碱基对的短链核昔酸的总称。寡核昔酸极易与它们的互补对链接，所以常用来作为探针确定DNA或RNA的结构，用于基因芯片、电泳、荧光原位杂交等过程中。'可被翻译为：A general term for a class of short chain nucleotides of less than 20 base pairs. Oligonucleoxylic acids are readily linked to their complementary pairs and are therefore commonly used as probes to determine the structure of DNA or RNA for use in gene microarrays, electrophoresis, and fluorescence in situ hybridization.\n'构成生物大分子结构单元的排列次序。如DNA分子是由4种核昔酸（A,T,G,C）排列组成，DNA序列就是组成某一DNA分子的核昔酸的排列次序。'可被翻译为：The arrangement of the structural units of biomacromolecules. For example, the DNA molecule is composed of four nucleotides (A,T,G,C), and the DNA sequence is the sequence of nucleotides that make up a DNA molecule.\n'由核昔酸聚合而成的生物大分子。包括脱氧核糖核酸(DNA)和核糖核酸(RNA)。'可被翻译为：A biomacromolecule polymerized from nucleotide. Includes deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).\n\n根据上述已知信息，请将'固定有寡核昔酸、基因组DNA或互补DNA等的生物芯片。利用这类芯片与标记的生物样品进行杂交，可对样品的基因表达谱生物信息进行快速定性和定量分析。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Biochips that contain oligonucleotide, genomic DNA, or complementary DNA. By hybridizing these chips with labeled biological samples, rapid qualitative and quantitative analysis of the bioinformation of the gene expression profile of the samples can be performed."
    },
    {
        "instruction":"已知信息：\n'由下级食品药品监督管理部门查处的，组织实施飞行检查的食品药品监督管理部门应当跟踪督导查处情况。'可被翻译为：Where an investigation is conducted by an inferior food and drug regulatory department, the food and drug regulatory department organizing the unannounced inspection shall follow, monitor and direct the investigation and sanction.\n'第三十一条 上级食品药品监督管理部门应当及时将其组织实施的飞行检查结果通报被检查单位所在地食品药品监督管理部门。'可被翻译为：Article 31 The food and drug regulatory department at higher level shall timely notify the results of an unannounced inspection organized by itself, to the local food and drug regulatory department.\n'经组织实施飞行检查的食品药品监督管理部门同意后，检查组方可结束检查。'可被翻译为：Article 22 The inspection team shall inform the organization being inspected of the\n'地方各级食品药品监督管理部门组织实施的飞行检查发现违法行为需要立案查处的，原则上应当直接查处。'可被翻译为：Where an illegal act found in an unannounced inspection organized by local food and drug regulatory departments at all levels is required for a case filing, investigation and sanction, it shall be directly investigated and sanctioned in principle.\n\n根据上述已知信息，请将'下级食品药品监督管理部门应当及时将其组织实施的飞行检查中发现的重大问题书面报告上一级食品药品监督管理部门，并于每年年底前将该年度飞行检查的总结报告报上一级食品药品监督管理部门。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The food and drug regulatory department at inferior level shall timely report the significant issues found in an unannounced inspection which conduction has been organized by itself, to food and drug regulatory department at the next higher level in written form, and submit an annual summary report of unannounced inspection at the end of each year."
    },
    {
        "instruction":"已知信息：\n'电子记录上签署的电子签名和手写签名应关联至其相应的电子记录，以确保无法通过普通手段对电子签名进行删除、复制或其他转移方式而实现电子记录的伪造。'可被翻译为：Electronic signatures and handwritten signatures executed to electronic records shall be linked to their respective electronic records to ensure that the signatures cannot be excised, copied, or otherwise transferred to falsify an electronic record by ordinary means.\n'使用封闭系统来生成、修改、维护或传送电子记录的人员应采用能够保证真实性、完整性、以及必要时的机密性的规程和管理方式，以确保签名者不能轻易否认签名的非真实记录。规程和管理的内容应包括：'可被翻译为：Persons who use closed systems to create, modify, maintain, or transmit electronic records shall employ procedures and controls designed to ensure the authenticity, integrity, and, when appropriate, the confidentiality of electronic records, and to ensure that the signer cannot readily repudiate the signed record as not genuine. Such procedures and controls shall include the following:\n'第八十二条 申办者应当准确、完整地记录与临床试验相关的信息，内容包括：'可被翻译为：Article 82 The sponsor shall accurately and completely record the information related to the clinical trial, including:\n'本节(a)(1), (a)(2), 和(a)(3)中明确的内容应采用电子记录相同的管理方式，且应作为易读电子记录（电子显示或打印输出）的一部分。'可被翻译为：(b) The items identified in paragraphs (a)(1), (a)(2), and (a)(3) of this section shall be subject to the same controls as for electronic records and shall be included as part of any human readable form of the electronic record (such as electronic display or printout).\n\n根据上述已知信息，请将'签署的电子记录应清楚表明与签名相关的信息，内容包括：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(a) Signed electronic records shall contain information associated with the signing that clearly indicates all of the following:"
    },
    {
        "instruction":"已知信息：\n'第五十四条 医疗器械注册证遗失的，注册人应当立即在原发证机关指定的媒体上登载遗失声明。自登载遗失声明之日起满1个月后，向原发证机关申请补发，原发证机关在20个工作日内予以补发。'可被翻译为：Article 54 Where a medical device registration certificate is lost, the registrant shall publish a loss declaration immediately at the media specified by the original certificate-issuing authority, and apply after 1 month of declaration to the original certificate-issuing authority for re-issuing the certificate. The original certificate-issuing authority shall re-issue the medical device registration certificate within 20 workdays.\n'第二十一条 药品生产许可证遗失的，药品上市许可持有人、药品生产企业应当向原发证机关申请补发，原发证机关按照原核准事项在十日内补发药品生产许可证。许可证编号、有效期等与原许可证一致。'可被翻译为：Article 21 In the event that a drug MAH or manufacturer has lost the Drug Manufacturing Certificate, they may apply to the original issuing authority for a replacement of the Certificate. The original issuing authority shall issue the replacing Drug Manufacturing Certificate with the same previously authorized contents within 10 days. The information such as Certificate number and valid term specified on the replacing Certificate shall be the same as that specified on the original Certificate.\n'第十九条  医疗器械生产许可证遗失的，应当向原发证部门申请补发。原发证部门应当及时补发医疗器械生产许可证，补发的医疗器械生产许可证编号和有效期限与原许可证一致。'可被翻译为：Article 19 If the Medical Device Manufacturing License is lost, the applicant shall apply to the former license issuing department for re-issuance. The former license issuing department shall promptly re-issue the Medical Device Manufacturing License, and the number and valid term of the re-issued Medical Device Manufacturing License shall be consistent with those of the former license.\n'第十九条  医疗器械经营许可证遗失的，应当向原发证部门申请补发。原发证部门应当及时补发医疗器械经营许可证，补发的医疗器械经营许可证编号和有效期限与原许可证一致。'可被翻译为：Article 19 If the Medical Device Distribution License is lost, an application for re-issuance shall be made to the former license issuing department. The former license issuing department shall promptly re-issue the Medical Device Distribution License, and the number and valid term of the re-issued Medical Device Distribution License shall be consistent with those of the former license.\n\n根据上述已知信息，请将'第四十五条 医疗器械注册证遗失的，注册人应当立即在原发证机关指定的媒体上登载遗失声明。自登载遗失声明之日起满1个月后，向原发证机关申请补发，原发证机关在20个工作日内予以补发。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 45 Where a medical device registration certificate is lost, the registrant shall publish a loss declaration immediately at the media specified by the original certificate-issuing authority, and apply after 1 month of declaration to the original certificate-issuing authority for re-issuing the certificate. The original certificate-issuing authority shall re-grant the medical device registration certificate within 20 workdays."
    },
    {
        "instruction":"已知信息：\n'药品零售企业销售药品时，应当开具标明药品名称、生产厂商、数量、价格、批号等内容的销售凭证。'可被翻译为：Where a drug retailer sells drugs, it shall provide sales document indicating drug name, manufacturer, quantity, price, batch number, etc.\n'第十一条 药品生产企业、药品批发企业销售药品时，应当开具标明供货单位名称、药品名称、生产厂商、批号、数量、价格等内容的销售凭证。'可被翻译为：Article 11    Where a drug manufacturer or wholesaler sells drugs, it shall provide sales document indicating supplier';s name, drug name, manufacturer, batch number, quantity, price, etc.\n'（三）做好拆零销售记录，内容包括拆零起始日期、药品的通用名称、规格、批号、生产厂商、有效期、销售数量、销售日期、分拆及复核人员等；'可被翻译为：(III) The records of dismantling sales shall be made, including the starting date of dismantling, adopted name, strength, lot number, manufacturer, and expiry date of drugs, sales quantity, sales date, dismantling and checking personnel, etc.;\n'第九十二条 企业应当做好药品销售记录。销售记录应当包括药品的通用名称、规格、剂型、批号、有效期、生产厂商、购货单位、销售数量、单价、金额、销售日期等内容。按照本规范第六十九条规定进行药品直调的，应当建立专门的销售记录。'可被翻译为：Article 92 Enterprises shall take records of drug sales. Sales records shall include the adopted name, strength, dosage form, lot number, expiry date, manufacturer, purchaser, sales quantity, unit price, amount and sales date of the drug. Special sales records shall be established for the direct transfer of drugs in accordance with Article 69 herein.\n\n根据上述已知信息，请将'第一百六十八条 企业销售药品应当开具销售凭证，内容包括药品名称、生产厂商、数量、价格、批号、规格等，并做好销售记录。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 168 Enterprises shall issue the proof of sales for drugs, including drug name, manufacturer, quantity, price, lot number and strength, and make the sales records."
    },
    {
        "instruction":"已知信息：\n'二、现有《药品生产许可证》在有效期内继续有效。《生产办法》施行后，对于药品生产企业申请变更、重新发证、补发等的，应当按照《生产办法》有关要求进行审查，符合规定的，发给新的《药品生产许可证》。变更、补发的原有效期不变，重新发证的有效期自发证之日起计算。'可被翻译为：2. The current Drug Manufacturing Certificate continues to be valid within the validity period. After the implementation of the Production Provisions, manufacturers' applications for alterations, renewal and re-issuance shall be reviewed in accordance with the relevant Production Provisions. While requirements are met, a new Drug Manufacturing Certificate shall be issued. The original validity period of alteration and reissuance remains unchanged, and the validity period of renewal is calculated from the current date of issuance.\n'第二十三条 药品生产企业在召回完成后，应当对召回效果进行评价，向所在地省、自治区、直辖市药品监督管理部门提交药品召回总结报告。'可被翻译为：Article 23 After completing the recall, the drug manufacturer shall assess the effect of the recall and submit the drug recall summary report to the local drug regulatory department of the province, autonomous region or municipality directly under the Central Government.\n'第十八条 药品生产许可证变更后，原发证机关应当在药品生产许可证副本上记录变更的内容和时间，并按照变更后的内容重新核发药品生产许可证正本，收回原药品生产许可证正本，变更后的药品生产许可证终止期限不变。'可被翻译为：Article 18 After any change made to the Drug Manufacturing Certificate, the original issuing authority shall record the content and time of changes in the duplicate of the Certificate, issue the newly-reviewed original copy of the Certificate based on the changes and withdraw the old original copy. The expiry date of the Certificate shall remain the same after changes filing.\n'第二十一条 药品生产许可证遗失的，药品上市许可持有人、药品生产企业应当向原发证机关申请补发，原发证机关按照原核准事项在十日内补发药品生产许可证。许可证编号、有效期等与原许可证一致。'可被翻译为：Article 21 In the event that a drug MAH or manufacturer has lost the Drug Manufacturing Certificate, they may apply to the original issuing authority for a replacement of the Certificate. The original issuing authority shall issue the replacing Drug Manufacturing Certificate with the same previously authorized contents within 10 days. The information such as Certificate number and valid term specified on the replacing Certificate shall be the same as that specified on the original Certificate.\n\n根据上述已知信息，请将'第二十三条 省、自治区、直辖市药品监督管理部门应当将药品生产许可证核发、重新发证、变更、补发、吊销、撤销、注销等办理情况，在办理工作完成后十日内在药品安全信用档案中更新。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 23 The drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall update the information on the activities, including issuance, re-issuance, changes, replacement, revocation, rescission and cancellation, done to the Drug Manufacturing Certificate in the drug safety credit archive of the NMPA within 10 days since the date such activities are conducted."
    },
    {
        "instruction":"已知信息：\n'第三十一条 有因检查需要由核查组抽取样品进行检验的，核查组按照药品抽样的有关要求，抽取样品并封样；抽取的样品按要求送交药品检验机构进行样品检验。'可被翻译为：Article 31 If the inspection team needs to take samples for cause-related inspection, the inspection team shall take samples and seal them in accordance with the relevant requirements for drug sampling; the samples shall be sent to the drug testing institution for sample testing as required.\n'第十三条 上级食品药品监督管理部门组织实施飞行检查的，可以适时通知被检查单位所在地食品药品监督管理部门。被检查单位所在地食品药品监督管理部门应当派员协助检查，协助检查的人员应当服从检查组的安排。'可被翻译为：Article 13 Where an unannounced inspection is organized by a higher level food and drug regulatory department, the local food and drug regulatory department may be notified at an appropriate time. The local food and drug regulatory department shall assign personnel to assist the inspection, and they shall follow the arrangements of the inspection team.\n'现场核查过程中认为有必要进行样品检验的，经报核查中心同意后，核查组按照药品抽样的有关要求，抽取样品并封样，抽样情况应当在核查报告中进行描述；样品按要求送交药品检验机构进行样品检验。'可被翻译为：If it is deemed necessary to conduct sample inspection during the on-site inspection, the inspection team shall, with the approval of CFDI, take samples and seal them in accordance with the relevant requirements on drug sampling, and the sampling situation shall be described in the inspection report. The samples shall be sent to the drug testing institution for sample testing as required.\n'第五十条 核查过程中抽取的样品，应当在抽样之日起10日内，送达指定药品检验机构。'可被翻译为：Article 50 Samples taken during inspection shall be delivered to the designated drug testing institutions within 10 days from the date of sampling.\n\n根据上述已知信息，请将'第十八条 需要抽取成品及其他物料进行检验的，检查组可以按照抽样检验相关规定抽样或者通知被检查单位所在地食品药品监督管理部门按规定抽样。抽取的样品应当由具备资质的技术机构进行检验或者鉴定，所抽取样品的检验费、鉴定费由组织实施飞行检查的食品药品监督管理部门承担。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 18 Where finished products and other materials shall be sampled for testing, the inspection team can take samples in accordance with the relevant regulations for sampling test, or notify the local food and drug regulatory department to take samples as required. The samples shall be tested or identified by certified technical institutions, and the testing or identification fees shall be borne by the food and drug regulatory department organizing the unannounced inspection."
    },
    {
        "instruction":"已知信息：\n'第六十四条 药品检验所应当依据核定的药品标准对抽取的样品进行检验，并在规定的时间内将药品注册检验报告送交国家食品药品监督管理局药品审评中心，同时抄送相关省、自治区、直辖市药品监督管理部门和申请人。'可被翻译为：Article 64 Drug testing institutes shall conduct sample testing according to the verified specifications, and within the specified timeline, provide testing reports to the Center for Drug Evaluation of the State Food and Drug Administration, and copy to the relevant drug regulatory departments of the provinces, autonomous regions, or municipalities directly under the Central Government and the applicants.\n'第五十九条 药品检验所应对申报的药品标准进行复核，并在规定的时间内将复核意见送交国家食品药品监督管理局药品审评中心，同时抄送通知其复核的省、自治区、直辖市药品监督管理部门和申请人。'可被翻译为：Article 59 Drug testing institutes shall verify the submitted drug specifications and give the verification opinions to the Center for Drug Evaluation of the State Food and Drug Administration within the specified timeline, and at the same time copy to the drug regulatory departments of the provinces, autonomous regions, or municipalities directly under the Central Government that notify them to conduct the verification, and the applicants.\n'第七十九条 药品检验所应当对抽取的样品进行检验，并在规定的时间内将药品注册检验报告送交国家食品药品监督管理局药品审评中心，同时抄送通知其检验的省、自治区、直辖市药品监督管理部门和申请人。'可被翻译为：Article 79 Drug testing institutes shall conduct sample testing, provide testing reports to the Center for Drug Evaluation of the State Food and Drug Administration within the specified timeline, and copy to the drug regulatory departments of the provinces, autonomous regions, or municipalities directly under the Central Government that notify them to conduct the verification, and the applicants.\n'第九十条 中国药品生物制品检定所完成进口药品注册检验后，应当将复核的药品标准、药品注册检验报告和复核意见送交国家食品药品监督管理局药品审评中心，并抄送申请人。'可被翻译为：Article 90 After completing the testing for import drug registration, the National Institute for the Control of Pharmaceutical and Biological Products shall give the verified specifications, certificate of analysis and opinions thereof to the Center for Drug Evaluation of the State Food and Drug Administration, and copy the applicants.\n\n根据上述已知信息，请将'第五十四条 接到注册检验通知的药品检验所应当按申请人申报的药品标准对样品进行检验，对申报的药品标准进行复核，并在规定的时间内将药品注册检验报告送交国家食品药品监督管理局药品审评中心，并抄送申请人。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 54 The drug testing institute that receives a notice for the testing for registration shall test the samples according to the drug specifications submitted by the applicant, verify the submitted drug specifications, and submit a certificate of analysis for drug registration to the Center for Drug Evaluation of the State Food and Drug Administration within the specified timeline, and copy to the applicant."
    },
    {
        "instruction":"已知信息：\n'化妆品注册人、备案人使用化妆品新原料生产化妆品的，相关化妆品申请注册、办理备案时应当通过信息服务平台经化妆品新原料注册人、备案人关联确认。'可被翻译为：If cosmetic registrants and filing persons use new cosmetic ingredients to produce cosmetics, the relevant cosmetic registration application and filing shall be associated and confirmed by the registrant or filing person of the new cosmetic ingredient through the information service platform.\n'化妆品原料安全信息登记平台上线后，化妆品注册人、备案人、境内责任人仍可以通过化妆品注册备案信息服务平台填报原料生产商出具的原料安全信息文件，也可以填写化妆品原料安全信息登记平台生成的原料报送码关联原料安全信息文件。'可被翻译为：After the launch of the Cosmetic Ingredient Safety Information Registration Platform, cosmetics registrants, filing applicants and persons in charge within the territory of China can still fill out and submit the safety information document of ingredients issued by raw material manufacturers through the Information Service Platform for Registration and Filing of Cosmetics, or fill in the safety information document of ingredients associated with the ingredients submission code generated by the platform.\n'为方便企业提前做好化妆品注册备案准备工作，自2021年4月1日起，境内的化妆品注册人、备案人、境内责任人和化妆品生产企业，可以通过全国一体化在线政务服务平台国家药监局网上办事大厅（https:\/\/zwfw.nmpa.gov.cn），按照《规定》的要求在化妆品注册备案信息服务平台（以下简称新注册备案平台）提交相关资料，办理注册备案用户账号；自2021年5月1日起，化妆品注册人、备案人、境内责任人，应当通过新注册备案平台申请特殊化妆品注册或者进行普通化妆品备案。'可被翻译为：In order to facilitate enterprises to makegood preparation for the registration and notification of cosmetics in advance, as of April 1, 2021, domestic cosmetic registration persons, notification persons, domestic responsible persons and cosmetic manufacturers may submit relevant documents and apply for the user account for registration and notification at the Information Service Platform of Cosmetics Registration and Notification(hereinafter referred to as the new platform) according to the requirements in the Rules through the NMPA Online Service Hall (https:\/\/zwfw.nmpa.gov.cn), a national integrated online government service platform. As of May 1, 2021, cosmetic registration persons, notification persons and domestic responsible persons shall apply for the registration of special cosmetics or file notification of the general cosmetics through the new platform.\n'第三十条 化妆品注册人、备案人应当选择符合法律、行政法规、强制性国家标准和技术规范要求的原料用于化妆品生产，对其使用的化妆品原料安全性负责。化妆品注册人、备案人申请注册、进行备案时，应当通过信息服务平台明确原料来源和原料安全相关信息。'可被翻译为：Article 30 Cosmetic registrants and filing persons shall select ingredients that meet the requirements of laws, administrative regulations, mandatory national standards and technical specifications for cosmetic production, and shall be responsible for the safety of cosmetic ingredients they use. When applying for registration and filing for filing, the cosmetic registrant and filing person shall clarify the source of ingredients and relevant information on ingredient safety through the information service platform.\n\n根据上述已知信息，请将'化妆品、化妆品新原料注册人、备案人按照规定通过化妆品、化妆品新原料注册备案信息服务平台（以下简称信息服务平台）申请注册、进行备案。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Registrants and filing persons of cosmetics and new cosmetic ingredients shall apply for registration and filing through the information service platform of registration and filing for cosmetics and new cosmetic ingredients (hereinafter referred to as the information service platform) in accordance with regulations."
    },
    {
        "instruction":"已知信息：\n'数据监查委员会（同义词：独立的数据监查委员会、数据 与安全性监查委员会）'可被翻译为：data monitoring committee\n'由申办者设立一个独立的数据监查委员会，它定期对研究进展、安全性数据和关键疗效终点进行评估，向申办者建议是否继续、调整或停止试验。'可被翻译为：An independent data monitoring committee that may be established by the sponsor to assess at intervals the progress of a clinical trial, the safety data, and the critical efficacy endpoints, and to recommend to the sponsor whether to continue, modify, or stop a trial.\n'通过对一数据矩阵进行特征分析、旋转变换等操作，以确定影响组成该特定矩阵的量测数据的因子数及其物理和化学本质，对量测数据进行定性和定量解释的过程。'可被翻译为：The process of performing qualitative and quantitative interpretation of a data matrix by performing operations such as characteristic analysis and rotation transformation to determine the number of factors affecting the measurement data composing the particular matrix and their physical and chemical nature.\n'对两个生物分析方法之间或同一生物分析方法用于不同实验室的潜在偏差的评估，以确定报告的数据是否有可比性。'可被翻译为：Assessment of potential bias between two bioanalytical methods or the same bioanalytical method used in different laboratories in order to determine whether reported data are comparable.\n\n根据上述已知信息，请将'毒理学家通过专业评判确定的一个独立因子，用于关联生物测定数据与人体安全性数据。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A factor determined by professional judgment of a toxicologist and applied to bioassay data to relate that data safely to humans."
    },
    {
        "instruction":"已知信息：\n'申请人、备案人对资料的真实性负责。'可被翻译为：The applicant and filing entity shall take full responsibility for the authenticity of the documents submitted.\n'申请人应当对其申请材料全部内容的真实性负责。'可被翻译为：The applicant shall be responsible for the authenticity of all information on the materials for application.\n'（四）对申报资料真实性有疑问的；'可被翻译为：(iv) There are doubts about the authenticity of the dossier;\n'（六）药品注册过程中认为申报资料不真实，申请人不能证明其真实性的；'可被翻译为：(6) During the drug registration process, the application dossier is considered untruthful, and the applicant cannot prove the authenticity thereof;\n\n根据上述已知信息，请将'申请人应当对申报资料的真实性负责。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The applicant shall be responsible for the authenticity of application dossiers."
    },
    {
        "instruction":"已知信息：\n'第一百七十五条 企业应当按照国家有关药品不良反应报告制度的规定，收集、报告药品不良反应信息。'可被翻译为：Article 175 Enterprises shall collect and report the information of ADRs in accordance with national provisions on ADR reporting system.\n'第一百七十条 销售特殊管理的药品和国家有专门管理要求的药品，应当严格执行国家有关规定。'可被翻译为：Article 170 The sales of drugs under special management and those with special management requirements of the State shall be carried out in strict accordance with the relevant national provisions.\n'第一百五十二条 中药材种植、采集和饲养的管理，依照有关法律、法规的规定执行。'可被翻译为：Article 152 Measures for cultivation, collection and breeding of Chinese medicinal materials shall be regulated in accordance with the provisions of applicable laws and administrative regulations.\n'第一百七十一条 每批产品均应当有相应的批生产记录，可追溯该批产品的生产历史以及与质量有关的情况。'可被翻译为：Article 171: A batch processing record should be kept for each batch of product so that the production history and quality related status of that batch can be traced.\n\n根据上述已知信息，请将'第一百七十一条 药品广告宣传应当严格执行国家有关广告管理的规定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 171 Drug advertising shall be conducted in strict accordance with the relevant national regulations on advertising management."
    },
    {
        "instruction":"已知信息：\n'能代替神经递质贮存于神经末梢囊泡中，并为神经冲动所释放的物质。'可被翻译为：A substance that can be stored in nerve end vesicles in place of neurotransmitters and released by nerve impulses.\n'神经末梢（突触）分泌的化学物质。可引起神经传导并通过受体特异性兴奋神经元。'可被翻译为：A chemical secreted by nerve endings (synapses). Can cause nerve conduction and excite neurons specifically through receptors.\n'一般为肽类，能增强或减弱神经元对神经递质反应，起调节作用。'可被翻译为：Usually peptides, which can enhance or weaken the response of neurons to neurotransmitters and play a regulatory role.\n'参与可兴奋细胞间的突触信号传递的、具有同源性的跨膜蛋白。神经递质通过与受体的结合开闭离子通道，改变质膜的离子通透性，从而改变突触后细胞的兴奋性。'可被翻译为：A homologous transmembrane protein involved in synaptic signaling between excitable cells. Neurotransmitters alter the permeability of ions in the plasma membrane by opening and closing ion channels by binding to receptors, thus altering the excitability of postsynaptic cells.\n\n根据上述已知信息，请将'神经冲动传递介质之后，突触前神经元通过神经递质转运器对神经递质重新吸收的过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process by which a presynaptic neuron reabsorbs a neurotransmitter via a neurotransmitter transporter after the nerve impulse transmission medium."
    },
    {
        "instruction":"已知信息：\n'药物溶解或分散于乳状液型基质中形成的均匀的半固体外用制剂。'可被翻译为：A uniform semisolid preparation for external use in which the drug is dissolved or dispersed in a emulsion type matrix.\n'药物与油脂性或水溶性基质混合制成的均匀的半固体外用制剂。'可被翻译为：A uniform semi-solid preparation for external use made by mixing a drug with an oily or water-soluble substrate.\n'以固体为分散相的液溶胶，即由不溶性的固体分散在液体中所形成的分散物系。固体粒子的线性大小在0.1pm以上。'可被翻译为：A liquid sol with a solid as a dispersing phase, that is, a dispersing system formed by an insoluble solid dispersed in a liquid. The linear size of solid particles is above 0.1pm.\n'固体药物高度分散在固体载体（或基质）中形成的分散体系。'可被翻译为：A dispersion system formed in a highly dispersed solid carrier (or substrate).\n\n根据上述已知信息，请将'大量的固体粉末（一般25%以上）均匀地分散在适宜的基质中所组成的半固体外用制剂。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A semi-solid external preparation composed of a large amount of solid powder (generally more than 25%) uniformly dispersed in a suitable substrate."
    },
    {
        "instruction":"已知信息：\n'以水为溶剂含有一种或-种以上的药物成分的内服液体制剂。'可被翻译为：An ingested liquid preparation containing one or more pharmaceutical ingredients in water as a solvent.\n'1.包含两个或多个原料药的FPP。\n2.含有两种或两种以上活性物质的制成品'可被翻译为：1.An FPP that contains two or more APIs.\n2.A finished pharmaceutical product that contains two or more actives.\n'经过所有生产阶段的产品，包括最终容器的包装和标签。药品成品可能含有一种或多种原料药。在某些情况下，它可能与医疗器械结合使用。'可被翻译为：A product that has undergone all stages of production, including packaging in its ﬁnal container and labelling. A finished pharmaceutical product may contain one or more APIs. In some cases, it may be in combination with a medical device.\n'未进行平台登记而与药品\/制剂注册申报资料一并提交研究资料的原料药，监管部门在药品制剂批准证明文件中标注原料药相关信息，可用于办理原料药GMP检查、进口通关等。'可被翻译为：For APIs not registered on the platform and whose research materials are submitted together with the drug\/preparation registration application dossiers, the regulatory department shall indicate the relevant APIs information in the drug\/preparation approval document, which maybe used for the GMP inspection of APIs and import customs clearance.\n\n根据上述已知信息，请将'含有一种以上原料药的制剂。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A drug product which contains more than one drug substance."
    },
    {
        "instruction":"已知信息：\n'针对特殊用途、通过劳动或努力生产且上市以满足需求或愿望的一个或多个产品。[HL7 患者安全]'可被翻译为：A thing or things produced by labour or effort for a specific use and marketed to satisfy a need or want. [HL7 Patient Safety]\n'为保证用药安全有效，由药师建立的患者治疗或预防疾病进行药物治疗过程的记录。包括为影响患者预后结果的专业活动（方案制定，实施，疗效、不良反应观察，评价、调整，患者教育）等内容。有纸质和电子两种形式。'可被翻译为：A record established by a pharmacist of a patient's treatment or prevention of a disease in order to ensure the safety and effectiveness of a drug. It includes professional activities that affect the outcome of the patient's prognosis (protocol development, implementation, efficacy, adverse reaction observation, evaluation, adjustment, patient education). Available in both paper and electronic form.\n'能够或确实接受为其提供或要求的产品或服务的个人或组织。NRA的客户包括接受或可能接受和使用由NRA提供的产品和服务的个人或团体。这些各方包括公众、患者、制造商、分销商、卫生从业人员、研究人员、卫生部以及依赖NRA的产品和服务作出公共卫生决定的其他个人和机构。'可被翻译为：A person or organization that could or does receive a product or a service that is intended for or required by this person or organization. Customers of an NRA include individuals or parties who receive or could receive and use products and services that are provided and offered by the NRA. These parties include the general public, patients, manufacturers, distributors, health practitioners, researchers, the ministry of health and other individuals and institutions that rely on the NRA’s products and services to make public health decisions.\n'为评估医疗器械的安全性和\/或性能而对一个或多个人类受试者进行的系统调查或研究(7)。'可被翻译为：Any systematic investigation or study in or on one or more human subjects, undertaken to assess the safety and\/or performance of a medical device (7).\n\n根据上述已知信息，请将'需要调查的观察结果，包括可能或可能不涉及个人或研究受试者人群的问题。[HL7 患者安全]'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An observation requiring investigation, and includes problems that might or might not involve individual or groups of investigative subjects.[HL7 Patient Safety]"
    },
    {
        "instruction":"已知信息：\n'国家药监局药审中心关于发布《中药新药复方制剂中医药理论申报资料撰写指导原则（试行）》《古代经典名方中药复方制剂说明书撰写指导原则（试行）》的通告'可被翻译为：NMPA CDE Announcement on Issuing the Guidance for the Preparation of Application Dossiers for TCM Theory of Compound Preparations of New Chinese Medicines (interim) and the Guidance for the Preparation of the Package Inserts of Compound Preparations of Chinese Medicines in Ancient Classic Prescriptions (interim)\n'中药注册按照中药创新药、中药改良型新药、古代经典名方中药复方制剂、同名同方药等进行分类。'可被翻译为：Registration of TCMs is classified into such categories as innovative TCMs, modified new drugs of TCMs, compound preparations of TCMs originated from classic recipes, TCMs with identical name and identical recipes, etc.\n'为规范和指导纳米药物研究与评价，在国家药品监督管理局的部署下，药审中心组织制定了《纳米药物质量控制研究技术指导原则(试行)》《纳米药物非临床药代动力学研究技术指导原则(试行)》《纳米药物非临床安全性评价研究技术指导原则(试行)》。根据《国家药监局综合司关于印发药品技术指导原则发布程序的通知》(药监综药管〔2020〕9号)要求，经国家药品监督管理局审查同意，于2021年8月27日发布实施。'可被翻译为：In order to standardize and guide the study and evaluation of nano drugs, under the deployment of the National Medical Products Administration, the Center for Drug Evaluation has organized to formulate the Technical Guidance for Quality Control Study of Nano Drugs (interim), Technical Guidance for Non-Clinical Pharmacokinetic Study of Nano Drugs (interim), and Technical Guidance for Non-Clinical Safety Evaluation Study of Nano Drugs (interim),which were issued and implemented on August 27, 2021 upon review and approval by the National Medical Products Administration.\n'《专门规定》共11章82条，包括总则、中药注册分类与上市审批、人用经验证据的合理应用、中药创新药、中药改良型新药、古代经典名方中药复方制剂、同名同方药、上市后变更、中药注册标准、药品名称和说明书等内容。《专门规定》与新修订《药品管理法》《药品注册管理办法》有机衔接，在药品注册管理通用性规定的基础上，进一步对中药研制相关要求进行细化，加强了中药新药研制与注册管理。'可被翻译为：The Special Provisions consists of 11 chapters and 82 articles, including general provisions, registration classification and marketing approval of TCMs, rational application of empirical evidence for human use, innovative TCMs, modified new drugs of TCMs, compound preparations of TCMs originated from classic recipes, TCMs with identical name and identical recipes, post-marketing changes, registration standards, drug names and package inserts of TCMs, etc.\n\n根据上述已知信息，请将'为加快构建中医药理论、人用经验和临床试验相结合的中药注册审评证据体系，规范中医药理论申报资料和古代经典名方中药复方制剂说明书相关内容的撰写，在国家药品监督管理局的部署下，药审中心组织制定了《中药新药复方制剂中医药理论申报资料撰写指导原则（试行）》和《古代经典名方中药复方制剂说明书撰写指导原则（试行）》。根据《国家药监局综合司关于印发药品技术指导原则发布程序的通知》要求，经国家药品监督管理局审查同意，于2021年10月15日发布实施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to speed up the construction of the evidence system for TCM registration evaluation combining TCM theory, experiences in human use and clinical trials, and standardize the preparation of application dossiers of TCM theory and the package inserts of compound preparations of Chinese medicines in ancient classic prescriptions, under the deployment of the National Medical Products Administration, the CDE has organized to formulate the Guidance for the Preparation of Application Dossiers for TCM Theory of Compound Preparations of New Chinese Medicines (interim) and the Guidance for the Preparation of the Package Inserts of Compound Preparations of Chinese Medicines in Ancient Classic Prescriptions (interim), which has, per the requirements of the Notice of the NMPA Comprehensive Department on Issuing the Release Procedures for Pharmaceutical Technical Guidance, been issued and implemented on October 15, 2021 upon the review and approval by the National Medical Products Administration."
    },
    {
        "instruction":"已知信息：\n'第八十条 验收药品应当做好验收记录，包括药品的通用名称、剂型、规格、批准文号、批号、生产日期、有效期、生产厂商、供货单位、到货数量、到货日期、验收合格数量、验收结果等内容。验收人员应当在验收记录上签署姓名和验收日期。'可被翻译为：Article 80 Acceptance inspection records shall be taken for drugs under acceptance inspection, including adopted name, dosage form, strength, approval number, lot number, date of production, expiry date, manufacturer, supplier, quantity of arrival, date of arrival, quantity qualified in acceptance inspection and results of acceptance inspection of drugs, etc. The acceptance inspection personnel shall sign his\/her name and indicate the date on the acceptance inspection record.\n'中药材销售记录应当包括品名、规格、产地、购货单位、销售数量、单价、金额、销售日期等内容；中药饮片销售记录应当包括品名、规格、批号、产地、生产厂商、购货单位、销售数量、单价、金额、销售日期等内容。'可被翻译为：The sales records of Chinese crude drugs shall include the name of the product, strength, place of production, purchaser, sales quantity, unit price, amount and sales date; those of Prepared Slices shall include the name of product, strength, lot number, place of production, manufacturer, purchaser, sales quantity, unit price, amount and sales date, etc.\n'第六十八条 采购药品应当建立采购记录。采购记录应当有药品的通用名称、剂型、规格、生产厂商、供货单位、数量、价格、购货日期等内容，采购中药材、中药饮片的还应当标明产地。'可被翻译为：Article 68 Purchase records shall be established for drugs purchased. Purchase records shall include the adopted name, dosage form, strength, manufacturer, supplier, quantity, price and date of purchase, etc. The place of production shall also be indicated for Chinese crude drugs and Prepared Slices.\n'第二十五条 医疗机构购进药品，必须建立并执行进货检查验收制度，并建有真实完整的药品购进记录。药品购进记录必须注明药品的通用名称、生产厂商（中药材标明产地）、剂型、规格、批号、生产日期、有效期、批准文号、供货单位、数量、价格、购进日期。'可被翻译为：Article 25    Where a medical institution purchases drugs, it shall establish and apply an examination and acceptance system, and keep authentic and complete purchase records. Purchase records shall indicate the adopted name of the drug in China, manufacturer (for Chinese crude drug, the origin should be noted), dosage form, date of expiry, drug approval number, supplier, quantity, price and date of purchase.\n\n根据上述已知信息，请将'中药材验收记录应当包括品名、产地、供货单位、到货数量、验收合格数量等内容。中药饮片验收记录应当包括品名、规格、批号、产地、生产日期、生产厂商、供货单位、到货数量、验收合格数量等内容，实施批准文号管理的中药饮片还应当记录批准文号。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Acceptance inspection records of Chinese crude drugs shall include the name of the product, the place of production, the supplier, the quantity of arrival, and quantity qualified in acceptance inspection, etc. Acceptance inspection records of Prepared Slices shall include the name of the product, strength, lot number, place of production, date of production, manufacturer, supplier, quantity of arrival and quantity qualified in acceptance inspection, etc. For Prepared Slices subject to the management of approval number, the approval number shall also be recorded."
    },
    {
        "instruction":"已知信息：\n'A型VDC的受体室应充满受体溶液，在池体顶部组装膜的制备和给药过程中，受体溶液应平衡到目标温度(通常为32°或37°)。在此期间可以运行搅拌子以加速温度稳定。在安装池体顶部组件之前，应测量并确保受体溶液温度在目标温度的±1°范围内。搅拌子可以运行，以帮助加快温度稳定。'可被翻译为：The receptor compartment of the Model A VDC should be filled with receptor solution that is equilibrated to the target temperature (typically 32° or 37°) during the preparation and dosing of the membrane in the cell top assembly. The stirrers can be run during this period to speed up temperature stabilization. The receptor solution temperature should be measured and ensured to be within ±1° of the target temperature prior to mounting the cell top assembly. The stirrers can be run to help speed up temperature stabilization.\n'应用于皮肤的产品在32±1°温度下进行测试(如果可能，在膜表面测量，或根据浸没池或VDC模型A的受体溶液的温度推断)。用于内部应用的产品(例如，直肠和阴道产品)在37±1°温度下进行测试。'可被翻译为：The test is conducted at 32 ± 1° for products applied to the skin (measured at the surface of the membrane, when possible, or inferred based upon the temperature of the receptor solution for immersion cells or VDC Model A). The test is conducted at 37 ± 1° for products intended for internal application (e.g., rectal and vaginal products).\n'系统应平衡，并在膜处测量温度。在上样之前，膜应在目标温度(通常为32°或37°)的±1°范围内。在平衡期间应打开搅拌子搅拌。'可被翻译为：The system should be equilibrated, and the temperature should be measured at the membrane. The membrane should be within ±1° of the target temperature (typically 32° or 37°) prior to applying the dosage form. The stirrers should be turned on during the equilibration period.\n'在整个测试过程中，应保持标称系统条件，如受体溶液的温度，使膜上的温度在IVRT期间保持在规定的参数范围内(例如，32±1°)。温度控制鉴定在设备一节中描述。'可被翻译为：During the entire test, the nominal system conditions, like the temperature of the receptor solution, should be maintained so that the temperature at the membrane remains within specified parameters (e.g., 32 ± 1°) for the duration of the IVRT. The temperature control qualification is described under Equipment.\n\n根据上述已知信息，请将'温度控制的确认:应平衡每个池体的温度使膜达到目标温度，并且设备的初始确认应验证在使用相关设备和方法参数时，该温度可在测试期间保持。根据VDC或FDC设备的设计，膜温度的测量通常可以方便地使用红外温度计，或使用安装在膜上的热电偶;对于浸没池，可以假设膜上的温度与溶解容器中受体溶液的体积相同，一旦达到平衡和稳定。在测试过程中，每个池体的温度通常应保持在目标温度(通常为32°或37°)的±1°内。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3. Qualification of Temperature Control: The temperature of each cell should be equilibrated to provide the target temperature at the membrane, and the initial qualification of the equipment should verify that the temperature can be maintained for the duration of the test when using the relevant equipment and method parameters. Depending on the VDC or FDC equipment design, a measurement of the membrane temperature can often be made conveniently using an infrared thermometer, or using a thermocouple mounted with the membrane; for immersion cells, the temperature at the membrane may be assumed to be the same as the bulk volume of the receptor solution in the dissolution vessel, once equilibrated and stabilized. The temperature of each cell should typically remain within ±1° of the target temperature (typically 32° or 37°) during the test."
    },
    {
        "instruction":"已知信息：\n'分析方法应根据现行WHO技术报告系列中发布的指南进行验证。'可被翻译为：10.6. Analytical procedures should be validated according to the guidelines as published in current WHO Technical Report Series (7).\n'WHO 清洁验证中包括HBEL时的考虑要点，WHO TRSXXX，2021'可被翻译为：14. WHO points to consider when including Health Based Exposure Limits in cleaning validation. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-fifth report. Geneva: World Health Organization; 2021: Annex 2, (WHO Technical Report Series, No. xxx, 2021).\n'清洁： 清洁方法总览、清洁方法开发和可清洁度、清洁方法、HBEL（允许日暴露值）信息报告、清洁验证样品分析的分析方法验证'可被翻译为：Cleaning: Cleaning validation master plan; Cleaning procedure development and cleanability; Cleaning procedures; Health Based Exposure Level (Permitted daily exposure); information reports; Analytical procedures validation for cleaning validation sample analysis\n'清洁程序和清洁验证'可被翻译为：iv. Cleaning procedures and cleaning validation\n\n根据上述已知信息，请将'对于清洁程序，应根据现行WHO技术报告系列中发布的指南进行开发和验证。在制订清洁程 序、清洁度研究和设定可接受限度时应考虑在清洁验证中使用HBEL时的考量要点。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"10.5. For cleaning procedures, development and validation should be done in accordance with the guidelines as published in current WHO Technical Report Series (6). Points to consider when using HBEL in cleaning validation (14) should be taken into account in establishing cleaning procedures, cleanability studies and setting acceptance limits."
    },
    {
        "instruction":"已知信息：\n'人员的培训\/资格认证'可被翻译为：a. Training\/qualification of personnel\n'确保有经过足够培训并具备经验的人员执行分析方法；'可被翻译为：ensure that adequately trained and experienced personnel are in place for analytical testing;\n'人员—检查培训记录、人员资格和经验，在样品收集、制备等过程观察分析人员，寻找可能会抑制微生物回收的错误。'可被翻译为：8. Personnel- review training records, personnel qualifications and experience. Observe analysts during sample collection, preparation, etc., and look for errors which may inhibit microbial recovery.\n'化验员资格评估，包括专业度、人员监测结果、培训记录和经验。还要注意是否在 本次或最近一次分析中对化验员的无菌检测操作进行了观察。'可被翻译为：Evaluate the analyst’s qualifications, including proficiency, personnel monitoring results, training record, and experience. Also note whether the sterility testing practice of the analyst was observed during this or a recent analysis.\n\n根据上述已知信息，请将'执行每一步分析操作人员的资格、培训和身份识别'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"8. Qualifications, training and identification of the personnel conducting each step of the analysis"
    },
    {
        "instruction":"已知信息：\n'正式的商业文件，概述了与另一个个人、团体或实体达成的协议的基本条款。这是签订更详细合同的第一步。其他名称包括但不限于谅解备忘录、合作合同或合作协议。'可被翻译为：A formal business document outlining the basic terms of an agreement with another individual, group or entity. It is one of the first steps towards a more detailed contract. Alternative names include, but are not limited to, memorandum of understanding, cooperation contract or collaboration agreement.\n'私人（合同）检测实验室质量协议、数据审核和相关问题，合同实验室是否有变化，为什么？'可被翻译为：13.Private (contract) testing laboratory quality agreements, data review, and associated problems; Have there been any changes in contract labs and why?\n'1.一份文件，说明试验的背景、基本原理和目标，并描述试验的设计、方法和组织，包括统计方面的考虑，以及试验进行和管理的条件。该文件应注明日期并由相关研究者\/机构和申办者签署，此外还可作为合同使用。\n2.给出试验的背景、基本原理和目标，并描述其设计、方法和组织的文件，包括统计方面的考虑以及进行和管理试验的条件。方案应注明日期，并由相关研究者或机构和申办者签署，此外还可作为合同使用。'可被翻译为：1.A document which gives the background, rationale and objectives of the trial and describes its design, methodology and organization, including statistical considerations, and the conditions under which it is to be performed and managed. It should be dated and signed by the investigator\/institution involved and the sponsor, and can, in addition, function as a contract.\n2.A document that gives the background, rationale and objectives of the trial and describes its design, methodology and organization, including statistical considerations and the conditions under which it is to be performed and managed. The protocol should be dated and signed by the investigator or institution involved and the sponsor, and can, in addition, function as a contract.\n'如果公司使用合同生产服务，检查合同生产商和\/或合同检测实验室是否签订有有效质量协议（就像公司与客户签订的协议一样），这样可以知悉各方在检测和数据生成、审核和归档方面的角色与职责。'可被翻译为：If the firm utilizes contract manufacturing services, is a contract manufacturer and\/or a contract \ntest laboratory, an active Quality Agreement, as established by the firm and customer, may \nprovide insight to the roles and responsibilities of each party for testing and data generation, \nreview and archival.\n\n根据上述已知信息，请将'1.以特定价格供应货物或从事工作的商业协议。\n2.一份注明日期并由研究者、机构和发起人签署的文件，列出任何关于财务问题和授权\/责任分配的协议。当议定书包含这些信息并签字时，它也可以作为合同。\n3.以一定价格供应货物或从事工作的商业协议;这可以在协议中包含质量要素，也可以在单独的合同中包含质量要素。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.Business agreement for the supply of goods or performance of work at a specified price.\n2.A document, dated and signed by the investigator, institution and sponsor, that sets out any agreements on financial matters and delegation\/distribution of responsibilities. The protocol may also serve as a contract when it contains such information and is signed.\n3.Business agreement for the supply of goods or performance of work at a speciﬁed price; this may include quality elements in the agreement, or in a separate contract."
    },
    {
        "instruction":"已知信息：\n'使设计具备良好地接受新版本输入信息的能力。本概念适用于整个系统、数据通信、协议、文件格式和计算机编程语言。例如，如果按照旧标准设计的产品收、阅读、查看或播放新标准或格式（不包括新功能）下的信息，则认为该产品是具备“向上兼容性”的。'可被翻译为：The ability of the design to gracefully accept input intended for newer versions of itself. The concept can be applied to entire systems, data \ncommunications, protocols, file formats and computer programming languages. For example, if products designed for the older standard can \nreceive, read, view or play the newer standard or format (excluding new functionality), then the product is said to be Forward Compatible.\n'设计用于使一个或多个气体容器同时排空和填充的设备或装置。'可被翻译为：Equipment or apparatus designed to enable one or more gas containers to be emptied and filled at the same time.\n'计算机系统设计和构建的一般术语，包括技术基础设备、信息（数据）和应用程序。'可被翻译为：A general term for the design and construction of computer systems, including technical infrastructure, information (data), and applications.\n'这是指使用成熟的计算机系统、编程语言、应用软件或过程，而不是可用的升级版本，并且根据当前的监管要求尚未合格。'可被翻译为：This refers to a mature computer system, programming language, application software, or processes that are used instead of available upgraded versions, and that have not been qualified according to current regulatory requirements.\n\n根据上述已知信息，请将'使设计具备良好地接受旧版本输入信息的能力。本概念可用于整个系统、数据通信、协议、文件格式和计算机编程语言。例如，如果使用新标准设计的产品可以接收、阅读、查看或播放使用旧标准或格式设计的产品信息，那么就说该产品是向下兼容的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The ability of the design to gracefully accept input created with older versions of itself. The concept can be applied to entire systems, data \ncommunications, protocols, file formats and computer programming languages. For example, if products designed for the new standard can \nreceive, read, view or play older standards or formats, then the product is said to be Backward Compatible."
    },
    {
        "instruction":"已知信息：\n'每天检查所有拭子\/海绵的浊度，如发现混浊则分离并转种培养。所有转种培养必须在 LFH 或 BSC 中进行。如果容器无法观察到混浊，则将所有环境监测样本培养 5-7天。无论之前是否转种培养，所有环境监测样本在 14 天培养之后均要进行转种培养。'可被翻译为：5. Check all swabs\/sponges daily for turbidity and subculture for isolation as turbidity is observed. All subculturing must be performed under LFH or BSC. If container does not allow for turbidity observation to be made, then subculture all environmental samples between Day 5 and 7. All environmental samples will be subcultured following day 14 incubation regardless of previous subculturing.\n'所有拭子在 25ºC- 30ºC 培养约 14 天，使其潜在被抑制的微生物得以恢复。'可被翻译为：3. All swabs are incubated at 25ºC- 30ºC for at least 14 days to allow for the resuscitation of potentially stressed microbes.\n'真菌培养基应该在 20º- 25ºC 培养 5-7 天。有时需适当延长培养时间，但通常需要超过 14 天，有专门的科学依据者除外。'可被翻译为：a. Fungal media should be incubated at 20ºto 25ºfor 5 to 7 days. In some cases, extended incubation times may be appropriate, but generally not beyond 14 days unless there is a specific scientific justification.\n'是否遵守方法—审核数据，查看培养时间（例如 USP <71>要求的 14 天）、温度（USP 要求的温度）是否足够或培养其用途是否适当'可被翻译为：6. Adherence to methods - Review data for adequacy of incubation time (for example 14 days for USP <71>), temperature (USP required temperatures) or appropriate media usage.\n\n根据上述已知信息，请将'再培养所有已培养的拭子直到满足全培养时间（14 天）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"7. Re-incubate all cultured swabs until the full incubation (14 days) timeframe are met."
    },
    {
        "instruction":"已知信息：\n'按日期安装'可被翻译为：install by date\n'安装确认（IQ）：证明工艺或系统所用装置（如机器、设备和仪器、计算机系统组件、测量装置、公用系统和生产）根据既定标准经过恰当选择，正确安装的文件化工作。'可被翻译为：installation qualification (IQ). Documented verification that the installations (such as machines equipment and instruments, computer system components, measuring devices, utilities and manufacturing) used in a processor system are appropriately selected and correctly installed, in accordance with established specifications.\n'定义为剩余的期限，从交货之日起，到到期日、复测日、按日期安装或在制造商确定的日期之前的其他用途。'可被翻译为：Defined as the period remaining, from the date upon delivery, to the expiry date, retest date, install by date or other use before date established by the manufacturer.\n'用于释药支架释放度测定的仪器装置。'可被翻译为：An instrument device for measuring the release degree of drug release support.\n\n根据上述已知信息，请将'仪器、装置或其他必须安装的日期。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The date by which an instrument, device or other has to be installed."
    },
    {
        "instruction":"已知信息：\n'经审评，符合附条件批准要求的，在药品注册证书中载明附条件批准药品注册证书的有效期、上市后需要继续完成的研究工作及完成时限等相关事项。'可被翻译为：Where requirements for conditional approval are met upon review, the Drug Approval License shall specify the validity period of the conditional Drug Approval License, the post-approval studies to be completed, the timeline for completing post-approval studies and other relevant details.\n'第六十九条 申请人在提出药品上市许可申请前，应当与药品审评中心沟通交流，经沟通交流确认后，在提出药品上市许可申请的同时，向药品审评中心提出优先审评审批申请。符合条件的，药品审评中心按照程序公示后纳入优先审评审批程序。'可被翻译为：Article 69 The applicant shall communicate with the CDE for confirmation prior to filing the drug marketing authorization application and then, when filing the drug marketing authorization application, submit a priority review and approval application to the CDE at the same time. Applications that meet the requirements shall be included into the priority review and approval procedure by the CDE after going through the prescribed public disclosure process.\n'第六十五条 审评过程中，发现纳入附条件批准程序的药品注册申请不能满足附条件批准条件的，药品审评中心应当终止该品种附条件批准程序，并告知申请人按照正常程序研究申报。'可被翻译为：Article 65 During review, where it is found that a drug registration application included into the conditional approval procedure does not meet the requirements for conditional approval, the CDE shall terminate the conditional approval procedure and inform the applicant to apply as per the normal review procedure.\n'国家药监局发布《医疗器械附条件批准上市指导原则》'可被翻译为：NMPA Issued the Guidelines for Conditional Approval for Marketing of Medical Devices\n\n根据上述已知信息，请将'第六十四条 申请附条件批准的，申请人应当就附条件批准上市的条件和上市后继续完成的研究工作等与药品审评中心沟通交流，经沟通交流确认后提出药品上市许可申请。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 64 Where conditional approval is applied for, the applicant shall communicate with the CDE about the conditions for conditional marketing approval and the studies to be completed after marketing. Upon confirmation through consultation and communication, a drug marketing authorization application may be filed."
    },
    {
        "instruction":"已知信息：\n'分析方法在生物基质中存在干扰物质（非特异性干扰）的情况下区分和\n测量待测物的能力。'可被翻译为：Ability of an analytical method to differentiate and measure the analyte in the presence of interfering substances in the biological matrix (non-specific interference).\n'来源有限的试验基质（如组织、脑脊液、胆汁）的替代物，或含有干扰性内源待测物的试验基质的替代物。'可被翻译为：An alternative to a study matrix of limited availability (e.g., tissue, cerebrospinal fluid, bile) or where the study matrix contains an interfering endogenous counterpart.\n'在基质中存在的可能影响待测物定量的物质。'可被翻译为：A substance that is present in the matrix that may affect the quantification of an analyte.\n'已知浓度的溶剂或溶剂混合物中的待测物，用于制备校正标样或QC样品。'可被翻译为：An analyte in a solvent or mixture of solvents at a known concentration, which is used to prepare calibration standards or QCs.\n\n根据上述已知信息，请将'由于样品中存在意外的待测物或其他干扰物质，而直接或间接改变或干扰响应。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The direct or indirect alteration or interference in response due to the presence of unintended analytes or other interfering substances in the sample."
    },
    {
        "instruction":"已知信息：\n'第四十一条 国务院卫生健康主管部门制定国家免疫规划；国家免疫规划疫苗种类由国务院卫生健康主管部门会同国务院财政部门拟订，报国务院批准后公布。'可被翻译为：Article 41 The competent health department under the State Council shall formulate the national immunization program; vaccine varieties in the national immunization program shall be proposed by the competent health department under the State Council jointly with the financial department under the State Council, and released upon approval by the State Council.\n'疾病预防控制机构配送非免疫规划疫苗可以收取储存、运输费用，具体办法由国务院财政部门会同国务院价格主管部门制定，收费标准由省、自治区、直辖市人民政府价格主管部门会同财政部门制定。'可被翻译为：Disease prevention and control institutions may charge storage and transportation fee for distributing non-immunization program vaccines; the specific measures shall be formulated by the financial department under the State Council in conjunction with the competent pricing department under the State Council; and the charging criteria shall be formulated by the competent pricing departments of the people's governments of provinces, autonomous regions and municipalities directly under the Central Government in conjunction with the financial departments at the same level.\n'国务院卫生健康主管部门建立国家免疫规划专家咨询委员会，并会同国务院财政部门建立国家免疫规划疫苗种类动态调整机制。'可被翻译为：The competent health department under the State Council shall establish an expert consultation committee on the national immunization program, and set up a dynamic adjustment mechanism for vaccines in the national immunization program jointly with the financial department under the State Council.\n'国务院卫生健康主管部门应当制定、公布国家免疫规划疫苗的免疫程序和非免疫规划疫苗的使用指导原则。'可被翻译为：The competent health department under the State Council shall formulate and issue immunization procedures for the national immunization program vaccines and guidelines for the use of non-immunization program vaccines.\n\n根据上述已知信息，请将'第三十二条 国家免疫规划疫苗由国务院卫生健康主管部门会同国务院财政部门等组织集中招标或者统一谈判，形成并公布中标价格或者成交价格，各省、自治区、直辖市实行统一采购。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 32 For national immunization program vaccines, the centralized bidding or unified negotiation shall be organized by the competent health department under the State Council jointly with the financial and other departments under the State Council. The winning price or transaction price shall be established and released, and each province, autonomous region and municipality directly under the Central Government shall implement unified procurement."
    },
    {
        "instruction":"已知信息：\n'（二）药品生产许可证有效期届满未重新发证的；'可被翻译为：(2) The Drug Manufacturing Certificate has expired but not been re-issued;\n'第一百二十条 国家食品药品监督管理局核发的药品批准文号、《进口药品注册证》或者《医药产品注册证》的有效期为5年。有效期届满，需要继续生产或者进口的，申请人应当在有效期届满前6个月申请再注册。'可被翻译为：Article 120 The valid term of a drug approval number, Import Drug License or Pharmaceutical Product License issued by the State Food and Drug Administration is five years. To continue its drug production or importation, the applicant shall submit a re-registration application six months prior to the expiry date.\n'第二十一条 药品生产许可证遗失的，药品上市许可持有人、药品生产企业应当向原发证机关申请补发，原发证机关按照原核准事项在十日内补发药品生产许可证。许可证编号、有效期等与原许可证一致。'可被翻译为：Article 21 In the event that a drug MAH or manufacturer has lost the Drug Manufacturing Certificate, they may apply to the original issuing authority for a replacement of the Certificate. The original issuing authority shall issue the replacing Drug Manufacturing Certificate with the same previously authorized contents within 10 days. The information such as Certificate number and valid term specified on the replacing Certificate shall be the same as that specified on the original Certificate.\n'药品生产许可证应当标明有效期和生产范围，到期重新审查发证。'可被翻译为：The valid term and the scope of manufacturing shall be indicated in the Drug Manufacturing Certificate. For renewal of the certificate on expiration, reexamination is required.\n\n根据上述已知信息，请将'第十九条 药品生产许可证有效期届满，需要继续生产药品的，应当在有效期届满前六个月，向原发证机关申请重新发放药品生产许可证。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 19 In the case of continuing the drug manufacturing following the expiration of the Drug Manufacturing Certificate, the company shall apply to the original issuing authority for renewal of the Drug Manufacturing Certificate 6 months ahead of the expiration."
    },
    {
        "instruction":"已知信息：\n'由单体经聚合而成的产物。包括由一种单体聚合而成的均聚物，和由两种或两种以上不同单体聚合而成的共聚物两大类。'可被翻译为：A product formed by polymerization of monomers. Includes homopolymers polymerized from one monomer, and copolymers polymerized from two or more different monomers.\n'由链霉菌产生的氧青霉烷类抗生素。是很强的B-内酰胺酶抑制剂。'可被翻译为：An oxypenicillanes antibiotic produced by Streptomyces. They are strong B-lactamase inhibitors.\n'主要由革兰氏阴性菌产生、由质粒介导的能赋予细菌对多种β-内酰胺类抗生素耐药的酶。'可被翻译为：Any of several plasmid-mediated enzymes produced primarily by Gram-negative bacteria that confer resistance to various β-lactam antibiotics.\n'由2〜10个单糖通过糖昔键连接形成直链或支链的低度聚合糖。'可被翻译为：A low-grade polymeric sugar consisting of 2 to 10 monosaccharides connected by glycoxi-bonds to form a straight or branched chain.\n\n根据上述已知信息，请将'β-内酰胺类抗生素在生产或储存过程中形成的自身聚合产物。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Self-polymerizing products formed during the production or storage of beta-lactam antibiotics."
    },
    {
        "instruction":"已知信息：\n'第一百三十八条 药品零售操作规程应当包括：'可被翻译为：Article 138 The operating procedure for drug retail shall include:\n'第一百三十五条 要求申请人重新制订药品标准的，申请人不得委托提出原复核意见的药品检验所进行该项药品标准的研究工作；该药品检验所不得接受此项委托。'可被翻译为：Article 135 Where the specifications are required to be reestablished, the applicant shall not entrust the drug testing institute that gave verification opinions to conduct the specification study of the drug; and the drug testing institute shall not accept such entrustment.\n'验收抽取的样品应当具有代表性。'可被翻译为：Samples taken for acceptance inspection shall be representative.\n'第一百三十三条 申请人应当提供药品注册检验所需要的有关资料、报送样品或者配合抽取检验用样品、提供检验用标准物质。报送或者抽取的样品量应当为检验用量的3倍；生物制品的注册检验还应当提供相应批次的制造检定记录。'可被翻译为：Article 133 An applicant shall provide the relevant data, samples and reference standards, or assist in sampling, which are required for the testing for drug registration. The amount of samples shall be three times the amount used for testing and, for biological products, manufacturing record for the relevant batches of products shall also be provided.\n\n根据上述已知信息，请将'第一百三十八条 申请人应当选取有代表性的样品进行标准的研究工作。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article138 An applicant shall select representative samples for drug registration specifications study."
    },
    {
        "instruction":"已知信息：\n'药物分散于熔融的材料中，再喷于冷气流中凝聚而成球或成囊的方法。'可被翻译为：The method in which the drug is dispersed in a molten material and then sprayed in a cold air stream to condense into a ball or capsule.\n'药物与-种或多种惰性固体骨架材料通过压制成型技术制成的片剂。药物分散在多孔或无孔的材料中，通过各种机制使药物缓慢释放。'可被翻译为：A tablet made of a drug with one or more inert solid skeleton materials by press molding. The drug is dispersed in porous or non-porous materials and is slowly released by various mechanisms.\n'药物溶解或分散于乳状液型基质中形成的均匀的半固体外用制剂。'可被翻译为：A uniform semisolid preparation for external use in which the drug is dissolved or dispersed in a emulsion type matrix.\n'药物及辅料以适当形式通过压制法（或滴制法）密封于软质囊材中而制成的固体制剂。'可被翻译为：A solid preparation made of drugs and excipients in an appropriate form by pressing (or dropping) sealed in soft sacs.\n\n根据上述已知信息，请将'药物溶解或分散或包裹于成膜材料中而制成的单层或多层膜状制剂。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A single or multilayer film-like preparation in which the drug is dissolved or dispersed or encased in a film-forming material."
    },
    {
        "instruction":"已知信息：\n'第二十三条 核查中心在注册核查时限内，组织实施注册核查工作，确定核查时间，通知申请人和被核查单位接受注册核查。需要进行动态生产现场核查的，结合申请人动态生产安排确定生产现场核查时间。'可被翻译为：Article 23 CFDI shall organize the implementation of the registration inspection work within the registration inspection time limit, determine the inspection time, and notify the applicant and the inspected institution to accept the registration inspection. If a dynamic manufacturing on-site inspection is required, Manufacturing Site Inspection time shall be determined based on the applicant's dynamic production arrangement.\n'第二十八条 在注册核查工作中，核查组有权对申请人和被核查单位、人员、设施设备、管理要求等进行核查，进入研制、生产及其他核查相关场地，调阅相关资料，询问相关人员。'可被翻译为：Article 28 During the registration inspection work, the inspection team has the right to inspect the applicant and the inspected institution, personnel, facilities and equipment, management requirements, etc., enter the development, manufacture, and other inspection related sites, read relevant dossiers, and inquire the relevant personnel.\n'第十三条  省、自治区、直辖市药品监督管理部门应当对申请资料进行审核，按照国家药品监督管理局制定的医疗器械生产质量管理规范的要求进行核查，并自受理申请之日起20个工作日内作出决定。现场核查可以与产品注册体系核查相结合，避免重复核查。需要整改的，整改时间不计入审核时限。'可被翻译为：Article 13 The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall examine the application dossiers, and conduct inspection in compliance with the requirements of the Good Manufacturing Practice for medical devices formulated by NMPA, and make decisions within 20 working days from the date of acceptance. The on-site inspection shall be combined with inspection of the product registration system, to avoid repeated inspection. If rectification is necessary, the rectification time shall not be included in the review time.\n'第七条 检查员依法对被核查单位相关品种注册研制、生产的情况进行核查。'可被翻译为：Article 7 Inspectors shall inspect the registration development and manufacturing of related varieties of the inspected institution in accordance with the law.\n\n根据上述已知信息，请将'第十三条 核查报告、核查结果仅针对该注册申请该次核查范围和内容，不覆盖该注册申请全部注册申报资料和相关研制行为的评价。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 13 The inspection report and inspection results are only for the scope and content of the inspection of the registration application, and do not cover all the registration application dossiers of the registration application and the evaluation of related development activities."
    },
    {
        "instruction":"已知信息：\n'机械力克服固体物料内部凝聚力、使之破碎的单元操作。'可被翻译为：Unit operation in which mechanical force overcomes the internal cohesion of a solid material and causes it to break.\n'用机械方法使两种或多种物料相互分散而达到均匀状态的设备。'可被翻译为：A device in which two or more materials are dispersed to a uniform state by mechanical means.\n'固体粒子群在机械力作用下产生的对流位移混合。'可被翻译为：Convective displacement mixing of solid particle swarm under the action of mechanical force.\n'固体物料的粉碎设备之一。由圆筒和内装的钢、瓷或玻璃圆球组成，靠球的运动使物料受到冲击力和研磨力而被粉碎。'可被翻译为：One of the crushing equipment of solid materials. It is composed of a cylinder and a steel, porcelain or glass ball, which is crushed by the impact force and grinding force.\n\n根据上述已知信息，请将'用机械力克服固体物料内部凝聚力、使之破碎的设备。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Mechanical force to overcome the internal cohesion of solid materials, so that it is broken equipment."
    },
    {
        "instruction":"已知信息：\n'(viii)批记录和发运记录应当能够追溯批产品的完整历史，并妥善保存、便于查阅；'可被翻译为：(viii) Records of manufacture including distribution which enable the complete history of a batch to be traced are retained in a comprehensible and accessible form;\n'第三百零二条 产品召回负责人应当能够迅速查阅到药品发运记录。'可被翻译为：Article 302: The distribution records should be readily available to the person(s) responsible for recalls.\n'用电子方法保存的批记录，应当采用磁带、缩微胶卷、纸质副本或其他方法进行备份，以确保记录的安全，且数据资料在保存期内便于查阅。'可被翻译为：Batch records stored electronically should be protected by back-up transfer on magnetic tape, microfilm, paper or other means. It is particularly important that the data are safe, and readily available throughout the period of retention.\n'第一百六十二条 每批药品应当有批记录，包括批生产记录、批包装记录、批检验记录和药品放行审核记录等与本批产品有关的记录。批记录应当由质量管理部门负责管理，至少保存至药品有效期后一年。'可被翻译为：Article 162: Each batch of drug should have a batch record, which includes related records of processing, packaging, testing, release, and etc. This batch record should be retained for at least one year after the product shelf life by the quality management department.\n\n根据上述已知信息，请将'（七）批记录和发运记录应当能够追溯批产品的完整历史，并妥善保存、便于查阅；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"7. Records of manufacture and distribution, which enable the complete history of a batch to be traced, are retained in a comprehensible and accessible form."
    },
    {
        "instruction":"已知信息：\n'一是细化注册人、备案人管理制度，强化企业主体责任落实。根据《条例》关于注册人、备案人的相关规定要求，细化落实化妆品、化妆品新原料注册人、备案人的责任义务及准入条件，加强对产品责任源头监管。建立新原料安全监测制度，对新原料注册人、备案人和化妆品注册人、备案人应当履行的安全监测义务进行了细化规定。'可被翻译为：1. The elaboration on the administration system for registration and notification persons to potentiate corporate principal responsibilities. In accordance with the related requirements of the Regulations, detailed provisions for responsibilities, obligations and access conditions are applied to registration and notification persons of cosmetics and new cosmetic ingredients to potentiate the supervision and liability of product at its source. A safety monitoring system for new cosmetic ingredients is established with detailed regulations on the safety monitoring obligations of registration and notification persons of cosmetics and new cosmetic ingredients.\n'变更后的注册人应当符合本办法关于注册人的规定，并对已经上市的产品承担质量安全责任。'可被翻译为：The altered registrant shall comply with requirements of a registrant in these Provisions and shall be responsible for the quality and safety of the products already on the market.\n'各省级药品监管部门应当落实辖区内药品上市后变更监管责任，细化工作要求，制定工作文件，明确工作时限，药品注册管理和生产监管应当加强配合，互为支撑，确保药品上市后变更监管工作平稳有序开展。'可被翻译为：Each provincial drug regulatory department shall implement the responsibility for supervision over change management of post-approval drugs at its administrative area, by specifying requirements, formulating working documents, and clarifying time limits. The cooperation between drug registration administration and production supervision should be consolidated for mutual support, to ensure the smooth and orderly implementation of change management of post-approval drugs.\n'第二十七条 化妆品注册人、备案人、受托生产企业应当建立化妆品质量安全责任制，落实化妆品质量安全主体责任。'可被翻译为：Article 27 The registrant, the filing entity and the contract manufacturer of cosmetics shall establish responsibility system for quality and safety of cosmetics, and implement subject responsibility for quality and safety of cosmetics.\n\n根据上述已知信息，请将'三是加强备案后监督管理，确保产品质量安全责任落实到位。明确备案后监督管理责任落实和工作要求，加大对备案产品违法违规行为的惩处力度；实施备案产品分级管理，合理配置监管资源。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3. The enhancement of supervision and administration of post-notification to ensure that the responsibilities for product quality and safety are in place. The responsibilities and requirements for the supervision and administration of post notification are clarified, with stricter penalties for violations of laws and regulations on filed products, which are subject to classification management to rationally allocate supervision resources."
    },
    {
        "instruction":"已知信息：\n'按照现行版本的USP确定要测试的正确件数以及每件要分析的产品数量。如 果可能，最好测试每件的全部内容。如果实验室政策要求测试的单元数超过 USP要求，则遵循实验室政策。'可被翻译为：Follow the current edition of the USP to determine the correct number of units to be tested and the amount of product to be analyzed from each unit. It is preferable to test the entire contents of each unit if possible. Follow laboratory policy if it requires testing more units than the USP requires.\n'如果这样做会降低可用于无菌测试的单元数量，该数量低于USP要求或ORS法规要 求，当有可行的替代方案时，则不应该牺牲产品单元作为系统控制。如果使用产品 单元将会使得子样品减少至USP或ORS法规所要求数量以下，则分析实验室应尽可 能使用除样品之外的其他物料进行控制。'可被翻译为：When there are viable alternatives, a product unit should not be sacrificed for use as a system control if this will reduce the number of units available for sterility testing below USP requirements or ORS policy requirements, except as provided in the preceding paragraph. If using a product unit would reduce the subsamples examined below the number required by USP or ORS policy, the analyzing laboratory should prepare a control from other material than a unit of the sample product whenever possible.\n'样本量执行USP现行版本要求。'可被翻译为：Follow the current edition of the USP for the amount of sample to be tested.\n'在开始样本检测序列之前，应根据USP<788>进行空白检测。环境空白必须符合USP<788>中所设定的要求方可开始样本检测。'可被翻译为：Prior to initiating the test sequence with a specimen, a blank determination is required and must be carried out according to USP<788> . The environmental blank must meet the requirements set forth in USP <788>in order to initiate testing of the specimen.\n\n根据上述已知信息，请将'如果所采集的单元数少于USP要求，则在执行下步操作之前与实验室主管讨论。 有因情形下采集的样本可使用少于USP要求的单元数量进行分析。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the number of units collected is less than the USP requirements, discuss with the laboratory supervisor before proceeding. Samples collected in a for-cause situation may be analyzed with a number of units less than the USP requirements."
    },
    {
        "instruction":"已知信息：\n'（七）确保相关信息及其纠正和预防措施已通过高层管理人员的评审。'可被翻译为：7. To ensure that the related information and its CAPA pass the review by the senior management.\n'（三）确定所需采取的纠正和预防措施，防止问题的再次发生。'可被翻译为：3. To determine necessary CAPA measures for preventing issues from re-occurring;\n'第三十七条  医疗器械注册人、备案人、受托生产企业应当建立纠正措施程序，确定产生问题的原因，采取有效措施，防止相关问题再次发生。'可被翻译为：Article 37 The registrant, filing entity or contract manufacturer of medical devices shall establish procedures for corrective actions, determine the cause for problems and take effective measures, to prevent recurrence of related problems.\n'（六）有信息提示相应产品的质量或者质量控制可能存在潜在风险的；'可被翻译为：(VI) There is information suggesting that the quality of the corresponding product or quality control has potential risks;\n\n根据上述已知信息，请将'（六）确保相关信息已传递到质量受权人和预防问题再次发生的直接负责人。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"6. To ensure that the related information is delivered to the Qualified Person and the person directly in charge of preventing issues from re-occurring;"
    },
    {
        "instruction":"已知信息：\n'某些脂溶性、挥发性的药物通过喷雾或气雾给药方式由呼吸道黏膜或肺泡上皮细胞吸收。'可被翻译为：Certain fat-soluble, volatile drugs are absorbed by respiratory mucosa or alveolar epithelium by spray or aerosol delivery.\n'通过雾化吸入器、干粉吸入器或定量吸入器所产生的气溶胶将药物传递到呼吸道达到局部或全身治疗目的的制剂。'可被翻译为：A preparation that delivers drugs to the respiratory tract for local or systemic therapeutic purposes through aerosols produced by atomizing inhalers, dry powder inhalers or quantitative inhalers.\n'一种或一种以上含药物粒子经特殊的给药装置给药后以气溶胶形式进入呼吸道的吸入制剂。按用途可分为吸入粉雾剂、非吸入粉雾剂和外用粉雾剂。'可被翻译为：An inhalation preparation in which one or more drug-containing particles are administered by a special drug delivery device and then enter the respiratory tract in aerosol form. It can be divided into inhaled powder, non-inhaled powder and external powder according to its use.\n'一种或一种以上含药物粒子经特殊的给药装置给药后以气溶胶形式进入呼吸道的吸入制剂。'可被翻译为：An inhaled preparation in which one or more drug-containing particles are administered by a special drug delivery device and enter the respiratory tract in aerosol form.\n\n根据上述已知信息，请将'药物粉末或溶液被雾化后随气体直接接触呼吸道黏膜或吸入肺的给药方式。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The form of administration in which a powder or solution is atomized and then directly exposed to the respiratory mucosa or inhaled into the lungs."
    },
    {
        "instruction":"已知信息：\n'在培养过程中，连续地向发酵罐中加入培养基，同时以相同的流量从发酵罐中流出培养液的发酵方式。'可被翻译为：In the culture process, the culture medium is continuously added to the fermenter, while the same flow rate from the fermenter flowing out of the culture liquid fermentation mode.\n'深层通气发酵'可被翻译为：submerged aerobic fermentation\n'将微生物或动植物的细胞和培养液一次性装入反应器中,进行培养，细胞不断增加，产物液不断形成,经过一段时间反应后,将整个反应体系取出的培养方法。'可被翻译为：A culture method in which the cells and culture medium of microorganisms or animals and plants are loaded into the reactor at one time for culture, the cells are continuously increased, the product liquid is continuously formed, and after a period of reaction, the whole reaction system is taken out.\n'在单一固相、气相、液相中进行的化学反应。即在反应过程中与其他物相没有物质交换的反应。'可被翻译为：A chemical reaction that takes place in a single solid, gas, or liquid phase. A reaction in which no substance is exchanged with another phase during the reaction.\n\n根据上述已知信息，请将'在培养过程中，除了不断进行通气，调节培养液的pH值、系统排出废气外，与外界没有其他交换的发酵方式。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"During the culture process, there is no other fermentation method of exchange with the outside world except for continuous ventilation, adjustment of the pH value of the culture solution, and exhaust gas from the system."
    },
    {
        "instruction":"已知信息：\n'（十一）如果医疗器械的预期目的是明确用于某种疾病的治疗，其分类应不低于第二类。'可被翻译为：(11) A medical device intended for the treatment of a certain disease, its class shall not be lower than class II.\n'在新药或其新用途的预先批准临床经验中，尤其是由于无法确定治疗剂量：对与任何剂量相关的药品的所有有害和非预期的反应，均应视为药物不良反应药物不良反应。“对药品的反应”这一短语意味着药品与不良事件之间的因果关系至少具有合理的可能性，例如不能排除\n关系。关于上市药品：对有毒药物的反应，是非预期事件，通常发生在用于人类预防、诊断或治疗疾病或改变生理功能的给药中（见 ICH 临床安全性数据管理指导原则：加速报告的定义和标准）[ICHE6 (R1) ]'可被翻译为：In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) cannot be established: all noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions. The phrase ‘responses to a medicinal product’ means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility,e.g. the relationship cannot be ruled out.Regarding marketed medicinal products: a response to a drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of diseases or for modification of physiological function (See the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).[ICHE6(R1)]\n'验证：证明和记录工艺、程序或方法可以实际并持续得到预期结果的活动'可被翻译为：validation. Action of proving and documenting that any process, procedure or method actually and consistently leads to the expected results.\n'药物不良反应的预期性'可被翻译为：expectedness of an adverse drug reaction\n\n根据上述已知信息，请将'根据调整后的过去消费量或预期的疾病模式和标准治疗，对每种药物的需要量进行仔细评估，预期与实际需求相当吻合。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A careful evaluation of the quantities needed of each medicine, based on either adjusted past consumption or anticipated pattern of diseases and standard treatment, which can be expected to match actual needs reasonably well."
    },
    {
        "instruction":"已知信息：\n'两种以上药物作用等于每一种化合物质单独作用的总和。'可被翻译为：The action of two or more drugs is equal to the sum of the separate actions of each chemical compound.\n'使阴、阳离子结合成化合物的静电作用。'可被翻译为：Electrostatic action to combine Yin and cation into a compound.\n'两种或两种以上物质混合会导致熔点降低。'可被翻译为：Mixing of two or more substances will result in a decrease in the melting point.\n'能与某些内源性配体的受体结合，并呈现该配体物质作用的化合物或药物。'可被翻译为：A compound or drug that binds to a receptor of some endogenous ligand and exhibits the action of that ligand substance.\n\n根据上述已知信息，请将'两种以上物质结合成化合物时互相作用的性质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The property of interaction between two or more substances combined to form a compound."
    },
    {
        "instruction":"已知信息：\n'第七十三条 药品到货时，收货人员应当核实运输方式是否符合要求，并对照随货同行单（票）和采购记录核对药品，做到票、账、货相符。'可被翻译为：Article 73 Upon arrival of drugs, the receiving personnel shall validate whether the mode of transportation meets the requirements, and check the drugs against the accompanying sheet (bill) and the purchase records to ensure consistency among bills, account and goods.\n'（四）相关印章、随货同行单（票）样式；'可被翻译为：(IV) Model of relevant seal and the accompanying sheet (bill);\n'随货同行单（票）应当包括供货单位、生产厂商、药品的通用名称、剂型、规格、批号、数量、收货单位、收货地址、发货日期等内容，并加盖供货单位药品出库专用章原印章。'可被翻译为：The accompanying sheet (bill) shall include the supplier, the manufacturer, the adopted name, dosage form, strength, lot number and quantity of drugs, the consignee, receiving address, shipping date and other contents, and stamped with the original special seal for drug ex-warehousing of the supplier.\n'第九十八条 药品出库时，应当附加盖企业药品出库专用章原印章的随货同行单（票）。'可被翻译为：Article 98 At the time of ex-warehousing of drugs, the accompanying sheet (bill) stamped with the original special seal for drug ex-warehousing of enterprises shall be attached.\n\n根据上述已知信息，请将'第一百五十三条 药品到货时，收货人员应当按采购记录，对照供货单位的随货同行单（票）核实药品实物，做到票、账、货相符。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 153 Upon arrival of drugs, the receiving personnel shall, in accordance with the purchase records, check the material objects according to the accompanying sheet (bill) provided by suppliers and ensure that the bills, account and goods are consistent."
    },
    {
        "instruction":"已知信息：\n'本附录旨在为无菌产品的生产提供指导。其中部分原则和指导，例如污染控制策略、厂房设计、洁净室分级、确认、验证、监测和人员更衣等，可用于支持其它非无菌但须控制和减少微生物、微粒和内毒素\/热原污染的产品的生产（例如某些液体、乳膏、软膏和低微生物负载的生物中间体）。如果生产商选择将本指南应用于非无菌产品，则应明确记录所应用的原则，并确认应证明符合这些原则。'可被翻译为：The intent of the Annex is to provide guidance for the manufacture of sterile products. However, some of the principles and guidance, such as contamination control strategy, design of premises, cleanroom classification,\nqualification, validation, monitoring and personnel gowning, may be used to support the manufacture of other products that are not intended to be sterile such as certain liquids, creams, ointments and low bioburden biological\nintermediates, but where the control and reduction of microbial, particulate and endotoxin\/pyrogen contamination is considered important. Where a manufacturer elects to apply guidance herein to non-sterile products, the manufacturer should clearly document which principles have been applied and acknowledge that compliance with\nthose principles should be demonstrated.\n'适用于无菌产品生产的一般原则。'可被翻译为：General principles as applied to the manufacture of sterile products.\n'本建议审核领域和条件清单不应作为完全清单。可能需要基于一些独特属性或各ORS 实验室所用程序增加其它审核领域。'可被翻译为：This suggested list of areas and conditions to review should not be considered as comprehensive. Additional areas of review may need to be added based on some of the unique features or procedures employed by individual ORS laboratories.\n'附录 1 的修订还应考虑其它 GMP 章节和附录以及其它法规文件中的相关变更。修订后的指南将力求保证\n一致性，消除歧义，并将技术的进步考虑进来。'可被翻译为：The revision of Annex 1 should also take into account related changes in other GMP chapters and annexes as well\nas in other regulatory documents. The revised guideline will seek to remove ambiguity and inconsistencies and\nwill take account of advances in technologies.\n\n根据上述已知信息，请将'包括本附录的一般原则适用的（无菌产品以外的）其它领域。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Includes additional areas (other than sterile products) where the general principles of the annex can be applied."
    },
    {
        "instruction":"已知信息：\n'2.2含有已知活性成份的新剂型（包括新的给药系统）、新处方工艺、新给药途径，且具有明显临床优势的药品。'可被翻译为：2.2 Drugs that contain known active ingredients with new dosage form (including new drug delivery system), new formulation process or new route of administration, and have significant clinical advantages.\n'（一）境内已有相同活性成分、适应症（或者功能主治）、剂型、规格的非处方药上市的药品；'可被翻译为：(1) Drugs with the same active ingredients, indications, dosage forms and strengths as non-prescription drugs that have been marketed within the territory of the People's Republic of China;\n'如果产品在相同的剂型中含有相同数量的相同活性，如果它们符合可比标准，并且如果它们打算通过相同的途径给药，则它们是药物等效物。药物等效并不一定意味着治疗等效，因为赋形剂和\/或制造工艺以及一些其他变量的差异可能导致产品性能的差异。'可被翻译为：Products are pharmaceutical equivalents if they contain the same amount of the same actives in the same dosage form, if they meet comparable standards, and if they are intended to be administered by the same route. Pharmaceutical equivalence does not necessarily imply therapeutic equivalence, as differences in the excipients and\/or manufacturing process and some other variables can lead to differences in product performance.\n'（一）经国家食品药品监督管理局确定的非处方药改变剂型，但不改变适应症或者功能主治、给药剂量以及给药途径的药品；'可被翻译为：(1) To alter the dosage form of a non-prescription drug determined by the State Food and Drug Administration without changing the indications or functions, dosage and route of administration; or\n\n根据上述已知信息，请将'药品含有相同的活性成分并且浓度、剂型及给药途径也相同。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The drug contains the same active ingredient in the same concentration, dosage form, and route of administration."
    },
    {
        "instruction":"已知信息：\n'打开一个无菌棉签（或海棉），用润湿剂（无菌水、盐水或 D\/E 中和肉汤）浸湿，按压装有湿润剂的容器挤出多余水分'可被翻译为：a. Open a sterile swab (or sponge). Dampen with wetting agent (sterile water, saline, or D\/E neutralizing broth) and squeeze off excess by pressing against the inside of the container holding the wetting agent.\n'用于静脉注射的无菌溶液，体积为100ml或更多，装在成品剂型的一个容器中。'可被翻译为：Sterile solutions intended for parenteral application with a volume of 100ml or more in one container of the finished dosage form.\n'装在喷瓶中的无菌消毒剂'可被翻译为：i. Sterile Disinfectant in a spray bottle\n'手动无菌工艺：操作人员手动配制、灌装、放置和\/或密封无菌产品敞口容器的无菌工艺。'可被翻译为：Manual aseptic processing— An aseptic process where the operator manually compounds, fills, places and \/or seals an open container with sterile product.\n\n根据上述已知信息，请将'用于冲洗的无菌水或装在螺帽容器中的无菌盐水'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"f. Sterile water for irrigation or sterile saline held in screw cap containers."
    },
    {
        "instruction":"已知信息：\n'充分描述仪器响应（例如，峰面积或高比或信号）与校正标样中待测物浓度（量）之间关系的数学表达式。响应函数是在给定浓度范围内定义的。另见校正曲线。'可被翻译为：A mathematical expression which adequately describes the relationship between instrument response (e.g., peak area or height ratio or signal) and the concentration (amount) of analyte in the calibration standards. Response function is defined within a given range. See also Calibration Curve.\n'校正标样中待测物的高、低浓度区间（包括两端浓度）。'可被翻译为：The interval between the upper and lower concentration (amounts) of analyte in the calibration standards (including these concentrations)\n'分析批中单个样品、QC和校正标样的所有数据的表格输出（例如，对于色谱法有保留时间、待测物和IS响应、浓度、稀释因子（如有）、采集时间；对于配体结合分析，有待测物响应、浓度、稀释因子）。'可被翻译为：Tabular output of all data from individual samples, QCs and calibration standards within the analytical run (e.g., for chromatography retention times, analyte and IS responses, concentrations, and dilution factors if any; for ligand binding assays analyte responses concentrations, dilution factors).\n'已知浓度的溶剂或溶剂混合物中的待测物，用于制备校正标样或QC样品。'可被翻译为：An analyte in a solvent or mixture of solvents at a known concentration, which is used to prepare calibration standards or QCs.\n\n根据上述已知信息，请将'仪器响应（例如峰面积、峰高或信号）与给定范围内校正标样中的待测物浓度（含量）的关系。也称为“标准曲线”。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The relationship between the instrument response (e.g., peak area, height or signal) and the concentration (amount) of analyte in the calibration standards within a given range. Also referred to as Standard Curve."
    },
    {
        "instruction":"已知信息：\n'第三十三条  医疗器械注册人、备案人、受托生产企业应当建立记录管理制度，确保记录真实、准确、完整和可追溯。'可被翻译为：Article 33 The registrant, filing entity or contract manufacturer of medical devices shall establish record management procedures, to ensure the authenticity, accuracy, integrity and traceability of the records.\n'医疗器械经营备案人应当确保提交的资料合法、真实、准确、完整和可追溯。'可被翻译为：The filing entity of medical device distribution shall guarantee that the materials submitted are legal, authentic, accurate, complete, and traceable.\n'第三十五条  医疗器械注册人、备案人应当建立并实施产品追溯制度，保证产品可追溯。受托生产企业应当协助注册人、备案人实施产品追溯。'可被翻译为：Article 35 The registrant or filing entity of medical devices shall establish and implement the procedures for tracing products, to guarantee the traceability of the products. The contract manufacturer shall assist with the registrant and the filing entity in tracing the products.\n'第三十一条  医疗器械注册人、备案人、受托生产企业应当加强采购管理，建立供应商审核制度，对供应商进行评价，确保采购产品和服务符合相关规定要求。'可被翻译为：Article 31 The registrant, filing entity or contract manufacturer of medical devices shall enhance purchase management, establish suppliers audit system, and evaluate the suppliers, to ensure that the purchased products and services conform to relevant regulations and requirements.\n\n根据上述已知信息，请将'医疗器械注册人、备案人、受托生产企业应当建立原材料采购验收记录制度，确保相关记录真实、准确、完整和可追溯。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The registrant, filing entity or contract manufacturer of medical devices shall establish procedures for purchasing, accepting and recording raw materials, to ensure authenticity, accuracy, integrity and traceability of related records."
    },
    {
        "instruction":"已知信息：\n'邮发工作文件征求意见，包括EAP，在WHO官网发布工作文件公开征求意见 2020年12月'可被翻译为：Mailing of working document to the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations (EAP) inviting comments and posting of the working document on the WHO website for public consultation December 2020\n'制订工作文件用于下一轮公开征求意见 2021年4月'可被翻译为：Preparation of working document for next round of public consultation. April 2021\n'WHO 数据完整性指南，草案，2019 (工作文件 QAS\/19.819)'可被翻译为：13. WHO guideline on data integrity. Draft for comments. Geneva: World Health Organization; 2019 (working document QAS\/19.819; https:\/\/www.who.int\/medicines\/areas\/quality_safety\/quality_assurance\/QAS19_819_rev1 _g uideline_on_data_integrity.pdf?ua=1, accessed 30 November 2020).\n'国家药监局已起草有关免于经营备案的第二类医疗器械产品目录，目前正在公开征求意见。产品目录发布后，按目录执行。'可被翻译为：NMPA has drafted a Catalogue of Class II Medical Devices Exempted from Distribution and Filing, for which public comments are currently solicited. After being issued, the Catalogue shall be executed.\n\n根据上述已知信息，请将'邮发修订后的工作文件征求意见，包括EAP，在WHO官网发布工作文件公开征求意见 2021年4月'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Mailing of revised working document inviting comments, including to the EAP, and posting of the working document on the WHO website for a second round of public consultation. April 2021"
    },
    {
        "instruction":"已知信息：\n'3.采用《中华人民共和国药典》及其他法定标准未收载的检验方法；'可被翻译为：3) Testing method adopted is not included in the Chinese Pharmacopoeia or other official standards;\n'超出标准(限度)'可被翻译为：OOS: Out of Specification\n'4.所有中间控制方法及标准；'可被翻译为：4) The instructions for any in-process controls with their limits;\n'提供检验及方法学验证所涉及的标准物质（对照品或标准品），应提供三倍量，以满足标准复核检验及首次进口检验。'可被翻译为：The standard substance (reference or standard product) involved in the test and method validation shall  be provided in triplication to satisfy the standard verification and inspection and initial import inspection.\n\n根据上述已知信息，请将'检验结果超出法定标准及企业制定标准的所有情形。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"All events that the testing results fail to meet the regulatory standards or acceptance criteria established by the manufacturer."
    },
    {
        "instruction":"已知信息：\n'无菌工艺模拟（APS）：对整个无菌生产工艺的模拟， 以确认工艺确保产品无菌性的能力。包括与日常生产相关的所有无菌操作，例如必要的设备装配、配料、灌装、冻干以及必要时的密封工艺。'可被翻译为：Aseptic Process Simulation (APS) - A simulation of the entire aseptic manufacturing process in order to verify the capability  of the  process  to  assure  product  sterility.  Includes  all  aseptic  operations  associated  with  routine manufacturing, e.g. equipment assembly, formulation, filling, lyophilization and sealing processes as necessary.\n'对整个无菌制造过程的模拟，以验证工艺确保产品无菌的能力。APS包括与常规生产相关的所有无菌操作(例如，必要时，设备组装、配方、灌装、冻干和密封过程)'可被翻译为：A simulation of the entire aseptic manufacturing process in order to verify the capability of the process to ensure product sterility. APS includes all aseptic operations associated with routine manufacturing (for example, equipment assembly, formulation, filling, lyophilization and  sealing processes, as necessary)\n'对于已冻干的产品，从不同的冻干负载取样。'可被翻译为：For products which have been lyophilized, samples taken from different lyophilization loads.\n'冻干产品'可被翻译为：freeze-dry product, lyophilizated product\n\n根据上述已知信息，请将'冻干产品的工艺模拟程序应代表整个无菌工艺链，包括在规定的、有文件记录且经过论证的条件（代表最\n差条件下的操作参数）下的灌装、转移、装载、冻干室停留的具有代表性的时长、卸载和密封。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process simulation procedure for lyophilized products should represent the entire aseptic processing chain including filling, transport, loading, a representative duration of the chamber dwell, unloading and sealing under specified, documented and justified conditions representing worst case operating parameters."
    },
    {
        "instruction":"已知信息：\n'第三十三条 药品进口备案中发现的其他问题，由口岸药品监督管理局按照《药品管理法》以及有关规定予以处理。'可被翻译为：Article 33 Other issues found in the record filing of drugs to be imported shall be disposed of by the drug regulatory departments at ports of entry in accordance with the Drug Administration Law and relevant regulations.\n'第三十六条 对于违反本办法进口备案和口岸检验有关规定的口岸药品监督管理局和口岸药品检验所，国家食品药品监督管理局将根据情节给予批评、通报批评，情节严重的停止其进口备案和口岸检验资格。'可被翻译为：Article 36 The State Food and Drug Administration shall, based on the seriousness of the circumstances, criticize or circulate a notice of criticism to the drug regulatory department at ports of entry or the drug control institute of port which violates relevant provisions for importation record filing and port testing, and shall suspend its qualification with respect to importation record filing and port testing if the circumstances are serious.\n'口岸药品检验所按照《进口药品口岸检验通知书》规定的抽样地点，抽取检验样品，进行质量检验，并将检验结果送交所在地口岸药品监督管理局。检验符合标准规定的，准予进口备案，由口岸药品监督管理局发出《进口药品通关单》；不符合标准规定的，不予进口备案，由口岸药品监督管理局发出《药品不予进口备案通知书》。'可被翻译为：A drug control institute of port shall take sample sat the sampling place specified in the Notice of Port Testing for Import Drugs, test the quality, and deliver the testing result to the local drug regulatory department at ports of entry. If the testing result is in conformity with relevant standards, the importation record filing shall be approved, and the drug regulatory department at ports of entry shall issue the Import Drug Note; if the testing result is not in conformity with relevant standards, the importation record filing shall not be approved, and the drug regulatory department at ports of entry shall issue the Notice of Non-Acceptance of Drug Import Filing.\n'第三十五条 口岸药品监督管理局和口岸药品检验所应当建立严格的进口备案资料和口岸检验资料的管理制度，并对进口单位的呈报资料承担保密责任。'可被翻译为：Article 35 Drug regulatory departments at ports of entry and drug control institutes of port shall establish a strict management system for the materials of importation record filing and the materials of port testing, and shall be responsible for the confidentiality of the materials submitted by importers.\n\n根据上述已知信息，请将'（五）对进口备案和口岸检验中发现的问题进行监督处理；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(V) to supervise and handle the issues found during importation record filing and port testing; and"
    },
    {
        "instruction":"已知信息：\n'对整个无菌制造过程的模拟，以验证工艺确保产品无菌的能力。APS包括与常规生产相关的所有无菌操作(例如，必要时，设备组装、配方、灌装、冻干和密封过程)'可被翻译为：A simulation of the entire aseptic manufacturing process in order to verify the capability of the process to ensure product sterility. APS includes all aseptic operations associated with routine manufacturing (for example, equipment assembly, formulation, filling, lyophilization and  sealing processes, as necessary)\n'APS 应尽可能模拟日常无菌生产工艺，并包括所有关键生产步骤，具体如下：'可被翻译为：The APS should imitate as closely as possible the routine aseptic manufacturing process and include all the critical manufacturing steps, specifically:\n'无菌工艺模拟（APS）（又称培养基模拟灌装）'可被翻译为：Aseptic process simulation (APS) (also known as media fill)\n'冻干工艺模拟应该全面模拟无菌工艺，除非污染物的活力或回收会受到影响。例如，应避免溶液沸溢或彻底冻干。在确定 APS 设计时要考虑的因素包括：'可被翻译为：The lyophilization process simulation should mimic all aspects of the process, except those that may affect the viability  or recovery of contaminants. For instance, boiling-over or actual freezing of the  solution  should be avoided. Factors to consider in determining APS design include, where applicable:\n\n根据上述已知信息，请将'无菌工艺模拟（APS）：对整个无菌生产工艺的模拟， 以确认工艺确保产品无菌性的能力。包括与日常生产相关的所有无菌操作，例如必要的设备装配、配料、灌装、冻干以及必要时的密封工艺。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Aseptic Process Simulation (APS) - A simulation of the entire aseptic manufacturing process in order to verify the capability  of the  process  to  assure  product  sterility.  Includes  all  aseptic  operations  associated  with  routine manufacturing, e.g. equipment assembly, formulation, filling, lyophilization and sealing processes as necessary."
    },
    {
        "instruction":"已知信息：\n'四、关于医疗器械生物学试验'可被翻译为：IV. Biological test of medical devices\n'包括物理、化学、生物学、微生物学试验和认可的限度要求。在整个再试验期限内，用于判断原料药是否合格。或在整个货架期内制剂必须符合其标准的要求。'可被翻译为：The combination of physical, chemical, biological, and microbiological tests and acceptance criteria that determine the suitability of a drug substance throughout its re-test period, or that a drug product should meet throughout its shelf life.\n'由生物源生产或从生物源中提取的物质，对其进行物化生物学试验、生产过程及其控制相结合，以表征和确定其质量。'可被翻译为：A substance that is produced by or extracted from a biological source and for which a combination of physicochemical-biological testing and the production process and its control is needed for its characterization and the determination of its quality.\n'生物学特异性'可被翻译为：biological specificity\n\n根据上述已知信息，请将'医疗器械生物学评价中涉及生物学试验的，其生物学试验报告由申请人在申请注册时作为研究资料提交。开展生物学试验，应当委托具有生物学试验资质的医疗器械检验机构按照相关标准进行试验。国外实验室出具的生物学试验报告，应当附有国外实验室表明其符合GLP实验室要求的质量保证文件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the biological evaluation of a medical device involves biological test, the applicant should submit the biological test report as part of the study materials when applying for registration. For biological tests, medical device testing institutions qualified for biological test shall be entrusted to carry out such tests according to relevant standards. Biological test reports issued by foreign laboratories should be attached with the quality assurance documents demonstrating its compliance with GLP laboratory requirements."
    },
    {
        "instruction":"已知信息：\n'第一百八十二条 厂房、设备、物料、文件和记录应当有编号（或代码），并制定编制编号（或代码）的操作规程，确保编号（或代码）的唯一性。'可被翻译为：Article 182: Premises, equipment, materials, documents and records should have codes (or reference numbers). Operation procedures should be established for the numbering\/coding system to ensure the uniqueness of the codes (or reference numbers).\n'第四十八条 应当根据药品品种、生产操作要求及外部环境状况等配置空调净化系统，使生产区有效通风，并有温度、湿度控制和空气净化过滤，保证药品的生产环境符合要求。'可被翻译为：Article 48: Production areas should be effectively ventilated, with air control facilities (including temperature, humidity and filtration) appropriate to the products handled, the operations undertaken within them and the external environment, to ensure that the production environment is in accordance with the requirements.\n'第一百四十二条 当影响产品质量的主要因素，如原辅料、与药品直接接触的包装材料、生产设备、生产环境（或厂房）、生产工艺、检验方法等发生变更时，应当进行确认或验证。必要时，还应当经药品监督管理部门批准。'可被翻译为：Article 142: Qualification or validation should be performed when there is a change in major factors influencing the product quality, including any change in starting materials, immediate packaging materials, production equipment and environment (or premises), manufacturing process or testing method, etc. Where necessary, the changes should be approved by drug regulatory departments.\n'第四十七条 生产区和贮存区应当有足够的空间，确保有序地存放设备、物料、中间产品、待包装产品和成品，避免不同产品或物料的混淆、交叉污染，避免生产或质量控制操作发生遗漏或差错。'可被翻译为：Article 47: The adequacy of the production area and storage area should ensure the orderly positioning of equipment, materials, intermediate, bulk and finished products, so as to avoid mixups, cross-contamination between different products and materials, and to avoid the omissions or errors of any of the manufacturing or quality control steps.\n\n根据上述已知信息，请将'第四十二条 厂房应当有适当的照明、温度、湿度和通风，确保生产和贮存的产品质量以及相关设备性能不会直接或间接地受到影响。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 42: Lighting, temperature, humidity and ventilation should be appropriate and such that they do not adversely affect, directly or indirectly, either the product quality during their manufacture and storage, or the accurate functioning of equipment."
    },
    {
        "instruction":"已知信息：\n'（七）药品与非药品、外用药与其他药品分开存放，中药材和中药饮片分库存放；'可被翻译为：(VII) Drugs and non-drugs, drugs for topical use and other drugs shall be stored separately, and Chinese crude drugs and Prepared Slices shall be stored separately;\n'文件应当分类存放，便于查阅。'可被翻译为：Documents should be laid out by categories and be easy to check.\n'第一百五十六条 文件应当分类存放、条理分明，便于查阅。'可被翻译为：Article 156: Documents should be laid out in an orderly fashion and be easy to check.\n'（三）经营中药饮片的，有存放饮片和处方调配的设备；'可被翻译为：(III) Those distributing Prepared Slices shall have equipment for storing such drugs and prescription dispensing;\n\n根据上述已知信息，请将'医疗机构应当将药品与非药品分开存放；中药材、中药饮片、化学药品、中成药应分别储存、分类存放。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A medical institution shall store drugs and non-drug products separately; Chinese crude drugs, prepared slices of Chinese crude drugs, pharmaceuticals, and traditional Chinese medicine preparations shall be stored separately by category."
    },
    {
        "instruction":"已知信息：\n'第一百零四条 企业应当根据药品的温度控制要求，在运输过程中采取必要的保温或者冷藏、冷冻措施。'可被翻译为：Article 104 Enterprises shall take necessary measures for heat preservation, or refrigeration and freezing during transportation in accordance with the temperature control requirements of drugs.\n'第一百零五条 在冷藏、冷冻药品运输途中，应当实时监测并记录冷藏车、冷藏箱或者保温箱内的温度数据。'可被翻译为：Article 105 During the transportation of refrigerated or frozen drugs, real-time monitoring and recording of temperature data in refrigerated vehicles, refrigerated container or thermal insulation container shall be conducted.\n'第一百零八条 县级以上人民政府应当制定药品安全事件应急预案。药品上市许可持有人、药品生产企业、药品经营企业和医疗机构等应当制定本单位的药品安全事件处置方案，并组织开展培训和应急演练。'可被翻译为：Article 108 The people's governments at or above the county level shall formulate emergency plans for drug safety incidents. MAHs, drug manufacturers, drug distributors, and medical institutions shall formulate their own action plans for handling drug safety incidents and organize and conduct training and drills.\n'第一百零一条 运输药品，应当根据药品的包装、质量特性并针对车况、道路、天气等因素，选用适宜的运输工具，采取相应措施防止出现破损、污染等问题。'可被翻译为：Article 101 For the transportation of drugs, appropriate means of transport shall be selected in light of the packaging and quality characteristics of the drugs and according to such factors as vehicle conditions, roads and weather, and corresponding measures shall be taken to prevent damage and contamination.\n\n根据上述已知信息，请将'第一百零六条 企业应当制定冷藏、冷冻药品运输应急预案，对运输途中可能发生的设备故障、异常天气影响、交通拥堵等突发事件，能够采取相应的应对措施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 106 Enterprises shall formulate a contingency plan for the transportation of refrigerated and frozen drugs, and be able to take corresponding measures to deal with such emergencies as equipment failure, abnormal weather influence and traffic congestion that may occur during the transportation."
    },
    {
        "instruction":"已知信息：\n'（八）所有因质量原因造成的退货、投诉、召回及调查；'可被翻译为：8. All quality-related returns, complaints, recalls and the investigations;\n'(iii)对不符合既定质量标准的所有批次及其调查进行回顾；'可被翻译为：(iii) A review of all batches that failed to meet established specification(s) and their investigation;\n'(iv)对所有重大偏差或不符合的情况、相关调查以及由此采取的纠正和预防措施的有效性进行回顾；'可被翻译为：(iv) A review of all significant deviations or non-conformances, their related investigations, and the effectiveness of resultant corrective and preventive actions taken;\n'12.确保所有与产品质量有关的投诉已经过调查，并得到及时、正确的处理；'可被翻译为：12) To ensure all quality related complaints are timely and properly investigated and handled;\n\n根据上述已知信息，请将'(viii)对所有与质量相关的退货、投诉和召回以及当时进行的调查进行回顾；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(viii) A review of all quality-related returns, complaints and recalls and the investigations performed at the time;"
    },
    {
        "instruction":"已知信息：\n'第一百三十三条 违反本法规定，医疗机构将其配制的制剂在市场上销售的，责令改正，没收违法销售的制剂和违法所得，并处违法销售制剂货值金额二倍以上五倍以下的罚款；情节严重的，并处货值金额五倍以上十五倍以下的罚款；货值金额不足五万元的，按五万元计算。'可被翻译为：Article 133 Where a medical institution sells self-made preparations in violation of this Law, it shall be ordered to make correction, and be subject to a confiscation of preparations illegally sold and the illegal gains therefrom and a fine of not less than two times but not more than five times of the value of the illegally sold preparations. In serious circumstances, the offender is subject to a fine of not less than five times but not more than fifteen times of the illegal value. If the illegal values are less than RMB 50,000, it shall be counted as RMB 50,000.\n'第三十二条 有下列情形之一的，依照《药品管理法》第七十三条规定，没收违法销售的药品和违法所得，并处违法销售的药品货值金额二倍以上五倍以下的罚款：'可被翻译为：Article 32    In accordance with the provisions in Article 73 of the Drug Administration Law, in any of the following circumstances, the drugs illegally sold and the illegal gains therefrom shall be confiscated,  and the drug manufacturer or distributor shall be fined not less than two times but not more than five times the value of the drugs illegally sold:\n'第一百二十九条 违反本法规定，药品上市许可持有人、药品生产企业、药品经营企业或者医疗机构未从药品上市许可持有人或者具有药品生产、经营资格的企业购进药品的，责令改正，没收违法购进的药品和违法所得，并处违法购进药品货值金额二倍以上十倍以下的罚款；情节严重的，并处货值金额十倍以上三十倍以下的罚款，吊销药品批准证明文件、药品生产许可证、药品经营许可证或者医疗机构执业许可证；货值金额不足五万元的，按五万元计算。'可被翻译为：Article 129 Where a drug MAH, drug manufacturer, drug distributor, or medical institution fails to procure drugs from a drug MAH or an enterprise which is qualified to manufacture or distribute drugs in violation of this Law, it shall be ordered to make rectification and illegally purchased drugs and the illegal gains therefrom shall be confiscated, and it shall be subject to a fine of not less than two times but not more than ten times the value of the drugs illegally purchased. In serious circumstances, the offender shall be subject to a fine of not less than ten times but not more than thirty time the value and revocation of relevant approval documents, Drug Manufacturing Certificate, Drug Distribution Certificate, and Pharmaceutical Preparation Certificate for Medical Institution. If the illegal values are less than RMB 50,000, it shall be counted as RMB 50,000.\n'生产、销售的疫苗属于假药，或者生产、销售的疫苗属于劣药且情节严重的，由省级以上人民政府药品监督管理部门对法定代表人、主要负责人、直接负责的主管人员和关键岗位人员以及其他责任人员，没收违法行为发生期间自本单位所获收入，并处所获收入一倍以上十倍以下的罚款，终身禁止从事药品生产经营活动，由公安机关处五日以上十五日以下拘留。'可被翻译为：Where manufactured or distributed vaccines are counterfeit, or adulterated with serious consequences, the legal representative, the main responsible person, the person directly in charge and personnel in key positions as well as other responsible personnel of vaccine MAHs shall be subject to a confiscation of income received from their affiliation during the occurrence of violations and a fine of not less than one time but not more than ten times the income, and shall be prohibited from engaging in drug manufacturing and operation for whole life, and detained by the public security department of not less than five days but not more than fifteen days.\n\n根据上述已知信息，请将'第一百二十条 知道或者应当知道属于假药、劣药或者本法第一百二十四条第一款第一项至第五项规定的药品，而为其提供储存、运输等便利条件的，没收全部储存、运输收入，并处违法收入一倍以上五倍以下的罚款；情节严重的，并处违法收入五倍以上十五倍以下的罚款；违法收入不足五万元的，按五万元计算。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 120 Anyone who knows or should know that drug is counterfeit or inferior or falls under drugs prescribed in paragraph one of item (1) to item (5) in Article 124 of this Law and provides conveniences such as storage and transportation, the income from the illegal storage and transportation shall be confiscated, and a fine of not less than one time but not more than five times the illegal income shall be imposed. In serious circumstances, the offender shall be subject to a fine of not less than five times but not more than fifteen times. If the illegal values are less than RMB 50,000, it shall be counted as RMB 50,000."
    },
    {
        "instruction":"已知信息：\n'单位时间内二氧化碳(CO2)产生量与耗氧量之比值。'可被翻译为：The ratio of carbon dioxide (CO2) production to oxygen consumption per unit time.\n'含有碳氢酸钠和有机酸，遇水可放出大量二氧化碳气体而呈泡腾状的片剂。'可被翻译为：An effervescent tablet containing sodium hydrocarbons and organic acids that releases large amounts of carbon dioxide gas when exposed to water.\n'消化液及生物体中所含的一些重要成分，消化和分解食物中的蛋白质、脂肪和淀粉等并使其易于被胃肠道吸收的药物。如胃蛋白酶、胰酶、淀粉酶等。'可被翻译为：Any of several important components contained in digestive juices and organisms; drugs that digest and break down proteins, fats, and starches in food and make them easily absorbed by the gastrointestinal tract. Such as pepsin, trypsin, amylase, etc.\n'在无氧条件下生长繁殖的一些细菌。分兼性厌氧菌与专性厌氧菌。'可被翻译为：Some bacteria that grow and reproduce in the absence of oxygen. Facultative and obligate anaerobic bacteria.\n\n根据上述已知信息，请将'应用于医疗及制药中的一些气体。如氧、二氧化碳、氨、氧化亚氮等。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Some gases used in medicine and pharmaceuticals. Such as oxygen, carbon dioxide, ammonia, nitrous oxide, etc."
    },
    {
        "instruction":"已知信息：\n'抗抑郁药'可被翻译为：antidepressants\n'抑制细胞活性'可被翻译为：cytostatic activity\n'通过抑制RNA聚合酶来阻断、抑制或者干扰核酸的代谢过程，最终抑制转录的一类化合物。'可被翻译为：A class of compounds that block, inhibit, or interfere with the metabolic process of nucleic acids by inhibiting RNA polymerase, ultimately inhibiting transcription.\n'单胺氧化酶抑制药'可被翻译为：monoamine oxidase inhibitor\n\n根据上述已知信息，请将'能抑制单胺氧化酶活性的一类抗抑郁药。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A class of antidepressants that inhibit the activity of monoamine oxidase."
    },
    {
        "instruction":"已知信息：\n'第十四条 企业负责人是药品质量的主要责任人，全面负责企业日常管理，负责提供必要的条件，保证质量管理部门和质量管理人员有效履行职责，确保企业实现质量目标并按照本规范要求经营药品。'可被翻译为：Article 14 The responsible person of an enterprise is the principal person in charge of drug quality, takes full responsibilities for daily management of the enterprise and provides necessary conditions to ensure that the quality management department or quality management personnel effectively fulfill the responsibilities and that the enterprise realizes quality objectives and handles drugs according to the requirements in this GSP.\n'第一百二十二条 企业负责人是药品质量的主要责任人，负责企业日常管理，负责提供必要的条件，保证质量管理部门和质量管理人员有效履行职责，确保企业按照本规范要求经营药品。'可被翻译为：Article 122 The responsible person of an enterprise is the principal person in charge of drug quality, takes responsibilities for daily management of the enterprise and provides necessary conditions to ensure that the quality management department or quality management personnel effectively fulfill the responsibilities and that the enterprise distributes drugs according to the requirements in this GSP.\n'第二十九条 药品生产企业的法定代表人、主要负责人应当对本企业的药品生产活动全面负责，履行以下职责：'可被翻译为：Article 29 The legal representative and principal of a drug manufacturer shall be responsible for drug manufacturing of the company in all aspects and perform the following duties:\n'第二十八条 药品上市许可持有人的法定代表人、主要负责人应当对药品质量全面负责，履行以下职责：'可被翻译为：Article 28 The legal representative and the principal of a drug MAH shall be fully responsible for drug quality and fulfill the following responsibilities:\n\n根据上述已知信息，请将'企业负责人是药品质量的主要责任人，全面负责企业日常管理。为确保企业实现质量目标并按照本规范要求生产药品，企业负责人应当负责提供必要的资源，合理计划、组织和协调，保证质量管理部门独立履行其职责。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The head of the manufacturer is principally liable for product quality and routine operation. In order to achieve the manufacturer’s quality objective and compliance with GMP, the head of the manufacturer should provide necessary resources, make appropriate plan, organization and coordination, and ensure that the quality management department can fulfill its responsibilities independently."
    },
    {
        "instruction":"已知信息：\n'技术转移项目应满足以下通用原则和要求：'可被翻译为：1.6. The technology transfer project should fulfil the following general principles and requirements.\n'适用于无菌产品生产的一般原则。'可被翻译为：General principles as applied to the manufacture of sterile products.\n'第四条 医疗器械临床试验应当遵循依法原则、伦理原则和科学原则。'可被翻译为：Article 4 Medical device clinical trials shall follow the lawful principles, ethical principles and scientific principles.\n'虽然本文重点在于药品，但其原则应可应用于其它产品如生物制品、先进疗法药品\/细胞和基因疗法产品、疫苗、医疗器械和病媒控制产品的生产、相关工艺和控制的转移。'可被翻译为：2.4. Although this document focuses on pharmaceutical products, the principles can also be applied to the transfer of production, related processes and controls for other products such as biopharmaceutical products, advanced therapy medicinal products\/cellular and gene therapy products, vaccines, medical devices and vector control products.\n\n根据上述已知信息，请将'本文提供的是技术转移原则指导。这些原则适用于临床试验用药以及上市药品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2.1. This document provides guiding principles on technology transfer. The principles apply to investigational products as well as marketed product."
    },
    {
        "instruction":"已知信息：\n'药物配伍时，发生化学反应，而使药物产生不同程度的变质或失效，降低疗效或增加副作用。'可被翻译为：When the drugs are compatible, chemical reactions occur, and the drugs have different degrees of deterioration or failure, reducing the efficacy or increasing side effects.\n'药物的体内过程（吸收、分布、代谢、消除）因其他药物或食物联合应用而发生改变，致使体内有效药量发生变化而效应相应变化，影响疗效或引发毒副作用。'可被翻译为：The internal process of a drug (absorption, distribution, metabolism, elimination) is changed due to the combined application of other drugs or food, resulting in changes in the effective amount of the drug in the body and corresponding changes in the effect, affecting the efficacy or causing toxic side effects.\n'药物在体内发生的化学结构改变。'可被翻译为：A change in the chemical structure of a drug in the body.\n'药物配伍'可被翻译为：compatibility of drugs\n\n根据上述已知信息，请将'药物配伍时发生的物理性质改变，因而得不到符合要求的制剂、降低疗效或增加副作用。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Physical properties change when drugs are compatible, so that they can not meet the requirements of the preparation, reduce the efficacy or increase side effects."
    },
    {
        "instruction":"已知信息：\n'不依靠电能或者其他能源，但是可以通过由人体或者重力产生的能量，发挥其功能的医疗器械。'可被翻译为：A medical device of which the effects are achieved not relying on electric or other forms of energy, but may use the energy directly generated by human body or gravity.\n'任何旨在供生产一种药物(医疗用品)制剂，并作为其活性成份的物质或混合物。这类物质旨在疾病的诊断，治疗、缓减，处置或预防以及影响人体的结构和功能等方面发挥药理作用或其它的直接效应。'可被翻译为：Any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body.\n'一种用于测定生理、病理、解剖参数，或者定量测定进出人体的能量或物质的医疗器械，其测量结果需要精确定量，并且该结果的准确性会对患者的健康和安全产生明显影响。'可被翻译为：A medical device intended to measure the physiological, pathological and anatomic parameters or make quantitative determination on the energies\/substances entering or leaving the human body. The measuring results shall be accurately quantified, and the accuracy of such results may have obvious effects on patient's health and safety.\n'-种能量依赖型“药泵”的跨膜糖蛋白。其功能是单向外排细胞内药物，具有广谱底物特征，直接导致肿瘤多药耐药。'可被翻译为：- An energy-dependent \"drug pump\" transmembrane glycoprotein. Its function is unidirectional exportation of intracellular drugs, with broad-spectrum substrate characteristics, which directly leads to multidrug resistance in tumors.\n\n根据上述已知信息，请将'任何依靠电能或者其他能源，而不是直接由人体或者重力产生的能量，发挥其功能的医疗器械。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Any medical device that operates on electric or other forms of energy excluding the energy directly generated by human body or gravity."
    },
    {
        "instruction":"已知信息：\n'WHO GMP验证指南，WHO TRS1019附录3附录6确认指南，2019'可被翻译为：9. WHO good manufacturing practices: guidelines on validation. Appendix 6. Guidelines on qualification. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-third report. Geneva: World Health Organization; 2019: Annex 3 (WHO Technical Report Series, No. 1019; https:\/\/www.who.int\/medicines\/areas\/quality_safety\/quality_assurance\/WHO_TRS_1019_ An nex3.pdf?ua=1, accessed 30 November 2020).\n'WHO GMP验证指南，WHO TRS1019附录3附录5计算机化系统验证，2019'可被翻译为：8. WHO good manufacturing practices: guidelines on validation. Appendix 5. Validation of computerized systems. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-third report. Geneva: World Health Organization; 2019: Annex 3 (WHO Technical Report Series, No. 1019; https:\/\/www.who.int\/medicines\/areas\/quality_safety\/quality_assurance\/WHO_TRS_1019_ An nex3.pdf?ua=1, accessed 30 November 2020).\n'WHO GMP验证指南，WHO TRS1019附录3附录4分析方法验证，2019'可被翻译为：7. WHO good manufacturing practices: guidelines on validation. Appendix 4. Analytical procedure validation. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty- third report. Geneva: World Health Organization; 2019: Annex 3 (WHO Technical Report Series, No. 1019; https:\/\/www.who.int\/medicines\/areas\/quality_safety\/quality_assurance\/WHO_TRS_1019_An  nex3.pdf?ua=1, accessed 30 November 2020).\n'WHO GMP验证指南，WHO TRS1019附录3，2019'可被翻译为：4. WHO good manufacturing practices: guidelines on validation. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-third report. Geneva: World Health Organization; 2019: Annex 3 (WHO Technical Report Series, No. 1019; https:\/\/www.who.int\/medicines\/areas\/quality_safety\/quality_assurance\/WHO_TRS_1019_ An nex3.pdf?ua=1, accessed 30 November 2020).\n\n根据上述已知信息，请将'WHO GMP验证指南，WHO TRS1019附录3 附录3清洁验证，2019'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"6. WHO good manufacturing practices: guidelines on validation. Appendix 3. Cleaning validation. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-third report. Geneva: World Health Organization; 2019: Annex 3 (WHO Technical Report Series, No. 1019; https:\/\/www.who.int\/medicines\/areas\/quality_safety\/quality_assurance\/WHO_TRS_1019_ An nex3.pdf?ua=1, accessed 30 November 2020)."
    },
    {
        "instruction":"已知信息：\n'为加强对医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定并于2020年5月19日发布了《无源医疗器械产品原材料变化评价指南》。'可被翻译为：To strengthen the supervision and guidance over medical device registration and further improve the quality of registration review, NMPA organized to formulate and released on May 19, 2020 the Guidelines for Evaluation of Changes in Raw Materials of Passive Medical Devices.\n'国家药监局关于发布医疗器械委托生产质量协议编制指南的通告'可被翻译为：NMPA Announcement on Issuing the Guidance for Preparation of Contract Production Quality Agreement of Medical Devices\n'国家药监局关于发布医疗器械注册质量管理体系核查指南的通告'可被翻译为：NMPA Issued the Guidelines for the Verification of Medical Device Registration Quality Management System\n'国家药监局关于发布医疗器械定期风险评价报告撰写规范的通告'可被翻译为：NMPA Issues the Writing Specification for Periodic Risk Evaluation Reports of Medical Devices\n\n根据上述已知信息，请将'国家药监局关于发布无源医疗器械产品原材料变化评价指南的通告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Issues Guidelines for Evaluation of Changes in Raw Materials of Passive Medical Devices"
    },
    {
        "instruction":"已知信息：\n'制冷设备'可被翻译为：refrigeration equipment\n'（三）冷库制冷设备的备用发电机组或者双回路供电系统；'可被翻译为：(III) Standby generators or dual-circuit power supply system of refrigeration equipment in freezers;\n'温度监控系统应允许记录和存储温度历史，以进行质量控制。存储单元应连接到警报和设施监视系统。关键存储单元应配备多级警报系统，以确保监视和响应中的备份。应例行监视存储单元的电源中断和其他潜在故障引起的温度故障。如果设备或电源出现故障，应提供备用制冷设备。'可被翻译为：Temperature-monitoringsystems should permit recording and storage of temperature history for quality control purposes. Storage units should be attached to alarms and facility monitoring systems. Critical storage units should be equipped with a multilevel alarm system to ensure backup in the monitoring and response.The storage units should be routinely monitored for temperature failure caused by power disruption and any other potential malfunctions. In the event of equipment or power failure, backup refrigeration should be available.\n'(ix)对任何以前产品工艺或设备纠正措施的充分性进行回顾；'可被翻译为：(ix) A review of adequacy of any other previous product process or equipment corrective actions;\n\n根据上述已知信息，请将'术语“制冷”或“制冷设备”是指以降低空气和产品温度和\/或控制相对湿度为目的的任何设备。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The term “refrigeration” or “refrigeration equipment” means any equipment whose purpose is to lower air and product temperatures and\/or to control relative humidity."
    },
    {
        "instruction":"已知信息：\n'在受控环境中处理无菌产品、容器或设备，其中空气供应、材料和人员受到调节，以防止微生物、内毒素\/热原和颗粒污染。'可被翻译为：The handling of sterile product, containers or devices in a controlled environment in which the air supply, materials and personnel are regulated to prevent microbial, endotoxin\/pyrogen and particle contamination.\n'人员对于在受控环境中保持无菌至关重要。需要进行彻底的无菌技术培训。'可被翻译为：Personnel are critical to the maintenance of asepsis in the controlled environment. Thorough training in aseptic techniques is required.\n'在无菌环境下准备的过程中、在所有工艺阶段（包括待包装产品灭菌之前和之后的阶段）、以及直至产品\n封装入最终容器中，都应按照工厂的 CCS 采取预防措施以最大程度减少微生物、内毒素\/热原和微粒污染。\n在洁净室应尽可能减少容易产生微粒和纤维的物料。'可被翻译为：Precautions to minimize microbial, endotoxin\/pyrogenic and particle contamination should be taken, as per the\nsite’s CCS, during the preparation of the aseptic environment, during all processing stages (including the stages\nbefore and after bulk product sterilisation), and until the product is sealed in its final container. The presence of\nmaterials liable to generate particles and fibres should be minimized in cleanrooms.\n'打开单元容器的工作区应该是一个 HEPA 过滤层流罩或一个替代的受控环境，以保 护打开的介质和产品暴露在环境或人员污染中。'可被翻译为：The work area for opening the unit container should be either a HEPA filtered laminar flow hood or an alternate controlled environment to safeguard the exposure of open media and product to either environmental or personnel contamination.\n\n根据上述已知信息，请将'无菌制备\/加工：在受控环境下对无菌产品、容器和\/或器械的处理，受控环境是指送风、物料和人员受到管控以防止微生物、内毒素\/热原和微粒污染。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Aseptic  preparation\/processing  -  The  handling  of  sterile  product,  containers  and\/or  devices  in  a  controlled environment   in   which    the   air    supply,   materials   and   personnel    are   regulated    to   prevent   microbial,\nendotoxin\/pyrogen and particle contamination."
    },
    {
        "instruction":"已知信息：\n'擦拭取样连接到进行产品生产或配料的供气设施的房间空气处理系统的排气（回风）格栅。'可被翻译为：7. Swab the exhaust (return) grid for the room air handling system that is connected to the facility air supply where the product manufacturing or compounding occurs.\n'定性擦拭取样'可被翻译为：2. Qualitative Swabbing\n'擦拭取样开口或脱落的天花板下的区域'可被翻译为：12.Swab any area under open or dislodged ceiling panels.\n'擦拭取样工作台前面椅子下面，尤其是人员抓住拉动椅子的前底部边缘'可被翻译为：4. Swab the underside of the chair in front of the work station. Specifically, on the front bottom rim where personnel would hold to pull up the chair.\n\n根据上述已知信息，请将'擦拭取样取样生产或配料期间人员已用过的实验室外套的外袖口。它们可能挂在更衣间的入口（前厅）处。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"10.Swab the exterior cuffs of the used lab coats worn by personnel during manufacturing or compounding. They may be hanging in the entry (ante) gowning room."
    },
    {
        "instruction":"已知信息：\n'（二）新药生产：150日；获准进入特殊审批程序的品种：120日；'可被翻译为：(2) new drug application for production: 150 days; any drug permitted to enter the special review and approval procedures: 120 days;\n'第一百三十一条 获准进入特殊审批程序的药品，药品检验所应当优先安排样品检验和药品标准复核。'可被翻译为：Article 131 Where a drug is permitted entering a special review and approval procedure, the drug testing institute shall give priority to sample testing and specification verification.\n'纳入优先审评审批程序的，注册核查工作时限为80日。'可被翻译为：If it is included in the priority evaluation and approval procedures, the time limit for registration inspection is 80 days.\n'第四条 国家鼓励研究创制新药，对创制的新药、治疗疑难危重疾病的新药实行特殊审批。'可被翻译为：Article 4 The State encourages the research and development of new drugs and adopts the special review and approval with respect to innovative drugs, new drugs for serious and life-threatening diseases and to address unmet medical needs and drugs.\n\n根据上述已知信息，请将'（一）新药临床试验：90日；获准进入特殊审批程序的品种：80日；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) new drug application for clinical trial: 90 days; any drug permitted to enter the special review and approval procedures: 80 days;"
    },
    {
        "instruction":"已知信息：\n'第六十三条 本办法下列用语的含义：'可被翻译为：Article 63 Terms used in these Provisions are defined as follows:\n'第六十三条 样品应当在取得《药品生产质量管理规范》认证证书的车间生产；新开办药品生产企业、药品生产企业新建药品生产车间或者新增生产剂型的，其样品生产过程应当符合《药品生产质量管理规范》的要求。'可被翻译为：Article 63 Samples shall be produced at a plant with the GMP Certificate. As for a new manufacturer, a new workshop established or the production of a dosage form added at an existing manufacturer, the sample production shall meet the GMP requirements.\n'第六十三条 本办法自2021年5月1日起施行。'可被翻译为：Article 63 These Provisions shall go into effect as of May 1, 2021.\n'第六十三条 许可事项变更申请的受理与审批程序，本章未作规定的，适用本办法第六章的相关规定。'可被翻译为：Article 63 Where provisions concerning acceptance and approval procedures of the application for change of permission items are not available in this chapter, Chapter VI of the Provisions shall prevail.\n\n根据上述已知信息，请将'样品的生产应当符合本办法第六十三条的规定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The production of samples shall be in conformity with the requirements in Article 63 in the Provisions."
    },
    {
        "instruction":"已知信息：\n'将物料或设备从较低等级别或未分级区域移动到较高级别洁净区时，应进行与风险相称的清洁和消毒，并符合 CCS 的规定。'可被翻译为：The movement of material or equipment from lower grade or unclassified area to higher-grade clean areas should be subject to cleaning and disinfection commensurate with the risk and in line with the CCS.\n'在RU准备使用的起始物料（API和辅料）的质量标准和关键物料属性应与SU所用的物料一致。'可被翻译为：12.11. The specification and critical material attributes of the starting materials (APIs and excipients) to be used at the RU should be consistent with those materials used at the SU.\n'药品生产过程中涉及的所有操作，包括加工、配制、配方、灌装、包装和标签。'可被翻译为：All operations involved in the production of a drug, including processing, compounding, formulating, filling, packaging, and labelling.\n'注：在取样之前，要执行所有 ORS 完整更衣和程序。在进入洁净区时，要遵守公司的程序\/指导，要求进入洁净区采集样品的微生物学家穿戴无菌洁净服。如果在无菌取样穿戴的 PPE 方面有争议，应在开始更衣前联系 ORS 总部。'可被翻译为：Note: All ORS full gowning and procedures should be performed prior to conducting the collection. The firm’s procedures\/guidelines should be adhered to when entering classified \narea; however, it is the expectation that the microbiologists entering the classified area, in order to perform sampling, will don sterile garments. If there is a dispute regarding the PPE to be donned for aseptic sampling, ORS Headquarters should be contacted prior to commencing gowning.\n\n根据上述已知信息，请将'取样物料（将所有准备带入公司配制\/加工前厅、洁净间或区域的物料进行消毒）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1. Sampling Materials (Disinfect all materials being brought into the ante-room, cleanroom, or area designated for compounding\/processing by the firm.)"
    },
    {
        "instruction":"已知信息：\n'一类能够模拟肽分子与受体或酶的相互作用，可激活或阻止某种生物活性的非肽、类肽或拟肽化合物。'可被翻译为：A class of non-peptide, peptide-like, or peptide-like compounds capable of mimicking the interaction of a peptide molecule with a receptor or enzyme that can activate or block a biological activity.\n'一种具有心脏保护作用的九肽物质。是激肽的一种。'可被翻译为：A nine-peptide substance with cardioprotective properties. It is a type of kinin.\n'激肽'可被翻译为：kinin\n'在肝中合成并存在于绝大多数体液的一类无活性内源性肽类。经酶解作用转变成活性的激肽，后者与炎症、血液凝固、补体反应等有关。'可被翻译为：A class of inactive endogenous peptides synthesized in the liver and present in most body fluids. Converted by enzymolysis into active kinin, which is involved in inflammation, blood clotting, and complement reaction.\n\n根据上述已知信息，请将'生物体中具有特定生物活性的各种肽。包括各种多肽类激素、激肽、神经多肽和与行为有关的肽。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Any of various peptides in an organism that have a specific biological activity. Including various polypeptide hormones, kinins, neuropeptides, and peptides associated with behavior."
    },
    {
        "instruction":"已知信息：\n'通过比较标准品与供试品两者对接种的试验菌产生抑菌圈的大小测定供试品效价的一种方法。'可被翻译为：A method of determining the titer of a test product by comparing the size of the inhibition zone produced by the standard product and the test product against the inoculated test bacteria.\n'供试品溶液'可被翻译为：test solution\n'进行色谱分析时，在供试品与对照品溶液中添加一定量参比物的定量方法。'可被翻译为：When performing chromatographic analysis, a quantitative method of adding a certain amount of reference substance to the solution of the test product and the control product.\n'在两个不同的波长处测定供试品溶液和对照品溶液的吸光度，以两波长处吸光度的差值（A4）作为定量的依据来测定含量的方法。'可被翻译为：The absorbance of test solution and control solution is measured at two different wavelengths, and the difference of absorbance at two wavelengths (A4) is used as a quantitative basis to determine the content of the method.\n\n根据上述已知信息，请将'利用抗生素在培养基内的扩散渗透作用，将已知浓度的标准品溶液与未知含量的供试品溶液在同样条件下分别加入放置在含有试验菌的小钢管内，通过比较抑菌圈大小，测定供试品效价的方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Using the diffusion and penetration effect of antibiotics in the medium, the standard solution with known concentration and the test product solution with unknown content were added and placed in a small steel tube containing test bacteria under the same conditions, and the titer of the test product was determined by comparing the size of the antibacterial zone."
    },
    {
        "instruction":"已知信息：\n'阀、过滤器、排水设施、取样点和使用点。'可被翻译为：Valves, filters, drains, sampling and user points.\n'1.药品从药品的生产场所或另一个中心点，通过各种运输方法，通过各种储存和\/或卫生机构，到最终用户或到中间点的分割和移动。\n2.药品的采购、购买、持有、储存、销售、供应、进口、出口或移动，但直接向患者或其代理人调剂或提供药品的除外。\n3.将血液和血液成分输送到其他血库、医院血库或血液和血浆来源的药品制造商的行为。它不包括发放用于输血的血液或血液成分。'可被翻译为：1.The division and movement of pharmaceutical products from the premises of the manufacturer of such products, or another central point, to the end user thereof, or to an intermediate point by means of various transport methods, via various storage and\/or health establishments.\n2.The procuring, purchasing, holding, storing, selling, supplying, importing, exporting, or movement of pharmaceutical products, with the exception of the dispensing or providing pharmaceutical products directly to a patient or his or her agent.\n3.The act of delivery of blood and blood components to other blood establishments, hospital blood banks or manufacturers of blood- and plasma-derived medicinal products. It does not include the issuing of blood or blood components for transfusion.\n'第四十八条 药品包装应当适合药品质量的要求，方便储存、运输和医疗使用。'可被翻译为：Article 48 Drug packaging shall conform to drug quality requirements and be convenient for storage, transportation, and medical use.\n'1.药典中确定的溶出度试验程序，一般为速释产品的一个时间点溶出度试验和修饰释放产品的三个或更多时间点溶出度试验。\n2.药典中确定的用于产品批次常规QC的溶出度试验程序，通常为速释产品的一个时间点溶出度试验和变释产品的三个或更多时间点溶出度试验。'可被翻译为：1.A dissolution test procedure identified in the pharmacopoeia, generally a one time point dissolution test for immediate-release products and a three or more time points dissolution test for modified release products.\n2.A dissolution test procedure identified in the pharmacopoeia for routine QC of product batches, generally a one time-point dissolution test for immediate-release products and a three or more time-points dissolution test for modified-release products.\n\n根据上述已知信息，请将'1.储存:将药品和原料储存到其使用点\n2.将药品储存到使用点。\n3.将医疗产品储存至使用点。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.The storing of pharmaceutical products and materials up to their point of use.\n2.The storing of pharmaceutical products up to the point of use.\n3.The storing of medical products up to the point of use."
    },
    {
        "instruction":"已知信息：\n'如果检出微生物，检查生产期间所用 EM 方法的充分性是否具备足够的灵敏度和适用性，例如'可被翻译为：If no microorganisms are detected, check the adequacy of the EM method used during manufacturing for proper sensitivity and applicability, for example\n'留样充分，留样检查记录'可被翻译为：r. Adequate reserve samples; documentation of reserve sample examination\n'(iv)应有手动的和\/或通过记录仪器的记录，证明所有要求的取样、检查和检验程序有效执行。任何偏差都应充分记录和调查；'可被翻译为：(iv) Records are made, manually and\/or by recording instruments, which demonstrate that all the required sampling, inspecting and testing procedures were actually carried out. Any deviations are fully recorded and investigated;\n'原材料和包装材料应得到充分控制并进行检测，确保生物负载水平和内毒素\/热原满足使用要求。'可被翻译为：Raw materials and packaging materials should be adequately controlled and tested to ensure that level of bioburden and endotoxin\/pyrogen are suitable for use.\n\n根据上述已知信息，请将'实施并记录中控、检测和检查（例如生物负载检查 pH，混合充分性）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"d. Implementation and documentation of in-process controls, tests, and examinations (e.g., bioburden determination pH, adequacy of mixing)"
    },
    {
        "instruction":"已知信息：\n'5.瞒报试验方案禁用的合并药物；'可被翻译为：5. Hide concomitant drugs prohibited by the trial protocol;\n'5.试验方案、SOP  或其他试验操作文件的偏离应及时记录、评估并如实反映在总结报告中。'可被翻译为：5. Deviations from study protocol, SOPs or other operational instructions should be recorded, and evaluated in a timely manner, and reported truthfully in the final report.\n'(2) 研究者应完整记录 AE(不良事件)、SAE， 与药物相关性判断标准符合试验方案规定和医疗常规。'可被翻译为：(2) The investigator shall keep intact records of AE (Adverse Event), SAE and judgement criteria of drug correlation, meeting the provisions of trial protocol and medical routines.\n'根据方案的规定，用于记录试验过程中每个试验对象的数据的文件。收集数据的程序应保证信息的保存、保留和检索，并便于核查、审计和检查。'可被翻译为：A document that is used to record data on each trial subject during the course of the trial, as defined by the protocol. The data should be collected by procedures which guarantee preservation, retention and retrieval of information and allow easy access for verification, audit and inspection.\n\n根据上述已知信息，请将'(5) 研究者按照临床试验方案规定的试验流程和评估方法实施试验(如访视、给药、采血、安全性检查和疗效评估等)，采取措施保证关键步骤实施的准确性， 并保存相关记录， 如偏离试验方案应予以记录和解释， 合并用药或合并治疗与禁用药物的记录符合方案规定的要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(5) The investigator implements the trial (such as visit, drug administration, blood drawing, safety examination and efficacy evaluation, etc.) in accordance with the trial procedures and evaluation methods specified in the clinical trial protocol, takes measures to ensure accuracy of the execution of key steps, and keeps the relevant records, for example, deviation from the trial protocol shall be recorded and explained, and records of concomitant medication or concomitant therapy and  prohibited drugs comply with the requirements of the protocol."
    },
    {
        "instruction":"已知信息：\n'第二十二条 医疗器械标准管理中心将审核通过后的医疗器械标准报批稿及审核结论等报送国家食品药品监督管理总局审查。审查通过的医疗器械国家标准送国务院标准化行政主管部门批准、发布；审查通过的医疗器械行业标准由国家食品药品监督管理总局确定实施日期和实施要求，以公告形式发布。'可被翻译为：Article 22 The Center for Medical Device Standardization Administration shall submit the reviewed medical device standards draft for approval and review conclusions to China Food and Drug Administration for examination. Medical device national standards passing the examination shall be submitted to the competent standardization administrative department under the State Council for approval and issuance; for medical device industry standards passing the examination, China Food and Drug Administration shall determine and announce the date and requirements for their implementation.\n'起草单位应当广泛调研、深入分析研究，积极借鉴相关国际标准，在对技术内容进行充分验证的基础上起草医疗器械标准，形成医疗器械标准征求意见稿，经医疗器械标准化技术委员会初步审查后，报送医疗器械标准管理中心。'可被翻译为：The drafting unit shall draft the medical device standard on the basis of full verification of the technical contents after conducting extensive surveys, in-depth analysis and research, and drawing experience from relevant international standards. The drafting unit shall then submit the draft for comment to the Center for Medical Device Standardization Administration after preliminary review by the technical committee on medical device standardization.\n'第二十条 医疗器械标准征求意见稿在医疗器械标准管理中心网站向社会公开征求意见，征求意见的期限一般为两个月。承担医疗器械标准计划项目的医疗器械标准化技术委员会对征集到的意见进行汇总后，反馈给标准起草单位，起草单位应当对汇总意见进行认真研究，对征求意见稿进行修改完善，形成医疗器械标准送审稿。'可被翻译为：Article 20 The medical device draft standard for comment shall be open to public consultation on the website of the Center for Medical Device Standardization Administration, lasting for a period of two months in general. The technical committee on medical device standardization that undertakes the medical device standards plan project shall summarize the comments received and give feedback to the drafting unit. The drafting unit shall carefully study the summarized suggestions, and modify the draft for comment to form the proposed draft.\n'涉及两个或者两个以上医疗器械标准化技术委员会的标准计划项目立项提案，应当由医疗器械标准管理中心负责协调，确定牵头医疗器械标准化技术委员会，并由其提出标准计划项目立项申请。'可被翻译为：Where the initiation proposal for the standards plan project involves two or more technical committees on medical device standardization, the Center for Medical Device Standardization Administration shall be responsible for coordinating and determining the leading technical committee which shall put forward the project initiation application for the standards plan project.\n\n根据上述已知信息，请将'第二十一条 承担医疗器械标准计划项目的医疗器械标准化技术委员会负责组织对医疗器械标准送审稿进行技术审查。审查通过后，将医疗器械标准报批稿、实施建议及相关资料报送医疗器械标准管理中心进行审核。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 21 The technical committee on medical device standardization that undertakes the medical device standards plan project shall be responsible for organizing the technical review of the proposed draft of the medical device standard. After the proposed draft passes the technical review, the draft for approval, implementation suggestions and relevant materials for medical device standards shall be submitted to the Center for Medical Device Standardization Administration for examination."
    },
    {
        "instruction":"已知信息：\n'对放置膜的供体和受体腔室孔的扩散面积的测量'可被翻译为：1. Measurements of the diffusional area of the orifices of the donor and receptor compartments between which the membrane is mounted\n'然而，无论扩散池制造商提供什么样的确认信息，进行测试的实验室都应该对每个扩散池进行初步确认。合格的扩散池可用于多次实验，不需要每次都再次确认(即重新确认)。每次试验前应确定孔和扩散池的状况。扩散池的某些部件，如o形环或管道，可能需要重新评估和偶尔更换。自动化系统变化太大，本章无法详细介绍;但是，应根据制造商的建议定期(例如每6-12个月)重新确认。'可被翻译为：However, regardless of what qualification information is provided by a diffusion cell manufacturer, the laboratory performing the test should perform an initial qualification of each diffusion cell. Qualified diffusion cells can be used in numerous experiments, and do not need to be qualified again (i.e., requalified) each time. The condition of the orifices and diffusion cells should be ascertained prior to each test. Certain diffusion cell components such as O-rings or tubing may require re-evaluation and occasional replacement. Automated systems are too varied to be covered in any detail within this chapter; however, they should be requalified routinely (e.g., every 6-12 months) based on the manufacturers’ recommendations.\n'每个扩散池的初始确认至少应包括:'可被翻译为：The initial qualification of each diffusion cell should, at minimum, include:\n'孔直径的确认:供体和受体室的孔直径可以用游标卡尺确定。应检查孔口是否有任何可能改变表面面积的碎片或其他损坏。'可被翻译为：1. Qualification of Orifice Diameter: The orifice diameter for the donor and receptor compartments can be determined using vernier calipers. The orifice should be inspected for any chips or other damage which may alter the surface area.\n\n根据上述已知信息，请将'皮肤应切割成适合扩散池的尺寸(大于孔的扩散面积)，以确保孔被完全覆盖。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Skin should be cut to the appropriate size for the diffusion cell (larger than the diffusional area of the orifice) to ensure that the orifice is completely covered."
    },
    {
        "instruction":"已知信息：\n'个体为了获得某些商品、服务或者为避免预期损失而愿意支付的最大金额。'可被翻译为：The maximum amount that an individual is willing to pay in order to obtain certain goods or services or to avoid expected loss.\n'法律:由政府的行政部门颁布的一种法律形式，规定了实施这些法律的实质性规定和程序通过授权立法的权力由授权这些权力的主要立法来界定和限制。'可被翻译为：A form of law, issued by an executive branch of government, specifying substantive regulations and procedures for implementing them. The power to pass delegated legislation is defined and limited by the primary legislation that delegated those powers.\n'1.纸盒:为了营销目的而放入一个或多个铝箔包装的钱包或纸盒\n2.纸盒:为了营销目的而放入一个或多个铝箔包装的钱包或纸盒'可被翻译为：1.A wallet or carton into which one or more foil packages are inserted for marketing purposes.\n2.A wallet or carton into which one or more foil packages are inserted for marketing purposes.\n'立法程序的第一阶段，由政府立法机构就某一主题(如药品管制)通过法律。法律一般规定了涉及主题事项的所有各方的作用、权利和义务(另见下文的法规)。'可被翻译为：The first state of the legislative process, in which laws are passed by the legislative body of government with regard to a subject matter, e.g. control of pharmaceuticals. Laws define the roles, rights and obligations of all parties involved in the subject matter in general terms (see also regulations below).\n\n根据上述已知信息，请将'政府或公司为了给予某个体授权而颁发的执照，或者用于软件规定使用者权利而规定的格式合同。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A license issued by a government or corporation to grant a license to an individual, or a form of contract that specifies the rights of users of software."
    },
    {
        "instruction":"已知信息：\n'第二十五条 根据飞行检查结果，食品药品监督管理部门可以依法采取限期整改、发告诫信、约谈被检查单位、监督召回产品、收回或者撤销相关资格认证认定证书，以及暂停研制、生产、销售、使用等风险控制措施。风险因素消除后，应当及时解除相关风险控制措施。'可被翻译为：Article 25 The food and drug regulatory department may take risk control measures in accordance with laws and regulations, such as rectification within a deadline, issuance of warning letter, warning meeting with the organization being inspected, monitoring of product recall, withdrawal or cancellation of relevant qualification certificates, as well as suspension of research and development, manufacture, sales, use and etc. in accordance with the results of unannounced inspection. After the risk factors are eliminated, the relevant risk control measures shall be terminated timely.\n'需要采取风险控制措施的，被检查单位应当按照食品药品监督管理部门的要求采取相应措施。'可被翻译为：Where risk control measures need to be taken, the organization being inspected shall conduct corresponding measures in accordance with the requirements of the food and drug regulatory department.\n'（十）其他需要采取的风险控制措施。'可被翻译为：(X) Other risk control measures required.\n'对受托生产企业监督检查中发现相关问题涉及注册人的，应当通报注册人所在地药品监督管理部门；发现可能存在医疗器械质量安全风险的，应当立即采取风险控制措施，并将相关情况通报注册人所在地药品监督管理部门。注册人所在地药品监督管理部门接到通报后，应当立即进行分析研判并采取相应的风险控制措施。'可被翻译为：If related problems found in supervision and inspection of the contract manufacturer involve the registrant, the drug regulatory department of the place where the registrant is located shall be informed; if it is found that there might be quality safety risks of the medical devices, risk control measures shall be taken immediately, and related information shall be informed to the drug regulatory department of the place where the registrant is located. Upon receipt of the notification, the drug regulatory department of the place where the registrant is located shall make analysis and judgment immediately, and take corresponding risk control measures.\n\n根据上述已知信息，请将'风险消除后，采取控制措施的药品监督管理部门应当解除控制措施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"After the risks are eliminated, the drug regulatory department that took the control actions shall terminate such actions."
    },
    {
        "instruction":"已知信息：\n'第三节 关联审评审批'可被翻译为：Section III Bundling Review and Approval\n'（七）药品\/制剂注册申请应与已登记原辅包进行关联，药品\/制剂获得批准时，即表明其关联的原辅包通过了技术审评，登记平台标识为“A”；未通过技术审评或尚未与制剂注册进行关联的标识为“I”。'可被翻译为：(7) The application for registration of the drug\/preparation shall be associated with the registered AEP. Where the drug\/preparation is approved, it indicates that its associated AEP has also passed the technical review, and marked as A on the registration platform; where the technical review failed or the association is unestablished, the identifier shall be I.\n'第四十一条 药品审评中心在审评药品制剂注册申请时，对药品制剂选用的化学原料药、辅料及直接接触药品的包装材料和容器进行关联审评。'可被翻译为：Article 41 When evaluating a drug registration application, the CDE shall conduct bundling review of the chemical active drug ingredients, excipients and primary packaging materials and containers used for the drug products.\n'国家药监局关于进一步完善药品关联审评审批和监管工作有关事宜的公告'可被翻译为：NMPA Issued the Announcement on Issues Concerning the Further Improvement of Drug-related Associated Review & Approval and Supervision\n\n根据上述已知信息，请将'关联审评时限与其关联药品制剂的审评时限一致。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The timeline for bundling review is the same as that for the review of the corresponding drug product."
    },
    {
        "instruction":"已知信息：\n'第十条 下列情形的进口药品，必须经口岸药品检验所检验符合标准规定后，方可办理进口备案手续。检验不符合标准规定的，口岸药品监督管理局不予进口备案：'可被翻译为：Article 10 In any of the following cases, the importation record filing of drugs to be imported shall proceed only after they have been tested and confirmed by the drug control institute of port that they meet the prescribed standards. If they do not meet the prescribed standards based on testing, the drug regulatory department at ports of entry shall not approve the importation record filing.\n'第四条 本办法所称进口备案，是指进口单位向允许药品进口的口岸所在地药品监督管理部门（以下称口岸药品监督管理局）申请办理《进口药品通关单》的过程。麻醉药品、精神药品进口备案，是指进口单位向口岸药品监督管理局申请办理《进口药品口岸检验通知书》的过程。'可被翻译为：Article 4 Importation record filing in the Provisions refers to the process that drug importers apply for the Drug Import Note to the local drug regulatory department at ports of entry where drug importation is permitted (hereinafter referred to as the drug regulatory department at ports of entry). Importation record filing of narcotic drugs and psychotropic substances in the Provisions refers to the process that drug importers apply for the Notice of Port Testing for Import Drugs from the drug regulatory department at ports of entry.\n'非首次进口药材，应当按照本办法规定直接向口岸药品监督管理部门办理备案。非首次进口药材实行目录管理，具体目录由国家药品监督管理局制定并调整。尚未列入目录，但申请人、药材基原以及国家（地区）均未发生变更的，按照非首次进口药材管理。'可被翻译为：Non-first importation of crude drugs shall be filed directly at drug regulatory department of ports according to the Provisions. Catalogue management shall be implemented for non-first import drugs, and the specific catalogue shall be formulated and adjusted by the NMPA. Those not yet included in the Catalogue but with no change of the applicant, origin or country (region) shall be managed as non-first import drugs.\n'第六条 进口单位持《进口药品通关单》向海关申报，海关凭口岸药品监督管理局出具的《进口药品通关单》，办理进口药品的报关验放手续。'可被翻译为：Article 6 An importer shall apply to the customs by presenting the Drug Import Note, while the customs shall perform customs clearance of the drug imports based on the Drug Import Note issued by the drug regulatory department at ports of entry.\n\n根据上述已知信息，请将'第四十条 进口暂未列入进口药品目录的原料药，应当遵照本办法的规定，到口岸药品监督管理局办理进口备案手续。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 40 To import drug substances which have been imported but have not yet been included in the list of imported drugs for the time being, the importer shall go through the formalities of importation record filing with the drug regulatory department at ports of entry in accordance with the regulations of the Provisions."
    },
    {
        "instruction":"已知信息：\n'当溶液与纯溶剂（或两种浓度不同的溶液）在半透膜隔开的情况下，溶剂（或较稀溶液中的溶剂）通过半透膜向溶液（或较浓溶液）扩散的现象。'可被翻译为：The diffusion of a solvent (or a solvent in a dilute solution) through a semi-permeable membrane into a solution (or a concentrated solution) when the solution is separated from the pure solvent (or two solutions of different concentrations) by a semi-permeable membrane.\n'在压力驱动下溶液中的溶剂（如水）以与自然渗透相反的方向通过半透膜进入膜的低压侧，从而达到有效分离的过程。'可被翻译为：Under the pressure drive, the solvent in the solution (such as water) enters the low-pressure side of the membrane through the semi-permeable membrane in the opposite direction of natural penetration, so as to achieve an effective separation process.\n'含有药物或芳香物质的浓糖水溶液。'可被翻译为：An aqueous solution of concentrated sugar containing a medicinal or aromatic substance.\n'表示物质分子扩散程度的物理量。'可被翻译为：A physical quantity indicating the degree of diffusion of the molecules of a substance.\n\n根据上述已知信息，请将'在透析过程中通过半透膜的物质。常含有在溶液中容易扩散的物质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A substance that passes through a semi-permeable membrane during dialysis. Often containing a substance that diffuses easily in solution."
    },
    {
        "instruction":"已知信息：\n'横坐标是质荷比（m\/z）、纵坐标是离子的相对强度，以基峰为100%、经过计算机处理的质谱棒状谱图。'可被翻译为：The horizontal coordinate is the mass charge ratio (m\/z), the vertical coordinate is the relative strength of the ion, with the base peak of 100%, after computer processing of mass spectrum rod-like spectrum.\n'质谱图'可被翻译为：mass spectrum\n'全扫描得到的分子离子([M+H][M-H]、[M+Na]+等)及所有碎片离子的质荷比与其对应的离子流的相对强度的坐标图。根据质谱图来决定解析化合物的结构、分子式。'可被翻译为：The coordinates of the mass-charge ratio of the molecular ions ([M+H][M-H], [M+Na]+, etc.) and all the fragment ions obtained by the full scan and the relative intensity of their corresponding ion currents. According to the mass spectrometry to determine the structure of the analytical compound, the molecular formula.\n'质谱分析中由丰度最高的核素组成的同位素峰。如氢原子的平均原子量为1.00794,丰度最高的同位素,H的质量为1.00783。'可被翻译为：An isotopic peak consisting of the most abundant nuclides in mass spectrometry. For example, the average atomic weight of the hydrogen atom is 1.00794, and the mass of the most abundant isotope,H, is 1.00783.\n\n根据上述已知信息，请将'以质谱图中指定质核比范围内最强峰为100%,其他离子峰对其归一化所得的强度。现在标准质谱图均以离子相对丰度值为纵坐标。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The maximum peak is 100% in the range of the specified mass nucleus ratio in the mass spectrum, and the intensity obtained by the normalization of other ion peaks. Now the standard mass spectrometry is the relative abundance value of ions as the ordinate."
    },
    {
        "instruction":"已知信息：\n'主要研究化学物质对眼的损害及其机制的毒理学分支学科。'可被翻译为：A branch of toxicology that studies the damage to the eye caused by chemical substances and its mechanisms.\n'利用毒理学的基本方法和技术，研究外源化学物对肝脏的损害作用特点及其机制的学科。'可被翻译为：It uses the basic methods and techniques of toxicology to study the characteristics and mechanisms of the damaging effects of foreign chemicals on the liver.\n'利用毒理学的基本方法和技术，研究外源化学物对肾脏的损害作用特点及其机制的学科。'可被翻译为：The discipline that studies the characteristics and mechanisms of the damaging effects of foreign chemicals on the kidney by using the basic methods and techniques of toxicology.\n'研究外源化学物对呼吸系统的损害作用，探讨检测方法以及阐述损害机制的毒理学分支学科。其研究有助于对中毒的诊断、治疗、预防以及中毒机制的探讨。'可被翻译为：The branch of toxicology that studies the damaging effects of foreign chemicals on the respiratory system, explores methods of detection, and elucidates mechanisms of damage. Its research is helpful for the diagnosis, treatment, prevention and mechanism of poisoning.\n\n根据上述已知信息，请将'在免疫学和毒理学基础上发展起来的一个毒理学分支学科。主要研究外源化学物质和物理因素对机体免疫系统的有害作用及其机制。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A subdiscipline of toxicology that developed out of immunology and toxicology. The study of the harmful effects of foreign chemicals and physical factors on the body's immune system and their mechanisms."
    },
    {
        "instruction":"已知信息：\n'1.产品生命周期的所有阶段，从最初的开发到营销，直到产品停产(ICH Q8 (4))\n2.医疗器械生命周期的所有阶段，从最初的构思到最终的退役和处置。\n3.产品生命周期的所有阶段，从最初的开发到营销，直到产品停产(4)。'可被翻译为：1.All phases in the life of a product from the initial development through marketing until the product’s discontinuation (ICH Q8 (4))\n2.All phases in the life of a medical device, from the initial conception to final decommissioning and disposal.\n3.All phases in the life of a product from the initial development through marketing until the product’s discontinuation (4).\n'质量体系应包括GXP要求，应用于产品和工艺，包括技术转移的生命周期阶段中。'可被翻译为：6.3. The quality system should incorporate GxP which should be applied to the life cycle stages of the products and processes, including the technology transfer.\n'发酵阶段'可被翻译为：fermentation stage\n'发芽阶段'可被翻译为：germination stage\n\n根据上述已知信息，请将'考虑到监管要求，从计算机化系统构思时开始，到系统退役和退役时结束的一段时间。系统生命周期通常包括规划阶段;包括设计阶段和编程测试阶段的开发阶段;包括系统集成和测试阶段的确认和发布阶段;验证阶段;发布阶段;一个运维阶段;最后是系统退役阶段。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The period of time that starts when a computerized system is conceived and ends when the system is retired and decommissioned, taking into consideration regulatory requirements. The system life-cycle typically includes a planning phase; a development phase that includes a design phase and a programming and testing phase; a qualification and release phase that includes a system integration and testing phase; a validation phase; a release phase; an operation and maintenance phase; and, finally, a system retirement phase."
    },
    {
        "instruction":"已知信息：\n'根据《中华人民共和国药品管理法》，经国务院批准，同意增设广西壮族自治区崇左市爱店口岸（以下简称爱店口岸）为药材进口边境口岸。现将有关事项公告如下：'可被翻译为：According to the Drug Administration Law of the People's Republic of China, upon the approval of the State Council, it is agreed to establish Aidian Port, ChongzuoCity, Guangxi Zhuang Autonomous Region(hereinafter referred to as Aidian Port) as a crude drug import port. The relevant issues are hereby announced as follows:\n'二、广西壮族自治区崇左市市场监督管理局为爱店口岸对应的口岸药品监督管理部门，自2022年3月10日起，开始承担爱店口岸进口药材的备案，组织口岸检验并进行监督管理工作。'可被翻译为：II. Chongzuo Administration for Market Regulation of Guangxi Zhuang Autonomous Region shall be the drug regulatory department corresponding to Aidian Port, and shall undertake the filing of imported crude drugs at Aidian Port from March 10, 2022, organize port inspection and conduct supervision and administration.\n'国家药监局 海关总署关于增设长春空港口岸为药品进口口岸的公告'可被翻译为：Announcement of NMPA and General Administration of Customs on the Establishment of Changchun Airport as a Drug Import Port\n'国家药监局 海关总署关于增设无锡航空口岸、江阴港口岸为药品进口口岸的公告'可被翻译为：NMPA and General Administration of Customs issued the Announcement on the Setting up of Wuxi Airport and Jiangyin Port as Drug Import Ports\n\n根据上述已知信息，请将'国家药监局 海关总署关于增设广西壮族自治区崇左市爱店口岸为药材进口边境口岸的公告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Announcement of NMPA and General Administration of Customs on the Establishment of Aidian Port as a Crude Drug Import Port"
    },
    {
        "instruction":"已知信息：\n'用于某些疾病的预防、治疗和诊断的酶。'可被翻译为：Enzymes used in the prevention, treatment, and diagnosis of certain diseases.\n'用于预防、治疗和诊断疾病的脂质。脂质系脂肪、类脂及其衍生物的总称。'可被翻译为：Lipids used to prevent, treat, and diagnose disease. Lipids are a general term for fats, lipids, and their derivatives.\n'按正常用法、用量应用药物预防、诊断或治疗疾病过程中，发生于治疗目的无关的有害反应。'可被翻译为：According to the normal usage, dosage of the drug to prevent, diagnose or treat the disease process, occurred in the therapeutic purpose unrelated harmful reactions.\n'1.治疗活动是指对身心疾病的成功预防、诊断和治疗;疾病症状的改善;以及对身体身心状态的有益改变或调节，以及对整体幸福感的发展。(见:《传统医学研究和评价方法一般准则》，日内瓦，世界卫生组织，2000年)。\n2.治疗活动是指对身心疾病的成功预防、诊断和治疗。治疗包括有益的身体和精神状态的改变或调节，总体幸福感的发展以及症状的改善。\n3.成功地预防、诊断和治疗身体和精神疾病，改善疾病的症状，以及有益地改变或调节身体的身体和精神状态，培养总体幸福感。'可被翻译为：1.Therapeutic activity refers to the successful prevention, diagnosis and treatment of physical and mental illnesses; improvement of symptoms of illnesses; as well as beneficial alteration or regulation of the physical and mental status of the body and development of a sense of general well-being. (In: General guidelines for methodologies on research and evaluation of traditional medi-cine, Geneva, World Health Organization, 2000).\n2.Therapeutic activity refers to the successful prevention, diagnosis and treatment of physical and mental illnesses. Treatment includes beneficial alteration or regulation of the physical and mental status of the body and development of a sense of general well-being as well as improvement of symptoms.\n3.Successful prevention, diagnosis and treatment of physical and mental illnesses, improvement of symptoms of illnesses, as well as beneficial alteration or regulation of the physical and mental status of the body and development of a sense of general well-being.\n\n根据上述已知信息，请将'用于预防、治疗和诊断疾病的糖胺聚糖。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A glycosaminoglycan used in the prevention, treatment, and diagnosis of disease."
    },
    {
        "instruction":"已知信息：\n'调查应当包括产品质量状况、伤害与产品的关联性、使用环节操作和流通过程的合规性等。自查应当包括采购、生产管理、质量控制、同型号同批次产品追踪等。'可被翻译为：Investigation shall include product quality profile, the correlation between the injury and the product, and compliance of the operation in the use and circulation process. Self-inspection shall include procurement, production management, quality control, and tracking of the same model and same batch of products.\n'调查内容应当包括医疗器械不良事件发生情况、医疗器械使用情况、患者诊治情况、既往类似不良事件、产品生产过程、产品贮存流通情况以及同型号同批次产品追踪等。'可被翻译为：The investigation content shall include the occurrence of medical device adverse events, use of medical devices, diagnosis and treatment of patients, previous similar adverse events, production process of products, storage and circulation of products and tracking of the products of the same model and same batch.\n'第三十三条  医疗器械经营企业、使用单位发现或者获知群体医疗器械不良事件的，应当在12小时内告知持有人，同时迅速开展自查，并配合持有人开展调查。自查应当包括产品贮存、流通过程追溯，同型号同批次产品追踪等；使用单位自查还应当包括使用过程是否符合操作规范和产品说明书要求等。必要时，医疗器械经营企业、使用单位应当暂停医疗器械的销售、使用，并协助相关单位采取相关控制措施。'可被翻译为：Article 33 In case of identifying or knowing group adverse events of medical device, medical device distributing enterprises and user facility shall notify MAHs within 12 hours, rapidly carry out self-inspection and cooperate with MAHs to carry out the investigation. Self-inspection shall include product storage, tracing of circulation process, and tracking of the products of the same model and same batch. Self-inspection of user facility shall also include whether the use process meets the operational specification and product instruction requirements. Medical device distributing enterprises and user facility shall suspend the sales and use of the medical devices when necessary and assist relevant units in taking relevant control measures.\n'对于仿制药等，根据是否已获得相应生产范围药品生产许可证且已有同剂型品种上市等情况，基于风险进行药品注册生产现场核查、上市前药品生产质量管理规范检查。'可被翻译为：For generic drugs or other products, drug registration inspection of the manufacturing site and\/or  pre-marketing GMP inspection shall be carried out based on risks, taking into consideration the circumstances such as whether Drug Manufacturing Certificate covering the corresponding manufacturing scope has been obtained and product of the same dosage form has been marketed,.\n\n根据上述已知信息，请将'现场检查应当包括生产质量管理体系运行情况、产品质量状况、生产过程、同型号同批次产品追踪等。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The on-site inspection shall include operation of production quality management system, product quality profile and production process as well as the tracking of products of the same model and same batch."
    },
    {
        "instruction":"已知信息：\n'进口第一类体外诊断试剂备案，备案人向国家食品药品监督管理总局提交备案资料。'可被翻译为：To apply for filing of import class I in-vitro diagnostic reagents, the filing entity shall submit the filing documents to China Food and Drug Administration.\n'境内第一类医疗器械备案，备案人向设区的市级食品药品监督管理部门提交备案资料。'可被翻译为：To apply for filing of class I domestic medical devices, the filing entity shall submit the filing documents to the food and drug regulatory department of the city consisting of districts .\n'医疗器械备案是医疗器械备案人向食品药品监督管理部门提交备案资料，食品药品监督管理部门对提交的备案资料存档备查。'可被翻译为：Medical device filing is a process that the filing entity submits the filing documents to the food and drug regulatory department and the food and drug regulatory department files the filing documents submitted by the filing entity.\n'境内第一类体外诊断试剂备案，备案人向设区的市级食品药品监督管理部门提交备案资料。'可被翻译为：To apply for filing of class I in-vitro diagnostic reagent, the filing entity shall submit the filing documents to the food and drug regulatory department of the city consisting of districts .\n\n根据上述已知信息，请将'进口第一类医疗器械备案，备案人向国家食品药品监督管理总局提交备案资料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To apply for filing of import class I medical devices, the filing entity shall submit the filing documents to China Food and Drug Administration."
    },
    {
        "instruction":"已知信息：\n'（一）产品名称和企业内部的产品代码；'可被翻译为：1. The name of the product and the internal code reference;\n'1.产品名称和产品代码。'可被翻译为：1) The name of the product, and its reference code;\n'（一）产品名称、规格、批号。'可被翻译为：1. The product name, strength, batch number;\n'（一）产品名称、型号、规格；'可被翻译为：(1) Name, model and specification of the product;\n\n根据上述已知信息，请将'（一）产品名称以及产品代码；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1. The designated name of the product and the code reference;"
    },
    {
        "instruction":"已知信息：\n'超文本标记语言。通常用于格式化网页。'可被翻译为：Hypertext Mark-up Language. Commonly used to format Web pages.\n'EDI 信息由一组字段组成，使用商定的标准进行结构化，以计算机可读格式制备，并能够自动和明确处理。[EMA]'可被翻译为：An EDI Message consists of a set of segments, structured using an agreed standard, prepared in a computer readable format and \ncapable of being automatically and unambiguously processed.[EMA]\n'在实际应用中被普遍认为是“标准”，但尚未被 ISO等正式标准机构认可的一类“标准”。'可被翻译为：A ‘standard’ which is in such widespread use that it is accepted as a standard but which has not been ratified by any official standards body, each as the ISO.\n'描述批号细节的标准操作程序。'可被翻译为：Standard operating procedure describing the details of the batch numbering.\n\n根据上述已知信息，请将'标准通用标记语言。以平台无关的方式描述结构化信息的 ISO 标准。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Standardized Generalized Markup Language. An ISO standard for describing structured information in a platform independent manner."
    },
    {
        "instruction":"已知信息：\n'以电感耦合等离子体为激发光源的一类光谱分析方法。是由原子发射光谱法衍生而来。'可被翻译为：A class of spectral analysis methods using inductively coupled plasma as excitation light source. It is derived from atomic emission spectrometry.\n'电感耦合等离子体-原子发射光谱'可被翻译为：inductively coupled plasma atomic emission spectroscopy\n'电感耦合等离子体-发射光谱in-'可被翻译为：inductively coupled plasma optical emission spectroscopy\n'等离子体解吸质谱法'可被翻译为：plasma desorption mass spectrometry\n\n根据上述已知信息，请将'以电感耦合等离子体为激发光源的发射光谱分析方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Method of emission spectrum analysis using inductively coupled plasma as excitation light source."
    },
    {
        "instruction":"已知信息：\n'收集瓶或试管应在空时称重，以确定收集完成后样品的确切体积。'可被翻译为：Collection vials or test tubes should be weighed when empty to determine the exact volume of sample present after collection has completed.\n'抽样取决于所使用的设备，在适当情况下应遵循制造商提供的说明。可以使用经过预热到与反应釜中受体温度一致的受体溶液，用于替代采样过程中去除的样品体积受体溶液，并且重要的是要确保在采样和在每个时间点重新填充受体溶液后膜下不存在气泡。'可被翻译为：Sampling is dependent upon the equipment used and should follow instructions provided by the manufacturer, when appropriate. The receptor solution used to replace the volume removed during sampling may be pre-warmed to the temperature of the receptor solution in the receptor compartment, and it is important to ensure that air bubbles are not present beneath the membrane after sampling and refilling the receptor solution at each time point.\n'FDCs应每个都确认合格，并通过制造商颁发的序列号或其他方式唯一识别。供体和受体区室的孔口面积可以用游标卡尺确定。为了准确地计算样品通过管道洗脱和收集之前的滞后时间，可以适当地限定每个流动扩散池(惰性)管的长度，以及它们相关的死体积。'可被翻译为：FDCs should be individually qualified and uniquely identifiable either by a manufacturer issued serial number or other means. The orifice area for the donor and receptor compartments can be determined using vernier calipers. It may be appropriate to qualify the lengths of (inert) tubing for each of the flow-through diffusion cells, and their associated dead volumes, to accurately calculate the lag time before a sample elutes through the tubing and is collected.\n'经验性测量每个VDC或浸没池的受体溶液室\/容器的体积，或经验性测量每个FDC的流出管长度'可被翻译为：2. Empirically measured volume of the receptor solution compartment\/vessel for each VDC or immersion cell, or the empirically measured outflow tube length for each FDC\n\n根据上述已知信息，请将'样品收集后，应称量小瓶或试管，以确定所收集受体溶液的确切体积。该体积用于测定每个样品中存在的药物总量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"After samples have been collected, the vials or test tubes should be weighed to determine the exact volume of receptor solution collected. This volume should be used when determining the total amount of drug present in each sample."
    },
    {
        "instruction":"已知信息：\n'经过指定的培养时间后，取掉小管，灭活（即灭菌）并用肥皂和水清洗。小管再次用于检测之前要加热灭菌。使用手动\/自动读碟器测量每个 ZOI 的直径。ZOI 应由经过资格确认的实验室员工测量。使用手动\/自动读碟器测量 ZOI。手动读碟器的示例包括 Fisher_x0002_Lily 读碟器或手动\/电子圆规；手动读取需要将数据录入（例如手写和\/或电子）纸质记录和\/或电子日志和\/或数据表。自动读碟器的例子包括 OMNICON 或 Trinity V3。与手动读取不同，自动读碟器允许计算机化系统对培养碟进行测量，不需要录入原始数据。'可被翻译为：After the specified incubation time, the penicylinders are removed, decontaminated (i.e. \nautoclaved) and washed with soap and water. The penicylinders are then heat sterilized prior to \nre-use in test. The diameter of each ZOI is measured with a manual\/automatic plate reader. ZOIs should only be measured by qualified laboratory personnel. ZOI measurements are taken with the use of a manual or automatic plate reader. Examples of a manual reader include a Fisher_x0002_Lily zone reader or manual\/electronic calipers; manual reads require data entry (e.g. handwritten and\/or electronic) onto hardcopy and\/or into electronic logbooks and\/or spreadsheets. Examples \nof automated plate readers include OMNICON or Trinity V3. Unlike manual reads, automated \nplate readers allow a computerized system to measure the plates and do not require data entry of \nraw data.\n'标准实验室玻璃仪器如烧杯、漏斗、烧瓶、圆颈培养瓶和1-2升的瓶子也是必须的。一 次性无菌设备，如试管 、培养皿和血清移液管，只要不影响效价检测的定量就可以一直 使用。其它设备包括不锈钢瓶、比色皿、血清移液管、单通道微量移液器、pH计、加热 板、可调温水浴锅、培养箱和手动\/自动平板计数器或紫外可见分光光度计。'可被翻译为：Standard laboratory glassware such as beakers, funnels, flasks, roux and 1-2 liter bottles are also required. Sterile and disposable equipment such as test tubes, petri-plates and serological pipettes may be used so long as the use of this equipment does not affect the quantitative aspect of potency testing. Additional equipment includes a stainless steel penicylinders, penicylinder dropper, cuvettes, pipettor and micropipette, pH meter, hot plate, adjustable- temperature water bath, incubator and a manual\/automatic plate reader or UV- VIS spectrophotometer.\n'抗生素效价采用碟法（管碟或扩散）或浊度法（浊度计）法测定。碟法和浊度法均会显 示出可测量的生长抑制性。例如，在管碟法测试中可观察到抑菌圈（ZOI）。浊度法测 定中，观察并测量混浊度。将生长抑制测量结果制表，作线性回归曲线，外推得到抗生 素效价值。'可被翻译为：Antibiotic potency testing is performed either by the plate (cylinder-plate or diffusion) or tube (turbidimetric) method. Both plate and tube methods demonstrate measurable levels of growth inhibition. For example, zones of inhibition (ZOIs) are observed and measured during cylinder plate testing. And, turbidity is observed and measured during tube testing. Growth inhibition measurements are tabulated and integrated into a linear regression curve, resulting in extrapolated antibiotic potency values.\n'效价计算列在 USP<81>中，管碟法和浊度法有分开说明。可采用传统手工算术进行计算，亦可采用电子表格如微软 EXCEL 进行计算。为了得到可靠和可重复的结果，应对电子表格进行验证。'可被翻译为：Potency calculations are listed in USP <81> and are specific to either the Plate or Tube Method. \nCalculations may be performed by traditional hand math or by electronic spreadsheet such as \nMicrosoft Excel. In order to achieve reliable and reproducible results, electronic spreadsheets \nshould be validated.\n\n根据上述已知信息，请将'用于对样品进行测量的设备应该有适当的验证和频繁的核查，确保结果可靠和可重复， 此类设备的例子包括称重天平、pH计、灭菌器、微生物计数器、手动\/自动读板器和紫 外可见光分光计。手动和自动读板器更多信息参见标题为抗生素效价测定章节：管碟法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Equipment used to provide a unit of measurement should have the appropriate validation and frequent verification checks to ensure reliable and reproducible results; examples of such equipment include a weight scale, pH meter, autoclave, micrometer, manual\/automatic plate reader and UV-VIS spectrophotometer. For more information on manual and automatic plate readers, see section titled Antibiotic Potency Testing: Plate Method."
    },
    {
        "instruction":"已知信息：\n'第三百零一条 因产品存在安全隐患决定从市场召回的，应当立即向当地药品监督管理部门报告。'可被翻译为：Article 301: Where a decision is made to recall a product from the market due to its existing or potential safety risks, it should be reported immediately to the drug regulatory department.\n'(x)建立召回系统，确保可从销售或供应中召回任何一批产品；'可被翻译为：(x) A system is available to recall any batch of product, from sale or supply;\n'（九）建立药品召回系统，确保能够召回任何一批已发运销售的产品；'可被翻译为：9. A system is available to recall any batch of product, from sale or supply.\n'第一百七十七条 企业应当协助药品生产企业履行召回义务，控制和收回存在安全隐患的药品，并建立药品召回记录。'可被翻译为：Article 177 Enterprises shall assist drug manufacturers in implementing the recall obligation, control and withdraw drugs with safety hazards, and establish drug recall records.\n\n根据上述已知信息，请将'第二百九十三条 企业应当建立产品召回系统，必要时可迅速、有效地从市场召回任何一批存在安全隐患的产品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 293: The manufacturer should establish a recall system, if necessary, to recall promptly and effectively any batch of products with potential safety risks from the market."
    },
    {
        "instruction":"已知信息：\n'实验动物在14〜28天内，每日给予供试品后所引起的毒性效应。'可被翻译为：Toxic effects caused by daily administration of test products in experimental animals for 14 to 28 days.\n'药物在短时间内反复使用后，耐受性在数分钟内快速形成的现象。'可被翻译为：A phenomenon in which tolerance develops rapidly within minutes of repeated use of a drug for a short period of time.\n'利物质按照凝点测定法测定时，由液体凝结为固体，在短时间内停留不变的最高温度。'可被翻译为：The maximum temperature at which a liquid condenses into a solid and remains unchanged for a short period of time when a substance is determined according to the freezing point method.\n'作用性质相同药物的联合应用，产生的相加或协同效应。'可被翻译为：The additive or synergistic effect produced by the combination of drugs with identical properties of action.\n\n根据上述已知信息，请将'应用药物后短时间内发生的毒性作用（14天内）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Toxic effects that occur within a short period of time after application of the drug (within 14 days)."
    },
    {
        "instruction":"已知信息：\n'国家为保证药品质量，保证人民群众用药安全、有效、质量可控而制定的技术法典，是药品研制、生产、经营、使用和监管的法定依据。'可被翻译为：The technical Code formulated by the State for the purpose of ensuring the quality of drugs and ensuring the safety, effectiveness and quality control of drug use by the people is the legal basis for the research, production, distribution, use and supervision of drugs.\n'为加强药品监督管理，由国家立法机关制定颁布的卫生法律。以保证药品质量、保障人体用药安全、维护人民健康和用药的合法权益。'可被翻译为：In order to strengthen drug supervision and administration, health laws are formulated and promulgated by the national legislature. To ensure the quality of drugs, ensure the safety of drug use, and safeguard the people's health and legitimate rights and interests in drug use.\n'第一条 为保证药品的安全、有效和质量可控，规范药品注册行为，根据《中华人民共和国药品管理法》（以下简称《药品管理法》）、《中华人民共和国行政许可法》（以下简称《行政许可法》）、《中华人民共和国药品管理法实施条例》（以下简称《药品管理法实施条例》），制定本办法。'可被翻译为：Article 1 The Provisions are formulated for the purposes of ensuring the safety, efficacy and quality of drugs and regulating drug registration in accordance with the Drug Administration Law of the People's Republic of China (hereinafter referred to as the Drug Administration Law), Administrative Permission Law of the People's Republic of China (hereinafter referred to as Administrative Permission Law) and the Regulations for Implementation of the Drug Administration Law of the People's Republic of China (hereinafter referred to as the Regulations for Implementation of the Drug Administration Law).\n'第一条 为了加强药品管理，保证药品质量，保障公众用药安全和合法权益，保护和促进公众健康，制定本法。'可被翻译为：Article 1 This Law is enacted to strengthen drug administration, ensure drug quality, protect drug safety and legitimate rights and interests of the public, and protect and promote public health.\n\n根据上述已知信息，请将'一个国家记载药品标准、规格的法典，是国家为保证药品质量、保证人民用药安全有效、质量可控而制定国家药品质量控制的技术标准。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A national code recording drug standards and specifications is a technical standard for drug quality control formulated by the State to ensure drug quality and ensure the safety, effectiveness and controllable quality of drug use for the people."
    },
    {
        "instruction":"已知信息：\n'第六十一条 化妆品最后一道接触内容物的工序在境内完成的为国产产品，在境外完成的为进口产品，在中国台湾、香港和澳门地区完成的参照进口产品管理。'可被翻译为：Article 61 Cosmetics of which the last process touching the contents completes in China are domestic products, and those that completes overseas are imported products. Those that completes in Taiwan, Hong Kong SAR and Macau SAR shall be regulated by the reference of imported products.\n'第五条 国家对化妆品生产实行许可管理。从事化妆品生产活动，应当依法取得化妆品生产许可证。'可被翻译为：Article 5 The state exercises licensing management for the manufacturing of cosmetics. To engage in manufacturing of cosmetics, the Cosmetics Manufacturing License shall be obtained in accordance with the law.\n'以一个产品名称申请注册或者进行备案的配合使用产品或者组合包装产品，任何一剂的最后一道接触内容物的工序在境外完成的，按照进口产品管理。'可被翻译为：For products used in conjunction or combination products that apply for registration or file for filing under one product name, if any of the last process touching the contents are produced overseas, the set shall be regulated as imported products.\n'化妆品生产许可证副本还应当载明化妆品生产许可变更情况。'可被翻译为：The duplicate of the Cosmetics Manufacturing License shall also indicate the change of the cosmetics manufacturing licensing.\n\n根据上述已知信息，请将'第六十三条 配制、填充、灌装化妆品内容物，应当取得化妆品生产许可证。标注标签的生产工序，应当在完成最后一道接触化妆品内容物生产工序的化妆品生产企业内完成。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 63 For the preparing, filling and canning of cosmetics contents, an entity shall obtain the Cosmetics Manufacturing License according to law. The manufacturing process of labeling shall be completed in the manufacturer of cosmetics that completes the last manufacturing process of contacting contents of cosmetics."
    },
    {
        "instruction":"已知信息：\n'已灭菌设备、组分和容器在使用前和灌装\/装配过程中的保持时间。'可被翻译为：The holding time for sterilised equipment, components, and containers before use and during filling\/assembly.\n'已灭菌产品在灌装前的保持时间。'可被翻译为：The holding time for sterilised product prior to filling.\n'隔离器或 RABS 的背景环境应确保将污染转移的风险降至最低。'可被翻译为：The background environment for isolators or RABS should ensure the risk of transfer of contamination is minimized.\n'限制性进入隔离系统（RABS）或隔离器有利于确保所需的条件，并最大限度减少关键区直接人为干预措施引起的微生物污染。在 CCS 中应讨论它们的使用。如要采用任何方法替代 RABS 或隔离器，应证明该替代方法的合理性。'可被翻译为：Restricted Access Barrier Systems (RABS) or isolators are beneficial in assuring required conditions and minimizing microbial contamination associated with direct human interventions in the critical zone. Their use should be considered in the CCS. Any alternative approaches to the use of RABS or isolators should be justified.\n\n根据上述已知信息，请将'已净化环境（例如 RABS 或隔离器）在使用前的保持时间。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The holding time for a decontaminated environment, such as the RABS or isolator before use."
    },
    {
        "instruction":"已知信息：\n'（三）有能对所生产药品进行质量管理和质量检验的机构、人员及必要的仪器设备；'可被翻译为：(3) have the institutions and personnel capable of meeting the quality control and testing requirements for drugs to be produced and the necessary instruments and equipment; and\n'（三）有能对所生产药品进行质量管理和质量检验的机构、人员；'可被翻译为：(3) having the institutions and personnel capable of quality control and testing for the drugs to be manufactured;\n'（二）有能对生产的医疗器械进行质量检验的机构或者专职检验人员以及检验设备；'可被翻译为：(2) having the institutions, full-time testing personnel and equipment capable of meeting the quality testing requirements for the medical devices manufactured;\n'四、药品上市许可持有人、药品生产企业以及制备正电子类放射性药品的医疗机构应当切实落实药品质量管理主体责任，严格实行生产全过程的质量控制和检验。质量检验合格的产品方可销售或使用。'可被翻译为：IV. Marketing authorization holders and manufacturers of radioactive pharmaceuticals and medical institutions preparing positron radioactive pharmaceuticals should earnestly fulfill the principal responsibility for drug quality management and strictly carry out quality control and inspection throughout the whole process of manufacturing. Products can be sold and used only after passing the quality tests.\n\n根据上述已知信息，请将'（四）有能对所生产药品进行质量管理和质量检验的必要的仪器设备；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(4) having instruments and equipment essential for quality management and testing for drugs to be manufactured;"
    },
    {
        "instruction":"已知信息：\n'2.基于制剂学因素的考虑'可被翻译为：2. Considerations based on pharmaceutics factors\n'对卫生保健技术的特点、效果或影响进行系统性评估。'可被翻译为：A systematic assessment of the characteristics, effectiveness, or impact of health care technology.\n'APS 应尽可能模拟日常无菌生产工艺，并包括所有关键生产步骤，具体如下：'可被翻译为：The APS should imitate as closely as possible the routine aseptic manufacturing process and include all the critical manufacturing steps, specifically:\n'对于境外已上市境内未上市的药品，需结合药品具体情况，按照临床评价的基本逻辑对原研药品的临床研究数据进行充分评价，根据评价结果确定临床试验要求。对于不同研发背景的药品，其所需开展的临床试验应具体问题具体分析。'可被翻译为：For the drugs marketed overseas but not marketed in China, full evaluation should be performed for the clinical study data of the originator drugs according to the basic logic of clinical evaluation and in combination with the actual situation of the drugs, and the clinical trial requirements should be determined according to the evaluation results. For drugs with different R & D backgrounds, the clinical trials required to be carried out should be determined case by case.\n\n根据上述已知信息，请将'对于仿制药制剂学方面评估，需基于药品特点具体问题具体分析。具体如下：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For pharmaceutical evaluation of generic drugs, analysis should be based on cases according to drug characteristics. The details are as follows:"
    },
    {
        "instruction":"已知信息：\n'（二）申请事项依法不属于本部门职权范围的，应当即时作出不予受理的决定，并告知申请人向有关行政机关申请；'可被翻译为：(2) Where an application item is not subject to the jurisdiction of the concerned departments by law, it shall be decided not to accept the application in time and informed to the applicant to apply to the relevant administrative departments;\n'（二）申请事项依法不属于本部门职权范围的，应当即时作出不予受理的决定，并告知申请人向有关行政机关申请。'可被翻译为：(2) Where an application item is not subject to the jurisdiction of the relevant authorities in accordance with the law, a decision of rejection shall be made in time and the applicant shall be informed to apply to the relevant authorities;\n'（一）申请事项依法不属于本部门职权范围的，应当即时作出不予受理的决定，并告知申请人向有关行政机关申请；'可被翻译为：(1)  For those application items that are not within its duties, the relevant department may make a prompt decision of non-acceptance and inform the applicant to resubmit the application to the applicable administrative agency;\n'（二）申请事项依法不属于药品监督管理部门职权范围的，应当作出不予受理的决定，出具不予受理通知书，并告知申请人向有关行政机关申请；'可被翻译为：(2) If the application items are not within the scope of authority of drug regulatory department in accordance with the law, the relevant department shall make a decision of non-acceptance, issue a notification of non-acceptance, and inform the applicant to resubmit the application to the applicable administrative authority；\n\n根据上述已知信息，请将'（四）申请事项不属于本行政机关职权范围的，应当即时作出不予受理的决定，并告知申请人向有关行政部门申请。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(4) If the subject matter of the application does not fall within the scope of this administrative authority, a decision of not accepting the application shall be made immediately, and the applicant shall be notified of applying to relevant administrative authority."
    },
    {
        "instruction":"已知信息：\n'第八条 设区的市级、县级药品监督管理部门负责本行政区域内药品不良反应报告和监测的管理工作；与同级卫生行政部门联合组织开展本行政区域内发生的药品群体不良事件的调查，并采取必要控制措施；组织开展本行政区域内药品不良反应报告和监测的宣传、培训工作。'可被翻译为：Article 8 Drug regulatory departments of municipalities with districts and of counties are responsible for management of ADR reporting and monitoring within their respective administrative regions; organize and carry out investigation on ADE clusters occurred within their administrative regions and take necessary control measures in conjunction with the health administrative departments at the same level; and organize and carry out publicity and training on ADR reporting and monitoring within their administrative regions.\n'（一）承担本行政区域内药品不良反应报告和监测资料的收集、评价、反馈和上报，以及药品不良反应监测信息网络的维护和管理；'可被翻译为：(I) Undertake the collection, evaluation, feedback and reporting of ADR reporting and monitoring data, and maintain and manage the information network for ADR monitoring within their respective administrative regions;\n'（三）组织开展本行政区域内严重药品不良反应的调查和评价，协助有关部门开展药品群体不良事件的调查；'可被翻译为：(III) Organize and carry out investigation and evaluation on serious ADRs within their respective administrative regions and assist relevant departments in investigating ADE clusters;\n'（四）组织开展本行政区域内药品不良反应报告和监测的宣传、培训工作。'可被翻译为：(IV) Organize and carry out publicity and training on ADR reporting and monitoring within their respective administrative regions.\n\n根据上述已知信息，请将'第十二条 设区的市级、县级药品不良反应监测机构负责本行政区域内药品不良反应报告和监测资料的收集、核实、评价、反馈和上报；开展本行政区域内严重药品不良反应的调查和评价；协助有关部门开展药品群体不良事件的调查；承担药品不良反应报告和监测的宣传、培训等工作。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 12 The ADR monitoring institutions of municipalities with districts and of counties are responsible for the collection, verification, evaluation, feedback, and reporting of ADR reporting and monitoring data within their respective administrative regions; conduct investigation and evaluation on serious ADRs within their respective administrative regions; assist relevant departments in investigating ADE clusters; and carry out publicity and training on ADR reporting and monitoring."
    },
    {
        "instruction":"已知信息：\n'种物质按照规定的方法测定，由固相融化成液相时的温度。是物质的-项物理常数。'可被翻译为：The temperature at which a substance melts from a solid phase into a liquid phase, as determined by a prescribed method. Is the physical constant of a substance.\n'相溶解度分析'可被翻译为：phase solubility analysis\n'一种用于测定生理、病理、解剖参数，或者定量测定进出人体的能量或物质的医疗器械，其测量结果需要精确定量，并且该结果的准确性会对患者的健康和安全产生明显影响。'可被翻译为：A medical device intended to measure the physiological, pathological and anatomic parameters or make quantitative determination on the energies\/substances entering or leaving the human body. The measuring results shall be accurately quantified, and the accuracy of such results may have obvious effects on patient's health and safety.\n'利用已吸附在固相表面的抗原和标记有某种酶的抗体进行结合，然后利用酶与底物的反应测定抗原-抗体复合物的方法。'可被翻译为：The antigen that has been adsorbed on the surface of the solid phase is combined with an antibody labeled with a certain enzyme, and then the reaction of the enzyme with the substrate is used to determine the antigen-antibody complex method.\n\n根据上述已知信息，请将'利用相溶解度来精确测量测定物质纯度的方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A method of using phase solubility to accurately measure the purity of a substance."
    },
    {
        "instruction":"已知信息：\n'（一）拖延、限制、拒绝检查人员进入被检查场所或者区域的，或者限制检查时间的；'可被翻译为：(i) Delaying, restricting and refusing the entering of the inspectors into the sites or areas being inspected, or limiting the inspection time and duration;\n'（四）干扰、拖延检查或者拒绝立案查处的；'可被翻译为：(iv) Intervening, delaying the inspection, or refuse to file a case for investigation and sanctions;\n'（四）参与国家药品监督管理局组织的药品注册核查、检验等工作；'可被翻译为：(4) Participating in drug registration inspection, testing and other tasks organized by the NMPA;\n'省、自治区、直辖市药品监督管理部门负责组织本行政区域生产或者进口的批签发产品的抽样工作，按照国家药品监督管理局药品抽样规定制定抽样管理程序，确定相对固定的抽样机构和人员并在批签发机构备案，定期对抽样机构和人员进行培训，对抽样工作进行督查指导。'可被翻译为：The drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government shall be responsible for organizing the sampling of products subject to lot release for production or importation within their respective administrative regions, formulating sampling management procedures in accordance with the drug sampling regulations of the NMPA, determining relatively fixed sampling institutions and personnel to file at the lot release institutions, training the sampling institutions and personnel and conducting supervision and guidance for sampling work.\n\n根据上述已知信息，请将'（四）拒绝或者限制拍摄、复印、抽样等取证工作的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(iv) Refusing or restricting the evidence collection activities, such as photos\/videos taking, documents copying, sampling, etc;"
    },
    {
        "instruction":"已知信息：\n'当真空阶段是循环的一部分，或系统在灭菌后返回到低于灭菌柜环境的压力时，灭菌柜应定期（通常为每周）进行泄漏测试。'可被翻译为：Leak tests on the steriliser should be carried out periodically (normally weekly) when a vacuum phase is part\nof the cycle or the system is returned, post-sterilisation, to a pressure lower than the environment surrounding the\nsteriliser.\n'用真空系统将容器或系统中的残余气体抽到海平面0.84巴的绝对真空水平。'可被翻译为：To remove residual gas from a container or system to a vacuum level of 0.84 bar absolute at sea level using a vacuum system.\n'气体和真空系统'可被翻译为：Gases and vacuum systems\n'1.这是一个不会对产品质量产生任何直接或间接影响的系统。这些系统仅根据GEP进行设计和调试。\n2.一个不会对产品质量产生任何直接或间接影响的系统。这些系统仅根据良好的工程实践进行设计和调试。'可被翻译为：1.This is a system that will not have any impact, either directly or indirectly, on product quality. These systems are designed and commissioned according to GEP only.\n2.A system that will not have any impact, either directly or indirectly, on product quality. These systems are designed and commissioned according to good engineering practice only.\n\n根据上述已知信息，请将'如果真空或压力系统的回流会对产品造成潜在风险，应采取措施阻止真空系统或压力系统关闭时产生的回流。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where backflow from vacuum or pressure systems poses a potential risk to the product, there should be mechanism(s) to prevent backflow when the vacuum or pressure system is shut off."
    },
    {
        "instruction":"已知信息：\n'一种由硬件和软件的架构、机制和算法组成的系统，可自动对工艺进行调整使工艺输出维持在预期范围内。例如前馈控制和反馈工艺控制。'可被翻译为：A system consisting of hardware and software architecture, mechanisms, and algorithms that automatically adjust a process to maintain the process output within a desired range. Examples include feedforward and feedback process controls.\n'SU与RU之间工艺能力差异的知识，包括其影响和风险，以及克服这些差异的控制策 略；'可被翻译为：Knowledge of the differences in process ability between the SU and RU, including the impact, risk and control strategies to overcome any differences;\n'对经过验证的工艺、组分、系统或分析测定方法的可能影响最终结果的变更，再次进行的验证。'可被翻译为：Revalidation of a validated process, component, system, or analytical determination method for changes that may affect the final result.\n'工艺承受物料的波动及工艺与设备改变，而不造成负面质量影响的能力。'可被翻译为：Ability of a process to tolerate variability of materials and changes of the process and equipment without negative impact on quality.\n\n根据上述已知信息，请将'一种确定工艺的影响因素与工艺输出之间相互关系 的、系统的、有序的方法，也称为“实验设计”。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A structured, organized method for determining the relationship between factors affecting a process and the output of that process. Also known as “Design of Experiments”."
    },
    {
        "instruction":"已知信息：\n'口岸药品检验机构应当将进口药材检验报告书报送口岸药品监督管理部门，并告知进口单位。'可被翻译为：Drug control institutions of ports shall submit the testing reports of importation of crude drugs to the drug regulatory departments of ports, and notify the importers.\n'允许药品进口的口岸或者允许药材进口的边境口岸所在地负责药品监督管理的部门（以下简称口岸药品监督管理部门）负责进口药材的备案，组织口岸检验并进行监督管理。'可被翻译为：Drug regulatory department where the ports allowing drug importation or where the border ports allowing the crude drugs importation are located (hereinafter referred to as drug regulatory department of ports) shall be responsible for the filing of crude drugs importation, organize the port testing and supervision and administration.\n'四是加强事中事后监管，强化溯源管理。针对监管实践中存在的问题，进一步明确进 口药材须经口岸检验合格后，方可上市销售 使用的要求；采购进口药材时，须向供货方 索要相关证明资料，严格执行药品追溯管理 的有关规定。同时，要求药材进口申请受 理、审批结果、有关违法违规的情形及其处罚结果应当在国家药品监督管理部门网站公开'可被翻译为：IV.Reinforce concurrent and ex post regulation and traceability management. In view of the problems existing in the supervision practice, it is further clarified that and the imported medicinal materials shall not be marketed for sale and use unless they pass the port inspection; and the purchase of imported medicinal materials supplier's relevant certification dossiers, as well as the strict compliance with the related provisions on drug traceability management. At the same time, it is stipulated that for the import of medicinal materials, the application&acceptance, the results of review and approval, the circumstances of violations of laws and regulations and the resulting penalties shall be disclosed on the websites of must be accompanied with the request of the national drug administration departments.\n'第二条 进口药材申请、审批、备案、口岸检验以及监督管理，适用本办法。'可被翻译为：Article 2 The Provisions are applicable to the application, approval, filing, port testing as well as supervision and administration of crude drugs importation.\n\n根据上述已知信息，请将'经口岸检验合格的进口药材方可销售使用。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The imported crude drugs can be sold and used only after passing the port testing."
    },
    {
        "instruction":"已知信息：\n'（六）更新疫苗说明书、标签按照规定应当经核准而未经核准。'可被翻译为：(6) implementing updates of vaccine package inserts and labels without approval which shall have been approved as required.\n'第二十七条 药品说明书和标签中禁止使用未经注册的商标以及其他未经国家食品药品监督管理局批准的药品名称。'可被翻译为：Article 27    Unregistered trademarks and other drug names unapproved by the State Food and Drug Administration shall not be used in the drug insert sheets and labels.\n'第三条 药品说明书和标签由国家食品药品监督管理局予以核准。'可被翻译为：Article 3    Drug insert sheets and labels shall be reviewed and approved by the State Food and Drug Administration.\n'（六）产品包装、标签及说明书是否与食品药品监管总局核准的内容一致；'可被翻译为：(VI) Whether the product package, label and package inserts are consistent with those approved by the CFDA;\n\n根据上述已知信息，请将'（三）使用未经核准的标签、说明书。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) use labels or packaging insert which have not been reviewed and approved."
    },
    {
        "instruction":"已知信息：\n'对于隔离器，应使用证明适合于任务和关键性的方法对手套系统进行检漏。应定期进行测试。一般来说，手套完整性测试至少应在每个批次或阶段性生产的开始和结束时进行。根据经过验证的阶段性生产长短，可能需要进行额外的手套完整性测试。'可被翻译为：For isolators, leak testing of the glove system should be performed using a methodology demonstrated to be suitable for the task and criticality. The testing should be performed at defined intervals. Generally glove integrity\ntesting should be performed at a minimum frequency of the beginning and end of each batch or campaign.\nAdditional glove integrity testing may be necessary depending on the validated campaign length.\n'操作过程中应定期消毒手套。如果工作服和手套损坏并存在任何产品污染风险，应立即更换。'可被翻译为：Gloves should be regularly disinfected during operations. Garments and gloves should be changed\nimmediately if they become damaged and present any risk of product contamination.\n'隔离器手套的指尖和护袖'可被翻译为：c. Fingertips & sleeves of Isolator gloves\n'应使用适当的杀孢子剂\/消毒剂对手套消毒。'可被翻译为：An appropriate sporicidal\/disinfectant is used to sanitize the gloves.\n\n根据上述已知信息，请将'应证明手套系统（用于隔离器和 RABS）的材料具有适当的机械和化学抗性。应在 CCS 中规定更换手套的频率。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The materials used for glove systems (for both isolators and RABS), should be demonstrated to have appropriate mechanical and chemical resistance. The frequency of glove replacement should be defined within the CCS."
    },
    {
        "instruction":"已知信息：\n'技术审评机构应当自收到复核申请之日起30个工作日内作出复核结论。'可被翻译为：The technical assessment agency shall make a re-evaluation conclusion within 30 working days from the date of receiving the re-evaluation application.\n'（三）需要申请人补充资料的，应当一次告知需要补充的全部内容；申请人应当在90个工作日内按照要求一次提供补充资料，技术审评机构收到补充资料后审评时限重新计算；未在规定时限内补充资料的，技术审评机构应当作出技术审评不通过的审评结论。'可被翻译为：(3) Where supplementary documents are required from the applicant, the applicant shall be notified once of all the contents to be supplemented; the applicant shall provide supplementary documents at one time as required within 90 working days, and the evaluation time limit shall be recalculated after the technical assessment agency receives the supplementary documents; if the supplementary documents are not submitted within the specified timeline, the technical assessment agency shall make an evaluation conclusion of disapproval.\n'第三十五条 技术审评过程中需要申请人补正资料的，技术审评机构应当一次告知需要补正的全部内容。申请人应当在１年内按照补正通知的要求一次提供补充资料；技术审评机构应当自收到补充资料之日起60个工作日内完成技术审评。申请人补充资料的时间不计算在审评时限内。'可被翻译为：Article 35 Where supplementary and correction materials are required during technical evaluation, the technical evaluation institution shall inform the applicant one-off of all the supplements to be completed. The applicant shall submit all necessary supplementary and correction materials one-off within one year according to the supplementation notice. The technical evaluation institution shall complete the technical evaluation within 60 workdays from the date of acceptance of the supplements. The time spent by applicant for supplementing such materials shall not be calculated in the overall evaluation time.\n'第四十五条 技术审评过程中需要申请人补正资料的，技术审评机构应当一次告知需要补正的全部内容。申请人应当在１年内按照补正通知的要求一次提供补充资料；技术审评机构应当自收到补充资料之日起60个工作日内完成技术审评。申请人补充资料的时间不计算在审评时限内。'可被翻译为：Article 45 Where supplementary and correction materials are required during technical evaluation, the technical evaluation institution shall inform the applicant one-off of all the supplements to be completed. The applicant shall submit all necessary supplementary and correction materials one-off within one year according to the supplementation notice. The technical evaluation institution shall complete the technical evaluation within 60 workdays from the date of acceptance of the supplements. The time spent by applicant for supplementing such materials shall not be calculated in the overall evaluation time.\n\n根据上述已知信息，请将'第十五条 技术审评结论为审评不通过的，技术审评机构应当告知申请人并说明理由。申请人有异议的，可以自收到技术审评结论之日起20个工作日内申请复核。复核的内容仅限于原申请事项以及申请资料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 15 If the evaluation conclusion is disapproval, the technical assessment agency shall notify the applicant and explain the reasons. If disagreements exist, the applicant may apply for re-evaluation within 20 working days from the date of receiving the evaluation conclusion. The content of the re-evaluation is limited to the original application items and application dossiers."
    },
    {
        "instruction":"已知信息：\n'2018年药品不良反应\/事件报告中，男女患者比为0.86:1，女性略多于男性。14岁以下儿童患者的报告占9.8%；65岁以上老年患者的报告占27.7%（图5）。'可被翻译为：In the 2018 ADR\/ADE reports, the ratio of male to female patients was 0.86:1, with men slightly outnumbered by women.Reports of pediatric patients under 14 years of age accounted for 9.8%; reports of elderly patients over the age of 65 accounted for27.7% (Figure 5).\n'药品不良反应\/事件报告涉及患者情况'可被翻译为：Patients involved in the ADR\/ADE reports\n'7.药品不良反应\/事件报告涉及患者情况'可被翻译为：7. Patients involved in the ADR\/ ADE reports\n'2019年全国药品不良反应监测网络收到严重药品不良反应\/事件报告15.6万份，严重药品不良反应\/事件报告占同期报告总数的10.3%（图2）。'可被翻译为：In 2019, the National ADR Monitoring Network received 156,000 reports of reports serious adverse drug reactions\/incidents, and serious ADR\/ADE reports accounted for 10.3 percent of the total reports for the same period (Figure 2).\n\n根据上述已知信息，请将'2019年药品不良反应\/事件报告中，男女患者比为0.86:1，女性略多于男性。14岁以下儿童患者占10.2%；65岁及以上老年患者占29.1%。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In the 2019 ADR\/ADE reports, the ratio of male to female patients was 0.86:1, with men slightly outnumbered by women. Reports of pediatric patients under 14 years of age accounted for 10.2 percent; and reports of elderly patients over 65 accounted for 29.1 percent."
    },
    {
        "instruction":"已知信息：\n'第十二条 申请人对检验结果有异议的，可以依照药品管理法的规定申请复验。药品检验机构应当在复验申请受理后20日内作出复验结论，并报告省级药品监督管理部门，通知申请人。'可被翻译为：Article 12 In the case of any objection to the testing results, the applicant may apply for re-testing in accordance with the provisions of the Drug Administration Law. Drug control institutions shall, within 20 days upon the acceptance of the application for re-testing, draw a re-testing conclusion, report to provincial drug regulatory department and notify the applicants.\n'（五）对有异议的检验结果进行复验；'可被翻译为：(V)  carrying out a verification test when the testing result is objected; and\n'第二十五条 进口单位对检验结果有异议的，可以依照药品管理法的规定申请复验。药品检验机构应当在复验申请受理后20日内作出复验结论，并报告口岸药品监督管理部门，通知进口单位。'可被翻译为：Article 25 In case of any objection to the testing results, the importer may apply for re-testing in accordance with the Drug Administration Law. Drug control institutions shall, within 20 days upon the acceptance of the application for re-testing, draw an arbitration conclusion, report to drug regulatory departments of ports and notify the importers.\n'第十六条 批签发机构收到申请资料及样品后，应当立即核对，交接双方登记签字确认后，妥善保存。批签发申请人无法现场签字确认的，应当提前递交书面承诺。'可被翻译为：Article 16 After receiving the application dossiers and samples, the lot release institution shall immediately verify and properly preserve the same after registration and signature confirmation by the two parties. If the lot release applicant cannot sign for confirmation on the spot, it shall submit a written commitment in advance.\n\n根据上述已知信息，请将'（四）批签发申请人书面承诺放弃复验的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(IV) The lot release applicant makes a written commitment to give up the re-test."
    },
    {
        "instruction":"已知信息：\n'堆积粉体的总体积中，粉体的空隙体积所占的比例。'可被翻译为：The proportion of the void volume of the powder in the total volume of the packed powder.\n'粉体质量除以粉体的粒容积（颗粒体积和颗粒内空隙）所求得的密度。'可被翻译为：The density obtained by dividing the mass of the powder by the particle volume (particle volume and void space within the particles) of the powder.\n'粉体质量除以粉体堆容积（包括颗粒体积和所有空隙）所求得的密度。'可被翻译为：The density obtained by dividing the mass of the powder by the pile volume of the powder (including the particle volume and all voids).\n'粉体质量除以粉体真体积（不包括颗粒内和颗粒间的空隙）所求得的密度。'可被翻译为：The density obtained by dividing the mass of the powder by the true volume of the powder (excluding the Spaces within and between particles).\n\n根据上述已知信息，请将'单位体积粉体的质量。单位多为g\/ml。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The mass of the powder per unit volume. Units are mostly in g\/ml."
    },
    {
        "instruction":"已知信息：\n'第二十条  有下列情形之一的，由原发证部门依法注销医疗器械经营许可证，并予以公告：'可被翻译为：Article 20 In one of the following circumstances, the former license issuing department shall cancel the Medical Device Distribution License according to law, and make announcements:\n'第二十一条  有下列情形之一的，由原发证部门依法注销医疗器械生产许可证，并予以公告：'可被翻译为：Article 21 In one of the following circumstances, the former license issuing department shall cancel the Medical Device Manufacturing License according to law, and make an announcement:\n'第一百一十条 具有下列情形之一的，由国家药品监督管理局注销药品注册证书，并予以公布：'可被翻译为：Article 110 In any of the following circumstances, the NMPA shall revoke the Drug Approval License, and disclose the information:\n'第二十三条 化妆品生产企业有下列情形之一的，原发证的药品监督管理部门应当依法注销其化妆品生产许可证，并在政府网站上予以公布：'可被翻译为：Article 23 In one of the following circumstances with the manufacturer of cosmetics, the drug regulatory department issued former license shall cancel the Cosmetics Manufacturing License according to law, and publish on the government website:\n\n根据上述已知信息，请将'第二十条 有下列情形之一的，药品生产许可证由原发证机关注销，并予以公告：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 20 In any of the following circumstances, the original issuing authority shall revoke the Drug Manufacturing Certificate and make an announcement:"
    },
    {
        "instruction":"已知信息：\n'如果医疗器械只有其通道标示为无菌和无热源，则器械通道必须与萃取液体接触，按 USP<161>执行完整的萃取程序。'可被翻译为：If only the device pathways are labeled as sterile and nonpyrogenic, the device pathways must come in contact with the extraction fluid for the entire course of the extraction per USP<161>.\n'控制系统的目的是确保无菌测试中使用的所有材料、培养基、淋洗液和设备的无菌性在 指定限度内。'可被翻译为：The objective of a control system is to ensure the sterility, within designated limits, of all items, media, rinsing fluids, and equipment used in a sterility test.\n'有无菌液体通道的器械'可被翻译为：Devices with sterile Fluid Pathway\n'过滤样品液体，在无菌条件下将滤膜对半剪开，将2半分别转移至一份适 用培养基中。如果是采用封闭式碳罐系统进行无菌测试，则使用接种后的 淋洗液淋洗各碳罐。'可被翻译为：Filter the rinse fluid and aseptically cut the filter membrane into two equal parts, transfer one half into each of two suitable media. If conducting the sterility test using a closed canister system, rinse each canister with the inoculated rinse fluid.\n\n根据上述已知信息，请将'所有仅通道标示为无菌的设备均应采用无菌液体D测试该通道，无菌液体D采用膜过 滤法测试。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"All devices with only the pathways labeled as sterile are to be tested by the pathway with sterile Fluid D and testing the Fluid D via membrane filtration."
    },
    {
        "instruction":"已知信息：\n'将抗体产生细胞与具有无限增殖能力的骨髓瘤细胞相融合，通过有限稀释法及克隆化使杂交瘤细胞成为纯一的单克隆细胞系而产生的抗体。由于这种抗体只针对一个抗原决定簇，又是单一的B细胞克隆产生的，故名。是结构和特异性完全相同的高纯度抗体。'可被翻译为：An antibody produced by fusing antibody-producing cells with myeloma cells with infinite proliferation capacity to make hybridoma cells into a single monoclonal cell line by limited dilution and cloning. This antibody is named because it targets only one antigenic determinant and is cloned from a single B cell. It is a high purity antibody with the exact same structure and specificity.\n'在规定培养条件下扩增MCB获得匀质的细胞悬液，并经分装成多个等份制备而成。'可被翻译为：The WCB is prepared from aliquots of a homogeneous suspension of cells obtained from culturing the MCB under defined culture conditions.\n'生产用细胞'可被翻译为：production cells\n'在指定条件下从选定的细胞克隆制备而得的单批细胞，它被分装到多个容器中，并在规定的条件下贮藏。MCB通常用于制备所有的工作细胞库。新旧MCB(源自同一前代细胞克隆)的检测项目应该一致。'可被翻译为：An aliquot of a single pool of cells which generally has been prepared from the selected cell clone under defined conditions, dispensed into multiple containers and stored under defined conditions. The MCB is used to derive all working cell banks. The testing performed on a new MCB (from a previous initial cell clone, MCB or WCB) should be the same as for the MCB unless justified.\n\n根据上述已知信息，请将'在制备单克隆抗体过程中，用骨髓瘤细胞和效应B细胞融合而成的细胞。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A cell formed by the fusion of myeloma cells and effector B cells in the process of making a monoclonal antibody."
    },
    {
        "instruction":"已知信息：\n'第七十三条  医疗器械生产的违法行为，医疗器械监督管理条例等法律法规已有规定的，依照其规定。'可被翻译为：Article 73 For illegal acts in manufacturing of medical devices, if there have been provisions prescribed in the Regulations on Supervision and Administration of Medical Devices and other laws and regulations, such provisions shall prevail.\n'第六十五条  医疗器械经营的违法行为，医疗器械监督管理条例等法律法规已有规定的，依照其规定。'可被翻译为：Article 65 For illegal acts in medical device distribution, there have been provisions prescribed in the Regulations on Supervision and Administration of Medical Devices and other laws and regulations, and such provisions shall prevail.\n'化妆品、化妆品新原料注册人未按照本办法的规定重新注册的，依照化妆品监督管理条例第五十九条的规定给予处罚；化妆品、化妆品新原料备案人未按照本办法的规定重新备案的，依照化妆品监督管理条例第六十一条第一款的规定给予处罚。'可被翻译为：If the registrant of cosmetics and new cosmetic ingredients fails to re-register in accordance with requirements of these Provisions, it shall be punished in accordance with Article 59 of the Regulations on Supervision and Administration of Cosmetics; if the filing person of cosmetics or new cosmetic ingredients fails to re-file the filing in accordance with requirements of these Provisions, fines shall be imposed as in the first paragraph of Article 61 of the Regulations on Supervision and Administration of Cosmetics.\n'为规范儿童化妆品生产经营活动，加强儿童化妆品监督管理，保障儿童使用化妆品安全，依据《化妆品监督管理条例》等法律法规，国家药监局组织制定了《儿童化妆品监督管理规定》（以下简称《规定》），于2021年10月8日予以公布，并就《规定》实施有关事宜公告如下：'可被翻译为：In order to regulate the production and distribution activities of children’s cosmetics, strengthen the supervision and administration of children's cosmetics and ensure the safety of children in the use of cosmetics, according to the Regulations for the Supervision and Administration of Cosmetics and other laws and regulations, the National Medical Products Administration has organized to formulate the Provisions for the Supervision and Administration of Children's Cosmetics(hereinafter referred to as the Provisions),which was issued on October 8. The issues related to the implementation of the Provisions are hereby announced as follows:\n\n根据上述已知信息，请将'第五十七条 化妆品生产经营的违法行为，化妆品监督管理条例等法律法规已有规定的，依照其规定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 57 For illegal acts in manufacturing and marketing of cosmetics, if there have been provisions prescribed in the Regulations on Supervision and Administration of Cosmetics and other laws and regulations, such provisions shall prevail."
    },
    {
        "instruction":"已知信息：\n'第一百四十一条 通过计算机系统记录数据时，相关岗位人员应当按照操作规程，通过授权及密码登录计算机系统，进行数据的录入，保证数据原始、真实、准确、安全和可追溯。'可被翻译为：Article 141 In case of recording data through the computer system, personnel at relevant posts shall, in accordance with the operating procedure, log into the computer system with authorization and password to enter the data, so as to ensure that the data are original, authentic, accurate, safe and traceable.\n'使用电子数据处理系统的，只有经授权的人员方可输入或更改数据，更改和删除情况应当有记录；应当使用密码或其他方式来控制系统的登录；关键数据输入后，应当由他人独立进行复核。'可被翻译为：If documentation is handled by electronic data processing methods, only authorized persons should be able to enter or modify data in the system and there should be a record of changes and deletions; access should be restricted by passwords or other means and the entry of critical data should be independently checked.\n'第一百六十九条 工艺规程不得任意更改。如需更改，应当按照相关的操作规程修订、审核、批准。'可被翻译为：Article 169: Master manufacturing documents should not be changed without authorization. When revision is needed, they should be revised, reviewed and approved according to relevant operation procedures.\n'第六十条 计算机系统运行中涉及企业经营和管理的数据应当采用安全、可靠的方式储存并按日备份，备份数据应当存放在安全场所，记录类数据的保存时限应当符合本规范第四十二条的要求。'可被翻译为：Article 60 The data concerning enterprise's operation and management in the operation of the computer system shall be saved in a secure and reliable way and backed up on a daily basis. Backup data shall be stored in a secure place. The storage duration of recorded data shall meet the requirements of Article 42 herein.\n\n根据上述已知信息，请将'第四十条 通过计算机系统记录数据时，有关人员应当按照操作规程，通过授权及密码登录后方可进行数据的录入或者复核；数据的更改应当经质量管理部门审核并在其监督下进行，更改过程应当留有记录。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 40 In case of recording data through a computer system, relevant personnel shall, in accordance with the operating procedures, enter or check the data only after they have been authorized and logged in with password. The change of data shall be reviewed by the quality management department and carried out under its supervision, which shall be recorded."
    },
    {
        "instruction":"已知信息：\n'每百万人口平均报告数量是衡量一个国家药品不良反应监测工作水平的重要指标之一。2019年我国每百万人口平均报告数为1，130份。'可被翻译为：The average number of reports per million population constitutes one of the major indicators to measure the level of a country's ADR monitoring work. The average number of reports per million population in China marked 1,130 in 2019.\n'2.每百万人口平均报告数量。2019年，我国每百万人口平均可疑医疗器械不良事件报告数为297份，比上年减少2.62%（图2）。'可被翻译为：2. Average number of reports per million population. In 2019, the average number of suspicious medical device adverse event reports per million population in China was 297, a decrease of 2.62 percent over the previous year(Figure 2).\n'2.每百万人口平均报告数量'可被翻译为：2. Average number of reports per million population In 2018, the average number of suspected medical device adverse events reported per million people in China was 305, an increase of 23 compared with 2017 (Figure 2)\n'每百万人口平均报告情况'可被翻译为：Average case report per million population\n\n根据上述已知信息，请将'每百万人口平均报告数量是衡量一个国家药品不良反应监测工作水平的重要指标之一。2018年我国每百万人口平均报告数为1119份。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"As one of the important indicators to measure the level of national ADR monitoring, the average number of reports per million people in China marked 1,119 in 2018."
    },
    {
        "instruction":"已知信息：\n'第二百四十二条 变更都应当评估其对产品质量的潜在影响。企业可以根据变更的性质、范围、对产品质量潜在影响的程度将变更分类（如主要、次要变更）。判断变更所需的验证、额外的检验以及稳定性考察应当有科学依据。'可被翻译为：Article 242: For all changes, the potential impact on product quality should be evaluated. The manufacturer should classify the changes (e.g. major or minor) depending on their nature and extent, and the effects these changes may impact on product quality. Scientific evidences should be provided to determine what validation activities, additional tests and stability studies are needed.\n'申请疫苗批签发的，还应当提交疫苗的生产工艺偏差、质量差异、生产过程中的故障和事故以及采取措施的记录清单和对疫苗质量影响的评估结论；可能影响疫苗质量的，还应当提交偏差报告，包括偏差描述、处理措施、风险评估结论、已采取或者计划采取的纠正和预防措施等。对可能影响质量的重大偏差，应当提供所在地省、自治区、直辖市药品监督管理部门的审核评估报告。'可被翻译为：When applying for the lot release of vaccines, the applicant shall also submit a list of records of process deviation, quality deviation, failures and accidents during the production as well as the corresponding measures taken, and the evaluation conclusion on the impact on the vaccine quality; in case of the vaccine quality may be affected, a deviation report shall also be submitted, including the deviation description, handling measures, conclusions of risk assessment, corrective and preventive measures taken or planned, etc. For major deviations that may affect the quality, the inspection and evaluation report of local drug regulatory departments of provinces, autonomous regions or municipalities directly under the Central Government shall be provided.\n'第二百三十六条 某些情况下，持续稳定性考察中应当额外增加批次数，如重大变更或生产和包装有重大偏差的药品应当列入稳定性考察。此外，重新加工、返工或回收的批次，也应当考虑列入考察，除非已经过验证和稳定性考察。'可被翻译为：Article 236: In certain situations, additional batches should be included in the on-going stability program. For example, an on-going stability study should be conducted after any significant change or significant deviation to the process or package. Besides, any reworking, reprocessing or recovery batches should be also considered included in the program, unless the validation and stability studies have been passed.\n'第二百五十一条 质量管理部门应当负责偏差的分类，保存偏差调查、处理的文件和记录。'可被翻译为：Article 251: The quality management department should be responsible for classifying deviations, and for the retention of all documents and records related to investigation and handling of deviations.\n\n根据上述已知信息，请将'第二百四十九条 任何偏差都应当评估其对产品质量的潜在影响。企业可以根据偏差的性质、范围、对产品质量潜在影响的程度将偏差分类（如重大、次要偏差），对重大偏差的评估还应当考虑是否需要对产品进行额外的检验以及对产品有效期的影响，必要时，应当对涉及重大偏差的产品进行稳定性考察。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 249: The potential impact of any deviation on product quality should be assessed. The manufacturer may classify the deviations (e.g. as minor or major) depending on the nature and scope of the deviations and extent of the potential impact on product quality. Additional tests and impact on the shelf life should be considered for the assessment of major deviations, and if necessary, stability studies should also be carried out for products involved in major deviations."
    },
    {
        "instruction":"已知信息：\n'国家药品监督管理局食品药品审核查验中心（以下简称核查中心）组织制定药品检查技术规范和文件，承担境外检查以及组织疫苗巡查等，分析评估检查发现风险、作出检查结论并提出处置建议，负责各省、自治区、直辖市药品检查机构质量管理体系的指导和评估。'可被翻译为：The Center for Food and Drug Inspection (CFDI) of NMPA shall organize the formulation of drug inspection technical standards and documents, undertake overseas inspection and organize vaccine inspection, analyze and assess risks found in inspection, make inspection conclusions and propose handling suggestions, and guide and assess the quality management systems of drug inspection agencies of provinces, autonomous regions and municipalities directly under the Central Government.\n'国家药品监督管理局食品药品审核查验中心（以下简称核查中心）承担批签发过程中的境外现场检查等工作。'可被翻译为：Center for Food and Drug Inspection of NMPA (hereinafter referred to as CFDI) shall be responsible for overseas on-site inspection during lot release.\n'第四十九条  省、自治区、直辖市药品监督管理部门应当制定年度医疗器械生产监督检查计划，确定医疗器械监督管理的重点，明确检查频次和覆盖范围，综合运用监督检查、重点检查、跟踪检查、有因检查和专项检查等多种形式强化监督管理。'可被翻译为：Article 49 The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall formulate annual supervision and inspection plan for manufacturing of medical devices, determine the key points of supervision and administration of medical devices, specify the inspection frequency and coverage, and make comprehensive use of multiple means such as supervision and inspection, key inspection, follow-up inspection, for-cause inspection and special inspection, etc. to strengthen supervision and administration.\n'第六十二条  进口医疗器械的生产应当符合我国医疗器械生产相关要求，并接受国家药品监督管理局组织的境外检查。代理人负责协调、配合境外检查相关工作。'可被翻译为：Article 62 Manufacturing of imported medical devices shall conform to relevant requirements for manufacturing of medical devices in China, and accept overseas inspection organized by NMPA. The agent shall be responsible for work related to coordinating and cooperating with overseas inspection.\n\n根据上述已知信息，请将'国家药品监督管理局食品药品审核查验中心组织拟订医疗器械检查制度规范和技术文件，承担重大有因检查和境外检查等工作，并对省、自治区、直辖市医疗器械检查机构质量管理体系进行指导和评估。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The Center for Food and Drug Inspection of NMPA shall organize and draft medical device inspection system specification and technical documents, assume significant for-cause inspection and overseas inspection, etc., and conduct instruction and evaluation of the quality management system of medical device inspection institutions of the province, autonomous region, or municipality directly under the central government."
    },
    {
        "instruction":"已知信息：\n'（一）申请人对拟上市销售医疗器械的安全性、有效性进行的研究及其结果无法证明产品安全、有效的；'可被翻译为：(I) The research conducted by the applicant and its result cannot prove the safety and effectiveness of the medical device to be sold on the market.\n'第四条 体外诊断试剂注册是食品药品监督管理部门根据注册申请人的申请，依照法定程序，对其拟上市体外诊断试剂的安全性、有效性研究及其结果进行系统评价，以决定是否同意其申请的过程。'可被翻译为：Article 4 In-vitro diagnostic reagent registration refers to the prescribed procedures conducted by the food and drug regulatory department upon an application submitted by the registration applicant to decide whether the medical device to be marketed can be sold based on a comprehensive evaluation of the research and results of its safety and effectiveness.\n'体外诊断试剂临床试验（包括与已上市产品进行的比较研究试验）是指在相应的临床环境中，对体外诊断试剂的临床性能进行的系统性研究。'可被翻译为：The clinical trial of in-vitro diagnostic reagents (including the comparative study made with the marketed products) refers to the systematic study on the clinical performance of in-vitro diagnostic reagents in the corresponding clinical environment.\n'第三条 医疗器械注册是食品药品监督管理部门根据医疗器械注册申请人的申请，依照法定程序，对其拟上市医疗器械的安全性、有效性研究及其结果进行系统评价，以决定是否同意其申请的过程。'可被翻译为：Article 3 Medical device registration refers to the prescribed procedures conducted by the food and drug regulatory department upon an application submitted by the registration applicant to decide whether the medical device to be marketed can be sold based on a comprehensive evaluation of the research and results of its safety and effectiveness.\n\n根据上述已知信息，请将'（一）申请人对拟上市销售体外诊断试剂的安全性、有效性进行的研究及其结果无法证明产品安全、有效的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(I) The research conducted by the applicant and its result cannot prove the safety and effectiveness of the in-vitro diagnostic reagent to be sold on the market."
    },
    {
        "instruction":"已知信息：\n'对于无菌工艺，应在 A 级条件下添加组件，并使用预灭菌的组件以确保关键表面的无菌性。'可被翻译为：For aseptic processes, the addition of components should be performed under grade A conditions, to ensure the sterility of critical surfaces, using pre-sterilised components.\n'所有与产品和组件接触的设备应在使用前进行灭菌。'可被翻译为：All product and component contact equipment should be sterilised prior to use.\n'确保无菌工艺中密闭系统的所有产品接触表面的无菌性至关重要。无菌工艺中任何密闭系统的设计和选择 都应确保维持无菌性。最终除菌级过滤器之后，无菌设备（例如管道\/管道系统）与已灭菌产品通路的连接应设计成无菌连接（例如通过内在无菌连接装置）。'可被翻译为：It  is  critical  to  ensure  the  sterility  of  all  product  contact  surfaces  of closed  systems  used  for  aseptic processing. The design and selection of any closed system used for aseptic processing should ensure maintenance of sterility. Connection of sterile equipment (e.g. tubing\/pipework) to the sterilised product pathway after the final sterilising grade filter should be designed to be connected aseptically (e.g. by intrinsic sterile connection devices).\n'对于无菌工艺，直接和间接接触产品的部件应进行灭菌。直接接触产品的部件是指产品通过的部件，例如灌装针或泵。间接接触产品的部件是不接触产品的设备部件，但可能与其它灭菌表面接触，其无菌性对整个产品的无菌性至关重要（例如胶塞桶和导槽等已灭菌物品，以及已灭菌组件）。'可被翻译为：For aseptic processes, direct and indirect product contact parts should be sterilised. Direct product contact parts are those that the product passes through, such as filling needles or pumps. Indirect product contact parts are equipment parts that do not contact the product, but may come into contact with other sterilised surfaces, the\nsterility of which is critical to the overall product sterility (e.g. sterilised items such as stopper bowls and guides, and sterilised components).\n\n根据上述已知信息，请将'应在工艺条件下评估产品与产品接触表面的吸附性和反应性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The  adsorption  and reactivity  of the product with product  contact  surfaces  should be  evaluated under process conditions."
    },
    {
        "instruction":"已知信息：\n'蒙脱土'可被翻译为：montmorillonite clay\n'具有两种价态的离子。如铁离子和锦离子就是双价离子，其中低价态是还原态，高价态是氧化态。'可被翻译为：An ion with two valence states. For example, iron and brocade ions are bivalent ions, where the low state is the reducing state and the high state is the oxidation state.\n'烷基三甲基季铁化合物'可被翻译为：alkyl trimethyl ammonium compound\n'十八烷基硅烷键合硅胶'可被翻译为：octadecylsilane chemically bonded silica\n\n根据上述已知信息，请将'蒙脱土中的无机阳离子被二甲基双十八烷基铁离子取代后的物质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A substance in montmorillonite after inorganic cations have been replaced by dimethyl dioctadecyl iron ions."
    },
    {
        "instruction":"已知信息：\n'如果时间紧急，并且上述问题已得到解决，则可在进行产品无菌测试时同步进行方法适用性测试。但是应注意的如果方法适用性试验与产品无菌检测同时进行，方法适用性试验失败，则产品检测结果是无效的，需要适当修改方法，中和抑菌性，再重复进行适用性试验和产品检测。'可被翻译为：Run the method suitability test concurrently with product sterility tests when time is critical, and problems associated with 1. above have been resolved. However, it should be noted that if the Method Suitability Test is run concurrently with the product sterility test and the Method Suitability Test should fail, the results of the product test are invalid and the Method Suitability Test as well as the product test will need to be repeated with proper method modification to neutralize the inhibiting property.\n'在抑菌效力试验之前，使用产品测试的微生物进行适用性试验（D部分），确定培养基是否存 在任何的抑菌特性。如果适用性测试失败，则适用性测试的结果是无效的，应对方法进行适当 修改以中和抑菌特性，再重复适用性测试。'可被翻译为：Prior to the Antimicrobial Effectiveness testing, determine if any antimicrobial properties exist by performing a Suitability testing utilizing microorganisms used for product testing (section D). Should the Suitability Test fail the results of Suitability test are invalid and will need to be repeated with proper method modification to neutralize the inhibiting property.\n'方法适用性试验—无菌性验证；准备测试（BET）。中和剂、产品稀释、过滤的适当性；在缓冲液制备用水含有毒化学污染物，不遵守方法（在检测中在肉汤中加入过量产品，但在方法适用性测试中则没有，等）'可被翻译为：2. Method suitability testing- validation for sterility; preparatory testing (BET). \nAppropriateness of neutralizers, product dilution, filtration; presence of toxic chemical contaminants in the water used to prepare the buffers. Not following method (excess of product added to broth during test but not during suitability testing, etc.)\n'如果采集的产品数量不足，但分析至关重要，则可以在14天培养其结束时进行 适用性试验。在开始进行产品无菌检测时，务必使用最佳判断和最大中和方法。 如果适用性试验结果显示有抑制作用，且结果为阴性，则检测结果无效。但如 果产品检出微生物，且适用性试验显示有抑制作用，则结果仍有效。'可被翻译为：If an insufficient amount of product is collected and the analysis is critical, the suitability test can be conducted at the end of the 14-day incubation period. Be sure to use best judgment and maximum neutralization approach when initially conducting the product sterility test. If the suitability results indicate inhibition then the results, if negative, are invalid. However, if the product test results indicate microbial presence and the suitability test shows inhibition, the results are still valid.\n\n根据上述已知信息，请将'适用性表明所测试的产品在测试条件下对微生物生长没有抑制作用。尽管期望在进行产品分析 前进行适用性试验，但同时进行产品测试和适用性试验也是可以接受的。但应注意的是，如果 同时进行适用性试验和产品测试，适用性试验失败，则产品检测结果是无效的，应对方法进行 适当修改，中和抑菌性，然后再重复进行适用性试验和产品检测方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Suitability demonstrates that the products tested do not exhibit inhibitory effects on the growth of microorganisms under the conditions of the tests. Although the intent is to perform the suitability test before performing the analysis of the product, it is acceptable to run the product test and the suitability test concurrently. However, it should be noted that if the suitability test is run concurrently with the product test and the suitability test should fail, the results of the product test are invalid and the suitability test as well as the product test will need to be repeated with proper method modification to neutralize the inhibiting property."
    },
    {
        "instruction":"已知信息：\n'第二条 在中华人民共和国境内销售、使用的医疗器械，其唯一标识系统应当符合本规则。'可被翻译为：Article 2  For medical devices sold and used within the territory of the People's Republic of China, their UDI system shall comply with the requirements of the Rules.\n'第八条 医疗器械的产品名称应当使用通用名称，通用名称应当符合国家食品药品监督管理总局制定的医疗器械命名规则。第二类、第三类医疗器械的产品名称应当与医疗器械注册证中的产品名称一致。'可被翻译为：Article 8 Product names of medical devices shall adopt general names, which shall meet the rules of nomenclature of medical devices formulated by China Food and Drug Administration. Product names of class II and class III medical devices shall be consistent with the product names in the corresponding medical device registration certificates.\n'医疗器械通用名称命名规则'可被翻译为：Rules for Medical Device Nomenclature\n'第二条 凡在中华人民共和国境内销售、使用的医疗器械，应当按照本规定要求附有说明书和标签。'可被翻译为：Article 2 All medical devices sold or used within the territory of the People's Republic of China shall be accompanied by the instructions and labels in accordance with the requirements of the Provisions.\n\n根据上述已知信息，请将'第二条 凡在中华人民共和国境内销售、使用的医疗器械应当使用通用名称，通用名称的命名应当符合本规则。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 2 All medical devices that are sold and used within the territory of the People's Republic of China shall use generic names and their naming shall conform to the Rules."
    },
    {
        "instruction":"已知信息：\n'1.活性药物成分(api)、药用辅料、包装材料或药品根据药典各论的要求或已批准上市许可的规范进行分析。\n2.一套测试制度，以验证产品是否符合规格。'可被翻译为：1.Analysis of active pharmaceutical ingredients (APIs), pharmaceutical excipients, packaging material or pharmaceutical products according to the requirements of a pharmacopoeial monograph or a specification in an approved marketing authorization.\n2.A regime of testing to verify that a lot complies with the specification.\n'多来源药品'可被翻译为：multisource pharmaceutical product\n'已在中国批准上市药品'可被翻译为：Pharmaceutical Product Approved in China\n'多来源(非专利)药品'可被翻译为：multisource (generic) pharmaceutical product(s)\n\n根据上述已知信息，请将'多来源药品批准和上市许可的体内和\/或体外测试要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In vivo and\/or in vitro testing requirements for approval of a multisource pharmaceutical product and marketing authorization."
    },
    {
        "instruction":"已知信息：\n'第十一条 药品监督管理部门设置或者指定的药品专业技术机构，承担依法实施药品监督管理所需的审评、检验、核查、监测与评价等工作。'可被翻译为：Article 11 The drug professional and technical institutions established or designated by drug regulatory departments shall perform review, testing, inspection, monitoring and assessment as required by the conduct of drug administration in accordance with the law.\n'省、自治区、直辖市药品监督管理部门设置或者指定的药品专业技术机构，承担依法实施药品监督管理所需的审评、检验、核查、监测与评价等工作。'可被翻译为：Specialized technical institutions for drugs set up or designated by drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government shall undertake the review, testing, inspection, monitoring and evaluation and other tasks required for drug supervision and administration in accordance with the law.\n'由国务院主管部门确定的口岸药品检验所对抵达口岸的进口药品依法实施的检验。'可被翻译为：The inspection of the imported drugs at the port of arrival by the port drug inspection office designated by the competent department under The State Council according to law.\n'本办法所称口岸检验，是指国家食品药品监督管理局确定的药品检验机构（以下称口岸药品检验所）对抵达口岸的进口药品依法实施的检验工作。'可被翻译为：Port testing in the Provisions refers to the testing of drugs to be imported upon the arrival at port, conducted by a drug control institute designated by the State Food and Drug Administration (hereinafter referred to as the drug control institute of port) in accordance with laws.\n\n根据上述已知信息，请将'由药品监督管理部门设置或确定，依法实施药品审批和药品质量监督检查所需的药品检验工作的技术部门。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Technical departments set up or designated by drug regulatory departments to carry out drug inspection work required for drug approval and drug quality supervision and inspection according to law."
    },
    {
        "instruction":"已知信息：\n'能够进行可重复的内部生物净化的外壳，其内部工作区域满足A级条件，可将其内部与外部环境(例如，周围洁净室空气和人员)不受损害地连续隔离。隔离器主要有两种类型:\n•□闭式隔离器系统通过与辅助设备的无菌连接来完成物料转移，而不是使用对周围环境的开口，从而排除隔离器内部的外部污染。封闭系统在整个操作过程中保持密封。\n•□开放式隔离系统的设计允许物料在操作期间通过一个或多个开口连续或半连续地进入或流出。开口设计(例如，使用连续超压)以排除外部污染物进入隔离器。'可被翻译为：An enclosure capable of being subject to reproducible interior biodecontamination, with an internal work zone meeting grade A conditions that provide uncompromised continuous isolation of its interior from the external environment (for example, surrounding cleanroom air and personnel). There are two major types of isolators:\n•□Closed isolator systems exclude external contamination of the isolator’s interior by accomplishing material transfer via aseptic connection to auxiliary equipment rather than use of openings to the surrounding environment. Closed systems remain sealed throughout operations.\n•□Open isolator systems are designed to allow for the continuous or semicontinuous ingress or egress of materials during operations through one or more openings. Openings are engineered (for example, using continuous overpressure) to exclude the entry of external contaminant into the isolator.\n'开放隔离器系统的设计允许操作过程中物料通过一个或多个开口连续或半连续进出。开口的设计（如使用连续过压）可以阻断外部污染进入隔离器。'可被翻译为：Open isolator systems are designed to allow for the continuous or semi-continuous ingress and\/or egress of materials  during  operations  through  one  or  more  openings.  Openings  are  engineered  (e.g.  using  continuous overpressure) to exclude the entry of external contaminant into the isolator.\n'密闭系统：产品未暴露于周围环境的系统。例如，对于散装产品的容器（例如罐或袋），可以使用彼此连 接的管道或管子作为一个系统，并且如果用于无菌产品，则在连接完成后对整个系统进行灭菌。密闭系统可以是（但不限于）大规模可重复使用系的统，例如原料药生产中所见到的系统，或一次性软袋和歧管系统，例如生物制品生产中所见到的系统。密闭系统在操作结束前不应被打开。本附录中使用的术语“密闭系统 ”并非指 RABS 或隔离器等系统。'可被翻译为：Closed system - A system in which the product is not exposed to the surrounding environment. For example, this can be achieved by the use of bulk product holders (such as tanks or bags) that are connected to each other by pipes or tubes as a system, and where used for sterile products, the full system is sterilised after the connections are made. Examples of these can be (but are not limited to) large scale reusable systems, such as those seen in active substance manufacturing, or disposable bag and manifold systems, such as those seen in the manufacture of biological products. Closed systems are not opened until the conclusion of an operation. The use of the term “closed systems” in this Annex does not refer to systems such as RABS or isolator systems.\n'确保无菌工艺中密闭系统的所有产品接触表面的无菌性至关重要。无菌工艺中任何密闭系统的设计和选择 都应确保维持无菌性。最终除菌级过滤器之后，无菌设备（例如管道\/管道系统）与已灭菌产品通路的连接应设计成无菌连接（例如通过内在无菌连接装置）。'可被翻译为：It  is  critical  to  ensure  the  sterility  of  all  product  contact  surfaces  of closed  systems  used  for  aseptic processing. The design and selection of any closed system used for aseptic processing should ensure maintenance of sterility. Connection of sterile equipment (e.g. tubing\/pipework) to the sterilised product pathway after the final sterilising grade filter should be designed to be connected aseptically (e.g. by intrinsic sterile connection devices).\n\n根据上述已知信息，请将'密闭隔离器系统通过与辅助设备的无菌连接而不是对周围环境开放来完成物料转移，从而阻断外部污染物进入隔离器内部。密闭系统在整个操作中保持密封。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Closed isolator  systems  exclude external  contamination of the  isolator's  interior by accomplishing material  transfer via aseptic connection to auxiliary equipment, rather than use of openings to the surrounding environment.Closed systems remain sealed throughout operations."
    },
    {
        "instruction":"已知信息：\n'在成型容器的挤出、成型或密封过程中，接触容器关键表面的空气或其它气体应进行适当的过滤。所用气体的质量和气体过滤系统的有效性应按照第 6.18 和 6.19 节进行定期确认。'可被翻译为：Air or other gases that make contact with critical surfaces of the container during extrusion, formation or sealing  of  the  moulded  container  should  undergo   appropriate  filtration.  The  quality  of  gas  used  and  the effectiveness of gas filtration systems should be verified periodically in accordance with paragraphs 6.18 and 6.19.\n'气体除菌过滤'可被翻译为：Sterilization Filtration of Gases\n'在无菌工艺中使用的气体应在使用点通过除菌级过滤器（标称孔径最大为 0.22μm）过滤。如果过滤器是按产品批次使用（例如用于过滤无菌灌装产品的表层气体）或作为产品容器的呼吸过滤器，则过滤器应进行完整性测试，并将结果作为批次认证\/放行的一部分进行审核。所有位于最终除菌级过滤器之后的输送管道均应进行灭菌。当工艺中使用气体时，应在使用点定期对气体进行微生物监测。'可被翻译为：Gases used in aseptic processes should be filtered through a sterilising grade filter (with a nominal pore size of a maximum of 0.22 μm) at the point of use. Where the filter is used on a batch basis (e.g. for filtration of gas used for overlay of aseptically filled products) or as product vessel vent filter, then the filter should be integrity\ntested and the results reviewed as part of the batch certification\/release process. Any transfer pipework or tubing that is located after the final sterilising grade filter should be sterilised. When gases are used in the process, microbial monitoring of the gas should be performed periodically at the point of use.\n'任何与产品接触的气体（例如用于给容器充气或用作产品填充的气体）应在尽可能靠近使用点的位置进行适当过滤。所用气体的质量和气体过滤系统的有效性应按照第 6.18 和 6.19 节进行定期确认。'可被翻译为：Any product contact gases, e.g. those used to inflate the container or used as a product overlay, should be appropriately filtered, as close to the point of use as possible. The quality of gases used and the effectiveness of gas filtration systems should be verified periodically in accordance with paragraphs 6.18 and 6.19.\n\n根据上述已知信息，请将'对于气体过滤，应避免过滤器或过滤设备意外润湿或潮湿。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For gas filtration, unintended moistening or wetting of the filter or filter equipment should be avoided."
    },
    {
        "instruction":"已知信息：\n'一类低等的真核生物，不能进行光合作用，以产生大量抱子进行繁殖，一般具有发达的菌丝体，营养方式为异养吸收型，陆生性较强。'可被翻译为：A class of low eukaryotes, unable to photosynthesis, to produce a large number of arms for reproduction, generally have developed mycelium, trophic mode is heterotrophic absorption type, strong terrestrial.\n'一类呈菌丝状生长、主要以抱子繁殖和陆生性强的革兰氏阳性原核微生物。由于菌落呈放射状而得名。'可被翻译为：A group of Gram-positive prokaryotic microorganisms with mycelial growth, mainly bearing offspring and strong terrestrial nature. They get their name from the radial form of the colony.\n'在合适的再生培养基上，原生质体可重新生成细胞壁成为完整的细胞，并恢复其分裂繁殖的能力。'可被翻译为：On a suitable regeneration medium, protoplasts can regenerate the cell wall into a complete cell and restore its ability to divide and multiply.\n'微生物的形状、大小、排列方式、细胞结构及染色特性等'可被翻译为：The shape, size, arrangement, cell structure and staining characteristics of microorganisms\n\n根据上述已知信息，请将'一类细胞直径约0.5Rm、长度在0.5~5pm,结构简单、细胞壁坚韧、以二等分裂方式繁殖和水生性较强的原核微生物。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A kind of prokaryotic microorganism with a cell diameter of about 0.5Rm and a length of 0.5~5pm. It has simple structure, tough cell wall, reproduction by secondary division and strong water nature."
    },
    {
        "instruction":"已知信息：\n'(4) 所有在仪器中进样的样品均记录在原始记录中， 并对样品分析过程中出现的异常情况进行调查和分析， 与申报资料一致。'可被翻译为：(4) Samples introduced into all the instruments are recorded in the original records, and investigation and analysis are conducted for abnormal circumstances occurred during the process of sample analysis, consist with the application dossier.\n'(1)方法学验证项目按照验证计划书的规定考察， 检测方法、实验过程和结果记录在原始记录中， 与申报资料一致。'可被翻译为：(1) Method validation items are examined according to the provision of the validation plan, there are the test method, experimental process and result records in the original records, which are consist with those in the application dossier.\n'(5) 配有可满足分析检测要求的取样、称量、配制、检测及数据分析的仪器及软件。仪器量具的量程、精度、分辨率等符合相应技术指标的要求， 仪器的型号和编号记录在原始记录中， 与申报资料一致。'可被翻译为：(5) It is equipped with instruments and software for sampling, weighing, formulating, testing and data analysis, which are meeting the requirements of analysis and testing. The range, accuracy and resolution of instruments and measuring tools meet the requirements of corresponding technical indicators, the model and number of the instruments are recorded in the original records, consistent with those in the application dossier.\n'(1) 试验样品分析按照分析计划执行， 分析批中样品预处理的过程和检测方法与方法学验证一致， 血药浓度数据与申报资料一致。'可被翻译为：(1) The test sample analysis is conducted according to the analysis plan, the preprocessing and testing method of the samples in the analysis batch are consist with the method validation, and the plasma concentration data is consistent with that in the application dossier.\n\n根据上述已知信息，请将'(5) 所有在仪器中进样的样品均记录在原始记录中， 并对方法学验证过程中出现的异常情况进行调查和分析， 与申报资料一致。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(5) All samples introduced into the instruments are recorded in the original records, and investigation and analysis is conducted for abnormal circumstances occurred during the process of method validation, which are consist with those in the application dossier."
    },
    {
        "instruction":"已知信息：\n'第三条 药品注册是指药品注册申请人（以下简称申请人）依照法定程序和相关要求提出药物临床试验、药品上市许可、再注册等申请以及补充申请，药品监督管理部门基于法律法规和现有科学认知进行安全性、有效性和质量可控性等审查，决定是否同意其申请的活动。'可被翻译为：Article 3 Drug registration refers to the process where drug registration applicants (hereinafter referred to as \"applicants\") submit applications for clinical trials, marketing authorization and renewal of registration as well as supplementary applications as per statutory procedures and relevant requirements, and where the drug regulatory departments decide whether or not to approve such applications after reviewing the safety, efficacy and quality according to laws and regulations and existing scientific recognition.\n'第九条 申请人应当为能够承担相应法律责任的企业或者药品研制机构等。境外申请人应当指定中国境内的企业法人办理相关药品注册事项。'可被翻译为：Article 9 Applicants shall be enterprises or drug R&D institutions that can undertake corresponding legal liability. Overseas applicants shall designate an enterprise legal person within the territory of the People's Republic of China to handle matters relating to drug registration.\n'第五十四条 申请人完成支持药品上市的药学相关研究，确定质量标准，并完成商业规模生产工艺验证后，可以在药品注册申请受理前向中检院或者省、自治区、直辖市药品监督管理部门提出药品注册检验；申请人未在药品注册申请受理前提出药品注册检验的，在药品注册申请受理后四十日内由药品审评中心启动药品注册检验。原则上申请人在药品注册申请受理前只能提出一次药品注册检验，不得同时向多个药品检验机构提出药品注册检验。'可被翻译为：Article 54 Having completed the relevant CMC study supporting drug marketing, the specifications establishment, and commercial-scale manufacturing process validation, the applicant may apply for drug registration testing to the NIFDC or the drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government before the drug registration application is accepted; Where the applicant does not propose drug registration testing before the drug registration application is accepted, the drug registration testing shall be initiated by the CDE within 40 days after accepting the drug registration application. In principle, the applicant can only propose drug registration testing once before the drug registration application is accepted, and may not propose drug registration testing to multiple drug testing institutions at the same time.\n'第六条 药品注册申请人(以下简称申请人)应当保证研制和注册活动全过程信息真实、准确、完整和可追溯，提出药品上市许可申请还应当提供真实、充分、可靠的数据资料和样品，具备药品上市商业化生产条件。申请人和被核查单位应当配合注册核查工作。'可被翻译为：Article 6 The applicant for drug registration (hereinafter referred to as the applicant) shall ensure that the information in the entire process of development and registration activities is true, accurate, complete, and traceable, and shall provide true, sufficient, and reliable data and samples when file an application for drug marketing authorization and shall possess the conditions for commercial production of drugs marketing. The applicant and the inspected institution shall cooperate with the registration inspection work.\n\n根据上述已知信息，请将'第十条 药品注册申请人（以下简称申请人），是指提出药品注册申请并承担相应法律责任的机构。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 10 An applicant for drug registration (hereinafter referred to as applicant) refers to the institution that submits a drug registration application and assumes corresponding legal liability."
    },
    {
        "instruction":"已知信息：\n'(7) 病例报告表、总结报告(或数据库) 中的SAE相关数据记录和报告情况与源数据一致，无漏记、误判和误记。'可被翻译为：The relevant data of SAEs recorded in the case report form and summary report (or database) are consist with the source data, without omission, misjudgment and error in recording.\n'(6) 病例报告表、总结报告(或数据库) 中记录的 AE 相关数据与源数据一致，无漏记、误判和误记。'可被翻译为：The relevant data of AEs recorded in the case report form and summary report (or database) are consist with the source data, without omission, misjudgment and error in recording.\n'(1) 病例报告表中入组、知情同意、病史或伴随疾病、访视、给药记录、病情记录等信息与试验源数据和\/或 HIS 系统一致。'可被翻译为：(1) The enrollment, informed consent, medical history or concomitant disease, visit, drug administration, disease record and other information in the case report form are consist with the source data and\/or and HIS system.\n'药物临床试验现场核查主要是核对注册申报资料与临床试验的原始记录和文件，评价试验实施、数据记录和结果报告是否符合试验方案和药物临床试验相关法规，同时关注受试者保护。必要时可对临床试验用药物进行抽查检验。'可被翻译为：The on-site inspection of drug clinical trials is mainly to check the registration application dossiers and the original records and documents of clinical trials, evaluate whether the implementation of the trial, data records and result reports comply with the trial protocol and relevant laws and regulations of drug clinical trials, and pay attention to the protection of subjects. If necessary, random sample and test can be conducted on drugs used in clinical trials.\n\n根据上述已知信息，请将'独立于直接参与试验的人员进行的系统检查，以确定试验的进行是否符合商定的方案，以及报告的数据是否与现场记录一致，例如，病例报告表格中报告或记录的数据是否与医院档案和其他原始记录中的数据一致。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A systematic examination, carried out independently of those directly involved in the trial, to determine whether the conduct of a trial complies with the agreed protocol and whether the data reported are consistent with the records on site, e.g. whether data reported or recorded in the case-report forms (CRFs) are consonant with those found in hospital files and other original records."
    },
    {
        "instruction":"已知信息：\n'第十一条 临床试验应当获得医疗器械临床试验机构伦理委员会的同意。列入需进行临床试验审批的第三类医疗器械目录的，还应当获得国家食品药品监督管理总局的批准。'可被翻译为：Article 11 Clinical trials shall be approved by the ethics committee of the medical device clinical trial institution. Clinical trials shall also be approved by China Food and Drug Administration if the corresponding investigational medical device is included in the class III medical device catalogue which requires clinical trial approval.\n'免于进行临床试验的体外诊断试剂目录由国家食品药品监督管理总局制定、调整并公布。'可被翻译为：The catalogue of in-vitro diagnostic reagent that is exempted from clinical trial shall be compiled, adjusted and published by China Food and Drug Administration.\n'境内第三类医疗器械由国家食品药品监督管理总局审查，批准后发给医疗器械注册证。'可被翻译为：Class III domestic medical devices shall be reviewed by China Food and Drug Administration, and the medical device registration certificate shall be issued after approval.\n'进口第二类、第三类医疗器械由国家食品药品监督管理总局审查，批准后发给医疗器械注册证。'可被翻译为：Import class II and class III medical devices shall be reviewed by China Food and Drug Administration, and the medical device registration certificate shall be issued after approval.\n\n根据上述已知信息，请将'第二十四条 第三类医疗器械进行临床试验对人体具有较高风险的，应当经国家食品药品监督管理总局批准。需进行临床试验审批的第三类医疗器械目录由国家食品药品监督管理总局制定、调整并公布。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 24 Where the clinical trial of a class III medical device poses high risks to human body, it shall be subject to approval by China Food and Drug Administration. The catalogue of class III medical devices subject to clinical trial approval shall be compiled, adjusted and published by China Food and Drug Administration."
    },
    {
        "instruction":"已知信息：\n'10.拒绝、不配合核查， 导致无法继续进行现场核查；'可被翻译为：10. Refuse or fail to cooperate with the inspection, resulting in the inability to continue on-site inspection;\n'第五十四条 申请人和(或)被核查单位存在拒绝、阻碍、限制核查，不配合提供必要证明性材料等情形，或者存在主观故意导致核查无法完成的，核查结果直接判定为不通过。'可被翻译为：Article 54 If the applicant and\/or the inspected institution refuses, obstructs, restricts the inspection, fails to cooperate in providing necessary supporting materials, etc., or have subjective intention to make the inspection fail, the inspection result is directly judged as not passed.\n'2.现场核查期间，申请人及被核查研究机构应积极配合核查工作，不得阻挠、干扰现场核查工作。'可被翻译为：2. The applicant and the testing facility under inspection should actively cooperate with inspection and should not obstruct or interfere with inspection.\n'被核查单位拒绝签字盖章的，核查组应当在现场核查报告中予以注明。被核查单位应当就拒绝签字盖章情况另行书面说明，由被核查单位负责人签字，并加盖被核查单位公章交核查组。'可被翻译为：If the inspected institution refuses to sign and seal, the inspection team shall indicate it in the on-site inspection report. The inspected institution shall give another written explanation on the refusal of signature and seal, which shall be signed by the person in charge of the inspected institution and stamped with the official seal of the inspected institution and submitted to the inspection team.\n\n根据上述已知信息，请将'8.拒绝、不配合核查，导致无法继续进行现场核查；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"8. Refusing or refusing to cooperate with the inspection, causing the discontinuation of on-site inspection;"
    },
    {
        "instruction":"已知信息：\n'污染控制策略（CCS）应在整个设施内实施，从而明确所有关键控制点，并评估所有用于管理药品质量和安全风险的控制措施（设计，程序性、技术性和组织性措施）和监测措施的有效性。CCS 的综合策略应建立起强有力的污染预防保障。应积极回顾并适当更新 CCS，并应推动生产和控制方法的持续改进。CCS 的有效性应成为定期管理回顾的一部分。如果控制系统已经建立并得到了妥善管理，则这些系统可能不需要更换，但应在 CCS 中提及，并应了解系统之间在相关方面的相互作用。'可被翻译为：A Contamination Control Strategy (CCS) should be implemented across the facility in order to define all critical control points and assess the effectiveness of all the controls (design, procedural, technical and organisational) and monitoring measures employed to manage risks to medicinal product quality and safety. The\ncombined strategy of the CCS should establish robust assurance of contamination prevention. The CCS should be actively reviewed and, where appropriate, updated and should drive continual improvement of the manufacturing and control methods. Its effectiveness should form part of the periodic management review. Where existing control systems are in place and are appropriately managed, these may not require replacement but should be referenced in the CCS and the associated interactions between systems should be understood.\n'在 FFS 确认过程中确定的控制措施应与 CCS 保持一致。应考虑的方面包括但不限于：'可被翻译为：The controls identified during qualification of FFS  should be in alignment with the CCS. Aspects to be considered include but are not limited to:\n'BFS 确认过程中确定的控制措施应与工厂的 CCS 保持一致。应考虑的方面包括但不限于：'可被翻译为：The controls identified during qualification of BFS should be in alignment with the site's CCS. Aspects to be considered include but are not limited to:\n'CCS 中要考虑的要素应包括（但不限于）:'可被翻译为：Elements to be considered within a CCS should include (but are not limited to):\n\n根据上述已知信息，请将'CCS 应考虑污染控制的所有方面，并进行持续、定期的回顾，酌情更新药品质量体系。现行体系如有变更，应在实施前后评估对 CCS 的任何影响。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The CCS should consider all aspects of contamination control with ongoing and periodic review resulting in updates within the pharmaceutical quality system as appropriate. Changes to the systems in place should be\nassessed for any impact on the CCS before and after implementation."
    },
    {
        "instruction":"已知信息：\n'由多个氨基酸借肽键线性连接而成。肽键就是氨基酸的a-竣基与相邻的另一氨基酸的a-氨基脱水缩合的共价键。'可被翻译为：It is formed by a linear connection of multiple amino acids by peptide bonds. a peptide bond is a covalent bond in which the A-carboxyl group of an amino acid is dehydrated and condensed with the A-amino group of another adjacent amino acid.\n'在肽或蛋白质的序列中，氨基酸之间的氨基和竣基脱水成键，因此肽或蛋白质分子中的氨基酸已不是完整的氨基酸，被称为残基。'可被翻译为：In the sequence of peptide or protein, the amino group and the carboxyl group between amino acids are dehydrated to form a bond, so the amino acid in the peptide or protein molecule is not a complete amino acid and is called residue.\n'同时含有一个或多个氨基和竣基的脂肪族有机酸。根据氨基和竣基的位置，有a氨基酸和0氨基酸等类型。参与蛋白质合成的常见的是20种L-a-氨基酸。'可被翻译为：Aliphatic organic acids containing one or more amino and carboxylic groups at the same time. Depending on the position of the amino group and the carboxyl group, there are such types as a amino acid and 0 amino acid. The common ones involved in protein synthesis are the 20 L-A-amino acids.\n'检验a-氨基酸的一种试剂。荀三酮与a-氨基酸反应产生蓝、紫或紫红色产物，但脯氨酸、羟基脯氨酸不产生特征的蓝色反应，而产生黄色。'可被翻译为：a reagent for the test of A-amino acids. Xuntrione reacts with A-amino acids to produce a blue, purple, or purple-red product, but proline and hydroxyproline do not produce the characteristic blue reaction and produce yellow.\n\n根据上述已知信息，请将'一分子氨基酸的a-竣基和一分子氨基酸的a-氨基脱水缩合形成的酰胺键，即—CO—NH—。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An amide bond formed by the dehydration condensation of the A-carboxyl group of an amino acid with the A-amino group of an amino acid, that is, -CO-NH --."
    },
    {
        "instruction":"已知信息：\n'1.使用申请中规定的生产设施中的生产设备按生产规模生产的一批原料药或制剂。\n2.在申请中指定的生产设施中使用生产设备按生产规模生产的一批API或FPP。'可被翻译为：1.A batch of an active pharmaceutical ingredient or finished pharmaceutical product manufactured at production scale by using production equipment in a production facility as specified in the application.\n2.A batch of an API or FPP manufactured at production scale by using production equipment in a production facility as specified in the application.\n'将某一生产工序生产的不符合质量标准的一批中间产品或待包装产品、成品的一部分或全部返回到之前的工序，采用相同的生产工艺进行再加工，以符合预定的质量标准。'可被翻译为：Subjecting all or part of a batch of intermediate, bulk or finished products that fails to meet the specifications to a previous step of the same manufacturing process in order to meet the predetermined specifications.\n'如果收集同一生产商同一产品的多个样品（相同的数量和形式），可仅使用其中一个样品进行 方法适用性试验。'可被翻译为：If multiple samples of the same product from the same manufacturer (same amount and form) are collected, one sample may be used for method suitability for all the samples collected.\n'使用不含产品的相同培养基接种相同的微生物作为阳性对照。'可被翻译为：Inoculate the same microorganism using the same medium without the product as a positive control.\n\n根据上述已知信息，请将'1.看到一批。\n2.相同设计、颜色、形状、大小和配方的避孕套集合。一个批次必须基本上同时生产，使用相同的工艺、相同规格的原材料、共同的设备、相同的润滑剂和任何其他添加剂或敷料，并使用相同的包装材料包装在同一类型的单个容器中。\n3.基本上在同一时间生产的一批原材料、部件或产品，并有一个批次识别码或编号。需要明确的批号标识和记录，以便在设备出现质量问题时进行有效的产品召回。许多生产的节育器的定义在第3节一般要求中给出。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.See batch.\n2.A collection of condoms of the same design, colour, shape, size and formulation. A lot must be manufactured at essentially the same time, using the same process, same specification of raw materials, common equipment, same lubricant and any other additive or dressing, and be packed in the same type of individual container, using the same packaging materials.\n3.A quantity of raw materials, components or iuds made at essentially the same time and having a single lot identification code or number. Clear lot identification and recording are required to permit effective product recall in the event of a quality problem with the device. The definition of a lot of manufactured iuds is given in section 3 on general requirements."
    },
    {
        "instruction":"已知信息：\n'也称摩尔吸光系数。反映分子对特定波长光的吸收能力（通常表示为 L\/mol\/cm ），并受溶剂等因素的影响。'可被翻译为：Molar Extinction Coefficient (also called molar absorptivity) reflects the efficiency with  which a molecule can absorb a photon at a particular wavelength (typically expressed as L mol-1 cm-1) and is influenced by several factors, such as solvent.\n'吸收光谱中两个极大吸收峰间的最小吸收波长。即物质在此经之间对光的吸收较小，一般不能作为定量的波长。'可被翻译为：The minimum absorption wavelength between two maximum absorption peaks in the absorption spectrum. That is, the absorption of light by a substance between these channels is small, and generally cannot be used as a quantitative wavelength.\n'把将来成本和产出折算成现值的方法。第\/年的贴现因子为l\/（l+r）'，其中r表示贴现率。'可被翻译为：A method of converting future costs and outputs into present values. The discount factor for the year\/is l\/ (l+r) ', where r represents the discount rate.\n'经紫外线（有时也可用可见光）照射后，能产生比所吸收紫外线波长更长的光的物质。'可被翻译为：A substance that, when irradiated by ultraviolet light (or sometimes visible light), produces light of a longer wavelength than the ultraviolet light it absorbs.\n\n根据上述已知信息，请将'由不对称分子组成的物质是光学各向异性的，即L与R两束圆偏振光在这类物质中的传播速度不相等的现象。假如光学各向异性物质在某一波长有吸收，那将在该时对L光和R光有不同的吸收，如该物质的吸光率是A,而对L光和R光的吸光率是Al和Ar，Al和Ar的差△A=Al-Ar，称为圆二色性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Substances consisting of asymmetrical molecules are optically anisotropic, that is, the phenomenon that two beams of circularly polarized light L and R travel at different speeds through such substances. If the optical anisotropic substance has absorption at A certain wavelength, it will have different absorption of L light and R light at that time, such as the absorption rate of the substance is A, and the absorption rate of L light and R light is Al and Ar, Al and Ar difference △A= al-ar, called circular dichroism."
    },
    {
        "instruction":"已知信息：\n'第二条 凡在中华人民共和国境内销售、使用的医疗器械应当使用通用名称，通用名称的命名应当符合本规则。'可被翻译为：Article 2 All medical devices that are sold and used within the territory of the People's Republic of China shall use generic names and their naming shall conform to the Rules.\n'医疗器械通用名称命名规则'可被翻译为：Rules for Medical Device Nomenclature\n'第四条 医疗器械通用名称应当使用中文，符合国家语言文字规范。'可被翻译为：Article 4 The generic names of medical devices shall be in Chinese and conform to the norms of the standard spoken and written Chinese language.\n'第一条 为加强医疗器械监督管理，保证医疗器械通用名称命名科学、规范，根据《医疗器械监督管理条例》，制定本规则。'可被翻译为：Article 1 The Rules is formulated in accordance with the Regulations on the Supervision and Administration of Medical Devices to enhance the supervision and administration of medical devices and ensure that the nomenclature of medical devices is scientific and normative.\n\n根据上述已知信息，请将'第八条 医疗器械的产品名称应当使用通用名称，通用名称应当符合国家食品药品监督管理总局制定的医疗器械命名规则。第二类、第三类医疗器械的产品名称应当与医疗器械注册证中的产品名称一致。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 8 Product names of medical devices shall adopt general names, which shall meet the rules of nomenclature of medical devices formulated by China Food and Drug Administration. Product names of class II and class III medical devices shall be consistent with the product names in the corresponding medical device registration certificates."
    },
    {
        "instruction":"已知信息：\n'违反本办法第九条第三款的规定，责令限期改正，处5万元以上10万元以下罚款；造成危害后果的，处10万元以上20万元以下罚款。'可被翻译为：In case of violation of the provisions in Paragraph 3, Article 9 of these Provisions, it shall be ordered to make correction within the time limit, and subject to a fine of not less than RMB 50,000 and not more than RMB 100,000; for hazardous consequences, a fine of not less than RMB 100,000 and not more than RMB 200,000 shall be imposed.\n'第三十九条 违反本办法第十八条的规定，责令限期改正；逾期不改正的，处5万元以上10万元以下罚款；造成危害后果的，处10万元以上20万元以下罚款。'可被翻译为：Article 39 In case of violation of the provisions of Article 18 of these Provisions, it shall be ordered to make correction within the time limit; where correction is not made within the prescribed period, a fine of not less than RMB 50,000 and not more than RMB 100,000 shall be imposed; for hazardous consequences, a fine of not less than RMB 100,000 and not more than RMB 200,000 shall be imposed.\n'第三十四条 违反本办法第九条第一款、第二款的规定，责令限期改正，处3万元以上5万元以下罚款；情节严重的，处5万元以上10万元以下罚款。'可被翻译为：Article 34 In case of violation of the provisions in Paragraph 1 and Paragraph 2, Article 9 of these Provisions, it shall be ordered to make correction within the time limit, and subject to a fine of not less than RMB 30,000 and not more than RMB 50,000; for severe circumstances, a fine of not less than RMB 50,000 and not more than RMB 100,000 shall be imposed.\n'第六十六条  有下列情形之一的，责令限期改正，并处1万元以上5万元以下罚款；情节严重的，处5万元以上10万元以下罚款；造成危害后果的，处10万元以上20万元以下罚款：'可被翻译为：Article 66 For any of the following circumstances, rectification shall be ordered within prescribed time limit, and a fine of not less than 10,000 yuan and not more than 50,000 yuan shall be imposed; for serious circumstances, a fine of not less than 50,000 yuan and not more than 100,000 yuan shall be imposed; and for hazardous consequences, a fine of not less than 100,000 yuan and not more than 200,000 yuan shall be imposed:\n\n根据上述已知信息，请将'第三十八条 违反本办法第十七条第一款的规定，责令限期改正，处3万元以上10万元以下罚款；造成危害后果的，处10万元以上20万元以下罚款。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 38 In case of violation of the provisions in Paragraph 1, Article 17 of these Provisions, it shall be ordered to make correction within the time limit, and subject to a fine of not less than RMB 30,000 and not more than RMB 100,000; for hazardous consequences, a fine of not less than RMB 100,000 and not more than RMB 200,000 shall be imposed."
    },
    {
        "instruction":"已知信息：\n'1.开展临床试验，应当获得药品监督管理部门许可， 生物等效性试验应按照要求完成备案。'可被翻译为：1. To conduct clinical trials, the approval from the drug administration shall be obtained, and the bioequivalence test shall be filed as required.\n'第十条 申请人在申请药品上市注册前，应当完成药学、药理毒理学和药物临床试验等相关研究工作。药物非临床安全性评价研究应当在经过药物非临床研究质量管理规范认证的机构开展，并遵守药物非临床研究质量管理规范。药物临床试验应当经批准，其中生物等效性试验应当备案；药物临床试验应当在符合相关规定的药物临床试验机构开展，并遵守药物临床试验质量管理规范。'可被翻译为：Article 10 Before applying for marketing registration of a drug, the applicant shall complete related research including Chemical, Manufacturing and Control (CMC), pharmacological and toxicological studies and drug clinical trials. Non-clinical safety evaluation studies shall be carried out in institutions meeting Good Laboratory Practice (GLP) requirements and be in compliance with the GLP. Drug clinical trials shall be approved, and bioequivalence studies shall be filed for record. Drug clinical trials shall be carried out in clinical trial institutions that comply with relevant regulations and adhere to the Good Clinical Practice (GCP).\n'生物等效性试验'可被翻译为：bioequivalence test\n'第二十一条 药物临床试验分为Ⅰ期临床试验、Ⅱ期临床试验、Ⅲ期临床试验、Ⅳ期临床试验以及生物等效性试验。根据药物特点和研究目的，研究内容包括临床药理学研究、探索性临床试验、确证性临床试验和上市后研究。'可被翻译为：Article 21 Drug clinical trials are classified as phase I, II, III, IV and bioequivalence trials. According to the drug characteristics and research purposes, the research includes clinical pharmacology studies, exploratory clinical trials, confirmatory clinical trials and post-marketing studies.\n\n根据上述已知信息，请将'第三十条 药物的临床试验（包括生物等效性试验），必须经过国家食品药品监督管理局批准，且必须执行《药物临床试验质量管理规范》。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 30 Any drug clinical trial, including bioequivalence study, shall be approved by the State Food and Drug Administration, and shall be in compliance with the Good Clinical Practice."
    },
    {
        "instruction":"已知信息：\n'从事药品生产活动，应当经所在地省、自治区、直辖市药品监督管理部门批准，依法取得药品生产许可证，严格遵守药品生产质量管理规范，确保生产过程持续符合法定要求。'可被翻译为：To carry out drug manufacturing activities, approval should be obtained from the drug regulatory department of corresponding province, autonomous region or municipality directly under the Central Government, the Drug Manufacturing Certificate shall be obtained, and the Good Manufacturing Practice for Pharmaceutical Products (GMP) should be strictly followed to ensure the manufacturing process continuously complies with statutory requirements.\n'第二十四条 疫苗应当按照经核准的生产工艺和质量控制标准进行生产和检验，生产全过程应当符合药品生产质量管理规范的要求。'可被翻译为：Article 24 Vaccines shall be produced and tested in accordance with the approved production process and specifications, and the entire production process shall meet the requirements prescribed by the good manufacturing practice for drugs.\n'中药饮片生产企业应当履行药品上市许可持有人的相关义务，确保中药饮片生产过程持续符合法定要求。'可被翻译为：Manufacturers of Prepared Slices shall fulfill relevant obligations of drug MAHs and ensure the manufacturing of Prepared Slices continuously complies with regulatory requirements.\n'第二十四条 从事药品生产活动，应当遵守药品生产质量管理规范，按照国家药品标准、经药品监督管理部门核准的药品注册标准和生产工艺进行生产，按照规定提交并持续更新场地管理文件，对质量体系运行过程进行风险评估和持续改进，保证药品生产全过程持续符合法定要求。生产、检验等记录应当完整准确，不得编造和篡改。'可被翻译为：Article 24 Engaging in drug manufacture activities shall comply with the GMP and the manufacturing process shall be in accordance with the national drug standards, drug registration specifications and the manufacturing process approved by drug regulatory departments. The site management file shall be submitted and continuously updated, the risk assessments and continuous improvements of the quality system operation shall be made to ensure a continuous compliance with statutory requirements throughout the whole process. Manufacturing and test records shall be complete and accurate. No fabrication or falsification is allowed.\n\n根据上述已知信息，请将'原料药生产企业应当按照核准的生产工艺组织生产，严格遵守药品生产质量管理规范，确保生产过程持续符合法定要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Manufacturers of active drug ingredients shall organize manufacturing according to approved manufacturing processes and strictly abide by good manufacturing practice to ensure the drug manufacturing continuously complies with statutory requirements."
    },
    {
        "instruction":"已知信息：\n'第四十条 开展体外诊断试剂临床试验，应当向申请人所在地省、自治区、直辖市食品药品监督管理部门备案。接受备案的食品药品监督管理部门应当将备案情况通报临床试验机构所在地的同级食品药品监督管理部门和卫生计生主管部门。'可被翻译为：Article 40 The clinical trial of in-vitro diagnostic reagents shall be filed with the food and drug regulatory department of the provinces, autonomous regions and municipalities directly under the central government where the applicant is located. The food and drug regulatory department accepting the filling shall report to the food and drug regulatory department and the competent health and family planning department at the same level where the clinical trial institution is located.\n'省级以上药品监督管理部门应当将年度报告情况通报同级卫生行政部门。'可被翻译为：The drug regulatory departments at provincial level or above shall notify the annual reports to the health administrative departments at the same level.\n'第七十五条 临床试验机构和研究者应当接受申办者的监查、核查以及伦理委员会的监督，并提供所需的与试验有关的全部记录。食品药品监督管理部门、卫生计生主管部门派检查员开展检查的，临床试验机构和研究者应当予以配合。'可被翻译为：Article 75 The clinical trial institution and the investigator shall be subject to the supervision and verification of the sponsor and supervision of the ethics committee and shall provide all required records related to the trial. The clinical trial institution and the investigator shall cooperate with the inspectors during the inspections assigned by the food and drug administration department and the competent health and family planning department.\n'第五十四条 对于严重不良事件和可能导致严重不良事件的器械缺陷，申办者应当在获知后5个工作日内向所备案的食品药品监督管理部门和同级卫生计生主管部门报告，同时应当向参与试验的其他临床试验机构和研究者通报，并经其医疗器械临床试验管理部门及时通知该临床试验机构的伦理委员会。'可被翻译为：Article 54 The sponsor shall, within five working days after being informed, report serious adverse events and device defects that may lead to serious adverse events to the food and drug administration department where the sponsor makes the registration and the competent health and family planning department of the same level, at the same time inform other clinical trial institutions and investigators involved in the trial, and in a timely manner notify the ethics committee of the clinical trial institution through the medical device clinical trial management department.\n\n根据上述已知信息，请将'接受备案的食品药品监督管理部门应当将备案情况通报临床试验机构所在地的同级食品药品监督管理部门以及卫生计生主管部门。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The food and drug administration department that accepts filing shall inform the local food and drug administration department and the competent health and family planning department of the same level where the clinical trial institution is located."
    },
    {
        "instruction":"已知信息：\n'血浆脂蛋白中密度为0.95〜1.006g\/cn?的脂蛋白。是血浆脂蛋白中密度极低的-类脂蛋白，可用超速离心或电泳法对血浆脂蛋白进行类别分离而确定。'可被翻译为：The medium density of plasma lipoprotein is 0.95 ~ 1.006g\/cn? Is a lipoprotein. Is a very low density of plasma lipoproteins - lipoproteins, which can be determined by class separation of plasma lipoproteins by ultracentrifugation or electrophoresis.\n'血浆脂蛋白中密度为1.063-1.21g\/cm3的脂蛋白。是血浆脂蛋白中密度较高的-类脂蛋白，灯用超速离心或电泳法对血浆脂蛋白进行类别分离而确定。'可被翻译为：Plasma lipoproteins have a density of 1.063-1.21g\/cm3. Is the higher density of the plasma lipoprotein - lipoprotein, light by ultracentrifugation or electrophoresis of plasma lipoprotein category separation to determine.\n'极低密度脂蛋白'可被翻译为：very low density lipoprotein\n'高密度脂蛋白'可被翻译为：high density lipoprotein\n\n根据上述已知信息，请将'血浆脂蛋白中密度为1.006-1.063g\/cn?的脂蛋白。是血浆脂蛋白中密度较低的-类脂蛋白，可用超速离心或电泳法对血浆脂蛋白进行类别分离而确定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The medium density of plasma lipoprotein is 1.006-1.063g\/cn? Is a lipoprotein. Is a lower density of plasma lipoprotein - lipoprotein, can be determined by ultra-fast centrifugation or electrophoresis of plasma lipoprotein class separation."
    },
    {
        "instruction":"已知信息：\n'第一百二十五条 本办法规定的期限以工作日计算。'可被翻译为：Article 125 The timelines stipulated in these Provisions shall be calculated in working days.\n'第四十四条    本办法规定的期限以工作日计算，不含法定节假日。'可被翻译为：Article 44 The time limit as prescribed in these Provisions shall be calculated by working days, excluding statutory holidays.\n'第四十五条 本办法规定的批签发工作期限以工作日计算，不含法定节假日。'可被翻译为：Article 45 The time limit for lot release as prescribed in these Provisions shall be calculated by working days, excluding statutory holidays.\n'第三十三条 本办法规定的日以工作日计算。'可被翻译为：Article 33 The days specified in the Provisions shall be calculated in working days.\n\n根据上述已知信息，请将'第七十三条 本办法规定的期限以工作日计算。药品生产许可中技术审查和评定、现场检查、企业整改等所需时间不计入期限。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 73 Timelines specified in these Provisions are calculated based on working days. Time needed for technical review and evaluation, on-site inspection and enterprise remediation in drug manufacturing licensing is not included into the timelines."
    },
    {
        "instruction":"已知信息：\n'本部分不适用于根据本章101.8（d）下取得的电子签名。'可被翻译为：(h) This part does not apply to electronic signatures obtained under 101.8(d) of this chapter.\n'本部分不适用于根据本章第112部分要求建立或维护的记录。符合本章第112部分要求的同时 也是其他适用的法规和条例所要求的记录，仍受本部分的约束。'可被翻译为：(k) This part does not apply to records required to be established or maintained by part 112 of this chapter. Records that satisfy the requirements of part 112 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.\n'本部分不适用于根据本章第121部分要求建立或维护的记录。符合本章第121部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。'可被翻译为：(o) This part does not apply to records required to be established or maintained by part 121 of this chapter. Records that satisfy the requirements of part 121 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.\n'本部分不适用于根据本章第117部分要求建立或维护的记录。符合本章第117部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。'可被翻译为：(i) This part does not apply to records required to be established or maintained by part 117 of this chapter. Records that satisfy the requirements of part 117 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.\n\n根据上述已知信息，请将'本部分不适用于根据本章101.11（d）下取得的电子签名。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(g) This part does not apply to electronic signatures obtained under 101.11(d) of this chapter."
    },
    {
        "instruction":"已知信息：\n'快速转移系统\/接口（RTP）：一种用于将物品转移到 RABS 或隔离器中的系统，最大程度降低对关键区的风险。一个例子是具有 a\/β接口的快速转移容器。'可被翻译为：Rapid  Transfer  System\/Port  (RTP)  -  A  System  used  for  the  transfer  of  items  into  RABS  or  isolators  that minimizes the risk to the critical zone. An example would be a rapid transfer container with an alpha\/beta port.\n'隔离器或 RABS 的背景环境应确保将污染转移的风险降至最低。'可被翻译为：The background environment for isolators or RABS should ensure the risk of transfer of contamination is minimized.\n'设计用于将人员与产品隔离，包含污染物或隔离两个区域的系统，可以是屏障隔离器(BI)或限制进入屏障系统(RABS):•BI是提供高效颗粒空气(HEPA)过滤空气的单元，可将其内部与外部环境(包括周围的洁净室空气和人员)不受损害地连续隔离。\n•RABS是一种屏障系统，可以减少或消除对关键区域的干预。在实践中，其污染控制水平低于屏障隔离器。'可被翻译为：A system designed to segregate people from the product, contain contaminants or segregate two areas, which could be a barrier isolator (BI) or a restricted access barrier system (RABS):•A BI is a unit supplied with high-efficiency particulate air HEPA) filtered air that provides uncompromised continuous isolation of its interior from the external environment, including surrounding clean room air and personnel.\n•A RABS is a type of barrier system that reduces or eliminates interventions into the critical zone. In practice, its level of contamination control is less than that of a barrier isolator.\n'限制性进入隔离系统（RABS）或隔离器有利于确保所需的条件，并最大限度减少关键区直接人为干预措施引起的微生物污染。在 CCS 中应讨论它们的使用。如要采用任何方法替代 RABS 或隔离器，应证明该替代方法的合理性。'可被翻译为：Restricted Access Barrier Systems (RABS) or isolators are beneficial in assuring required conditions and minimizing microbial contamination associated with direct human interventions in the critical zone. Their use should be considered in the CCS. Any alternative approaches to the use of RABS or isolators should be justified.\n\n根据上述已知信息，请将'用于将物品转移到RABS或隔离器的系统，以最大限度地降低对关键区域的风险。一个例子是带有alpha\/beta端口的快速转移容器。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A system used for the transfer of items into RABS or isolators that minimizes the risk to the critical zone. An example would be a rapid transfer container with an alpha\/beta port."
    },
    {
        "instruction":"已知信息：\n'第三十九条 违反本办法第十八条的规定，责令限期改正；逾期不改正的，处5万元以上10万元以下罚款；造成危害后果的，处10万元以上20万元以下罚款。'可被翻译为：Article 39 In case of violation of the provisions of Article 18 of these Provisions, it shall be ordered to make correction within the time limit; where correction is not made within the prescribed period, a fine of not less than RMB 50,000 and not more than RMB 100,000 shall be imposed; for hazardous consequences, a fine of not less than RMB 100,000 and not more than RMB 200,000 shall be imposed.\n'第三十四条 违反本办法第九条第一款、第二款的规定，责令限期改正，处3万元以上5万元以下罚款；情节严重的，处5万元以上10万元以下罚款。'可被翻译为：Article 34 In case of violation of the provisions in Paragraph 1 and Paragraph 2, Article 9 of these Provisions, it shall be ordered to make correction within the time limit, and subject to a fine of not less than RMB 30,000 and not more than RMB 50,000; for severe circumstances, a fine of not less than RMB 50,000 and not more than RMB 100,000 shall be imposed.\n'第三十五条 违反本办法第十一条的规定，责令限期改正；逾期不改正的，处1万元以上3万元以下罚款；情节严重的，处3万元以上5万元以下罚款。'可被翻译为：Article 35 In case of violation of the provisions in Article 11 of these Provisions, it shall be ordered to make correction within the time limit; where correction is not made within the prescribed period, a fine of not less than RMB 10,000 and not more than RMB 30,000 shall be imposed; for severe circumstances, a fine of not less than RMB 30,000 and not more than RMB 50,000 shall be imposed.\n'违反本办法第九条第三款的规定，责令限期改正，处5万元以上10万元以下罚款；造成危害后果的，处10万元以上20万元以下罚款。'可被翻译为：In case of violation of the provisions in Paragraph 3, Article 9 of these Provisions, it shall be ordered to make correction within the time limit, and subject to a fine of not less than RMB 50,000 and not more than RMB 100,000; for hazardous consequences, a fine of not less than RMB 100,000 and not more than RMB 200,000 shall be imposed.\n\n根据上述已知信息，请将'第三十六条 违反本办法第十三条、第十九条第二款的规定，责令限期改正；逾期不改正的，处5万元以上10万元以下罚款。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 36 In case of violation of the provisions in Article 13, Paragraph 2 of Article 19 of these Provisions, it shall be ordered to make correction within the time limit; where correction is not made within the prescribed period, a fine of not less than RMB 50,000 and not more than RMB 100,000 shall be imposed."
    },
    {
        "instruction":"已知信息：\n'第三十五条 本办法自发布之日起施行。'可被翻译为：Article 35 The Provisions shall come into force on the date of issuance.\n'第三十五条 本办法自2020年1月1日起施行。原国家食品药品监督管理局2005年11月24日公布的《进口药材管理办法（试行）》同时废止。'可被翻译为：Article 35 The Provisions shall come into force as of January 1, 2020. The Provisions for Medicinal Material Import (Interim) promulgated by the former China Food and Drug Administration on November 24, 2005, shall be repealed simultaneously.\n'本公告自2019年9月1日起施行。'可被翻译为：This Announcement shall come into force on September 1, 2019.\n'第四十二条 本办法自2022年12月1日起施行。'可被翻译为：Article 42 These Provisions shall go into effect as of December 1, 2022.\n\n根据上述已知信息，请将'第三十五条 本办法自2015年9月1日起施行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 35 The Provisions shall be effective as of September 1, 2015."
    },
    {
        "instruction":"已知信息：\n'证明任何程序、生产过程、设备、物料、活动或系统确实能达到预期结果的有文件证明的一系列活动。'可被翻译为：A documented set of activities that demonstrate that any procedure, production process, equipment, material, activity, or system actually achieves an expected result.\n'证明厂房、设施、设备能正确运行并可达到预期结果的一系列活动。'可被翻译为：A series of actions proving that the premises, facilities and equipment work correctly and actually lead to the expected results.\n'验证：证明和记录工艺、程序或方法可以实际并持续得到预期结果的活动'可被翻译为：validation. Action of proving and documenting that any process, procedure or method actually and consistently leads to the expected results.\n'确认：证明设施、系统或设备经过恰当安装和\/或正确运行并得到预期结果，有能力达到既定标准的文件化证明'可被翻译为：qualification. Documented evidence that premises, systems or equipment are able to achieve the predetermined specifications when properly installed, and\/or work correctly and lead to the expected results.\n\n根据上述已知信息，请将'证明任何操作规程（或方法）、生产工艺或系统能够达到预期结果的一系列活动。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A series of actions of proving that any operation procedure (or method), manufacturing process or system actually leads to the expected results."
    },
    {
        "instruction":"已知信息：\n'1.确保原辅料、包装材料、中间产品、待包装产品和成品符合经注册批准的要求和质量标准；'可被翻译为：1) To ensure that all starting materials, packaging materials, intermediate, bulk and finished products meet the registration requirements and specifications;\n'（三）由经授权的人员按照规定的方法对原辅料、包装材料、中间产品、待包装产品和成品取样。'可被翻译为：3. Samples of starting materials, packaging materials, intermediate, bulk and finished products are taken by authorized personnel with approved methods.\n'第一百六十四条 物料和成品应当有经批准的现行质量标准；必要时，中间产品或待包装产品也应当有质量标准。'可被翻译为：Article 164: There should be appropriately authorized and dated specifications for materials and finished products; where appropriate, they should be also available for intermediate or bulk products.\n'第五十七条 仓储区应当有足够的空间，确保有序存放待验、合格、不合格、退货或召回的原辅料、包装材料、中间产品、待包装产品和成品等各类物料和产品。'可被翻译为：Article 57: Storage areas should be of sufficient capacity to allow orderly storage of the various categories of materials and products: starting and packaging materials, intermediate, bulk and finished products, products in quarantine, released, rejected, returned or recalled.\n\n根据上述已知信息，请将'（二）应当有批准的操作规程，用于原辅料、包装材料、中间产品、待包装产品和成品的取样、检查、检验以及产品的稳定性考察，必要时进行环境监测，以确保符合本规范的要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2. Approved procedures are available for sampling, inspection and testing starting materials, packaging materials, intermediate, bulk, and finished products, and stability study, and where appropriate for monitoring environmental conditions, to ensure the compliance with GMP."
    },
    {
        "instruction":"已知信息：\n'2~20个氨基酸残基通过肽键连接形成的肽。'可被翻译为：Peptides formed from 2 to 20 amino acid residues connected by peptide bonds.\n'任何由两个或两个以上的氨基酸通过一个氨基酸的竣基与另一个氨基酸的氨基连接而成的自然界存在的或合成的化合物。一般将含50个氨基酸残基以下的这类化合物称为肽。'可被翻译为：Any naturally occurring or synthetic compound consisting of two or more amino acids joined by the carboxyl group of one amino acid to the amino group of another amino acid. Such compounds containing less than 50 amino acid residues are generally referred to as peptides.\n'在肽或蛋白质的序列中，氨基酸之间的氨基和竣基脱水成键，因此肽或蛋白质分子中的氨基酸已不是完整的氨基酸，被称为残基。'可被翻译为：In the sequence of peptide or protein, the amino group and the carboxyl group between amino acids are dehydrated to form a bond, so the amino acid in the peptide or protein molecule is not a complete amino acid and is called residue.\n'多肽链中氨基酸残基的连接方式和排列。'可被翻译为：The pattern and arrangement of amino acid residues in a polypeptide chain.\n\n根据上述已知信息，请将'由20个以上的氨基酸残基组成的肽。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A peptide consisting of more than 20 amino acid residues."
    },
    {
        "instruction":"已知信息：\n'鼓励中药生产企业优先使用符合本规范要求的中药材。药品批准证明文件等有明确要求的，中药生产企业应当按照规定使用符合本规范要求的中药材。相关中药生产企业应当依法开展供应商审核，按照本规范要求进行审核检查，保证符合要求。'可被翻译为：TCM manufacturers are encouraged to give priority to the use of Chinese crude drugs that meet the GAP requirements. Where there are explicit requirements in the drug approval documents, TCM manufacturers should use the Chinese crude drugs that meet the GAP requirements according to the provisions. Relevant TCM manufacturers should carryout supplier audit according to law and conduct audit and inspection in accordance with the GAP requirements to ensure the compliance with the requirements.\n'第八十三条 企业应当根据药品的质量特性对药品进行合理储存，并符合以下要求：'可被翻译为：Article 83 Enterprises shall carry out proper storage of drugs according to their quality characteristics and conform to the following requirements:\n'第一百七十九条 药品零售连锁企业总部的管理应当符合本规范药品批发企业相关规定，门店的管理应当符合本规范药品零售企业相关规定。'可被翻译为：Article 179 The management of the headquarters of drug retail chain enterprise shall comply with the relevant provisions of the GSP for drug wholesale enterprises, and the management of its stores shall comply with the relevant provisions of the GSP for drug retail enterprises.\n'药品生产企业销售药品、药品流通过程中其他涉及储存与运输药品的，也应当符合本规范相关要求。'可被翻译为：Drug sales conducted by drug manufacturers and drug storage as well as transportation involved in the process of drug circulation, shall meet relevant requirements of the GSP.\n\n根据上述已知信息，请将'（一）在批准放行前，应当对每批药品进行质量评价，保证药品及其生产应当符合注册和本规范要求，并确认以下各项内容：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1. Each batch of drugs, prior to release, should undergo quality assessment, so as to ensure that the products and manufacturing comply with the registration requirements and the Provisions, and the following activities should be confirmed:"
    },
    {
        "instruction":"已知信息：\n'三、增加无锡市药品安全检验检测中心为口岸药品检验机构。自本公告发布之日起，无锡市药品安全检验检测中心开始承担无锡航空口岸、江阴港口岸的药品口岸检验工作。'可被翻译为：III. Wuxi Center for Drug Safety Inspection and Testing is added as the port drug inspection agency. As of the date of issuance of this Announcement, WuxiCenter for Drug Safety Inspection and Testing starts to undertake the drug port inspection at Wuxi Airport and Jiangyin Port.\n'二、增加吉林省药品监督管理局为口岸药品监督管理部门，由其承担长春空港口岸药品进口备案的具体工作。'可被翻译为：II. Jilin Medical Products Administration is added as the port drug regulatory authority, which shall undertake the specific drug import filing at Changchun AirPort.\n'三、广西壮族自治区食品药品检验所为爱店口岸对应的口岸药品检验机构，自2022年3月10日起，开始承担爱店口岸的药材口岸检验工作。'可被翻译为：III. Guangxi Institute for Food and Drug Control, the drug inspection institution corresponding to Aidian Port, should undertake the crude drug port inspection at Aidian Port from March 10, 2022.\n'本办法所称口岸检验，是指国家食品药品监督管理局确定的药品检验机构（以下称口岸药品检验所）对抵达口岸的进口药品依法实施的检验工作。'可被翻译为：Port testing in the Provisions refers to the testing of drugs to be imported upon the arrival at port, conducted by a drug control institute designated by the State Food and Drug Administration (hereinafter referred to as the drug control institute of port) in accordance with laws.\n\n根据上述已知信息，请将'三、增加吉林省药品检验研究院为口岸药品检验机构。自本公告发布之日起，吉林省药品检验研究院开始承担长春空港口岸的药品口岸检验工作。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"III. Jilin Institute for Drug Control is added as the port drug testing institute. As of the date of issuance of this Announcement, Jilin Institute for Drug Control starts to undertake the drug port testing at Changchun Airport."
    },
    {
        "instruction":"已知信息：\n'手性化合物分子含有一个以上不对称中心时，异构体混合物中一个非对映体对其他非对映体的过量。'可被翻译为：When a chiral compound molecule contains more than one asymmetric center, an excess of one diastereomer in the isomer mixture to the other diastereomers.\n'一个化学反应中，产生的某一对映体多于其相应的对映体的程度。'可被翻译为：The degree to which a chemical reaction produces more enantiomers than its corresponding enantiomers.\n'又称\"［对映］异构体优劣比”。较高活性对映体（优对映体）与较低活性对映体（劣对映体）间生物活性强度的比值。'可被翻译为：Also known as \"the ratio of [enantiomer] to good\". The ratio of the strength of biological activity between the more active enantiomer (superior enantiomer) and the less active enantiomer (inferior enantiomer).\n'利用微生物或动、植物组织中的酶进行选择性不对称分解，从外消旋体中拆分出相应对映体的方法。'可被翻译为：The method of using microorganisms or enzymes in animal and plant tissues for selective asymmetric decomposition to separate the corresponding enantiomers from the racemes.\n\n根据上述已知信息，请将'一类光学活性化合物或结构单元通过暂时参与到一个有机合成中以便能够进行不对称反应，在两个对映体中选择性形成一个对映体。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A class of optically active compounds or structural units that selectively form an enantiomer between two enantiomers by temporarily participating in an organic synthesis in order to perform an asymmetric reaction."
    },
    {
        "instruction":"已知信息：\n'第一百三十二条 在药品储存、陈列等区域不得存放与经营活动无关的物品及私人用品，在工作区域内不得有影响药品质量和安全的行为。'可被翻译为：Article 132 Items and personal belongings irrelevant to drug distribution activities shall not be stored in the storage and display areas of drugs. There shall be no action in the working areas that may affect the quality and safety of drugs.\n'（十一）未经批准的人员不得进入储存作业区，储存作业区内的人员不得有影响药品质量和安全的行为；'可被翻译为：(XI) The unapproved personnel shall not enter the storage area, and the personnel in storage area shall not have any action affecting the quality and safety of drugs;\n'（一）指导和督促储存人员对药品进行合理储存与作业。'可被翻译为：(I) Guiding and urging the storage personnel to store and operate the drugs in a reasonable manner;\n'第一百六十条 企业应当定期进行卫生检查，保持环境整洁。存放、陈列药品的设备应当保持清洁卫生，不得放置与销售活动无关的物品，并采取防虫、防鼠等措施，防止污染药品。'可被翻译为：Article 160 Enterprises shall carry out regular sanitary inspection and keep the environment clean and tidy. The equipment used for the storage or display of drugs shall be kept clean and sanitary, and shall not be placed with any item unrelated to the sales activities. Insect-proof and rat-proof measures shall be taken to prevent the contamination to drugs.\n\n根据上述已知信息，请将'（十二）药品储存作业区内不得存放与储存管理无关的物品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(XII) Items irrelevant to storage management shall not be stored in the storage area of drugs."
    },
    {
        "instruction":"已知信息：\n'分子或离子在外界电场作用下，正负电荷中心发生偏移而产生极性或增强极性的现象。'可被翻译为：A phenomenon in which the center of the positive and negative charges of a molecule or ion shifts under the action of an external electric field, resulting in polarity or enhanced polarity.\n'由于某些条件的变化使乳剂类型发生转变的现象。'可被翻译为：The phenomenon that the type of emulsion changes due to the change of some conditions.\n'原子或分子中电子激发前存在的低能量轨道。'可被翻译为：A low energy orbital in an atom or molecule that exists before the electrons are excited.\n'p轨道或兀轨道平行交盖使电子发生离域的现象。'可被翻译为：The phenomenon of delocalization of the electrons caused by the parallel intersection of the p or compound orbitals.\n\n根据上述已知信息，请将'由于极性键的存在使分子的其他G键电子发生偏移的现象。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Due to the existence of polar bonds, the other G-bond electrons of the molecule are offset."
    },
    {
        "instruction":"已知信息：\n'(良好的贸易和分销规范)是质量保证的一部分，通过对贸易和分销过程中发生的众多活动进行充分控制，确保药品质量得到保持。'可被翻译为：(Good trade and distribution practices are) that part of quality assurance that ensures that the quality of pharmaceutical products is maintained by means of adequate control throughout the numerous activities which occur during the trade and the distribution process.\n'对供应链的深入了解并控制，包括：'可被翻译为：In depth knowledge and control of the supply chain to include:\n'生产过程中直接影响成品质量的重要的生产方法、生产过程控制方法和技术。'可被翻译为：Important production methods, production process control methods and technologies that directly affect the quality of finished products in the production process.\n'有源非接触人体器械：根据对医疗效果的影响程度分为基本不影响、轻微影响、重要影响。'可被翻译为：Active non-body-contacting devices: little impact, minor impact, and significant impact according to the impact on treatment.\n\n根据上述已知信息，请将'根据HACCP原则编制的文件，以确保在生产和供应链中对药品质量有重要影响的危害得到控制。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A document prepared in accordance with the principles of HACCP to ensure the control of hazards which are significant for pharmaceutical quality in the production and supply chain."
    },
    {
        "instruction":"已知信息：\n'对批准疫苗注册申请时提出进一步研究要求的，疫苗持有人应当在规定期限内完成研究。'可被翻译为：Where further studies are required when approval is given to a vaccine registration application, the vaccine MAH shall complete the studies within the specified period.\n'第七十八条 对附条件批准的药品，药品上市许可持有人应当采取相应风险管理措施，并在规定期限内按照要求完成相关研究；逾期未按照要求完成研究或者不能证明其获益大于风险的，国务院药品监督管理部门应当依法处理，直至注销药品注册证书。'可被翻译为：Article 78 For drugs given conditional approval, MAHs shall adopt corresponding risk management measures and complete relevant studies within the stipulated period in accordance with regulations. Where MAHs are unable to complete the study within the stipulated period as required or are unable to prove that the benefits outweigh the risks, the drug regulatory department under the State Council shall handle the matter in accordance with the law, until the drug approval license is revoked.\n'第六十七条 对附条件批准的药品，持有人逾期未按照要求完成研究或者不能证明其获益大于风险的，国家药品监督管理局应当依法处理，直至注销药品注册证书。'可被翻译为：Article 67 For a conditionally approved drug, where the MAH fails to complete the studies as required within the specified timeline or fails to prove that the benefits outweigh risks, the NMPA shall handle the matter in accordance with the law until the Drug Approval License is revoked.\n'第五十七条 疫苗上市许可持有人应当建立健全疫苗全生命周期质量管理体系，制定并实施疫苗上市后风险管理计划，开展疫苗上市后研究，对疫苗的安全性、有效性和质量可控性进行进一步确证。'可被翻译为：Article 57 Vaccine MAHs shall establish and improve quality management systems for whole life cycle of vaccines, formulate and implement vaccine post-marketing risk management plans, and conduct vaccine post-marketing studies to further verify the safety, effectiveness and quality management of vaccines.\n\n根据上述已知信息，请将'对批准疫苗注册申请时提出进一步研究要求的疫苗，疫苗上市许可持有人应当在规定期限内完成研究；逾期未完成研究或者不能证明其获益大于风险的，国务院药品监督管理部门应当依法处理，直至注销该疫苗的药品注册证书。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where further study is required when a vaccine's registration application is approved, the vaccine MAH shall complete the study within the prescribed time limit; where the study fails to be completed on time or fails to prove that the benefits outweigh the risks, the drug regulatory department under the State Council shall take actions in accordance with law up to revoke the vaccine's registration certificate."
    },
    {
        "instruction":"已知信息：\n'细胞的冷冻保存'可被翻译为：CRYOPRESERVATION OF CELLS\n'如果收获的细胞中含有血浆，则应使用抗凝剂对样品进行适当处理来防止凝聚。此外，某些细胞在离心时易于结团或聚集，而一些细胞可能对其中的一个或多个种群表现出过度的损伤或损失。从贴壁或非贴壁培养中收获的细胞可能包括大量死细胞或比较脆弱的细胞。因此，应优化离心和洗涤步骤，并针对产品的细胞含量、悬浮液体积、悬浮介质和容器等进行优化，并在操作前后对细胞产品进行适当评估。在冻存过程开始之前，预冷冻处理不应导致细胞受到压力（例如，表现出早期凋亡标志物升高或温度休克反应的细胞），否则细胞损失将高于预期。'可被翻译为：If cells areharvested with plasma present, samples should be properly processed with ananticoagulant to prevent clotting. In addition, some cells are prone toclumping or aggregation when centrifuged, and some cell products may exhibitexcessive damage or loss of one or more populations within the product. Cellsharvested from adherent or nonadherent culture may include substantial numbersof dead or fragile cells. Therefore, centrifugation and wash steps should beoptimized and specific for the product's cellular contents, suspension volume,suspension medium, and container, along with appropriate evaluation of thecellular product before and after these manipulations. Prefreeze processingshould not result in cells that are stressed (e.g., cells that demonstrateelevated early apoptotic markers or temperature-shock responses) before thestart of the freezing process, or cell losses will be higher than expected.\n'准备低温保存的细胞应该在指数生长或最快速生长阶段和培养进入平台期之前进行收集。在此阶段收集细胞可确保细胞最具活力和均一性。冻存细胞的最佳浓度取决于细胞类型、用途和最佳回收率。对于制造细胞库来说，这个值通常在106到107 \/mL之间，但是出于其他目的可能会有所不同。在细胞收获的前一天完全更新生长培养基也会有益处。此外，大多数细胞悬浮液通过离心洗涤和在等渗介质中重悬来达到特定的细胞浓度。在冷冻过程开始前，预冷冻处理不应使细胞受到压力，否则在冷冻过程中或解冻后细胞损失将会高于预期。'可被翻译为：Toprepare for cryopreservation of cultured cells, cells should be harvestedduring exponential or the most rapid phase of growth and before the cultureenters stationary phase. Harvesting cells during this phase ensures that thecells are most viable and uniform. The optimal concentration of cells willdepend on the cell type, purpose, and best recovery. Typically this liesbetween 10 and 10 \/mL for manufacturing cell banks but may be different forother purposes. Complete growth medium renewal a day before cell harvest alsocan be beneficial. Additionally, most cell suspensions benefit from washing bycentrifugation and resuspension in an isotonic medium to a specific cellconcentration. Prefreeze processing should not result in cells that arestressed before the start of the freezing process, or cell losses duringfreezing or after thaw will be higher than expected.\n'批次记录应该是详细的，包括细胞的历史记录以及从收到细胞到释放细胞库或产品开始的所有活动。该记录应包括有关冷冻保存过程的详细信息，包括程序、使用的设备（具有唯一标识符）以及冷冻保存的打印记录。冷冻保存的细胞的活力应随时间进行监控，以确定冷冻过程和储存条件的有效性。在细胞系的每个批处理文件中捕获的信息必须可追溯到原始来源，并且所有文件都应根据现有的质量管理体系进行维护和更新。'可被翻译为：The batch recordshould be detailed, including the history of the cells and all activitiesstarting from their receipt to release of the cell banks or products for use.The record should include detailed information about the cryopreservationprocess, including the procedure, the equipment used (with unique identifier),and a printed record of the freeze prolile. The viabilities of thecryopreserved cells should be monitored over time to ascertain theeffectiveness of the freezing process and the storage conditions. Theinformation captured in each batch file of a cell line must be traceable to theoriginal source, and all documents should be maintained and updated accordingto the quality management system in place.\n\n根据上述已知信息，请将'冷冻保存之前对细胞条件进行优化是获得成功的关键。预冻处理的性质和程度取决于为保存而收获的原始细胞的状态、细胞悬液的组成及冷冻保存的特定处理步骤。预冷冻过程可能包括亚种群的选择、体外扩增或激活或启动因子孵育。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Optimizing the condition of the cells immediately before cryopreservation is critical to a successful outcome. The nature and extent of prefreeze processing depends onthe state of the original cells harvested for preservation, the composition of the cell suspension, and the specific processing steps leading into cryopreservation.Prefreeze processing may include selection of subpopulations, ex vivo expansion, or incubation with activating or priming factors."
    },
    {
        "instruction":"已知信息：\n'一次性系统（SUS）：使用一次性的产品接触组件代替可重复使用的设备的系统，例如不锈钢输送线或散 装容器。本文件中的 SUS 是指那些用于无菌产品生产的 SUS ，通常由一次性组组件组成，例如袋子、过滤器、管子、接头、储瓶和传感器。'可被翻译为：Single Use Systems (SUS) - Systems in which product contact components are used only once to replace reusable equipment such as stainless steel transfer lines or bulk containers. SUS covered in this document are those that are used in manufacturing processes of sterile products and are typically made up of disposable components such as bags, filters, tubing, connectors, storage bottles and sensors.\n'无菌工艺应被明确定义。无菌工艺相关风险以及任何相关要求应被识别、评估并适当控制。工厂的 CCS应明确规定这些控制的可接受标准、监测要求及其有效性审核。应描述并执行控制这些风险的方法和程序。可接受的残留风险应形成正式记录。'可被翻译为：The aseptic process should be clearly defined. The risks associated with the aseptic process, and any\nassociated requirements, should be identified, assessed and appropriately controlled. The site's CCS should clearly\ndefine the acceptance criteria for these controls, requirements for monitoring and the review of their effectiveness.\nMethods and procedures to control these risks should be described and implemented. Accepted residual risks\nshould be formally documented.\n'批包装： 包装材料规格、已执行的批包装文件、验证、取样方案、产品和缺陷可接受质量水平（AQL）、包装验证'可被翻译为：Packaging: Packaging material specification; Master of executed packaging record; Validation; Sampling plan; Acceptance Quality Level (AQL) for products and defects; Packaging validation\n'应设定可接受标准，从而确定转移是否成功。应对结果进行统计学趋势分析，以证明工艺能力。'可被翻译为：12.39. Acceptance criteria should be set to determine the success of the transfer. Statistical trending of results should be undertaken in order to demonstrate capability of the procedure.\n\n根据上述已知信息，请将'应建立并执行 SUS 可接受标准，可接受标准应与产品和工艺的风险或关键性相适应。接收时，应对每件 SUS 进行检查以确保其按照已批准的质量标准生产、供应和交付。应在使用前对外包装（例如外包装盒、产品袋的外观）、标签印刷进行目检，审核所附文件（例如，合格证书和灭菌证明），并形成文件记录。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Acceptance criteria should be established and implemented for SUS corresponding to the risks or criticality of the products and its processes. On receipt, each piece of SUS should be checked to ensure that they have been manufactured, supplied and delivered in accordance with the approved specification. A visual inspection of the outer packaging  (e.g.  appearance of exterior carton, product pouches), label printing,  and review  of attached documents (e.g. certificate of conformance and proof of sterilisation) should be carried out and documented prior to use."
    },
    {
        "instruction":"已知信息：\n'清除率'可被翻译为：clearance\n'清除因子'可被翻译为：purge factor\n'病毒清除'可被翻译为：virus removal\n'选择最佳接收液作为IVRT方法开发初始步骤的一个优点是，在使用接收液对不同膜评估前，可先采用选定的接收液对样品分析方法进行优化。'可被翻译为：One advantage of selecting an optimal receptor solution as an initial step in IVRT method development is that it allows for the sample analysis method to be optimized for the selected receptor solution sample matrix before proceeding to an evaluation of different membranes using that receptor solution.\n\n根据上述已知信息，请将'附录 B 详细列出了可以使用的不同清除技术，以及不使用洗脱液清除样品中微生物的替代方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Annex B has a comprehensive list of the different removal techniques that can be employed and alternatives for samples where removal of microorganisms by elution is not used."
    },
    {
        "instruction":"已知信息：\n'（一）所使用的试验用医疗器械的信息，包括名称、型号、规格、接收日期、批号或者系列号等；'可被翻译为：(1) The information of the investigational medical device, including name, model, specification, date of receipt, lot number or serial number;\n'第八十九条 试验用医疗器械的使用由临床试验机构和研究者负责，研究者应当保证所有试验用医疗器械仅用于该临床试验的受试者，在试验期间按照要求储存和保管试验用医疗器械，在临床试验后按照国家有关规定和与申办者的协议对试验用医疗器械进行处理。上述过程需由专人负责并记录。研究者不得把试验用医疗器械转交任何非临床试验参加者。'可被翻译为：Article 89 The use of investigational medical devices shall be in the charge of the clinical trial institution and the investigator. The investigator shall ensure that all investigational medical devices are used only for the subjects of the clinical trial, well stored and kept during the trial in accordance with relevant requirements, and properly handled after the clinical trial in accordance with relevant state regulations and the agreement with the sponsor. The above process shall be designated to and recorded by identified personnel. The investigator shall not hand over the investigational medical device to any non-clinical trial participants.\n'第八十八条 试验用医疗器械的记录包括生产日期、产品批号、序列号等与生产有关的记录，与产品质量和稳定性有关的检验记录，运输、维护、交付各临床试验机构使用的记录，以及试验后回收与处置日期等方面的信息。'可被翻译为：Article 88 The records of investigational medical device shall include the production-related records such as production date, product batch number and serial number, inspection records related to product quality and stability, records of transportation, maintenance and delivery to the clinical trial institutions, and information such as return and disposal dates after the trial.\n'第七十八条 临床试验结束时，研究者应当确保完成各项记录、报告。同时，研究者还应当确保收到的试验用医疗器械与所使用的、废弃的或者返还的数量相符合，确保剩余的试验用医疗器械妥善处理并记录存档。'可被翻译为：Article 78 Upon the completion of the clinical trial, the investigator shall ensure that the records and reports are completed. At the same time, the investigator shall also ensure that the number of investigational medical devices received is consistent with that of the used, discarded or returned devices, and ensure that the remaining investigational medical devices are properly handled, recorded and documented.\n\n根据上述已知信息，请将'（三）每个受试者使用试验用医疗器械的记录，包括每次使用的日期、时间、试验用医疗器械的状态等；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) Using records of the investigational medical device by each subject, including the date and time of each use and the state of the investigational medical device;"
    },
    {
        "instruction":"已知信息：\n'如果有足够的测试单元可用，则系统控制的首选是实际产品。为了设计合适的无菌 测试而必须牺牲复杂的医疗器械时，在清洁、重新包装和灭菌后，可以考虑将其用 于系统控制。'可被翻译为：The first choice for the system control is the actual product, if enough test units are available. When complex medical devices must be sacrificed in order to design a suitable sterility test, consider using them for a system control after cleaning, repacking and sterilizing.\n'在所有分析操作过程中，“系统控制”用于证明样品完整性的维护。在分析中与产 品接触的任何设备，以及分析人员的任何操作都必须加以控制。因此，用于“系统 控制”的所有设备、液体和培养基必须与被分析的实际样品尽可能接近的方式进行 处理。用于系统控制的所有物料必须通过分析实验室进行灭菌。物料灭菌的方法不 必与产品相同，但是必须使物料无菌。'可被翻译为：A \"system control\" is used to demonstrate maintenance of sample integrity during all analytical manipulations. Any piece of equipment that comes in contact with the product under analysis, along with any manipulations by the analysts, must be controlled. Thus, all equipment, fluids, and culture media for the \"system control\" must be handled in a manner which duplicates, as closely as possible, the manipulations of the actual sample being analyzed. All materials used as system controls must be sterilized by the analyzing laboratory. However, the method of sterilization need not be the same as for the product, but they must render the material sterile.\n'系统控制'可被翻译为：System Control\n'膜过滤：测试的每个歧管上离真空源连接最远的过滤漏斗用于系统控制。或者， 如果使用封闭罐系统进行无菌测试，则应用分析过程中使用的相同批次的罐进行 系统控制。'可被翻译为：Membrane Filtration: A filter funnel from the vacuum source connection on each manifold used in the test is used for the system control. Alternatively, if a closed canister system is used to conduct the sterility test a canister set from the same lot used during the analysis should be used for the system control.\n\n根据上述已知信息，请将'在设计无菌检测的“系统控制”时，必须注意尽可能多的复制样品产品的大部分。 以新颖和创新的方式满足这些要求，使系统控制有意义。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In designing \"system controls\" for sterility testing, care must be taken to duplicate the sample product for most aspects, as nearly as possible. Be novel and innovative to meet this requirement and make the system control meaningful."
    },
    {
        "instruction":"已知信息：\n'正交设计'可被翻译为：orthogonal design\n'试验设计'可被翻译为：Experimental Design\n'这是稳定性试验方案的一种简略设计方法。据此方法，在指定的取样时间点，只需从所有因子组合的总样品数中取出一组进行测定。在随后的取样时间点，则测定所有因子组合的总体样品中的另一组样品。此设计假定在特定时间点被测定的每一组样品的稳定性具有代表性。同一种制剂中样品的各种差异应作为因子加以考，如不同的批号、规格、大小不同的相同包装容器，在某些情况可能连包装容器也不同。'可被翻译为：The design of a stability schedule such that a selected subset of the total number of possible samples for all factor combinations is tested at a specified time point. At a subsequent time point, another subset of samples for all factor combinations is tested. The design assumes that the stability of each subset of samples tested represents the stability of all samples at a given time point. The differences in the samples for the same drug product should be identified as, for example, covering different batches, different strengths, different sizes of the same container closure system, and, possibly in some cases, different container closure systems.\n'（四）试验设计；'可被翻译为：(4) Trail design;\n\n根据上述已知信息，请将'研究多因素多水平的一种设计方法。它是根据正交性从全面试验中挑选出部分有代表性的点进行试验，这些有代表性的点具备了\"均匀分散，齐整可比”的特点，正交试验 设计是分式析因设计的主要方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A design method to study multi-factors and multi-levels. It is to select some representative points from the comprehensive test according to the orthogonality, these representative points have the characteristics of \"uniform dispersion, uniform comparison\", orthogonal experimental design is the main method of fractional factorial design."
    },
    {
        "instruction":"已知信息：\n'包括可预测地将温度保持在与周围环境不同的水平上，但不是主动或被动地控制在精确的预定义限制内的任何环境。'可被翻译为：Includes any environment in which the temperature is predictably maintained at a level different from that of the surrounding environment, but is not actively or passively controlled within precise predefined limits.\n'在研究期间，应监控和报告实验室环境的温度和湿度。如适用，建议将温度控制在21℃±2℃、湿度控制在50%RH±20%RH之间。'可被翻译为：Ambient laboratory temperature and humidity during the study should be monitored and reported. An environmentally controlled temperature range of 21°C ± 2°C is recommended, and, if feasible, a humidity range of 50% ± 20% relative humidity is recommended.\n'在开始计算灭菌时间之前，整个负载应达到要求的温度。对于在负载内使用参照探头控制的灭菌循环，应特别注意，负载探头温度在循环开始前应控制在规定的温度范围内。'可被翻译为：The whole of the load should reach the required temperature before measurement of the sterilising\ntime-period starts. For sterilisation cycles controlled by using a reference probe within the load, specific\nconsideration should be given to ensuring the load probe temperature is controlled within defined temperature\nrange prior to cycle commencement.\n'环境和产品温度。'可被翻译为：Environmental and product temperature.\n\n根据上述已知信息，请将'包括温度被主动或被动控制在与周围环境不同的水平上的任何环境，其温度在精确的预定义限制范围内。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Includes any environment in which the temperature is actively or passively controlled at a level different from that of the surrounding environment within precise predefined limits."
    },
    {
        "instruction":"已知信息：\n'2020年1月16日，国家药监局、海关总署和市场监管总局联合发布了《关于实施〈进口药材管理办法〉及有关事项的公告》，明确了关于首次进口药材的申请和审批、进口药材的备案和口岸检验问题。'可被翻译为：On January 16, 2020, the National Medical Products Administration, the General Administration of Customs and the State Administration for Market Regulation issued the Announcement on Implementing the Measures for the Administration of Imported Medicinal Materials and related matters to clarify issues pertaining to the application and approval of initial import, record filing and port inspection of imported medicinal materials.\n'国家药监局 海关总署关于增设广西壮族自治区崇左市爱店口岸为药材进口边境口岸的公告'可被翻译为：Announcement of NMPA and General Administration of Customs on the Establishment of Aidian Port as a Crude Drug Import Port\n'国家药监局关于实施新修订《药品生产监督管理办法》有关事项的公告'可被翻译为：NMPA Issued the Announcement on Issues Pertaining to the Implementation of the Newly Revised Provisions for the Supervision and Administration of Drug Production\n'国家药监局关于进口医疗器械产品在中国境内企业生产有关事项的公告'可被翻译为：NMPA issued the Announcement on Matters Concerning the Production of Imported Medical Devices in Domestic Enterprises in China\n\n根据上述已知信息，请将'国家药监局 海关总署 市场监管总局关于实施《进口药材管理办法》有关事项的公告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Announcement of NMPA, GAC, and SAMR on Implementing the Measures for the Administration of Imported Medicinal Materials"
    },
    {
        "instruction":"已知信息：\n'1类：境内外均未上市的创新药。指含含有新的结构明确的、具有药理作用的化合物，且具有临床价值的药品。'可被翻译为：Class 1: Innovative drugs that have not been marketed in China or overseas. They refer to drugs that contain new compounds with clear structures and pharmacological effects, and have clinical values.\n'2.3含有已知活性成份的新复方制剂，且具有明显临床优势。'可被翻译为：2.3 New compound preparations that contain known active ingredients and havesignificant clinical advantages.\n'一类具有新的化学结构，但其结构与己知药物大同小异，具有自主知识产权，且其治疗作用与已知药物相同的新药。'可被翻译为：A new drug that has a new chemical structure, but its structure is much the same as that of a known drug, has independent intellectual property rights, and has the same therapeutic effect as a known drug.\n'化学药品注册分类分为创新药、改良型新药、仿制药、境外已上市境内未上市化学药品，分为以下5个类别：'可被翻译为：The registration classification of chemical drugs covers innovative drugs, modified new drugs, generic drugs and chemical drugs marketed overseas but not in China, which fall into the following 5 categories:\n\n根据上述已知信息，请将'（一）化学药品1类为创新药，应含有新的结构明确的、具有药理作用的化合物，且具有临床价值，不包括改良型新药中2.1类的药品。含有新的结构明确的、具有药理作用的化合物的新复方制剂，应按照化学药品1类申报。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) Class 1 chemical drugs are innovative drugs that contain new compounds with clear structures and pharmacological effects and have clinical values. Class 2.1 drugs in modified new drugs are not included. New compound preparations containing new compounds with clear structures and pharmacological effects shall be applied in accordance with Class 1 chemical drugs."
    },
    {
        "instruction":"已知信息：\n'本办法第十条规定情形以外的药品，抽样完成后，口岸药品检验所应当在进口单位持有的《进口药品通关单》原件上注明“已抽样”的字样，并加盖抽样单位的公章。'可被翻译为：In the case of drugs other than those specified in Article 10 of the Provisions, when sampling is completed, the drug control institute of port shall indicate \"Sampled\" on the original Import Drug Note held by the importer, and affix the seal of sampling entity.\n'第二十二条 口岸药品检验机构收到进口药材口岸检验通知书后，应当在2日内与进口单位商定现场抽样时间，按时到规定的存货地点进行现场抽样。现场抽样时，进口单位应当出示产地证明原件。'可被翻译为：Article 22 Drug control institutions of ports shall, within 2 days after receiving the notice for port testing for importation of crude drugs, negotiate with the importers on site sampling time, and carry out on-site sampling at the specified storage location on time. During on-site sampling, importers shall show the original certificate of the place of production.\n'对麻醉药品、精神药品，抽样完成后，应当在《进口准许证》原件上注明“已抽样”的字样，并加盖抽样单位的公章。'可被翻译为：In the case of the narcotic drugs and psychotropic substances, when sampling is completed, the drug control institute of port shall indicate \"Sampled\" on the Import License, and affix the seal of sampling entity.\n'第二十四条 口岸药品检验所现场抽样时，应当注意核查进口品种的实际到货情况，做好抽样记录并填写《进口药品抽样记录单》。'可被翻译为：Article 24 When carrying out on-site sampling, the drug control institute of port shall impose close inspection on the actual condition of the imported drugs upon arrival, make sampling records, and fill in the Record of Sampling for Import Drugs.\n\n根据上述已知信息，请将'第二十三条 口岸药品检验机构应当对产地证明原件和药材实际到货情况与口岸药品监督管理部门提供的备案资料的一致性进行核查。符合要求的，予以抽样，填写进口药材抽样记录单，在进口单位持有的进口药品通关单原件上注明“已抽样”字样，并加盖抽样单位公章；不符合要求的，不予抽样，并在2日内报告所在地口岸药品监督管理部门。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 23 Drug control institutions of ports shall check the consistency of the original certificate of the place of production and actual arrival of crude drugs with the filing materials provided by drug regulatory departments of ports. For those meeting the requirements, the sampling shall be conducted, the sampling record for importation of crude drugs shall be filled out, and the original Drug Import Note held by the importers shall be marked with \"Sampling Completed\" and stamped with the official seal of the sampling unit; for those not meeting the requirements, the sampling will not be conducted and the information shall be reported to local drug regulatory departments of ports within 2 days."
    },
    {
        "instruction":"已知信息：\n'在无菌性测试中所用的每种培养基（THIO和SCD）管在整个检测时间段内均需 直接暴露于测试环境中（例如，层流罩）。或者，实验室可使用节b中详细说明 的琼脂沉淀板。'可被翻译为：Tubes of each medium (THIO and SCD) used in the sterility analysis are exposed to the immediate environment of the test (e.g., laminar flow hood) for the duration of the test. Alternatively, a laboratory may use agar settling plates as detailed in section b.\n'医疗器械的分析（除净化棉、纱布、缝合线和手术敷料外）'可被翻译为：Analysis of Medical Devices (ex. Purified Cotton, Gauze, Sutures and Surgical Dressings)\n'下面列出的分析用所有物品要单独控制。试验中使用的每种培养基都测试了每个高 压灭菌器中的一个设备。因此，对于在THIO和SCD中测试的样品，在每个培养基 中检测来自每个灭菌器（烘箱或高压灭菌器）装载的一个物品，测试中使用的每个 镊子、注射器等总共进行两个控制。'可被翻译为：All equipment items used in the analysis listed below will be controlled individually. One item from each autoclave lot of equipment is tested in each medium used in the test. Therefore, for a sample tested in THIO and SCD, one item from each sterilizer load (oven or autoclave) is tested in each medium giving a total of two controls for each forceps, syringe, etc., used in the test.\n'预先确定每种抗生素的中值标准品（【S3】）的吸光度。参考USP<81>中测试参数 和可接受数据要求'可被翻译为：Absorbance values of the media reference standard ([S3]) are predetermined per antibiotic. Refer USP<81> for testing parameters and acceptable data requirements.\n\n根据上述已知信息，请将'USP 分析手术敷料\/棉花\/纱布（包装内）的方法要求最少 100 mg，在每种培养基中进行 测试。对于单独包装的一次性用品，建议在每种培养基中对整个单元进行测试。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The USP method for analysis of surgical dressing\/cotton\/gauze (in packages) calls for a minimum quantity of 100 mg, to be tested in each medium. It is recommended that an entire unit shall be tested in each medium for individually packaged single-use articles."
    },
    {
        "instruction":"已知信息：\n'通告进一步声明，2020年10月1日起生产的医疗器械，在其上市销售前，注册人应当按照相关标准或规范要求，将最小销售单元的产品标识及相关数据上传到医疗器械唯一标识数据库；任何相关数据发生变化的，应当保证数据的变更和更新。当医疗器械最小销售单元的产品标识发生变化时，应根据新增的产品标识，将数据上传到医疗器械唯一标识数据库。'可被翻译为：The Announcement further states that, before the sale of medical devices produced since October 1, 2020, the registrant shall, in accordance with the relevant standards or specifications, upload the product identification and related data of the minimum sales unit and higher-level packaging to the unique identification database of medical devices; and ensure data alteration and update where any data related changes arise. When the product identification of the minimum sales unit of the medical device changes, the data should be uploaded to the unique identification database per the newly added product identification.\n'第六条 注册人\/备案人负责按照本规则创建和维护医疗器械唯一标识，在产品或者包装上赋予医疗器械唯一标识数据载体，上传相关数据，利用医疗器械唯一标识加强产品全过程管理。'可被翻译为：Article 6  Registrant\/filing entities shall be responsible for creating and maintaining UDI according to the Rules, assigning UDI data carrier on the product or package, uploading relevant data and using UDI to strengthen the life-cycle management of products.\n'第十四条 注册人\/备案人应当按照相关标准或者规范要求上传、维护和更新唯一标识数据库中的相关数据，并对数据的真实性、准确性、完整性负责。'可被翻译为：Article 14 Registrant\/filing entities shall upload, maintain and update relevant data in the UDID in accordance with relevant standards or specifications, and be liable for the authenticity, accuracy and completeness of the data.\n'第四十八条 特殊化妆品取得注册证后，注册人应当在产品投放市场前，将上市销售的产品标签图片上传至信息服务平台，供社会公众查询。'可被翻译为：Article 48 After obtaining the registration license of special cosmetics, the registrant shall upload the picture of the marketed product label to the information service platform for public inquiry before the products are put on the market.\n\n根据上述已知信息，请将'注册人\/备案人应当在产品上市销售前，将产品标识和相关数据上传至医疗器械唯一标识数据库。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Registrant\/filing entities shall upload UDI-DI and relevant data into the UDID prior to marketing and sales of the product."
    },
    {
        "instruction":"已知信息：\n'专供滴入鼻腔内使用的液体制剂。'可被翻译为：A liquid preparation intended for use by drops into the nasal cavity.\n'液体制剂'可被翻译为：liquid preparation\n'均相液体制剂'可被翻译为：homogeneous liquid preparation\n'内服液体制剂'可被翻译为：oral liquid preparation\n\n根据上述已知信息，请将'经肛门灌入直肠使用的液体制剂。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A liquid preparation for use by anal injection into the rectum."
    },
    {
        "instruction":"已知信息：\n'1.当档案(申请)基于等效性证据而不是通过体内等效性试验获得批准时，术语生物豁免适用于监管药物批准过程。\n2.当档案(申请)基于等效性证据而不是通过体内等效性试验获得批准时，术语生物豁免适用于监管药品批准过程。'可被翻译为：1.The term biowaiver is applied to a regulatory drug approval process when the dossier (application) is approved based on evidence of equivalence other than through in vivo equivalence testing.\n2.The term biowaiver is applied to a regulatory pharmaceutical product approval process when the dossier (application) is approved based on evidence of equivalence other than through in vivo equivalence testing.\n'一、如果经申报人评估符合M9要求，申报人可直接在药品注册申请中提出免除人体生物等效性试验。国家药监局不会单独发布免人生物等效性试验或简化人生物等效性试验的品种目录。'可被翻译为：I. If M9 requirements are met according to the assessment by the applicant, the applicant can directly propose exemption of human bio equivalence test in the drug registration application. NMPA will not issue a separate catalogue of varieties exempted from human bioequivalence test or subject to simplified human bio equivalence test.\n'三、如果先前发布的《人类生物等效性试验豁免指南》与M9指南不一致，应以M9指南为准。'可被翻译为：III. In case of inconsistency between the previously issued Guideline for Exemption from Human Bio equivalence Tests and the M9 Guideline, the M9 Guideline shall prevail.\n'第三十五条 仿制药、按照药品管理的体外诊断试剂以及其他符合条件的情形，经申请人评估，认为无需或者不能开展药物临床试验，符合豁免药物临床试验条件的，申请人可以直接提出药品上市许可申请。豁免药物临床试验的技术指导原则和有关具体要求，由药品审评中心制定公布。'可被翻译为：Article 35 For generic drugs, in vitro diagnostic reagents managed as drugs and other eligible circumstances, where the applicant, upon assessment, considers that drug clinical trials are not needed or cannot be carried out and the conditions for waiving drug clinical trials are met, an application may be filed directly for drug marketing authorization. The technical guidelines and specific requirements for waiving drug clinical trials shall be formulated and published by the CDE.\n\n根据上述已知信息，请将'二、申请豁免进行人体生物等效性试验，须在申请表中注明。经评审不能豁免，实质缺陷不能纠正的，不要求申请人提供补充材料，不予批准注册申请。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"II. Applying for exemption from human bio equivalence tests shall be indicated in the application form. If the exemption cannot be made after evaluation, and the substantial defects cannot be corrected, the applicant will not be required to provide supplementary materials, and the registration application shall be disapproved."
    },
    {
        "instruction":"已知信息：\n'违反本法规定，批签发机构未按照规定发给批签发证明或者不予批签发通知书的，由国务院药品监督管理部门责令改正，给予警告，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予降级或者撤职处分；情节严重的，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予开除处分。'可被翻译为：If a lot release institution fails to issue a lot release certificate or a not-release notice in violation of this Law, the drug regulatory department under the State Council shall order to make rectifications and give a warning to the said institution, and give a downgrade or dismissal as punishment to the main responsible person, executive in charge, and other directly responsible personnel according to law; and in serious circumstances, an expulsion from organization.\n'第八十八条 违反本法规定，疾病预防控制机构、接种单位有下列情形之一的，由县级以上人民政府卫生健康主管部门责令改正，给予警告；情节严重的，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予警告直至撤职处分，责令负有责任的医疗卫生人员暂停六个月以上一年以下执业活动；造成严重后果的，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予开除处分，由原发证部门吊销负有责任的医疗卫生人员的执业证书：'可被翻译为：Article 88 In cases where violation of this Law by disease prevention and control institution or immunization entity involves any of the following circumstances, the competent health department of the people's government at or above the county level shall order to make rectification, give a warning, and confiscate the illegal income; and in serious circumstances, impose sanctions of a warning and up to dismissal on the main responsible person, directly responsible persons and other directly responsible personnel according to law, and order the responsible medical personnel to suspend practice activities for more than six months and less than one year; for serious consequences, give an expulsion to the principal and executive in charge and other directly responsible personnel according to law, and responsible medical and health personnel shall be revoked of business certificate by original issuing department:\n'第八十七条 违反本法规定，疾病预防控制机构、接种单位有下列情形之一的，由县级以上人民政府卫生健康主管部门责令改正，给予警告，没收违法所得；情节严重的，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予警告直至撤职处分，责令负有责任的医疗卫生人员暂停一年以上十八个月以下执业活动；造成严重后果的，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予开除处分，由原发证部门吊销负有责任的医疗卫生人员的执业证书：'可被翻译为：Article 87 Where any disease prevention and control institution or immunization entity is under any of the following circumstances in violation of this Law, the competent health department of the people's government at or above the county level shall order to make rectification, give a warning, and confiscate the illegal income; and in serious circumstances, impose sanctions of a warning and up to  dismissal on the main responsible person, directly responsible persons and other directly responsible personnel according to law, and order the responsible medical personnel to suspend practice activities for more than one year and less than eighteen months; and for serious consequence, give an expulsion to the main responsible person and executive in charge and other directly responsible personnel according to law, and responsible medical and health personnel shall be revoked of business certificate by original issuing department:\n'第一百六十条 药品监督管理部门及其工作人员违反本法的规定，有下列情形之一的，由其上级行政机关或者监察机关责令改正；情节严重的，对直接负责的主管人员和其他直接责任人员依法给予行政处分：'可被翻译为：Article 160 Any drug regulatory department or its staff members that violate the provisions of this Provisions and constitute any of the circumstances below shall be instructed by its superior administrative department or supervisory departments to make rectification. If the circumstances are serious, administrative sanctions shall be given to the persons directly in charge and the other persons directly responsible in accordance with law:\n\n根据上述已知信息，请将'第八十四条 违反本法规定，批签发机构有下列情形之一的，由国务院药品监督管理部门责令改正，给予警告，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予警告直至降级处分：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 84 Where a lot release institution has one of the following circumstances in violation of this Law, the drug regulatory department under the State Council shall order to make rectifications and give a warning to the said institution, and give warnings until downgrade as punishment to the principal, director in charge and other directly responsible personnel:"
    },
    {
        "instruction":"已知信息：\n'同样，由于微生物本身的坚固性，它不需要像动物细胞系那样严格地控制冷却速率。因此，冷冻系统或方法的选择对细胞库的生存力影响较小。可简单地将冷冻容器转移到大约-80°的冰箱中过夜，然后转移到气相液氮中。或者，微生物细胞库不使用液氮存储，也可以存储在约-80°冰箱中。但是，如果可以使用液氮对于微生物长期储存（例如，几年）是比较好的选择。如果使用控制速率的冷冻器，那么它应该完全有能力在预期范围内提供统一的冷却速率，例如，1°-5°\/min。'可被翻译为：Again,because of their inherent robustness, microbial cells do not require as strict control of cooling rate as do animal cell lines. Consequently, the choice of freezing system or method has a smaller effect on the viability of the cell bank. Filled cryocontainers simply can be transferred into an approximately −80° freezer overnight followed by transfer to vapor phase liquid nitrogen. Alternatively, microbial cell banks may not use liquid nitrogen storage but can be stored at approximately−80°. However, if liquid-nitrogen storage is available, it is preferred for long-term storage (e.g., years). If acontrolled-rate freezer is employed, then it should be fully qualitied to deliver a uniform cooling rate that is within an expected range, e.g.,1°–5°\/min.\n'淋巴细胞用于多种临床应用，包括治疗癌症、病毒感染和自身免疫性疾病的免疫治疗。基于淋巴细胞的疗法可以由已经体外选择或激活的混合淋巴细胞群或淋巴细胞亚群组成，例如调节性T细胞、自然杀伤细胞和活化的T细胞。与造血细胞一样，淋巴细胞通常使用10%的DMSO溶液冷冻保存，冷却速度控制在1℃\/min。'可被翻译为：Lymphocytes are used for a variety ofclinical applications including immunotherapy to treat cancer, viral infection,and autoimmune disease. Therapy based on lymphocytes may consist of mixedlymphocyte populations or lymphocyte subpopulations that have been selected oractivated ex vivo, e.g., regulatory T cells, natural killer cells, andactivated T cells. As with hematopoietic cells, lymphocytes typically arecryopreserved using a 10% DMSO solution and a controlled cooling rate of1°\/min.\n'细胞通常使用两种不同类型的冻存方式：控制速率的冷却方式（使用可编程的冷冻机）和被动的冷却方式（包括使用隔热容器）。液氮罐上附有冷冻装置，按照一个预先编好的程序增加或减少进入腔室的冷氮气流量来控制腔室的温度。控制冷冻速率的方案通常包括几个步骤，每个步骤都应该评估和限定特定的细胞类型。'可被翻译为：Two different types of freezing typically are used for cells: controlled-ratecooling (using programmable freezers) and passive cooling (including use of insulated containers). Controlled-rate freezers are attached to liquid nitrogen supplies. The temperature of the chamber should be controlled by increasing or decreasing the flow of cold nitrogen gas into the chamber according to a preprogrammed step. Controlled-rate freezing protocols typically involve several steps, each of which should be evaluated and qualitied for a specific cell type.\n'使用受控速率冷冻装置可更精确地控制冷冻环境，从而在细胞外冰晶形成时为冷却速率范围狭窄（与最大存活率相关）或敏感的细胞提供更一致（且更高）的解冻后恢复能力。将温度探针放置在要冷冻的细胞附近或同时进行低温保存的模拟细胞悬液中，用于监视冷冻过程并提供过程控制。如果融合潜热的释放被延迟或控制不当，则进行冷冻保存的细胞可能会受到破坏，并且复苏后的活力可能会降低。'可被翻译为：The useof controlled-rate freezing provides more precise control of the freezingenvironment and therefore may provide more consistent (and higher) post-thaw recoveryfor cells that may have a narrow range of cooling rates associated with maximum survival or cells that are sensitive to the temperature at which ice forms in theextracellular solution. Temperature probes placed near the cells being frozen,or in a mock cell suspension that undergoes cryopreservation simultaneously, areused to monitor the freezing process and to provide process control. If releaseof the latent heat of fusion is delayed or poorly controlled, cells undergoing cryopreservationmay be damaged and may have diminished viability after thaw.\n\n根据上述已知信息，请将'对于微生物细胞而言，控制冷却和升温的速度并不那么重要，但是仍然应使用温水浴（例如30°–35°）尽快融化细胞。可以将温度调节至菌株的孵育温度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Controllingthe rates of cooling and warming is less critical for microbial cells, but thecells still should be thawed as quickly as possible using a warm water bath(e.g., 30°–35°). Temperatures can be adjusted to the incubation temperature ofthe strain."
    },
    {
        "instruction":"已知信息：\n'第一百六十五条 物料的质量标准一般应当包括：'可被翻译为：Article 165: Specifications for materials should include, if applicable:\n'第一百零三条 应当建立物料和产品的操作规程，确保物料和产品的正确接收、贮存、发放、使用和发运，防止污染、交叉污染、混淆和差错。'可被翻译为：Article 103: Operation procedures for handling and managing materials and products should be established to ensure the proper receiving, storage, dispensing, use and distribution of materials and products, to prevent any risk of contamination, cross-contamination, mixups and errors.\n'第六十条 接收、发放和发运区域应当能够保护物料、产品免受外界天气（如雨、雪）的影响。接收区的布局和设施应当能够确保到货物料在进入仓储区前可对外包装进行必要的清洁。'可被翻译为：Article 60: Receiving, dispatch and distribution bays should protect materials and products from the weather (e.g. raining, snowing). Reception areas should be designed and equipped to allow containers of incoming materials to be cleaned where necessary before storage.\n'第三十九条 应当根据厂房及生产防护措施综合考虑选址，厂房所处的环境应当能够最大限度地降低物料或产品遭受污染的风险。'可被翻译为：Article 39: Premises should be situated in an environment that, when considered together with measures to protect the manufacturing process, presents minimal risk of causing contamination of materials or products.\n\n根据上述已知信息，请将'第一百八十九条 在生产的每一阶段，应当保护产品和物料免受微生物和其他污染。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 189: At every stage of processing, products and materials should be protected from microbial and other contamination."
    },
    {
        "instruction":"已知信息：\n'第七十七条 企业应当按照验收规定，对每次到货药品进行逐批抽样验收，抽取的样品应当具有代表性：'可被翻译为：Article 77 Enterprises shall carry out sampling inspection for acceptance lot by lot for drugs of each arrival in accordance with the provisions on acceptance inspection, and the samples taken shall be representative:\n'第一百五十四条 企业应当按规定的程序和要求对到货药品逐批进行验收，并按照本规范第八十条规定做好验收记录。'可被翻译为：Article 154 Enterprises shall conduct acceptance inspection on the drugs arrived lot by lot in accordance with the prescribed procedures and requirements, and make acceptance inspection records in accordance with Article 80 herein.\n'第八十一条 企业应当建立库存记录，验收合格的药品应当及时入库登记；验收不合格的，不得入库，并由质量管理部门处理。'可被翻译为：Article 81 Enterprises shall keep inventory records, and in a timely manner warehouse and register the drugs that are qualified in the acceptance inspection; those failed in the acceptance inspection shall not be warehoused and shall be instead handled by the quality management department.\n'第一百五十八条 验收合格的药品应当及时入库或者上架，验收不合格的，不得入库或者上架，并报告质量管理人员处理。'可被翻译为：Article 158 Drugs that are qualified in the acceptance inspection shall be warehoused or put on the shelf without delay; those failed the acceptance inspection shall not be warehoused or put on the shelf and shall be instead reported to the quality management personnel for handling.\n\n根据上述已知信息，请将'第七十二条 企业应当按照规定的程序和要求对到货药品逐批进行收货、验收，防止不合格药品入库。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 72 Enterprises shall, in accordance with the prescribed procedures and requirements, receive and inspect the arrived drugs lot by lot, so as to prevent unqualified drugs from being warehoused."
    },
    {
        "instruction":"已知信息：\n'血浆中药物浓度下降一半所需的时间。'可被翻译为：The time it takes for the concentration of the drug in the plasma to drop by half.\n'药物在体内分布达到平衡状态后血浆药物浓度降低一半所需的时间。'可被翻译为：The time it takes for the plasma drug concentration to decrease by half after the distribution of the drug in the body reaches equilibrium.\n'能使人或兔血浆中的纤维蛋白原转变为纤维蛋白而引起血浆凝固的酶，一般指由致病性葡萄球菌产生的凝固酶。'可被翻译为：An enzyme that causes plasma coagulation by converting fibrinogen to fibrin in human or rabbit plasma, generally coagulase produced by pathogenic staphylococcus.\n'凝血酶原时间'可被翻译为：prothrombin time\n\n根据上述已知信息，请将'在缺乏血小板的血浆中加入过量的组织因子后，凝血酶原转化为凝血酶导致血浆凝固所需的时间。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The time required for the conversion of prothrombin to thrombin resulting in plasma clotting after the addition of an excess of tissue factors to platelet-deficient plasma."
    },
    {
        "instruction":"已知信息：\n'注：无热源移液管、微量移液头、试管和其它用品均有商业化产品可及。'可被翻译为：NOTE: Pyrogen free pipettes, micropipettor tips, test tubes, and other accessories are commercially available.\n'移液管'可被翻译为：Pipettes\n'用于对样品进行测量的设备应该有适当的验证和频繁的核查，确保结果可靠和可重复， 此类设备的例子包括称重天平、pH计、灭菌器、微生物计数器、手动\/自动读板器和紫 外可见光分光计。手动和自动读板器更多信息参见标题为抗生素效价测定章节：管碟法。'可被翻译为：Equipment used to provide a unit of measurement should have the appropriate validation and frequent verification checks to ensure reliable and reproducible results; examples of such equipment include a weight scale, pH meter, autoclave, micrometer, manual\/automatic plate reader and UV-VIS spectrophotometer. For more information on manual and automatic plate readers, see section titled Antibiotic Potency Testing: Plate Method.\n'本节提供的程序信息可用于动力学分析方法。动力学色度和浊度试剂可通过商业化获取。 分析过程可作为试剂盒采购。控制标准内毒素、检测中所用LAL试剂和无热源水的 COA应保存。其它物料如无热源移液管、微量移液头、试管和96阱微生物碟可从不同 供应商处采购。实验室亦应保存显示这些物料无热源的COA。'可被翻译为：This section provides procedural information that can be applied to kinetic assays. The Kinetic Chromogenic and Turbidimetric reagents are commercially available. Assay may be purchased as a kit. A certificate of analysis should be maintained for the control standard endotoxin, Limulus Amebocyte Lysate (LAL), and pyrogen free water used in the assay. Other materials such as pyrogen free pipettes, micropipettor tips, test tubes, and 96- well microplates may be purchased from various vendors. Certificates of analysis indicating these materials are pyrogen-free should also be maintained by the laboratory.\n\n根据上述已知信息，请将'标准实验室玻璃仪器如烧杯、漏斗、烧瓶、圆颈培养瓶和1-2升的瓶子也是必须的。一 次性无菌设备，如试管 、培养皿和血清移液管，只要不影响效价检测的定量就可以一直 使用。其它设备包括不锈钢瓶、比色皿、血清移液管、单通道微量移液器、pH计、加热 板、可调温水浴锅、培养箱和手动\/自动平板计数器或紫外可见分光光度计。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Standard laboratory glassware such as beakers, funnels, flasks, roux and 1-2 liter bottles are also required. Sterile and disposable equipment such as test tubes, petri-plates and serological pipettes may be used so long as the use of this equipment does not affect the quantitative aspect of potency testing. Additional equipment includes a stainless steel penicylinders, penicylinder dropper, cuvettes, pipettor and micropipette, pH meter, hot plate, adjustable- temperature water bath, incubator and a manual\/automatic plate reader or UV- VIS spectrophotometer."
    },
    {
        "instruction":"已知信息：\n'2019年，国家医疗器械不良事件监测信息系统接收可疑医疗器械不良事件报告39万余份，每百万人口平均报告数为297份，全国96.70%的区县报告了医疗器械不良事件，系统基层注册用户达到31万余家，其中医疗器械注册人达19662家。与2018年相比，全国医疗器械不良事件报告数量保持平稳，系统基层注册用户数量持续增加，新旧医疗器械不良事件监测信息系统实现平稳过渡。'可被翻译为：In 2019, the National Medical Device Adverse Event Monitoring Information System received more than 390,000 reports of suspected medical device adverse events,with an average number of 297 reports per million population; 96.70 percent of districts and counties across China reported medical device adverse events, and the registered users at the grassroots level of the system topped 310,000, covering 19,662 medical device registrants. Compared with 2018, the number of medical device adverse event reports nationwide has remained stable, the number of registered users at the grassroots level of the system has continued to increase, and a smooth transition has been achieved from the old to the new medical device adverse event monitoring information system.\n'2018年，我国每百万人口平均可疑医疗器械不良事件报告数为305份，与2017年相比增长23份(图2)。'可被翻译为：Figure 2 Comparison of the number of suspected medical device adverse events reported per million people across China from2014 to 2018\n'2018年，全国医疗器械不良事件监测信息系统共收到可疑医疗器械不良事件报告406974份，较2017年增长8.19%，反映出我国医疗器械不良事件报告意识不断增强、报告收集能力有效提升（图1)。'可被翻译为：In 2018, the National Medical Device Adverse Event Monitoring Information System received a total of 406,974 reports of suspected medical device adverse events,an increase of 8.19% over 2017, reflecting the increasing awareness of China's medical device adverse event reporting and the effective enhancement of report collection capabilities (Figure 1) .\n'1.全国医疗器械不良事件报告数量。2019年，国家医疗器械不良事件监测信息系统共收到可疑医疗器械不良事件报告396345份，比上年减少2.61%（图1）。'可被翻译为：1. Number of Medical Device Adverse Event Report. In 2019, the National Medical Device Adverse Event Monitoring Information System has received a total of 396,345 reports of suspected medical device adverse events, a decrease of 2.61 percent YOY(See Figure 1) .\n\n根据上述已知信息，请将'2018年，全国医疗器械不良事件监测信息系统接收可疑医疗器械不良事件报告40余万份，报告质量得到提高。系统基层注册用户达到27万余家，其中生产企业1.3万余家，较去年增长16.44%。全国95.9%的区县报告了医疗器械不良事件，每百万人口平均报告数为305份。此外，国家药品不良反应监测中心完成医疗器械不良事件监测新信息系统的搭建测试，实现了我国医疗器械不良事件在线报告系统的新旧更替，为《医疗器械不良事件监测和再评价管理办法》(以下简称《办法》)的贯彻落实提供有力支撑。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In 2018, the Information System for National Medical Device Adverse Event Monitoring has received more than 400,000 Reports for Suspected Adverse Events of Medical Devices, and the quality of the reports was improved. There are more than 270,000registered users at the grassroots level of the system, of which more than 13,000 are manufacturers, an increase of 16.44% over last year. 95.9% of districts and counties across China reported medical device adverse events,with an average of 305 reports per million people. In addition, the National Center for Adverse Drug Reaction Monitoring completed the establishment of a new information system for monitoring adverse events in medical devices, realizing the replacement of the online reporting system for such events in China,provide strong support for the implementation of the Administrative Measures for Monitoring and Re-evaluating the Adverse Events of Medical Devices (hereinafter referred to as the Measures) ."
    },
    {
        "instruction":"已知信息：\n'第十九条 检查组认为证据可能灭失或者以后难以取得的，以及需要采取行政强制措施的，可以通知被检查单位所在地食品药品监督管理部门。被检查单位所在地食品药品监督管理部门应当依法采取证据保全或者行政强制措施。'可被翻译为：Article 19 Where the inspection team deems that evidence may be lost or difficult to acquire afterwards, and administrative compulsory measures need to be taken, it may notify the local food and drug regulatory department. The local food and drug regulatory department shall take evidence preservation or administrative compulsory measures in accordance with laws and regulations.\n'风险消除后，采取控制措施的药品监督管理部门应当解除控制措施。'可被翻译为：After the risks are eliminated, the drug regulatory department that took the control actions shall terminate such actions.\n'（十）其他需要采取的风险控制措施。'可被翻译为：(X) Other risk control measures required.\n'第二十五条 根据飞行检查结果，食品药品监督管理部门可以依法采取限期整改、发告诫信、约谈被检查单位、监督召回产品、收回或者撤销相关资格认证认定证书，以及暂停研制、生产、销售、使用等风险控制措施。风险因素消除后，应当及时解除相关风险控制措施。'可被翻译为：Article 25 The food and drug regulatory department may take risk control measures in accordance with laws and regulations, such as rectification within a deadline, issuance of warning letter, warning meeting with the organization being inspected, monitoring of product recall, withdrawal or cancellation of relevant qualification certificates, as well as suspension of research and development, manufacture, sales, use and etc. in accordance with the results of unannounced inspection. After the risk factors are eliminated, the relevant risk control measures shall be terminated timely.\n\n根据上述已知信息，请将'需要采取风险控制措施的，被检查单位应当按照食品药品监督管理部门的要求采取相应措施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where risk control measures need to be taken, the organization being inspected shall conduct corresponding measures in accordance with the requirements of the food and drug regulatory department."
    },
    {
        "instruction":"已知信息：\n'通过物理作用使菌种发生遗传信息改变的物质。'可被翻译为：A substance that changes the genetic information of a strain by physical action.\n'物理诱变剂的一种。用紫外线进行照射使菌种发生遗传信息改变。'可被翻译为：A type of physical mutagen. The genetic information of the strain is altered by exposure to ultraviolet light.\n'对生物体的遗传物质进行人为的操作，使之发生修饰和改变的过程。'可被翻译为：The process of artificially manipulating the genetic material of an organism so that it is modified or altered.\n'在单位面积上使均一物质发生断裂所需的最小力。'可被翻译为：The minimum force required to break a homogeneous substance per unit area.\n\n根据上述已知信息，请将'通过化学作用使菌种发生遗传信息改变的物质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A substance that causes the genetic information of a strain to be altered by chemical action."
    },
    {
        "instruction":"已知信息：\n'用元素符号表示物质分子的组成及分子量的化学式。'可被翻译为：A chemical formula in which the constituent and molecular weight of a substance are expressed by an element symbol.\n'表示粒子的投影面与圆的接近程度。'可被翻译为：Indicates how close the projection plane of the particle is to the circle.\n'空气干燥程度的物理量。在一定温度下单位体积空气中含有的水分子越少则空气越干燥，反之则越潮湿。'可被翻译为：The physical quantity of air dryness. At a given temperature, the less water molecules a unit volume of air contains, the drier the air, and the more humid the air is.\n'在透析过程中通过半透膜的物质。常含有在溶液中容易扩散的物质。'可被翻译为：A substance that passes through a semi-permeable membrane during dialysis. Often containing a substance that diffuses easily in solution.\n\n根据上述已知信息，请将'表示物质分子扩散程度的物理量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A physical quantity indicating the degree of diffusion of the molecules of a substance."
    },
    {
        "instruction":"已知信息：\n'第一百二十四条 省、自治区、直辖市药品监督管理部门应当自受理申请之日起6个月内对药品再注册申请进行审查，符合规定的，予以再注册；不符合规定的，报国家食品药品监督管理局。'可被翻译为：Article 124 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall review the application dossiers within six months starting from the date of acceptance, and approve the re-registration application if regulations are conformed to, or report to the State Food and Drug Administration if regulations are not conformed to.\n'第一百二十七条 国家食品药品监督管理局收到省、自治区、直辖市药品监督管理部门意见后，经审查不符合药品再注册规定的，发出不予再注册的通知，并说明理由。'可被翻译为：Article 127 After receiving the opinions from the drug regulatory departments of the provinces, autonomous regions, or municipalities directly under the Central Government, the State Food and Drug Administration shall review the application. Where the regulations on drug re-registration are not conformed to, a notice of rejection for re-registration shall be issued with reasons.\n'第一百二十三条 省、自治区、直辖市药品监督管理部门对申报资料进行审查，符合要求的，出具药品再注册申请受理通知书；不符合要求的，出具药品再注册申请不予受理通知书，并说明理由。'可被翻译为：Article 123 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall review the application dossiers, and issue a acceptance notice of drug re-registration application if requirements are met, or issue a non-acceptance notice, in which reasons shall be given, of drug re-registration application if requirements are not met.\n'进口药品的再注册申请由申请人向国家食品药品监督管理局提出。'可被翻译为：Where applying for an import drug re-registration, the applicant shall submit the application to the State Food and Drug Administration.\n\n根据上述已知信息，请将'第一百二十五条 进口药品的再注册申请由国家食品药品监督管理局受理，并在6个月内完成审查，符合规定的，予以再注册；不符合规定的，发出不予再注册的通知，并说明理由。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 125 The State Food and Drug Administration shall deal with import drug re-registration applications, complete the review within six months, and approve the re-registration application if regulations are conformed to, or issue a non-acceptance notice, in which reasons shall be given, if regulations are not conformed to."
    },
    {
        "instruction":"已知信息：\n'接受了外源遗传物质（如质粒DNA等）使遗传特性发生了改变的细菌。可以通过选择培养液等方法鉴定获得。'可被翻译为：Bacteria that have received foreign genetic material (such as plasmid DNA) that has altered their genetic characteristics. It can be identified by selecting culture medium, etc.\n'一种自主复制的圆形染色体外DNA元件。它通常携带几个基因，其中一些基因赋予了对各种抗生素的抗性;这种耐药性通常被用来区分含有质粒和不含质粒的生物体。'可被翻译为：An autonomously replicating, circular, extrachromosomal DNA element. It usually carries a few genes, some of which confer resistance to various antibiotics; such resistance is often used to discriminate between organisms that contain the plasmid and those that do not.\n'参与DNA复制的蛋白质复合物。其中至少含有DNA聚合酶及引发体（引发酶与其他分子的复合物）、单链结合蛋白、解旋体等。复制体位于每个复制叉处进行染色体DNA复制的聚合反应。'可被翻译为：A protein complex involved in DNA replication. It contains at least DNA polymerase and initiator (complex of initiator enzyme with other molecules), single chain binding protein, unspin body, etc. The replicators are located at each fork for the polymerization of chromosomal DNA replication.\n'病毒核酸在细胞复制过程中形成的中间产物。如单链DNA或RNA病毒在复制期间形成的双链中间物。'可被翻译为：An intermediate product formed by viral nucleic acids during cell replication. Double-stranded intermediates, such as those formed by single-stranded DNA or RNA viruses during replication.\n\n根据上述已知信息，请将'能够进行独立复制的单位，如质粒DNA等。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A unit, such as plasmid DNA, that is capable of independent replication."
    },
    {
        "instruction":"已知信息：\n'在2020年7月1日前，已受理但尚未批准的药品生产许可申请，按照新《生产办法》的有关规定进行办理。'可被翻译为：Applications for drug production licenses that have been accepted before July 1, 2020 but not yet approved afterwards shall be processed in accordance with the relevant provisions of the new Production Provisions.\n'第七条 从事制剂、原料药、中药饮片生产活动，申请人应当按照本办法和国家药品监督管理局规定的申报资料要求，向所在地省、自治区、直辖市药品监督管理部门提出申请。'可被翻译为：Article 7 To engage in the manufacturing activities of preparations, active drug ingredients or Prepared Slices, the applicant shall submit an application to the drug regulatory department of province, autonomous region or municipality directly under the Central Government where the manufacturer is located according to the requirements on application documents specified in these Provisions and by the NMPA.\n'（2020年1月22日国家市场监督管理总局令第28号公布 自2020年7月1日起施行）'可被翻译为：(Promulgated by Decree No.28 of State Administration for Market Regulation on January 22, 2020)\n'本决定自2017年7月1日起施行。'可被翻译为：This decision shall be effective as of July 1, 2017.\n\n根据上述已知信息，请将'一、自2020年7月1日起，从事制剂、原料药、中药饮片生产活动的申请人，在申请新的药品生产许可时，应当按照《生产办法》有关规定办理。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1. From July 1, 2020, applicants engaged in the production of preparations, APIs, and TCM slices should follow the relevant provisions of the Production Provisions while applying new for drug production licenses."
    },
    {
        "instruction":"已知信息：\n'第一百七十三条 原版空白的批生产记录应当经生产管理负责人和质量管理负责人审核和批准。批生产记录的复制和发放均应当按照操作规程进行控制并有记录，每批产品的生产只能发放一份原版空白批生产记录的复制件。'可被翻译为：Article 173: The master batch processing records should be reviewed and approved by the heads of production and quality management. The reproduction and issuance should be managed and recorded according to operation procedures, and only one copy of reproduced master records can be issued for the manufacture of each batch.\n'第一百七十七条 批包装记录应当依据工艺规程中与包装相关的内容制定。记录的设计应当注意避免填写差错。批包装记录的每一页均应当标注所包装产品的名称、规格、包装形式和批号。'可被翻译为：Article 177: A batch packaging record should be based on the relevant parts of the Packaging Instructions, and avoid transcription errors. The record should carry the product name, strength, package size and batch number on every page.\n'3.确保批生产记录和批包装记录经过指定人员审核并送交质量管理部门；'可被翻译为：3) To ensure that the batch records of processing and packaging are evaluated and signed by a designated person before they are sent to the quality management department;\n'第一百六十二条 每批药品应当有批记录，包括批生产记录、批包装记录、批检验记录和药品放行审核记录等与本批产品有关的记录。批记录应当由质量管理部门负责管理，至少保存至药品有效期后一年。'可被翻译为：Article 162: Each batch of drug should have a batch record, which includes related records of processing, packaging, testing, release, and etc. This batch record should be retained for at least one year after the product shelf life by the quality management department.\n\n根据上述已知信息，请将'第一百七十八条 批包装记录应当有待包装产品的批号、数量以及成品的批号和计划数量。原版空白的批包装记录的审核、批准、复制和发放的要求与原版空白的批生产记录相同。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 178: The batch packaging record should carry the batch number and the quantity of bulk product, as well as the batch number and the planned quantity of finished product. The requirements of review, approval, reproducing and issuance of original blank batch packaging record is the same as that of original blank batch processing record."
    },
    {
        "instruction":"已知信息：\n'第六十四条  药品监督管理部门及其工作人员在监督检查中，应当严格规范公正文明执法，严格执行廉政纪律，不得索取或者收受财物，不得谋取其他利益，不得妨碍企业的正常经营活动。'可被翻译为：Article 64 During the supervision and inspection, the drug regulatory departments and their staff shall enforce the law in a strict, procedure-based, impartial and non-abusive manner, and strictly enforce the discipline of clean government, shall not ask for or accept property, seek for other interests, or hinder normal distribution activities of the enterprises.\n'第六十三条 国家药品监督管理局和省、自治区、直辖市药品监督管理部门在生产监督管理工作中，不得妨碍药品上市许可持有人、药品生产企业的正常生产活动，不得索取或者收受财物，不得谋取其他利益。'可被翻译为：Article 63 When conducting supervision and administration, the drug regulatory department of the province, autonomous region or municipality directly under the Central Government and the NMPA shall not impede the normal manufacturing activities of MAHs and drug manufacturers, request or accept any money or gift or seek any other benefits.\n'第一百六十一条 药品监督管理部门及其工作人员在药品注册过程中索取或者收受他人财物或者谋取其他利益，构成犯罪的，依法追究刑事责任；尚不构成犯罪的，依法给予行政处分。'可被翻译为：Article 161 If any drug regulatory department and its staff members request for or accept money or valuable articles from others, or pursue other interests in the process of drug registrations, where a crime is committed, criminal liabilities shall be investigated by law; where a crime is not committed, administrative sanctions shall be given by law.\n'（四）批签发过程中收受、索取批签发申请人财物或者谋取其他利益的。'可被翻译为：(IV)  Accepting or asking for the property or other interests of the lot release applicant during the process of lot release.\n\n根据上述已知信息，请将'第七十二条  药品监督管理部门及其工作人员在监督检查中，应当严格规范公正文明执法，严格执行廉政纪律，不得索取或者收受财物，不得谋取其他利益，不得妨碍企业的正常生产活动。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 72 During the supervision and inspection, the drug regulatory departments and their staff shall enforce the law in a strict, procedure-based, impartial and non-abusive manner, strictly enforce the discipline of clean government, and shall not ask for or accept property, seek for other interests, or hinder normal manufacturing activities of the enterprises."
    },
    {
        "instruction":"已知信息：\n'第十七条 药品生产企业在启动药品召回后，一级召回在1日内，二级召回在3日内，三级召回在7日内，应当将调查评估报告和召回计划提交给所在地省、自治区、直辖市药品监督管理部门备案。省、自治区、直辖市药品监督管理部门应当将收到一级药品召回的调查评估报告和召回计划报告国家食品药品监督管理局。'可被翻译为：Article 17 After starting the drug recall procedure, the drug manufacturer shall submit the investigation and assessment reports and recall plan to the local drug regulatory department of the province, autonomous region or municipality directly under the Central Government for record within 1 day in the case of Class 1 recall, 3 days in the case of Class 2 recall and 7 days in the case of Class 3 recall. The local drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall submit the received investigation and assessment reports and plan for Class 1 recall to the State Food and Drug Administration.\n'第十六条 药品生产企业在作出药品召回决定后，应当制定召回计划并组织实施，一级召回在24小时内，二级召回在48小时内，三级召回在72小时内，通知到有关药品经营企业、使用单位停止销售和使用，同时向所在地省、自治区、直辖市药品监督管理部门报告。'可被翻译为：Article 16 After making the decision to recall the drug, the drug manufacturer shall make the recall plan and organize its implementation, notify the relevant drug distributors and users to stop selling and using the drug within 24 hours in the case of Class 1 recall, 48 hours in the case of Class 2 recall and 72 hours in the case of Class 3 recall, and at the same time report the case to the local drug regulatory department of the province, autonomous region or municipality directly under the Central Government.\n'第二十三条 药品生产企业在召回完成后，应当对召回效果进行评价，向所在地省、自治区、直辖市药品监督管理部门提交药品召回总结报告。'可被翻译为：Article 23 After completing the recall, the drug manufacturer shall assess the effect of the recall and submit the drug recall summary report to the local drug regulatory department of the province, autonomous region or municipality directly under the Central Government.\n'第二十条 医疗器械生产企业在实施召回的过程中，应当根据召回计划定期向所在地省、自治区、直辖市食品药品监督管理部门提交召回计划实施情况报告。'可被翻译为：Article 20 During the recall process, the medical device manufacturer shall, according to the recall plan, regularly submit a report on the implementation of the recall plan to the food and drug regulatory department of the province, autonomous region, and municipality directly under the central government where it is located.\n\n根据上述已知信息，请将'第二十一条 药品生产企业在实施召回的过程中，一级召回每日，二级召回每3日，三级召回每7日，向所在地省、自治区、直辖市药品监督管理部门报告药品召回进展情况。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 21 During implementation of the recall, the drug manufacturer shall give updates to the local drug regulatory department of the province, autonomous region or municipality directly under the Central Government on the recall progress daily in the case of Class 1 recall, every 3 days in the case of Class 2 recall and every 7 days in the case of Class 3 recall."
    },
    {
        "instruction":"已知信息：\n'第六十四条 实验室的设计应当确保其适用于预定的用途，并能够避免混淆和交叉污染，应当有足够的区域用于样品处置、留样和稳定性考察样品的存放以及记录的保存。'可被翻译为：Article 64: Laboratories should be designed to suit its intended use and avoid mixups and cross-contamination. There should be adequate space for samples handling, storage of retention and stability samples, and storage of records.\n'3.除稳定性较差的原辅料外，用于制剂生产的原辅料（不包括生产过程中使用的溶剂、气体或制药用水）和与药品直接接触的包装材料的留样应当至少保存至产品放行后二年。如果物料的有效期较短，则留样时间可相应缩短。'可被翻译为：3) Except for those less stable starting materials, reference samples of starting materials (other than solvents, gases or water for pharmaceutical use used in the manufacturing process) and immediate packaging materials should be retained for at least two years after the release of product. That period may be shortened if the shelf life of the materials is shorter.\n'（四）物料的留样：'可被翻译为：4. Reference samples of materials:\n'（二）留样应当能够代表被取样批次的物料或产品。'可被翻译为：2. The reference samples should be representative of the batch of material or product from which they are taken.\n\n根据上述已知信息，请将'第二百二十五条 企业按规定保存的、用于药品质量追溯或调查的物料、产品样品为留样。用于产品稳定性考察的样品不属于留样。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 225: The reference samples are materials or products that are being kept by the manufacturer according to the operation procedures for quality traceability or investigation. Samples for product stability study are not reference samples."
    },
    {
        "instruction":"已知信息：\n'（二）因化妆品质量安全违法行为被公安机关拘留或者给予其他治安管理处罚的；'可被翻译为：(2) those who are arrested or receive other public security punishment by the public security authorities due to illegal act related with quality and safety of cosmetics;\n'（四）因化妆品违法行为受到行政处罚后1年内又实施同一性质的违法行为，或者因违反化妆品质量安全法律、法规受到刑事处罚后又实施化妆品质量安全违法行为；'可被翻译为：(4) committing illegal acts of the same nature within 1 year after receiving administrative punishment due to illegal acts related with cosmetics, or committing illegal acts concerning quality and safety of cosmetics after receiving criminal punishment due to violation of laws and regulations on quality and safety of cosmetics;\n'因涉嫌化妆品质量安全犯罪被立案侦查或者提起公诉，且有证据证明可能危害人体健康的，化妆品电子商务平台经营者可以依法或者依据平台服务协议和交易规则暂停向平台内化妆品经营者提供电子商务平台服务。'可被翻译为：If the cosmetic marketers within the platform are placed on a file for investigation or are initiated a public prosecution due to being suspected of crime related with quality and safety of cosmetics, and there are evidences proving that this might cause potential harm to human health, then the operators of cosmetic e-commerce platform could suspend provision of e-commerce platform services for the cosmetic marketers within the platform in accordance with the laws or with the service agreement and trading provisions of the platform.\n'质量安全负责人应当具备化妆品、化学、化工、生物、医学、药学、食品、公共卫生或者法学等化妆品质量安全相关专业知识和法律知识，熟悉相关法律、法规、规章、强制性国家标准、技术规范，并具有5年以上化妆品生产或者质量管理经验。'可被翻译为：The person in charge of quality and safety shall have professional knowledge and legal knowledge related with quality and safety of cosmetics in aspects of cosmetics, chemistry, chemical engineering, biology, medicine, pharmacy, food, public health, or law, etc., be familiar with relevant laws, regulations, provisions, mandatory national standards, and technical specifications, and have at least 5 years of experience in manufacturing or quality management of cosmetics.\n\n根据上述已知信息，请将'（一）因化妆品质量安全相关犯罪被人民法院判处刑罚的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) those who are sentenced to penalties by the People’s Court due to crime related with quality and safety of cosmetics;"
    },
    {
        "instruction":"已知信息：\n'第八十条 应当制定设备的预防性维护计划和操作规程，设备的维护和维修应当有相应的记录。'可被翻译为：Article 80: Preventive maintenance plans and procedures should be established, and the maintenance and repair activities should be recorded.\n'（三）厂房和设备的维护、清洁和消毒；'可被翻译为：3. Maintenance, cleaning and sanitation of premises and equipment;\n'4.确保厂房和设备的维护保养，以保持其良好的运行状态；'可被翻译为：4) To ensure that the premises and equipment are maintained and serviced to function in a sound operating state;\n'设备与仪器： 设备和仪器清单、预防性维护信息、确认总览'可被翻译为：Equipment and instruments: List of equipment and instruments; Preventive maintenance information; Overview of qualification\n\n根据上述已知信息，请将'预防性维护——按照确保没有额外污染风险的标准，对设备、公用设施和厂房进行维护（包括计划内和计划外维护）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Preventative maintenance - maintaining equipment, utilities and premises (planned and unplanned\nmaintenance) to a standard that will ensure there is no additional risk of contamination."
    },
    {
        "instruction":"已知信息：\n'含有原液并通常与辅料放在一起的一种药品类型。'可被翻译为：A pharmaceutical product type that contains a drug substance, generally, in association with excipients.\n'药物与适宜的辅料制成的具有一定粒度的干燥颗粒状制剂。'可被翻译为：A dry granular preparation with a certain particle size made of drugs and appropriate excipients.\n'原液是指最终可与辅料一起制成成品的物质。它由 预期产品、产品相关物质、产品相关杂质和工艺相关杂质组成。它也可能含包括其他的辅料成分,如缓冲剂。'可被翻译为：The material which is subsequently formulated with excipients to produce the drug product. It can be composed of the desired product, product-related substances, and product- and process-related impurities. It may also contain excipients including other components such as buffers.\n'采用USP<1724>中描述的统计学方法对释放速率之间的不等效性进行评估。具体来说，将对照标示规格配方制剂与具有相同规格、不同配方制剂的各6杯释放速率，按USP<1724>中描述的统计学方法进行比较。所有12杯应在同一天平行运行，具有相同规格、不同配方制剂的释放速率应与对照标示规格配方制剂的释放速率不等效。'可被翻译为：Determination of inequivalence between release rates should be evaluated using the statistical approach described in USP General Chapter<1724>. Specifically, the release rates from 6 cells dosed with the nominal reference strength formulation should be compared with the release rates from 6 cells dosed with an altered formulation, also at the nominal reference strength, using the statistical approach described in USP General Chapter<1724>. All 12 cells being compared should have been run in parallel on the same day, and the release rate from the altered formulation at the same nominal reference strength should fail to show equivalence to the release rate from the nominal reference strength formulation.\n\n根据上述已知信息，请将'可与辅料一起生产制剂的未经配方的药物。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The unformulated drug substance that may subsequently be formulated with excipients to produce the dosage form."
    },
    {
        "instruction":"已知信息：\n'已经备案的产品不再生产或者进口的，备案人应当及时报告承担备案管理工作的药品监督管理部门取消备案。'可被翻译为：If the products that have been filed are no longer produced or imported, the filing person shall promptly report to the drug regulatory department responsible for the filing administration for cancelling the filing.\n'第六十二条  再评价结果表明已注册或者备案的医疗器械存在危及人身安全的缺陷，且无法通过技术改进、修改说明书和标签等措施消除或者控制风险，或者风险获益比不可接受的，持有人应当主动申请注销医疗器械注册证或者取消产品备案；持有人未申请注销医疗器械注册证或者取消备案的，由原发证部门注销医疗器械注册证或者取消备案。药品监督管理部门应当将注销医疗器械注册证或者取消备案的相关信息及时向社会公布。'可被翻译为：Article 62 Where the re-evaluation results indicate that the registered or filed medical devices have defects that endanger personal safety, and cannot be eliminated or controlled risks through such measures as technical advances and revision of instructions and labels, or the risk\/benefit ratio is unacceptable, MAHs shall voluntarily apply for the cancellation of medical device registration certificate or filing. In case MAHs do not apply for the cancellation of medical device registration certificate or filing, the original issuing authority shall cancel the medical device registration certificate or filing. The drug regulatory departments shall promptly release to the public the information related to the medical device registration certificate or filing cancelled.\n'第六十五条 已注册的医疗器械有法律、法规规定应当注销的情形，或者注册证有效期未满但注册人主动提出注销的，食品药品监督管理部门应当依法注销，并向社会公布。'可被翻译为：Article 65 Where, for a registered medical device, there exists a revocation situation in accordance with laws and regulations, or a registrant applies for revocation before the expiration of a registration certificate, the food and drug regulatory department shall revoke the registration certificate according to law and disclose to the society.\n'第七十五条 已注册的体外诊断试剂有法律、法规规定应当注销的情形，或者注册证有效期未满但注册人主动提出注销的，食品药品监督管理部门应当依法注销，并向社会公布。'可被翻译为：Article 75 Where, for a registered in-vitro diagnostic reagent, there exists a revocation situation in accordance with laws and regulations, or a registrant applies for revocation before the expiration of a registration certificate, the food and drug regulatory department shall revoke the registration certificate according to law and disclose to the society.\n\n根据上述已知信息，请将'第四十二条 已经注册的产品不再生产或者进口的，注册人应当主动申请注销注册证。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 42 If the registered product is no longer produced or imported, the registrant shall take the initiative to apply for cancellation of the registration license."
    },
    {
        "instruction":"已知信息：\n'在生产、取样、包装或重新包装、贮存或运输等操作过程中，原辅料、中间产品、待包装产品、成品受到具有化学或微生物特性的杂质或异物的不利影响。'可被翻译为：Adverse impacts of impurities with chemical or microbiological properties or foreign matters, into starting materials, intermediate, bulk, or finished products during production, sampling, packaging or repackaging, storage or transport.\n'污染：在生产、取样、包装或再包装、储存或运输过程中，意外地将微生物性质的杂质（微生物、热原的\n数量和类型）或外源微粒物引入原材料、中间体、原料药或药品中，可能对产品质量产生不利影响。'可被翻译为：Contamination  -  The  undesired  introduction  of impurities  of a  microbiological  nature  (quantity  and  type  of microorganisms, pyrogen), or of foreign particle matter, into or onto a raw material, intermediate, active substance or drug product during production, sampling, packaging or repackaging, storage or transport with the potential to adversely impact product quality.\n'用于代表在原材料、API 起始物料、中间体或 API 中微生物的水平和类型(例如，有害的或无害的)。生物负荷不被认为是污染，除非其水平超标或检测到有害微生物。'可被翻译为：The level and type (e.g. objectionable or not) of micro-organisms that can be present in raw materials, API starting materials, intermediates or APIs. Bioburden should not be considered contamination unless the levels have been exceeded or defined objectionable organisms have been detected.\n'在贮藏和运输中用以保护中间体或 API 的任何物料。'可被翻译为：Any material intended to protect an intermediate or API during storage and transport.\n\n根据上述已知信息，请将'在生产、抽样，包装或重新包装、贮存或运输过程中混入原材料、中间体或 API 中，具有化学或微生物性质的杂质或外来物质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The undesired introduction of impurities of a chemical or microbiological nature, or of foreign matter, into or onto a raw material, intermediate, or API during production, sampling, packaging or repackaging, storage or transport."
    },
    {
        "instruction":"已知信息：\n'质谱进样器之一。由阀、贮槽和针孔漏组成。'可被翻译为：One of the mass spectrometry sampler. It consists of a valve, a storage tank and a pinhole leak.\n'液相色谱进样时隔膜进样器的部分。'可被翻译为：Part of the diaphragm injector during liquid chromatographic injection.\n'直接液体进样'可被翻译为：direct liquid introduction\n'冷柱头进样器'可被翻译为：cold on-column injector\n\n根据上述已知信息，请将'质谱进样器之一。主要用于固体样品及高沸点液体样品的进样。将微克(Rg)量样品置于末端封闭的毛细管底部，插入进样杆顶端。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"One of the mass spectrometry samplers. It is mainly used for solid samples and high boiling point liquid samples. Place the microgram (Rg) measure sample at the bottom of the capillary tube with closed end and insert it into the top of the injector rod."
    },
    {
        "instruction":"已知信息：\n'活性药物成分 （API）：准备用于制剂生产成为其中活性成分的物质或其混合物。此类物质用于改变药效活性或其它直接影响诊断、治愈、缓解、治疗或预防疾病影响或影响人体结构和功能。'可被翻译为：active pharmaceutical ingredient (API). Any substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to affect the structure and function of the body.\n'表现为具有治疗或预防人类疾病特性的任何物质或物质组合；可能用于人类或给予人类的任何物质或物质组合，以通过发挥药理学、免疫学或代谢作用或进行医学诊断来恢复、矫正或改变生理功能。[ISO 11615]\n任何可能用于人类或动物、治疗或预防疾病的物质或物质组合，以便进行医学诊断或恢复、纠正或改变生理功能[ENV 13607] [65\/65\/EEC号指令，修订版]'可被翻译为：Any substance or combination of substances presented as having properties for treating or preventing disease in human beings;Any substance or combination of substances which might be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis.[ISO 11615]Any substance or combination of substances which might be administered to human beings or animals for treating or preventing disease, with the view to making medical diagnosis or to restore, correct or modify physiological functions [ENV 13607] [Directive 65\/65\/EEC, modified]\n'1.看到药物。\n2.任何用于人用或兽用的物质或药品，旨在改变或探索生理系统或病理状态，以使接受者受益。在本文件中，术语“药物”和“药品”(见下文)可互换使用。\n3.为治疗或预防人类疾病，或为了对人类进行医学诊断，或为了恢复、纠正或改变人类的生理功能而销售或制造用于销售的任何物质或物质的组合。'可被翻译为：1.See drug.\n2.Any substance or pharmaceutical product for human or veterinary use that is intended to modify or explore physiological systems or pathological states for the benefit of the recipient. In this document, the terms medicine and pharmaceutical product (see below) are used interchangeably.\n3.Any substance or combination of substances marketed or manufactured to be marketed for treating or preventing disease in human beings, or with a view to making a medical diagnosis in human beings, or to restoring, correcting or modifying physiological functions in human beings.\n'治疗或诊断眼部疾病，并直接施于眼部的制剂。'可被翻译为：A preparation for the treatment or diagnosis of diseases of the eye and applied directly to the eye.\n\n根据上述已知信息，请将'任何旨在供生产一种药物(医疗用品)制剂，并作为其活性成份的物质或混合物。这类物质旨在疾病的诊断，治疗、缓减，处置或预防以及影响人体的结构和功能等方面发挥药理作用或其它的直接效应。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body."
    },
    {
        "instruction":"已知信息：\n'（三）每批药品均应当由质量受权人签名批准放行。'可被翻译为：3. The release of each batch of products should be approved with signature by the Qualified Person.\n'（三）物料放行管理和产品放行；'可被翻译为：(3) Material release management and product release;\n'第一百五十四条 文件的起草、修订、审核、批准均应当由适当的人员签名并注明日期。'可被翻译为：Article 154: The drafting, revision, review and approval of documents should be signed and dated by appropriate personnel.\n'第二百二十八条 应当分别建立物料和产品批准放行的操作规程，明确批准放行的标准、职责，并有相应的记录。'可被翻译为：Article 228: Operation procedures for release of the materials and products should be respectively established with well defined criteria and responsibilities. Relevant records should be available.\n\n根据上述已知信息，请将'（三）物料应当由指定人员签名批准放行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3. The release of materials should be approved with signature by a designated person."
    },
    {
        "instruction":"已知信息：\n'除菌级过滤器：一种经过适当验证、可以去除液体或气体中的特定微生物以得到无菌滤液的过滤器。通常这种过滤器的孔径等于或小于 0.22μm。'可被翻译为：Sterilising grade filter - A filter that, when appropriately validated, will remove a defined microbial challenge\nfrom a fluid or gas producing a sterile effluent. Usually such filters have a pore size equal or less than 0.22μm.\n'在无菌工艺中使用的气体应在使用点通过除菌级过滤器（标称孔径最大为 0.22μm）过滤。如果过滤器是按产品批次使用（例如用于过滤无菌灌装产品的表层气体）或作为产品容器的呼吸过滤器，则过滤器应进行完整性测试，并将结果作为批次认证\/放行的一部分进行审核。所有位于最终除菌级过滤器之后的输送管道均应进行灭菌。当工艺中使用气体时，应在使用点定期对气体进行微生物监测。'可被翻译为：Gases used in aseptic processes should be filtered through a sterilising grade filter (with a nominal pore size of a maximum of 0.22 μm) at the point of use. Where the filter is used on a batch basis (e.g. for filtration of gas used for overlay of aseptically filled products) or as product vessel vent filter, then the filter should be integrity\ntested and the results reviewed as part of the batch certification\/release process. Any transfer pipework or tubing that is located after the final sterilising grade filter should be sterilised. When gases are used in the process, microbial monitoring of the gas should be performed periodically at the point of use.\n'进行这种测试是为了验证过滤器可以从气体或液体中去除细菌。该测试通常使用标准生物进行，如微小Brevundimonas，最低浓度为107菌落形成单位\/cm2'可被翻译为：This test is performed to validate that a filter can remove bacteria from a gas or liquid. The test is usually performed using a standard organism, such as Brevundimonas diminuta, at a minimum concentration of 107 colony-forming units\/cm2\n'关键无菌气体和空气的排气过滤器（与产品的无菌性直接相关）的完整性应通过使用后测试进行核实，过滤器留在过滤器组件或壳体中。'可被翻译为：The integrity of critical sterile gas and air vent filters (that are directly linked to the sterility of the product) should be verified by testing after use, with the filter remaining in the filter assembly or housing.\n\n根据上述已知信息，请将'一种过滤器，经过适当验证后，将从产生无菌流出物的流体或气体中去除特定的微生物挑战。通常这种过滤器的孔径等于或小于0.22微米(µm)。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A filter that, when appropriately validated, will remove a defined microbial challenge from a fluid or gas producing a sterile effluent. Usually such filters have a pore size equal to or less than 0.22 micrometres (µm)."
    },
    {
        "instruction":"已知信息：\n'第五十六条 化妆品、化妆品新原料注册人未按照本办法规定申请特殊化妆品、化妆品新原料变更注册的，由原发证的药品监督管理部门责令改正，给予警告，处1万元以上3万元以下罚款。'可被翻译为：Article 56 If the registrant of cosmetics and new cosmetic ingredients fails to apply for the change of registration for special cosmetics and new cosmetic ingredients in accordance with the requirements of these Provisions, the drug regulatory department that originally issued the license shall give an order for rectification, give a disciplinary warning, and impose a fine of not less than 10,000 yuan but no more than 30,000 yuan.\n'第五十七条 化妆品新原料注册人、备案人违反本办法第二十一条规定的，由省、自治区、直辖市药品监督管理部门责令改正；拒不改正的，处5000元以上3万元以下罚款。'可被翻译为：Article 57 If the registrant or filing person of new cosmetic ingredients violates the requirements of Article 21 of these Provisions, the drug regulatory department of the province, autonomous region, or municipality directly under the central government shall give an order for rectification; the person that refuses to do so shall be fined not less than 5,000 yuan but no more than 30,000 yuan.\n'化妆品、化妆品新原料注册人未按照本办法的规定重新注册的，依照化妆品监督管理条例第五十九条的规定给予处罚；化妆品、化妆品新原料备案人未按照本办法的规定重新备案的，依照化妆品监督管理条例第六十一条第一款的规定给予处罚。'可被翻译为：If the registrant of cosmetics and new cosmetic ingredients fails to re-register in accordance with requirements of these Provisions, it shall be punished in accordance with Article 59 of the Regulations on Supervision and Administration of Cosmetics; if the filing person of cosmetics or new cosmetic ingredients fails to re-file the filing in accordance with requirements of these Provisions, fines shall be imposed as in the first paragraph of Article 61 of the Regulations on Supervision and Administration of Cosmetics.\n'化妆品、化妆品新原料注册人、备案人按照规定通过化妆品、化妆品新原料注册备案信息服务平台（以下简称信息服务平台）申请注册、进行备案。'可被翻译为：Registrants and filing persons of cosmetics and new cosmetic ingredients shall apply for registration and filing through the information service platform of registration and filing for cosmetics and new cosmetic ingredients (hereinafter referred to as the information service platform) in accordance with regulations.\n\n根据上述已知信息，请将'化妆品、化妆品新原料备案人未按照本办法规定更新普通化妆品、化妆品新原料备案信息的，由承担备案管理工作的药品监督管理部门责令改正，给予警告，处5000元以上3万元以下罚款。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the filing person of cosmetics and new cosmetics ingredients fails to update the filing information of general cosmetics and new cosmetics ingredients in accordance with the requirements of these Provisions, the drug regulatory department responsible for the filing administration shall order corrections, give warnings, and impose a fine of no less than 5,000 yuan but no more than 30,000 yuan."
    },
    {
        "instruction":"已知信息：\n'计算机科学与心理学相结合而产生的研究用计算机实现人的智能行为和功能的一门学科。人工智能的智能范畴一般包括人的智能行为，如图像和声音识别、学习、计划、决策、解决问题、自然语言理解等。'可被翻译为：The combination of computer science and psychology is the study of the use of computers to implement human intelligent behavior and function. The intelligence category of artificial intelligence generally includes human intelligent behavior, such as image and sound recognition, learning, planning, decision making, problem solving, natural language understanding, etc.\n'专家知识'可被翻译为：expert knowledge\n'使特定功能和过程达到一致的详细书面说明。'可被翻译为：Detailed written instructions to achieve uniformity of the performance of a specific function and\/or process(es).\n'第三十八条 对于复杂或者有争议的问题，核查中心可召开注册核查专家会审会，听取核查、审评、检验等方面的专家意见。核查中心应当综合专家意见作出核查审核结论。'可被翻译为：Article 38 For complex or controversial issues, CFDI may hold a review meeting of registration inspection experts to listen to expert opinions on inspection, evaluation, and test. CFDI shall inspect and review conclusion based on the opinions of experts.\n\n根据上述已知信息，请将'运用特定领域的专门知识，通过推理来模拟通常由人类专家才能解决的各种复杂的、具体的问题，达到与专家具有同等解决问题能力的计算机智能程序系统。它能对决策的过程做出解释，并有学习功能，即能自动增长解决问题所需的知识。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The use of specialized knowledge in a specific field, through reasoning to simulate a variety of complex, specific problems usually solved by human experts, to achieve and experts have the same problem-solving ability of the computer intelligent program system. It can explain the decision-making process, and has a learning function, that is, it can automatically increase the knowledge needed to solve the problem."
    },
    {
        "instruction":"已知信息：\n'第三十四条 普通化妆品上市或者进口前，备案人按照国家药品监督管理局的要求通过信息服务平台提交备案资料后即完成备案。'可被翻译为：Article 34 Before a general cosmetic is marketed or imported, the filing person shall complete the filing by submitting the filing dossiers through the information service platform as required by the NMPA.\n'第十八条 化妆品新原料备案人按照国家药品监督管理局的要求提交资料后即完成备案。'可被翻译为：Article 18 The filing of new cosmetic ingredient is completed when the filing person submits the dossiers as required.\n'注册申请人首次申请特殊化妆品注册或者备案人首次进行普通化妆品备案的，应当提交其符合前款规定要求的证明资料。'可被翻译为：To apply for registration of special cosmetics for the first time or filing of general cosmetics for the first time, the applicant for registration or the filing person shall submit the document that meets the requirements as set forth before.\n'第五条 国家药品监督管理局负责特殊化妆品、进口普通化妆品、化妆品新原料的注册和备案管理，并指导监督省、自治区、直辖市药品监督管理部门承担的化妆品备案相关工作。国家药品监督管理局可以委托具备相应能力的省、自治区、直辖市药品监督管理部门实施进口普通化妆品备案管理工作。'可被翻译为：Article 5 The National Medical Products Administration (NMPA) is responsible for the registration and filing administration of special cosmetics, imported general cosmetics and new cosmetic ingredients, and guiding and supervising the related cosmetic filing work undertaken by the drug regulatory departments of provinces, autonomous regions, and municipalities. The NMPA may entrust the drug regulatory departments of provinces, autonomous regions, and municipalities directly under the Central Government that have corresponding capabilities to implement the filing administration of imported general cosmetics.\n\n根据上述已知信息，请将'第三十八条 特殊化妆品生产或者进口前，注册申请人应当按照国家药品监督管理局的要求提交申请资料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 38 Before a special cosmetic is produced or imported, the registrant shall submit the application dossiers as required by the NMPA."
    },
    {
        "instruction":"已知信息：\n'第十五条 国家鼓励疫苗上市许可持有人加大研制和创新资金投入，优化生产工艺，提升质量控制水平，推动疫苗技术进步。'可被翻译为：Article 15 To facilitate the progress of vaccine technology, the State encourages vaccine MAHs to increase capital investment on research, development and innovation, to optimize production process, and to promote quality control level.\n'焦红强调，《疫苗管理法》兼顾安全、发展和创新。为积极地促进我国疫苗质量的进一步提升，《疫苗管理法》中作出一系列的新规来鼓励疫苗的创新和发展'可被翻译为：Jiao emphasized that the Law also takes into account safety, development and innovation. To actively promote the further improvement of the quality of vaccines in China, the Law has made a series of new regulations to encourage the innovation and development of vaccines.\n'第一条 为了加强疫苗管理，保证疫苗质量和供应，规范预防接种，促进疫苗行业发展，保障公众健康，维护公共卫生安全，制定本法。'可被翻译为：Article 1 This Law is enacted to enhance the vaccine administration, to ensure the quality and supply of vaccines, to standardize the immunization, to promote the development of the vaccine industry,  and to safeguard public health and safety.\n'第九十八条 国家鼓励疫苗生产企业按照国际采购要求生产、出口疫苗。'可被翻译为：Article 98 The State encourages vaccine manufacturers to produce and export vaccines to meet the international demand.\n\n根据上述已知信息，请将'国家制定疫苗行业发展规划和产业政策，支持疫苗产业发展和结构优化，鼓励疫苗生产规模化、集约化，不断提升疫苗生产工艺和质量水平。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The State formulates development planning and industry policies for the vaccine industry to support development and structural optimization of the vaccine industry, and encourages scale and intensive production and constant improvement on the production process and quality of vaccines."
    },
    {
        "instruction":"已知信息：\n'中药饮片生产企业销售其生产的中药饮片，应当履行药品上市许可持有人相关义务。'可被翻译为：The manufacturer of prepared slices of Chinese crude drugs shall perform relevant obligations as the MAH of the drug when selling the prepared slices of Chinese crude drugs.\n'中药饮片生产企业应当履行药品上市许可持有人的相关义务，确保中药饮片生产过程持续符合法定要求。'可被翻译为：Manufacturers of Prepared Slices shall fulfill relevant obligations of drug MAHs and ensure the manufacturing of Prepared Slices continuously complies with regulatory requirements.\n'第四十九条 省、自治区、直辖市药品监督管理部门负责对本行政区域内药品上市许可持有人，制剂、化学原料药、中药饮片生产企业的监督管理。'可被翻译为：Article 49 The drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall, within its administrative region, be responsible for the supervision and administration of the drug MAHs, and manufacturers of drug products, chemical active drug ingredients and Prepared Slices.\n'第二十九条 中药材、中药饮片的标签管理规定由国家食品药品监督管理局另行制定。'可被翻译为：Article 29    The labeling provisions for Chinese crude drugs and prepared slices of Chinese crude drugs shall be formulated separately by the State Food and Drug Administration.\n\n根据上述已知信息，请将'第三十九条 中药饮片生产企业履行药品上市许可持有人的相关义务，对中药饮片生产、销售实行全过程管理，建立中药饮片追溯体系，保证中药饮片安全、有效、可追溯。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 39 Manufacturers of decoction pieces of Chinese medicine shall fulfill relevant obligations of an MAH, and shall implement whole chain management for the manufacture and distribution of decoction pieces of Chinese medicine and establish a traceability system for decoction pieces of Chinese medicine to ensure the safety, efficacy, and traceability thereof."
    },
    {
        "instruction":"已知信息：\n'（四）拆零销售应当使用洁净、卫生的包装，包装上注明药品名称、规格、数量、用法、用量、批号、有效期以及药店名称等内容；'可被翻译为：(IV) For dismantling sales, clean and sanitary package shall be used, on which the name, strength, quantity, usage, dosage, lot number, and expiry date of the drug, and name of the drug store shall be indicated;\n'最小单位药品的重量均匀度。用于评价制剂单位包装装量与平均装量偏离的程度。'可被翻译为：The evenness of the weight of the smallest unit of medicine. Used to evaluate the degree to which the unit pack size of a drug preparation deviates from the average pack size.\n'第十七条 药品的内标签应当包含药品通用名称、适应症或者功能主治、规格、用法用量、生产日期、产品批号、有效期、生产企业等内容。'可被翻译为：Article 17    The inner label shall bear such drug information as the adopted name in China, indications or functions, strength, dose and usage, production date, batch number, expiry date and manufacturer.\n'医疗器械标签是指在医疗器械或者其包装上附有的用于识别产品特征和标明安全警示等信息的文字说明及图形、符号。'可被翻译为：Medical device labels refer to the information in the forms of  text, graphics and symbols that are printed or attached on medical devices or their packages, and are used for identifying product features and indicating safety warnings, etc..\n\n根据上述已知信息，请将'贴于药品包装上用于指示药物名称、剂型、装量、用法用量等信息的标志。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A mark affixed to the package of a drug to indicate the name, dosage form, dosage, usage, and other information."
    },
    {
        "instruction":"已知信息：\n'6.临床试验各环节参与人员具有能够承担临床试验工作相应的教育、培训和经验，并得到主要研究者的授权。'可被翻译为：6. The participants in all aspects of clinical trials shall be qualified in education, training and experience correspondingly to undertake the work of clinical trials, and shall be authorized by the principal investigator.\n'1.研究机构名称、研究场所地址及所开展的研究内容应与申报资料相符；在多场所研究中，所有参与研究的机构及其承担职责应完整、准确地反映在申报资料中；'可被翻译为：1. The name of the testing facility, the address of the testing facility site and the content of the study carried out should be consistent with that in the application dossiers; for a multi-site study, all testing facilities involved and their responsibilities performed should be fully and accurately reported in the application dossiers;\n'(1)研究所需实验系统的来源应清晰合规，应完整保存 实验系统购入(转入)、质量鉴定等相关证明性文件；应完整保留适用性评估资料。'可被翻译为：(1) The source of the test system used in the study should be clear and compliant with the related regulation, and the relevant supporting documentation for acquisition and characterization of the test system should be kept completely; documentation for assessing suitability of the test system should be kept completely.\n'(1)研究所需实验动物的来源应清晰合规。实验动物供 应商应具有相应的资质证明；应完整保留实验动物合格证及其他相关证明性文件；'可被翻译为：(1) The source of laboratory animals used in the study should be clear and compliant with the related regulations. Suppliers should have corresponding qualification as required for manufacture or supply of laboratory animals; the guarantee certificate or other relevant documentation for the quality of laboratory animals should be maintained completely;\n\n根据上述已知信息，请将'6.参与研究人员应具有研究所需专业知识和资格、工作 经验和培训经历，并应完整保留主要研究人员档案；参与研究的人员应与申报资料一致。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"6. The study personnel should be of adequate knowledge, qualifications, working experience and training to perform their duties in the study, and the personnel files of those who play important roles in the study should be retained completely; the personnel involved in the study should be consistent with that specified in the application dossiers."
    },
    {
        "instruction":"已知信息：\n'新药研制单位依法向药品监督管理部门提出新药相关科学研究结果的一系列申请。新药申请分申请临床研究和申请生产上市两个阶段。'可被翻译为：The research and development unit for a new drug shall submit a series of applications for the results of scientific research related to the new drug to the drug regulatory department in accordance with law. A new drug application is divided into two stages: application for clinical research and application for production and marketing.\n'第七十条 新药进入监测期之日起，国家食品药品监督管理局已经批准其他申请人进行药物临床试验的，可以按照药品注册申报与审批程序继续办理该申请，符合规定的，国家食品药品监督管理局批准该新药的生产或者进口，并对境内药品生产企业生产的该新药一并进行监测。'可被翻译为：Article 70 Starting from the date a new drug enters the observation period, any other application for the clinical trial of the same drug already approved by the State Food and Drug Administration may proceed along drug registration application, review and approval procedures; where regulations are conformed to, the State Food and Drug Administration shall approve the production or importation of the same drug. The observations of the drugs produced by the domestic manufacturers should be conducted together with the drug already in the observation period.\n'经国家药品监督管理部门批准上市，临床必需且不可替代或者不可完全替代，在一定时间或一定\n区域内供应不足或不稳定的药品。'可被翻译为：Drugs that have been approved for market release by the national drug regulatory authority, deemed clinically necessary and irreplaceable, or not entirely substitutable. These drugs may experience insufficient or unstable supply within a specific period or region.\n'第四章 新药申请的申报与审批'可被翻译为：Chapter IV  Application and Approval of New Drugs\n\n根据上述已知信息，请将'生产新药必须经国家药品监督管理部门批准，取得批准文号的过程。新药的申报和审批分为临床研究和生产上市两个阶段。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process in which the production of a new drug must be approved by the State drug regulatory department and the approval number is obtained. The application and approval of a new drug is divided into two stages: clinical research and production and listing."
    },
    {
        "instruction":"已知信息：\n'主要以机械方式与物料结合的水分。结合力很弱，干燥速度较快。'可被翻译为：Moisture that is mainly mechanically bound to the material. The binding force is very weak and the drying speed is fast.\n'在一定状态下，物料表面的水蒸气压与空气中水蒸气分压相等时物料中所含的水分。是该干燥条件下无法除去的水分。'可被翻译为：In a certain state, the water vapor pressure on the surface of the material is equal to the water vapor partial pressure in the air. It is the moisture that cannot be removed under this drying condition.\n'物料中所含大于平衡水分的那一部分水。在干燥过程中能被除去。'可被翻译为：The portion of the material containing more water than the equilibrium moisture. It can be removed during drying.\n'药物与蛋白质之间的结合处于动态平衡，与蛋白结合力强的药物分子将已经与白蛋白结合、但结合力弱的药物分子置换出来的现象。'可被翻译为：The binding between the drug and the protein is in homeostasis, a phenomenon in which the drug molecule with strong binding force to the protein replaces the drug molecule that is already bound to albumin but has weak binding force.\n\n根据上述已知信息，请将'主要以物理化学方式与物料结合的水分。结合力较强，干燥速度缓慢。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Moisture that binds primarily to the material in a physicochemical manner. The binding force is strong and the drying speed is slow."
    },
    {
        "instruction":"已知信息：\n'疾病预防控制机构、接种单位在接收或者购进疫苗时，应当索取前款规定的证明文件，并保存至疫苗有效期满后不少于五年备查。'可被翻译为：When accepting or purchasing vaccines, disease prevention and control institutions and immunization entities shall ask for the abovementioned supporting documents and keep such documents for no less than five years upon the expiration date of vaccines for reference.\n'第三十九条 疫苗上市许可持有人应当按照规定，建立真实、准确、完整的销售记录，并保存至疫苗有效期满后不少于五年备查。'可被翻译为：Article 39 Vaccine MAHs shall establish authentic, accurate and complete sales records as required, and keep such records for no less than five years upon the expiration date of vaccines for reference.\n'（三）未按照规定建立并保存疫苗接收、购进、储存、配送、供应、接种、处置记录；'可被翻译为：(3) failing to establish and maintain records of vaccine reception, purchase, storage, distribution, supply, inoculation, and disposal as required;\n'疾病预防控制机构、接种单位接收或者购进疫苗时，应当索取本次运输、储存全过程温度监测记录，并保存至疫苗有效期满后不少于五年备查；对不能提供本次运输、储存全过程温度监测记录或者温度控制不符合要求的，不得接收或者购进，并应当立即向县级以上地方人民政府药品监督管理部门、卫生健康主管部门报告。'可被翻译为：When accepting or purchasing vaccines, disease prevention and control institutions and immunization entities shall ask for the temperature monitoring records during the whole process of transportation and storage, and keep such records for no less than five years upon the expiration date of vaccines for reference; where the temperature monitoring records during the whole process of transportation and storage cannot be provided or the temperature control fails to meet the requirements, disease prevention and control institutions and immunization entities shall not accept or purchase the vaccines concerned. Instead, they shall immediately report to the drug regulatory departments and the competent health departments of the people's governments at or above the county level.\n\n根据上述已知信息，请将'疾病预防控制机构、接种单位、疫苗配送单位应当按照规定，建立真实、准确、完整的接收、购进、储存、配送、供应记录，并保存至疫苗有效期满后不少于五年备查。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Disease prevention and control institutions, immunization entities and vaccine distribution entities shall establish authentic, accurate and complete records of acceptance, purchase, storage, distribution and supply as required, and keep such records for no less than five years upon the expiration date of vaccines for reference."
    },
    {
        "instruction":"已知信息：\n'研究在0.1〜100nm之间的物质组成体系的运动规律、相互作用以及实际应用中相关技术问题的学科。'可被翻译为：The discipline of studying the movement law, interaction and related technical problems in practical application of the material composition system between 0.1 and 100nm.\n'研究中国药学各学科发展历史及规律的学科，是历史学科的分支学科。'可被翻译为：The discipline of studying the development history and laws of various disciplines of Chinese pharmacy is a branch discipline of history.\n'研究药物与机体免疫系统之间相互作用规律的学科。'可被翻译为：The study of the laws governing the interaction between drugs and the body's immune system.\n'分子的一种振动形式。分子中两个化学键端的原子同时做反向垂直于平面方向的运动。'可被翻译为：A form of vibration in a molecule. Atoms at two chemically bonded ends of a molecule move simultaneously in opposite directions perpendicular to the plane.\n\n根据上述已知信息，请将'研究大量粒子（原子、分子）集合的宏观运动规律的学科。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The study of macroscopic laws of motion of large collections of particles (atoms, molecules)."
    },
    {
        "instruction":"已知信息：\n'第六十条  设区的市级负责药品监督管理的部门应当建立并及时更新辖区内医疗器械经营企业信用档案。信用档案中应当包括医疗器械经营企业许可备案、监督检查结果、违法行为查处、质量抽查检验、自查报告、不良行为记录和投诉举报等信息。'可被翻译为：Article 60 The department in charge of drug supervision and administration at the level of a city divided into districts shall establish and promptly update credit files of the medical device distributors within their administrative areas. The credit files shall include information such as a medical device distributor’s licensing or filing, supervision and inspection results, investigation and punishment of illegal acts, sample testing of quality, self-inspection report, records of misconducts, and compliant reporting, etc.\n'从事第二类、第三类医疗器械生产活动，应当经所在地省、自治区、直辖市药品监督管理部门批准，依法取得医疗器械生产许可证；从事第一类医疗器械生产活动，应当向所在地设区的市级负责药品监督管理的部门办理医疗器械生产备案。'可被翻译为：To engage in manufacturing of Class II and Class III medical devices, an entity shall obtain approval from the drug regulatory department of the local province, autonomous region, or municipality directly under the central government, and acquire Medical Device Manufacturing License according to law; to engage in manufacturing of Class I medical devices, an entity shall handle medical device manufacturing filing formalities at the local department in charge of drug supervision and administration at the level of a city divided into districts.\n'受托生产企业增加生产第二类、第三类医疗器械，且与该产品注册人不在同一省、自治区、直辖市，或者增加生产第一类医疗器械，且与该产品备案人不在同一设区的市的，受托生产企业所在地药品监督管理部门还应当将相关情况通报注册人、备案人所在地药品监督管理部门。'可被翻译为：If the contract manufacturer increases the manufacturing of Class II and Class III medical devices, and is not in the same province, autonomous region or municipality directly under the central government with the registrant, or increases the manufacturing of Class I medical devices, and is not in the same city divided into districts with the filing entity, the drug regulatory department of the place where the contract manufacturer is located shall also inform related conditions to the drug regulatory departments of the places where the registrant and the filing entity are located.\n'省、自治区、直辖市药品监督管理部门负责本行政区域第二类、第三类医疗器械生产监督管理，依法按照职责负责本行政区域第一类医疗器械生产监督管理，并加强对本行政区域第一类医疗器械生产监督管理工作的指导。'可被翻译为：The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall be responsible for supervision and administration of Class II and Class III medical device manufacturing within their administrative areas, be responsible for the supervision and administration of Class I medical device manufacturing within their administrative areas in accordance with their duties according to law, and strengthen guidance for the supervision and administration of Class I medical device manufacturing within their administrative areas.\n\n根据上述已知信息，请将'第六十七条  省、自治区、直辖市药品监督管理部门应当建立并及时更新辖区内第二类、第三类医疗器械注册人、受托生产企业信用档案，设区的市级负责药品监督管理的部门应当依法按照职责建立并及时更新辖区内第一类医疗器械备案人、受托生产企业信用档案。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 67 The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall establish and timely update the credit files of the registrant or the contract manufacturer of Class II and Class III medical devices within the jurisdiction area, the department in charge of drug supervision and administration at the level of a city divided into districts shall establish and promptly update the credit files of Class I medical device filing entity or the contract manufacturer within the jurisdiction area according to its duties."
    },
    {
        "instruction":"已知信息：\n'第七条 国家药品监督管理局加强信息化建设，为公众查询化妆品信息提供便利化服务。'可被翻译为：Article 7 The NMPA shall enhance informatization construction, to provide convenient services for the public in inquiring information on cosmetics.\n'第七条  国家药品监督管理局加强医疗器械经营监督管理信息化建设，提高在线政务服务水平。'可被翻译为：Article 7 NMPA shall strengthen the construction of information technology for supervision and administration of medical device distribution, and improve the level of online government services.\n'第七条  国家药品监督管理局加强医疗器械生产监督管理信息化建设，提高在线政务服务水平。'可被翻译为：Article 7 NMPA shall strengthen the construction of information technology regarding supervision and administration of medical device manufacturing, and improve the online government services.\n'（六）为其他医疗器械注册人、备案人和生产经营企业专门提供贮存、运输服务的；'可被翻译为：(6) transportation and storage services are specifically provided to other registrants, filing entities, manufacturers and distributors of medical devices;\n\n根据上述已知信息，请将'第十条 国家药品监督管理局加强信息化建设，为注册人、备案人提供便利化服务。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 10 The NMPA shall strengthen informatization to provide convenient services for registrants and filing persons."
    },
    {
        "instruction":"已知信息：\n'一个批次的待包装品或成品的所有生产记录。批生产记录能提供该批产品的生产历史，以及与质量有关的情况。'可被翻译为：All production records for a batch of goods to be packaged or finished. Batch production records provide the production history of the batch, as well as information related to quality.\n'生产批次'可被翻译为：production batch\n'（三）所有不符合质量标准的批次及其调查；'可被翻译为：3. All batches that failed to meet the established specifications and their investigations;\n'第一百八十五条 应当建立划分产品生产批次的操作规程，生产批次的划分应当能够确保同一批次产品质量和特性的均一性。'可被翻译为：Article 185: Operation procedures should be established to differentiate production batches, and the differentiations of production batches should achieve homogenous quality and property of the product within the same batch.\n\n根据上述已知信息，请将'文件记录—审核并取得显示被污染的批次的所有记录副本；确定在“不良”批次前后是否生产了其它批次。审核与受污染批次相关的所有活动和设备。可能有普通水源、混合罐、管着、原料、灭菌器、过滤器等被交叉污染了，将微生物转给后续产品批次。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1. Documentation- Review and obtain copies of all records for lots indicating contamination; determine if there are other lots manufactured either before or after the “bad” lot(s). Review all associated activity and equipment related to the contaminated lot. There may be common water sources, mixing tanks, piping, raw material, sterilizers, filters, etc. that may have been cross contaminated and transferred microbes to subsequent lots of products."
    },
    {
        "instruction":"已知信息：\n'一分子氨基酸的a-竣基和一分子氨基酸的a-氨基脱水缩合形成的酰胺键，即—CO—NH—。'可被翻译为：An amide bond formed by the dehydration condensation of the A-carboxyl group of an amino acid with the A-amino group of an amino acid, that is, -CO-NH --.\n'任何由两个或两个以上的氨基酸通过一个氨基酸的竣基与另一个氨基酸的氨基连接而成的自然界存在的或合成的化合物。一般将含50个氨基酸残基以下的这类化合物称为肽。'可被翻译为：Any naturally occurring or synthetic compound consisting of two or more amino acids joined by the carboxyl group of one amino acid to the amino group of another amino acid. Such compounds containing less than 50 amino acid residues are generally referred to as peptides.\n'同时含有一个或多个氨基和竣基的脂肪族有机酸。根据氨基和竣基的位置，有a氨基酸和0氨基酸等类型。参与蛋白质合成的常见的是20种L-a-氨基酸。'可被翻译为：Aliphatic organic acids containing one or more amino and carboxylic groups at the same time. Depending on the position of the amino group and the carboxyl group, there are such types as a amino acid and 0 amino acid. The common ones involved in protein synthesis are the 20 L-A-amino acids.\n'生物体中广泛存在的一类生物大分子，由核酸编码的a氨基酸之间通过a氨基和a竣基形成的肽键连接而成的肽链，经翻译后加工而生成的具有特定立体结构的、有活性的大分子。'可被翻译为：a class of biological macromolecules widely present in living organisms, consisting of a peptide chain formed by a peptide bond between A amino acid encoded by nucleic acid through A amino group and A carboxyl group, and an active macromolecule with a specific three-dimensional structure generated by post-translational processing.\n\n根据上述已知信息，请将'由多个氨基酸借肽键线性连接而成。肽键就是氨基酸的a-竣基与相邻的另一氨基酸的a-氨基脱水缩合的共价键。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"It is formed by a linear connection of multiple amino acids by peptide bonds. a peptide bond is a covalent bond in which the A-carboxyl group of an amino acid is dehydrated and condensed with the A-amino group of another adjacent amino acid."
    },
    {
        "instruction":"已知信息：\n'质量体系应包括GXP要求，应用于产品和工艺，包括技术转移的生命周期阶段中。'可被翻译为：6.3. The quality system should incorporate GxP which should be applied to the life cycle stages of the products and processes, including the technology transfer.\n'技术转移是一个控制所有流程及其文件记录和专业经验的逻辑程序。技术转移可涉及开发、生产和检测场所。'可被翻译为：1.1. Technology transfer is a logical procedure that controls the transfer of any process, together with its documentation and professional expertise. Technology transfers may involve development, manufacturing and testing sites.\n'要执行的确认和验证的程度应基于风险评估的原则确定，同时考虑产品所处生命周期阶段。'可被翻译为：10.1. The extent of qualification and validation to be performed should be determined on the basis of risk management principles, taking into account the product’s life cycle phase.\n'技术转移应包括来自SU的相关文件、数据、信息和知识，使得RU能够有效实施指定的工艺或方法，例如生产和QC。成功的技术转移应证明RU可以常规化地按SU与RU之间预定的标准生产出所转移的产品、工艺或方法。'可被翻译为：1.7. A technology transfer should include relevant documentation, data, information and knowledge from the SU in order to enable the RU to effectively perform the specified process or procedure in, for example, production and QC. A successful transfer of technology should result in proof that the RU can routinely reproduce the transferred product, process or procedure against a predefined set of specifications as agreed between the SU and RU.\n\n根据上述已知信息，请将'技术转移要求由经过培训的具备丰富知识并在质量体系内工作的人员进行规划，有适当的文件记录、有包括所有开发、生产和质量控制（QC）（适用时）的数据和信息。同时还要考虑产品所处生命周期阶段。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.4. A technology transfer requires a planned approach by trained, knowledgeable personnel working within a quality system, with appropriate documentation, data and information covering all aspects of development, production and quality control (QC), as applicable, and considering the stage of the product life cycle."
    },
    {
        "instruction":"已知信息：\n'根据《中华人民共和国广告法》规定，经商国家卫生健康委，同意将《阿尔茨海默病及相关病杂志》列入允许发布处方药广告的医学、药学专业刊物名单'可被翻译为：According to the Advertisement Law of the People's Republic of China, upon the consultation with the National Health Commission, the Journal of Alzheimer’s Disease and Related Diseases is approved to be included in the list of medical and pharmaceutical journals approved to advertise prescription drugs.\n'国家药监局关于发布《医疗器械产品技术要求编写指导原则》的通告'可被翻译为：NMPA Notice on Issuing the Guidance for Compiling the Product Technical Requirements for Medical Devices\n'国家药监局关于发布禁止委托生产医疗器械目录的通告'可被翻译为：NMPA Announcement on Issuing the List of Medical Devices Prohibited from Contract Manufacturing\n'国家药监局关于发布医疗器械生产质量管理规范附录独立软件的通告'可被翻译为：NMPA Issued the Announcement on Medical Device GMP Appendix: Independent Software\n\n根据上述已知信息，请将'国家药监局关于公布允许发布处方药广告的医学药学专业刊物名单的通告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Announcement on Issuing the List of Medical and Pharmaceutical Journals Approved to Advertise Prescription Drugs"
    },
    {
        "instruction":"已知信息：\n'质量风险管理应作为系统性流程执行，用于评估、控制、沟通和回顾风险。'可被翻译为：6.5. Quality risk management should be implemented as a systematic process for the assessment, control, communication and review of risks.\n'质量风险管理 （QRM）：贯穿药品整个生命周期的质量风险评估、控制、沟通和回顾系统化流程'可被翻译为：quality risk management (QRM). A systematic process for the assessment, control, communication and review of risks to the quality of the pharmaceutical product throughout the product’s life cycle.\n'公用设施系统所用控制措施的性质和程度应与该公用设施相关的产品质量风险相称。应通过风险评估来确定其影响并进行记录，作为 CCS 的一部分。'可被翻译为：The nature and extent of controls applied to utility systems should be commensurate with the risk to product quality associated with the utility. The impact should be determined via a risk assessment and documented as part\nof the CCS.\n'质量风险管理'可被翻译为：quality risk management\n\n根据上述已知信息，请将'质量风险管理流程的工作水平、正式程度和文件应与风险水平相称。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"6.8. The level of effort, formality and documentation of the quality risk management process should be commensurate with the level of risk."
    },
    {
        "instruction":"已知信息：\n'药品批准上市后，持有人应当按照国家药品监督管理局核准的生产工艺和质量标准生产药品，并按照药品生产质量管理规范要求进行细化和实施。'可被翻译为：After the drug is approved for marketing, the MAH shall manufacture the drug in accordance with the manufacturing process and specifications approved by NMPA, and follow the requirements of Good Manufacturing Practice (GMP) for specifics and implementation.\n'第三十七条 药品上市许可持有人应当建立年度报告制度，每年将药品生产销售、上市后研究、风险管理等情况按照规定向省、自治区、直辖市人民政府药品监督管理部门报告。'可被翻译为：Article 37 MAHs shall establish an annual reporting system to report information including drug manufacturing and distribution, post-marketing studies, and risk management to the drug regulatory departments of the people's governments of provinces, autonomous regions and municipalities directly under the central government in accordance with regulations.\n'疾病预防控制机构应当按照规定向接种单位供应疫苗。'可被翻译为：Disease prevention and control institutions shall supply vaccines to immunization entities as required.\n'疫苗上市许可持有人应当按照规定对疫苗生产全过程和疫苗质量进行审核、检验。'可被翻译为：Vaccine MAHs shall examine and test the whole process of vaccine manufacturing and vaccine quality as required.\n\n根据上述已知信息，请将'疫苗上市许可持有人应当按照规定向国家药品监督管理局进行年度报告。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The vaccine MAHs shall, in accordance with the provisions, submit an annual report to the NMPA."
    },
    {
        "instruction":"已知信息：\n'氨基糖'可被翻译为：amino sugar\n'氨基糖昔类抗生素'可被翻译为：aminoglycoside antibiotics\n'氨基糖昔钝化酶'可被翻译为：aminoglycoside modifying enzyme\n'糖与肽相连组成的抗生素。'可被翻译为：An antibiotic consisting of a sugar attached to a peptide.\n\n根据上述已知信息，请将'由氨基糖或氨基环醇与糖组成的抗生素。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An antibiotic consisting of amino sugars or aminocyclic alcohols combined with sugars."
    },
    {
        "instruction":"已知信息：\n'被吸收入血的毒物随血流转运至组织器官的过程。'可被翻译为：The process by which poison absorbed into the bloodstream is transported by the bloodstream to tissues and organs.\n'药物通过吸收经血液循环（或直接进入血管）而分布到机体有关部位发挥的作用。'可被翻译为：The role of a drug in its distribution to relevant parts of the body by absorption through the blood circulation (or directly into the blood vessels).\n'药物从给药部位进入血液循环的过程。'可被翻译为：The process by which the drug enters the bloodstream from the site of administration.\n'药物在胃肠道吸收后进入肝脏，经胆汁排入肠中，并再次被肠道吸收的过程。'可被翻译为：The process by which a drug enters the liver after being absorbed in the gastrointestinal tract, drains into the intestine through bile, and is absorbed again by the intestine.\n\n根据上述已知信息，请将'药物吸收后随血液循环到各组织器官中的过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process by which a drug is absorbed and circulates through the bloodstream to various tissues and organs."
    },
    {
        "instruction":"已知信息：\n'信用档案中应当包括生产许可备案和生产产品品种、委托生产、监督检查结果、违法行为查处、质量抽查检验、不良行为记录和投诉举报等信息。'可被翻译为：The credit file shall include manufacturing licensing filing and manufactured product variety, entrusted manufacturing, supervision and inspection results, investigation of illegal acts, sample testing of quality, records of dishonest behaviors and complaint report, etc.\n'第六十七条  省、自治区、直辖市药品监督管理部门应当建立并及时更新辖区内第二类、第三类医疗器械注册人、受托生产企业信用档案，设区的市级负责药品监督管理的部门应当依法按照职责建立并及时更新辖区内第一类医疗器械备案人、受托生产企业信用档案。'可被翻译为：Article 67 The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall establish and timely update the credit files of the registrant or the contract manufacturer of Class II and Class III medical devices within the jurisdiction area, the department in charge of drug supervision and administration at the level of a city divided into districts shall establish and promptly update the credit files of Class I medical device filing entity or the contract manufacturer within the jurisdiction area according to its duties.\n'第五十条  设区的市级、县级负责药品监督管理的部门应当对医疗器械经营企业符合医疗器械经营质量管理规范要求的情况进行监督检查，督促其规范经营活动。'可被翻译为：Article 50 The department in charge of drug supervision and administration at the level of a city divided into districts or at county level shall supervise and inspect whether the medical device distributors conform to requirements of the Good Supply Practice for medical devices or not, and urge the enterprises to regulate their distribution activities.\n'第五十一条  设区的市级、县级负责药品监督管理的部门应当结合医疗器械经营企业提交的年度自查报告反映的情况加强监督检查。'可被翻译为：Article 51 The department in charge of drug supervision and administration at the level of a city divided into districts or at county level shall strengthen its supervision and inspection in combination with the conditions reflected in the annual self-inspection report submitted by the medical device distributors.\n\n根据上述已知信息，请将'第六十条  设区的市级负责药品监督管理的部门应当建立并及时更新辖区内医疗器械经营企业信用档案。信用档案中应当包括医疗器械经营企业许可备案、监督检查结果、违法行为查处、质量抽查检验、自查报告、不良行为记录和投诉举报等信息。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 60 The department in charge of drug supervision and administration at the level of a city divided into districts shall establish and promptly update credit files of the medical device distributors within their administrative areas. The credit files shall include information such as a medical device distributor’s licensing or filing, supervision and inspection results, investigation and punishment of illegal acts, sample testing of quality, self-inspection report, records of misconducts, and compliant reporting, etc."
    },
    {
        "instruction":"已知信息：\n'第八条 召回药品的生产企业所在地省、自治区、直辖市药品监督管理部门负责药品召回的监督管理工作，其他省、自治区、直辖市药品监督管理部门应当配合、协助做好药品召回的有关工作。'可被翻译为：Article 8 The local drug regulatory department of the province, autonomous region or municipality directly under the Central Government where the manufacturer of the recalled drug is located is responsible for supervising and managing recall of the drug. The drug regulatory departments of other provinces, autonomous regions or municipalities directly under the Central Government shall cooperate and assist in work relating to recall of the drug.\n'医疗器械生产企业所在地省、自治区、直辖市食品药品监督管理部门应当在收到召回事件报告表1个工作日内将召回的有关情况报告国家食品药品监督管理总局。'可被翻译为：The food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the medical device manufacturer is located shall report the relevant situation of the recall to the China Food and Drug Administration within 1 working day after receiving the recall event report form.\n'医疗器械经营企业、使用单位所在地省、自治区、直辖市食品药品监督管理部门收到报告后，应当及时通报医疗器械生产企业所在地省、自治区、直辖市食品药品监督管理部门。'可被翻译为：After receiving the report, the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the medical device distributor or using unit is located shall, in a timely manner, inform the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the medical device manufacturer is located.\n'第二十条 医疗器械生产企业在实施召回的过程中，应当根据召回计划定期向所在地省、自治区、直辖市食品药品监督管理部门提交召回计划实施情况报告。'可被翻译为：Article 20 During the recall process, the medical device manufacturer shall, according to the recall plan, regularly submit a report on the implementation of the recall plan to the food and drug regulatory department of the province, autonomous region, and municipality directly under the central government where it is located.\n\n根据上述已知信息，请将'第八条 召回医疗器械的生产企业所在地省、自治区、直辖市食品药品监督管理部门负责医疗器械召回的监督管理，其他省、自治区、直辖市食品药品监督管理部门应当配合做好本行政区域内医疗器械召回的有关工作。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 8 The food and drug regulatory department of the province, autonomous region and municipality directly under the Central Government where the manufacturer of the recalled medical device is located shall be responsible for the supervision and administration of the recall, and the food and drug regulatory departments of other provinces, autonomous regions and municipalities directly under the Central Government shall cooperate in the recall of medical devices within their respective administrative areas."
    },
    {
        "instruction":"已知信息：\n'非脂溶性小分子物质，在特殊膜蛋白质帮助下，由高浓度向低浓度一侧转运的过程。'可被翻译为：The process by which a non-fat-soluble small molecule is transported from one side of the biofilm to the other with the help of special membrane proteins.\n'脂溶性药物溶于脂质膜的跨膜转运。'可被翻译为：The transmembrane transport of fat-soluble drugs that dissolve in lipid membranes.\n'某些脂溶性、挥发性的药物通过喷雾或气雾给药方式由呼吸道黏膜或肺泡上皮细胞吸收。'可被翻译为：Certain fat-soluble, volatile drugs are absorbed by respiratory mucosa or alveolar epithelium by spray or aerosol delivery.\n'肽或蛋白质与脂的结合物。具有脂质的溶解特性。'可被翻译为：A combination of peptides or proteins and lipids. Having the dissolving properties of lipids.\n\n根据上述已知信息，请将'非脂溶性或脂溶性很小的物质，借助于细胞膜上的运载蛋白或通道蛋白的帮助，顺浓度梯度和（或）顺电位梯度（电位差）通过细胞膜的转运过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Non-fat soluble or very little fat soluble substances, with the help of carrier proteins or channel proteins on the cell membrane, along the concentration gradient and\/or along the potential gradient (potential difference) of the transport process through the cell membrane."
    },
    {
        "instruction":"已知信息：\n'药理毒理学研究现场核查主要是对药理毒理学研究情况，包括药理和(或)毒理研究的条件、方案执行情况、数据记录和结果报告等方面进行的核查。'可被翻译为：The on-site inspection of Pharmacological and Toxicological study is mainly to inspect the Pharmacological and Toxicological study, including the conditions of pharmacology and\/or toxicology study, protocol implementation situation, data records and result reports etc.\n'药理毒理学研究现场核查的目的主要是通过对药理毒  理学研究的原始资料进行数据可靠性的核实和\/或实地确证，  检查药理毒理学研究的合规性，核实相关申报资料的真实性、一致性。'可被翻译为：The purpose of on-site inspection of Pharmacological and Toxicological study is to check the compliance of Pharmacological and Toxicological study and verify the authenticity and consistency of relevant application dossiers through the inspection and \/ or on-site confirmation of the data integrity of the original data of Pharmacological and Toxicological study.\n'2. 药品注册核查要点与判定原则（药理毒理学研究）（试行）'可被翻译为：2.《Key Points and Determination Principles of Drug Registration Inspection(Pharmacological and Toxicological Study)(Trial)》\n'(药理毒理学研究)'可被翻译为：(Pharmacological and Toxicological Study)\n\n根据上述已知信息，请将'(二)药理毒理学研究现场核查主要是对药理毒理学研 究情况，包括研究条件、方案执行情况、数据记录和结果报 告等方面进行核查。基于注册需要和风险原则，可仅对部分药理毒理学试验项目的部分内容进行核查。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(II) On-site inspection of Pharmacological and Toxicological study is mainly to inspect the study conditions of Pharmacological and Toxicological, including study conditions, protocol implementation, data records and result reports. Based on registration requirements and risk principles, only part of the content of some Pharmacological and Toxicological trial items can be inspected."
    },
    {
        "instruction":"已知信息：\n'国家药品监督管理局食品药品审核查验中心（以下简称核查中心）承担批签发过程中的境外现场检查等工作。'可被翻译为：Center for Food and Drug Inspection of NMPA (hereinafter referred to as CFDI) shall be responsible for overseas on-site inspection during lot release.\n'第二条 国家药品监督管理局组织的在境内开展的药品研制、生产现场注册核查适用本程序。国家药品监督管理局食品药品审核查验中心(以下简称核查中心)组织实施注册核查工作。'可被翻译为：Article 2 This Procedure is applicable to the domestic registration inspection of drug development site and manufacturing site organized by the National Medical Products Administration (NMPA). The Center for Food and Drug Inspection of NMPA (hereinafter referred to as CFDI) organizes the implementation of registration inspection work.\n'一、药品注册申请人在国家药品监督管理局组织核查前经自查发现药物临床试验数据存在真实性问题的，应主动申请撤回注册申请，国家药品监督管理局将公布其名单，不追究其责任。'可被翻译为：I. If the drug registration applicants found inauthenticity of clinical trial data by self-examination before NMPA verification, they shall take the initiative to apply for withdrawal of registration application, NMPA shall announce the list of applicants and varieties withdrawn without affixing accountability.\n'(一)适用于由国家药品监督管理局药品审评中心启动、 由国家药品监督管理局食品药品审核查验中心组织实施的药品注册研制现场核查中的药理毒理学研究现场核查。'可被翻译为：(I) It is applicable to the on-site inspection of Pharmacological and Toxicological study in the research and development (R&D) on-site inspection of drug registration initiated by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) and organized and implemented by the Center for Food and Drug Inspection (CFDI) of NMPA.\n\n根据上述已知信息，请将'二、国家药品监督管理局食品药品审核查验中心将在其网站公示现场核查计划，并通知药品注册申请人及其所在地省级药品监管部门，公示10个工作日后，该中心将通知现场核查日期，不再接受药品注册申请人的撤回申请。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"II. NMPA Center for Food and Drug Inspection shall publicize on its website and inform the applicants of drug registration and the competent local provincial drug regulatory authority of the on-site verification plan. The Center shall, 10 working days after the public notification, inform the date for on-site verification and no longer accept the applicants' withdrawal of drug registration applications."
    },
    {
        "instruction":"已知信息：\n'第一百零五条 申请仿制的药品属于按非处方药管理的，申请人应当在《药品注册申请表》的“附加申请事项”中标注非处方药项。'可被翻译为：Article 105 Where the applied generic drug is regulated as a non-prescription drug, the applicant shall indicate the item of non-prescription drug in the \"additional application items\" of the Application Form for Drug Registration.\n'第一百零七条 属于以下情况的，申请人可以在《药品注册申请表》的“附加申请事项”中标注非处方药项，符合非处方药有关规定的，按照非处方药审批和管理；不符合非处方药有关规定的，按照处方药审批和管理。'可被翻译为：Article 107 For any of the following circumstances, the applicant may indicate the item of non-prescription drug in the \"additional application items\" of the Application Form for Drug Registration. If relevant requirements for non-prescription drugs apply, the drug shall be reviewed and approved, and regulated as a non-prescription drug; if relevant requirements for non-prescription drugs do not apply, it shall be reviewed and approved, and regulated as a prescription drug:\n'第一百零六条 申请仿制的药品属于同时按处方药和非处方药管理的，申请人可以选择按照处方药或者非处方药的要求提出申请。'可被翻译为：Article 106 Where the applied generic drug is regulated as both a prescription and non-prescription drug, the applicant may submit an application for either a prescription or non-prescription drug according to the respective requirements.\n'（一）境内已有相同活性成分、适应症（或者功能主治）、剂型、规格的非处方药上市的药品；'可被翻译为：(1) Drugs with the same active ingredients, indications, dosage forms and strengths as non-prescription drugs that have been marketed within the territory of the People's Republic of China;\n\n根据上述已知信息，请将'第一百零九条 进口的药品属于非处方药的，适用进口药品的申报和审批程序，其技术要求与境内生产的非处方药相同。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 109 For the registration application of an import drug categorized as non-prescription drug, the application, review and approval procedures for import drugs shall apply, and the technological requirements shall be the same as those for the domestically produced non-prescription drugs."
    },
    {
        "instruction":"已知信息：\n'第三节 持续稳定性考察'可被翻译为：Section 3 On-going Stability Program\n'第二百三十三条 持续稳定性考察应当有考察方案，结果应当有报告。用于持续稳定性考察的设备（尤其是稳定性试验设备或设施）应当按照第七章和第五章的要求进行确认和维护。'可被翻译为：Article 233: The on-going stability program should be described in a protocol and results formalized as a report. The equipment used for the on-going stability program (in particular, the equipment and facilities for stability study) should be qualified and maintained following the general rules of Chapters 7 and 5.\n'第二百三十七条 关键人员，尤其是质量受权人，应当了解持续稳定性考察的结果。当持续稳定性考察不在待包装产品和成品的生产企业进行时，则相关各方之间应当有书面协议，且均应当保存持续稳定性考察的结果以供药品监督管理部门审查。'可被翻译为：Article 237: Results of on-going stability studies should be made available to key personnel and, in particular, to the Authorized Person(s). Where on-going stability studies are carried out at a site other than the site of manufacture of the bulk or finished product, there should be a written agreement between the parties concerned. Results of on-going stability studies should be available at both sites for review by regulatory authority.\n'第二百三十四条 持续稳定性考察的时间应当涵盖药品有效期，考察方案应当至少包括以下内容：'可被翻译为：Article 234: The protocol for an on-going stability program should extend to the end of the shelf life period and should at least include the following contents:\n\n根据上述已知信息，请将'13.确保完成产品的持续稳定性考察计划，提供稳定性考察的数据；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"13) To ensure the implementation of on-going stability study and make the stability data available;"
    },
    {
        "instruction":"已知信息：\n'（二）新《办法》发布至实施前受理的药品注册申请，按照新《办法》规定的范围和《关于鼓励药品创新实行优先审评审批的意见》（食药监药化管〔2017〕126号）规定的程序执行。'可被翻译为：(2) Drug registration applications accepted between the issuance and the implementation of the new Provisions shall be handled in accordance with the scope stipulated in the new Provisions and the Opinions on Encouraging Priority Review and Examination and procedures prescribed in the Opinions on Fueling Pharmaceutical Innovation via Prioritized Review & Approval (CFDA Department of Drug and Cosmetics Supervision [2017] No.126) .\n'药品注册申请受理、审评和审批的有关工作程序，新《办法》及其相关文件尚未作调整的，按照现行规定执行。'可被翻译为：For working procedures related to drug registration application & acceptance, review & approval, if no adjustments have been made by the new Provisions and related documents, the existing relevant stipulations shall apply.\n'（一）新《办法》发布前受理的药品注册申请，按照《关于鼓励药品创新实行优先审评审批的意见》（食药监药化管〔2017〕126号）规定的范围和程序执行。'可被翻译为：(1) Drug registration applications accepted before the issuance of the new Provisions shall be implemented in accordance with the scope and procedures stipulated in the Opinions on Fueling Pharmaceutical Innovation via Prioritized Review & Approval (CFDA Department of Drug and Cosmetics Supervision [2017] No. 126) .\n'三、新《办法》实施前，以委托生产形式申请成为上市许可持有人的药品注册申请，按照《药品上市许可持有人制度试点方案》的有关规定提交相关申报资料；新《办法》实施后，按新发布的申报资料要求提交相关申报资料。'可被翻译为：3. Before the implementation of the new Provisions, the submission of dossiers for drug registration application by MAH in the form of entrusted production shall follow the relevant provisions of the Pilot Plan on Drug Marketing Authorization Holder System; after the implementation of the new Provisions, the submission of application dossiers shall follow the newly released requirements.\n\n根据上述已知信息，请将'（三）新《办法》实施后受理的药品注册申请，按照新《办法》规定的范围和程序执行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) Drug registration applications accepted after the implementation of the new Provisions shall be executed in accordance with the scope and procedures prescribed by the new Provisions."
    },
    {
        "instruction":"已知信息：\n'开放式系统系指由负责系统中电子记录内容的人员不对使用访问进行管理的计算环境。'可被翻译为：(9) Open system means an environment in which system access is not controlled by persons who are responsible for the content of electronic records that are on the system.\n'限于授权人员登录的系统访问。'可被翻译为：(d) Limiting system access to authorized individuals.\n'(2) 采用电子记录的计算机化系统经过系统验证， 并保存验证记录。计算机化系统设置用户管理、角色管理和权限管理，不同人员或角色具有唯一登录权限。'可被翻译为：(2) Electronic data collection system passes the system verification, and retains verification record. Set user management, role management and permission management for the computerized system, different personnel or roles have the unique logon rights.\n'（十六）计算机系统的管理；'可被翻译为：(XVI) Computer system management;\n\n根据上述已知信息，请将'封闭系统系指由负责系统中电子记录内容的人员管理系统访问的计算机环境。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(4) Closed system means an environment in which system access is controlled by persons who are responsible for the content of electronic records that are on the system."
    },
    {
        "instruction":"已知信息：\n'二、口服固体制剂每剂量单位含羟考酮碱不超过5毫克，且不含其它麻醉药品、精神药品或药品类易制毒化学品的复方制剂列入第二类精神药品管理；'可被翻译为：2. Oral solid preparations containing no more than 5 mg of oxycodone base perdose unit, barring other narcotic drugs,psychotropic drugs or pharmaceutical precursor chemicals, shall be subject to the management of Class II psychotropic drugs;\n'一、口服固体制剂每剂量单位含羟考酮碱大于5毫克，且不含其它麻醉药品、精神药品或药品类易制毒化学品的复方制剂列入第一类精神药品管理；'可被翻译为：1. Oral solid preparations containing more than 5 mg of oxycodone base perdose unit, barring other narcotic drugs,psychotropic drugs or pharmaceutical precursor chemicals, shall be subject to the management of Class I psychotropic drugs;\n'国家药监局 公安部 国家卫生健康委关于将含羟考酮复方制剂等品种列入精神药品管理的公告'可被翻译为：NMPA, Ministry of Public Security, National Health Commission issued the Announcement on the Inclusion of Oxycodone-Containing Compound Preparations in the Management of Psychotropic Substances\n'根据《麻醉药品和精神药品管理条例》有关规定，国家药品监督管理局、公安部、国家卫生健康委员会决定将含羟考酮复方制剂等品种列入精神药品管理。'可被翻译为：In accordance with the relevant provisions of the Regulations on the Control of Narcotic Drugs and Psychotropic Drugs, the National Medical Products Administration, the Ministry of Public Security, and the National Health Commission have decided to regulate varieties including oxycodone-containing medicines as psychotropic drugs.\n\n根据上述已知信息，请将'三、丁丙诺啡与纳洛酮的复方口服固体制剂列入第二类精神药品管理。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3. Compound oral solid preparations of buprenorphine and naloxone shall be subject to the management of Class II psychotropic drugs."
    },
    {
        "instruction":"已知信息：\n'研究化学药物及天然活性成分的化学结构、理化性质、化学合成、体内代谢、化学结构与药效的相互关系，药物作用的化学机制，以及寻找新药的途径和方法的一门学科。与创制和发展新药有关的化学规律和方法均属药物化学研究的范畴。'可被翻译为：The study of chemical drugs and natural active ingredients of chemical structure, physical and chemical properties, chemical synthesis, in vivo metabolism, chemical structure and efficacy of the relationship between the chemical mechanism of drug action, as well as the search for new ways and methods of a discipline. The chemical laws and methods related to the creation and development of new drugs belong to the category of pharmaceutical chemistry research.\n'研究、设计和选用药物工业生产途径的一门学科，也是研究、选用适宜的中间体和确定合成路线、工艺原理和工业生产过程，实现制药生产过程最优化的一门学科。'可被翻译为：Research, design and selection of pharmaceutical industrial production pathway is a discipline, but also research, selection of appropriate intermediates and determine the synthesis route, process principles and industrial production process, to achieve the optimization of pharmaceutical production process of a discipline.\n'研究老年人群用药规律和益寿延年的一门药学学科。是人类老年学在药学的一门分支学科。其研究内容涉及老年生理学、老年病理学、老年药理学、药物剂量学、药动学、药效学、药物不良反应等诸方面。'可被翻译为：It studies the law of drug use and prolonging life of the elderly population. It is a branch of human gerontology in pharmacy. Its research content involves geriatric physiology, geriatric pathology, geriatric pharmacology, dosimetry, pharmacokinetics, pharmacodynamics, adverse drug reactions and so on.\n'研究防治疾病所用药物的一门学科。包括生药学、制药工艺学、药剂学、药理学、药物化学、药物分析、临床药学、药事管理学等分支学科。'可被翻译为：The study of drugs used to prevent and treat diseases. Including pharmacognosy, pharmaceutical technology, pharmacy, pharmacology, medicinal chemistry, pharmaceutical analysis, clinical pharmacy, pharmaceutical management and other subdisciplines.\n\n根据上述已知信息，请将'研究用微生物发酵或与化学合成方法结合制取药物的一门学科。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A discipline that studies the preparation of drugs by microbial fermentation or in combination with chemical synthesis."
    },
    {
        "instruction":"已知信息：\n'第二十八条 技术审评过程中需要申请人补正资料的，技术审评机构应当一次告知需要补正的全部内容。申请人应当在1年内按照补正通知的要求一次提供补充资料。技术审评机构应当自收到补充资料之日起40个工作日内完成技术审评。申请人补充资料的时间不计算在审评时限内。'可被翻译为：Article 28 Where supplementary and correction materials are required during technical evaluation, the technical evaluation institution shall inform the applicant one-off of all the supplements to be completed. The applicant shall submit all necessary supplementary and correction materials one-off within one year according to the supplementation notice. The technical evaluation institution shall complete the technical evaluation within 40 workdays from the date of acceptance of the supplements. The time spent by applicant for supplementing such materials shall not be calculated in the overall evaluation time.\n'第三十五条 技术审评过程中需要申请人补正资料的，技术审评机构应当一次告知需要补正的全部内容。申请人应当在１年内按照补正通知的要求一次提供补充资料；技术审评机构应当自收到补充资料之日起60个工作日内完成技术审评。申请人补充资料的时间不计算在审评时限内。'可被翻译为：Article 35 Where supplementary and correction materials are required during technical evaluation, the technical evaluation institution shall inform the applicant one-off of all the supplements to be completed. The applicant shall submit all necessary supplementary and correction materials one-off within one year according to the supplementation notice. The technical evaluation institution shall complete the technical evaluation within 60 workdays from the date of acceptance of the supplements. The time spent by applicant for supplementing such materials shall not be calculated in the overall evaluation time.\n'第四十五条 技术审评过程中需要申请人补正资料的，技术审评机构应当一次告知需要补正的全部内容。申请人应当在１年内按照补正通知的要求一次提供补充资料；技术审评机构应当自收到补充资料之日起60个工作日内完成技术审评。申请人补充资料的时间不计算在审评时限内。'可被翻译为：Article 45 Where supplementary and correction materials are required during technical evaluation, the technical evaluation institution shall inform the applicant one-off of all the supplements to be completed. The applicant shall submit all necessary supplementary and correction materials one-off within one year according to the supplementation notice. The technical evaluation institution shall complete the technical evaluation within 60 workdays from the date of acceptance of the supplements. The time spent by applicant for supplementing such materials shall not be calculated in the overall evaluation time.\n'第八十七条 药品注册申请受理后，需要申请人在原申报资料基础上补充新的技术资料的，药品审评中心原则上提出一次补充资料要求，列明全部问题后，以书面方式通知申请人在八十日内补充提交资料。申请人应当一次性按要求提交全部补充资料，补充资料时间不计入药品审评时限。药品审评中心收到申请人全部补充资料后启动审评，审评时限延长三分之一；适用优先审评审批程序的，审评时限延长四分之一。'可被翻译为：Article 87 After the drug registration application is accepted, where it is necessary for the applicant to provide new technical dossier on the basis of the original submission dossier, the CDE shall, in principle, make a one-time requirement for supplementary dossier. The CDE shall list all the issues and inform the applicant in a written notice to submit supplementary dossier within 80 days. The applicant shall submit all the supplementary dossier together as required in one submission, and the time needed for the supplement of dossier will not be counted into the drug review timeline. The CDE shall restart review upon receiving all the supplementary dossier from the applicant, and the review timeline shall be extended by 1\/3 of the original review timeline; where the priority review and approval procedure is applicable, the review timeline shall be extended by 1\/4 of the original review timeline.\n\n根据上述已知信息，请将'（三）需要申请人补充资料的，应当一次告知需要补充的全部内容；申请人应当在90个工作日内按照要求一次提供补充资料，技术审评机构收到补充资料后审评时限重新计算；未在规定时限内补充资料的，技术审评机构应当作出技术审评不通过的审评结论。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) Where supplementary documents are required from the applicant, the applicant shall be notified once of all the contents to be supplemented; the applicant shall provide supplementary documents at one time as required within 90 working days, and the evaluation time limit shall be recalculated after the technical assessment agency receives the supplementary documents; if the supplementary documents are not submitted within the specified timeline, the technical assessment agency shall make an evaluation conclusion of disapproval."
    },
    {
        "instruction":"已知信息：\n'(良好的贸易和分销规范)是质量保证的一部分，通过对贸易和分销过程中发生的众多活动进行充分控制，确保药品质量得到保持。'可被翻译为：(Good trade and distribution practices are) that part of quality assurance that ensures that the quality of pharmaceutical products is maintained by means of adequate control throughout the numerous activities which occur during the trade and the distribution process.\n'1.质量管理的一部分，确保产品始终按照适合其预期用途的质量标准生产和控制，并符合上市许可、临床试验许可或产品规范的要求。GMP涉及生产和质量控制。GMP的主要目的是管理和尽量减少药品生产中固有的风险，以确保产品的质量、安全性和有效性。\n2.质量保证的一部分，确保药品的生产和控制始终符合其预期用途和上市许可要求的质量标准。'可被翻译为：1.That part of quality management which ensures that products are consistently produced and controlled according to the quality standards appropriate to their intended use and as required by the marketing authorization, clinical trial authorization or product specification. GMP are concerned with both production and quality control. GMP are aimed primarily at managing and minimizing the risks inherent in pharmaceutical manufacture to ensure the quality, safety and efficacy of products.\n2.That part of quality assurance that ensures that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization.\n'1.确保药品按照批准的工艺规程生产、贮存，以保证药品质量；'可被翻译为：1) To ensure that products are produced and stored according to approved master manufacturing documents in order to obtain the required quality;\n'1.在整个产品生命周期内对产品质量风险进行评估、控制、沟通和审查的系统过程。\n2.质量风险管理是对药品在整个生命周期内的质量风险进行评估、控制、沟通和评审的系统过程。'可被翻译为：1.A systematic process for the assessment, control, communication and review of risks to the quality of the product across the product’s life cycle.\n2.Quality risk management is a systematic process for the assessment, control, communication and review of risks to the quality of the pharmaceutical product throughout the product life- cycle.\n\n根据上述已知信息，请将'1.(良好贮存规范)是质量保证的一部分，通过在整个贮存过程中适当的控制来确保药品的质量得到保持。\n2.质量保证的一部分，通过在医疗产品的整个储存过程中进行适当的控制，确保保持医疗产品的质量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.(Good storage practices are) that part of quality assurance that ensures that the quality of pharmaceutical products is maintained by means of adequate control throughout the storage thereof.\n2.That part of quality assurance that ensures that the quality of medical products is maintained by means of adequate control throughout the storage thereof."
    },
    {
        "instruction":"已知信息：\n'菌落的生长表明可能存在大肠杆菌，应通过鉴定试验证实。应使用快速鉴定试剂盒或 DNA 测序将分离株鉴定至属，如有可能，鉴定至种。如果不存在菌落或鉴定测试为 阴性，则产品符合测试要求。'可被翻译为：Growth of colonies indicates the possible presence of E. coli. This is confirmed by identification test. Isolates should be identified to genus and, if possible, species using rapid identification kits or DNA sequencing. The product complies with the test if no colonies are present or if the identification tests are negative.\n'发育良好，有或没有黑色中心的红色菌落的生长表明可能存在沙门氏菌。应通过鉴定 试验证实。应使用快速鉴定试剂盒或 DNA 测序将分离株鉴定至属，如有可能，鉴定至 种。如果没有观察到生长或确认性鉴定测试为阴性，则产品符合测试要求。'可被翻译为：The possible presence of Salmonella is indicated by the growth of well-developed, red colonies, with or without black centers. This is confirmed by identification tests. Isolates should be identified to genus and, if possible, species using rapid identification kits or DNA sequencing. The product complies with the test if no growth is observed or if the confirmatory identification tests are negative.\n'白色菌落的生长可能表明存在白色念珠菌，应通过鉴别试验进行证实。应使用快速鉴 定试剂盒或DNA测序将分离物鉴定至属，如有可能，鉴定至种。如果不存在菌落或 鉴定试验为阴性，则产品符合试验要求。'可被翻译为：Growth of white colonies may indicate the presence of C. albicans. This is confirmed by identification test. Isolates should be identified to genus and, if possible, species using rapid identification kits or DNA sequencing. The product complies with the test if no colonies are present or if the identification tests are negative.\n'黄色或白色菌落被黄色区域包围，表明可能存在金黄色葡萄球菌，应通过鉴别测试证 实。应使用快速鉴定试剂盒或 DNA 测序将分离株鉴定至属，如有可能，鉴定至种。 如果没有观察到生长或确认性鉴定测试为阴性，则产品符合测试要求。'可被翻译为：The possible presence of S. aureus is indicated by the growth of yellow or white colonies surrounded by a yellow zone. This is confirmed by identification tests. Isolates should be identified to genus and, if possible, species using rapid identification kits or DNA sequencing. The product complies with the test if no growth is observed or if the confirmatory identification tests are negative.\n\n根据上述已知信息，请将'菌落的生长表明可能存在铜绿假单胞菌，应通过鉴定试验证实。应使用快速鉴定试剂 盒或 DNA 测序将分离株鉴定至属，如有可能，鉴定至种。如果未检出菌落或鉴定测 试为阴性，则产品符合测试要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Growth of colonies indicates the possible presence of P. aeruginosa. This is confirmed by identification test. Isolates should be identified to genus and, if possible, species using rapid identification kits or DNA sequencing. The product complies with the test if no colonies are present or if the identification tests are negative."
    },
    {
        "instruction":"已知信息：\n'国家药监局关于发布医用康复器械通用名称命名指导原则等6项指导原则的通告'可被翻译为：NMPA Announcement on Issuing 6 Guidance including the Guidance for Nomenclature of the Generic Names of Medical Rehabilitation Devices\n'国家药监局关于发布医用成像器械通用名称命名指导原则等3项指导原则的通告'可被翻译为：NMPA Issues Three Guidances including the Guidance for Nomenclature for Generic Names of Medical Imaging Devices\n'为进一步规范医疗器械通用名称，加强医疗器械全生命周期管理，国家药品监督管理局组织制定了《神经和心血管手术器械通用名称命名指导原则》《医用诊察和监护器械通用名称命名指导原则》，并于2021年8月25日发布。'可被翻译为：To further standardize the generic names of medical devices and strengthen the whole life cycle management for them, the NMPA has organized to formulate the Guidance for Nomenclature for Generic Names of Neurosurgical and Cardiovascular Surgical Devices, and Guidance for Nomenclature for Generic Names of Devices for Medical Diagnosis, Examination and Monitoring, which were issued on August 25, 2021.\n'国家药监局发布《医疗器械通用名称命名指导原则》'可被翻译为：NMPA Issued the Guidelines for Nomenclature for Common Names of Medical Devices\n\n根据上述已知信息，请将'国家药监局关于发布神经和心血管手术器械通用名称命名指导原则等2项指导原则的通告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Announcement on Issuing 2 Guidance including the Guidance for Nomenclature of the Generic Names of Neurosurgical and Cardiovascular Surgical Devices"
    },
    {
        "instruction":"已知信息：\n'（一）法定代表人（企业负责人）、质量负责人身份证明、学历或者职称相关材料复印件；'可被翻译为：(1) copies of the identity and the academic degree or professional title of the legal representative (the person in charge of the enterprise) and the person in charge of quality;\n'（一）与经营范围和经营规模相适应的质量管理机构或者质量管理人员，质量管理人员应当具有相关专业学历或者职称；'可被翻译为：(1) having quality management agencies or quality management personnel compatible with the distribution scope and scale, and the quality management personnel shall have relevant professional degrees or titles;\n'（四）生产管理、质量检验岗位从业人员学历、职称一览表；'可被翻译为：(4) the list of academic degrees and professional titles of personnel on manufacturing management and quality testing positions;\n'（三）每一生产工序的负责人签名。'可被翻译为：3. The signatures of the person responsible for each stage of production;\n\n根据上述已知信息，请将'（三）生产、质量和技术负责人的身份、学历、职称相关材料复印件；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) copies of related materials such as identities, academic degrees and professional titles of the persons in charge of manufacturing, quality and technology;"
    },
    {
        "instruction":"已知信息：\n'第七十三条 省、自治区、直辖市食品药品监督管理部门按照属地管理原则，对进口体外诊断试剂代理人注册与备案相关工作实施日常监督管理。'可被翻译为：Article 73 The food and drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall, in accordance with the principle of territorial administration, perform routine supervision and administration over the work concerning registration and filing done by agents for import in-vitro diagnostic reagents.\n'第六十四条 设区的市级食品药品监督管理部门应当定期对备案工作开展检查，并及时向省、自治区、直辖市食品药品监督管理部门报送相关信息。'可被翻译为：Article 64 The food and drug regulatory departments of the cities consisting of districts shall perform regular examination over the filing of medical devices and timely report relevant information to the food and drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government.\n'第五条 国家药品监督管理局负责特殊化妆品、进口普通化妆品、化妆品新原料的注册和备案管理，并指导监督省、自治区、直辖市药品监督管理部门承担的化妆品备案相关工作。国家药品监督管理局可以委托具备相应能力的省、自治区、直辖市药品监督管理部门实施进口普通化妆品备案管理工作。'可被翻译为：Article 5 The National Medical Products Administration (NMPA) is responsible for the registration and filing administration of special cosmetics, imported general cosmetics and new cosmetic ingredients, and guiding and supervising the related cosmetic filing work undertaken by the drug regulatory departments of provinces, autonomous regions, and municipalities. The NMPA may entrust the drug regulatory departments of provinces, autonomous regions, and municipalities directly under the Central Government that have corresponding capabilities to implement the filing administration of imported general cosmetics.\n'第六十一条 国家食品药品监督管理总局负责全国医疗器械注册与备案的监督管理工作，对地方食品药品监督管理部门医疗器械注册与备案工作进行监督和指导。'可被翻译为：Article 61 China Food and Drug Administration shall be responsible for the supervision and administration of medical device registration and filing nationwide, and supervise and guide the medical device registration and filing by local food and drug regulatory departments.\n\n根据上述已知信息，请将'第六十三条 省、自治区、直辖市食品药品监督管理部门按照属地管理原则，对进口医疗器械代理人注册与备案相关工作实施日常监督管理。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 63 The food and drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall, in accordance with the principle of territorial administration, perform routine supervision and administration over the work concerning registration and filing done by agents for import medical devices."
    },
    {
        "instruction":"已知信息：\n'1.质量管理的一部分侧重于设定质量目标，规定必要的操作过程和相关资源以实现质量目标。\n2.作为质量管理的一部分，质量策划需要设定质量目标，并规定实现质量目标所需的操作过程和相关资源。'可被翻译为：1.Part of quality management focused on setting quality objectives and specifying necessary operational processes and related resources to fulfil the quality objectives.\n2.Part of quality management, quality planning entails setting quality objectives and specifying necessary operational processes and related resources to fulﬁl the quality objectives.\n'质量管理的一部分，着重于设定质量目标，并详细规定必要的操作程序和相关资源以实 现质量目标。(ISO 9000:2005)'可被翻译为：Part of quality management focused on setting quality objectives and specifying necessary operational processes and related resources to fulfil the quality objectives. (ISO 9000:2005)\n'质量目标'可被翻译为：quality objectives\n'第七条 企业应当配备足够的、符合要求的人员、厂房、设施和设备，为实现质量目标提供必要的条件。'可被翻译为：Article 7: The manufacturer should be adequately resourced with competent personnel, suitable and sufficient premises, equipment and facilities for achieving its quality objective.\n\n根据上述已知信息，请将'质量规划：质量管理的一部分，主要是设置质量目标和指定必要的操作流程和相关的资源以达成质量目标'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"quality planning. Part of quality management, focused on setting quality objectives and specifying necessary operational processes and related resources to fulfil the quality objectives."
    },
    {
        "instruction":"已知信息：\n'第二十一条 化妆品新原料注册人、备案人应当建立化妆品新原料上市后的安全风险监测和评价体系，对化妆品新原料的安全性进行追踪研究，对化妆品新原料的使用和安全情况进行持续监测和评价。'可被翻译为：Article 21 Registrants and filing persons of new cosmetic ingredients shall establish a safety risk monitoring and evaluation system after the launch of new cosmetic ingredients, conduct follow-up research on the safety of new cosmetic ingredients, and continue to monitor and evaluate the use and safety of new cosmetic ingredients.\n'第二十三条 使用化妆品新原料生产化妆品的化妆品注册人、备案人，应当及时向化妆品新原料注册人、备案人反馈化妆品新原料的使用和安全情况。'可被翻译为：Article 23 The registrant and filing person of cosmetics who use new cosmetic ingredients to produce cosmetics shall give prompt feedback on the use and safety of the new cosmetic ingredients to the registrant and filing person of new cosmetic ingredients.\n'化妆品新原料注册人、备案人应当在化妆品新原料安全监测每满一年前30个工作日内，汇总、分析化妆品新原料使用和安全情况，形成年度报告报送国家药品监督管理局。'可被翻译为：Registrants and filing persons of new cosmetic ingredients shall, within 30 working days before a year period of safety monitoring of new cosmetic ingredients, prepare an annual report summarizing and analyzing the use and safety conditions of new ingredients, and submit it to the NMPA.\n'（三）不属于化妆品新原料或者化妆品备案范围的。'可被翻译为：(3) Those that do not fall into the filing scope of new cosmetic ingredients or cosmetics.\n\n根据上述已知信息，请将'（三）其他与化妆品新原料安全有关的情况。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) Other circumstances related to the safety of new cosmetic ingredients."
    },
    {
        "instruction":"已知信息：\n'第十九条    疫苗批签发应当逐批进行资料审核和抽样检验，其他生物制品批签发可以采取资料审核的方式，也可以采取资料审核和样品检验相结合的方式进行，并可根据需要进行现场核实。对不同品种检验项目和检验比例，由中检院负责组织论证，并抄报国家药品监督管理局。批签发机构按照确定的检验要求进行检验。'可被翻译为：Article 19  For the lot release of vaccines, dossier review and sample testing shall be conducted lot by lot. For other biological products, lot release may be conducted by means of independent dossier review or by combining dossier review with sample testing, and on-site verification may be conducted as required. For the testing items and testing proportion for different varieties, the NIFDC shall organize the demonstration and submit a copy to the NMPA. Each lot release institution shall conduct test in accordance with the determined specifications.\n'食品药品监管总局指定的批签发机构负责批签发的受理、资料审核、现场核实、样品检验等工作，并依法作出批签发决定。'可被翻译为：The lot release institutions designated by the CFDA shall be responsible for the acceptance, dossier review, on-site inspection and sample testing and making the decision on lot release in accordance with the law.\n'对疫苗批签发申请资料或者样品的真实性有疑问，或者存在其他需要进一步核实的情况的，批签发机构应当予以核实，必要时应当采用现场抽样检验等方式组织开展现场核实。'可被翻译为：If there is any doubt about the authenticity of the application dossier or samples for lot release of vaccines or any other situation which requires further verification, lot release institutions shall make the verification, and may organize on-site verifications such as sampling on-site for testing if necessary.\n'第二十八条 批签发机构根据资料审核、样品检验或者现场检查等结果作出批签发结论。符合要求的，签发生物制品批签发证明，加盖批签发专用章，发给批签发申请人。'可被翻译为：Article 28 The lot release institution shall make decision on lot release based on dossier review, sample test or on-site inspection and other results. If the requirements are met, the institution shall issue a Certificate for Lot Release of Biological Products which is affixed with the special seal for lot release, and send it to the lot release applicant.\n\n根据上述已知信息，请将'第十八条 批签发可以采取资料审核的方式，也可以采取资料审核和样品检验相结合的方式进行，并可根据需要进行现场核实。对不同品种所采用的批签发方式及检验项目和检验比例，由中检院负责组织论证，各批签发机构按照确定的批签发方式和检验要求进行检验。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 18 Lot release may be conducted by means of independent dossier review or by combining dossier review with sample test, and on-site inspection may be conducted as required. For the lot release mode as well as the testing items and testing proportion for different products, the NIFDC shall organize the demonstration and each lot release institution shall conduct test in accordance with the determined mode for lot release and specifications."
    },
    {
        "instruction":"已知信息：\n'一组相互关联或相互作用的活动，它们使用输入来交付预期的结果。在nra的背景下，生产和服务提供过程应与基本监管功能相一致。'可被翻译为：A set of interrelated or interacting activities that use inputs to deliver an intended result. In the context of NRAs, the production and service provision processes should coincide with basic regulatory functions.\n'以静默或公告的方式提供最新软件和系统功能的过程。更具体地说，无论用户是否知情，更新都会自动进行。'可被翻译为：A process used to bring up-to-date software and system functionalities in a silent or announced way. More specifically, the update takes place automatically with or without the user’s knowledge.\n'证明分析程序(或方法)适合其预期用途的形成文件的过程。'可被翻译为：The documented process by which an analytical procedure (or method) is demonstrated to be suitable for its intended use.\n'1.混合是将材料或不同批次组合在一起，以生产出均匀的中间产品或成品的过程。\n2.混合:混合材料或不同批次以生产一种均匀的中间或成品的过程'可被翻译为：1.Blending is the process of combining materials or different batches to produce a homogenous intermediate or finished product.\n2.The process of combining materials or different batches to produce a homogeneous intermediate or finished product.\n\n根据上述已知信息，请将'过程或子过程无法提供预期结果的不同方式。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Different ways that a process or subprocess can fail to provide the anticipated result."
    },
    {
        "instruction":"已知信息：\n'以下均为只含有与检查有关的微生物信息的 FDA 指南文件。大多情况下，放在CBER 通用信息或 CBER 指南网页中。'可被翻译为：Listed below are all the FDA guidance documents that contain only microbiological information relevant to inspection. In most cases these will be listed in the general website for CBER or CBER guidelines.\n'与执法目的的分析有关。'可被翻译为：Related to analysis for law enforcement purposes.\n'在 FDA 合规项目指导手册 7356.002 中列出的 6 个检查系统中有 5 个的关键要素与微生物问题有关。有些例子是为澄清问题（不包括标签系统）'可被翻译为：Some of the key coverage elements in five of the six Inspectional Systems listed in FDA Compliance Program Guidance Manual Program 7356.002 that relate to microbiological issues. Some examples are included for clarification. (Labeling system not included).\n'检查所有相关产品的各论（并不是所有产品都有微生物要求）；以下是含有强制微生物要求的法规章节'可被翻译为：Review all relevant product monographs (not all have microbiological requirements); the following are regulatory chapters that contain enforceable microbiology requirements\n\n根据上述已知信息，请将'标题为“检查”和“分析”的章节与“附件 A”与 FDA 微生物学家有关。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The sections entitled “Inspectional” and “Analytical” and “Attachment A” are pertinent to an FDA microbiologist."
    },
    {
        "instruction":"已知信息：\n'三、申请人应当充分评估其拟申报药械组合产品的属性。对于药械组合产品不能确定管理属性的，申请人应当在申报注册前向国家药品监督管理局医疗器械标准管理中心（以下简称标管中心）申请药械组合产品属性界定。'可被翻译为：III. The Applicant shall fully evaluate the attributes of the drug-device combination products to be applied for. For the drug device combination products whose attribute cannot be determined, the applicants shall apply for attribute definition to Center for Medical Device Standards Management, NMPA (hereinafter referred to as the \"CMDSM\")prior to registration application.\n'五、申请人根据产品属性界定结果，向国家药品监督管理局申报药品或者医疗器械注册申请，并在申请表中注明“药械组合产品”。'可被翻译为：V. Applicants shall submit drug or medical device registration application to NMPA based on determination results on product attribute, and indicate \"drug-device combination products\" in the application form.\n'为进一步规范药械组合产品属性界定工作，根据国家药品监督管理局事业单位“三定”规定，现就调整药械组合产品属性界定有关事项通告如下：'可被翻译为：To further standardize the definition of the attributes of Drug\/Device Combination Products, according to the Three- Determinations (of posts, duties and staffing) regulations for NMPA institutions, on May 31, 2019, NMPA announced the relevant matters as follows:\n'四、标管中心对受理的药械组合产品属性界定申请资料进行审查，按程序提出属性界定意见，在药械组合产品属性界定信息系统中告知申请人，并及时在其网站对外公布药械组合产品属性界定结果。'可被翻译为：IV. The CMDSM shall review the dossiers for accepted attribute definition application of drug-device combination products, propose opinions on attribute definition as per the procedure, inform the applicants in the Information System for Attribute Definition of Drug-Device Combination Products, and in a timely manner issue the attribute definition results of drug-device combination products to the public on website.\n\n根据上述已知信息，请将'第一百二十二条 拟申报注册的药械组合产品，已有同类产品经属性界定为药品的，按照药品进行申报；尚未经属性界定的，申请人应当在申报注册前向国家药品监督管理局申请产品属性界定。属性界定为药品为主的，按照本办法规定的程序进行注册，其中属于医疗器械部分的研究资料由国家药品监督管理局医疗器械技术审评中心作出审评结论后，转交药品审评中心进行综合审评。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 122 For a drug-device combination product, where other products of the same category have been defined as drugs, drug registration application shall be submitted; where attribute of a product has not been defined, the applicant shall apply for product attribute definition to the NMPA before submitting the registration application. For a drug-device combination product defined as one with drug as the predominant part, its registration shall comply with the procedures specified in these Provisions; study data on the medical device part shall be reviewed by the Center of Medical Device Evaluation of NMPA (CMDE), which shall then forward its review conclusions to the CDE for comprehensive review."
    },
    {
        "instruction":"已知信息：\n'为贯彻落实《化妆品注册备案管理办法》，规范和指导化妆品新原料注册与备案工作，国家药监局制定了《化妆品新原料注册备案资料管理规定》，现予公布，自2021年5月1日起施行。'可被翻译为：In order to implement the Provisions for Registration and Notification of Cosmetics and standardize and guide the registration and notification of new cosmetic ingredients, the NMPA has developed the Rules for Registration and Notification Dossiers of New Cosmetic Ingredients, which is hereby issued and shall take effect as of May 1,2021.\n'为贯彻落实《化妆品注册备案管理办法》，规范和指导化妆品注册与备案工作，国家药监局制定了《化妆品注册备案资料管理规定》，现予公布，自2021年5月1日起施行。'可被翻译为：In order to implement the Provisions for Registration and Notification of Cosmetics and standardize and guide the registration and notification of cosmetics, the NMPA has developed the Rules for Registration and Notification Dossiers of Cosmetics, which is hereby issued and shall take effect as of May 1, 2021.\n'国家药监局关于发布《化妆品新原料注册备案资料管理规定》的公告'可被翻译为：NMPA Announcement on Issuing the Rules for Registration and Notification Dossiers of New Cosmetic Ingredients\n'为贯彻落实《化妆品监督管理条例》《化妆品注册备案管理办法》相关规定，进一步规范化妆品注册备案管理工作，现就实施《化妆品注册备案资料管理规定》（以下简称《规定》）有关事项公告如下：'可被翻译为：In order to implement the Regulations for the Supervision and Administration of Cosmetics and the Provisions for Registration and Notification of Cosmetics and further standardize the administration on registration and notification of cosmetics, the issues about implementing the Rules for the Registration and Notification Dossiers of Cosmetics (hereinafter referred to as the Rules) is hereby announced as follows:\n\n根据上述已知信息，请将'为指导化妆品和新原料注册人、备案人规范开展注册备案和提交注册备案资料，依据《化妆品监督管理条例》《化妆品注册备案管理办法》《化妆品注册备案资料管理规定》《化妆品新原料注册备案资料管理规定》等相关规定，国家药监局组织制定了《化妆品注册备案资料提交技术指南（试行）》，于2021年4月12日予以发布。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to guide registrants and filing applicants of cosmetics and new raw materials to carry out registration and notification and submit relevant documents in a standardized manner, according to the Regulations for the Supervision and Administration of Cosmetics, Provisions for Registration and Notification of Cosmetics, Provisions for Registration and Notification Dossier of Cosmetics, Provisions for Registration and Notification Dossier of New Cosmetic Raw Materials and other relevant provisions, NMPA has organized to formulate the Technical Guidelines for Submitting Registration and Notification Dossier of Cosmetics (Interim), which was issued on 2021, April 12."
    },
    {
        "instruction":"已知信息：\n'第一百五十七条 国家食品药品监督管理局接到复审申请后，应当在50日内作出复审决定，并通知申请人。维持原决定的，国家食品药品监督管理局不再受理再次的复审申请。'可被翻译为：Article 157 The State Food and Drug Administration shall make a second review decision, and notify the applicant the decision within 50 days after receiving an application for second review. Where the original decision is affirmed, the State Food and Drug Administration shall not accept any further application for second review thereof.\n'第三十五条    原批签发机构或者中检院应当在收到批签发申请人的复审申请之日起20日内作出是否复审的决定，复审  内容仅限于原申请事项及原报送资料。需要复验的，其样品为原批签发机构保留的样品，其时限按照本办法第二十二条规定执行。'可被翻译为：Article 35 The original lot release institution or the NIFDC shall decide whether or not to re-review within 20 days since the day when it receives the lot release applicant's application for re-review, and the content of re-review is only limited to the items in the original application or the original dossiers submitted by the applicant. If re-test is required, the sample shall be the one retained by the original lot release institution, and the time limit shall conform to Article 22 hereof.\n'第一百五十六条 申请人对国家食品药品监督管理局作出的不予批准决定有异议的，可以在收到不予批准的通知之日起60日内填写《药品注册复审申请表》，向国家食品药品监督管理局提出复审申请并说明复审理由。'可被翻译为：Article 156 If holding any dispute on the unapproval decision made by the State Food and Drug Administration, an applicant may, within 60 days after receiving the decision, fill in the Application Form for Drug Registration Second Review, and submit the application to the State Food and Drug Administration and provide reasons.\n'第三十四条 原批签发机构或者中检院应当在收到批签发申请人的复审申请之日起20日内作出是否复审的决定，复审内容仅限于原申请事项及原报送资料。按规定需要复验的，其样品为原批签发机构保留的样品，其时限按照本办法第二十二条规定执行。'可被翻译为：Article 34 The original lot release institution or the NIFDC shall decide whether or not to re-review within 20 days since the day when it receives the lot release applicant's application for re-review, and the content of re-review is only limited to the items in the original application or the original dossiers submitted by the applicant. If re-test is required as stipulated, the sample shall be the one retained by the original lot release institution, and the time limit shall conform to Article 22 hereof.\n\n根据上述已知信息，请将'第一百五十八条 复审需要进行技术审查的，国家食品药品监督管理局应当组织有关专业技术人员按照原申请时限进行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 158 Where there is any need for technical review in second review, the State Food and Drug Administration shall organize relevant technical personnel to conduct review within the timeline as that for the original application."
    },
    {
        "instruction":"已知信息：\n'第三十二条 批签发机构应当对批签发工作情况进行年度总结，由中检院汇总分析后，于每年3月底前向食品药品监管总局报告。'可被翻译为：Article 32 Lot release institutions shall summarize their annual lot release work. The NIFDC, after summarization and analysis, shall report to the CFDA before the end of March each year.\n'国家监测机构应当对全国医疗器械不良事件年度监测情况进行汇总分析，形成年度报告，于每年3月底前报国家药品监督管理局。'可被翻译为：National monitoring agencies shall carry out Meta-analysis on the annual monitoring information of medical device adverse events nationwide, complete annual report and submit it to the NMPA by the end of March each year.\n'第九条    中检院应当根据批签发工作需要，对批签发机构进行评估，评估情况及时报告国家药品监督管理局。'可被翻译为：Article 9 The NIFDC shall, in accordance with the needs of lot release, make an evaluation on the lot release institutions and report the evaluation results to the NMPA in a timely manner.\n'第三十三条 批签发申请人对生物制品批签发通知书有异议的，可以自收到生物制品批签发通知书之日起7日内，向原批签发机构或者直接向中检院提出复审申请。'可被翻译为：Article 33 If the lot release applicant holds objection to the Notice of Lot Release of Biological Products, it may propose an application for re-review to the original lot release institution or directly to the NIFDC within 7 days after receiving the Notice.\n\n根据上述已知信息，请将'第三十三条    批签发机构应当对批签发工作情况进行年度总结，由中检院汇总分析后，于每年3月底前向国家药品监督管理局报告。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 33 Lot release institutions shall summarize their annual lot release work. The NIFDC, after summarization and analysis, shall report to the NMPA before the end of March each year."
    },
    {
        "instruction":"已知信息：\n'构成生物大分子结构单元的排列次序。如DNA分子是由4种核昔酸（A,T,G,C）排列组成，DNA序列就是组成某一DNA分子的核昔酸的排列次序。'可被翻译为：The arrangement of the structural units of biomacromolecules. For example, the DNA molecule is composed of four nucleotides (A,T,G,C), and the DNA sequence is the sequence of nucleotides that make up a DNA molecule.\n'编码于DNA或RNA（一些病毒）核昔酸序列中的可遗传的生物信息。'可被翻译为：The heritable biological information encoded in the nucleotide sequence of DNA or RNA (some viruses).\n'一种负责从脱氧核糖核酸（DNA）或核糖核酸（RNA）模板制造核糖核酸的酶。'可被翻译为：An enzyme responsible for making RNA from deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) templates.\n'（l）DNA或RNA的一种突变形式，在多核昔酸链内插入了一个或多个额外核昔酸的过程。（2）在DNA或RNA链中增加一个或多个额外核昔酸的过程。'可被翻译为：(l) A mutated form of DNA or RNA in which one or more additional nucleotides are inserted into a polynucleoxylic acid chain. (2) A process by which one or more additional nucleotides are added to a strand of DNA or RNA.\n\n根据上述已知信息，请将'由核昔酸聚合而成的生物大分子。包括脱氧核糖核酸(DNA)和核糖核酸(RNA)。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A biomacromolecule polymerized from nucleotide. Includes deoxyribonucleic acid (DNA) and ribonucleic acid (RNA)."
    },
    {
        "instruction":"已知信息：\n'申请资料不齐全或者不符合规定形式的，批签发机构应当在5日内一次性书面告知批签发申请人需要补正的全部内容及资料补正时限。逾期不告知的，自收到申请资料和样品之日起即为受理。'可被翻译为：If the application dossiers are incomplete or nonconforming to the prescribed form, the lot release institution shall inform the lot release applicant of all contents to be supplemented and corrected and the time limit for supplementation in writing all at once within 5 days. Where the lot release institution fails to notify the applicant within the time limit, it shall be regarded as acceptance as of the date of receipt of application dossiers and samples.\n'（四）申请资料不齐全或者不符合法定形式的，应当当场或者在5个工作日内一次告知申请人需要补正的全部内容以及提交补正资料的时限。逾期不告知的，自收到申请资料之日起即为受理；'可被翻译为：(4) If the application documents are incomplete or do not conform to statutory form, the applicant shall be notified of all contents ought to be supplemented and corrected on site or within 5 working days one-off. If no notification is made within the prescribed time limit, the application shall be deemed to have been accepted upon receipt of the application documents;\n'（三）申请资料不齐全或者不符合规定形式的，出具补正通知书，一次告知申请人需要补正的全部内容，逾期未告知的，自收到申请资料之日起即为受理；'可被翻译为：(3) Where the application dossiers are incomplete or do not conform to the prescribed form, a notice of supplement shall be issued to notify the applicant of all the contents that need to be supplemented and corrected at one time. If no notice is made within the time limit, the application shall be deemed as accepted since the date of receipt; and\n'（四）申报资料不齐全或者不符合法定形式的，应当当场或者在5日内一次告知申请人需要补正的全部内容，逾期不告知的，自收到申报资料之日起即为受理；'可被翻译为：(4) Where the dossier is incomplete or not conformed with the defined format, the applicant shall be informed on-site or within five days at once of what to be supplemented or corrected; if it is not informed to the applicant within the timeline, the application is regarded as accepted on the date the dossier is received; and\n\n根据上述已知信息，请将'申请资料不齐全或者不符合规定形式的，批签发机构应当在5日内一次性书面告知批签发申请人需要补正的全部内容及资料补正时限。逾期不告知的，自收到申请资料之日起即为受理。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the application dossiers are incomplete or nonconforming to the prescribed form, the lot release institution shall inform the lot release applicant of all contents to be supplemented and corrected and the time limit for supplementation in writing all at once within 5 days. Where the lot release institution fails to notify the applicant within the time limit, it shall be regarded as acceptance as of the date of receipt of application dossiers."
    },
    {
        "instruction":"已知信息：\n'有毒成分是化学定义的物质或物质群，其毒性占主导地位，尽管它们可能有助于草药材料或草药制剂的治疗活性。'可被翻译为：Toxic constituents are substances or group(s) of substances that are chemically defined and their toxic property is predominant, although they may contribute to the therapeutic activities of the herbal material or herbal preparation.\n'1.药用植物材料中经化学定义并对控制有兴趣的成分。标记物通常在未发现或不确定具有已知治疗活性的成分时使用，可用于计算成品中植物材料或制剂的数量。在测试起始原料时，必须定量确定植物材料或制剂中的标记物。\n2.标记物是草药材料中用于控制目的的化学成分。它们可能对临床疗效有帮助，也可能没有。然而，在第一种情况下，他们对临床疗效全权负责的证据可能可用，也可能不可用。当没有发现已知治疗活性成分或不确定成分时，通常使用标记物，并可用于识别草药材料或制剂或计算其在成品中的数量。'可被翻译为：1.Constituents of a medicinal plant material which are chemically defined and of interest for control purposes. Markers are generally employed when constituents of known therapeutic activity are not found or are uncertain, and may be used to calculate the quantity of plant material or preparation in the finished product. When starting materials are tested, markers in the plant material or preparation must be determined quantitatively.\n2.Markers are chemically defined constituents of a herbal material utilized for control purposes. They may or may not contribute to the clinical efficacy. In the first case, however, evidence that they are solely responsible for the clinical efficacy may or may not be available. Markers are generally employed when constituents of known therapeutic activity are not found or are uncertain, and may be used to identify the herbal material or preparation or calculate their quantity in the finished product.\n'1.化学物质:经化学定义并已知有助于植物材料或制剂的治疗活性的物质或物质群\n2.具有已知治疗活性的成分是化学上确定的物质或一组物质，已知有助于草药材料或制剂的治疗活性。(见:《传统医学研究和评价方法一般准则》，日内瓦，世界卫生组织，2000年)。\n3.具有已知治疗活性的成分是化学定义的物质或物质组，已知有助于草药材料或制剂的治疗活性(3,4)。'可被翻译为：1.Substances or groups of substances which are chemically defined and known to contribute to the therapeutic activity of a plant material or of a preparation.\n2.Constituents with known therapeutic activity are substances or group of substances which are chemically defined and known to contribute to the therapeutic activity of a herbal material or of a preparation. (In: General guidelines for methodologies on research and evaluation of traditional medicine, Geneva, World Health Organization, 2000).\n3.Constituents with known therapeutic activity are substances or group(s) of substances which are chemically defined and known to contribute to the therapeutic activity of the herbal material or of a preparation (3, 4).\n'具有公认药理学(生物学)活性的成分是化学定义的特征成分(物质或物质组)，其中药理学(生物学)活性与草药材料或草药制剂的治疗或毒理学作用的相关性尚未完全确定。'可被翻译为：Constituents with recognized pharmacological (biological) activities are characteristic constituents (substances or group(s) of substances) which are chemically defined and where the relevance of the pharmacological (biological) activities for the therapeutic or toxicological effects of the herbal material or herbal preparation has not yet been fully established.\n\n根据上述已知信息，请将'1.标记物(标记物质)是中草药中化学定义的成分的参比物质。它们可能对治疗活性有贡献，也可能没有。然而，即使它们对治疗活动有贡献，也可能没有证据表明它们对临床疗效负有全部责任。\n2.参考物质:指草药的化学成分。它们可能有助于也可能不有助于其治疗活性。然而，即使它们有助于治疗活性，也可能没有证据表明它们对材料的临床疗效负全部责任(10)。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.Markers (marker substances) are reference substances that are chemically defined constituents of a herbal material. They may or may not contribute to the therapeutic activity. However, even when they contribute to the therapeutic activity, evidence that they are solely responsible for the clinical efficacy may not be available.\n2.Reference substances that are chemically defined constituents of a herbal material. They may or may not contribute to their therapeutic activity. However, even when they contribute to the therapeutic activity, evidence that they are solely responsible for the material’s clinical efficacy may not be available (10)."
    },
    {
        "instruction":"已知信息：\n'一种或一种以上含药物粒子经特殊的给药装置给药后以气溶胶形式进入呼吸道的吸入制剂。按用途可分为吸入粉雾剂、非吸入粉雾剂和外用粉雾剂。'可被翻译为：An inhalation preparation in which one or more drug-containing particles are administered by a special drug delivery device and then enter the respiratory tract in aerosol form. It can be divided into inhaled powder, non-inhaled powder and external powder according to its use.\n'制气溶胶药物经呼吸道（口腔或鼻腔）给药时所需要的专用器具或装置。'可被翻译为：A special apparatus or device for the administration of aerosols through the respiratory tract (mouth or nose).\n'可以一种以上方式给药给病人的固体剂型，例如，可分散或整体口服。'可被翻译为：A solid dosage form that can be administered to patients in more than one manner, e.g. may be dispersed or taken orally as a whole.\n'经过某种途径给药后，药物通过特殊载体或弹头的作用特异性地浓集于靶部位的给药系统。'可被翻译为：A drug delivery system in which the drug is specifically concentrated at the target site by the action of a special carrier or warhead after delivery by a certain route.\n\n根据上述已知信息，请将'一种或一种以上含药物粒子经特殊的给药装置给药后以气溶胶形式进入呼吸道的吸入制剂。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An inhaled preparation in which one or more drug-containing particles are administered by a special drug delivery device and enter the respiratory tract in aerosol form."
    },
    {
        "instruction":"已知信息：\n'只有一套冲模，适用于实验室试制或小批量生产的一种小型台式压片设备。'可被翻译为：A small benchtop tablet pressing device with only one set of dies suitable for laboratory trial production or small batch production.\n'压片机冲模的一部分，用于施加压片所需的压力。'可被翻译为：A part of the die of a tablet press that is used to apply the pressure required to press the sheet.\n'用适合的消毒剂对套好手套的手消毒（即，杀孢子剂或 70%无菌乙醇）'可被翻译为：1. Disinfect gloved hands with a suitable sanitizing agent (i.e. sporicidal agent or sterile 70% alcohol).\n'把固体物料压缩成片剂的设备。'可被翻译为：A device for compressing solid materials into tablets.\n\n根据上述已知信息，请将'常用的压片设备。旋转台上具有多套冲模，适合进行片剂的批量生产。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A commonly used tablet pressing device. The rotary table has multiple sets of stamping dies, suitable for mass production of tablets."
    },
    {
        "instruction":"已知信息：\n'如果产品的阶段式生产在 CCS 中经过适当论证并经过验证，过滤器使用人员应：'可被翻译为：Where campaign manufacture of a product has been appropriately justified in the  CCS and validated, the filter user should:\n'执行有效的验证和确认研究并进行记录，以证明给定液体和给定除菌过滤工艺中过滤器的使用时间不会影响最终除菌级过滤器的性能或滤液质量。'可被翻译为：Conduct and document effective validation and qualification studies to demonstrate that the duration of filter use for a given  sterile  filtration process and for a given  fluid does not compromise performance of the final sterilising grade filter or filtrate quality.\n'评估并记录与给定液体除菌过滤工艺中过滤器的使用时间相关的风险。'可被翻译为：Assess and document the risks associated with the duration of filter use for the sterile filtration process for a given fluid.\n'如果除菌过滤工艺已作为多个过滤器组成的单个系统经过验证，能保证给定液体的无菌性，则该过滤系统被认为是单个灭菌单元，系统内的所有过滤器应在使用后通过完整性测试。'可被翻译为：If the sterilising filtration process has been validated as a system consisting of multiple filters to achieve the sterility for a given fluid, the filtration system is considered to be a single sterilising unit and all filters within the system should satisfactorily pass integrity testing after use.\n\n根据上述已知信息，请将'液体的除菌过滤应按照相关药典要求进行验证。验证可以根据产品的不同规格或种类进行分组，但应在最差条件下进行。分组的基本依据应经过论证并用文件记录。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Sterile  filtration  of liquids  should be validated  in  accordance with relevant Pharmacopeia requirements. Validation can be grouped by different strengths or variations of a product but should be done under worst-case conditions. The rationale for grouping should be justified and documented."
    },
    {
        "instruction":"已知信息：\n'RABS 的设计应通过具有单向流和关键区域初始气流保护确保 A 级条件。应保持从关键区到支持性背景环境的正向气流。'可被翻译为：RABS:\nThe design of RABS should ensure grade A conditions with unidirectional airflow and first air protection in thecritical zone. A positive airflow from the critical zone to the supporting background environment should be maintained.\n'单向流：以单一方向、稳定和均匀方式、以及足够速度移动的气流，可不断地将粒子从关键操作区或检测区清除的气流。'可被翻译为：Unidirectional airflow - An airflow moving in a single direction, in a robust and uniform manner, and at sufficient speed, to reproducibly sweep particles away from the critical processing or testing area.\n'A 级：进行高风险操作的关键区域（例如，无菌生产线，灌装区，胶塞加料盘，敞口内包装或在初始气流保护下进行无菌连接）。通常情况下，这种条件是通过局部气流保护实现的，例如 RABS 或隔离器内的单向流操作台。应证明并确认整个 A 级区的单向流维护状态。应通过厂房、设备、工艺和程序性设计尽量减少操作人员对 A 级区的直接干预（例如，不使用隔离器和手套箱技术作为保护）。'可被翻译为：Grade A: The critical zone for high-risk operations (e.g. aseptic processing line, filling zone, stopper bowl, open primary packaging or for making aseptic connections under the protection of first air). Normally, such conditions are provided by a localised airflow protection, such as unidirectional airflow workstations within RABS or isolators. The maintenance of unidirectional airflow should be demonstrated and qualified across the whole of the grade A area. Direct intervention (e.g. without the protection of barrier and glove port technology) into the grade\nA area by operators should be minimized by premises, equipment, process and procedural design.\n'风险评估应包括确定关键监测位置，这些位置在加工过程中出现微生物可能会对产品质量产生影响（例如 A 级，无菌工艺区以及与作为 A 级区背景的 B 级区）。还应包括对空气可视化研究等其他信息的考虑。这 些风险评估应定期回顾，以确认工厂环境监测计划的有效性。监测计划应在趋势分析和场地的 CCS 中予以考虑。'可被翻译为：The risk assessment should include the determination of critical monitoring locations, those locations where the presence of microorganisms during processing may have an impact upon product quality, (e.g. grade A, aseptic processing areas and the grade B areas that directly interface with the grade A area). Consideration of other information such as air visualisation studies should also be included. These risk assessments should be reviewed regularly in order to confirm the effectiveness of the site's environmental monitoring programme. The monitoring programme should be considered in the overall context of the trend analysis and the CCS for the site.\n\n根据上述已知信息，请将'洁净区中对生产过程不重要的活动应保持在最低限度，特别是在进行无菌操作时。人员移动应缓慢、受控\n并有条不紊，以避免由于过度活动导致的微粒和微生物的过量脱落。执行无菌操作的操作人员应始终遵循\n无菌技术，以防止气流的变化可能将较低质量的空气引入关键区域。应限制关键区附近的移动，应避免单\n向流（初始气流）通路的阻塞。应考虑将气流可视化研究的回顾作为培训计划的一部分。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Activities in clean areas that are not critical to the production processes should be kept to a minimum,\nespecially when aseptic operations are in progress. Movement of personnel should be slow, controlled and\nmethodical to avoid excessive shedding of particles and organisms due to over-vigorous activity. Operators\nperforming aseptic operations should adhere to aseptic technique at all times to prevent changes in air currents\nthat may introduce air of lower quality into the critical zone. Movement adjacent to the critical zone should be\nrestricted and the obstruction of the path of the unidirectional (first air) airflow should be avoided. A review of\nairflow visualisation studies should be considered as part of the training programme."
    },
    {
        "instruction":"已知信息：\n'第一百零六条 企业应当制定冷藏、冷冻药品运输应急预案，对运输途中可能发生的设备故障、异常天气影响、交通拥堵等突发事件，能够采取相应的应对措施。'可被翻译为：Article 106 Enterprises shall formulate a contingency plan for the transportation of refrigerated and frozen drugs, and be able to take corresponding measures to deal with such emergencies as equipment failure, abnormal weather influence and traffic congestion that may occur during the transportation.\n'第六十条 接收、发放和发运区域应当能够保护物料、产品免受外界天气（如雨、雪）的影响。接收区的布局和设施应当能够确保到货物料在进入仓储区前可对外包装进行必要的清洁。'可被翻译为：Article 60: Receiving, dispatch and distribution bays should protect materials and products from the weather (e.g. raining, snowing). Reception areas should be designed and equipped to allow containers of incoming materials to be cleaned where necessary before storage.\n'第一百零三条 企业应当严格按照外包装标示的要求搬运、装卸药品。'可被翻译为：Article 103 Enterprises shall carry, load and unload drugs in strict accordance with the requirements on the outer package.\n'第一百四十四条 营业场所应当具有相应设施或者采取其他有效措施，避免药品受室外环境的影响，并做到宽敞、明亮、整洁、卫生。'可被翻译为：Article 144 Business premises shall be equipped with appropriate facilities or other effective measures shall be taken to prevent drugs from being affected by the outdoor environment, and the premises shall also be spacious, bright, clean and hygienic.\n\n根据上述已知信息，请将'（四）有防止室外装卸、搬运、接收、发运等作业受异常天气影响的措施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(IV) Protective measures against the impact of abnormal weather during outdoor loading and unloading, handling, receiving, shipment, and other operations shall be in place."
    },
    {
        "instruction":"已知信息：\n'第七条 化妆品、化妆品新原料注册人、备案人依法履行产品注册、备案义务，对化妆品、化妆品新原料的质量安全负责。'可被翻译为：Article 7 The registrant and filing person of cosmetics and new cosmetic ingredients shall perform product registration and filing obligations in accordance with law and shall be responsible for the quality and safety of cosmetics and new cosmetic ingredients.\n'第二十三条 使用化妆品新原料生产化妆品的化妆品注册人、备案人，应当及时向化妆品新原料注册人、备案人反馈化妆品新原料的使用和安全情况。'可被翻译为：Article 23 The registrant and filing person of cosmetics who use new cosmetic ingredients to produce cosmetics shall give prompt feedback on the use and safety of the new cosmetic ingredients to the registrant and filing person of new cosmetic ingredients.\n'一是细化注册人、备案人管理制度，强化企业主体责任落实。根据《条例》关于注册人、备案人的相关规定要求，细化落实化妆品、化妆品新原料注册人、备案人的责任义务及准入条件，加强对产品责任源头监管。建立新原料安全监测制度，对新原料注册人、备案人和化妆品注册人、备案人应当履行的安全监测义务进行了细化规定。'可被翻译为：1. The elaboration on the administration system for registration and notification persons to potentiate corporate principal responsibilities. In accordance with the related requirements of the Regulations, detailed provisions for responsibilities, obligations and access conditions are applied to registration and notification persons of cosmetics and new cosmetic ingredients to potentiate the supervision and liability of product at its source. A safety monitoring system for new cosmetic ingredients is established with detailed regulations on the safety monitoring obligations of registration and notification persons of cosmetics and new cosmetic ingredients.\n'第二十条 安全监测的期限内，化妆品新原料注册人、备案人可以使用该化妆品新原料生产化妆品。'可被翻译为：Article 20 During the safety monitoring period, registrants and filing persons of new cosmetic ingredients may use the new cosmetic ingredient to produce cosmetics.\n\n根据上述已知信息，请将'（四）按照与注册人、备案人的协议，对投放境内市场的化妆品、化妆品新原料承担相应的质量安全责任；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(4) In accordance with the agreement with the registrants and filing persons, assuming corresponding quality and safety responsibilities for cosmetics and new cosmetic ingredients released in the domestic market; and"
    },
    {
        "instruction":"已知信息：\n'2019年8月26日，经第十三届全国人大常委会第十二次会议修订通过，修订后的《中华人民共和国药品管理法》（以下称药品管理法）自2019年12月1日起施行。国家药监局正在抓紧开展配套规章、规范性文件和技术指南的制修订工作，并将按程序陆续发布。现就贯彻实施新修订的药品管理法有关事项公告如下：'可被翻译为：Revised and adopted by the Twelfth Session of the Standing Committee of the 13th National People's Congress on August 26,2019, the revised Drug Administration Law of the People's Republic of China(hereinafter referred to as DAL) shall be implemented as from December 1,2019. NMPA is stepping up work on the development, formulation and revision of supporting regulations, normative documents and technical guidelines, which will be released in accordance with procedures. We hereby announce the issues pertaining to the implementation of the newly revised DALas follows:\n'《中华人民共和国药品管理法》已由中华人民共和国第十三届全国人民代表大会常务委员会第十二次会议于2019年8月26日修订通过，现予公布，自2019年12月1日起施行。'可被翻译为：The Drug Administration Law of the People's Republic of China adopted at the 12th Meeting of the Standing Committee of the Thirteenth National People's Congress on August 26, 2019 is hereby promulgated and shall go into effect as of December 1, 2019.\n'（1984年9月20日第六届全国人民代表大会常务委员会第七次会议通过 2001年2月28日第九届全国人民代表大会常务委员会第二十次会议第一次修订 根据2013年12月28日第十二届全国人民代表大会常务委员会第六次会议《关于修改〈中华人民共和国海洋环境保护法〉等七部法律的决定》第一次修正 根据2015年4月24日第十二届全国人民代表大会常务委员会第十四次会议《关于修改〈中华人民共和国药品管理法〉的决定》第二次修正 2019年8月26日第十三届全国人民代表大会常务委员会第十二次会议第二次修订）'可被翻译为：(Adopted at the 7th Meeting of the Standing Committee of the Sixth National People's Congress on September 20, 1984; revised for the first time at the 20th Meeting of the Standing Committee of the Ninth National People's Congress on February 28, 2001; amended for the first time in accordance with the Decision on Revising Seven Laws Including the Marine Environmental Protection Law of the People's Republic of China adopted at the 6th Meeting of the Standing Committee of the Twelfth National People's Congress on December 28, 2013; amended for the second time in accordance with the Decision on Revising the Drug Administration Law of the People's Republic of China adopted at the 14th Meeting of the Standing Committee of the Twelfth National People's Congress on April 24, 2015; revised for the second time at the 12th Meeting of the Standing Committee of the Thirteenth National People's Congress on August 26, 2019)\n'《中华人民共和国疫苗管理法》已由中华人民共和国第十三届全国人民代表大会常务委员会第十一次会议于2019年6月29日通过，现予公布，自2019年12月1日起施行。'可被翻译为：The Vaccine Administration Law of the People's Republic of China, adopted at the 11th Meeting of the Standing Committee of the Thirteenth National People's Congress on June 29, 2019, is hereby promulgated and shall go into effect as of December 1, 2019.\n\n根据上述已知信息，请将'2018年10月，《药品管理法（修正草案）》提交第十三届全国人大常委会第六次会议进行初次审议，并于会后公开征求社会公众意见。审议中，有意见提出现行《药品管理法》自2001年修订以来，没有进行大的修改，建议将历年来药品领域改革成果和行之有效的做法上升为法律，将修正草案改为修订草案。2019年4月，第十三届全国人大常委会第十次会议对《药品管理法（修订草案）》进行审议。2019年8月26日，第十三届全国人大常委会第十二次会议进行第三次审议并表决通过。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In October 2018, the DAL Amendment Draft was submitted to the Sixth Session of the Standing Committee of the 13thNational People's Congress for initial deliberation, and subsequent solicitation of public comments. During the deliberation,taken into account that no major revisions have been made since the DAL revision in2001, it was recommended that the results of the reform of the pharmaceutical sector and effective practices over the years be raised to the law, and the draft amendments be changed to the revised drafts. In April2019, the Tenth Session of the Standing Committee of the 13th National People'sCongress deliberated the Revised Draft of DAL, which has been passed by voting on August 26, 2019 at the third deliberation of the Twelfth Session of the Standing Committee of the 13th National People'sCongress."
    },
    {
        "instruction":"已知信息：\n'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药监局组织制定了影像型超声诊断设备同品种临床评价技术审查指导原则等2项注册技术审查指导原则，于2021年1月15日予以发布。'可被翻译为：In order to strengthen the supervision and guidance over medical device registration and further improve the quality of registration review, the NMPA has organized to formulate 2 technical review guidelines for registration including the Guidelines for Technical Review of Clinical Evaluation of Ultrasound Diagnostic Imaging Equipment Based on Predicate Products, which are hereby promulgated on January 15, 2021.\n'国家药监局关于发布《医用磁共振成像系统同品种临床评价技术审查指导原则（2020年修订版）》的通告'可被翻译为：NMPA Notice on Issuing the Guidance for Technical Review of Clinical Evaluation of Equivalent Devices of Medical Magnetic Resonance Imaging Systems (Revision 2020)\n'国家药监局关于发布5项注册技术审查指导原则的通告'可被翻译为：NMPA Announcement on Issuing 5 Technical Review Guidances for Registration\n'国家药监局关于发布肢体加压理疗设备等13项注册技术审查指导原则的通告'可被翻译为：NMPA Announcement on the Issuance of 13 Guidelines for Technical Review of the Registration of Augmented Extremity Compression Therapy Equipment and Others\n\n根据上述已知信息，请将'国家药监局关于发布影像型超声诊断设备同品种临床评价技术审查指导原则等2项注册技术审查指导原则的通告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Announcement on Issuing of Two Registration Technical Review Guidelines Including the Guidelines for Technical Review of Clinical Evaluation of Ultrasound Diagnostic Imaging Equipment Based on Predicate Products"
    },
    {
        "instruction":"已知信息：\n'（五）供应商和生产商（如不同）标识的批号；'可被翻译为：5. The batch number of the supplier, and of the producer if different;\n'（四）供应商和生产商（如不同）的名称；'可被翻译为：4. The name of the supplier, and of the producer if different;\n'生产操作前，还应当核对物料或中间产品的名称、代码、批号和标识，确保生产所用物料或中间产品正确且符合要求。'可被翻译为：Before the processing operation starts , the names, codes, batch numbers and labeling of all materials and intermediate products should also be checked , to guarantee that they are correct and in accordance with the requirements.\n'（四）拆零销售应当使用洁净、卫生的包装，包装上注明药品名称、规格、数量、用法、用量、批号、有效期以及药店名称等内容；'可被翻译为：(IV) For dismantling sales, clean and sanitary package shall be used, on which the name, strength, quantity, usage, dosage, lot number, and expiry date of the drug, and name of the drug store shall be indicated;\n\n根据上述已知信息，请将'1.产品或物料的名称、剂型、规格、批号或供货批号，必要时注明供应商和生产商（如不同）的名称或来源；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1) Name of the material or product, dosage form, strength, batch number or shipping batch number, where appropriate, the name of the manufacturer and\/or supplier;"
    },
    {
        "instruction":"已知信息：\n'如果上市许可持有人（MAH）不是制造商，则双方之间应达成技术协议，确定他们各自在生产产品质量回顾方面的责任。最终批放行的授权人员（AP）与上市许可持有人(MAH)应确保及时进行质量回顾和回顾准确性。'可被翻译为：Where the Marketing Authorisation holder is not the manufacturer, there should be a technical agreement in place between the various parties that defines their respective responsibilities in producing the product quality review. The Authorised Person responsible for final batch certification together with the Marketing Authorisation holder should ensure that the quality review is performed in a timely manner and is accurate.\n'14.确保完成产品质量回顾分析；'可被翻译为：14) To ensure that the product quality reviews are done;\n'第二百七十八条 为确保委托生产产品的质量和委托检验的准确性和可靠性，委托方和受托方必须签订书面合同，明确规定各方责任、委托生产或委托检验的内容及相关的技术事项。'可被翻译为：Article 278: To ensure the product quality of contract manufacture, and the accuracy and reliability of contract analysis, there must be a written contract between the contract giver and the contract acceptor, which clearly establishes the duties of each party, and covers the manufacture and\/or analysis arranged under contract and any technical arrangements made in connection with it.\n'第八节 产品质量回顾分析'可被翻译为：Section 8 Product Quality Review\n\n根据上述已知信息，请将'第二百六十八条 药品委托生产时，委托方和受托方之间应当有书面的技术协议，规定产品质量回顾分析中各方的责任，确保产品质量回顾分析按时进行并符合要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 268: For contract manufacturing, a written technical agreement should be in place between contract giver and contract acceptor, which defines their respective responsibilities of the product quality review to ensure that the quality review is performed on schedule according to the requirements."
    },
    {
        "instruction":"已知信息：\n'质量控制（QC） 为确保起始物料、中间体、包材和成品（FPP）符合既定的鉴别、含量、纯度和其它属性标准所执行的所有工作，包括设置标准、取样、检测和分析清场。'可被翻译为：quality control (QC). All measures taken, including the setting of specifications, sampling, testing and analytical clearance, to ensure that starting materials, intermediates, packaging materials and finished pharmaceutical products (FPP) conform with established specifications for identity, strength, purity and other characteristics.\n'各种材料（如辅料、包材、生物材料等）与生物体间相互作用的程度。'可被翻译为：The degree of interaction between various materials (such as excipients, packaging materials, biological materials, etc.) and living organisms.\n'SU应提供一份生产、灌装、包装和QC检测所用设备和仪器清单（或类似文件）。该清单应包括相关设备和仪器（包括一次性使用者）的厂商与型号，以确保对其运行原理的相似性进行评估。'可被翻译为：9.1. The SU should provide a list (or similar document) of equipment and instruments involved in the production, filling, packing and QC testing. It should include the makes and models of the relevant equipment and instruments, including those of single-use, to ensure evaluation of similar principles of operation.\n'辅料质量标准应该由SU提供转移给RU工厂。'可被翻译为：12.13. The specifications of excipients should be made available by the SU for transfer to be RU site.\n\n根据上述已知信息，请将'对于包材QC检测，应提供质量标准，包括图纸、原图和材料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"12.21. For QC testing of packaging components, specifications should be provided including drawings, artwork and material."
    },
    {
        "instruction":"已知信息：\n'第六十一条  进口医疗器械注册人、备案人应当指定我国境内企业法人作为代理人，代理人应当协助注册人、备案人履行医疗器械监督管理条例和本办法规定的义务。'可被翻译为：Article 61 The registrant or filing entity of imported medical devices shall designate the domestic enterprise legal person as the agent, who shall assist the registrant or filing entity to fulfill the obligations prescribed in the Regulations on Supervision and Administration of Medical Devices and these Provisions.\n'第十四条 境外申请人或者备案人应当通过其在中国境内设立的代表机构或者指定中国境内的企业法人作为代理人，配合境外申请人或者备案人开展相关工作。'可被翻译为：Article 14 An overseas applicant or filing entity shall conduct related work with the support of its representative office established in China or an enterprise legal person in China designated by it as its agent.\n'第十六条 境外申请人或者备案人应当通过其在中国境内设立的代表机构或者指定中国境内的企业法人作为代理人，配合境外申请人或者备案人开展相关工作。'可被翻译为：Article 16 An overseas applicant or filing entity shall conduct related work with the support of its representative office established in China or an enterprise legal person in China designated by it as its agent.\n'备案人、境内责任人地址变化导致备案管理部门改变的，备案人应当重新进行备案。'可被翻译为：If the address of the filing person or the domestic responsible person changes which causes the filing administration department changes, the filing person shall re-file.\n\n根据上述已知信息，请将'第八条 注册人、备案人在境外的，应当指定我国境内的企业法人作为境内责任人。境内责任人应当履行以下义务：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 8 Overseas registrants and filing persons shall designate an enterprise legal person within the territory of China as the domestic responsible person. The domestic responsible person shall fulfill the following obligations:"
    },
    {
        "instruction":"已知信息：\n'在一个设备内同时进行多次部分气化和部分冷凝以分离液体混合物组分的方法。'可被翻译为：The method of partially vaporizing and partially condensing several times at the same time in a device to separate the liquid mixture components.\n'以压力为推动力，过滤含有微粒的溶液的固体膜分离过程。当溶液通过微孔膜后，悬浮物（胶体、细菌）和粒径较大的微球被截留而被除去。'可被翻译为：The process of separating a solid membrane from a solution containing particles by using pressure as a driving force. When the solution passes through the microporous membrane, suspended matter (colloids, bacteria) and larger microspheres are trapped and removed.\n'将一定量的混合物（固体、液体或混悬液）分成其组分按梯度而改变的若干小部分的分离过程。'可被翻译为：The separation process by which a given amount of a mixture (solid, liquid, or suspension) is divided into small parts whose components vary according to gradient.\n'在高真空下操作的蒸憎方法。这时蒸气分子的平均自由程大于蒸发表面与冷凝表面之间的距离，从而可利用料液中各组分蒸发速率的差异，对液体混合物进行分离。分子蒸循是一种特殊的液-液分离技术，它不同于传统蒸僧依靠沸点差分离原理，而是靠不同物质分子运动平均自由程的差别实现分离。'可被翻译为：Steaming method operated under high vacuum. At this time, the mean free path of the vapor molecules is greater than the distance between the evaporation surface and the condensation surface, so that the liquid mixture can be separated by the difference in the evaporation rate of each component in the feed liquid. Molecular distillation is a special liquid-liquid separation technology, which is different from the traditional distillation relying on the principle of boiling point difference separation, but by the difference of the mean free path of molecular motion of different substances to achieve separation.\n\n根据上述已知信息，请将'以压力为推动力，依靠膜的选择性将液体中的组分进行分离的方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A method of separating the components of a liquid by means of the selectivity of the membrane, driven by pressure."
    },
    {
        "instruction":"已知信息：\n'容器和密闭器不应对药品有析出性、反应性或吸收性'可被翻译为：f. Containers and closures should not be additive, reactive, or absorptive to the drug product\n'如果在筛选试验中发现具有反应性，使用相同的方法进行两次重新测试，并且至少有一次重复测试也是具有反应性的，则认为捐赠具有重复反应性。'可被翻译为：A donation is considered to be repeatedly reactive if it is found reactive in a screening test, is retested in duplicate using the same assay, and at least one of the repeat tests is also reactive.\n'DNA反应性'可被翻译为：reactive\n'将棉签（或带有手柄的海绵）用固定压力擦拭被监测表面（或设备）'可被翻译为：b. Apply swab (or sponge with handle) to surface (or equipment) being monitored with firm application pressure.\n\n根据上述已知信息，请将'设备表面不应该具有反应性、析出或吸收性'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"ii. Equipment surfaces should not be reactive, additive, or absorptive"
    },
    {
        "instruction":"已知信息：\n'低温保护剂溶液通常是高渗的而不是生理的。例如，通常用于细胞冻存的10% DMSO溶液的浓度大约为1.4摩尔渗透压浓度(Osm\/L)。随着细胞失水，引入这种类型溶液中的细胞迅速脱水，以减少细胞内外的渗透压差。DMSO缓慢渗透到细胞内使其重新平衡。这可能会导致体积偏移，从而导致细胞活力的丧失。因此，冷冻保存溶液通常是逐步添加或逐渐地(如使用注射泵)或从容器的侧面缓慢添加到细胞悬浮液中，以防止由于渗透压造成细胞损失。应开发引入或去除冷冻保存液的方法并评估其对细胞活力和功能的影响。'可被翻译为：Cryoprotectant solutions typically are hypertonic and are not physiological. For example, a10% DMSO solution used commonly in cell preservation has a concentration of approximately 1.4 osmolarity (Osm\/L). Cells introduced into this type of solution rapidly dehydrate as water leaves the cell in order to reduce the difference in osmotic potential between the inside and outside of the cell. DMSO slowly permeates the cell to re-equilibrate. This may cause excursions in volume that can result in a loss of cell viability. Therefore, cryopreservation solutions commonly are added to a cell suspension in stepwise additions or gradually(e.g.,using asy ringe pump) or slowly dispensing down the side of the container to prevent cell losses resulting from osmotic stress. The method for introducing or removing a cryopreservation solution should be developed and evaluated for its impact on cell viability and functionality.\n'细胞离心后，立即从细胞沉淀中除去培养基，并通过缓慢添加预冷的冻存培养基轻轻重悬细胞。根据活细胞数量和目标细胞浓度（通常，细胞库活细胞密度大约1×107个细胞\/ mL），立即用适当体积的冷冻保存介质稀释细胞悬液。如上一节所述，冷冻储藏介质是高渗的，应限制暴露时间。将最终的细胞悬浮液转移到一个容器中，在小瓶灌装期间可以在其中轻轻混合细胞，促进细胞库的均匀性。'可被翻译为：Immediately following centrifugation of cells, growth medium is removed from cell pellets,and cells are gently resuspended by slow addition of cryopreservation medium that is often precooled for many cell types. The cell suspension is immediately diluted with an appropriate volume of cryopreservation medium based on viable cell count and targeted cell density (typically, cell banks are produced at aviable cell density of approximately 1 × 107 cells\/mL). As mentionedin the previous section, cryopreservation medium is highly hypertonic, and exposure time should be limited. The\n'DMSO对溶液中的细胞有毒。在输注或进一步处理之前，可通过稀释或洗涤细胞悬液来降低毒性。由于冻存过程中当细胞从高渗溶液过渡到等渗溶液时，融化的细胞对体积膨胀更敏感，稀释和洗涤溶液的方法必须仔细设计和验证。使用常规离心机或自动化设备进行细胞洗涤会给细胞带来额外的机械应力，因此具体在临床实践中，必须通过恰当的方法评估细胞损失。'可被翻译为：DMSO is toxic to cells in liquid suspension. Toxicity maybe reduced by diluting or washing the cell suspension before infusion orfurther manipulation. Because cryopreserved, thawed cells are more sensitive tovolumetric expansion when the cells transition from a hypertonic solution to anisotonic solution, the dilution and washing solutions and methods must becarefully designed and validated. Cell washing using either a conventionalcentrifuge or an automated device can result in additional mechanical stress tothe cells, so cell losses must be assessed by an appropriate method before aspecific method isimplemented in clinical practice.\n'临床使用的造血干细胞可以从骨髓、外周血或脐带血中获得。每种来源对冻存都有其特殊的要求。例如，外周血祖细胞（UCB）产品含有大量的细胞，并且可以在具有较高细胞浓度的多个袋中冷冻。UCB的保存方案可能包括使用注射泵引入冻存液，同时最大程度减少渗透压力。对于UCB，通常在解冻后使用专门的溶液来稀释或去除DMSO，同时最大程度降低细胞渗透压力。'可被翻译为：HSCs cryopreserved for clinical use may be obtained from bone marrow, mobilized peripheral blood, or umbilical cord blood (UCB). Each source has unique requirements for preservation. For example, peripheral blood progenitor cell products contain larger numbers of cells and may be frozen in multiple bags with relatively high cell concentrations. Protocols for UCB preservation may include the use of syringe pumps to introduce cryopreservation solutions while minimizing osmotic stresses. For UCB, specialized solutions often are used after thaw to dilute or remove DMSO while minimizing osmotic stress for the cells.\n\n根据上述已知信息，请将'对于DMSO，当两种溶液混合时，会产生较大的混合焓导致样品加热。这种加热的温度可能会高到足以损坏细胞的程度，因此通常将包含DMSO的溶液在混合前进行预冷。预冷可减少溶液混合过程中产生的热量，减少细胞渗透体积的变化，并减少细胞暴露于DMSO中的损伤。在冷冻之前，对细胞暴露于冷冻保护剂的时间应加以限制，并且常规研发工作中确定允许无有害影响的最大允许时间。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In thecase of DMSO, a large latent enthalpy of mixing results in sample heating whenthe two solutions are mixed. This heating can be high enough to damage the cells, so solutions that contain DMSO commonly are precooled before mixing.Prechilling the solution reduces heating associated with mixing of the solution, reducesthe osmotic volume changes that the cells experience, and reduces cell lossesassociated with exposure to DMSO. The time that cells are exposed to the cryoprotectant,prior to freezing, should be limited and the maximum time allowable, withoutdeleterious effects, should be determined during development work for routineuse."
    },
    {
        "instruction":"已知信息：\n'污水'可被翻译为：sewage\n'饮用水'可被翻译为：drinking water, potable water\n'照明'可被翻译为：lighting\n'清洗'可被翻译为：purge\n\n根据上述已知信息，请将'照明、饮用水、清洗和厕所设施，污水和废物处置'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"v. Lighting, potable water, washing and toilet facilities, sewage and refuse disposal"
    },
    {
        "instruction":"已知信息：\n'至少采用两种不同的识别方式，例如识别码和密码。'可被翻译为：(1) Employ at least two distinct identification components such as an identification code and password.\n'初始和定期的设备检测，例如含有或生成识别码或密码信息的记号或卡，以确保其运行正常，且未遭受未经授权的修改。'可被翻译为：(e) Initial and periodic testing of devices, such as tokens or cards, that bear or generate identification code or password information to ensure that they function properly and have not been altered in an unauthorized manner.\n'保持每一组的识别码和密码的唯一性，即不存在两个个体拥有同组识别码和密码的现象。'可被翻译为：(a) Maintaining the uniqueness of each combined identification code and password, such that no two individuals have the same combination of identification code and password.\n'同时使用识别码和密码的电子签名应给予管理以确保其安全性和完整性，管理内容应包括：'可被翻译为：Persons who use electronic signatures based upon use of identification codes in combination with passwords shall employ controls to ensure their security and integrity. Such controls shall include:\n\n根据上述已知信息，请将'保证定期检查、收回或修订识别码和密码（例如，解决密码老化）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(b) Ensuring that identification code and password issuances are periodically checked, recalled, or revised (e.g., to cover such events as password aging)."
    },
    {
        "instruction":"已知信息：\n'第七十四条  有下列情形之一的，依照医疗器械监督管理条例第八十一条的规定处罚：'可被翻译为：Article 74 In one of the following circumstances, punishment shall be imposed in accordance with provisions in Article 81 of the Regulations on Supervision and Administration of Medical Devices:\n'第三十七条 化妆品的标签存在下列情节轻微，不影响产品质量安全且不会对消费者造成误导的情形，可以认定为化妆品监督管理条例第六十一条第二款规定的标签瑕疵：'可被翻译为：Article 37 Where the labeling of cosmetics has the following minor circumstances under which the product quality and safety are not affected and no misleading is caused, it can be deemed as a label defect as specified in paragraph 2 of Article 61, of the Regulations on Supervision and Administration of Cosmetics:\n'第六十九条 药品上市许可持有人和药品生产企业未按照药品生产质量管理规范的要求生产，有下列情形之一，属于《药品管理法》第一百二十六条规定的情节严重情形的，依法予以处罚：'可被翻译为：Article 69 Where a drug MAH or drug manufacturer has failed to carry out manufacturing activities as per GMP requirements in any of the following circumstances and the circumstance belongs to the serious circumstances as specified in Article 126 under the Drug Administration Law, penalties shall be imposed according to law:\n'第六十七条  有下列情形之一的，药品监督管理部门应当对持有人开展重点检查：'可被翻译为：Article 67 In case of any of following situations, drug regulatory departments shall carry out the key inspection for MAHs.\n\n根据上述已知信息，请将'第六十一条 有下列情形之一的，属于化妆品监督管理条例规定的情节严重情形：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 61 Any of the following circumstances shall belong to the serious circumstances stipulated in the Regulations on Supervision and Administration of Cosmetics:"
    },
    {
        "instruction":"已知信息：\n'医疗机构未按照规定报告疑似药品不良反应的，责令限期改正，给予警告；逾期不改正的，处五万元以上五十万元以下的罚款。'可被翻译为：Where a medical institution fails to report suspected adverse drug reactions, the offender shall be ordered to make correction within the time limit and be given a disciplinary warning. Where correction is not made within the prescribed period, it shall be subject to a fine of not less than RMB 50,000 but not more than RMB 500,000.\n'药品经营企业未按照规定报告疑似药品不良反应的，责令限期改正，给予警告；逾期不改正的，责令停产停业整顿，并处五万元以上五十万元以下的罚款。'可被翻译为：Where a drug distributor fails to report suspected adverse drug reactions as required, the offender shall be ordered to make correction within the time limit and be given a disciplinary warning. Where correction is not made within the prescribed period, it shall be subject to production suspension for rectification and be fined not less than RMB 50,000 but not more than RMB 500,000.\n'第八十三条 违反本法规定，疫苗上市许可持有人有下列情形之一的，由省级以上人民政府药品监督管理部门责令改正，给予警告；拒不改正的，处二十万元以上五十万元以下的罚款；情节严重的，责令停产停业整顿，并处五十万元以上二百万元以下的罚款：'可被翻译为：Article 83 In cases where vaccine MAHs' violation of this Law involves any of the following circumstances, the drug regulatory departments of the people's governments at or above the provincial level shall order to make rectification and give a warning; and those who refuse to make rectification shall be subject to a fine of not less than RMB 200,000 yuan but not more than RMB 500,000 yuan; in serious circumstances, the offender shall be subject to an order to stop production for rectification and a fine of not less than RMB 500,000 yuan but not more than RMB 2,000,000 yuan:\n'生产、销售的中药饮片不符合药品标准，尚不影响安全性、有效性的，责令限期改正，给予警告；可以处十万元以上五十万元以下的罚款。'可被翻译为：Where the decoction pieces of Chinese medicine produced and sold do not meet the national drug standards, but do not affect safety and effectiveness, an order shall be given to make rectifications within a time limit and a disciplinary warning shall be issued and a fine of not less than RMB 100,000 but not more than RMB 500,000 shall be imposed.\n\n根据上述已知信息，请将'第一百二十七条 违反本法规定，有下列行为之一的，责令限期改正，给予警告；逾期不改正的，处十万元以上五十万元以下的罚款：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 127 In any of the following circumstances in violation of this Law, the offender shall be ordered to make correction within the time limit and be given a disciplinary warning. Where correction is not made within the prescribed period, it shall be subject to a fine of not less than RMB 100,000 but not more than RMB 500,000."
    },
    {
        "instruction":"已知信息：\n'化妆品电子商务平台经营者知道或者应当知道平台内化妆品经营者被依法禁止从事化妆品生产经营活动的，不得向其提供电子商务平台服务。'可被翻译为：If the operators of cosmetic e-commerce platform know or shall know that the cosmetic marketers in the platform are prohibited from engaging in manufacturing and marketing of cosmetics according to law, they shall not provide e-commerce platform services to such marketers.\n'第四十八条 化妆品电子商务平台经营者发现有下列严重违法行为的，应当立即停止向平台内化妆品经营者提供电子商务平台服务：'可被翻译为：Article 48 In case of discovering the following serious illegal acts, the operator of cosmetic e-commerce platform shall immediately suspend provision of e-commerce platform services for the marketers of cosmetics in the platform:\n'化妆品集中交易市场开办者、展销会举办者应当建立入场化妆品经营者档案，审查入场化妆品经营者的市场主体登记证明，如实记录经营者名称或者姓名、联系方式、住所等信息。入场化妆品经营者档案信息应当及时核验更新，保证真实、准确、完整，保存期限不少于经营者在场内停止经营后2年。'可被翻译为：The organizer of centralized trading market and expos shall establish files of the participated marketers of cosmetics, review the registration certificate of participated marketers as a market entity, and truthfully record the marketers’ title or name, contact information, domicile and other information. The files information of the participated marketers of cosmetics shall be verified and updated in a timely manner, to ensure its authenticity, accuracy and integrity, and shall be not less than 2 years after the marketers suspend the marketing.\n'第四十六条 化妆品电子商务平台经营者应当设置化妆品质量管理机构或者配备专兼职管理人员，建立平台内化妆品日常检查、违法行为制止及报告、投诉举报处理等化妆品质量安全管理制度并有效实施，加强对平台内化妆品经营者相关法规知识宣传。鼓励化妆品电子商务平台经营者开展抽样检验。'可被翻译为：Article 46 The operator of cosmetic e-commerce platform shall establish cosmetics quality management institution or be staffed with full-time and part-time management personnel, establish and effectively implement the system for quality and safety of cosmetics management such as routine inspection of cosmetics, stopping and reporting of illegal acts, handling of complaints and reports, etc., and strengthen promotion of relevant laws and regulations to marketers of cosmetics in the platform. The operators of an e-commerce platform are encouraged to carry out sample testing.\n\n根据上述已知信息，请将'第四十五条 化妆品电子商务平台经营者应当对申请入驻的平台内化妆品经营者进行实名登记，要求其提交身份、地址、联系方式等真实信息，进行核验、登记，建立登记档案，并至少每6个月核验更新一次。化妆品电子商务平台经营者对平台内化妆品经营者身份信息的保存时间自其退出平台之日起不少于3年。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 45 The operators of cosmetic e-commerce platform shall register the real names of the cosmetic marketers who apply for being stationed in the platform, ask them to submit authentic information on their identity, address and contact information, etc., conduct verification and registration, establish registration files, and carry out verification and updating at least once every 6 months. Operator of an e-commerce platform shall keep identity information of the cosmetic marketers inside the platforms for not less than 3 years from the date of their withdrawal from the platform."
    },
    {
        "instruction":"已知信息：\n'1.工作范围是经过验证的关键参数的范围，在该范围内可生产可接受的产品。\n2.经验证的关键参数范围，在此范围内可生产可接受的产品。'可被翻译为：1.Operating range is the range of validated critical parameters within which acceptable products can be manufactured.\n2.The range of validated critical parameters within which acceptable products can be manufactured.\n'已证明了的可接受范围'可被翻译为：proven acceptable range\n'引入某系统的超出正常操作范围或条件（例如，工艺参数、物料属性、设备条件或环境）的非计划性工艺输入变化。'可被翻译为：Unplanned changes to process inputs beyond normal operating range or conditions (e.g., process parameter, material property, equipment condition, or environment) that are introduced into a system.\n'一个确定的工艺参数范围，在保持其它参数不变的前提下，在该参数范围内的任何运行均可生产出符合相关质量标准的产品。'可被翻译为：A characterised range of a process parameter for which operation within this range, while keeping other parameters constant, will result in producing a material meeting relevant quality criteria.\n\n根据上述已知信息，请将'制造商在正常操作期间选择作为参数可接受值的范围。这个范围必须在工作范围内。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The range that the manufacturer selects as the acceptable values for a parameter during normal operations. This range must be within the operating range."
    },
    {
        "instruction":"已知信息：\n'分析测试报告'可被翻译为：analytical test report\n'结果报告，包括样品分析的最终结论，该报告由另一个国家的实验室或没有适当设施进行某些测试的现场提交，并由进行测试的官方药物控制实验室签发。这通常与分析证书的式样相同。(参见第三部分17.3节)。'可被翻译为：The report of the results, including the final conclusion of the analysis of a sample which has been submitted by a laboratory in another country or in the field not having appropriate facilities to perform certain tests, and issued by the official pharmaceutical control laboratory that performed the test. This is often in the same style as a certificate of analysis.(see Part Three, section 17.3).\n'选择进行适用性测试的装置应采用与样品分析相同的消毒程序。'可被翻译为：Units selected for suitability testing should be subjected to the same disinfection procedure utilized in the sample analysis.\n'1.将已完成的验证程序的记录、结果和评价集合在一起的文件。它也可能包含改进工艺和\/或设备的建议。\n2.对已完成的验证程序的记录、结果和评价进行汇总和总结的文件。它也可能包含工艺和\/或设备改进的建议。\n3.记录和总结验证的记录、结果和评价的文件。它还应包含验证结果的结论。'可被翻译为：1.A document in which the records, results and evaluation of a completed validation programmed are assembled. It may also contain proposals for the improvement of processes and\/or equipment.\n2.A document in which the records, results and evaluation of a completed validation programme are assembled and summarised. It may also contain proposals for the improvement of processes and\/or equipment.\n3.A document in which the records, results and evaluation of validation are documented and summarized. It should also contain a conclusion of the outcome of the validation.\n\n根据上述已知信息，请将'分析测试报告通常包括对所采用的测试程序的描述、分析结果、讨论、结论和\/或对一个或多个的建议'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An analytical test report usually includes a description of the test procedure(s) employed, results of the analysis, discussion and conclusions and\/or recommendations for one or more"
    },
    {
        "instruction":"已知信息：\n'第二百七十二条 应当有专人及足够的辅助人员负责进行质量投诉的调查和处理，所有投诉、调查的信息应当向质量受权人通报。'可被翻译为：Article 272: There should be designated person(s) supported by sufficient staff for investigating and handling of the quality complaints, and the Qualified Person should be made aware of any complaints and investigations.\n'第三百零二条 产品召回负责人应当能够迅速查阅到药品发运记录。'可被翻译为：Article 302: The distribution records should be readily available to the person(s) responsible for recalls.\n'第二百九十三条 企业应当建立产品召回系统，必要时可迅速、有效地从市场召回任何一批存在安全隐患的产品。'可被翻译为：Article 293: The manufacturer should establish a recall system, if necessary, to recall promptly and effectively any batch of products with potential safety risks from the market.\n'第二百九十八条 应当制定召回操作规程，确保召回工作的有效性。'可被翻译为：Article 298: Operation procedures for recall should be established to ensure the effectiveness of recalls.\n\n根据上述已知信息，请将'第二百九十九条 应当指定专人负责组织协调召回工作，并配备足够数量的人员。产品召回负责人应当独立于销售和市场部门；如产品召回负责人不是质量受权人，则应当向质量受权人通报召回处理情况。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 299: A person should be designated as responsible for execution and coordination of recalls and should be supported by sufficient staff. This responsible person should be independent of the sales and marketing organization. If this person is not the Authorized Person, the latter should be made aware of any recall activity."
    },
    {
        "instruction":"已知信息：\n'第三十八条  持有人应当对上市医疗器械安全性进行持续研究，对产品的不良事件报告、监测资料和国内外风险信息进行汇总、分析，评价该产品的风险与受益，记录采取的风险控制措施，撰写上市后定期风险评价报告。'可被翻译为：Article 38 MAHs shall conduct continuous research on the safety of medical devices once they are on the market, summarize and analyze the adverse event reports, monitoring data and domestic and overseas risk profile of products, evaluate its  risks and benefits, record the risk control measures taken and completepost-market periodic risk evaluation report.\n'第四十八条  持有人通过医疗器械不良事件监测，发现存在可能危及人体健康和生命安全的不合理风险的医疗器械，应当根据情况采取以下风险控制措施，并报告所在地省、自治区、直辖市药品监督管理部门：'可被翻译为：Article 48 In case of identifying the medical devices with improper risks that may endanger human health or life safety through medical device adverse event monitoring, MAHs shall take following risk control measures according to the situations and report to the drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government where they locate:\n'第十六条  医疗器械经营企业、使用单位应当履行下列主要义务：'可被翻译为：Article 16 Medical device distributing enterprises and user facilities shall fulfill following major obligations:\n'境外持有人指定的代理人应当承担境内销售的进口医疗器械的不良事件监测工作，配合境外持有人履行再评价义务。'可被翻译为：Agents designated by overseas MAHs shall undertake adverse event monitoring of the imported medical devices sold within the territory of China and cooperate with overseas MAHs to fulfill the obligation of re-evaluation.\n\n根据上述已知信息，请将'第十四条  持有人应当对其上市的医疗器械进行持续研究，评估风险情况，承担医疗器械不良事件监测的责任，根据分析评价结果采取有效控制措施，并履行下列主要义务：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 14 MAHs shall carry out continuous research on the medical devices already marketed, evaluate the risks, assume the responsibilities of medical device adverse event monitoring, take effective control measures based on the analysis and evaluation results, and fulfill the following main obligations:"
    },
    {
        "instruction":"已知信息：\n'某一时点某人群中患有某种疾病的频率。'可被翻译为：The frequency of a disease in a population at a given point in time.\n'在药物的理想使用条件下，特定人群中患有特定疾病的个体接受药物治疗后可能获得的效益。'可被翻译为：The benefit that an individual with a particular disease in a particular population might receive after receiving the drug under the ideal conditions of use of the drug.\n'在药物的临床实际使用条件（即自然状态）下，特定人群中患有特定疾病的个体接受药物治疗后可能获得的收益。'可被翻译为：The amount of benefit that an individual with a particular disease in a particular population is likely to receive from the drug under the actual conditions of clinical use of the drug (i.e., its natural state).\n'应用量子力学的基本原理和方法，研究物质分子的结构和化学反应中微观过程的一门基础学科。'可被翻译为：A basic discipline that applies the basic principles and methods of quantum mechanics to the study of the structure of matter molecules and the microscopic processes involved in chemical reactions.\n\n根据上述已知信息，请将'一种由结果探索病因的回顾性研究方法。其基本原理是以现在确诊的患有某特定疾病'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A retrospective study method in which the cause is explored by the results. It is based on the present diagnosis of a particular disease"
    },
    {
        "instruction":"已知信息：\n'管理药品监管活动的全部范围的国家机构，根据国家药品立法至少包括以下所有职能:■新产品和现有产品的上市许可;\n■质量控制实验室检测;\n■药物不良反应监测;\n■提供药品信息，促进合理用药;\n■对制造商、批发商和分销渠道进行良好生产规范(GMP)检查和许可;\n■执行操作;\n■监测药物使用情况。'可被翻译为：A national body that administers the full spectrum of medicine regulatory activities, including at least all of the following functions in conformity with national medicine legislation:■marketing authorization of new products and variations of existing products;\n■quality control laboratory testing;\n■monitoring of adverse drug reactions;\n■provision of information on medicines and promotion of rational use of medicines;\n■good manufacturing practice (GMP) inspections and licensing of manufacturers, wholesalers and distribution channels;\n■enforcement operations;\n■monitoring of drug utilization.\n'1.负责医疗产品上市许可和其他监管活动的国家机构。\n2.在某一特定国家有权控制医疗产品进口和分销的管理机构。另见监管机构。'可被翻译为：1.The national agency responsible for the marketing authorization of, and other regulatory activities concerning, medical products.\n2.A regulatory body with authority in a specific country to control the importation and distribution of medical products. See also regulatory authority.\n'由国家监管机构认可的主管监管机构对文件证据的评估，以证明符合所需的良好规范(良好生产规范(GMP)、良好实验室规范和良好临床规范)，以支持上市许可和其他监管决定。案头评估可用于支持新的上市许可，或用于常规GMP检查(包括在所要求的指定产品生命周期管理框架内)。'可被翻译为：The evaluation of documentary evidence by a competent regulatory authority recognized by the national regulatory authority, for compliance with the required good practices (good manufacturing practices (GMP), good laboratory practices and good clinical practices) in support of marketing authorization and other regulatory decisions. Desk assessment may be performed in support of a new marketing authorization, or for routine GMP inspection (including in the frame of specified product(s) life-cycle management as required).\n'1.质量管理的一部分，确保产品始终按照适合其预期用途的质量标准生产和控制，并符合上市许可、临床试验许可或产品规范的要求。GMP涉及生产和质量控制。GMP的主要目的是管理和尽量减少药品生产中固有的风险，以确保产品的质量、安全性和有效性。\n2.质量保证的一部分，确保药品的生产和控制始终符合其预期用途和上市许可要求的质量标准。'可被翻译为：1.That part of quality management which ensures that products are consistently produced and controlled according to the quality standards appropriate to their intended use and as required by the marketing authorization, clinical trial authorization or product specification. GMP are concerned with both production and quality control. GMP are aimed primarily at managing and minimizing the risks inherent in pharmaceutical manufacture to ensure the quality, safety and efficacy of products.\n2.That part of quality assurance that ensures that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization.\n\n根据上述已知信息，请将'1.药监局:由成员国政府指定的管理药品在该国上市许可的机构\n2.负责药品注册和其他监管活动的国家机构。\n3.药监局:管理包括药监局在内的所有药品管理活动的国家机构\n至少符合国家药品立法的下列所有职能:\n•新产品的上市许可和现有产品的变型;\n•质量控制实验室检测;\n•药物不良反应监测;\n•提供药品信息，促进合理用药;\n•良好生产规范(GMP)检查和对制造商、批发商的许可\n以及分销渠道;\n•执法行动;\n•监测药物使用情况。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.An authority appointed by the government of a Member State to administer the granting of marketing authorizations for pharmaceutical products in that country.\n2.The national agency responsible for the registration of and other regulatory activities concerning pharmaceutical products.\n3.A national body that administers the full spectrum of drug regulatory activities, including at \nleast all of the following functions in conformity with national drug legislation:\n •  marketing authorization of new products and variation of existing products; \n•  quality control laboratory testing; \n•  adverse drug reaction monitoring; \n•  provision of drug information and promotion of rational drug use; \n•  good manufacturing practice (GMP) inspections and licensing of manufacturers, wholesalers \nand distribution channels; \n•  enforcement operations; \n•  monitoring of drug utilization."
    },
    {
        "instruction":"已知信息：\n'三、药品经营企业申请换发药品经营许可证的，药品监督管理部门按照换证工作程序和开办有关要求进行审查，符合《药品经营质量管理规范》和换发要求（或经整改后符合换发要求）的，予以换证；经整改后，仍不符合要求的，不予换证。'可被翻译为：3. Where a drug distributor applies for renewal of a drug distribution license, the drug administration departments shall conduct a review in accordance with the procedures for renewal of licenses and relevant requirements for establishment. The license shall be renewed if the conditions comply with the GSP and the renewal requirements (or conditions met after rectification). Where the requirements are still not met after rectification, the license shall not be renewed.\n'药品经营企业应当按照《药品经营许可证》许可的经营范围经营药品。'可被翻译为：A drug distributor shall operate within the approved distribution scope in the Drug Supply Certificate.\n'新冠肺炎疫情防控期间，药品经营许可证到期需要申请换发或变更许可事项的，必要时，可根据实际情况采取相对灵活的监管措施。企业如因疫情原因，无法按时完成申请材料和现场检查准备等工作的，其药品经营许可证的有效期可延长，最长可顺延至当地疫情防控应急响应解除后90日。药品经营许可证申请变更、需要现场检查的，可以采取告知承诺的方式，药品监督管理部门在企业提交变更申请和符合《药品经营质量管理规范》的承诺后，先行办理有关许可事项变更，并在当地疫情防控应急响应解除后90日内完成现场检查。'可被翻译为：During the prevention & control of the COVID-19 epidemic, relatively flexible regulatory measures can be taken, where necessary, for registration items of renewals and alterations. Where the enterprise cannot complete the application dossiers and on-site inspection preparations on time due to the epidemic situation, the validity period of its Drug Distribution License may be extended up to 90 days after the local epidemic prevention and control emergency response is lifted. Where the application for alterations of Drug Distribution License requires on-site inspection, the method of Informing & Pledging may be adopted. After the applicant submitted the application for alteration and commitment for GSP compliance, drug regulatory department shall handle the relevant licensing matters as a first step, and then complete the on-site inspection within 90 days after the local emergency response for epidemic prevention & control is lifted.\n'（二）报验单位的《药品经营许可证》和《企业法人营业执照》复印件；'可被翻译为：(II) photocopies of Drug Supply Certificate and Business License for Legal Person of the applicant for testing;\n\n根据上述已知信息，请将'二、新开办药品经营企业申请核发药品经营许可证的，药品监督管理部门可将筹建和验收程序合并执行，按照《药品经营质量管理规范》及现场检查指导原则等有关要求，对申办企业组织检查。符合要求的，发给药品经营许可证。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2. Where a newly establishing drug distributor applies for the issuance of a Drug Distribution License, the drug administration departments may combine  the examination & approval procedures for establishment preparation and acceptance, and organize inspection over the applicant pursuant to the relevant requirements of the Good Supply Practice for Pharmaceutical Products (GSP) and on-site inspection guidelines. A Drug Distribution License shall be issued if requirements are met."
    },
    {
        "instruction":"已知信息：\n'用火焰或干热空气进行灭菌的方法。'可被翻译为：Method of sterilization by flame or dry hot air.\n'若釆用的是未纳入现行药典的灭菌方法，或灭菌方法用于非简单的水溶液，则需要特别注意。应尽可能首选加热灭菌方法。'可被翻译为：Particular attention should be given when the adopted product sterilisation method is not described in the\ncurrent edition of the Pharmacopoeia, or when it is used for a product which is not a simple aqueous solution.\nWhere possible, heat sterilisation is the method of choice.\n'滤过灭菌'可被翻译为：filtration sterilization\n'用紫外线照射杀灭微生物的方法。'可被翻译为：Method of killing microorganisms with ultraviolet radiation.\n\n根据上述已知信息，请将'又称\"过滤灭菌”。用滤过方法除去活的或死的微生物的方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Also known as \"filtration sterilization\". A method of removing living or dead microorganisms by filtration."
    },
    {
        "instruction":"已知信息：\n'申请人应按照eCTD技术文件（附件1—4）要求准备和提交eCTD申报资料光盘，并在eCTD注册申请新报资料受理后5个工作日内，提交纸质资料。申请人如未按照规定时间提交纸质资料，按终止药品注册程序处理。同时，申请人应承诺所提交的电子资料与纸质资料内容完全一致，如因资料一致性产生的任何问题由申请人自行承担。'可被翻译为：Applicants should prepare and submit the eCTD application dossiers on CD-ROM as required by the eCTD technical documents(Attachments 1-4), and submit the paper dossiers within 5 working days upon the acceptance of the eCTD registration application dossiers. If an applicant fails to submit the paper dossiers within the specified time, the drug registration process will be terminated. At the same time, the applicant should make commitment that the electronic dossiers submitted is completely consistent with the paper dossiers. The applicant should bear the responsibilities for any problem arising from the inconsistency.\n'为确保eCTD稳步推进，减少对申报工作的影响，对于上述注册申请，申请人仍可选择现有注册方式进行注册申报。'可被翻译为：In order to ensure a steady promotion of the eCTD and minimize its impact on the application, applicants can still choose the existing registration method for the above registration applications.\n'2019年6月24日，正式启用eRPS系统。医疗器械注册申请人、注册人可进行线上医疗器械注册电子申报，无需提交纸质资料。同时，国家药品监督管理局保留纸质资料的提交途径。'可被翻译为：On June 24, 2019, the eRPS system was officially launched. Medical device registration applicants and registrants can apply for online electronic registration of medical devices without submitting paper dossiers. Meanwhile, NMPA reserves the means of submitting paper dossiers.\n'eCTD申报资料格式和实施要求'可被翻译为：Format of eCTD application dossiers and implementation requirements\n\n根据上述已知信息，请将'采用eCTD申报的注册申请，申请人无需再单独提交核查检验用申报资料光盘和临床试验数据库光盘。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For registrations application with eCTD submission, there is no need for applicants to submit the CD-ROM of the application dossiers for verification and inspection and theCD-ROM of clinical trial database separately."
    },
    {
        "instruction":"已知信息：\n'静脉药物集中配置'可被翻译为：pharmacy intravenous admixture service\n'医疗机构为患者提供静脉用药集中调配专业技术服务的部门。静脉用药调配中心通过静脉用药处\n方医嘱审核干预、加药混合调配、参与静脉输液使用评估等药学服务，为临床提供优质可直接静脉输\n注的成品输液。'可被翻译为：The healthcare institution has a specialized department that provides centralized compounding services for intravenous medications. The Intravenous Medication Compounding Center, through services such as reviewing and intervening in intravenous medication prescriptions, compounding and mixing medications, and participating in assessments of intravenous infusion usage, delivers high-quality finished intravenous infusions ready for direct administration in clinical settings.\n'静脉留置针输液'可被翻译为：infusion via in-dwelling venous catheter\n'输液'可被翻译为：infusion\n\n根据上述已知信息，请将'为保证静脉输液用药的特殊质量要求和安全，将传统分散于各病区护理站配置输液的方式，改为集中到药房管理的、输液配置室中配置的管理方式。细胞毒类药物和肠外营养输液是集中配制的重点。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to ensure the special quality requirements and safety of intravenous infusion, the traditional distribution of intravenous infusion distributed in nursing stations in each ward was changed to the centralized management of the pharmacy and the distribution of intravenous infusion room. Infusion of cytotoxic drugs and parenteral nutrition is the focus of centralized preparation."
    },
    {
        "instruction":"已知信息：\n'将不同的医疗干预措施进行对比时，计算一种干预措施相对于另一种干预措施增加的成本与相对增加的效果的比值的一种分析方法。'可被翻译为：A method of analysis that calculates the ratio of the increased cost of one intervention relative to another to the relative increased effect when comparing different medical interventions.\n'将不同的医疗干预措施进行对比时，一种干预措施相对于另一种干预措施增加的成本。'可被翻译为：The increased cost of one intervention relative to another when different medical interventions are compared.\n'将不同的医疗干预措施进行对比时，一种干预措施相对于另一种干预措施增加的成本与相对增加的效果的比值。'可被翻译为：The ratio of the increased cost of one intervention relative to another to the relative increased effectiveness when comparing different medical interventions.\n'英国的一个对医疗干预措施的临床和成本效果给出明确信息的权威机构。其目的在于帮助改善英国国民医疗保健系统资源的利用。'可被翻译为：A British authority that gives clear information on the clinical and cost effectiveness of medical interventions. Its aim is to help improve the use of NHS resources in the UK.\n\n根据上述已知信息，请将'计算并给出可供选择的医疗干预措施的成本和健康结果的分析方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A method of calculating and providing an analysis of the costs and health outcomes of alternative medical interventions."
    },
    {
        "instruction":"已知信息：\n'国际性药学学术组织，成立于1912年，总部设在荷兰海牙。国际药学联合会除有药学学术科研团体外，还吸收制药企业、教育及个人会员。'可被翻译为：International pharmaceutical academic organization, founded in 1912, headquartered in The Hague, Netherlands. In addition to pharmaceutical academic research groups, the International Pharmaceutical Federation also attracts members from pharmaceutical enterprises, education and individuals.\n'第八条 鼓励参与国际标准化活动，参与制定和采用国际医疗器械标准。'可被翻译为：Article 8 Participation in international standardization activities and formulation of international medical device standards as well as adoption of such standards are encouraged.\n'医疗器械促进协会（AAMI）\/国际标准组织 （ISO）'可被翻译为：6. Association for the Advancement of Medical Instrumentation (AAMI)\/ International Organization for Standardization (ISO).\n'中国药学科学工作者自愿组成的并依法登记成立的学术性、公益性、非营利性的法人社会团体，创立于1907年。是中国科学技术协会团体会员，国际药学联合会等国际学术组织会员。会址设在北京。'可被翻译为：Founded in 1907, it is an academic, public welfare and non-profit legal person social organization voluntarily formed by Chinese pharmaceutical scientists and registered in accordance with law. It is a group member of China Association for Science and Technology, a member of international Pharmaceutical Federation and other international academic organizations. The association is located in Beijing.\n\n根据上述已知信息，请将'国际标准化组织-成立于1946 年，是制定国际标准的主要组织。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"International Standards Organization - founded in 1946, it is the principal international standards-setting organization."
    },
    {
        "instruction":"已知信息：\n'先将容器或系统中的残余气体排出，然后将容器或系统加压至2bar，然后将用于净化的气体排出至1.013 bar，以清除容器或系统中的残余气体。'可被翻译为：To remove the residual gas from a container or system by first venting the residual gas from the container or system, then pressurizing the container or system to 2 bar and thereafter venting the gas used for purging to 1.013 bar.\n'用真空系统将容器或系统中的残余气体抽到海平面0.84巴的绝对真空水平。'可被翻译为：To remove residual gas from a container or system to a vacuum level of 0.84 bar absolute at sea level using a vacuum system.\n'在低于-150°C的温度下在1.013巴液化的气体。'可被翻译为：A gas that liquefies at 1.013 bar at temperatures below –150 °C .\n'在成型容器的挤出、成型或密封过程中，接触容器关键表面的空气或其它气体应进行适当的过滤。所用气体的质量和气体过滤系统的有效性应按照第 6.18 和 6.19 节进行定期确认。'可被翻译为：Air or other gases that make contact with critical surfaces of the container during extrusion, formation or sealing  of  the  moulded  container  should  undergo   appropriate  filtration.  The  quality  of  gas  used  and  the effectiveness of gas filtration systems should be verified periodically in accordance with paragraphs 6.18 and 6.19.\n\n根据上述已知信息，请将'通过打开容器或系统使其进入大气，将容器或系统中的残余气体降至1.013巴。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To remove the residual gas from a container or system down to 1.013 bar by opening the container or system to the atmosphere."
    },
    {
        "instruction":"已知信息：\n'供体和受体区室的孔口面积可以用游标卡尺确定。供体隔室的体积可以用供体隔室的直径和高度来计算。'可被翻译为：Orifice area for the donor and receptor compartments can be determined using vernier calipers. Volume of the donor compartment can be calculated using the donor compartment diameter and height.\n'FDC系统一般应与本章所描述的设备描述相匹配。其他设计也可以有充分的科学依据，只要它们由皮肤将供体隔室与受体隔室分开。'可被翻译为：FDC systems should generally match the description of the equipment described in this chapter. Other designs can be used with sufficient scientific justification so long as they consist of a donor compartment separated from a receptor compartment by the skin.\n'浸没池是一种惰性外壳，可容纳膜和供体隔室。'可被翻译为：immersion cell which is an inert housing that holds a membrane and donor compartment.\n'浸没池应符合本章所列仪器的描述。其他设计也可以有充分的科学依据，只要它们是由一层膜将供体隔室与受体隔室隔开的。'可被翻译为：Immersion cells should match the description of one of the instruments listed in this chapter. Other designs can be used with sufficient scientific justification so long as they consist of a donor compartment separated from a receptor compartment by a membrane.\n\n根据上述已知信息，请将'FDC的部件如图8-10所示。将皮肤置于受体隔室上方，并由供体隔室和夹紧机构保持在原位。皮肤应保持在供体和受体间室之间的水平面上。供体和受体隔室应由惰性材料制成。供体室的孔的表面积，它定义了试验的药物输送表面积，尺寸应该在标称值的±5%以内。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The components of the FDC are displayed in Figures 8–10. The skin is placed above the receptor compartment and kept in place by the donor compartment and a clamping mechanism. The skin should be held in a horizontal plane between the donor and receptor compartments. The donor and receptor compartments should be made out of an inert material. The surface area of the orifices of the donor compartment, which define the dosage delivery surface area for the test, should be sized within ±5% of the nominal value."
    },
    {
        "instruction":"已知信息：\n'分子力学'可被翻译为：molecular mechanics\n'分子模拟'可被翻译为：molecular simulation\n'研究大量粒子（原子、分子）集合的宏观运动规律的学科。'可被翻译为：The study of macroscopic laws of motion of large collections of particles (atoms, molecules).\n'分子的一种振动形式。分子中两个化学键端的原子同时做反向垂直于平面方向的运动。'可被翻译为：A form of vibration in a molecule. Atoms at two chemically bonded ends of a molecule move simultaneously in opposite directions perpendicular to the plane.\n\n根据上述已知信息，请将'建立在牛顿力学基础上的分子模拟方法。通过求解分子中每个原子的牛顿力学方程来模拟分子运动和分子的行为，通过时间的微小增量，求解每个原子的位置和运动速度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A method of molecular simulation based on Newtonian mechanics. Simulate the motion of molecules and the behavior of molecules by solving the equations of Newtonian mechanics for each atom in the molecule, solving the position and speed of motion of each atom by small increments of time."
    },
    {
        "instruction":"已知信息：\n'用生物活性来表示某些生物活性物质，如抗生素、激素、疫苗、血液制品、维生素及酶的量值，以国际公认的单位表示。'可被翻译为：The amount of certain bioactive substances, such as antibiotics, hormones, vaccines, blood products, vitamins, and enzymes, expressed in internationally recognized units.\n'生物活性物质'可被翻译为：bioactive substance\n'利用微生物药物的作用机制、生物合成途径、理化特性及耐药等机制，寻找特定结构类型或生物活性物质的过程。'可被翻译为：The process of searching for a specific structural type or bioactive substance by using the mechanism of action, biosynthetic pathway, physicochemical properties and drug resistance of microbial drugs.\n'对生物活性物质具有识别和结合能力，并具有介导细胞信号转导功能的蛋白质。'可被翻译为：A protein that recognizes and binds to biologically active substances and mediates cell signal transduction.\n\n根据上述已知信息，请将'世界卫生组织经过国际协作标定后，对生物或合成来源的物质用国际单位表示生物活性的生物标准物质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"After the World Health Organization has been calibrated by international collaboration, the biological reference material of biological or synthetic origin is expressed in international units of biological activity."
    },
    {
        "instruction":"已知信息：\n'分子中含有能吸收紫外-可见光而产生电子跃迁结构的基团。'可被翻译为：The molecule contains groups that can absorb UV-visible light and produce electronic transition structures.\n'原子或分子中电子激发前存在的低能量轨道。'可被翻译为：A low energy orbital in an atom or molecule that exists before the electrons are excited.\n'电子跃迁'可被翻译为：electron transition\n'原子组成分子时，原子轨道线性组合成分子轨道，组成的分子轨道的能量若高于原子轨道的能量，则该分子轨道叫做反键轨道。'可被翻译为：When atoms form a molecule, the atomic orbitals are linearly combined into molecular orbitals, and if the energy of the constituent molecular orbitals is higher than the energy of the atomic orbitals, the molecular orbitals are called antibonding orbitals.\n\n根据上述已知信息，请将'原子或分子中的电子从一个原子轨道向另一轨道的跃迁。电子跃迁需要极大的能量，并可被可见光、紫外光和X射线诱发。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The transition of electrons in an atom or molecule from one atomic orbital to another. Electron transitions require great energy and can be induced by visible, ultraviolet, and X-ray light."
    },
    {
        "instruction":"已知信息：\n'第九十一条 国家食品药品监督管理局药品审评中心应当在规定的时间内组织药学、医学及其他技术人员对申报资料进行审评，必要时可以要求申请人补充资料，并说明理由。'可被翻译为：Article 91 The Center for Drug Evaluation of the State Food and Drug Administration shall organize pharmaceutical, medical and other technical personnel to conduct technical review of the submitted dossiers within the specified timeline, and may request, with reasons, applicants to provide supplementary materials when necessary.\n'第八十条 国家食品药品监督管理局药品审评中心应当在规定的时间内组织药学、医学及其他技术人员对审查意见和申报资料进行审核，必要时可以要求申请人补充资料，并说明理由。'可被翻译为：Article 80 The Center for Drug Evaluation of the State Food and Drug Administration shall organize pharmaceutical, medical and other technical personnel to conduct technical review of the submitted dossiers within the specified timeline, and may request, with reasons, applicants to provide supplementary materials when necessary.\n'第五十五条 国家食品药品监督管理局药品审评中心收到申报资料后，应在规定的时间内组织药学、医学及其他技术人员对申报资料进行技术审评，必要时可以要求申请人补充资料，并说明理由。完成技术审评后，提出技术审评意见，连同有关资料报送国家食品药品监督管理局。'可被翻译为：Article 55 After receiving submitted dossiers, the Center for Drug Evaluation of the State Food and Drug Administration shall organize pharmaceutical, medical and other technical personnel to conduct technical review of the submitted dossiers within the specified timeline, and may request, with reasons, applicants to provide supplementary materials when necessary. After completing technical reviews, the Center for Drug Evaluation shall give technical review opinions and report together with relevant documents to the State Food and Drug Administration.\n'第九十四条 国家食品药品监督管理局药品审评中心应当在规定的时间内组织药学、医学及其他技术人员对报送的临床试验等资料进行全面审评，必要时可以要求申请人补充资料，并说明理由。'可被翻译为：Article 94 The Center for Drug Evaluation of the State Food and Drug Administration shall organize pharmaceutical, medical and other technical personnel to conduct comprehensive review of the submitted clinical trial data within the specified timeline, and may request, with reasons, applicants to provide supplementary materials when necessary.\n\n根据上述已知信息，请将'第六十条 国家食品药品监督管理局药品审评中心收到申报资料后，应当在规定的时间内组织药学、医学及其他技术人员对申报资料进行审评，必要时可以要求申请人补充资料，并说明理由。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 60 After receiving submitted dossiers, the Center for Drug Evaluation of the State Food and Drug Administration shall organize pharmaceutical, medical and other technical personnel to conduct technical review of the submitted dossiers within the specified timeline, and may request, with reasons, applicants to provide supplementary materials when necessary."
    },
    {
        "instruction":"已知信息：\n'以稳定的速度和近似平行的流线流过洁净区的整个横截面积的整流气流(现代标准不再指层流，而是采用了术语“单向气流”)。'可被翻译为：A rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines (modern standards no longer refer to laminar flow, but have adopted the term unidirectional airflow).\n'单向流：以单一方向、稳定和均匀方式、以及足够速度移动的气流，可不断地将粒子从关键操作区或检测区清除的气流。'可被翻译为：Unidirectional airflow - An airflow moving in a single direction, in a robust and uniform manner, and at sufficient speed, to reproducibly sweep particles away from the critical processing or testing area.\n'提供过滤单向气流的机柜(以前称为层流气流单元)。'可被翻译为：A cabinet supplied with filtered unidirectional airflow (previously referred to as a laminar airflow unit).\n'单向气流(UDAF)'可被翻译为：unidirectional airflow (udaf)\n\n根据上述已知信息，请将'1.单向气流是在洁净区的整个横截面积上以稳定的速度和近似平行的流线进行整流的气流(另见紊流)。(现代标准不再指层流，而是采用了“单向气流”一词。)\n2.以稳定的速度和近似平行的流线流过洁净区的整个横截面积的整流气流(参见紊流)。(现代标准不再指层流，而采用了单向气流这一术语。)\n3.一种以强劲和均匀的方式沿单一方向移动的气流，并以足够的速度可重复地将颗粒从关键加工或测试区域扫走。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.Unidirectional airflow is a rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines (see also turbulent flow).(Modern standards no longer refer to laminar flow, but have adopted the term unidirectional airflow.)\n2.A rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines (see also turbulent air flow). (Modern standards no longer refer to laminar flow, but have adopted the term unidirectional airflow.)\n3.An airflow moving in a single direction in a robust and uniform manner and at sufficient speed to reproducibly sweep particles away from the critical processing or testing area."
    },
    {
        "instruction":"已知信息：\n'(1) 色谱使用自动积分， 同一个分析批中采用相同的积分参数。如果色谱重积分和手动积分， 记录修改理由并保留原始和重积分的图谱和数据， 与申报资料一致。'可被翻译为：(1) Chromatogram adopts automatic integration; the same integration parameters are used in the same analysis batch. If reintegration and manual integration of chromatogram are adopted, record the reason of modification and retain the original and reintegrated chromatogram and data, which are consist with the application dossier.\n'(1) 试验样品分析按照分析计划执行， 分析批中样品预处理的过程和检测方法与方法学验证一致， 血药浓度数据与申报资料一致。'可被翻译为：(1) The test sample analysis is conducted according to the analysis plan, the preprocessing and testing method of the samples in the analysis batch are consist with the method validation, and the plasma concentration data is consistent with that in the application dossier.\n'(6) 申报资料中的受试者编号、给药周期、给药顺序、制剂种类等信息与源数据之间一致。'可被翻译为：(6) The subject number, drug administration cycle, administration order, types of preparation and other information are consistent with the source data.\n'(10) 源数据、病例报告表、数据库及申报资料之间数据一致。'可被翻译为：(10) Data consistency between source data, CRF, database and application dossier.\n\n根据上述已知信息，请将'抽查药(毒)代动力学生物样本分析数据，包括申报资 料中提交的纸质图谱是否与原始图谱一致，申报资料中提交的分析数据是否与原始分析数据一致；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To sample and audit the pharmacokinetic (toxicokinetic) data, including chromatograms and analytical data, for the purpose of verifying consistency with those submitted in the application;"
    },
    {
        "instruction":"已知信息：\n'在一段时间内，给药剂量、给药途径、频率和给药间隔。'可被翻译为：The route, frequency and duration of administration of the dose of a medicine over a period of time.\n'代谢的一级动力学模式,药代动力学参数与给药剂量无关,药物浓度衰减在半对数坐标系上呈直线。'可被翻译为：In the first-order kinetic model of metabolism, the pharmacokinetic parameters are independent of the dose, and the drug concentration decays in a straight line on the semilog coordinate system.\n'血药浓度达稳态时，在一个剂量间隔时间内，血药浓度一时间曲线下面积除以给药间隔时间的商值。'可被翻译为：When steady-state plasma concentration is reached, the area under the plasma concentration curve is divided by the quotient of the dosing interval during one dose interval.\n'针对患者的病情和个体化情况所选择或调整的治疗药物、剂量、用法、给药频次及给药疗程。'可被翻译为：The selection or adjustment of therapeutic drugs, dosage, usage, frequency of administration and course of administration according to the patient's condition and individual situation.\n\n根据上述已知信息，请将'在一级动力学药物中，按固定间隔时间给予固定剂量，在每次给药时体内总有前次给药存留量，多次给药形成不断蓄积，随着给药次数的增加，体内总药量的蓄积率逐渐增力口，直至在剂量间隔内消除的药量等于给药剂量，从而达到平衡时的浓度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In primary kinetic drugs, a fixed dose is given at a fixed interval, and there is always a residual amount of the previous administration in the body during each administration, and multiple administration forms continuous accumulation. With the increase of administration times, the accumulation rate of the total amount of drug in the body gradually increases until the amount of drug eliminated in the dose interval is equal to the dose given, so as to achieve the equilibrium concentration."
    },
    {
        "instruction":"已知信息：\n'当无菌灌装的无菌产品的轧盖作为洁净工艺在 A 级送风保护下进行时，应在轧盖前剔除无塞或跳塞的西林瓶作报废处理。应有经适当确认的自动化方法检测胶塞高度。'可被翻译为：Where capping of aseptically filled sterile product is conducted as a clean process with grade A air supply\nprotection, vials with missing or displaced stoppers should be rejected prior to capping. Appropriately qualified,\nautomated methods for stopper height detection should be in place.\n'生效\/取代日期 2009年3月1日\/2010年3月1日 注：西林瓶轧盖相关规定自2010年3月1日起实施。'可被翻译为：Date for coming into operation and superseding 01 March 2009\/01 March 2010 Note: Provisions on capping of vials were implemented on 01 March 2010.\n'无菌灌装，容器密封（如安瓶、西林瓶密封），敞口或半压塞西林瓶的转移。'可被翻译为：Aseptic filling, sealing of containers such as ampoules, vial closure, transfer of open or partially stoppered vials.\n'不应浸泡西林瓶，因为消毒剂可能通过封盖处迁移，进入产品'可被翻译为：Vials should not be soaked due to the possibility of migration of disinfectant under the closure and into the product.\n\n根据上述已知信息，请将'修订：调整洁净室分级表，新增培养基模拟灌装、生物负载监测和西林瓶轧盖相关指南。2005年11月-2007年12月'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Revision to align classification table of clean rooms, to include guidance on media simulations,bioburden monitoring and capping of vials November 2005 to December 2007"
    },
    {
        "instruction":"已知信息：\n'国家药监局药审中心关于发布《低分子量肝素类仿制药免疫原性研究指导原则(试行)》的通告'可被翻译为：NMPA CDE Announcement on Issuing the Guidance for Immunogenicity Study of Generic Drugs of Low Molecular Weight Heparin (Interim)\n'为指导我国皮肤外用化学仿制药研发，提供可参考的技术标准，在国家药品监督管理局的部署下，药审中心组织制定了《皮肤外用化学仿制药研究技术指导原则（试行）》。并于3月3日发布实施。'可被翻译为：In order to guide the R&D of dermatological generic drugs for topical use in China and provide technical standards that can be used as references, the CDE, under the guidance of NMPA, has organized to formulate the Technical Guidance for Studies of Dermatological Generic Drugs for TopicalUse (Interim), which was issued and implemented as of March 3.\n'国家药监局药审中心关于发布《药物免疫原性研究技术指导原则》的通告'可被翻译为：Notice of CDE of China NMPA on Issuing the Technical Guidance for Immunogenicity Studies of Drugs\n'国家药监局药审中心关于发布《纳米药物质量控制研究技术指导原则（试行）》《纳米药物非临床药代动力学研究技术指导原则（试行）》《纳米药物非临床安全性评价研究技术指导原则（试行）》的通告'可被翻译为：NMPA CDE Announcement on Issuing the Technical Guidance for Quality Control Study of Nano Drugs (interim), Technical Guidance for Non-Clinical Pharmacokinetic Study of Nano Drugs (interim), and Technical Guidance for Non-Clinical Safety Evaluation Study of Nano Drugs (interim)\n\n根据上述已知信息，请将'国家药监局药审中心关于发布《皮肤外用化学仿制药研究技术指导原则（试行）》的通告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Notice of CDE of China NPMA on Issuing the Technical Guidance for Studies of Dermatological Generic Drugs for Topical Use (Interim)"
    },
    {
        "instruction":"已知信息：\n'10件以内，抽样1件；11件－50件，每增加10件加抽1件，不足10件者以10件计；51件－100件，每增加20件加抽1件，不足20件者以20件计；101件以上，每增加50件加抽1件，不足50件者以50件计；1001件以上，每增加100件加抽1件，不足100件者以100件计；'可被翻译为：If the quantity is less than 10, take 1 product for sampling; if the quantity is 11 to 50, take additional 1 product for sampling for every additional 10, and the odd less than 10 shall be counted as 10; if the quantity is 51 to 100, take additional 1 product for sampling for every additional 20, and the odd less than 20 shall be counted as 20; if the quantity is more than 101, take additional 1 product for sampling for every additional 50, and the odd less than 50 shall be counted as 50; if the quantity is more than 1001, take additional 1 product for sampling for every additional 100, and the odd less than 100 shall be counted as 100;\n'3．药品包装为1－5公斤的（含1公斤），每50公斤抽样1件，不足50公斤者以50公斤计；'可被翻译为：3. If the products within one package are 1 (including) to 5 kg, take 1 product for sampling for every 50 kg, and the odd less than 50 kg shall be counted as 50 kg;\n'2．药品包装为5－10公斤的（含5公斤），每100公斤抽样1件，不足100公斤者以100公斤计；'可被翻译为：2. If the products within one package are 5 kg (including) to 10 kg, take 1 product for sampling for every 100 kg, and the odd less than 100 kg shall be counted as 100 kg;\n'4．1公斤以下的，每20公斤抽样1件，不足20公斤者以20公斤计（原装抽样）。'可被翻译为：4. If the products within one package are less than 1 kg, take 1 product for sampling for every 20 kg, and the odd less than 20 kg shall be counted as 20 kg (taking samples from original package).\n\n根据上述已知信息，请将'100－1000毫升（含1000毫升）的注射液，每1万瓶抽样1件，不足1万瓶的按1万瓶计。1000毫升以上的注射液（含透析液），每5000瓶（袋）抽样1件，不足5000瓶（袋）的按5000瓶计。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the injection is 100 ml to 1000 ml (including), take 1 product for sampling for every 10,000 vials, and the odd less than 10,000 vials shall be counted as 10,000. If the injection (including dialysate) is more than 1000 ml, take 1 product for sampling for every 5,000 vials (bags), and the odd less than 5,000 vials (bags)shall be counted as 5,000."
    },
    {
        "instruction":"已知信息：\n'药物粉末在自下而上的气流中保持悬浮状态，再喷入润湿剂或黏合剂的液体使粉末聚结成颗粒的方法。'可被翻译为：The method in which the drug powder is kept suspended in the bottom-up air flow and then sprayed with the liquid of wetting agent or binder to condense the powder into particles.\n'固体物料压缩成型的性能。'可被翻译为：Solid material compression molding performance.\n'悬浮在气体或液体中的固体或液体微粒，由于布朗运动、涡流、热效应或声波等的作用，相互碰撞而团聚成较大颗粒的过程。'可被翻译为：The process by which solid or liquid particles suspended in a gas or liquid collide with each other to form larger particles due to Brownian motion, eddy currents, thermal effects, or sound waves.\n'悬浮在液体中的固体颗粒的连续沉降的行为。'可被翻译为：The act of continuous settling of solid particles suspended in a liquid.\n\n根据上述已知信息，请将'可使物料聚结成颗粒或压缩成型的具有黏性的固体粉末或液体。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A viscous solid powder or liquid that condenses materials into particles or compresses them."
    },
    {
        "instruction":"已知信息：\n'西门子医学诊断产品（上海）有限公司报告，由于涉及产品存在特定批次检查出现结果偏差，但质控无法检测到的问题，生产商Siemens Healthcare Diagnostics Inc.对高敏C反应蛋白校准液High Sensitivity C Reactive Protein Calibrator (hsCRP CAL)主动召回。召回级别为三级。涉及产品的型号、规格及批次等详细信息见《医疗器械召回事件报告表》。'可被翻译为：According to a report of Siemens Healthcare Diagnostics Inc., due to discrepancy in the testing results of particular batches of High Sensitivity C Reactive Protein Calibrator (hsCRP CAL) which cannot be identified in quality control, the manufacturer initiated the voluntary recall of the product. The recall is identified as a Class III recall. For details on product models, specifications and batches, see the Report Form of Medical Device Recall.\n'在液相中进行的化学合成反应。反应物处于高分散状态，反应一般进行得完全且迅速。'可被翻译为：A chemical synthesis reaction that takes place in a liquid phase. The reactants are in a highly dispersed state, and the reaction generally proceeds completely and rapidly.\n'光致敏反应'可被翻译为：photosensitivity reaction\n'不同患者对相同剂量的同一种药物所表现出的不同反应。即使患者的年龄、性别和生活环境完全相同，对于同一剂量的同一种药物也可有不同反应。表现形式有三种：高敏性、耐受性和特异质。'可被翻译为：Different patients show different reactions to the same drug at the same dose. Different reactions to the same dose of the same drug can occur even in patients of exactly the same age, sex, and living environment. There are three forms of response: hypersensitivity, tolerance, and idiosyncrasy.\n\n根据上述已知信息，请将'Siemens Healthcare Diagnostics Inc.对高敏C反应蛋白校准液主动召回'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Siemens Healthcare Diagnostics Inc. voluntarily recalls High Sensitivity C Reactive Protein Calibrator"
    },
    {
        "instruction":"已知信息：\n'（六）药品生产厂房不得用于生产对药品质量有不利影响的非药用产品。'可被翻译为：6. The production of non-drugs with adverse effects on drug should not be allowed in premises used for drugs.\n'（一）药品上市许可持有人和药品生产企业变更生产地址、生产范围应当经批准而未经批准的；'可被翻译为：(1) A drug MAH or a manufacturer changes the manufacturing facility or scope of manufacturing without approval;\n'第六十九条 药品上市许可持有人和药品生产企业未按照药品生产质量管理规范的要求生产，有下列情形之一，属于《药品管理法》第一百二十六条规定的情节严重情形的，依法予以处罚：'可被翻译为：Article 69 Where a drug MAH or drug manufacturer has failed to carry out manufacturing activities as per GMP requirements in any of the following circumstances and the circumstance belongs to the serious circumstances as specified in Article 126 under the Drug Administration Law, penalties shall be imposed according to law:\n'药品上市许可持有人自行生产药品的，应当依照本法规定取得药品生产许可证；委托生产的，应当委托符合条件的药品生产企业。药品上市许可持有人和受托生产企业应当签订委托协议和质量协议，并严格履行协议约定的义务。'可被翻译为：MAHs that manufacture their own drug products shall obtain a Drug Manufacturing Certificate in accordance with provisions of this Law. Where a drug is contracted out, the MAH shall entrust a qualified drug manufacturer. The MAH and the contract manufacture shall sign agreements on entrustment quality and shall comply with their obligations under the agreements.\n\n根据上述已知信息，请将'药品上市许可持有人和药品生产企业不得在药品生产厂房生产对药品质量有不利影响的其他产品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Drug MAHs and manufacturers shall not manufacture other products having negative influence on drug quality in drug manufacturing workshops."
    },
    {
        "instruction":"已知信息：\n'第十一条    新批准上市的生物制品首次申请批签发前，批签发申请人应当在生物制品批签发管理系统内登记建档。登记时应当提交以下资料：'可被翻译为：Article 11 Before the initial application for lot release of the new biological product approved for marketing, the lot release applicant shall register and file in the Information Management System for Lot Release (hereinafter referred to as IMS). The following materials shall be submitted for registration:\n'第十三条 按照批签发管理的生物制品在生产、检验完成后，批签发申请人应当在批签发信息管理系统内填写生物制品批签发申请表，并根据申请批签发产品的药品生产企业所在地或者拟进口口岸所在地，向相应属地的批签发机构申请批签发。'可被翻译为：Article 13 After completion of manufacturing and testing of biological products subject to lot release administration, the lot release applicant shall fill out the Application Form for Lot Release of Biological Products in the Information Management System for Lot Release, and apply to the lot release institution under jurisdiction for lot release in the place where the drug manufacturer applying for lot release is located or the place where the port at which the drug is to be imported is located.\n'登记信息发生变化时，批签发申请人应当及时在批签发信息管理系统内变更。'可被翻译为：In case of any change in the registered information, the lot release applicant shall make a timely change in the Information Management System for Lot Release.\n'相关资料符合要求的，中检院应当在10日内完成所申请品种在批签发信息管理系统内的登记确认。'可被翻译为：For relevant materials in line with the requirements, the NIFDC shall complete the registration confirmation of the product under application in the Information Management System for Lot Release within 10 days.\n\n根据上述已知信息，请将'第十一条 新批准上市的生物制品首次申请批签发前，批签发申请人应当在批签发信息管理系统内登记建档。登记时应当提交以下资料：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 11 Before the initial application for lot release of the new biological product approved for marketing, the lot release applicant shall register and file in the Information Management System for Lot Release. The following materials shall be submitted for registration:"
    },
    {
        "instruction":"已知信息：\n'（二）在使用医疗器械过程中是否发生过故障或者伤害；'可被翻译为：(2) whether any malfunction or injury occurred during the use of the medical device;\n'（六）受试者若发生与临床试验相关的伤害或者死亡，给予的治疗和保险措施是否充分。'可被翻译为：(6) Whether the treatment and insurance measures to be given to the subjects who suffer from trial-related injuries and death are sufficient.\n'（十一）如发生与试验相关的伤害，受试者可以获得治疗和经济补偿；'可被翻译为：(11) The subjects may receive treatment and economic compensation for any trial-related injuries.\n'可能对健康或环境造成重大伤害风险的产品或物质。'可被翻译为：A product or substance that may present a substantial risk of injury, to health or to the environment.\n\n根据上述已知信息，请将'（三）在现有使用环境下是否会造成伤害，是否有科学文献、研究、相关试验或者验证能够解释伤害发生的原因；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) whether it would cause injury under the existing use environment, and whether there are scientific literatures, researches, relevant tests, or verifications that can explain the cause of the injury;"
    },
    {
        "instruction":"已知信息：\n'国家药监局关于发布影像型超声诊断设备同品种临床评价技术审查指导原则等2项注册技术审查指导原则的通告'可被翻译为：NMPA Announcement on Issuing of Two Registration Technical Review Guidelines Including the Guidelines for Technical Review of Clinical Evaluation of Ultrasound Diagnostic Imaging Equipment Based on Predicate Products\n'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药监局组织制定了《医用磁共振成像系统同品种临床评价技术审查指导原则（2020年修订版）》，并于2021年1月27日发布。'可被翻译为：To strengthen the supervision and guidance of medical device registration and further improve the quality of registration review, the NMPA organized to formulate the Guidance (Revision 2020) for Technical Review of Clinical Evaluation of Equivalent Devices of Medical Magnetic Resonance Imaging Systems which was issued on January 27, 2021.\n'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定了《肺炎支原体IgM\/IgG抗体检测试剂注册技术审查指导原则》《隐球菌荚膜多糖抗原检测试剂注册技术审查指导原则》和《遗传性耳聋相关基因突变检测试剂注册技术审查指导原则》，于2021年1月18日予以发布。'可被翻译为：To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on January 18, 2021 the Guidelines for Technical Review of the Registration of Mycoplasma Pneumoniae IgM\/IgG Antibody Detection Reagents, Guidelines for Technical Review of the Registration of Cryptococcus Capsular Polysaccharide Antigen Detection Reagents, and Guidelines for Technical Review of the Registration of Hereditary Hearing Loss Gene Mutation Detection Reagents.\n'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局于2019年5月22日组织制定并发布了《合成树脂牙注册技术审查指导原则》《宫内节育器注册技术审查指导原则》《植入式给药装置注册技术审查指导原则》，'可被翻译为：To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA organized the formulation of and published the Guidelines for Technical Review of the Registration of Synthetic Resin Teeth, the Guidelines for Technical Review of the Registration of IUD, and  the Guidelines for  Technical Review of the Registration of Implantable Drug Delivery System on May 22, 2019.\n\n根据上述已知信息，请将'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药监局组织制定了影像型超声诊断设备同品种临床评价技术审查指导原则等2项注册技术审查指导原则，于2021年1月15日予以发布。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to strengthen the supervision and guidance over medical device registration and further improve the quality of registration review, the NMPA has organized to formulate 2 technical review guidelines for registration including the Guidelines for Technical Review of Clinical Evaluation of Ultrasound Diagnostic Imaging Equipment Based on Predicate Products, which are hereby promulgated on January 15, 2021."
    },
    {
        "instruction":"已知信息：\n'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局于2020年3月10日组织制定并发布了《用于放射治疗的X射线图像引导系统注册技术审查指导原则》和《正电子发射\/X射线计算机断层成像系统注册技术审查指导原则》。'可被翻译为：To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on March 10, 2020 the Guidelines for Technical Review of the Registration of X-ray Image Guided Systems for Radiotherapy and Guidelines for Technical Review of the Registration of Positron Emission \/ X-Ray Computed Tomography Systems.\n'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定并于2020年3月10日发布了《植入式左心室辅助系统注册技术审查指导原则》。'可被翻译为：To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on March 10, 2020 the Guidelines for Technical Review of the Registration of Implantable Left Ventricular Assist System.\n'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定并于2020年5月14日发布了《登革病毒核酸检测试剂注册技术审查指导原则》。'可被翻译为：To strengthen the supervision and guidance over medical device registration and further improve the quality of registration review ,NMPA organized to formulate and released on May 14, 2020 the Technical Review Guidance for the Registration of Dengue Virus Nucleic Acid Detection Reagents.\n'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定并于2020年3月10日发布了《半导体激光脱毛机注册技术审查指导原则》。'可被翻译为：To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on March 10, 2020 the Guidelines for Technical Review of the Registration of Semiconductor Laser Hair Removal Machines.\n\n根据上述已知信息，请将'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定了《视力筛查仪注册技术审查指导原则》和《乳腺X射线系统注册技术审查指导原则》，并于6月24日发布。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To strengthen the supervision and guidance of medical device registration, and further improve the quality of registration review, the NMPA organized to formulation of the Guidelines for Technical Review of Vision Screener Registration and the Guidelines for Technical Review of Mammography System Registration, which were published on June 24."
    },
    {
        "instruction":"已知信息：\n'2019年，注册基层用户总数比上年增长15.69%。其中，注册人注册基层用户比上年增长41.92%，经营企业和使用单位的注册基层用户分别比上年增长24.22%和2.28%。'可被翻译为：In 2019, the total number of registered grassroots users increased by 15.69 percent over the previous year. Among them, the registered grassroots users of registrants, distributors and user units have increased by 41.92 percent, 24.22 percent and 2.28 percent over 2017, respectively.\n'2018年，注册基层用户总数比2017年增长8.87%。显示我国医疗器械不良事件监测范围不断扩大。其中，生产企业、经营企业和使用单位的注册基层用户分别比2017年增长16.44%、11.59%和4.97%(图5)。'可被翻译为：In 2018, the total number of registered grassroots users increased by 8.87% over2017. It shows that the scope of monitoring of adverse events of medical devices in China has been expanding. Among them, the registered grassroots users of manufacturers,distributors and user units have increased by 16.44%, 11.59% and 4.97% over 2017,respectively (Figure 5) .\n'截至2018年12月31日，在全国医疗器械不良事件监测信息系统注册的基层用户（包括生产企业、经营企业和使用单位)共275715家，其中生产企业13854家，占注册基层用户总数的5.02%;经营企业143535家，占注册基层用户的52.06%;使用单位118326家，占注册基层用户的42.92%(图4)。'可被翻译为：Figure 4 Status of registered grassroots users in the National Medical Device Adverse Event Monitoring Information System in 2018\n'截至2019年12月31日，在国家医疗器械不良事件监测信息系统中注册的基层用户（包括注册人、经营企业和使用单位）共318986家，其中注册人19662家，占用户总数的6.16%；经营企业178295家，占用户总数的55.89%；使用单位121029家，占用户总数的37.94%。'可被翻译为：As of Dec 31, 2019, there were a total of 318,986 grassroots user units (incl.registrants, distributors and user units)registered in the National Medical Device Adverse Event Monitoring Information System, covering 19,662 registrants(6.16%); 178,295 distributors (55.89%); and 121,029 user units (37.94%).\n\n根据上述已知信息，请将'2020年，注册基层用户总数比上年增长10.03%。其中，注册人注册基层用户比上年增长38.31%，经营企业和使用单位的注册基层用户分别比上年增长11.52%和3.24%。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In 2020, the total number of registered grassroots users increased by 10.03% compared with the previous year. Among them, the registered grassroots users of registrants, distributors and using units have increased by 38.31%, 11.52% and 3.24% compared with the previous year, respectively."
    },
    {
        "instruction":"已知信息：\n'申请人应当对申报资料的真实性负责。'可被翻译为：The applicant shall be responsible for the authenticity of application dossiers.\n'申请人、备案人对资料的真实性负责。'可被翻译为：The applicant and filing entity shall take full responsibility for the authenticity of the documents submitted.\n'（二）供货单位应当提供符合规定的资料且对其真实性、有效性负责；'可被翻译为：(II) The supplier shall provide materials meeting the provisions and bear responsibilities for their authenticity and validity;\n'（四）申请材料不齐全或者不符合形式审查要求的，应当当场或者在五日内发给申请人补正材料通知书，一次性告知申请人需要补正的全部内容，逾期不告知的，自收到申请材料之日起即为受理；'可被翻译为：(4) If the application materials are incomplete or do not meet the requirements for format examination, the notification on correcting and supplementing materials of amendments shall be sent to the applicant on the spot or within five days, with all the content needs to be corrected or supplemented at one time. The application materials shall be deemed as accepted since the date of submission if there is no notification after the timeline.\n\n根据上述已知信息，请将'申请人应当对其申请材料全部内容的真实性负责。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The applicant shall be responsible for the authenticity of all information on the materials for application."
    },
    {
        "instruction":"已知信息：\n'稳定性，是指医疗器械唯一标识应当与产品基本特征相关，产品的基本特征未变化的，产品标识应当保持不变。'可被翻译为：Stability means that UDI shall be co-related to the basic features of the corresponding product, and UDI-DI shall remain the same unless basic characteristics of the product are changed.\n'足够的设备设计、尺寸和位置'可被翻译为：i. Adequacy of equipment design, size, and location\n'所用仪器的动态范围（可以精确测量和计数的颗粒尺寸范围）必须包括待测样品 中最小颗粒尺寸。'可被翻译为：The dynamic range of the instrument used (range of sizes of particles that can be accurately sized and counted) must include the smallest particle size to be enumerated in the test articles.\n'注：萃取体积可能需要根据医疗器械的尺寸进行调整。'可被翻译为：Note: Extract volume may need to be adjusted depending on medical device size.\n\n根据上述已知信息，请将'生长过程中尺寸的变化保持比例关系。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Isometric growth occurs when proportional relationships are preserved as size changes during growth."
    },
    {
        "instruction":"已知信息：\n'选择最佳接收液作为IVRT方法开发初始步骤的一个优点是，在使用接收液对不同膜评估前，可先采用选定的接收液对样品分析方法进行优化。'可被翻译为：One advantage of selecting an optimal receptor solution as an initial step in IVRT method development is that it allows for the sample analysis method to be optimized for the selected receptor solution sample matrix before proceeding to an evaluation of different membranes using that receptor solution.\n'由合成材料(例如，混合纤维素酯、尼龙、聚砜、聚醚砜)组成的过滤膜(例如，孔径为0.45-µm)通常适合于IVRT方法，因为它们通常对大多数药物具有低吸附性，并且它们允许药物通过膜扩散。由合成材料组成的过滤膜，有时具有不同的孔径，通常在IVRT方法开发期间进行评估。其他类型的简单的单层合成膜，如透析膜，也可能适用于IVRT方法。使用生物膜或模拟生物膜的合成膜不适合IVRT方法，因为这种膜可能不恰当地影响药物的表观释放速度。'可被翻译为：Filter membranes (e.g., 0.45-µm pore size) comprised of synthetic materials (e.g., mixed cellulose esters, nylon, polysulfone, polyethersulfone) are frequently suitable for IVRT methods as they are typically resistant to binding most drugs, and they permit drugs to diffuse through the membrane. Filter membranes comprised of a synthetic material, sometimes with different pore sizes, are commonly evaluated during IVRT method development. Other types of simple, monolayer synthetic membranes, like dialysis membranes, may also be suitable for an IVRT method. The use of biological membranes or synthetic membranes developed to emulate a biological membrane are not appropriate for an IVRT method because such membranes may inappropriately influence the apparent rate of drug release.\n'IVRT膜'可被翻译为：IVRT Membrane\n'如果拟采用IVRT研究支持BE论证，在ANDA申请中，应递交IVRT方法开发报告，说明IVRT方法是如何优化的，并提供证据说明所选的IVRT方法参数是合理的或必要的，尤其是所选的方法参数与本指南和USP<1724>中推荐或描述的参数不一致时（注释12）。监管机构在审核方法开发报告时，比较关注IVRT方法参数选择的合理性，以及它们是否具有合适的灵敏度和重现性。应在方法开发报告中清楚的说明每组数据对应的方法参数，阐述优化IVRT方法所做的努力，证明所选的方法参数是合适的。'可被翻译为：If an IVRT study is intended to support a demonstration of BE, the IVRT method development report should be submitted in the ANDA to show how the IVRT method was optimized, and to support a demonstration that the method parameters selected for the IVRT are appropriate or necessary, particularly in situations where the method parameters are different from the methods recommended in this guidance and described in the United States Pharmacopeia (USP) General Chapter <1724>.（注释12）The Agency’s interest in reviewing the method development report is to understand why specific IVRT method parameters were selected and whether they are suitably sensitive and reproducible. This method development report should clearly indicate\/distinguish the method parameters used for each set of data, illustrate the efforts made to optimize the IVRT method, and demonstrate that the method parameters selected for the IVRT are appropriate.\n\n根据上述已知信息，请将'一般情况下，在IVRT方法开发中，（使用相同的接收介质）对不同的膜进行评估；通常采用合成膜过滤溶液中的微粒物质。在IVRT膜的选择中，可根据膜的有效孔径（如0.45μm），以及它们对药物的预期惰性。应在IVRT方法开发报告中，提供每种膜对化合物结合的信息和膜本身对IVRT方法中所选接收液的惰性（根据IVRT方法开发的前一阶段），以及在IVRT中所用的每种膜的药物释放线性和精密度信息，这些信息有助于解释IVRT方法中膜选择的合理性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"It is conventional to evaluate different membranes during IVRT method development (all using the same receptor solution); these membranes are frequently synthetic membranes used for the filtration of particulate matter in solutions. IVRT membranes are selected based upon their effective pore size (e.g., 0.45 micrometers (μm)), as well as their expected inertness to binding the drug. Information should be provided in the IVRT method development report on each membrane’s binding to the drug and its chemical compatibility with relevant receptor solution(s) selected for the IVRT method (based on the preceding phase of IVRT method development), as well as information on the linearity and precision of the resulting release rate when each membrane is used in an IVRT, as this information can help to explain why a specific membrane is optimal for the IVRT method."
    },
    {
        "instruction":"已知信息：\n'第一百四十六条 药品监督管理部门或者其设置、指定的药品检验机构在药品监督检验中违法收取检验费用的，由政府有关部门责令退还，对直接负责的主管人员和其他直接责任人员依法给予处分；情节严重的，撤销其检验资格。'可被翻译为：Article 146 Where a drug regulatory department or its designated drug control institution illegally collects inspection fees during drug supervision and inspection, the relevant government department shall order it to return the fees and punish the persons directly in charge and other directly responsible persons in accordance with the law. In serious circumstances, the qualification for testing shall be annulled.\n'药品监督管理部门或者其设置、指定的药品专业技术机构的工作人员参与药品生产经营活动的，依法给予处分。'可被翻译为：Where the staff of a drug regulatory department or a drug professional and technical institution established or appointed by the drug regulatory department participate in drug manufacturing and business activities, they shall be punished in accordance with the law.\n'第一百六十条 药品监督管理部门及其工作人员违反本法的规定，有下列情形之一的，由其上级行政机关或者监察机关责令改正；情节严重的，对直接负责的主管人员和其他直接责任人员依法给予行政处分：'可被翻译为：Article 160 Any drug regulatory department or its staff members that violate the provisions of this Provisions and constitute any of the circumstances below shall be instructed by its superior administrative department or supervisory departments to make rectification. If the circumstances are serious, administrative sanctions shall be given to the persons directly in charge and the other persons directly responsible in accordance with law:\n'第三十九条 食品药品监督管理部门、批签发机构及其工作人员违反本办法规定，有下列情形之一的，由其上级行政机关或者监察机关责令改正；情节严重的，对直接负责的主管人员和其他直接责任人员依法给予行政处分：'可被翻译为：Article 39 Any food and drug regulatory department, or lot release institution or its staff members that violate the provisions herein and in case of any of the circumstances below shall be ordered by its superior administrative authority or supervisory authority to make rectification. If the circumstances are serious, administrative sanctions shall be given to persons directly in charge and other directly responsible persons in accordance with law:\n\n根据上述已知信息，请将'第一百四十五条 药品监督管理部门或者其设置、指定的药品专业技术机构参与药品生产经营活动的，由其上级主管机关责令改正，没收违法收入；情节严重的，对直接负责的主管人员和其他直接责任人员依法给予处分。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 145 Where a drug regulatory department or its designated drug professional and technical institutions participate in drug manufacturing and business activities, it shall be ordered by its higher-level competent administrative department to make correction, and its illegal income shall be confiscated. In serious circumstances, the persons directly in charge and other directly responsible persons shall be punished in accordance with the law."
    },
    {
        "instruction":"已知信息：\n'第四十四条 食品药品监督管理部门在组织产品技术审评时可以调阅原始研究资料,并组织对申请人进行与产品研制、生产有关的质量管理体系核查。'可被翻译为：Article 44 The food and drug regulatory department may refer to the original research data when organizing a technical evaluation for product registration, and organize an inspection of the applicant’s quality management system concerning product research, development and production.\n'第九条 医疗器械注册申请人和备案人应当建立与产品研制、生产有关的质量管理体系，并保持有效运行。'可被翻译为：Article 9 The registration applicant and filling entity of medical devices shall establish a quality management system related to product research, development and manufacture and shall keep its effective operation.\n'第十条 体外诊断试剂注册申请人和备案人应当建立与产品研制、生产有关的质量管理体系，并保持有效运行。'可被翻译为：Article 10 The registration applicant and filling entity of in-vitro diagnostic reagents shall establish the quality management system related to product research, development and manufacture and shall keep its effective operation.\n'境内第二类、第三类医疗器械注册质量管理体系核查，由省、自治区、直辖市食品药品监督管理部门开展，其中境内第三类医疗器械注册质量管理体系核查，由国家食品药品监督管理总局技术审评机构通知相应省、自治区、直辖市食品药品监督管理部门开展核查，必要时参与核查。省、自治区、直辖市食品药品监督管理部门应当在30个工作日内根据相关要求完成体系核查。'可被翻译为：For domestic class II and class III medical device registration, the quality management system shall be inspected by the food and drug regulatory department of the provinces, autonomous regions and municipalities directly under the central government. In case the quality management system inspection is for a domestic class III medical device, the technical evaluation institution of China Food and Drug Administration shall notify the food and drug regulatory department of the corresponding province, autonomous region and municipality directly under the central government to carry out the inspection, and participate in the inspection when necessary. The food and drug regulatory department of the province, autonomous region or municipality directly under the central government shall complete the inspection within 30 workdays according to relevant requirements.\n\n根据上述已知信息，请将'第三十四条 食品药品监督管理部门在组织产品技术审评时可以调阅原始研究资料，并组织对申请人进行与产品研制、生产有关的质量管理体系核查。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 34 The food and drug regulatory department may refer to the original research data when organizing a technical evaluation for product registration, and organize an inspection of the applicant's quality management system concerning product research, development and production."
    },
    {
        "instruction":"已知信息：\n'指包装中直接接触原料药或制剂的包装，包括包装上的标签。'可被翻译为：Immediate (primary) pack is that constituent of the packaging that is in direct contact with the drug substance or drug product, and includes any appropriate label.\n'（七）药品制剂无中文说明书或者中文说明书与批准的说明书不一致的；'可被翻译为：(VII) there is no Chinese insert sheet for the pharmaceutical preparation or the Chinese insert sheet is inconsistent with the approved one;\n'（五）药品包装、标签、说明书符合有关规定；'可被翻译为：(V) The package, label and package insert of drugs shall comply with relevant provisions;\n'原材料(起始物料，试剂、溶剂)、工艺辅助材料、中间体，APIs 和包装及标签材料的总称。'可被翻译为：A general term used to denote raw materials (starting materials, reagents, solvents), process aids, intermediates, APIs and packaging and labelling materials.\n\n根据上述已知信息，请将'（七）药品说明书及包装、标签的式样（原料药和制剂中间体除外）；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(VII) insert sheet, patterns of its packaging and labeling(except for drug substances and intermediate preparations);"
    },
    {
        "instruction":"已知信息：\n'七、新《办法》实施前附条件批准的药品，应当按照新修订《药品管理法》第七十八条有关附条件批准药品上市后管理的规定执行。'可被翻译为：7. Drugs approved with conditions before the implementation of the new Provisions shall follow the provisions in Article 78 of the newly revised Drug Administration Law concerning post-marketing management of conditionally approved drugs.\n'（一）不具备资质销售药品的；'可被翻译为：(1) having no qualification for selling drugs;\n'（七）其他违反本办法规定的。'可被翻译为：(VII)  Other violations of the Provisions.\n'（七）特殊管理的药品的规定；'可被翻译为：(VII) Provisions for drugs under special management;\n\n根据上述已知信息，请将'（七）不具备《药品管理法》规定的生产条件的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(7) the production conditions prescribed in the Drug Administration Law are not met;"
    },
    {
        "instruction":"已知信息：\n'（五）与经营的医疗器械相适应的专业指导、技术培训和售后服务的质量管理机构或者人员。'可被翻译为：(5) having quality management agencies or personnel providing professional guidance, technical training, and after-sales services compatible with the distributed medical devices.\n'（四）与经营的医疗器械相适应的质量管理制度；'可被翻译为：(4) having a quality management system compatible with the distributed medical devices;\n'（一）与经营范围和经营规模相适应的质量管理机构或者质量管理人员，质量管理人员应当具有相关专业学历或者职称；'可被翻译为：(1) having quality management agencies or quality management personnel compatible with the distribution scope and scale, and the quality management personnel shall have relevant professional degrees or titles;\n'第二十三条 医疗机构设置的药房，应当具有与所使用药品相适应的场所、设备、仓储设施和卫生环境，配备相应的药学技术人员，并设立药品质量管理机构或者配备质量管理人员，建立药品保管制度。'可被翻译为：Article 23    The pharmacy established by a medical institution shall have the premise, equipment, storage facilities, hygienic environment, and pharmaceutical professionals required for drug dispensing. It shall also have the drug quality control units or personnel, and establish a system for drug storage.\n\n根据上述已知信息，请将'（三）有与所经营药品相适应的质量管理机构或者人员；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) have the units or personnel necessary for quality control of the drugs to be distributed; and"
    },
    {
        "instruction":"已知信息：\n'第八条 注册核查遵循公开、公平、公正的原则，以临床价值或者问题为导向，促进药物的研发和上市。'可被翻译为：Article 8 Registration inspection shall follow the principles of openness, fairness, and justice, and be guided by clinical value or problems to promote the drug development and approval.\n'第六条 药品注册工作应当遵循公开、公平、公正的原则。'可被翻译为：Article 6 The drug registration shall follow the principles of openness, fairness and justice.\n'第四条 医疗器械注册与备案应当遵循公开、公平、公正的原则。'可被翻译为：Article 4 The medical device registration and filing shall be conducted under the principles of publicity, equity and justice.\n'第五条 体外诊断试剂注册与备案应当遵循公开、公平、公正的原则。'可被翻译为：Article 5 The in-vitro diagnostic reagent registration and filing shall be conducted under the principles of publicity, equity and justice.\n\n根据上述已知信息，请将'第七条 药品注册管理遵循公开、公平、公正原则，以临床价值为导向，鼓励研究和创制新药，积极推动仿制药发展。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 7 The administration of drug registration shall follow the principles of openness, fairness and impartiality, emphasize clinical values, and aim at encouraging the research and development of new drugs and facilitating the development of generic drugs."
    },
    {
        "instruction":"已知信息：\n'通过膜的运动而转运大分子物质的过程。包括胞饮和胞吐。'可被翻译为：The process of transporting macromolecular substances through the motion of a membrane. Including pinocytosis and exocytosis.\n'大分子物质从细胞内转运到细胞外的过程。'可被翻译为：The transport of macromolecules from the inside to the outside of the cell.\n'通过病毒核酸进入细胞而实现的遗传转化。'可被翻译为：Genetic transformation through the entry of viral nucleic acids into cells.\n'非脂溶性小分子物质，在特殊膜蛋白质帮助下，由高浓度向低浓度一侧转运的过程。'可被翻译为：The process by which a non-fat-soluble small molecule is transported from one side of the biofilm to the other with the help of special membrane proteins.\n\n根据上述已知信息，请将'大分子物质通过膜的内陷形成小泡而进入细胞的过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process by which macromolecules enter a cell through the invagination of a membrane to form vesicles."
    },
    {
        "instruction":"已知信息：\n'第一百零五条 在冷藏、冷冻药品运输途中，应当实时监测并记录冷藏车、冷藏箱或者保温箱内的温度数据。'可被翻译为：Article 105 During the transportation of refrigerated or frozen drugs, real-time monitoring and recording of temperature data in refrigerated vehicles, refrigerated container or thermal insulation container shall be conducted.\n'第五十一条 运输冷藏、冷冻药品的冷藏车及车载冷藏箱、保温箱应当符合药品运输过程中对温度控制的要求。冷藏车具有自动调控温度、显示温度、存储和读取温度监测数据的功能；冷藏箱及保温箱具有外部显示和采集箱体内温度数据的功能。'可被翻译为：Article 51 The refrigerated vehicle, vehicle-mounted refrigerated container or thermal insulation container for transportation of refrigerated or frozen drugs shall conform to the requirements for temperature control during the transportation of drugs. The refrigerated vehicle has the function of automatically controlling temperature, displaying temperature, storing and reading temperature monitoring data; the refrigerated container and thermal insulation container have the function of externally displaying and collecting the temperature data in the container.\n'疫苗在储存、运输全过程中应当处于规定的温度环境，冷链储存、运输应当符合要求，并定时监测、记录温度。'可被翻译为：Vaccines shall be kept under the stipulated temperature during the whole process of storage and transportation; cold-chain storage and transportation shall comply with requirements, and temperature shall be monitored and recorded on a regular basis.\n'生物样本交接记录，运输温度记录完整；'可被翻译为：Records of transfer and records of temperature monitoring during transportation should be retained completely;\n\n根据上述已知信息，请将'第七十四条 冷藏、冷冻药品到货时，应当对其运输方式及运输过程的温度记录、运输时间等质量控制状况进行重点检查并记录。不符合温度要求的应当拒收。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 74 Upon arrival of refrigerated and frozen drugs, the inspection shall focus on the status of quality control over the means of transportation, temperature record during the transportation, and transportation time, records shall be taken, and those failing to meet temperature requirements shall be rejected."
    },
    {
        "instruction":"已知信息：\n'以一个产品名称申请注册或者进行备案的配合使用产品或者组合包装产品，任何一剂的最后一道接触内容物的工序在境外完成的，按照进口产品管理。'可被翻译为：For products used in conjunction or combination products that apply for registration or file for filing under one product name, if any of the last process touching the contents are produced overseas, the set shall be regulated as imported products.\n'第六十三条 配制、填充、灌装化妆品内容物，应当取得化妆品生产许可证。标注标签的生产工序，应当在完成最后一道接触化妆品内容物生产工序的化妆品生产企业内完成。'可被翻译为：Article 63 For the preparing, filling and canning of cosmetics contents, an entity shall obtain the Cosmetics Manufacturing License according to law. The manufacturing process of labeling shall be completed in the manufacturer of cosmetics that completes the last manufacturing process of contacting contents of cosmetics.\n'中国台湾、香港、澳门产品：国妆特制字+四位年份数+本年度注册产品顺序数。'可被翻译为：Products from Taiwan of, Hong Kong SAR and Macau SAR: 国妆特制字 + year (four digits) + serial number of products registered this year.\n'尚未进行包装但已完成所有其他加工工序的产品。'可被翻译为：Any product which has completed all processing stages up to, but not including, final packaging.\n\n根据上述已知信息，请将'第六十一条 化妆品最后一道接触内容物的工序在境内完成的为国产产品，在境外完成的为进口产品，在中国台湾、香港和澳门地区完成的参照进口产品管理。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 61 Cosmetics of which the last process touching the contents completes in China are domestic products, and those that completes overseas are imported products. Those that completes in Taiwan, Hong Kong SAR and Macau SAR shall be regulated by the reference of imported products."
    },
    {
        "instruction":"已知信息：\n'以治疗目的拟递送至细胞中的具有转录或翻译活性的遗传物质。不包括或化学合成的寡核苷酸。'可被翻译为：Transcriptionally or translationally active genetic material transferred by a vector intended to confer biological  activity following expression in cells\n'基因治疗递送工具，用于将含有转录\/翻译活性的治疗用 遗传物质或改变宿主细胞基因组的遗传物质递送至细胞。既包括基因修饰病毒如腺病毒或腺相关病毒，以及非病毒如质粒和基因修饰微生物，也包括可将遗传物质或基因编辑 成分转导至细胞的靶向纳米颗粒。'可被翻译为：Gene therapy delivery vehicles or carriers, containing transcriptionally\/translationally active therapeutic genetic  material or genetic material to alter the host genome that is manufactured to transfer the genetic material into the cells. They include both genetically modified viruses, such as adenovirus or adeno-associated virus, and non-viral vectors, such as plasmids and gene modified microorganisms, and can include targeted nanoparticles which have the capability to transfer genetic materials or gene editing components to the cells.\n'GT产品急性暴露后，由于遗传序列整合进宿主基因组、 删除、插入或基因组编辑后 的其它改变 ，或由于携带导入基因的病毒的潜伏感染，或由于转导遗传物质的染色体外 游离形式，转导或修饰的遗传序列在宿主中持续存在。'可被翻译为：The continued  presence  of transferred  or modified  genetic sequences in the host after acute exposure to a GT product, due either to integration of the genetic sequence into the host genome, deletion, insertion, or otherwise  modified following genome editing, to latent infection with the viral vector bearing the transgene, or to the transferred genetic material in episomal form.\n'利用将治疗性遗传物质递送至细胞中（例如，病毒转导和质粒转染） 。'可被翻译为：Delivery of therapeutic genetic material into the cells using vectors (e.g., transduction for viral vectors and transfection for plasmids).\n\n根据上述已知信息，请将'通过转导的遗传物质的表达（转录\/翻译）或通过特异性改变人类细胞目的基因组来发挥作用的治疗产品。此定义用于本指导原则。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Therapeutic products that mediate their effect by the expression (transcription\/translation) of transferred genetic  materials, or by specifically altering the target genome of human cells.This definition is for the purpose of this guideline."
    },
    {
        "instruction":"已知信息：\n'（三）医疗器械注册人、备案人和受托生产企业名称、生产许可证号或者备案编号；'可被翻译为：(3) name of the registrant, filing entity and contract manufacturer of the medical device, manufacturing license number or filing number;\n'（三）生产企业的名称、住所、生产地址、联系方式及生产许可证编号或者生产备案凭证编号，委托生产的还应当标注受托企业的名称、住所、生产地址、生产许可证编号或者生产备案凭证编号；'可被翻译为：(3) Name, residence, manufacturing address, contacts and production license number or filing number of medical device manufacturer. For contract manufacturing, name, address, manufacturing address, production license number or filing number of contracted manufacturer shall be also specified.\n'（三）医疗器械注册证编号或者备案凭证编号；'可被翻译为：(3) Registration certificate number or filing number of the medical device.\n'（四）生产企业的名称、住所、生产地址、联系方式及生产许可证编号或者生产备案凭证编号，委托生产的还应当标注受托企业的名称、住所、生产地址、生产许可证编号或者生产备案凭证编号；'可被翻译为：(4) Name, residence, manufacturing address, contacts and  production license number or filing number of medical device manufacturer. For contract manufacturing, name, address, manufacturing address, production license number or filing number of contracted manufacturer shall be also specified.\n\n根据上述已知信息，请将'（三）医疗器械注册人、备案人和受托生产企业名称、生产许可证编号或者备案编号。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) name of the registrant, filing entity and contract manufacturer of the medical device, manufacturing license number or filing number."
    },
    {
        "instruction":"已知信息：\n'可用于存储ttspp的总容量，考虑到所采用的负载支撑系统的类型(地板支撑托盘，可调节托盘货架或货架单元)，根据可以在商店中实现的利用率进行修改。'可被翻译为：The total volume available for storing TTSPPs, taking account of the type of load support system employed (floor-standing pallets, adjustable pallet racking or shelving units), as modified by the utilization factor that can be achieved in the store.\n'一种分配程序，以确保在分发和\/或使用较新的和相同的库存项目之前分发和\/或使用最旧的库存。'可被翻译为：A distribution procedure to ensure that the oldest stock is distributed and\/or used before a newer and identical stock item is distributed and\/or used.\n'人工神经网络中处理单元的类型之一，实现系统处理结果的输出的单元。'可被翻译为：One of the types of processing units in artificial neural networks, the unit that realizes the output of the system's processing results.\n'具有高非法价值的对时间和温度敏感的药品(TTSPPs):毒药、麻醉品、精神药品、易燃或易爆物质和放射性物质。'可被翻译为：Time- and temperature-sensitive pharmaceutical products (TTSPPs) with high illicit value: poisons, narcotics, psychotropic products, inflammable or explosive substances and radioactive materials.\n\n根据上述已知信息，请将'考虑到库存单位(SKU)的类型、负载支持系统的类型和仓库中使用的库存管理系统，在实践中可以可靠地实现的可用于存储温度敏感药品(TTSPPS)的总体容量的百分比。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The percentage of the total volume available for storing temperature-sensitive pharmaceutical products (TTSPPS) that can reliably be achieved in practice, taking account of the types of stock-keeping unit (SKU), the types of load support system and the stock management systems used in the store."
    },
    {
        "instruction":"已知信息：\n'药物通过口服或注射，进入血液后再作用于病变部位的给药方式。'可被翻译为：The drug is administered orally or by injection, enters the blood stream, and then acts on the lesion site.\n'将药物定位注入目标神经核团的给药方法。'可被翻译为：A method of administration in which a drug is localised into a target neural nucleus.\n'不经过制粒过程直接把药物和辅料的混合物进行压片的方法。'可被翻译为：The process of pressing a mixture of drugs and excipients directly into tablets without going through the pelletizing process.\n'将以水为溶媒的药物注射液(药液)直接注射入静脉的给药方法。'可被翻译为：A method of administration in which a drug injection (liquid) with water as the solvent is injected directly into a vein.\n\n根据上述已知信息，请将'需要药物主要作用于中枢神经系统时，把药物直接注入脊髓蛛网膜下腔的方法。注射点定位以左右韶后上棘的连线与后正中线的交接处，穿过韧带和硬脑脊膜、有脑脊液溢出的部位。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A method of injecting a drug directly into the subarachnoid space of the spinal cord when it is required to act primarily on the central nervous system. The injection point is located at the intersection of the line of the superior spine of the left and right Shao Shao and the median line of the back, through the ligament and the dura, where there is cerebrospinal fluid overflow."
    },
    {
        "instruction":"已知信息：\n'流动相的极性大于固定相极性的色谱方法。'可被翻译为：Chromatographic method in which the polarity of mobile phase is greater than that of stationary phase.\n'用于低压梯度的液相色谱泵。将不同极性的溶剂按预先设定的比例在泵前混合后，再由'可被翻译为：Liquid chromatography pumps for low pressure gradients. The solvent of different polarity is mixed in front of the pump in a pre-set ratio, and then by\n'采用极性固定相和相对非极性流动相，称为正相。'可被翻译为：The polar fixed phase and the relatively non-polar mobile phase are called the positive phase.\n'采用相对非极性固定相和极性流动相，称为反相。'可被翻译为：The use of a relatively non-polar fixed phase and a polar mobile phase is called a reverse phase.\n\n根据上述已知信息，请将'采用高压输液系统，将具有不同极性的单一溶剂或不同比例的混合溶剂、缓冲液等流动相泵入固定相的色谱柱，对供试品进行分离测定的方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Using high pressure infusion system, the single solvent with different polarity or different proportion of mixed solvent, buffer and other mobile phase is pumped into the stationary phase column, and the test product is separated and determined."
    },
    {
        "instruction":"已知信息：\n'第五条 药品生产企业应当按照本办法的规定建立和完善药品召回制度，收集药品安全的相关信息，对可能具有安全隐患的药品进行调查、评估，召回存在安全隐患的药品。'可被翻译为：Article 5 Drug manufacturers shall establish and improve the drug recall system according to these Provisions, collect relevant drug safety information, investigate and assess drugs with potential safety hazards and recall drugs with safety hazards.\n'药品生产企业应当对药品可能存在的安全隐患进行调查。'可被翻译为：Article 11 Drug manufacturers shall investigate potential safety hazards of drugs.\n'第十四条 医疗器械生产企业按照本办法第十条、第十二条的要求进行调查评估后，确定医疗器械产品存在缺陷的，应当立即决定并实施召回，同时向社会发布产品召回信息。'可被翻译为：Article 14 After the medical device manufacturer carries out an investigation and assessment in accordance with the requirements of Articles 10 and 12 of these Provisions, if it is confirmed that the medical device product is defective, it shall immediately decide and implement a recall, and disclose the product recall information to the society.\n'第二十五条 药品监督管理部门经过调查评估，认为存在本办法第四条所称的安全隐患，药品生产企业应当召回药品而未主动召回的，应当责令药品生产企业召回药品。'可被翻译为：Article 25 When the drug manufacturer doesn't take the initiative to recall the drug that is found to have safety hazards described in Article 4 of these Provisions during investigation and assessment conducted by the drug regulatory department, the drug regulatory department shall order the drug manufacturer to recall the drug.\n\n根据上述已知信息，请将'第十五条 药品生产企业应当对收集的信息进行分析，对可能存在安全隐患的药品按照本办法第十二条、第十三条的要求进行调查评估，发现药品存在安全隐患的，应当决定召回。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 15 Drug manufacturers shall analyze information collected, investigate and assess drugs with potential safety hazards according to requirements of Article 12 and Article 13 of these Provisions and recall the drugs found to have safety hazards immediately."
    },
    {
        "instruction":"已知信息：\n'第三十五条 技术审评过程中需要申请人补正资料的，技术审评机构应当一次告知需要补正的全部内容。申请人应当在１年内按照补正通知的要求一次提供补充资料；技术审评机构应当自收到补充资料之日起60个工作日内完成技术审评。申请人补充资料的时间不计算在审评时限内。'可被翻译为：Article 35 Where supplementary and correction materials are required during technical evaluation, the technical evaluation institution shall inform the applicant one-off of all the supplements to be completed. The applicant shall submit all necessary supplementary and correction materials one-off within one year according to the supplementation notice. The technical evaluation institution shall complete the technical evaluation within 60 workdays from the date of acceptance of the supplements. The time spent by applicant for supplementing such materials shall not be calculated in the overall evaluation time.\n'第四十五条 技术审评过程中需要申请人补正资料的，技术审评机构应当一次告知需要补正的全部内容。申请人应当在１年内按照补正通知的要求一次提供补充资料；技术审评机构应当自收到补充资料之日起60个工作日内完成技术审评。申请人补充资料的时间不计算在审评时限内。'可被翻译为：Article 45 Where supplementary and correction materials are required during technical evaluation, the technical evaluation institution shall inform the applicant one-off of all the supplements to be completed. The applicant shall submit all necessary supplementary and correction materials one-off within one year according to the supplementation notice. The technical evaluation institution shall complete the technical evaluation within 60 workdays from the date of acceptance of the supplements. The time spent by applicant for supplementing such materials shall not be calculated in the overall evaluation time.\n'（三）需要申请人补充资料的，应当一次告知需要补充的全部内容；申请人应当在90个工作日内按照要求一次提供补充资料，技术审评机构收到补充资料后审评时限重新计算；未在规定时限内补充资料的，技术审评机构应当作出技术审评不通过的审评结论。'可被翻译为：(3) Where supplementary documents are required from the applicant, the applicant shall be notified once of all the contents to be supplemented; the applicant shall provide supplementary documents at one time as required within 90 working days, and the evaluation time limit shall be recalculated after the technical assessment agency receives the supplementary documents; if the supplementary documents are not submitted within the specified timeline, the technical assessment agency shall make an evaluation conclusion of disapproval.\n'申请人对补正资料通知内容有异议的，可以向相应的技术审评机构提出书面意见，说明理由并提供相应的技术支持资料。'可被翻译为：Where the applicant has an objection to the content of the notice for supplements or corrections, it may submit its written opinions to the corresponding technical evaluation institution, to explain its reasons and provide corresponding technical supporting materials.\n\n根据上述已知信息，请将'第二十八条 技术审评过程中需要申请人补正资料的，技术审评机构应当一次告知需要补正的全部内容。申请人应当在1年内按照补正通知的要求一次提供补充资料。技术审评机构应当自收到补充资料之日起40个工作日内完成技术审评。申请人补充资料的时间不计算在审评时限内。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 28 Where supplementary and correction materials are required during technical evaluation, the technical evaluation institution shall inform the applicant one-off of all the supplements to be completed. The applicant shall submit all necessary supplementary and correction materials one-off within one year according to the supplementation notice. The technical evaluation institution shall complete the technical evaluation within 40 workdays from the date of acceptance of the supplements. The time spent by applicant for supplementing such materials shall not be calculated in the overall evaluation time."
    },
    {
        "instruction":"已知信息：\n'定量研究毒物在体内吸收、分布、生物转化、排泄等过程随时间变化的动态规律的学科。'可被翻译为：The subject of quantitative study of the dynamic laws of the absorption, distribution, biotransformation and excretion of toxicants in the body over time.\n'研究药物与机体（包括病原体）间相互作用规律的一门学科。主要内容包括研究药物对机体的作用规律和阐明药物作用和作用机制（称为药效学）；研究药物在机体内的吸收、分布、代谢和排泄的过程及血药浓度随时间变化的规律（称为药动学）。药动学和药效学是药物治疗学的理论基础。'可被翻译为：A discipline that studies the law of interaction between drugs and the organism (including pathogens). The main contents include the study of the law of drug action on the body and the elucidation of drug action and mechanism of action (called pharmacodynamics); The process of drug absorption, distribution, metabolism and excretion in the body and the law of blood drug concentration change with time (called pharmacokinetics). Pharmacokinetics and pharmacodynamics are the theoretical basis of pharmacotherapeutics.\n'药物在体内的吸收分布生物转化和排泄。'可被翻译为：The absorption and distribution of drugs in the body Biotransformation and excretion.\n'研究药物及其剂型在体内的吸收、分布、代谢、排泄等过程，阐明药物的剂型因素、机体生物因素和药效之间相互关系的一门学科。'可被翻译为：The study of the absorption, distribution, metabolism, excretion and other processes of drugs and their dosage forms in the body, and the elucidation of the relationship between drug dosage forms, biological factors and efficacy.\n\n根据上述已知信息，请将'全称\"药物代谢动力学”。主要研究机体对药物的处置的动态变化，包括药物在机体内的吸收、分布、生物转化及排泄的过程，尤其是血药浓度随时间变化规律的学科。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Full name \"Pharmacokinetics\". It mainly studies the dynamic changes of the body's treatment of drugs, including the absorption, distribution, biotransformation and excretion processes of drugs in the body, especially the discipline of blood drug concentration changes with time."
    },
    {
        "instruction":"已知信息：\n'又称“C8柱二一种常用的高效液相色谱键合硅胶填料，是一种化学键合硅胶固定相。'可被翻译为：Also known as \"C8 column two, a commonly used high performance liquid chromatography bonded silica gel filler, is a chemically bonded silica gel stationary phase.\n'又称\"氨基柱”。鼠基键合在硅胶基质上的色谱键合硅胶填料。'可被翻译为：Also known as \"amino column\". Chromatography-bonded silicone fillers with mouse group bonding on a silicone matrix.\n'氟基硅烷键合硅胶'可被翻译为：nitrile groups chemically bonded silica\n'十八烷基硅烷键合硅胶'可被翻译为：octadecylsilane chemically bonded silica\n\n根据上述已知信息，请将'又称“C]8柱\"。最常用的反相色谱键合硅胶填料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Also known as \"C]8 column\". Most commonly used reversed phase chromatography bonding silica gel fillers."
    },
    {
        "instruction":"已知信息：\n'第五十二条 对于因品种特性或者注册核查工作遇到特殊情况，确需延长时限的，书面告知申请人延长时限，并通知药品审评中心，必要时通知其他相关专业技术机构。延长时限不超过原时限的二分之一。'可被翻译为：Article 52 If it is necessary to extend the time limit due to the variety characteristics or special circumstances of registration inspection, the applicant shall be informed in writing of the extension of the time limit, and CDE shall be notified, or other relevant professional and technical institutions shall be notified when necessary. The extension time limit shall not exceed one half of the original time limit.\n'审评过程中基于风险启动药品注册核查、检验，相关技术机构应当在规定时限内完成核查、检验工作。'可被翻译为：Where drug registration inspection and testing are initiated during review based on risks, relevant technical institutions shall complete inspection and testing within specified timelines.\n'因品种特性及检验项目原因确需延长批签发时限的，经中检院审核确定后予以公开。'可被翻译为：If the time limit for lot release indeed needs to be extended due to product characteristics or testing item, the NIFDC shall determine and publicize the time limit after review.\n'第十一条 省级药品检验机构收到检验样品和相关资料后，应当在30日内完成样品检验，向申请人出具进口药材检验报告书，并报送省级药品监督管理部门。因品种特性或者检验项目等原因确需延长检验时间的，应当将延期的时限、理由书面报告省级药品监督管理部门并告知申请人。'可被翻译为：Article 11 Provincial drug control institutions shall, within 30 days upon the receipt of test samples and related materials, complete the sample testing, issue the testing report of imported drugs to the applicants, and submit it to the provincial drug regulatory department. Where it is necessary to extend the testing time due to characteristics of varieties or testing items, the duration and reasons of the extension shall be reported to provincial drug regulatory department in written form and notified to the applicants.\n\n根据上述已知信息，请将'第一百零二条 因品种特性及审评、核查、检验等工作遇到特殊情况确需延长时限的，延长的时限不得超过原时限的二分之一，经药品审评、核查、检验等相关技术机构负责人批准后，由延长时限的技术机构书面告知申请人，并通知其他相关技术机构。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 102 Where it is necessary to extent the timeline due to product characteristics and special circumstances in review, inspection and\/or testing, the extension shall not be longer than 1\/2 of the original timeline. After the extension is approved by the person in charge of a technical institution for drug review, inspection or testing, the technical institution which extends the timeline shall inform the applicant in a written notice and notify other relevant technical institutions."
    },
    {
        "instruction":"已知信息：\n'5.经批准的工艺规程和操作规程；'可被翻译为：5) Approved master manufacturing documents and operation procedures;\n'本规范所指的文件包括质量标准、工艺规程、操作规程、记录、报告等。'可被翻译为：The documentation in the Provisions includes specifications, master manufacturing documents, operation procedures, records, reports, and etc.\n'第一百六十九条 工艺规程不得任意更改。如需更改，应当按照相关的操作规程修订、审核、批准。'可被翻译为：Article 169: Master manufacturing documents should not be changed without authorization. When revision is needed, they should be revised, reviewed and approved according to relevant operation procedures.\n'第三十二条 文件的起草、修订、审核、批准、分发、保管，以及修改、撤销、替换、销毁等应当按照文件管理操作规程进行，并保存相关记录。'可被翻译为：Article 32 The drafting, revision, review, approval, distribution and retention as well as the amendment, revocation, replacement and destruction of documents, shall be conducted in accordance with the documentation control operating procedures, and relevant records shall be kept.\n\n根据上述已知信息，请将'（一）审核和批准产品的工艺规程、操作规程等文件；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1. The review and approval of master manufacturing documents, procedures, etc;"
    },
    {
        "instruction":"已知信息：\n'（1）降低或阻碍某一化学反应的物质。（2）降低或抑制另一种物质（如酶）活性的物质。'可被翻译为：(1) A substance that reduces or hinders a chemical reaction. (2) A substance that reduces or inhibits the activity of another substance, such as an enzyme.\n'不引起机体机能形态、生长、发育和寿命的改变，不引起机体功能能力的降低，也不引起机体对额外应激状态代偿能力的损伤。'可被翻译为：Does not cause changes in the body's functional form, growth, development and life span, does not cause a reduction in the body's functional capacity, nor does it cause an injury to the body's compensatory ability for additional stress.\n'能显著降低溶液表面张力的一类物质。'可被翻译为：A class of substances that can significantly reduce the surface tension of a solution.\n'某物质能降低胆固醇合成的能力。'可被翻译为：A substance that reduces the ability to synthesize cholesterol.\n\n根据上述已知信息，请将'能降低机体内胆固醇水平的物质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A substance that lowers the level of cholesterol in the body."
    },
    {
        "instruction":"已知信息：\n'国家药监局关于发布《已上市生物制品变更事项及申报资料要求》的通告'可被翻译为：NMPA Announcement on Issuing the Requirements for Change Items and Application Dossiers of Marketed Biological Products\n'国家药监局关于发布《已上市中药变更事项及申报资料要求》的通告'可被翻译为：NMPA Notice on Issuing the Requirements for Change Items of Marketed Traditional Chinese Medicines and Application Dossiers\n'国家药监局关于发布化学药品注册分类及申报资料要求的通告'可被翻译为：NMPA Issues Requirements for Registration Classification and Application Dossiers of Chemical Drugs\n'为配合药品注册管理办法实施，国家药品监督管理局组织制定了《已上市化学药品变更事项及申报资料要求》，已于2021年2月3日发布实施。'可被翻译为：To cooperate with the implementation of the Provisions for Drug Registration, the NMPA has organized to formulate the Requirements for Change Items of Marketed Chemicals and Application Dossier, which has been issued and implemented on February 3, 2021.\n\n根据上述已知信息，请将'国家药监局关于发布已上市化学药品变更事项及申报资料要求的通告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Notice on Issuing the Requirements for Change Items of Marketed Chemicals and Application Dossier"
    },
    {
        "instruction":"已知信息：\n'测定粉体比表面积的最基本方法，系将烘干脱气处理后的样品置于液氮中，由覆满粉体表面所需气体分子的值换算出粉体比表面积。'可被翻译为：The most basic method to determine the specific surface area of the powder is to place the sample after drying and degassing treatment in liquid nitrogen, and convert the specific surface area of the powder from the value of the gas molecules required to cover the surface of the powder.\n'当相对湿度增大到一定水平时水溶性药物的吸湿量会急剧增加，一般把此一水平称为该药物的临界相对湿度。'可被翻译为：When the relative humidity increases to a certain level, the moisture absorption of water-soluble drugs will increase sharply, and this level is generally called the critical relative humidity of the drug.\n'比表面积'可被翻译为：specific surface area\n'可能有必要在 2 份分离物上进行基因型鉴定（产品来源和生产区域分离物），查看其是否为同一种属'可被翻译为：i. It may be necessary to perform a genotype identification on the two isolates (product source and manufacturing area isolate) if they are the same species.\n\n根据上述已知信息，请将'物质的表面具有表面张力6在恒温恒压下可逆地增大表面积必，则需功。必，因为所需的功等于物系自由能的增加，且这一增加是由于物系的表面积增大所致，故称为表面能。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The surface of a substance has surface tension 6 If the surface area is reversibly increased at constant temperature and pressure, work is required. Yes, because the work required is equal to the increase in the free energy of the system of matter, and this increase is caused by the increase in the surface area of the system of matter, it is called the surface energy."
    },
    {
        "instruction":"已知信息：\n'（五）组织检查本行政区域内药品生产、经营企业的药品不良反应报告和监测工作的开展情况，并与同级卫生行政部门联合组织检查本行政区域内医疗机构的药品不良反应报告和监测工作的开展情况；'可被翻译为：(V)  Organize inspection of ADR reporting and monitoring carried out by drug manufacturers and distributors within their administrative regions; jointly with the health administrative departments at the same level, organize inspection of ADR reporting and monitoring carried out by medical institutions within their administrative regions.\n'（四）组织开展本行政区域内药品不良反应报告和监测的宣传、培训工作。'可被翻译为：(IV) Organize and carry out publicity and training on ADR reporting and monitoring within their respective administrative regions.\n'（六）组织开展本行政区域内药品不良反应报告和监测的宣传、培训工作。'可被翻译为：(VI)  Organize and carry out publicity and training on ADR reporting and monitoring within their administrative regions.\n'第十三条 药品生产、经营企业和医疗机构应当建立药品不良反应报告和监测管理制度。药品生产企业应当设立专门机构并配备专职人员，药品经营企业和医疗机构应当设立或者指定机构并配备专（兼）职人员，承担本单位的药品不良反应报告和监测工作。'可被翻译为：Article 13 Drug manufacturers, distributors and medical institutions shall establish ADR reporting and monitoring management systems. To undertake the task of ADR reporting and monitoring within the enterprises or institutions, drug manufacturers shall establish specialized departments and allocate full-time personnel while drug distributors and medical institutions shall establish or designate departments and allocate full-time or part-time personnel.\n\n根据上述已知信息，请将'（五）组织检查药品生产、经营企业的药品不良反应报告和监测工作的开展情况，并与卫生部联合组织检查医疗机构的药品不良反应报告和监测工作的开展情况。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(V)  Organize inspection of ADR reporting and monitoring carried out by drug manufacturers and distributors; organize inspection of ADR reporting and monitoring carried out by medical institutions jointly with the Ministry of Health."
    },
    {
        "instruction":"已知信息：\n'第三十三条 申办者应当在开展药物临床试验前在药物临床试验登记与信息公示平台登记药物临床试验方案等信息。药物临床试验期间，申办者应当持续更新登记信息，并在药物临床试验结束后登记药物临床试验结果等信息。登记信息在平台进行公示，申办者对药物临床试验登记信息的真实性负责。'可被翻译为：Article 33 The sponsor shall, before carrying out the drug clinical trial, submit the drug clinical trial protocol and other information on the drug clinical trial registry and information disclosure platform. During the drug clinical trial, the sponsor shall continually update the registered information and, after the drug clinical trial ends, submit results of the drug clinical trial and other related information. Information posted on the platform shall be disclosed to the public. The sponsor is responsible for the authenticity of registered information about the drug clinical trial.\n'（三）各临床试验机构原则上应当同期开展和结束临床试验；'可被翻译为：(3) In principle the clinical trial institutions shall start and end the clinical trial at the same time;\n'第三十二条 药物临床试验应当在批准后三年内实施。药物临床试验申请自获准之日起，三年内未有受试者签署知情同意书的，该药物临床试验许可自行失效。仍需实施药物临床试验的，应当重新申请。'可被翻译为：Article 32 A drug clinical trial shall be conducted within three years after approval. Where no subject has signed any informed consent form within three years since the date when the clinical trial application was approved, the drug clinical trial permit shall cease to be valid automatically. Where the sponsor plans to continue the drug clinical trial, a new drug clinical trial application shall be submitted.\n'药物临床试验终止后，拟继续开展药物临床试验的，应当重新提出药物临床试验申请。'可被翻译为：Where the sponsor plans to continue a drug clinical trial after it has been terminated, a new drug clinical trial application shall be submitted.\n\n根据上述已知信息，请将'（三）药物临床试验结束后未登记临床试验结果等信息。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) Fail to register the clinical trial results and other information after completion of clinical trials."
    },
    {
        "instruction":"已知信息：\n'业务连续性计划'可被翻译为：business continuity plan\n'13.确保完成产品的持续稳定性考察计划，提供稳定性考察的数据；'可被翻译为：13) To ensure the implementation of on-going stability study and make the stability data available;\n'1.遵循正确的程序并符合标准的状态。\n2.采取所有必要的措施以确保和保持符合HACCP计划中建立的标准。'可被翻译为：1.The state wherein correct procedures are being followed and criteria are being met.\n2.The taking of all necessary actions to ensure and maintain compliance with the criteria established in the HACCP plan.\n'跨产品生命周期中的一序列有计划的活动，用于监测和维持模型的性能，以确保其模型始终适用于预期和批准用途。'可被翻译为：A set of planned activities over the product lifecycle to monitor and sustain the model’s performance to continually ensure its suitability for the intended and approved purpose. \n\n\n根据上述已知信息，请将'定义由管理层支持和资助的持续过程的文件化计划，以确保采取必要步骤来识别潜在损失的影响，维持可行的恢复策略和恢复计划，并通过人员培训、计划测试和维护确保服务的连续性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A documented plan that defines the ongoing process supported by management and funded to ensure that the necessary steps are taken to identify the impact of potential losses, maintain viable recovery strategies and recovery plans, and assure continuity of services through personnel training, plan testing and maintenance."
    },
    {
        "instruction":"已知信息：\n'第八十七条 生产设备应当有明显的状态标识，标明设备编号和内容物（如名称、规格、批号）；没有内容物的应当标明清洁状态。'可被翻译为：Article 87: Production equipment should be clearly labeled to indicate the equipment reference number and the contents (e.g. product name, strength, batch number, etc.). The equipment without contents should be labeled to indicate its cleaning status.\n'第一百一十九条 中间产品和待包装产品应当有明确的标识，并至少标明下述内容：'可被翻译为：Article 119: Intermediate and bulk products should be clearly labeled, including at least the following information:\n'管道流向、斜率、直径和长度'可被翻译为：Pipeline flow direction, slopes, diameter and length.\n'第八十九条 企业应当将药品销售给合法的购货单位，并对购货单位的证明文件、采购人员及提货人员的身份证明进行核实，保证药品销售流向真实、合法。'可被翻译为：Article 89 Enterprises shall sell drugs to legal purchasers and validate the certificates of the purchasers and the identity certificates of the purchasing personnel and the pickup personnel, so as to ensure that the flow of drug sales is authenticate and lawful.\n\n根据上述已知信息，请将'第八十九条 主要固定管道应当标明内容物名称和流向。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 89: Main fixed pipes should be clearly labeled to indicate the contents and the direction of flow."
    },
    {
        "instruction":"已知信息：\n'与药物具有相同的分子式，但其分子中原子的空间排列不同并且为不能重合的镜像的化合物。'可被翻译为：A compound with the same molecular formula as the drug substance that differs in the spatial arrangement of atoms within the molecule and is a non-superimposable mirror image.\n'与现有药物分子在化学结构上具有相似性的化合物。'可被翻译为：A compound having a chemical structure similar to that of existing drug molecules.\n'组合化学'可被翻译为：combinatorial chemistry\n'具有生物活性的化合物，经化学结构修饰后形成新化合物，后者在体内经酶的作用释出原药发挥作用。'可被翻译为：The chemical modification of a biologically active compound to form a new compound, which is released in the body by the action of enzymes.\n\n根据上述已知信息，请将'组合化学中表示包含数量较多且为不同结构的化合物集合。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Combinatorial chemistry refers to a collection of compounds containing a large number and different structures."
    },
    {
        "instruction":"已知信息：\n'以临床效果指标作为健康产出，对两个或多个可选择的医疗干预进行经济学评价的方法。'可被翻译为：A method for the economic evaluation of two or more alternative medical interventions using clinical outcome indicators as health outcomes.\n'将成本和结果均转换为货币单位，对两个或多个可选择的医疗干预进行经济学评价方法。'可被翻译为：A method for economic evaluation of two or more alternative medical interventions by converting both costs and outcomes into monetary units.\n'是药物经济学评价最常用的研究角度，指一项干预措施的所有成本和产出都考虑在内，而不论这项干预应用于哪些个体或人群。'可被翻译为：This is the most commonly used research perspective for pharmacoeconomic evaluation, where all costs and outputs of an intervention are taken into account, regardless of the individual or population to which the intervention is applied.\n'致力于在药物经济学、健康产出评估和公共政策相关问题的研究的国际组织。'可被翻译为：An international organization dedicated to research on issues related to pharmacoeconomics, health outcomes evaluation, and public policy.\n\n根据上述已知信息，请将'以质量生命调整年作为健康产出，对两个或多个可选择的医疗干预进行经济学评价方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Quality life adjustment years (QLS) were used as health outcomes to evaluate two or more alternative medical interventions."
    },
    {
        "instruction":"已知信息：\n'药审中心受理1类创新药注册申请共700件（319个品种），（化学药的品种数以活性成分统计，中药和生物制品的品种数均以药品通用名称统计，下同），品种数较2018年增长了20.8%。其中，受理1类创新药的新药临床试验（IND）申请302个品种，较2018年增长了26.4%；受理1类创新药的新药上市申请（NDA）17个品种，较2018年减少了8个品种。'可被翻译为：CDE has accepted a total of 700 applications(involving 319 varieties, increased by 20.8% as compared with those in 2018) for the registration of Class 1 innovative drugs(the number of varieties of chemical drugs is based on the statistical analysis of active ingredients, while the varieties of TCMs and biological products are all counted by their generic names, the same below), covering 302 INDs (increased by 26.4% as compared with those in 2018) and 17 NDAs (decreased by 8 varieties as compared with those in 2018) for Class 1 innovative drugs.\n'药审中心受理5.1类化药进口原研药注册申请75件（涉及50个品种），受理1类进口创新药注册申请85件（涉及42个品种），创新药的适应症主要集中在抗肿瘤、循环系统和消化系统领域。'可被翻译为：CDE accepted 75 applications for registration of Class 5.1 imported chemical brand name drugs (involving 50 varieties), and85 applications for registration of imported innovative drugs (incl. 42 varieties). The indications for innovative drugs are mainly focused on anti-tumor, circulatory and digestive systems.\n'药审中心受理1-6类中药新药注册申请39件，其中受理中药NDA 8件（涉及8个品种），较2017年增长了7倍；中药IND 31件（涉及29个品种），其中1类中药创新药IND申请有2件（涉及1个品种）。'可被翻译为：CDE accepted 39 applications for registration of Class 1-6 new TCMs, covering 8 NDAs (8varieties involved), increasing 8 times than that in 2017; 31 INDs (incl. 29 varieties), 2of which were for Class 1 innovative TCM(involving 1 variety).\n'药审中心受理国产1类创新药注册申请448件（涉及222个品种），其中受理临床申请403件（涉及198个品种），上市申请45件（涉及24个品种）。按药品类型统计，化药323件（涉及115个品种），中药2件（涉及1个品种），生物制品123件（涉及106个品种），创新药的适应症主要集中在抗肿瘤、内分泌系统和消化系统领域。'可被翻译为：CDE accepted 448 applications for the registration of domestically-produced Class1 innovative drugs (involving 222 varieties),of which 403 were for INDs (involving 198varieties), and 45 were for NDAs (involving24 varieties). As per drug-specific statistics,323 applications were for chemical drugs(involving 115 varieties), 2 for TCMs(involving 1 variety), and 123 biologicals(involving 106 varieties). The indications of innovative drugs are mainly concentrated in the field of anti-tumor and endocrine systems,and digestive systems.\n\n根据上述已知信息，请将'药审中心受理1类化药创新药注册申请157个品种，整体较2017年略有增加，其中受理创新药NDA 16个品种，较2017年增长了一倍。2018年受理的157个化药创新药注册申请中，国产化药创新药注册申请为115个品种，进口化药创新药注册申请为42个品种，2015年至2018年创新药注册申请受理情况详见图4。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"CDE accepted registration applications for 157 varieties of Class 1 innovative chemicals, covering 16 innovative NDAs (up by 100% YOY), 115 varieties of domestically produced innovative chemicals, and 42 imported ones. For such details from 2015 to 2018, see Figure 4."
    },
    {
        "instruction":"已知信息：\n'×1械注×2××××3×4××5××××6。其中：'可被翻译为：×1 XZ ×2××××3×4××5××××6. Among which,\n'核磁共振氢谱中自旋分裂峰个数，表示某基团上六个相临的氢偶合时产生的分裂峰，显示的就为七重峰。'可被翻译为：The number of spin-splitting peaks in the nuclear magnetic resonance hydrogen spectrum indicates the splitting peak produced when six adjacent hydrogens on a certain group are coupled, and the seven-fold peak is displayed.\n'以质谱图中指定质核比范围内最强峰为100%,其他离子峰对其归一化所得的强度。现在标准质谱图均以离子相对丰度值为纵坐标。'可被翻译为：The maximum peak is 100% in the range of the specified mass nucleus ratio in the mass spectrum, and the intensity obtained by the normalization of other ion peaks. Now the standard mass spectrometry is the relative abundance value of ions as the ordinate.\n'为衡量正常色谱峰与不正常色谱峰的指标。'可被翻译为：To measure the normal chromatographic peak and abnormal chromatographic peak index.\n\n根据上述已知信息，请将'核磁共振谱中出现的一类多重峰。其峰数为5,峰高比为1：4：6：4：1。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A class of multimodal peaks occurring in NMR spectra. It has a peak number of 5 and a peak-to-height ratio of 1:4:6:4:1."
    },
    {
        "instruction":"已知信息：\n'用于对样品进行测量的设备应该有适当的验证和频繁的核查，确保结果可靠和可重复， 此类设备的例子包括称重天平、pH计、灭菌器、微生物计数器、手动\/自动读板器和紫 外可见光分光计。手动和自动读板器更多信息参见标题为抗生素效价测定章节：管碟法。'可被翻译为：Equipment used to provide a unit of measurement should have the appropriate validation and frequent verification checks to ensure reliable and reproducible results; examples of such equipment include a weight scale, pH meter, autoclave, micrometer, manual\/automatic plate reader and UV-VIS spectrophotometer. For more information on manual and automatic plate readers, see section titled Antibiotic Potency Testing: Plate Method.\n'抗生素效价采用碟法（管碟或扩散）或浊度法（浊度计）法测定。碟法和浊度法均会显 示出可测量的生长抑制性。例如，在管碟法测试中可观察到抑菌圈（ZOI）。浊度法测 定中，观察并测量混浊度。将生长抑制测量结果制表，作线性回归曲线，外推得到抗生 素效价值。'可被翻译为：Antibiotic potency testing is performed either by the plate (cylinder-plate or diffusion) or tube (turbidimetric) method. Both plate and tube methods demonstrate measurable levels of growth inhibition. For example, zones of inhibition (ZOIs) are observed and measured during cylinder plate testing. And, turbidity is observed and measured during tube testing. Growth inhibition measurements are tabulated and integrated into a linear regression curve, resulting in extrapolated antibiotic potency values.\n'管碟法是最常使用的 USP<81>测试方法。管碟法使用固体培养基（琼脂）证明抗生素活性（即抑菌圈（ZOI））。该方法需要使用 5 点标准曲线【S1】-【S5】、中值标准品【S3】、供试抗生素\/未知样品【U3】、经过确认的接种物、不锈钢小管和含有生长琼脂的培养碟。参见图 1 中一次独立碟法测试及一式三份标准曲线和未知样品琼脂平板的放置示例。'可被翻译为：The Plate Method is the most commonly used USP <81> test. The Plate Method uses a solid \nmedium (agar) to demonstrate antibiotic activity (i.e. zones of inhibitions (ZOIs)). This method \nrequires the use of a five-point standard curve [S1] – [S5], median reference standard [S3], test \nantibiotic\/ unknown sample [U3], verified inoculum, stainless steel penicylinders and petri_x0002_plates containing growth agar. See Diagram 1 for an example of one independent test run for the \nPlate Method and placement of the standard curve and unknown sample onto triplicate agar \nplates.\n'检查无菌测试培养基转移至增菌碟上培养时所用的实验室区域。工作空间杂乱或表面未灭菌可能会导致培养碟的污染。'可被翻译为：f. Review laboratory areas used for sub-culturing the sterility test medium onto enrichment plates. Cluttered work space or un- sanitized surfaces may cause plate contamination.\n\n根据上述已知信息，请将'经过指定的培养时间后，取掉小管，灭活（即灭菌）并用肥皂和水清洗。小管再次用于检测之前要加热灭菌。使用手动\/自动读碟器测量每个 ZOI 的直径。ZOI 应由经过资格确认的实验室员工测量。使用手动\/自动读碟器测量 ZOI。手动读碟器的示例包括 Fisher_x0002_Lily 读碟器或手动\/电子圆规；手动读取需要将数据录入（例如手写和\/或电子）纸质记录和\/或电子日志和\/或数据表。自动读碟器的例子包括 OMNICON 或 Trinity V3。与手动读取不同，自动读碟器允许计算机化系统对培养碟进行测量，不需要录入原始数据。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"After the specified incubation time, the penicylinders are removed, decontaminated (i.e. \nautoclaved) and washed with soap and water. The penicylinders are then heat sterilized prior to \nre-use in test. The diameter of each ZOI is measured with a manual\/automatic plate reader. ZOIs should only be measured by qualified laboratory personnel. ZOI measurements are taken with the use of a manual or automatic plate reader. Examples of a manual reader include a Fisher_x0002_Lily zone reader or manual\/electronic calipers; manual reads require data entry (e.g. handwritten and\/or electronic) onto hardcopy and\/or into electronic logbooks and\/or spreadsheets. Examples \nof automated plate readers include OMNICON or Trinity V3. Unlike manual reads, automated \nplate readers allow a computerized system to measure the plates and do not require data entry of \nraw data."
    },
    {
        "instruction":"已知信息：\n'第一百七十七条 批包装记录应当依据工艺规程中与包装相关的内容制定。记录的设计应当注意避免填写差错。批包装记录的每一页均应当标注所包装产品的名称、规格、包装形式和批号。'可被翻译为：Article 177: A batch packaging record should be based on the relevant parts of the Packaging Instructions, and avoid transcription errors. The record should carry the product name, strength, package size and batch number on every page.\n'第一百七十三条 原版空白的批生产记录应当经生产管理负责人和质量管理负责人审核和批准。批生产记录的复制和发放均应当按照操作规程进行控制并有记录，每批产品的生产只能发放一份原版空白批生产记录的复制件。'可被翻译为：Article 173: The master batch processing records should be reviewed and approved by the heads of production and quality management. The reproduction and issuance should be managed and recorded according to operation procedures, and only one copy of reproduced master records can be issued for the manufacture of each batch.\n'第一百七十五条 批生产记录的内容应当包括：'可被翻译为：Article 175: A batch processing record should include:\n'第一百七十八条 批包装记录应当有待包装产品的批号、数量以及成品的批号和计划数量。原版空白的批包装记录的审核、批准、复制和发放的要求与原版空白的批生产记录相同。'可被翻译为：Article 178: The batch packaging record should carry the batch number and the quantity of bulk product, as well as the batch number and the planned quantity of finished product. The requirements of review, approval, reproducing and issuance of original blank batch packaging record is the same as that of original blank batch processing record.\n\n根据上述已知信息，请将'第一百七十二条 批生产记录应当依据现行批准的工艺规程的相关内容制定。记录的设计应当避免填写差错。批生产记录的每一页应当标注产品的名称、规格和批号。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 172: A batch processing record should be based on the relevant parts of the currently approved master manufacturing documents. Such records should be designed to avoid transcription errors. The record should carry the product name, dosage form, strength and batch number on every page."
    },
    {
        "instruction":"已知信息：\n'第五十八条 疫苗上市许可持有人应当对疫苗进行质量跟踪分析，持续提升质量控制标准，改进生产工艺，提高生产工艺稳定性。'可被翻译为：Article 58 Vaccine MAHs shall carry out quality tracking analysis for vaccines and continuously improve quality control standards, production process and stability of the production process.\n'第二十四条 疫苗应当按照经核准的生产工艺和质量控制标准进行生产和检验，生产全过程应当符合药品生产质量管理规范的要求。'可被翻译为：Article 24 Vaccines shall be produced and tested in accordance with the approved production process and specifications, and the entire production process shall meet the requirements prescribed by the good manufacturing practice for drugs.\n'第五十九条 疫苗上市许可持有人应当根据疫苗上市后研究、预防接种异常反应等情况持续更新说明书、标签，并按照规定申请核准或者备案。'可被翻译为：Article 59 Vaccine MAHs shall continue to update the package inserts and labels based on the post-marketing study or adverse reactions of vaccines and apply for approval or file the record as required.\n'国务院药品监督管理部门应当在其网站上及时公布疫苗说明书、标签内容。'可被翻译为：The drug regulatory department under the State Council shall publish the content of vaccine package inserts and labels on its websites in a timely manner.\n\n根据上述已知信息，请将'第二十一条 国务院药品监督管理部门在批准疫苗注册申请时，对疫苗的生产工艺、质量控制标准和说明书、标签予以核准。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 21 The drug regulatory department under the State Council shall examine and approve the production process, quality control standards, package inserts and labels of vaccines during the approval process of the vaccine registration application."
    },
    {
        "instruction":"已知信息：\n'第一条 为规范药品生产质量管理，根据《中华人民共和国药品管理法》、《中华人民共和国药品管理法实施条例》，制定本规范。'可被翻译为：Article 1: These provisions of Good Manufacturing Practice (GMP) for Drugs, in accordance with the Drug Administration Law of the People's Republic of China and the Regulations for Implementation of the Drug Administration Law of the People's Republic of China, are enacted to regulate the manufacturing and quality management of Drugs.\n'第一条 为规范药品说明书和标签的管理，根据《中华人民共和国药品管理法》和《中华人民共和国药品管理法实施条例》制定本规定。'可被翻译为：Article 1    The Provisions are enacted with a view to regulating drug insert sheets and labels in accordance with the Drug Administration Law of the People's Republic of China and the Regulations for Implementation of the Drug Administration Law of the People's Republic of China.\n'第一条 为加强药品安全监管，保障公众用药安全，根据《中华人民共和国药品管理法》、《中华人民共和国药品管理法实施条例》、《国务院关于加强食品等产品安全监督管理的特别规定》，制定本办法。'可被翻译为：Article 1 The Provisions are formulated with a view to strengthening supervision of drug safety to ensure the safe use of drugs for the public in accordance with Drug Administration Law of the People's Republic of China, Regulations for the Implementation of the Drug Administration Law of the People's Republic of China and Special Rules of the State Council on Strengthening the Supervision and Management of the Safety of Food and Other Products.\n'第一条 为加强生物制品监督管理，规范生物制品批签发行为，保证生物制品安全、有效，根据《中华人民共和国药品管理法》（以下简称《药品管理法》）有关规定，制定本办法。'可被翻译为：Article 1 In order to strengthen the supervision and administration of biological products, regulate the lot release of biological products, and ensure the safety and efficacy of biological products, these Provisions are hereby formulated in accordance with relevant regulations in the Drug Administration Law of the People's Republic of China (hereinafter referred to as the Drug Administration Law).\n\n根据上述已知信息，请将'第一条 为加强药品经营质量管理，规范药品经营行为，保障人体用药安全、有效，根据《中华人民共和国药品管理法》、《中华人民共和国药品管理法实施条例》，制定本规范。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 1 To strengthen quality management of drug distribution, standardize drug distribution activities, and guarantee safe and effective use of drugs on human body, the Good Supply Practice for Drugs (GSP) is formulated in accordance with the Drug Administration Law of the People's Republic of China and the Regulations for Implementation of the Drug Administration Law of the People's Republic of China."
    },
    {
        "instruction":"已知信息：\n'注意，如果在需氧碟上发现有生长，则应与厌氧碟上的生长情况进行比较。在 分离完成之后进一步对其进行鉴别。'可被翻译为：Note if any growth is observed on aerobic plate and compare to growth on anaerobic plates. Proceed with identification when isolation is complete.\n'注意，如果在厌氧碟中发现有生长，其与需氧碟中的生长是不一样的。挑选单 个代表性菌落，进行空气耐受性测试，以确定所回收的是否严格厌氧菌。在分 离完成后，进一步对所有严格厌氧菌进行鉴别'可被翻译为：Note if any growth is observed on the anaerobic plate which differs from growth on the aerobic plate. Pick a single representative colony and perform an aero-tolerance test in order to determine if a strict anaerobe has been recovered. Proceed with identification of any strict anaerobes recovered when isolation is complete.\n'转接种SCD肉汤至通用生长培养基，并在有氧情况下培养。划线转接种一个培养 碟，在22.5 ± 2.5 ºC有氧情况下培养。'可被翻译为：Sub culture SCD broth to general growth medium and incubate aerobically. Streak one plate; incubate aerobically at 22.5 ± 2.5 ºC.\n'检查分离时所用的原始碟，查看是否可能在使用前就被污染（即，在琼脂表面未接种位置生长，表面下生长）'可被翻译为：g. Check the original plates used for isolation for possible pre- existing contamination (i.e. growth in non-streaked locations on the agar surface, subsurface growth)\n\n根据上述已知信息，请将'注意，如果在通用生长培养碟中发现生长，则在分离完成后进一步进行鉴别。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Note if any growth is observed on general growth medium plate. Proceed with identification when isolation is complete."
    },
    {
        "instruction":"已知信息：\n'为推动药品注册技术标准与国际接轨，经研究，国家药品监督管理局决定适用《Q2（R1）：分析方法论证：正文和方法学》等11个国际人用药品注册技术协调会（ICH）指导原则（详见附件）。现就有关事项公告如下。'可被翻译为：To keep pace with the international technical standards for drug registration, NMPA has decided to apply 11 ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) guidelines, including the Q2(R1): Validation of Analytical Procedures: Text and Methodology. The relevant matters are hereby announced as follows.\n'国家药监局关于适用《E9（R1）：临床试验中的估计目标与敏感性分析》国际人用药品注册技术协调会指导原则的公告'可被翻译为：NMPA Announcement on the Application of ICH Guideline E9 (R1): Estimands and Sensitivity Analysis in Clinical Trials\n'国家药监局关于适用13个国际人用药品注册技术协调会指导原则的公告'可被翻译为：NMPA issues announcement on the adoption of 13 ICH safety guidelines\n'国家药监局关于适用《S5（R3）》和《S11》国际人用药品注册技术协调会指导原则的公告'可被翻译为：NMPA Announcement on Adopting ICH Guidelines S5 (R3) and S11\n\n根据上述已知信息，请将'国家药监局关于适用《Q2（R1）：分析方法论证：正文和方法学》等11个国际人用药品注册技术协调会指导原则的公告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Announcement of NMPA on Applying 11 ICH Guidelines Including Q2 (R1): Validation of Analytical Procedures: Text and Methodology"
    },
    {
        "instruction":"已知信息：\n'药代动力学'可被翻译为：Pharmacokinetics\n'临床药理学，应关注药代动力学（PK）、药效动力学（PD）、药代动力学\/药效动力学（PK\/PD）相关性、药物相互作用等，为临床安全有效应用提供依据。应参考ICHE5和E17等指导原则，对中国患者人群与境外研究人群可能存在的PK和\/或PD种族差异进行评估。'可被翻译为：In terms of clinical pharmacology, attention should be paid to pharmacokinetics (PK),pharmacodynamics (PD), PK\/PD correlation and drug interaction, providing basis for safe and effective clinical application. Possible racial differences in PK and\/or PD between Chinese patient populations and foreign study populations should be evaluated by referencing ICH E5 and E17 guidelines, etc.\n'该术语适用于与合格评定机构有关的第三方认证，该机构正式证明了其执行特定合格评定任务的能力(2)。'可被翻译为：The term applied to third party attestation related to a conformity assessment body conveying formal demonstration of its competence to carry out specific conformity assessment tasks (2).\n'代谢的一级动力学模式,药代动力学参数与给药剂量无关,药物浓度衰减在半对数坐标系上呈直线。'可被翻译为：In the first-order kinetic model of metabolism, the pharmacokinetic parameters are independent of the dose, and the drug concentration decays in a straight line on the semilog coordinate system.\n\n根据上述已知信息，请将'在该指导原则的全文中均用术语“动力学”表达其含义，该术语在此并不是具体指药代和\/或毒代动力学。尚无可更好地表达该术语的单词。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The term \"kinetics\" is used consistently throughout this guideline, irrespective of intending to mean pharmaco- and\/or toxicokinetics. No better single term was available."
    },
    {
        "instruction":"已知信息：\n'重伤(也称为健康状况严重恶化)是:——危及生命的疾病或伤害;——身体功能的永久性损伤或对身体的永久性损伤;—需要医疗或手术干预以防止身体功能永久性损伤或身体结构永久性损伤的情况(28)。'可被翻译为：Serious injury (also known as serious deterioration in state of health) is either: –– life- threatening illness or injury; –– permanent impairment of a body function or permanent damage to a body; –– a condition necessitating medical or surgical intervention to prevent permanent impairment of a body function or permanent damage to a body structure (28).\n'在任何剂量下发生的以下任何不良医学事件：\n- 导致死亡，\n- 危及生命，\n- 需要住院或者延长住院时间，\n- 导致永久性或显著的残疾\/功能丧失，\n或- 先天性异常\/出生缺陷\n（参见ICH E2A和ICH E6）。'可被翻译为：Any untoward medical occurrence that at any dose: - results in death,   - is life -threatening,   - requires inpatient hospitali sation or prolongation of existing hospitali sation,   - results in persistent or significant disability\/incapacity,   or  - is a congenital anomaly\/birth defect   (see ICH E2A and ICH E6 ).\n'在任何剂量下发生的任何不良医疗事件：\n- 导致死亡\n- 危及生命\n- 需要住院治疗或延长现有住院治疗\n- 导致永久的或严重的残疾或功能损失，或\n- 治疗现有住院治疗永久的或严重的残疾或功能损失先天性异常\/出生缺陷\n（见 ICH 指导原则临床安全数据管理：加速报告的定义和标准）。[ICH E6 (R1) ]'可被翻译为：Any untoward medical occurrence that at any dose: \n- results in death, \n- is life-threatening, \n- requires inpatient hospitalization or prolongation of existing hospitalization, \n- results in persistent or significant disability\/incapacity, or \n- is a congenital anomaly\/birth defect (see the ICH Guideline for Clinical Safety Data Management: \nDefinitions and Standards for Expedited Reporting).[ICH E6(R1)]\n'（四）严重不良事件和可能导致严重不良事件的器械缺陷的记录与报告。'可被翻译为：(4) Records and reports of serious adverse events and device defects which may cause serious adverse events.\n\n根据上述已知信息，请将'严重不良事件，是指临床试验过程中发生的导致死亡或者健康状况严重恶化，包括致命的疾病或者伤害、身体结构或者身体功能的永久性缺陷、需住院治疗或者延长住院时间、需要进行医疗或者手术介入以避免对身体结构或者身体功能造成永久性缺陷；导致胎儿窘迫、胎儿死亡或者先天性异常、先天缺损等事件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The serious adverse event refers to event of death or serious deterioration of physical health during the clinical trial, including deadly illnesses or injuries, permanent defect in body structure or body function, and event where hospitalization or prolonged hospitalization, medical or surgical intervention is needed to avoid permanent defect to body structure or body function; and events that causes fetal distress, fetal death, or congenital anomalies or defects."
    },
    {
        "instruction":"已知信息：\n'（一）未履行监督检查职责，或者发现违法行为不及时查处；'可被翻译为：(1) failing to perform duties of supervision and inspection, or failing to promptly investigate and punish any illegal act that has been identified;\n'五、关于药品违法行为查处'可被翻译为：V. Investigation and prosecution of drug related illegal activities\n'第二十八条 对第三方平台、药品上市许可持有人、药品批发企业通过网络销售药品违法行为的查处，由省级药品监督管理部门负责。对药品网络零售企业违法行为的查处，由市县级药品监督管理部门负责。'可被翻译为：Article 28 The provincial drug regulatory departments shall be responsible for investigating and handling the illegal acts of drug sales through the Internet by third-party platforms, MAHs, and drug wholesalers. The municipal and county-level drug regulatory departments shall be responsible for investigating and handling the illegal acts of online drug retailers.\n'（二）未及时消除区域性重大药品安全隐患，造成本行政区域内发生特别重大药品安全事件，或者连续发生重大药品安全事件；'可被翻译为：(2) fail to promptly eliminate serious regional drug safety hazards and causing a severe drug safety incident within their administrative region or recurrent serious drug safety incidents; or\n\n根据上述已知信息，请将'（二）对发现的药品安全违法行为未及时查处；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(2) failing to promptly investigate and deal with drug safety violation upon discovery;"
    },
    {
        "instruction":"已知信息：\n'修订内容涉及药品标签的，应当一并进行修订；说明书及标签其他内容应当与原批准内容一致。在补充申请备案后9个月内对所有已出厂的药品说明书及标签予以更换。'可被翻译为：If the modification relates to the label of the drug, the latter shall be modified together; the other content of the package insert and the label shall be consistent with the original approved ones. All the insert sheets and labels of exfactory drugs shall be changed within 9 months after the record filing of the supplementary application.\n'一、本品的上市许可持有人应依据《药品注册管理办法》等有关规定，按照甲巯咪唑制剂说明书修订要求（见附件），提出修订说明书的补充申请，于2021年5月3日前报国家药品监督管理局药品审评中心或省级药品监管部门备案。'可被翻译为：I. The marketing authorization holder of this product shall, in accordance with the Provisions for Drug Registration and the revision requirements for the package insert of methimazole preparations, submit a supplementary application as such before May 3, 2021 to the Center for Drug Evaluation of NMPA or provincial drug regulatory department for filing.\n'药品批准上市后，持有人应当持续开展药品安全性和有效性研究，根据有关数据及时备案或者提出修订说明书的补充申请，不断更新完善说明书和标签。药品监督管理部门依职责可以根据药品不良反应监测和药品上市后评价结果等，要求持有人对说明书和标签进行修订。'可被翻译为：After a drug is marketed after approval, the MAH shall continue to carry out studies on drug safety and efficacy, promptly file for record or submit supplementary applications for revision of the package inserts based on the relevant data, and keep updating and improving the package inserts and labels. Drug regulatory departments may, as per their duties, require the MAH to revise the package inserts and labels based on the results of adverse drug reaction monitoring and post-marketing evaluation.\n'一、本品的上市许可持有人应依据《药品注册管理办法》等有关规定，按照妇产科用米索前列醇片说明书修订要求（见附件），提出修订说明书的补充申请，于2021年5月24日前报国家药品监督管理局药品审评中心或省级药品监管部门备案。'可被翻译为：I. The marketing authorization holders of this product shall, in accordance with relevant provisions such as the Provisions for Drug Registration, submit the supplementary application for revising the package insert according to the requirements for revising the package insert of Misoprostol Tablets for obstetrical and gynecological application, and report to the Center for Drug Evaluation of NMPA or provincial drug regulatory authorities for filing prior to May 24, 2021.\n\n根据上述已知信息，请将'一、相关品种的上市许可持有人可依据《药品注册管理办法》等有关规定，按照相应修订建议，向国家药监局药品审评中心提出补充申请，修订说明书【适应症】和【用法用量】项有关内容，并同时完善说明书安全性信息等相关内容。修订内容涉及药品标签的，应当一并进行修订。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"I. The marketing authorization holders of relevant varieties may, based on the Provisions for Drug Registration and in accordance with corresponding revision suggestions, submit the supplementary application to the Center for Drug Evaluation of NMPA, revise the [Indications] and [Usage and Dosage] of the package insert, and simultaneously improve the safety information and other relevant contents in the package insert. If revision relates to the drug label, the latter shall be modified together."
    },
    {
        "instruction":"已知信息：\n'毛细管色谱分析中，在毛细管柱的出口端引入的一路气流。其作用是减少柱后的死体积，改善柱效，满足检测器的最佳气体流速，以提高检测器的灵敏度。'可被翻译为：In capillary chromatography, a stream of air introduced at the exit of a capillary column. Its role is to reduce the dead volume behind the column, improve the column efficiency, meet the best gas flow rate of the detector, in order to improve the sensitivity of the detector.\n'以胶束为假固定相的一种电动色谱法。是电泳技术与色谱技术的结合，在毛细管中进行。'可被翻译为：An electrokinetic chromatography using micelles as a pseudostationary phase. It is a combination of electrophoresis and chromatography and is carried out in capillary tubes.\n'在色谱柱上对获得分离的组分进行检测的仪器。如采用毛细管电泳法或毛细管电色谱法进行分析时，就是在毛细管出口端的某个位置，除去聚酰亚胺涂层后作为检测池进行检测。'可被翻译为：An instrument for the detection of separated components on a chromatographic column. For analysis, such as by capillary electrophoresis or capillary electrochromatography, the polyimide coating is removed at a certain position at the outlet of the capillary tube and used as a detection pool for detection.\n'一种高效液相色谱一质谱联用的仪器接口。属于大气压电离的范畴，包括电喷雾、离子的形成及离子的传递三个步骤。'可被翻译为：An instrument interface for high performance liquid chromatography-mass spectrometry. It belongs to the category of atmospheric pressure ionization, including electrospray, ion formation and ion transfer three steps.\n\n根据上述已知信息，请将'一种与电离装置结合在一起的接口。以喷雾探针为进样渠道，色谱柱后流出物以l~2ml\/min流速，经过喷雾探针中心部位的不锈钢毛细管流入，形成气溶胶，并在毛细管出口前被加热管剧烈加热，其溶剂迅速蒸发，体积迅速膨胀后以超音速喷出毛细管，从而形成由微小液滴、粒子和蒸气组成的雾状混合物。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An interface that is combined with an ionization device. With the spray probe as the sample channel, the effluent after the chromatograph column flows through the stainless steel capillary in the center of the spray probe at the flow rate of l~2ml\/min, forming an aerosol, and is heated violently by the heating tube before the capillary outlet, the solvent evaporates rapidly, and the volume expands rapidly after ejecting the capillary tube at supersonic speed. Thus forming a mist mixture composed of tiny droplets, particles and vapors."
    },
    {
        "instruction":"已知信息：\n'国家药品监督管理局化妆品技术审评机构（以下简称技术审评机构）负责特殊化妆品、化妆品新原料注册的技术审评工作，进口普通化妆品、化妆品新原料备案后的资料技术核查工作，以及化妆品新原料使用和安全情况报告的评估工作。'可被翻译为：The cosmetic technical assessment agency of the NMPA (hereinafter referred to as the technical assessment agency) is responsible for the technical assessment of the registration of special cosmetics and new cosmetic ingredients, the technical verification of imported general cosmetics and the new cosmetic ingredients after filing, and the evaluation of the use and safety reports of new cosmetic ingredients.\n'第二十六条 化妆品新原料安全监测期满3年后，技术审评机构应当向国家药品监督管理局提出化妆品新原料是否符合安全性要求的意见。'可被翻译为：Article 26 After three-year safety monitoring period for new cosmetic ingredients, the technical assessment agency shall submit an opinion on whether the new cosmetic ingredients meet the safety requirements to the NMPA.\n'对存在安全问题的化妆品新原料，由国家药品监督管理局撤销注册或者取消备案；未发生安全问题的，由国家药品监督管理局纳入已使用的化妆品原料目录。'可被翻译为：For new cosmetic ingredients with safety issues, the NMPA shall revoke the registration or nullify the filing; if no safety issues are found, the NMPA shall include them into the inventory of existing cosmetic ingredients.\n'化妆品新原料注册人、备案人应当在化妆品新原料安全监测每满一年前30个工作日内，汇总、分析化妆品新原料使用和安全情况，形成年度报告报送国家药品监督管理局。'可被翻译为：Registrants and filing persons of new cosmetic ingredients shall, within 30 working days before a year period of safety monitoring of new cosmetic ingredients, prepare an annual report summarizing and analyzing the use and safety conditions of new ingredients, and submit it to the NMPA.\n\n根据上述已知信息，请将'第二十五条 技术审评机构收到省、自治区、直辖市药品监督管理部门或者化妆品新原料注册人、备案人的反馈或者报告后，应当结合不良反应监测机构的化妆品年度不良反应统计分析结果进行评估，认为通过调整化妆品新原料技术要求能够消除安全风险的，可以提出调整意见并报告国家药品监督管理局；认为存在安全性问题的，应当报请国家药品监督管理局撤销注册或者取消备案。国家药品监督管理局应当及时作出决定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 25 The technical assessment agency shall, after receiving the feedback or report from the drug regulatory department of the province, autonomous region, or municipality, or the registrant and filing person of new cosmetic ingredients, assess the situation in accordance with the annual statistical analysis results of cosmetic adverse reactions from the adverse reaction monitoring agency. When believing that the safety risks can be eliminated by adjusting technical requirements of the new cosmetic ingredients, the technical assessment agency may propose opinions of adjustment and report to the NMPA; when believing that there are safety issues, the technical assessment agency shall report to the NMPA and request to revoke the registration or nullify the filing. The NMPA shall make decisions in a timely manner."
    },
    {
        "instruction":"已知信息：\n'两方或多方之间的正式协议。公司和组织可以使用谅解备忘录建立正式的合作伙伴关系。谅解备忘录不具有法律约束力，但它们具有一定程度的严肃性和相互尊重，比君子协议更有力。'可被翻译为：A formal agreement between two or more parties. Companies and organizations can use MoUs to establish official partnerships. MoUs are not legally binding but they carry a degree of seriousness and mutual respect, stronger than a gentlemen’s agreement.\n'合作协议'可被翻译为：cooperation agreement\n'如果公司使用合同生产服务，检查合同生产商和\/或合同检测实验室是否签订有有效质量协议（就像公司与客户签订的协议一样），这样可以知悉各方在检测和数据生成、审核和归档方面的角色与职责。'可被翻译为：If the firm utilizes contract manufacturing services, is a contract manufacturer and\/or a contract \ntest laboratory, an active Quality Agreement, as established by the firm and customer, may \nprovide insight to the roles and responsibilities of each party for testing and data generation, \nreview and archival.\n'1.以特定价格供应货物或从事工作的商业协议。\n2.一份注明日期并由研究者、机构和发起人签署的文件，列出任何关于财务问题和授权\/责任分配的协议。当议定书包含这些信息并签字时，它也可以作为合同。\n3.以一定价格供应货物或从事工作的商业协议;这可以在协议中包含质量要素，也可以在单独的合同中包含质量要素。'可被翻译为：1.Business agreement for the supply of goods or performance of work at a specified price.\n2.A document, dated and signed by the investigator, institution and sponsor, that sets out any agreements on financial matters and delegation\/distribution of responsibilities. The protocol may also serve as a contract when it contains such information and is signed.\n3.Business agreement for the supply of goods or performance of work at a speciﬁed price; this may include quality elements in the agreement, or in a separate contract.\n\n根据上述已知信息，请将'正式的商业文件，概述了与另一个个人、团体或实体达成的协议的基本条款。这是签订更详细合同的第一步。其他名称包括但不限于谅解备忘录、合作合同或合作协议。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A formal business document outlining the basic terms of an agreement with another individual, group or entity. It is one of the first steps towards a more detailed contract. Alternative names include, but are not limited to, memorandum of understanding, cooperation contract or collaboration agreement."
    },
    {
        "instruction":"已知信息：\n'境内第一类体外诊断试剂备案，备案人向设区的市级食品药品监督管理部门提交备案资料。'可被翻译为：To apply for filing of class I in-vitro diagnostic reagent, the filing entity shall submit the filing documents to the food and drug regulatory department of the city consisting of districts .\n'医疗器械备案是医疗器械备案人向食品药品监督管理部门提交备案资料，食品药品监督管理部门对提交的备案资料存档备查。'可被翻译为：Medical device filing is a process that the filing entity submits the filing documents to the food and drug regulatory department and the food and drug regulatory department files the filing documents submitted by the filing entity.\n'体外诊断试剂备案是备案人向食品药品监督管理部门提交备案资料，食品药品监督管理部门对提交的备案资料存档备查。'可被翻译为：In-vitro diagnostic reagent filing is a process that the filing entity submits the filing documents to the food and drug regulatory department and the food and drug regulatory department files the filing documents submitted by the filing entity.\n'进口第一类医疗器械备案，备案人向国家食品药品监督管理总局提交备案资料。'可被翻译为：To apply for filing of import class I medical devices, the filing entity shall submit the filing documents to China Food and Drug Administration.\n\n根据上述已知信息，请将'境内第一类医疗器械备案，备案人向设区的市级食品药品监督管理部门提交备案资料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To apply for filing of class I domestic medical devices, the filing entity shall submit the filing documents to the food and drug regulatory department of the city consisting of districts ."
    },
    {
        "instruction":"已知信息：\n'为贯彻落实《中华人民共和国疫苗管理法》规定，按照《关于药品信息化追溯体系建设的指导意见》（国药监药管〔2018〕35号）等文件要求，国家药监局组织制订了3项信息化标准：《药品追溯系统基本技术要求》《疫苗追溯基本数据集》《疫苗追溯数据交换基本技术要求》于2019年8月27日发布，自发布之日起实施。'可被翻译为：To implement the provisions of the Vaccine Administration Law of the People's Republic of China, per the Guiding Opinions on the Construction of Drug Informationization Traceability System (NMPA Department of Drug Supervision (2018) No. 35) and other documents, NMPA has organized the formulation of three Informationization Standards: the Basic Technical Requirements for Drug Traceability System, Basic Dataset for Vaccine Traceability, and Basic Technical Requirements for Vaccine Traceability Data Exchange, which were released on August 27, 2019, and effective as of the date of publication.\n'国家药监局发布《药品上市许可持有人和生产企业追溯基本数据集》等5个标准'可被翻译为：NMPA Released Five Informatization Standards Including the Basic Data Set for Traceability of Drug Marketing Authorization Holders and Manufacturers\n'筛选信息数据集'可被翻译为：Screening Information Dataset\n'桥接数据集'可被翻译为：bridging data package\n\n根据上述已知信息，请将'为贯彻落实《中华人民共和国药品管理法》的规定，按照《国家药品监督管理局关于药品信息溯源系统建设的指导意见》(国家药品监督管理局[2018]35号)等文件要求，国家药监局组织编制了《药品上市许可持有人和生产企业溯源基本数据集》。《药品经营企业可追溯性基本数据集》、《使用单位可追溯性基本数据集》、《消费者可追溯性药品基本数据集》、《药品可追溯性数据交换基本技术要求》于2020年3月11日发布，自发布之日起施行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To implement the provisions of the Drug Administration Law of the People's Republic of China, in accordance with the requirements of the Guiding Opinions of the China National Drug Administration on the Construction of Drug Information Traceability System (CNDA Department of Drug Supervision [2018] No. 35) and other documents, NMPA organized the formulation of the Basic Data Sets for Traceability of Drug Marketing Authorization Holders and Manufacturers, Basic Data Sets for Traceability of Drug Distributors, Basic Data Sets for Traceability of Drug Using Units, Basic Data Sets for Traceable Drugs for Consumers, and Basic Technical Requirements for Traceability Data Exchange of Drugs, which were issued on March 11, 2020, and effective as of the issuing date."
    },
    {
        "instruction":"已知信息：\n'第一百零五条 药品监督管理部门应当依照法律、法规的规定对药品研制活动进行监督检查，必要时可以对为药品研制提供产品或者服务的单位和个人进行延伸检查，有关单位和个人应当予以配合，不得拒绝和隐瞒。'可被翻译为：Article 105 Drug regulatory departments shall, in accordance with laws and regulations, supervise and inspect drug R&D activities and, when necessary, carry out extended inspection of entities and individuals providing products or services for drug R&D. Relevant entities and individuals shall provide cooperation and shall not refuse inspection or conceal information.\n'第九十九条 药品监督管理部门应当依照法律、法规的规定对药品研制、生产、经营和药品使用单位使用药品等活动进行监督检查，必要时可以对为药品研制、生产、经营、使用提供产品或者服务的单位和个人进行延伸检查，有关单位和个人应当予以配合，不得拒绝和隐瞒。'可被翻译为：Article 99 Drug regulatory departments shall, in accordance with the laws and regulations, supervise and inspect drug research and development, manufacturing, distribution, and use of drugs by institutions, and other activities, and where necessary, conduct extended inspection on institutions and individuals providing products or services for drug research and development, manufacture, distribution, and use. Relevant organizations and individuals shall cooperate and shall not refuse inspection or conceal information.\n'必要时，药品监督管理部门可以对为药品研制、生产、经营、使用提供产品或者服务的单位和个人进行延伸检查。'可被翻译为：When necessary, the drug regulatory department may conduct extended inspection over the units or individuals that provide products or services for the research and development, manufacturing, distribution, and use of drugs.\n'第四十六条 药品监督管理部门依照法律法规规定，对注册人、备案人的注册、备案相关活动进行监督检查，必要时可以对注册、备案活动涉及的单位进行延伸检查，有关单位和个人应当予以配合，不得拒绝检查和隐瞒有关情况。'可被翻译为：Article 46 The drug regulatory department shall supervise and inspect the activities of registration and filing conducted by the registrant and the filing person in accordance with the provisions of laws and regulations, and may conduct extended inspections of the entities involved when necessary. The relevant entities and individuals shall cooperate, and shall not refuse the inspection or conceal relevant information.\n\n根据上述已知信息，请将'药品监督管理部门应当加强对疫苗上市许可持有人的现场检查；必要时，可以对为疫苗研制、生产、流通等活动提供产品或者服务的单位和个人进行延伸检查；有关单位和个人应当予以配合，不得拒绝和隐瞒。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The drug regulatory departments shall strengthen the on-site inspection on vaccine MAHs. If necessary, regulatory departments may conduct extended inspections on entities or individuals who provide products or services for vaccine development, manufacture and distribution, and relevant entities and individuals shall cooperate and not reject the inspection or conceal any information."
    },
    {
        "instruction":"已知信息：\n'进口麻醉药品、精神药品,海关凭国家食品药品监督管理局核发的麻醉药品、精神药品《进口准许证》办理报关验放手续。'可被翻译为：To import narcotic drugs and psychotropic substances, the customs shall perform customs clearance on the basis of the Import License for narcotic drugs and psychotropic substances issued by the State Food and Drug Administration.\n'第六十六条 进口、出口麻醉药品和国家规定范围内的精神药品，应当持有国务院药品监督管理部门颁发的进口准许证、出口准许证。'可被翻译为：Article 66 Anyone who wishes to import or export narcotic drugs or psychotropic substances that fall within the scope specified by the State shall produce the Import License or Export License issued by the drug regulatory department under the State Council.\n'药品注册申请人应当按照《药品业务应用系统企业操作指南》（见附件）通过国家药品监督管理局网上办事大厅（https:\/\/zwfw.nmpa.gov.cn\/）完成用户注册及药品业务应用系统授权绑定操作，自2021年1月1日起可在网上办理药品注册业务。'可被翻译为：Applicants for drug registration shall complete user registration and authorization based binding of the drug business application system through the Online Service Hall of the NMPA (https:\/\/zwfw.nmpa.gov.cn\/) as per the Operation Guidelines for Enterprises on Pharmaceutical Related Application System. As of January 1, 2021, drug registration can be applied online.\n'第四十二条 进口麻醉药品、精神药品凭《进口药品注册证》（或者《医药产品注册证》），按照国务院麻醉药品、精神药品管理的有关法规办理《进口准许证》。'可被翻译为：Article 42 To import narcotic drugs and psychotropic substances, the importer shall, on the premise of obtaining the Import Drug License (or the Pharmaceutical Product License), apply for the Import License in accordance with the relevant regulations on the administration of narcotic drugs and psychotropic substances as specified by the State Council.\n\n根据上述已知信息，请将'为落实国务院常务会议关于进出口环节监管证件实现网上申报、网上办理的工作要求，国家药监局整合开发了药品业务应用系统，用于进出口环节药品监管证件业务办理，包括药品出口销售证明、出口欧盟原料药证明文件、麻醉药品和精神药品进出口准许证、首次进口药材等事项。该系统同时具备麻醉药品和精神药品研制立项、中药提取物备案的网上申请与办理功能。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to implement the requirements of the Executive meeting of The State Council on the implementation of online declaration and online processing of import and export regulatory documents, the State Food and Drug Administration has integrated and developed a drug business application system for the import and export process of drug regulatory documents. Including drug export sales certificates, export documents of EU raw material drugs, narcotics and psychotropic drugs import and export permits, first import of medicinal materials and other matters. The system also has the function of online application and management for the development of narcotic drugs and psychotropic drugs and the filing of traditional Chinese medicine extracts."
    },
    {
        "instruction":"已知信息：\n'关键质量属性（CQA）、关键工艺参数（CPP）和中控；'可被翻译为：critical quality attributes (CQAs), critical process parameters (CPPs) and in-process controls;\n'公用设施的设计、安装、确认、操作、维护和监测方式应确保该公用设施系统按预期运行。'可被翻译为：Utilities should be designed, installed, qualified, operated, maintained and monitored in a manner to ensure that the utility system functions as expected.\n'关键工艺参数——工艺参数，其变动对关键质量属性产生影响，因此应对其进行监测或控制，以确保该工艺生产出符合预期的产品质量。（Q8 R2）'可被翻译为：Critical Process Parameter – process parameter whose variability has an impact on a critical quality attribute and therefore should be monitored or controlled to assure the process produces the desired product quality. (Q8(R2))\n'所有VDC系统都应定期进行适当维护和重新确认(如前所述)。相关VDC系统(加热\/调温、水浴和循环管\/歧管、磁力搅拌\/搅拌、机械取样等)和VDC系统的其他部件应保持清洁，并对其运行进行评估，以确保每个扩散池能保持皮肤表面温度在目标范围内(32±1°)，保持搅拌速度在规定范围内。并支持在规定的测试方法范围内进行性能测试。'可被翻译为：All VDC systems should be properly maintained and requalified on a regular basis (as described previously). The relevant VDC systems (heating\/thermoregulation, water bath and circulation tubes\/manifolds, magnetic impeller\/stirring, mechanical sampling, etc.) and other components of the VDC system should be kept clean and their operation should be evaluated to ensure that each diffusion cell can maintain the skin surface temperature within the target range (32 ± 1°), maintain the stirring speed within the specified range, and support the performance of the test within the specifications of the test method.\n\n根据上述已知信息，请将'高风险公用设施的关键参数和关键质量属性的结果应定期进行趋势分析，以确保系统性能保持适当。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Results for critical parameters and critical quality attributes of high risk utilities should be subject to regular trend analysis to ensure that system capabilities remain appropriate."
    },
    {
        "instruction":"已知信息：\n'由于不同DNA链的断裂和连接而产生DNA片段的交换和重新组合，形成新DNA分子的过程。'可被翻译为：The process of the exchange and recombination of DNA fragments resulting from the breaking and joining of different DNA strands to form new DNA molecules.\n'编码于DNA或RNA（一些病毒）核昔酸序列中的可遗传的生物信息。'可被翻译为：The heritable biological information encoded in the nucleotide sequence of DNA or RNA (some viruses).\n'通常仅限于单个DNA碱基对的遗传密码改变。'可被翻译为：Changes in the genetic codes, usually confined to a single DNA base pair.\n'经脱氧核糖核酸(DNA)重组技术(基因工程技术)产生的新细胞或新个体。'可被翻译为：A new cell or individual produced by deoxyribonucleic acid (DNA) recombination technology (genetic engineering).\n\n根据上述已知信息，请将'除去并连接DNA、RNA或多肽链片段，形成新的遗传重组体或改变原有的遗传结构的过程。如DNA重组时的剪接过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process of removing and joining fragments of a DNA, RNA, or polypeptide chain to form a new genetic recombination or to alter the original genetic structure. The process of splicing, as in DNA recombination."
    },
    {
        "instruction":"已知信息：\n'一种用于软膏剂溶出研究的装置。'可被翻译为：The invention relates to an apparatus for studying the dissolution of ointment.\n'溶出介质'可被翻译为：dissolution media\n'溶出曲线'可被翻译为：dissolution profile\n'溶出速率'可被翻译为：dissolution rate\n\n根据上述已知信息，请将'用于度量两个药品溶出特性的方法。常用相似因子仪）表示。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A method for measuring the dissolution characteristics of two drugs. Commonly used similitude factor meter) representation."
    },
    {
        "instruction":"已知信息：\n'就本指南而言，无菌产品是指暴露于无菌条件下的一种或多种灭菌元件，并最终构成无菌原料药或无菌成品。这些要素包括成品药品的容器、瓶盖和组分。或者，通过终端灭菌过程实现无菌的产品。'可被翻译为：For the purpose of this guidance, sterile product refers to one or more of the sterilized elements exposed to aseptic conditions and, ultimately, making up the sterile active substance or finished sterile product. These elements include the containers, closures and components  of the finished drug product. Or, a product that is rendered sterile by a terminal sterilization process.\n'无菌检验应在无菌条件下进行。用于无菌检验的取样应代表整个批次，尤其应该特别包括该批次中被认为污染风险最大的部分样品，例如：'可被翻译为：The sterility test should be performed under aseptic conditions. Samples taken for sterility testing should be representative of the whole of the batch but should in particular include samples taken from parts of the batch considered to be most at risk of contamination, for example:\n'（四）性能确认应当证明厂房、设施、设备在正常操作方法和工艺条件下能够持续符合标准；'可被翻译为：4. Performance qualification is to verify that the premises, facilities and equipment, under normal operating procedures and process conditions, can consistently meet performance specifications;\n'对整个无菌制造过程的模拟，以验证工艺确保产品无菌的能力。APS包括与常规生产相关的所有无菌操作(例如，必要时，设备组装、配方、灌装、冻干和密封过程)'可被翻译为：A simulation of the entire aseptic manufacturing process in order to verify the capability of the process to ensure product sterility. APS includes all aseptic operations associated with routine manufacturing (for example, equipment assembly, formulation, filling, lyophilization and  sealing processes, as necessary)\n\n根据上述已知信息，请将'把整个制备过程控制在无菌条件下进行的一种操作方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A process in which the entire preparation process is controlled under sterile conditions."
    },
    {
        "instruction":"已知信息：\n'质量管理的一部分，着重于设定质量目标，并详细规定必要的操作程序和相关资源以实 现质量目标。(ISO 9000:2005)'可被翻译为：Part of quality management focused on setting quality objectives and specifying necessary operational processes and related resources to fulfil the quality objectives. (ISO 9000:2005)\n'质量规划：质量管理的一部分，主要是设置质量目标和指定必要的操作流程和相关的资源以达成质量目标'可被翻译为：quality planning. Part of quality management, focused on setting quality objectives and specifying necessary operational processes and related resources to fulfil the quality objectives.\n'质量目标'可被翻译为：quality objectives\n'实现质量方针和确保质量目标系统的全方面的总和。（ICH Q10）'可被翻译为：The sum of all aspects of a system that implements quality policy and ensures that quality objectives are met. (ICH Q10)\n\n根据上述已知信息，请将'1.质量管理的一部分侧重于设定质量目标，规定必要的操作过程和相关资源以实现质量目标。\n2.作为质量管理的一部分，质量策划需要设定质量目标，并规定实现质量目标所需的操作过程和相关资源。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.Part of quality management focused on setting quality objectives and specifying necessary operational processes and related resources to fulfil the quality objectives.\n2.Part of quality management, quality planning entails setting quality objectives and specifying necessary operational processes and related resources to fulﬁl the quality objectives."
    },
    {
        "instruction":"已知信息：\n'下表是技术转移通常所需文件举例'可被翻译为：The table below provides an example of documentation commonly required for the transfer of technology.\n'注：这些仅为举例。所需文件应根据不同任务具体识别。'可被翻译为：*Note: These are examples. All the required documents should be identified for the different tasks.\n'技术转移工作有文件记录安排。'可被翻译为：arrangements are made for the documented technology transfer.\n'技术转移：控制工艺及其文件和专业知识进行转移的逻辑程序。技术转移可涉及开发、生产和\/或检测场所。'可被翻译为：transfer of technology. A logical procedure that controls the transfer of any process, together with its documentation and professional expertise. Technology transfers may involve development, manufacture and\/or testing sites.\n\n根据上述已知信息，请将'技术转移通常所需文件举例'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Example of documentation commonly required for the transfer of technology*"
    },
    {
        "instruction":"已知信息：\n'醛糖还原酶抑制药'可被翻译为：aldose reductase inhibitors\n'醛糖的伯醇基被氧化为竣基的产物。'可被翻译为：A product in which the primary alcohol group of an aldose is oxidized to a carboxyl group.\n'减轻咳嗽症状而止咳的药物。中枢性镇咳药，使用受到限制，如可待因、右美沙芬、喷托维林等；和外周性镇咳药，如甘草制剂、那可汀等。'可被翻译为：A cough suppressant that relieves the symptoms of cough. Central antitussive drugs whose use is restricted, such as codeine, dextromethorphan, pentoverine, etc.; And peripheral antitussive drugs, such as licorice preparations, narcotin, etc.\n'醛糖'可被翻译为：aldose\n\n根据上述已知信息，请将'能抑制醛糖还原酶，阻止体内葡萄糖转化为山梨醇积聚而引发的糖尿病性外周神经病症状的一药物。如依帕司他。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A drug that inhibits aldose reductase and prevents the conversion of glucose in the body to the accumulation of sorbitol in diabetic peripheral neuropathy symptoms. Such as epalrestat."
    },
    {
        "instruction":"已知信息：\n'一种通过选择3个合适的波长，经过计算消除共存组分的分光光度法。'可被翻译为：A spectrophotometric method for calculating the elimination of coexisting components by selecting three suitable wavelengths.\n'一种利用多组分样品中各组分的色谱峰面积占总峰面积的百分比进行色谱定量的方法。通常仅用于有关物质检查。'可被翻译为：The method uses the percentage of the chromatographic peak area of each component in the total peak area of a multi-component sample for chromatographic quantification. Usually used only for the examination of the substance in question.\n'用以分离组分挥发度相近的混合液的一种特殊蒸僧方法。它是向被分离的混合液中加入一种特定的较易挥发的第三组分，此第三组分与被分离的混合液中的一个或几个组分形成低共沸点的共沸溶液，从而增大被分离混合液中各组分的挥发度差异，使之易于分离。'可被翻译为：A special steaming method is used to separate the mixed liquid with similar volatile components. It is to be separated into the mixed liquid to add a specific more volatile third component, the third component and be separated in the mixed liquid to form a low azeotrope point of one or several components, so as to increase the volatile difference of the components in the mixed liquid to be separated, so that it is easy to separate.\n'用于同时测定多组分混合物的一种方法。当组分A和B的吸收曲线有一等吸收点时,利用此等吸收点所处的波长进行测定，可简化结果处理。'可被翻译为：A method for simultaneous determination of multicomponent mixtures. When the absorption curves of components A and B have first order absorption points, the determination using the wavelength at which these absorption points are located simplifies the processing of the results.\n\n根据上述已知信息，请将'两种以上组分共存时，根据各组分吸收光谱相互重叠的程度分别考虑建立的光谱分析方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When more than two kinds of components coexist, the spectral analysis method is respectively considered according to the degree of overlap of the absorption spectra of each component."
    },
    {
        "instruction":"已知信息：\n'证明当局是否对该药品的实际生产企业进行定期检查'可被翻译为：Does the certifying authority arrange for periodic inspections of the manufacturing plant in which the dosage form is produced\n'证明当局'可被翻译为：Certifying authority\n'第二十条 医疗器械临床评价是指申请人或者备案人通过临床文献资料、临床经验数据、临床试验等信息对产品是否满足使用要求或者适用范围进行确认的过程。'可被翻译为：Article 20 Clinical evaluation of medical devices refers to the process that the applicant or filing entity validates whether the products under registration can meet their intended use and indications based on the information of clinical literature, clinical experience data and clinical trials.\n'第二十八条 体外诊断试剂临床评价是指申请人或者备案人通过临床文献资料、临床经验数据、临床试验等信息对产品是否满足使用要求或者预期用途进行确认的过程。'可被翻译为：Article 28 Clinical evaluation of in-vitro diagnostic reagents refers to the process that the applicant or filing entity validates whether the products under registration can meet their intended use and indications based on the information of clinical literature, clinical experience data and clinical trials.\n\n根据上述已知信息，请将'申请人所提供的信息是否满足证明当局的要求'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product"
    },
    {
        "instruction":"已知信息：\n'是指出现在治疗期间的、但在治疗前未曾发生或比治疗\n前明显恶化的事件。'可被翻译为：An event that emerges during treatment having been absent pre-treatment, or worsens relative to the pre-treatment state.\n'药品治疗过程所发生的任何不良的医疗卫生事件。而这种事件不一定与药品治疗有因果关系。包\n括两个要素：一是不良事件的发生是由上市药品或药品临床试验期间引起的相关事件；二是产生的结\n果对人体有害。按照事件产生成因，分类为药品标准缺陷、药品质量问题、药品不良反应、用药错误\n以及药品滥用等事件。'可被翻译为：Any adverse medical occurrence during the course of drug therapy, regardless of causality with the treatment. It includes two elements: firstly, the occurrence of the adverse event is related to the marketed drug or during clinical trials; secondly, the result is harmful to the human body. Based on the cause of the event, it is classified into events such as drug standard defects, drug quality issues, adverse drug reactions, medication errors, and drug abuse.\n'第七十条 研究者负责作出与临床试验相关的医疗决定，在发生与临床试验相关的不良事件时，临床试验机构和研究者应当保证为受试者提供足够、及时的治疗和处理。当受试者出现并发疾病需要治疗和处理时，研究者应当及时告知受试者。'可被翻译为：Article 70 The investigator is responsible for making medical decisions related to the clinical trial. When any adverse event related to the clinical trial occurs, the clinical trial institution and the investigator shall ensure that the subjects are in a timely manner provided with adequate treatment and solution. When the subjects develop complications which require treatment, the investigator shall promptly inform the subjects of the situation.\n'治疗引发事件'可被翻译为：treatment emergent\n\n根据上述已知信息，请将'根据所有治疗中的潜在发生情况，对受试者进行的分类。以两种治疗为例 ，针对特定的，有四个主层：任一治疗期间均不会发生事件的受试者，在 A 治疗期间会发生事件但在 B 治疗期间不会发生事件的受试者，在 B 治疗期间会发生事件但在 A 治疗期间不会发生事件的受试者，以及在两种治疗期间均会发生事件的受试者。在本文件中，主层是指主分层定义的任何分层（或分层组合）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Classification of subjects according to the potential occurrence of an intercurrent event on all treatments. With two treatments, there are four principal strata with respect to a given intercurrent event: subjects who would not experience the event on either treatment, subjects who would experience the event on treatment A but not B, subjects who would experience the event on treatment B but not A, and subjects who would experience the event on both treatments. In this document a principal stratum refers to any of the strata (or combination of strata) defined by principal stratification."
    },
    {
        "instruction":"已知信息：\n'第五条 国家药品监督管理局负责特殊化妆品、进口普通化妆品、化妆品新原料的注册和备案管理，并指导监督省、自治区、直辖市药品监督管理部门承担的化妆品备案相关工作。国家药品监督管理局可以委托具备相应能力的省、自治区、直辖市药品监督管理部门实施进口普通化妆品备案管理工作。'可被翻译为：Article 5 The National Medical Products Administration (NMPA) is responsible for the registration and filing administration of special cosmetics, imported general cosmetics and new cosmetic ingredients, and guiding and supervising the related cosmetic filing work undertaken by the drug regulatory departments of provinces, autonomous regions, and municipalities. The NMPA may entrust the drug regulatory departments of provinces, autonomous regions, and municipalities directly under the Central Government that have corresponding capabilities to implement the filing administration of imported general cosmetics.\n'国家药品监督管理局化妆品技术审评机构（以下简称技术审评机构）负责特殊化妆品、化妆品新原料注册的技术审评工作，进口普通化妆品、化妆品新原料备案后的资料技术核查工作，以及化妆品新原料使用和安全情况报告的评估工作。'可被翻译为：The cosmetic technical assessment agency of the NMPA (hereinafter referred to as the technical assessment agency) is responsible for the technical assessment of the registration of special cosmetics and new cosmetic ingredients, the technical verification of imported general cosmetics and the new cosmetic ingredients after filing, and the evaluation of the use and safety reports of new cosmetic ingredients.\n'国家药品监督管理局负责制定化妆品生产许可证式样。省、自治区、直辖市药品监督管理部门负责化妆品生产许可证的印制、发放等管理工作。'可被翻译为：The NMPA shall be responsible for making template of the Cosmetics Manufacturing License. The drug regulatory department of the province, autonomous region or municipality directly under the central government shall be responsible for printing, issuing and other management work of the cosmetics manufacturing license.\n'第六条 省、自治区、直辖市药品监督管理部门负责本行政区域内以下药品注册相关管理工作：'可被翻译为：Article 6 The drug regulatory departments of the provinces, autonomous regions, and municipalities directly under the Central Government are responsible for the following administrative tasks pertaining to drug registration within their respective administrative regions:\n\n根据上述已知信息，请将'第六条 省、自治区、直辖市药品监督管理部门负责本行政区域内国产普通化妆品备案管理工作，在委托范围内以国家药品监督管理局的名义实施进口普通化妆品备案管理工作，并协助开展特殊化妆品注册现场核查等工作。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 6 The drug regulatory departments of provinces, autonomous regions and municipalities are responsible for the filing administration of domestic general cosmetics within their administrative areas, implementing the filing administration of imported general cosmetics in the name of the NMPA within the scope of entrustment, and assisting in the on-site inspection for registration of special cosmetics etc."
    },
    {
        "instruction":"已知信息：\n'为一组蛋白酶，使纤溶酶原激活生成有活性的纤溶酶。包括：①组织纤溶酶激动剂，如阿替普酶（tPA）等；②尿激酶：③链激酶。'可被翻译为：For a group of proteases, plasminogen is activated to produce an active plasminase. It includes: ① tissue plasminase agonists, such as Alteplase (tPA); ② urokinase: ③ streptokinase.\n'可与血管紧张素转化酶结合，抑制其活性的抗高血压药物。如卡托普利、依那普利、赖诺普利、福辛普利、雷米普利、苯那普利等。'可被翻译为：Antihypertensive drugs that can bind to angiotensin converting enzyme and inhibit its activity. Such as captopril, enalapril, Lisinopril, Fosinopril, Ramipril, Benazepril, etc.\n'竞争组胺受体，阻滞组胺所引起过敏反应的药物。有组胺H1阻滞剂，如苯海拉明、异丙嗪、西替利嗪等；H2受体阻滞剂，如西咪替丁。'可被翻译为：A drug that competes with histamine receptors and blocks allergic reactions caused by histamine. There are histamine H1 blockers such as diphenhydramine, promethazine, cetirizine, etc.; And H2 blockers such as cimetidine.\n'血液凝固过程中与纤维蛋白溶解有关的物质的统称。包括纤维蛋白溶解酶（简称纤溶酶）、纤溶酶的激活物与抑制物3个组成部分。'可被翻译为：Any of various substances associated with fibrinolysis during blood clotting. It consists of three components: fibrinolytic enzyme (plasminase for short), activator and inhibitor of plasminase.\n\n根据上述已知信息，请将'可使血管中血栓纤维蛋白凝块溶解、恢复血供的药物。如阿替普酶、尿激酶、链激酶、瑞替普酶、拉诺替普酶等。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"It can dissolve thrombus fibrin clot in blood vessels and restore blood supply. Such as alteplase, urokinase, streptokinase, Reteplase, Lanoteplase, etc."
    },
    {
        "instruction":"已知信息：\n'包装操作的转移应该遵守与产品工艺相同的程序原则。'可被翻译为：12.25. The transfer of packaging operations should follow the same procedural principles as those of the product processing.\n'RU应该完成以下任务：'可被翻译为：12.24. The RU should address the following tasks:\n'在转移过程中，RU应该找出设施、系统和能力方面的所有差异，并与SU进行讨论。SU应该与RU合作，了解潜在影响，并圆满解决这些问题，从而确保产品质量一致。基于从SU处收到的信息，RU应该考虑其自己生产和包装该产品达到所需标准的能力，应在开始常规生产之前建立相关的现场操作程序和文件。'可被翻译为：12.23. During the transfer process, the RU should identify any differences in facilities, systems and capabilities and discuss these with the SU. The SU should cooperate with the RU to understand the potential impact and satisfactorily address this in order to assure equivalent product quality. based on the information received from the SU, the RU should consider its own capability to manufacture and pack the product to the required standards and should develop the relevant site operating procedures and documentation before the start of routine production.\n'RU应向RU提供所有工艺开发历史信息，这些信息可让RU在成功转移之后进行进一步开发和\/或工艺优化。'可被翻译为：12.17. The SU should provide any information on the history of process development which may be required to enable the RU to perform any further development and or process optimization after successful transfer.\n\n根据上述已知信息，请将'RU应该确定是否需要对包装工艺进行确认和验证。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"12.26. RU should determine the need for qualification and validation for the packaging process."
    },
    {
        "instruction":"已知信息：\n'又称\"碳水化合物”。多羟基醛、多羟基酮以及能水解而生成多羟基醛或多羟基酮的有机化合物。由碳、氢、氧三种元素组成的一类化合物，其中氢和氧的比例与水分子中氢和氧的比例相同。'可被翻译为：Also known as \"carbohydrate\". Polyhydroxy aldehydes, polyhydroxy ketones, and organic compounds capable of hydrolysis to produce polyhydroxy aldehydes or polyhydroxy ketones. A class of compounds consisting of three elements, carbon, hydrogen, and oxygen, in which the ratio of hydrogen to oxygen is the same as in the water molecule.\n'链霉素的特征反应。链霉素在碱性溶液中，链霉糖经分子重排步骤生成麦芽酚（a-甲基干羟基T毗喃酮），麦芽酚与高铁离子在微酸性溶液中形成紫红色配位化合物。这一反应用于链霉素的鉴别。'可被翻译为：Characteristic reaction of streptomycin. Streptomycin In an alkaline solution, streptomycin underwent a molecular rearrangement step to form maltol (A-methyl dry hydroxyl T pyrone), maltol and high iron ions in a slightly acidic solution to form a purplish red coordination compound. This reaction is used in the identification of streptomycin.\n'含有a-甲基的醛酮在碱溶液中遇碘，生成不溶于水的碘仿的反应。用于鉴别醛酮与醇等化合物。'可被翻译为：a reaction in which an aldehyde-ketone containing A-methyl meets iodine in a base solution to form an insoluble iodoform in water. Used to distinguish aldehydes from alcohols and other compounds.\n'结合物是指一个活性成分(如多肽、碳水化合物等) 通过共价键或非共价键与载体(如蛋白质、多肽、无机盐等)连接，以增强制品的效力或稳定性。'可被翻译为：A conjugated product is made up of an active ingredient (for example, peptide, carbohydrate) bound covalently or noncovalently to a carrier (for example, protein, peptide, inorganic mineral) with the objective of improving the efficacy or stability of the product.\n\n根据上述已知信息，请将'药物与含有多羟基化合物载体（如聚乙烯毗咯烷酮（PVP）等）以恰当比例形成的非结晶性无定型物。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An amorphous substance formed in appropriate proportions with a carrier containing polyhydroxyl compounds, such as polyvinylpirolidone (PVP)."
    },
    {
        "instruction":"已知信息：\n'第三十二条 药品监督管理部门可以采取暂停生产、销售、使用或者召回药品等控制措施。卫生行政部门应当采取措施积极组织救治患者。'可被翻译为：Article 32 Drug regulatory departments may take such control measures as suspension of production, sales and use or recall of drugs. Health administrative departments shall take active measures to organize treatment of patients.\n'第九条  省、自治区、直辖市药品监督管理部门负责本行政区域内医疗器械不良事件监测和再评价的监督管理工作，会同同级卫生行政部门和相关部门组织开展本行政区域内发生的群体医疗器械不良事件的调查和处理，依法采取紧急控制措施。'可被翻译为：Article 9 The drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall be responsible for the supervision and administration of medical device adverse event monitoring and re-evaluation within their respective administrative regions, organize the investigation and handling of group adverse events of medical device that occurs within their respective administrative regions jointly with the health administrative departments at the same level and relevant authorities, and take emergency control measures according to law.\n'（五）组织检查本行政区域内药品生产、经营企业的药品不良反应报告和监测工作的开展情况，并与同级卫生行政部门联合组织检查本行政区域内医疗机构的药品不良反应报告和监测工作的开展情况；'可被翻译为：(V)  Organize inspection of ADR reporting and monitoring carried out by drug manufacturers and distributors within their administrative regions; jointly with the health administrative departments at the same level, organize inspection of ADR reporting and monitoring carried out by medical institutions within their administrative regions.\n'第三十四条  省、自治区、直辖市药品监督管理部门在获知本行政区域内发生的群体医疗器械不良事件后，应当会同同级卫生行政部门及时开展现场调查，相关省、自治区、直辖市药品监督管理部门应当配合。调查、评价和处理结果应当及时报国家药品监督管理局和国务院卫生行政部门，抄送持有人所在地省、自治区、直辖市药品监督管理部门。'可被翻译为：Article 34 After knowing the group adverse events of medical device that occurs within their respective administrative regions, the drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall promptly carry out on-site investigation jointly with the health administrative departments at the same level, and the drug regulatory departments of relevant provinces, autonomous regions and municipalities directly under the central government shall cooperate. Investigation, re-evaluation and handling results shall be promptly reported to the NMPA and the Health Administrative Department of the State Council, and copied to local drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government where MAHs locate.\n\n根据上述已知信息，请将'同级卫生行政部门应当在本行政区域内暂停医疗机构使用相关医疗器械，采取措施积极组织救治患者。相关持有人应当予以配合。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The health administrative departments at the same level shall suspend the use of relevant medical devices in the medical institutions within their respective administrative regions and take measures to actively organize the treatment for patients. The relevant MAHs shall be cooperative."
    },
    {
        "instruction":"已知信息：\n'（二）协助注册人、备案人开展化妆品不良反应监测、化妆品新原料安全监测与报告工作；'可被翻译为：(2) Assisting the registrants and filing persons in carrying out cosmetic adverse reaction monitoring, safety monitoring and reporting of new cosmetic ingredients;\n'第二十三条 使用化妆品新原料生产化妆品的化妆品注册人、备案人，应当及时向化妆品新原料注册人、备案人反馈化妆品新原料的使用和安全情况。'可被翻译为：Article 23 The registrant and filing person of cosmetics who use new cosmetic ingredients to produce cosmetics shall give prompt feedback on the use and safety of the new cosmetic ingredients to the registrant and filing person of new cosmetic ingredients.\n'（一）以注册人、备案人的名义，办理化妆品、化妆品新原料注册、备案；'可被翻译为：(1) In the name of the registrants and filing persons, handling the registration and filing of cosmetics and new cosmetic ingredients;\n'化妆品注册人、备案人使用化妆品新原料生产化妆品的，相关化妆品申请注册、办理备案时应当通过信息服务平台经化妆品新原料注册人、备案人关联确认。'可被翻译为：If cosmetic registrants and filing persons use new cosmetic ingredients to produce cosmetics, the relevant cosmetic registration application and filing shall be associated and confirmed by the registrant or filing person of the new cosmetic ingredient through the information service platform.\n\n根据上述已知信息，请将'（三）协助注册人、备案人实施化妆品、化妆品新原料召回工作；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) Assisting the registrants and filing persons in implementing the recall of cosmetics and new cosmetic ingredients;"
    },
    {
        "instruction":"已知信息：\n'每个容器接种一个准备好的标准化接种菌并混合。所用混悬液接种菌的体积为产品体积的0.5% 到1.0%。加入1，2和3类产品的测试微生物浓度使得接种后立即测试的制备物浓度在每毫升产 品含1105至1106 CFU之间。加入4类产品（抗酸性产品）的最终测试微生物浓度在每毫升 产品含1103至1104CFU之间。'可被翻译为：of the prepared and standardized inoculums and mix. The volume of the suspension inoculums used is 0.5% to 1.0% of the volume of the product. The concentration of the test organisms added to the product for Categories 1, 2 and 3 is such that concentration of the test preparation immediately after inoculation is between 1x105 and 1x106 colony forming organisms (CFU) per mL of product. For category 4 products (antacids) the final concentration of the test organisms is between 1x103 and 1x104 CFU\/mL of product.\n'接种物浓度的估计值可以通过挑战微生物的比浊法获得，然后通过平板计数确认。'可被翻译为：The estimate of inoculum concentration may be obtained by turbidimetric procedures for the challenge microorganisms and later confirmed by plate count.\n'为了确定微生物平板计数（CFU）必须大于等于（≥）微生物接种菌计算值的50%，应使用准备 用于分析产品的方法（倾注平板法或平板涂布法）制作用于促菌生长能力试验的固体培养基。'可被翻译为：Solid media tested for growth promotion is to be set up using the method that will be used to analyze the product (pour plate or spread plate) to determine a microbial plate count (CFU) which must be ≥ 50% of the microorganism inoculum’s calculated value.\n'通过用无菌盐水洗涤生长物来收获培养物，以获得约 1x108 CFU\/mL 的微生物（参见微生物 计数测试 和特定微生物测试 ）。对于 A. 巴西曲霉 ATCC 16404 培养，使用含有 0.05% 聚山梨醇酯 80 的无菌盐水。'可被翻译为：Harvest the cultures by washing the growth with sterile saline to obtain a microbial count of about 1x108 CFU\/mL (see Microbial Enumeration Tests and Tests for Specified Microorganisms ). For the A. brasiliensis ATCC 16404 culture, use sterile saline containing 0.05% polysorbate 80.\n\n根据上述已知信息，请将'立即测定每个接种混悬液中活菌的浓度，并通过平板计数法计算CFU\/mL的初始浓度（参见微 生物计数测试和特定微生物测试）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Immediately determine the concentration of viable organisms in each inoculum suspension and calculate the initial concentration of CFU\/mL by the plate count method (see Microbial Enumeration Tests )."
    },
    {
        "instruction":"已知信息：\n'IVRT灵敏度是检测释放速率变化的能力，其中，释放速率为配方制剂中药物浓度的函数。如果在相同的日期，对RS、较高规格和较低规格的配方制剂进行平行研究，相对于RS，较高规格或较低规格的配方制剂能分别呈现出较高或较低释放速率，则认为IVRT方法是灵敏的。'可被翻译为：IVRT sensitivity is the ability to detect changes in the release rate, as a function of drug concentration in the formulation. If the IVRT method consistently identifies higher or lower rates of release for test formulations with increased or decreased drug concentrations, respectively, relative to the formulation at the nominal strength of the RS run in parallel on the same day, the IVRT method would generally be considered sensitive.\n'采用USP<1724>中描述的统计学方法对释放速率之间的不等效性进行评估。具体来说，将对照标示规格配方制剂与具有相同规格、不同配方制剂的各6杯释放速率，按USP<1724>中描述的统计学方法进行比较。所有12杯应在同一天平行运行，具有相同规格、不同配方制剂的释放速率应与对照标示规格配方制剂的释放速率不等效。'可被翻译为：Determination of inequivalence between release rates should be evaluated using the statistical approach described in USP General Chapter<1724>. Specifically, the release rates from 6 cells dosed with the nominal reference strength formulation should be compared with the release rates from 6 cells dosed with an altered formulation, also at the nominal reference strength, using the statistical approach described in USP General Chapter<1724>. All 12 cells being compared should have been run in parallel on the same day, and the release rate from the altered formulation at the same nominal reference strength should fail to show equivalence to the release rate from the nominal reference strength formulation.\n'因此，不同规格产品释放率的比例线性可能受到不同规格配方差异的影响，而这些差异与IVRT方法的比例响应性无关。因配方差异与IVRT方法无关，且考虑到IVRT方法对释放速率差异的响应可能不是完全成比例的，因此，要求配方浓度与IVRT平均释放率（斜率）相关性的最小r2值≥0.95。'可被翻译为：Thus, the proportional linearity of release rates across different strengths of the product may be impacted by formulation differences across the strengths that are independent of the proportional responsiveness of the IVRT method. The minimum r2 value ≥ 0.95 for the correlation of the formulation concentration to the average IVRT release rate (slope) takes into account that the IVRT method’s response to differences in release rates may not appear to be perfectly proportional because of formulation differences that are independent of the IVRT method.\n'具体来说，将对照标示规格制剂（即100%规格）和150%规格配方制剂各6杯的释放速率，按USP<1724>中描述的统计学方法进行比较。所有12杯应在同一天平行运行，150%规格配方制剂的释放速率应与对照制剂的释放速率不等效。'可被翻译为：Specifically, the release rates from six cells dosed with the nominal reference strength formulation should be compared with the release rates from 6 cells dosed with the formulation at 150% the nominal reference strength, using the statistical approach described in USP General Chapter<1724>. All 12 cells being compared should have been run in parallel on the same day, and the release rate from the formulation at 150% the nominal reference strength should fail to show equivalence to the release rate from the nominal reference strength formulation.\n\n根据上述已知信息，请将'IVRT专属性是不同规格制剂产品释放速率变换比例的函数，其中一些或可能所有配方制剂均是小批量实验室批次，每种规格的配方成分略有不同，以适应不同规格产品中活性成分的不同含量。这种不同规格制剂产品配方的轻微变化可能影响不同规格制剂产品释放速率的理想变化比例。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"IVRT specificity is a function of the proportionality of release rates across different strengths of the product, some, or all of which may be formulated as small-scale laboratory batches, with each strength having a slightly different formulation composition to accommodate for the different amount of the active ingredient in that strength of the product. These slight formulation differences across the different strengths of the product may impact the ideal proportionality of release rates across the different strengths of the product."
    },
    {
        "instruction":"已知信息：\n'预先确定每种抗生素的中值标准品（【S3】）的吸光度。参考USP<81>中测试参数 和可接受数据要求'可被翻译为：Absorbance values of the media reference standard ([S3]) are predetermined per antibiotic. Refer USP<81> for testing parameters and acceptable data requirements.\n'浊度法还要求，每条标准曲线的测定百分比系数（%R2）应 NLT90%（即相关系数NLT0.950），且中值对照品【S3】的吸光度值要根据不同抗生素分别预先确定。参见USP<81>中检测参数和可接受数据要求。'可被翻译为：The Tube Method further states: The percentage coefficient of determinations (%R2) for each \nstandard curve will be NLT 90% (i.e. correlation coefficient of NLT 0.950) and\n2) Absorbance values of the media reference standard [S3] are predetermined per antibiotic. \nRefer USP <81> for testing parameters and acceptable data requirements.\n'USP<81>要求管碟法和浊度法符合以下标准：（1）测试抗生素【U3】的计算效价必须为中值标准品【S3】的 80-125%，（2）所有测量数据和计算数据的相对标准偏差 NMT 10%，且（3）进行三次独立检测，每次测试一式三份样品。管碟法还要求：（1）每条标准曲线的测试百分比系数（%R2）NLT 95%（即相关系数 NLT 0.9750），且（2）所有中值标准品（S3）的 ZOI 应在 14-16mm。参见 USP<81>中检测参数和可接受数据要求。'可被翻译为：USP <81> states the following criteria for both the Plate and Tube Methods: 1) The calculated \npotency of the test antibiotic [U3] must be 80% to 125% of the median reference standard [S3] \n2) Relative standard deviation for all measured and calculated data is NMT 10% and 3) Testing \nis performed in triplicate over a period of three independent test runs. The Plate Method further \nstates: 1) The percentage coefficient of determinations (%R2) for each standard curve will be \nNLT 95% (i.e. correlation coefficient of NLT 0.9750) and 2) ZOIs for all media reference standard (S3 will measure between 14-16 mm). Refer to USP <81> for testing parameters and acceptable data requirements.\n'USP<81> 【抗生素微生物含量】是人用抗生素效价测定的基本生物含量参考资料。在测 定之前，应查阅USP<81>和相应的药物各论中的检测要求、可接受标准和适用性。 USP<81>中列出了需要检测微生物效价的具体人用抗生素，该清单可能会随时间变化。 所有USP<81>中未列出的其它人用抗生素一般采用CFR 21节300-499或USP HPLC方 法检测。最后，兽用抗生素一般采用JOAC、AOAC、实验写到信息公告（LIBS）和\/或 生产商的方法进行化学方法测定。'可被翻译为：USP<81> Antibiotics- Microbial Assays, is the primary reference for bioassay of human antibiotic potency testing. Prior to testing, the current USP<81> and respective drug monograph should be reviewed for testing requirements, acceptance criteria and applicability. USP<81> lists specific human antibiotics to be tested for microbial potency; this list can change at any time. All other human antibiotics not listed in USP<81> are typically tested using CFR 21 Parts 300-499 or USP HPLC methods. Lastly, animal antibiotics are typically tested using chemistry methods as published in JOAC, AOAC, Laboratory Information Bulletins (LIBs) and\/or manufacturer’s methodology.\n\n根据上述已知信息，请将'预先测定培养基对照标准（【S3】）的单位抗生素吸光度值。参见 USP<81>中检测\n参数和可接受的数据要求'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2. Absorbance values of the media reference standard ([S3]) are predetermined per antibiotic. \nRefer USP <81> for testing parameters and acceptable data requirements."
    },
    {
        "instruction":"已知信息：\n'（七）禁忌症、注意事项、警示以及提示的内容；'可被翻译为：(7) Contraindications, precautions, warnings and suggestive descriptions.\n'分析测试报告通常包括对所采用的测试程序的描述、分析结果、讨论、结论和\/或对一个或多个的建议'可被翻译为：An analytical test report usually includes a description of the test procedure(s) employed, results of the analysis, discussion and conclusions and\/or recommendations for one or more\n'8.取样注意事项，包括为降低取样过程产生的各种风险所采取的预防措施，尤其是无菌或有害物料的取样以及防止取样过程中污染和交叉污染的注意事项；'可被翻译为：8) Precautions of sampling, including preventive measures taken to minimize risks in sampling process, especially for sterile materials or hazardous materials, and precautions to prevent contamination and cross-contamination in the sampling process;\n'第二十五条 临床试验审批是指国家食品药品监督管理总局根据申请人的申请，对拟开展临床试验的医疗器械的风险程度、临床试验方案、临床受益与风险对比分析报告等进行综合分析，以决定是否同意开展临床试验的过程。'可被翻译为：Article 25 The examination and approval of a clinical trial is a process that China Food and Drug Administration conducts a comprehensive analysis to the degree of risk the device may entail, clinical trial protocol, comparative analysis report on clinical benefit and risk of the device to be put on clinical trial, to determine whether to approve the clinical trial.\n\n根据上述已知信息，请将'（十五）临床试验结果分析、讨论，尤其是适应症、适用范围、禁忌症和注意事项；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(15) Analysis and discussion of clinical trial results, in particular, indications, scope of application, contraindications and precautions;"
    },
    {
        "instruction":"已知信息：\n'医疗器械说明书和标签中的文字、符号、表格、数字、图形等应当准确、清晰、规范。'可被翻译为：Words, symbols, tables, figures and graphics in the instructions and labels of medical devices shall be accurate, clear and standardized.\n'第七条 药品说明书和标签应当使用国家语言文字工作委员会公布的规范化汉字，增加其他文字对照的，应当以汉字表述为准。'可被翻译为：Article 7    Drug insert sheets and labels shall be written in standardized Chinese characters published by the National Language Commission. The versions in other languages shall comply with the Chinese version.\n'药品说明书和标签中的表述应当科学、规范、准确，文字应当清晰易辨，不得以粘贴、剪切、涂改等方式进行修改或者补充。'可被翻译为：The descriptions in drug package inserts and labels shall be scientific, standardized and accurate; texts shall be clear and legible. Any modification or supplement by means of pasting, cutting, or erasing made to the package inserts and labels is not allowed.\n'第五条 药品说明书和标签的文字表述应当科学、规范、准确。非处方药说明书还应当使用容易理解的文字表述，以便患者自行判断、选择和使用。'可被翻译为：Article 5    The wording in drug insert sheets and labels shall be scientific, standardized and accurate. The insert sheet of a non-prescription drug shall be written intelligibly and convenient for patients to judge, choose and use the drug on their own.\n\n根据上述已知信息，请将'（一）文字、符号、数字的字号不规范，或者出现多字、漏字、错别字、非规范汉字的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) the font size of characters, symbols, and numbers is not standardized, or there are multiple characters, missing characters, wrongly written characters, and non-standard Chinese characters;"
    },
    {
        "instruction":"已知信息：\n'一种应用天然蛋白质阵列分析技术进行结构测定的蛋白质组学学科。'可被翻译为：A discipline of proteomics that uses natural protein array analysis techniques for structural determination.\n'光电二极管阵列检测器'可被翻译为：photodiode array detector\n'根据不同的蛋白质在硫酸校溶液中具有不同的溶解度而进行的蛋白质分离技术。用于酶、蛋白质的分离纯化。'可被翻译为：The technique of protein separation according to the different solubility of different proteins in sulfuric acid calibration solutions. Used for the separation and purification of enzymes and proteins.\n'蛋白质沉降分析'可被翻译为：sedimentation analysis of protein\n\n根据上述已知信息，请将'高密度的蛋白质阵列，是蛋白质阵列的发展。在几平方厘米的面积中可以包含几万个不同的蛋白质点，可用于大规模的分析。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"High-density protein arrays are the development of protein arrays. Tens of thousands of different protein spots can be contained in an area of a few square centimeters, which can be used for large-scale analysis."
    },
    {
        "instruction":"已知信息：\n'4.对于涉及微生物限度、无菌等项目的规范，为避免样品污染，还应提供用于该检验的独立包装样品。'可被翻译为：4.For specifications involving microbial limits, sterility and other test items, to avoid sample contamination, the individually packaged samples for this test shall also be provided.\n'无菌检验应在无菌条件下进行。用于无菌检验的取样应代表整个批次，尤其应该特别包括该批次中被认为污染风险最大的部分样品，例如：'可被翻译为：The sterility test should be performed under aseptic conditions. Samples taken for sterility testing should be representative of the whole of the batch but should in particular include samples taken from parts of the batch considered to be most at risk of contamination, for example:\n'第五十一条 药品注册检验，包括标准复核和样品检验。标准复核，是指对申请人申报药品标准中设定项目的科学性、检验方法的可行性、质控指标的合理性等进行的实验室评估。样品检验，是指按照申请人申报或者药品审评中心核定的药品质量标准对样品进行的实验室检验。'可被翻译为：Article 51 Drug registration testing consists of specification verification and sample testing. Specification verification refers to laboratory assessment of the scientific basis of items included in the drug specifications submitted by the applicant, the feasibility of testing methods and the rationality of quality control criteria. Sample testing refers to laboratory testing conducted on samples according to the drug specifications submitted by the applicant or approved by the CDE.\n'第一百三十三条 申请人应当提供药品注册检验所需要的有关资料、报送样品或者配合抽取检验用样品、提供检验用标准物质。报送或者抽取的样品量应当为检验用量的3倍；生物制品的注册检验还应当提供相应批次的制造检定记录。'可被翻译为：Article 133 An applicant shall provide the relevant data, samples and reference standards, or assist in sampling, which are required for the testing for drug registration. The amount of samples shall be three times the amount used for testing and, for biological products, manufacturing record for the relevant batches of products shall also be provided.\n\n根据上述已知信息，请将'4.对于涉及微生物限度、无菌等项目的标准，为避免样品污染，还应提供用于该检验的独立包装样品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4.For specifications involving microbial limits, sterility and other test items, to avoid sample contamination, the individually packaged samples for this test shall also be provided."
    },
    {
        "instruction":"已知信息：\n'核查，是指由申办者组织的对临床试验相关活动和文件进行系统性的独立检查，以确定此类活动的执行、数据的记录、分析和报告是否符合临床试验方案、标准操作规程、本规范和有关适用的管理要求。'可被翻译为：The verification refers to the systematic independent inspection of relevant clinical trial activities and documents organized by the sponsor, so as to determine whether the implementation of such activities, data recording, analysis and reporting conform to the clinical trial protocol, standard operating procedures, the GCP and applicable management requirements.\n'检查员，是指监管部门选派的对医疗器械临床试验项目进行检查的人员。'可被翻译为：The inspector refers to the person who is selected by the regulatory department to inspect the medical device clinical trial project.\n'监查，是指申办者为保证开展的临床试验能够遵循临床试验方案、标准操作规程、本规范和有关适用的管理要求，选派专门人员对临床试验机构、研究者进行评价调查，对临床试验过程中的数据进行验证并记录和报告的活动。'可被翻译为：The supervision refers to the activities performed by special personnel who are selected by the sponsor of carrying out the evaluation and investigation of the clinical trial institutions and the investigators, and verifying, recording and reporting data during the clinical trial, so as to ensure that the clinical trial carried out is in conformity with the clinical trial protocol, standard operating procedures, this GCP and applicable management requirements.\n'对系统文件方面采取相应的控制，内容包括：'可被翻译为：(k) Use of appropriate controls over systems documentation including:\n\n根据上述已知信息，请将'检查，是指监管部门对临床试验的有关文件、设施、记录和其他方面进行的监督管理活动。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The inspection refers to the supervision and administration activities carried out by the regulatory department for inspecting relevant clinical trial documents, facilities, records and other aspects."
    },
    {
        "instruction":"已知信息：\n'未鉴定的降解产物'可被翻译为：unidentified degradation product\n'已鉴定的降解产物'可被翻译为：identified degradation product\n'新药制剂质量标准中，其限度在总的认可标准中控制而不单独控制的降解产物。'可被翻译为：A degradation product that is limited by a general acceptance criterion, but not individually listed with its own specific acceptance criterion, in the new drug product specification.\n'特定的降解产物'可被翻译为：specified degradation product\n\n根据上述已知信息，请将'已被列入新药制剂质量标准中并规定了认可标准的降解产物。一个特定的降解产物可以是结构已经鉴定或未鉴定的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A degradation product that is individually listed and limited with a specific acceptance criterion in the new drug product specification. A specified degradation product can be either identified or unidentified."
    },
    {
        "instruction":"已知信息：\n'现场核查过程中认为有必要进行样品检验的，经报核查中心同意后，核查组按照药品抽样的有关要求，抽取样品并封样，抽样情况应当在核查报告中进行描述；样品按要求送交药品检验机构进行样品检验。'可被翻译为：If it is deemed necessary to conduct sample inspection during the on-site inspection, the inspection team shall, with the approval of CFDI, take samples and seal them in accordance with the relevant requirements on drug sampling, and the sampling situation shall be described in the inspection report. The samples shall be sent to the drug testing institution for sample testing as required.\n'第十八条 需要抽取成品及其他物料进行检验的，检查组可以按照抽样检验相关规定抽样或者通知被检查单位所在地食品药品监督管理部门按规定抽样。抽取的样品应当由具备资质的技术机构进行检验或者鉴定，所抽取样品的检验费、鉴定费由组织实施飞行检查的食品药品监督管理部门承担。'可被翻译为：Article 18 Where finished products and other materials shall be sampled for testing, the inspection team can take samples in accordance with the relevant regulations for sampling test, or notify the local food and drug regulatory department to take samples as required. The samples shall be tested or identified by certified technical institutions, and the testing or identification fees shall be borne by the food and drug regulatory department organizing the unannounced inspection.\n'第五十条 核查过程中抽取的样品，应当在抽样之日起10日内，送达指定药品检验机构。'可被翻译为：Article 50 Samples taken during inspection shall be delivered to the designated drug testing institutions within 10 days from the date of sampling.\n'第五十八条 在药品审评、核查过程中，发现申报资料真实性存疑或者有明确线索举报，或者认为有必要进行样品检验的，可抽取样品进行样品检验。'可被翻译为：Article 58 During the drug review and inspection process, where it is found that the authenticity of the application dossier is in doubt or reports with confirmed evidence are received, when necessary, sampling and testing shall be performed.\n\n根据上述已知信息，请将'第三十一条 有因检查需要由核查组抽取样品进行检验的，核查组按照药品抽样的有关要求，抽取样品并封样；抽取的样品按要求送交药品检验机构进行样品检验。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 31 If the inspection team needs to take samples for cause-related inspection, the inspection team shall take samples and seal them in accordance with the relevant requirements for drug sampling; the samples shall be sent to the drug testing institution for sample testing as required."
    },
    {
        "instruction":"已知信息：\n'第一百三十条 在营业场所内，企业工作人员应当穿着整洁、卫生的工作服。'可被翻译为：Article 130 In the business premises, personnel of enterprises shall wear neat and hygienic working clothes.\n'（二）有与所经营药品相适应的营业场所、设备、仓储设施和卫生环境；'可被翻译为：(2) have the premises, equipment, warehouses, and hygienic environment required for drug distribution;\n'第一百四十三条 企业的营业场所应当与其药品经营范围、经营规模相适应，并与药品储存、办公、生活辅助及其他区域分开。'可被翻译为：Article 143 Business premises of enterprises shall be in line with their business scope and scale, and be separated from the areas for drug storage, offices, living and other areas.\n'第一百六十条 企业应当定期进行卫生检查，保持环境整洁。存放、陈列药品的设备应当保持清洁卫生，不得放置与销售活动无关的物品，并采取防虫、防鼠等措施，防止污染药品。'可被翻译为：Article 160 Enterprises shall carry out regular sanitary inspection and keep the environment clean and tidy. The equipment used for the storage or display of drugs shall be kept clean and sanitary, and shall not be placed with any item unrelated to the sales activities. Insect-proof and rat-proof measures shall be taken to prevent the contamination to drugs.\n\n根据上述已知信息，请将'第一百四十四条 营业场所应当具有相应设施或者采取其他有效措施，避免药品受室外环境的影响，并做到宽敞、明亮、整洁、卫生。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 144 Business premises shall be equipped with appropriate facilities or other effective measures shall be taken to prevent drugs from being affected by the outdoor environment, and the premises shall also be spacious, bright, clean and hygienic."
    },
    {
        "instruction":"已知信息：\n'第三十六条 药品经营企业、使用单位违反本办法第六条规定的，责令停止销售和使用，并处1000元以上5万元以下罚款；造成严重后果的，由原发证部门吊销《药品经营许可证》或者其他许可证。'可被翻译为：Article 36 Drug distributors and users who violate the provisions in Article 6 of these Provisions shall be ordered to stop selling and using the drug and fined an amount more than 1,000 Yuan and less than 50 ,000Yuan; for those who have caused serious consequences, the original certificate-issuing department shall revoke their Drug Supply Certificate or other certificates.\n'第三十二条 药品生产企业违反本办法第十六条规定，未在规定时间内通知药品经营企业、使用单位停止销售和使用需召回药品的，予以警告，责令限期改正，并处3万元以下罚款。'可被翻译为：Article 32 Drug manufacturers who fail to notify the drug distributor and user to stop selling and using the drug to be recalled within the specified time in violation of the provisions in Article 16 of these Provisions shall be warned, ordered to rectify the situation within a time limit and fined (an amount) less than 30,000 Yuan.\n'第三十三条 医疗器械经营企业、使用单位拒绝配合有关医疗器械缺陷调查、拒绝协助医疗器械生产企业召回医疗器械的，予以警告，责令限期改正；逾期拒不改正的，处3万元以下罚款。'可被翻译为：Article 33 A medical device distributor or using unit that refuses to cooperate in relevant medical device defect investigation or refuses to assist the medical device manufacturer in recalling the medical device shall be warned and ordered to rectify the situation within a time limit; if it fails to do so within the time limit, a fine of not more than 30,000 Yuan shall be imposed.\n'第七十一条  医疗器械经营企业、使用单位有下列情形之一的，依照《医疗器械监督管理条例》第六十八条的规定，由县级以上药品监督管理部门和卫生行政部门依据各自职责责令改正，给予警告；拒不改正的，处5000元以上2万元以下罚款；情节严重的，责令停产停业，直至由发证部门吊销相关证明文件：'可被翻译为：Article 71 In any of the following circumstances for medical device distributing enterprises and user facility, in accordance with Article 68 of the Regulations for the Supervision and Administration of Medical Devices, the drug regulatory departments and the health administrative departments above the county level according to their respective responsibilities should order to make correction and give warning, and a  fine between 5,000 RMB and  20,000 RMB should be imposed if MAHs refused to make correction; in serious circumstances, the production shall be ordered to stop until the relevant certificates are revoked by the original issuing authority:\n\n根据上述已知信息，请将'第三十二条 医疗器械经营企业、使用单位违反本办法第七条第一款规定的，责令停止销售、使用存在缺陷的医疗器械，并处5000元以上3万元以下罚款；造成严重后果的，由原发证部门吊销《医疗器械经营许可证》。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 32 A medical device distributor or using unit that violates the Provisions of the Paragraph 1, Article 7 of these Provisions shall be ordered to stop the sale and use of defective medical devices, and a fine of not less than 5,000 Yuan but not more than 30,000 Yuan shall be imposed concurrently; for those who have caused serious consequences, the former license issuing department shall revoke their Medical Device Distribution License."
    },
    {
        "instruction":"已知信息：\n'根据监管机构制定的要求，对制造商产生的证据和采取的程序进行系统检查，以确定医疗器械是安全的，并按制造商的预期运行，因此符合医疗器械安全和性能的基本原则(32)。'可被翻译为：The systematic examination of evidence generated, and procedures undertaken, by the manufacturer, under requirements established by the regulatory authority, to determine that a medical device is safe and performs as intended by the manufacturer and, therefore conforms to the Essential principles of safety and performance for medical devices (32).\n'（九）试验用医疗器械的研制符合适用的医疗器械质量管理体系相关要求的声明；'可被翻译为：(9) Statement that the research and development of investigational medical device conforms to the relevant requirements of the applicable medical device quality management system;\n'第三十一条 企业制定质量管理体系文件应当符合企业实际。文件包括质量管理制度、部门及岗位职责、操作规程、档案、报告、记录和凭证等。'可被翻译为：Article 31 The quality management system documents formulated by enterprises shall conform to their actual situation. Documents include quality management system, departmental and post responsibilities, operating procedures, archives, reports, records and vouchers, etc.\n'注册检验样品的生产应当符合医疗器械质量管理体系的相关要求，注册检验合格的方可进行临床试验或者申请注册。'可被翻译为：The production of samples for registration testing shall comply with relevant requirements of quality management system for medical devices. Clinical trials or registration application can be carried out only after the products passed the registration testing.\n\n根据上述已知信息，请将'文件化证据，通常是质量管理体系的输出，证明医疗器械符合立法规定的相关安全、性能和标签原则(32)。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The documented evidence, normally an output of the quality management system that demonstrates the medical device complies with the relevant principles of safety, performance and labelling specified through legislation (32)."
    },
    {
        "instruction":"已知信息：\n'（三）首营企业：采购药品时，与本企业首次发生供需关系的药品生产或者经营企业。'可被翻译为：(III) First commercial enterprise: the drug manufacturer or distributor that has the supply and demand relation with the enterprise in the purchase of drugs;\n'采购中涉及的首营企业、首营品种，采购部门应当填写相关申请表格，经过质量管理部门和企业质量负责人的审核批准。必要时应当组织实地考察，对供货单位质量管理体系进行评价。'可被翻译为：For the first commercial enterprise or first commercial variety involved in the purchase, the purchasing department shall fill in relevant application forms, which shall be reviewed and approved by the quality management department and the quality responsible person of an enterprise. If necessary, field investigation shall be organized to evaluate the quality management system of the supplier.\n'第六十三条 采购首营品种应当审核药品的合法性，索取加盖供货单位公章原印章的药品生产或者进口批准证明文件复印件并予以审核，审核无误的方可采购。'可被翻译为：Article 63 For the purchase of first commercial variety, the legality of the drugs shall be validated, and copies of the Drug Manufacturing Certificate or Import License of the drugs stamped with the official seal of the supplier shall be requested and reviewed. The purchase shall be made only for those qualified in the review.\n'第六十二条 对首营企业的审核，应当查验加盖其公章原印章的以下资料，确认真实、有效：'可被翻译为：Article 62 For the review of first commercial enterprise, the following materials stamped with its official seal shall be checked to confirm their authenticity and validity:\n\n根据上述已知信息，请将'（四）首营品种：本企业首次采购的药品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(IV) First commercial varieties: drugs purchased by the enterprise for the first time;"
    },
    {
        "instruction":"已知信息：\n'第九条 国家食品药品监督管理总局可以组织医疗器械分类专家委员会制定、调整医疗器械分类目录。'可被翻译为：Article 9 The China Food and Drug Administration may organize a medical device classification experts committee to formulate and adjust the medical device classification catalogue.\n'第二十四条 第三类医疗器械进行临床试验对人体具有较高风险的，应当经国家食品药品监督管理总局批准。需进行临床试验审批的第三类医疗器械目录由国家食品药品监督管理总局制定、调整并公布。'可被翻译为：Article 24 Where the clinical trial of a class III medical device poses high risks to human body, it shall be subject to approval by China Food and Drug Administration. The catalogue of class III medical devices subject to clinical trial approval shall be compiled, adjusted and published by China Food and Drug Administration.\n'《国家食品药品监督管理总局关于调整部分医疗器械行政审批事项审批程序的决定》（国家食品药品监督管理总局令第32号）'可被翻译为：Decision of CFDA on Adjusting Approval Procedures for Certain Administrative Examination and Approval Items of Medical Devices (Decree No. 32 of China Food and Drug Administration)\n'调整后的审批决定由国家食品药品监督管理总局医疗器械技术审评中心负责人签发。申请人对审批结论不服的，可以向国家食品药品监督管理总局提起行政复议或者依法提起行政诉讼。'可被翻译为：The adjusted approval decisions shall be issued by the head of the Center for Medical Device Evaluation of CFDA. Applicants who disagree with the approval decisions may apply for an administrative reconsideration to CFDA or file for an administrative lawsuit in accordance with law.\n\n根据上述已知信息，请将'第八条 国家食品药品监督管理总局根据医疗器械生产、经营、使用情况，及时对医疗器械的风险变化进行分析、评价，对医疗器械分类目录进行调整。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 8 The China Food and Drug Administration shall analyze and evaluate the risk changes timely according to the situation in medical device production, distribution and use, and adjust the medical device classification catalogue."
    },
    {
        "instruction":"已知信息：\n'第一条 为规范药品注册生产现场核查(以下简称注册核查)和上市前药品生产质量管理规范符合性检查(以下简称上市前 GMP 检查) 的衔接，保证注册核查和上市前 GMP 检查同步实施工作的质量和效率， 根据《中华人民共和国药品管理法》《中华人民共和国疫苗管理法》《药品注册管理办法》《药品生产监督管理办法》，制定本程序。'可被翻译为：Article 1 In order to standardize the work procedure for collaborative drug registration inspection of manufacturing site (hereinafter referred to as registration inspection) and Pre-market Good Manufacturing Practice (GMP) compliance inspection (hereinafter referred to as Pre-market GMP inspection), and to ensure the quality and efficiency of collaborative registration inspection and Pre-market GMP inspection, this Procedures is formulated in accordance with the Drug Administration Law of the People's Republic of China, Vaccine Administration Law of the People's Republic of China, Measures for Administration of Drug Registration and Measures for Supervision and Administration of Drug Production.\n'核查中心和省级局可分别组建检查组， 或共同组建一个检查组。原则上注册核查与上市前 GMP 检查选择在同一生产周期内开展。'可被翻译为：The CFDI and the provincial authority may form separate inspection teams or jointly form an inspection team. In principle, the registration inspection, and the Pre-market GMP inspection should be carried out in the same production period.\n'第六条 根据法规要求和职能， 核查中心和省级局按程序组建检查组，完成药品注册现场核查和上市前 GMP 检查工作。'可被翻译为：Article 6 In accordance with the requirements and functions of laws and regulations, the CFDI and provincial authorities shall form inspection team in accordance with procedures to complete the drug registration inspection and Pre-market GMP inspection.\n'药品注册生产现场核查和上市前药品生产质量管理规范检查衔接工作程序(试行)'可被翻译为：Work Procedure for Collaborative Drug Registration Inspection of Manufacturing Site and Pre-market Good Manufacturing Practice (GMP) Inspection (Trial)\n\n根据上述已知信息，请将'第九条 检查组依据现场检查情况，分别撰写注册核查、上市前 GMP 检查报告，分别作出注册核查、上市前GMP 检查结论。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 9 The inspection team shall write registration inspection and Pre-market GMP inspection reports and draw conclusions on registration inspection and Pre-market GMP inspection respectively based on the on-site inspection."
    },
    {
        "instruction":"已知信息：\n'在一定条件下，把特定的基因（群）加以大量复制的现象。'可被翻译为：The phenomenon of making a large number of copies of specific genes (groups) under certain conditions.\n'利用碱性药物在一定pH条件下与某些酸性染料结合显色，进行分光光度法测定药物含量的方法。'可被翻译为：The use of alkaline drugs in a certain pH condition and some acidic dyes combined color, spectrophotometric method to determine the drug content.\n'一种物质在不同条件下形成两种或两种以上不同晶体结构的现象。'可被翻译为：The phenomenon in which a substance forms two or more different crystal structures under different conditions.\n'在一定条件下，产生的不利于应用和治疗的合用药物之间的配伍变化。'可被翻译为：Changes in compatibility between drugs that are not conducive to application and treatment under certain conditions.\n\n根据上述已知信息，请将'药物与材料在一定条件下形成新相析出的现象。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The phenomenon of the formation of new phase precipitation between the drug and the material under certain conditions."
    },
    {
        "instruction":"已知信息：\n'一种独立分析方法的定量限是样品中某待测物能以适当的精密度和准确度被定量检出的最低量。定量限是一种针对样品中低含量物质定量分析的参数，特别用于杂质和\/或降解产物的测定。（ICH Q2）'可被翻译为：Limit of Quantitation: The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices, and is used particularly for the determination of impurities and\/or degradation products. (ICH Q2)\n'某一分析方法的检测限度是样品中的被分析物能够被检测到的最低量，但不一定要准确定量。'可被翻译为：The detection limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be detected but not necessarily quantitated as an exact value.\n'使用预先定义其精密度和准确度的方法，使样品中的待测物可被定量测定的最低浓度。'可被翻译为：The lowest amount of an analyte in a sample that can be quantitatively determined using a method with predefined precision and accuracy\n'样品中可通过预先定义的精密度和准确度进行定量测定的待测物最高浓度。'可被翻译为：The highest amount of an analyte in a sample that can be quantitatively determined with pre_x0002_defined precision and accuracy\n\n根据上述已知信息，请将'某一分析方法的定量限度是指在合适的准确性和精密度下，能够定量测定样品中被分析物的最低量。它是样品中含量下，能够定量测定样品中被分析物的最低量。它是样品中含量低的化合物定量测定的参数，特别适用于杂质和\/或降解产物的测定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices, and is used particularly for the determination of impurities and\/or degradation products."
    },
    {
        "instruction":"已知信息：\n'（一）对符合法定条件的药品注册申请不予受理的；'可被翻译为：(1) not accepting a drug registration application that is in conformity with regulatory requirements;\n'（二）对符合法定条件的申请作出不予批签发结论的；'可被翻译为：(II)  Making the decision of disapproval of lot release for the application meeting the statutory requirements;\n'（一）对不符合法定条件的申请作出准予批签发结论或者超越法定职权作出批签发结论的；'可被翻译为：(I)   Making the conclusions of approval for lot release for the application that does not meet the statutory requirements or acting beyond statutory authority to do so;\n'（二）对符合法定条件的申请作出不予注册决定或者不在法定期限内作出准予注册决定的；'可被翻译为：(2) making a decision to disapprove a registration application conformed with the regulatory requirements, or failing to make a decision to  approve a registration application within the regulatory timeline; and\n\n根据上述已知信息，请将'（一）对符合法定条件的批签发申请不予受理的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(I) Not accepting the lot release application that is in conformity with statutory requirements;"
    },
    {
        "instruction":"已知信息：\n'柱色谱分离法中用于将待分离物质从色谱柱中解吸或洗脱出来的试剂。'可被翻译为：A reagent used in column chromatography to desorption or eluate the substance to be separated from the column.\n'用于填充液相色谱柱的粒状固定相。'可被翻译为：A granular stationary phase used to fill liquid chromatographic columns.\n'流动相携带待测组分在色谱柱内向前移动并流出色谱柱的过程。'可被翻译为：The process by which the mobile phase carries the components under test forward within and out of the column.\n'一种质量型气相色谱检测器。其结构与火焰电离检测器类似，不同点在于以热电偶代替火焰顶端的电极。组分从色谱柱流出后，在火焰中燃烧，热电偶即测量燃烧温度以获得相应的色谱信号。'可被翻译为：A mass-type gas chromatographic detector. Its structure is similar to that of a flame ionization detector, except that a thermocouple replaces the electrode at the top of the flame. After the component flows out of the column, it burns in the flame. The thermocouple measures the combustion temperature to obtain the corresponding chromatographic signal.\n\n根据上述已知信息，请将'1975年由美国陶氏化学公司(DowChemical)的斯莫尔(Small),史蒂文斯(Stevens)和鲍曼(Bowman)发明的一种色谱技术。采用电导检测器的离子交换色谱，用于无机离子的分析，是一项新的液相色谱分析技术。已有多种分离方式和多种检测器可分为带有抑制柱的离子色谱(双柱离子色谱)和单柱离子色谱。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A chromatographic technique invented in 1975 by Small, Stevens and Bowman of DowChemical in the United States. Ion exchange chromatography with conductance detectors, for the analysis of inorganic ions, is a new analytical technique for liquid chromatography. There are a variety of separation methods and a variety of detectors that can be divided into ion chromatography with suppression columns (double column ion chromatography) and single column ion chromatography."
    },
    {
        "instruction":"已知信息：\n'第一百六十条 企业应当定期进行卫生检查，保持环境整洁。存放、陈列药品的设备应当保持清洁卫生，不得放置与销售活动无关的物品，并采取防虫、防鼠等措施，防止污染药品。'可被翻译为：Article 160 Enterprises shall carry out regular sanitary inspection and keep the environment clean and tidy. The equipment used for the storage or display of drugs shall be kept clean and sanitary, and shall not be placed with any item unrelated to the sales activities. Insect-proof and rat-proof measures shall be taken to prevent the contamination to drugs.\n'第四十六条 为降低污染和交叉污染的风险，厂房、生产设施和设备应当根据所生产药品的特性、工艺流程及相应洁净度级别要求合理设计、布局和使用，并符合下列要求：'可被翻译为：Article 46: In order to minimize the risks of contamination and cross-contamination, premises, facilities and equipment should be designed, laid out and used appropriately in accordance with the properties of the manufactured product and its process, as well as the corresponding cleanliness level, and the following requirements should be met:\n'第四十八条 应当根据药品品种、生产操作要求及外部环境状况等配置空调净化系统，使生产区有效通风，并有温度、湿度控制和空气净化过滤，保证药品的生产环境符合要求。'可被翻译为：Article 48: Production areas should be effectively ventilated, with air control facilities (including temperature, humidity and filtration) appropriate to the products handled, the operations undertaken within them and the external environment, to ensure that the production environment is in accordance with the requirements.\n'第二十九条  医疗器械注册人、备案人、受托生产企业应当按照所生产产品的特性、工艺流程以及生产环境要求合理配备、使用设施设备，加强对设施设备的管理，并保持其有效运行。'可被翻译为：Article 29 The registrant, filing entity or contract manufacturer of medical devices shall, based on the characteristics, technical process and requirements for manufacturing environment of the manufactured products, rationally equip and use of the facilities and equipment, strengthen the management of the facilities and equipment, and maintain their effective operation.\n\n根据上述已知信息，请将'第四十条 企业应当有整洁的生产环境；厂区的地面、路面及运输等不应当对药品的生产造成污染；生产、行政、生活和辅助区的总体布局应当合理，不得互相妨碍；厂区和厂房内的人、物流走向应当合理。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 40: The manufacturer should have a neat manufacturing environment. The ground, roads, and transportation in plant area should not introduce contamination to the manufacturing. The general layout of production, administration, living and ancillary areas should be well designed to avoid interference from each other. Premises and buildings should be well designed to ensure the logical flow of materials and personnel."
    },
    {
        "instruction":"已知信息：\n'第三十五条 疫苗上市许可持有人应当按照采购合同约定，向疾病预防控制机构供应疫苗。'可被翻译为：Article 35 Vaccine MAHs shall supply vaccines to disease prevention and control institutions in accordance with the procurement contract.\n'第三十七条 疾病预防控制机构、接种单位、疫苗上市许可持有人、疫苗配送单位应当遵守疫苗储存、运输管理规范，保证疫苗质量。'可被翻译为：Article 37 Disease prevention and control institutions, immunization entities, vaccine MAHs and vaccine distribution entities shall comply with the provision for vaccine storage and transportation to ensure vaccine quality.\n'疫苗上市许可持有人、疾病预防控制机构自行配送疫苗应当具备疫苗冷链储存、运输条件，也可以委托符合条件的疫苗配送单位配送疫苗。'可被翻译为：Vaccine MAHs and disease prevention and control institutions shall operate under the vaccine cold-chain storage and transportation conditions when delivering vaccines on their own, or they may also entrust qualified vaccine distribution entities to distribute vaccines.\n'疾病预防控制机构应当按照规定向接种单位供应疫苗。'可被翻译为：Disease prevention and control institutions shall supply vaccines to immunization entities as required.\n\n根据上述已知信息，请将'第三十六条 疫苗上市许可持有人应当按照采购合同约定，向疾病预防控制机构或者疾病预防控制机构指定的接种单位配送疫苗。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 36 Vaccine MAHs shall deliver vaccines to disease prevention and control institutions or immunization entities designated by disease prevention and control institutions in accordance with the procurement contract."
    },
    {
        "instruction":"已知信息：\n'第十九条 用于运输、储藏的包装的标签，至少应当注明药品通用名称、规格、贮藏、生产日期、产品批号、有效期、批准文号、生产企业，也可以根据需要注明包装数量、运输注意事项或者其他标记等必要内容。'可被翻译为：Article 19    The label on the package for transportation and storage shall bear at least the adopted name in China, strength, storage, production date, batch number, expiry date, approval number and manufacturer. Other information such as packaging quantity, precautions for transportation or other marks may be included when necessary.\n'第十八条 药品外标签应当注明药品通用名称、成份、性状、适应症或者功能主治、规格、用法用量、不良反应、禁忌、注意事项、贮藏、生产日期、产品批号、有效期、批准文号、生产企业等内容。适应症或者功能主治、用法用量、不良反应、禁忌、注意事项不能全部注明的，应当标出主要内容并注明“详见说明书”字样。'可被翻译为：Article 18    The outer label of a drug shall indicate such information as the adopted name in China, ingredients, description, indications or functions, strength, dose and usage, adverse reactions, contraindications, precautions, storage, production date, batch number, expiry date, approval number and manufacturer. Where indications or functions, dose and usage, adverse reactions, contraindications and precautions cannot be fully noted, main information plus a \"See drug insert sheet for details.\" notice shall be indicated.\n'标签或者说明书应当注明药品的通用名称、成份、规格、上市许可持有人及其地址、生产企业及其地址、批准文号、产品批号、生产日期、有效期、适应症或者功能主治、用法、用量、禁忌、不良反应和注意事项。标签、说明书中的文字应当清晰，生产日期、有效期等事项应当显著标注，容易辨识。'可被翻译为：The label or package insert shall indicate the adopted name of the drug in China, its ingredients and strength, the name and address of the MAH, the name and address of the manufacturer, approval number, product batch number, production date, date of expiration, indications or functions, dosage and administration, contraindications, adverse drug reactions, and precautions. The wording of the label and package insert shall be clear, and the production date and date of expiration shall be prominent and discernible.\n'（四）拆零销售应当使用洁净、卫生的包装，包装上注明药品名称、规格、数量、用法、用量、批号、有效期以及药店名称等内容；'可被翻译为：(IV) For dismantling sales, clean and sanitary package shall be used, on which the name, strength, quantity, usage, dosage, lot number, and expiry date of the drug, and name of the drug store shall be indicated;\n\n根据上述已知信息，请将'第二十条 原料药的标签应当注明药品名称、贮藏、生产日期、产品批号、有效期、执行标准、批准文号、生产企业，同时还需注明包装数量以及运输注意事项等必要内容。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 20    The label for drug substance shall include the adopted name in China, storage, production date, batch number, expiry date, applied specifications, approval number and manufacturer. Other necessary information such as packaging quantity and precautions for transportation shall also be indicated."
    },
    {
        "instruction":"已知信息：\n'中药材销售记录应当包括品名、规格、产地、购货单位、销售数量、单价、金额、销售日期等内容；中药饮片销售记录应当包括品名、规格、批号、产地、生产厂商、购货单位、销售数量、单价、金额、销售日期等内容。'可被翻译为：The sales records of Chinese crude drugs shall include the name of the product, strength, place of production, purchaser, sales quantity, unit price, amount and sales date; those of Prepared Slices shall include the name of product, strength, lot number, place of production, manufacturer, purchaser, sales quantity, unit price, amount and sales date, etc.\n'第一百六十八条 企业销售药品应当开具销售凭证，内容包括药品名称、生产厂商、数量、价格、批号、规格等，并做好销售记录。'可被翻译为：Article 168 Enterprises shall issue the proof of sales for drugs, including drug name, manufacturer, quantity, price, lot number and strength, and make the sales records.\n'第九十二条 企业应当做好药品销售记录。销售记录应当包括药品的通用名称、规格、剂型、批号、有效期、生产厂商、购货单位、销售数量、单价、金额、销售日期等内容。按照本规范第六十九条规定进行药品直调的，应当建立专门的销售记录。'可被翻译为：Article 92 Enterprises shall take records of drug sales. Sales records shall include the adopted name, strength, dosage form, lot number, expiry date, manufacturer, purchaser, sales quantity, unit price, amount and sales date of the drug. Special sales records shall be established for the direct transfer of drugs in accordance with Article 69 herein.\n'第九十五条 药品出库复核应当建立记录，包括购货单位、药品的通用名称、剂型、规格、数量、批号、有效期、生产厂商、出库日期、质量状况和复核人员等内容。'可被翻译为：Article 95 Records shall be established for ex-warehousing check of drugs, including the purchaser, adopted name, dosage form, strength, quantity, lot number, expiry date, and manufacturer of drugs, ex-warehousing date, quality status and checker, etc.\n\n根据上述已知信息，请将'（三）做好拆零销售记录，内容包括拆零起始日期、药品的通用名称、规格、批号、生产厂商、有效期、销售数量、销售日期、分拆及复核人员等；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(III) The records of dismantling sales shall be made, including the starting date of dismantling, adopted name, strength, lot number, manufacturer, and expiry date of drugs, sales quantity, sales date, dismantling and checking personnel, etc.;"
    },
    {
        "instruction":"已知信息：\n'组织药品活动的法律条件。(另见下文立法。)'可被翻译为：The legal conditions under which pharmaceutical activities should be organized. (See also legislation below.)\n'立法程序的第二阶段(第一阶段是立法，见上文)。法规是专门为实现立法的行政和技术目标而提供的法律机制。'可被翻译为：The second stage of the legislative process (the first stage being legislation, see above). Regulations are specifically designed to provide the legal machinery to achieve the administrative and technical goals of legislation.\n'立法程序的第一阶段，由政府立法机构就某一主题(如药品管制)通过法律。法律一般规定了涉及主题事项的所有各方的作用、权利和义务(另见下文的法规)。'可被翻译为：The first state of the legislative process, in which laws are passed by the legislative body of government with regard to a subject matter, e.g. control of pharmaceuticals. Laws define the roles, rights and obligations of all parties involved in the subject matter in general terms (see also regulations below).\n'第一条 为了规范药品网络销售和药品网络交易平台服务活动，保障公众用药安全，根据《中华人民共和国药品管理法》（以下简称药品管理法）等法律、行政法规，制定本办法。'可被翻译为：Article 1 These Provisions are formulated in accordance with the Drug Administration Law of the People's Republic of China (hereinafter referred to as the Drug Administration Law) and other laws and administrative regulations in order to regulate online drug sales and online drug transaction platform services, and safeguard the drug safety of the public.\n\n根据上述已知信息，请将'组织药品活动的法律条件(另见上文立法)'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The legal conditions under which pharmaceutical activities should be organized (see also legislation above)"
    },
    {
        "instruction":"已知信息：\n'第三十条  医疗器械经营企业应当建立并实施产品追溯制度，保证产品可追溯。'可被翻译为：Article 30 The medical device distributors shall establish and implement product traceability system, to guarantee traceability of the products.\n'第三十六条  医疗器械注册人、备案人、受托生产企业应当按照国家实施医疗器械唯一标识的有关要求，开展赋码、数据上传和维护更新，保证信息真实、准确、完整和可追溯。'可被翻译为：Article 36 The registrant, filing entity or contract manufacturer of medical devices shall, in accordance with relevant requirements of the state for implementing Unique Device Identification (UDI) of medical devices, carry out code assignment, data uploading, maintenance and updating, to guarantee the authenticity, accuracy, integrity and traceability of the information.\n'第四条  按照医疗器械风险程度，医疗器械经营实施分类管理。'可被翻译为：Article 4 Medical device distribution is subject to classified management in accordance with their degree of risks.\n'企业应当按照国家有关规定配备执业药师，负责处方审核，指导合理用药。'可被翻译为：Enterprises shall, in accordance with the relevant national provisions, be equipped with licensed pharmacists to be responsible for the audit of prescriptions and guide rational use of drugs.\n\n根据上述已知信息，请将'医疗器械经营企业应当按照国家有关规定执行医疗器械唯一标识制度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The medical device distributors shall execute Unique Device Identification (UDI) system of medical devices in accordance with relevant regulations of the State."
    },
    {
        "instruction":"已知信息：\n'由于化合物的结构改变，如发生共瓶作用、引入助色团，以及溶剂改变等原因，使紫外吸收峰向长波方向移动的现象。'可被翻译为：Due to the structural change of the compound, such as the occurrence of co-bottling, the introduction of chromophores, and the change of solvents, the phenomenon that the ultraviolet absorption peak moves in the direction of long wave.\n'由于化合物结构改变，比如核酸复性或其他原因，使吸收度减弱的效应。'可被翻译为：The effect of a structural change of a compound, such as the renaturation of nucleic acids or other reasons, resulting in a reduction in absorbency.\n'由于化合物结构改变，比如核酸分子受热、碱等处理时，解链变性或断链或其他原因，使吸收度增加的现象。'可被翻译为：Due to the structural change of the compound, such as when the nucleic acid molecule is treated with heat, alkali, etc., the chain denaturation or chain breaking or other reasons, the phenomenon of increased absorption.\n'紫外检测器的一种，可用于化合物的紫外全波长扫描，确定化合物的最大吸收的检测器。'可被翻译为：A type of ultraviolet detector that can be used to scan a compound in the ultraviolet full wavelength to determine the maximum absorption of the compound.\n\n根据上述已知信息，请将'化合物的结构改变时或受溶剂影响使紫外吸收峰向短波方向移动的现象。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The phenomenon in which the ultraviolet absorption peak shifts to the shortwave direction when the structure of the compound is changed or affected by the solvent."
    },
    {
        "instruction":"已知信息：\n'精神药物公约'可被翻译为：convention on psychotropic substances\n'国家为保证药品质量，保证人民群众用药安全、有效、质量可控而制定的技术法典，是药品研制、生产、经营、使用和监管的法定依据。'可被翻译为：The technical Code formulated by the State for the purpose of ensuring the quality of drugs and ensuring the safety, effectiveness and quality control of drug use by the people is the legal basis for the research, production, distribution, use and supervision of drugs.\n'（一）一级召回：使用该药品可能引起严重健康危害的;'可被翻译为：(Ⅰ)  Class 1 recall: Use of the drug may cause serious harms to health;\n'（一）一级召回：使用该医疗器械可能或者已经引起严重健康危害的；'可被翻译为：(1) Class I recalls: the use of the medical device may cause or has caused serious hazards to health;\n\n根据上述已知信息，请将'联合国于1971年为保证精神药物仅限于医疗及科研的需用，并防止非法使用而产生依懒性，危害健康而制定的文件。我国于1985加入该公约。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The United Nations issued a document in 1971 to ensure that psychotropic substances are limited to medical and scientific needs, and to prevent the illegal use of psychotropic substances resulting in laziness and harm to health. China acceded to the Convention in 1985."
    },
    {
        "instruction":"已知信息：\n'乙型肝炎病毒(HBV)'可被翻译为：hepatitis b virus(hbv)\n'一种包膜双链DNA病毒，是乙型肝炎的病原体。'可被翻译为：An enveloped double-stranded DNA virus that is the causative agent of hepatitis B.\n'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局于2020年3月10日组织制定并发布了《EB病毒核酸检测试剂注册技术审查指导原则》《乙型肝炎病毒e抗原、e抗体检测试剂注册技术审查指导原则》《地中海贫血相关基因检测试剂注册技术审查指导原则》《乙型肝炎病毒耐药相关的基因突变检测试剂注册技术审查指导原则》。'可被翻译为：To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on March 10, 2020 the Guidelines for Technical Review of the Registration of EB Virus Nucleic Acid Detection Reagents, Guidelines for Technical Review of the Registration of HBV e Antigen, e Antibody Detection Reagents, Guidelines for Technical Review of the Registration of Thalassemia-Related Gene Detection Reagents, and Guidelines for Technical Review of the Registration of HBV-Resistant Gene Mutation Detection Reagents.\n'人工抗原'可被翻译为：artificial antigen\n\n根据上述已知信息，请将'乙型肝炎病毒周围的抗原。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The antigen on the periphery of the hepatitis B virus."
    },
    {
        "instruction":"已知信息：\n'IVRT选择性是指IVRT方法区分对照外用制剂和改变规格的配方制剂（50%和150%规格）之间，释放速率差异的能力，应证明改变配方制剂规格后，其释放速率与对照外用制剂相比，在统计学上不等效。可以根据USP<1724>中描述的统计学方法，对释放速率的不等效性进行评估。'可被翻译为：IVRT selectivity is the ability of the IVRT method to discriminate the drug release rates between the reference topical product and the altered (50% and 150% nominal strength) concentration test formulations such that their release rates are determined to be statistically inequivalent compared to that from the nominal reference strength formulation. Determination of inequivalence between release rates should be evaluated using the statistical approach described in USP General Chapter<1724>.\n'IVRT补充选择性是IVRT方法区分对照外用制剂和具有相同规格、不同配方的制剂之间，释放速率差异的能力，应证明它们的释放速率在统计学上不等效。'可被翻译为：IVRT supplemental selectivity is the ability of the IVRT method to discriminate the drug release rates between the reference topical product and an altered formulation with the same nominal reference strength, such that their release rates are determined to be statistically inequivalent.\n'IVRT旨在表征在一组特定条件下半固体制剂的稳态药物释放率(即，一组给定的方法参数)。IVRT方法通常是精确和可重复的。然而，如果IVRT方法的参数发生变化，则测量的释放率也可能发生变化。值得注意的是，当IVRT方法一致时，测试制剂和参比制剂之间释放速率的变化反映了制剂中物质的物理化学性质和\/或结构排列的差异。因此，IVRT方法可以提供一种敏感和鉴别的方法来监测测试物与参考制剂的物理化学或结构特性的差异。'可被翻译为：An IVRT is intended to characterize a steady-state drug release rate from a semisolid formulation under a specific set of conditions (i.e., a given set of method parameters). IVRT methods are typically precise and reproducible. However, if the parameters of the IVRT method change, then the release rate measured may also change. Notably, when the IVRT method is consistent, then changes in the release rate between a test and reference formulation are reflective of a difference in the physicochemical properties and\/or the structural arrangement of matter in the formulations. Thus, IVRT methods can provide a sensitive and discriminating way to monitor for differences in the physicochemical or structural properties of a test versus the reference formulation.\n'在IVRT正式研究中，可以在扩散池上以交替给药方式依次放置自研外用制剂和RS。有两种可供选择的交替模式（ABABAB 或 BABABA）。可随机选择上述两种方式中的一种。'可被翻译为：In the IVRT pivotal study, the test topical product and RS should be dosed in an alternating pattern on successive diffusion cells. There are two possible sequences for the alternating pattern (either ABABAB or BABABA). One of these two dosing sequences should be randomly selected.\n\n根据上述已知信息，请将'IVRT或IVPT之间的选择应基于制剂评估的预期目标，如表2所示。表3进一步描述了两种方法内在的实验差异。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The selection between IVRT or IVPT should be based on the intended objective(s) of the formulation assessment, as described in Table 2. Intrinsic experimental differences between the two methodologies are further described in Table 3."
    },
    {
        "instruction":"已知信息：\n'用于测试的培养基需要通过用适当微生物的培养基接种来测试促菌生长能力。最好选择测试微 生物用于促菌生长能力试验（D部分）。'可被翻译为：Media used for testing needs to be tested for growth promotion by inoculating the medium with appropriate microorganisms. It is preferable that test microorganisms be chosen for growth promotion testing (Section D).\n'培养基促生长'可被翻译为：Growth Promotion of the Media\n'是否进行了促生长试验？'可被翻译为：ii. Have they performed growth promotion?\n'培养基的促生长、指示 性和抑制特性'可被翻译为：Growth Promotion, Indicative and Inhibitory Properties of the Media\n\n根据上述已知信息，请将'试剂和培养基适当存贮、有效期和促生长试验'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4. Reagents and media- proper storage, expiration date, and growth promotion"
    },
    {
        "instruction":"已知信息：\n'基因疗法'可被翻译为：gene therapy\n'1.产品包括但不限于成品药品、医疗器械、疫苗和IVD产品。\n2.指药品、疫苗和体外诊断(未来可能包括医疗器械)。\n3.包括药品、疫苗、诊断和医疗器械的术语。\n4.包括药品、疫苗、诊断和医疗器械的术语。\n5.就本文件而言，该术语包括药品、疫苗、血液和血液制品以及医疗器械，包括体外诊断。\n6.医疗产品包括各种各样的制成品，如成品药品、医疗器械、疫苗和ivd产品。'可被翻译为：1.Products including, but not limited to, finished pharmaceutical products, medical devices, vaccines and IVD products.\n2.Refers to medicines, vaccines and in vitro diagnostics (and in the future may include medical devices).\n3.A term that includes medicines, vaccines, diagnostics and medical devices.\n4.A term that includes medicines, vaccines, diagnostics and medical devices.\n5.For the purpose of this document, the term includes medicines, vaccines, blood and blood products and medical devices, including in-vitro diagnostics.\n6.Medical products include a wide range of manufactured items, such as finished pharmaceutical products, medical devices, vaccines and ivd products.\n'本文提供的是技术转移原则指导。这些原则适用于临床试验用药以及上市药品。'可被翻译为：2.1. This document provides guiding principles on technology transfer. The principles apply to investigational products as well as marketed product.\n'质量体系应包括GXP要求，应用于产品和工艺，包括技术转移的生命周期阶段中。'可被翻译为：6.3. The quality system should incorporate GxP which should be applied to the life cycle stages of the products and processes, including the technology transfer.\n\n根据上述已知信息，请将'虽然本文重点在于药品，但其原则应可应用于其它产品如生物制品、先进疗法药品\/细胞和基因疗法产品、疫苗、医疗器械和病媒控制产品的生产、相关工艺和控制的转移。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2.4. Although this document focuses on pharmaceutical products, the principles can also be applied to the transfer of production, related processes and controls for other products such as biopharmaceutical products, advanced therapy medicinal products\/cellular and gene therapy products, vaccines, medical devices and vector control products."
    },
    {
        "instruction":"已知信息：\n'采用经过验证的有效抑菌剂，用无菌抹布清洁样品容器外表。放在经过消毒的托盘 或放在经过适当消毒的层流罩或生物安全柜表面上，让容器干燥。'可被翻译为：Cleanse outer surfaces of sample containers with sterile wipes using a validated effective antimicrobial agent. Place on a disinfected tray or surface in a properly disinfected laminar flow hood or biosafety cabinet. Allow containers to dry.\n'打开单元容器的工作区应该是一个 HEPA 过滤层流罩或一个替代的受控环境，以保 护打开的介质和产品暴露在环境或人员污染中。'可被翻译为：The work area for opening the unit container should be either a HEPA filtered laminar flow hood or an alternate controlled environment to safeguard the exposure of open media and product to either environmental or personnel contamination.\n'拭子处理必须在 HEPA 过滤 II 级生物安全柜（BSC）或 HEPA 过滤层流罩（LFH）内无菌操作，其中的空气级别应该等于或优于擦拭取样点。'可被翻译为：1. All processing of swabs must be aseptically performed within a HEPA Filtered II Biological Safety Cabinet (BSC) or HEPA Filtered Laminar Flow Hood (LFH) with an air classification at the same rating or better than that from which the swab was collected\n'非无菌发网和胡须罩（如需要）'可被翻译为：a. Nonsterile Hair net and beard cover (if needed)\n\n根据上述已知信息，请将'如可能的话，在无菌条件下打开容器，在层流罩中或生物安全柜中称重。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Aseptically open containers and perform weighing procedures in a laminar flow hood or biological safety cabinet if possible."
    },
    {
        "instruction":"已知信息：\n'（一）在试验前确认临床试验机构已具有适当的条件，包括人员配备与培训符合要求，实验室设备齐全、工作情况良好，预期有足够数量的受试者，参与研究人员熟悉试验要求。'可被翻译为：(1) Before the trial, confirm that the clinical trial institution has appropriate conditions, where the staffing and training meets requirements, laboratory equipment is complete and works properly, there are sufficient subjects as expected and the investigators involved are familiar with the trial requirements.\n'（二）在试验前、中、后期监查临床试验机构和研究者是否遵循有关法规、本规范和临床试验方案。'可被翻译为：(2) Verify whether the clinical trial institutions and investigators follow relevant regulations, this GCP and the clinical trial protocol before, during and after the trial.\n'（四）各临床试验机构试验样本量以及分配、符合统计分析要求的理由；'可被翻译为：(4) The trial sample size and distribution among clinical trial institutions, and the reasons why such arrangement meets statistical analysis requirements;\n'国家鼓励符合条件的医疗机构、疾病预防控制机构等依法开展疫苗临床试验。'可被翻译为：The State encourages eligible medical institutions and disease prevention and control institutions to conduct vaccine clinical trials in accordance with law.\n\n根据上述已知信息，请将'（二）临床试验机构的人员配备以及设备条件等是否符合试验要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(2) Whether the staffing and equipment conditions of clinical trial institutions meet the trial requirements."
    },
    {
        "instruction":"已知信息：\n'原材料（起始物料，试剂、溶剂）、工艺辅助材料、中间体，APIs 和包装及标签材料的总称。'可被翻译为：A general term used to denote starting materials, reagents, and solvents intended for use in the production of intermediates or APIs.\n'1.用于表示起始原料(活性药物成分和赋形剂)、试剂、溶剂、工艺助剂、中间体、包装材料和标签材料的总称。\n2.用于表示原材料(起始原料、试剂、溶剂)、工艺助剂、中间体、原料药以及包装和标签材料的通用术语。\n3.用于表示起始原料、工艺助剂、中间体、活性药物成分、包装和标签材料的术语。'可被翻译为：1.A general term used to denote starting materials (active pharmaceutical ingredients and excipients), reagents, solvents, process aids, intermediates, packaging materials and labelling materials.\n2.A general term used to denote raw materials (starting materials, reagents, solvents), process aids, intermediates, APIs and packaging and labelling materials.\n3.A term used to denote starting materials, process aids, intermediates, active pharmaceutical ingredients, packaging and labelling materials.\n'用于表示起始物料(原料药和赋形剂)、试剂、溶剂、工艺助剂、中间体、包装材料和标签材料的通用术语。'可被翻译为：A general term used to denote starting materials (APIs and excipients), reagents, solvents, process aids, intermediates, packaging materials and labelling materials.\n'（七）药品说明书及包装、标签的式样（原料药和制剂中间体除外）；'可被翻译为：(VII) insert sheet, patterns of its packaging and labeling(except for drug substances and intermediate preparations);\n\n根据上述已知信息，请将'原材料(起始物料，试剂、溶剂)、工艺辅助材料、中间体，APIs 和包装及标签材料的总称。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A general term used to denote raw materials (starting materials, reagents, solvents), process aids, intermediates, APIs and packaging and labelling materials."
    },
    {
        "instruction":"已知信息：\n'第九十五条 申请进口药品制剂，必须提供直接接触药品的包装材料和容器合法来源的证明文件、用于生产该制剂的原料药和辅料合法来源的证明文件。原料药和辅料尚未取得国家食品药品监督管理局批准的，应当报送有关生产工艺、质量指标和检验方法等规范的研究资料。'可被翻译为：Article 95 To apply for importation of pharmaceutical preparations, approved documents for the lawful sources of the immediate packaging materials and containers and those of the drug substances and the excipients used for the pharmaceutical preparations shall be provided. Where drug substances and excipients are not yet approved by the State Food and Drug Administration, relevant data of manufacturing processes, specifications and testing methods, etc. shall be submitted.\n'4.试验用药品运输和储存过程中的条件符合方案要求。'可被翻译为：4. The conditions during the transportation and storage of investigational medicinal products meet the requirements of the protocol.\n'1.在药品的生产、管理和销售过程中可能对健康造成不良影响的任何情况。\n2.潜在的危害来源(15)。'可被翻译为：1.Any circumstance in the production, control and distribution of a pharmaceutical which can cause an adverse health effect.\n2.A potential source of harm (15).\n'一、 自2022年12月1日起，对签发的《出口欧盟原料药证明文件》和《药品出口销售证明》启用电子证明。电子证明与纸质证明具有同等效力。'可被翻译为：1. From Dec 1, 2022, the electronic certificates of the Documentation for Export of APIs to EU and Certificate of a Pharmaceutical Product will be put into use. The electronic certificate and the paper version are equally authentic.\n\n根据上述已知信息，请将'1.具有试验用药品的来源证明、检验报告和在符合 GMP 条件下生产的证明文件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1. There are proof of origin, certificate of analysis, and documentation of manufacture under GMP conditions of investigational medicinal products."
    },
    {
        "instruction":"已知信息：\n'省级药品监督管理部门与同级卫生行政部门联合对设区的市级、县级的调查进行督促、指导，对药品群体不良事件进行分析、评价，对本行政区域内发生的影响较大的药品群体不良事件，还应当组织现场调查，评价和调查结果应当及时报国家食品药品监督管理局和卫生部。'可被翻译为：Provincial drug regulatory departments, jointly with the health administrative departments at the same level, shall supervise and guide the investigation conducted by drug regulatory departments of municipalities with districts and counties, analyze and evaluate ADE clusters, and organize on-site investigation on ADE clusters that occur within their administrative regions and have a major impact. The evaluation and investigation results shall be reported to the SFDA and the Ministry of Health in a timely manner.\n'第八条 设区的市级、县级药品监督管理部门负责本行政区域内药品不良反应报告和监测的管理工作；与同级卫生行政部门联合组织开展本行政区域内发生的药品群体不良事件的调查，并采取必要控制措施；组织开展本行政区域内药品不良反应报告和监测的宣传、培训工作。'可被翻译为：Article 8 Drug regulatory departments of municipalities with districts and of counties are responsible for management of ADR reporting and monitoring within their respective administrative regions; organize and carry out investigation on ADE clusters occurred within their administrative regions and take necessary control measures in conjunction with the health administrative departments at the same level; and organize and carry out publicity and training on ADR reporting and monitoring within their administrative regions.\n'第三十四条  省、自治区、直辖市药品监督管理部门在获知本行政区域内发生的群体医疗器械不良事件后，应当会同同级卫生行政部门及时开展现场调查，相关省、自治区、直辖市药品监督管理部门应当配合。调查、评价和处理结果应当及时报国家药品监督管理局和国务院卫生行政部门，抄送持有人所在地省、自治区、直辖市药品监督管理部门。'可被翻译为：Article 34 After knowing the group adverse events of medical device that occurs within their respective administrative regions, the drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall promptly carry out on-site investigation jointly with the health administrative departments at the same level, and the drug regulatory departments of relevant provinces, autonomous regions and municipalities directly under the central government shall cooperate. Investigation, re-evaluation and handling results shall be promptly reported to the NMPA and the Health Administrative Department of the State Council, and copied to local drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government where MAHs locate.\n'（二）与同级卫生行政部门联合组织开展本行政区域内发生的影响较大的药品群体不良事件的调查和处理，并发布相关信息；'可被翻译为：(II) Jointly with the health administrative departments at the same level, organize and carry out investigation and handling of ADE clusters that have a major impact within their administrative regions, and release relevant information;\n\n根据上述已知信息，请将'第二十八条 设区的市级、县级药品监督管理部门获知药品群体不良事件后，应当立即与同级卫生行政部门联合组织开展现场调查，并及时将调查结果逐级报至省级药品监督管理部门和卫生行政部门。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 28 Drug regulatory departments of municipalities with districts and counties shall, upon knowing of ADE clusters, immediately conduct on-site investigation jointly with the health administrative departments at the same level, and promptly report the investigation results level by level to the provincial drug regulatory departments and health administrative departments."
    },
    {
        "instruction":"已知信息：\n'医疗器械注册人、备案人、经营企业经营条件发生重大变化，不再符合医疗器械经营质量管理体系要求的，应当立即采取整改措施；可能影响医疗器械安全、有效的，应当立即停止经营活动，并向原经营许可或者备案部门报告。'可被翻译为：In case of significant changes in distribution conditions of the registrant, filing entity and distributor of the medical devices, thus not conforming to requirements of the quality management system for medical device distribution, rectification measures shall be taken immediately; if safety and effectiveness of the medical devices might be influenced, distribution activities shall be suspended immediately, and report shall be made to the former licensing department or filing department.\n'经自查发现生产条件发生变化，不再符合化妆品生产质量管理规范要求的，化妆品注册人、备案人、受托生产企业应当立即采取整改措施；发现可能影响化妆品质量安全的，应当立即停止生产，并向所在地省、自治区、直辖市药品监督管理部门报告。影响质量安全的风险因素消除后，方可恢复生产。省、自治区、直辖市药品监督管理部门可以根据实际情况组织现场检查。'可被翻译为：Where changes occur in the manufacturing conditions are discovered upon internal audit, so that the conditions no longer meet the requirements of Good Manufacturing Practice for cosmetics, the registrant, the filing entity and the contract manufacturer of cosmetics shall immediately take measures for rectification; upon discovering that the quality and safety of cosmetics may be affected, they shall immediately stop the manufacturing and report the matter to the drug regulatory department of the province, autonomous region or municipality directly under the central government where it is located. Manufacturing can be resumed only upon removal of the risk factors affecting the quality and safety. The drug regulatory department of the province, autonomous region or municipality directly under the central government may organize on-site inspection based on actual conditions.\n'第四十二条  医疗器械经营企业发现其经营的医疗器械不符合强制性标准、经注册或者备案的产品技术要求，或者存在其他缺陷的，应当立即停止经营，通知医疗器械注册人、备案人等有关单位，并记录停止经营和通知情况。医疗器械注册人、备案人认为需要召回的，应当立即召回。'可被翻译为：Article 42 If a medical device distributor finds that the medical devices involved in its distribution activities do not conform to mandatory standards, or to registered or filed technical specifications for the products, or have other defects, it shall suspend the distribution immediately, notify the registrant, filing entity and other relevant units of the medical devices, and record the conditions of distribution suspension and notification. If the registrant and filing entity of the medical devices deem that the products need to be recalled, recalls shall be performed immediately.\n'第六十六条  医疗器械注册人、备案人、受托生产企业对存在的医疗器械质量安全风险，未采取有效措施消除的，药品监督管理部门可以对医疗器械注册人、备案人、受托生产企业的法定代表人或者企业负责人进行责任约谈。涉及跨区域委托生产的，约谈情况应当通报相关药品监督管理部门。'可被翻译为：Article 66 If the registrant, filing entity or contract manufacturer of medical devices fails to take effective measures for removing existing quality and safety risks of the medical devices, the drug regulatory department may make responsibility interview with the legal representative or the person in charge of the enterprise of the registrant, filing entity or contract manufacturer of medical devices. If cross-region entrusted manufacturing is involved, the interview condition shall be informed to related drug regulatory departments.\n\n根据上述已知信息，请将'第四十四条  医疗器械注册人、备案人、受托生产企业的生产条件发生变化，不再符合医疗器械质量管理体系要求的，应当立即采取整改措施；可能影响医疗器械安全、有效的，应当立即停止生产活动，并向原生产许可或者生产备案部门报告。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 44 Where changes occur in the manufacturing conditions of the registrant, filing entity, and contract manufacturer of medical devices, so that the conditions cease to meet the requirements of the quality management system for medical devices, measures for rectification shall be taken immediately; where the safety and effectiveness of the medical devices may possibly be affected, the enterprise shall immediately stop manufacturing and report the matter to the former department that issued the Manufacturing License or accepted for filing."
    },
    {
        "instruction":"已知信息：\n'（四）生产步骤操作人员的签名；必要时，还应当有操作（如称量）复核人员的签名。'可被翻译为：4. Signatures of the operator of different steps of production and, where appropriate, of the person who checked each of these operations (e.g. weighing);\n'（三）包装操作负责人签名。'可被翻译为：3. The signatures of the responsible person carrying out the packaging operation;\n'（七）中间控制结果的记录以及操作人员的签名。'可被翻译为：7. A record of the results obtained from in-process controls and the signatures of the person(s) carrying them out;\n'（三）每一生产工序的负责人签名。'可被翻译为：3. The signatures of the person responsible for each stage of production;\n\n根据上述已知信息，请将'（四）包装工序的操作人员签名。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4. The signatures of the operators of the different steps;"
    },
    {
        "instruction":"已知信息：\n'第四十三条 药品审评中心在审评药品制剂注册申请时，对药品制剂选用的化学原料药、辅料及直接接触药品的包装材料和容器进行关联审评，需补充资料的，按照补充资料程序要求药品制剂申请人或者化学原料药、辅料及直接接触药品的包装材料和容器登记企业补充资料，可以基于风险提出对化学原料药、辅料及直接接触药品的包装材料和容器企业进行延伸检查。'可被翻译为：Article 43 When evaluating a drug registration application, the CDE conducts bundling review of the chemical active drug ingredients, excipients and primary packaging materials and containers of the drug product. Where supplementary dossiers are needed, the drug product applicant or the enterprise that registers chemical active drug ingredients, excipients and primary packaging materials and containers shall be required to provide supplementary dossiers in compliance with relevant procedures. When necessary, extended inspection on enterprises of chemical active drug ingredients, excipients and primary packaging materials and containers may be proposed based on risks.\n'第四十二条 药品制剂申请人提出药品注册申请，可以直接选用已登记的化学原料药、辅料及直接接触药品的包装材料和容器；选用未登记的化学原料药、辅料及直接接触药品的包装材料和容器的，相关研究资料应当随药品制剂注册申请一并申报。'可被翻译为：Article 42 When submitting a drug registration application, the drug product applicant may directly select chemical active drug ingredients, excipients and primary packaging materials and containers that have been registered; where chemical active drug ingredients, excipients and primary packaging materials and containers that have not been registered are selected, relevant study data shall be submitted together with the drug registration application.\n'第十四条 国家药品监督管理局建立化学原料药、辅料及直接接触药品的包装材料和容器关联审评审批制度。在审批药品制剂时，对化学原料药一并审评审批，对相关辅料、直接接触药品的包装材料和容器一并审评。药品审评中心建立化学原料药、辅料及直接接触药品的包装材料和容器信息登记平台，对相关登记信息进行公示，供相关申请人或者持有人选择，并在相关药品制剂注册申请审评时关联审评。'可被翻译为：Article 14 The NMPA shall establish a bundling review and approval system for chemical active drug ingredients, excipients and primary packaging materials and containers. When reviewing and approving drug products, the review and approval for the chemical active drug ingredients and review for the relevant excipients and primary packaging materials and containers shall be carried out together. The CDE shall establish a platform for registries of chemical active drug ingredients, excipients and primary packaging materials and containers, release relevant registry information to applicants or MAHs for their selection, and conduct the bundling review when reviewing registration applications of relevant drug products.\n'化学原料药、辅料及直接接触药品的包装材料和容器生产企业应当按照关联审评审批制度要求，在化学原料药、辅料及直接接触药品的包装材料和容器登记平台登记产品信息和研究资料。药品审评中心向社会公示登记号、产品名称、企业名称、生产地址等基本信息，供药品制剂注册申请人选择。'可被翻译为：Manufacturers of chemical active drug ingredients, excipients and primary packaging materials and containers shall register product information and research data on the registry platform for chemical active drug ingredients, excipients and primary packaging materials and containers in accordance with requirements of the bundling review and approval system. The CDE shall disclose general information including registry number, product name, enterprise name, and manufacturing address etc. to the public for selection by drug product registration applicants.\n\n根据上述已知信息，请将'第四十一条 药品审评中心在审评药品制剂注册申请时，对药品制剂选用的化学原料药、辅料及直接接触药品的包装材料和容器进行关联审评。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 41 When evaluating a drug registration application, the CDE shall conduct bundling review of the chemical active drug ingredients, excipients and primary packaging materials and containers used for the drug products."
    },
    {
        "instruction":"已知信息：\n'一种高效液相色谱一质谱联用的仪器接口。属于大气压电离的范畴，包括电喷雾、离子的形成及离子的传递三个步骤。'可被翻译为：An instrument interface for high performance liquid chromatography-mass spectrometry. It belongs to the category of atmospheric pressure ionization, including electrospray, ion formation and ion transfer three steps.\n'最早研究的液相色谱-质谱联用（LC-MS）接口之一。其工作原理是液相流出物滴在不锈钢或聚酰亚胺丝（带）上，由加热器和真空泵除去溶剂，样品经瞬间气化进入离子源或直接由带送入离子源。'可被翻译为：One of the earliest studied liquid chromatography-mass spectrometry (LC-MS) interfaces. Its working principle is that liquid phase effluent drops on stainless steel or polyimide wire (belt), the solvent is removed by heater and vacuum pump, the sample is vaporized into the ion source instantaneously or directly from the belt into the ion source.\n'根据分子大小进行分离的一种液相色谱技术。'可被翻译为：A liquid chromatographic technique for separation based on molecular size.\n'用于填充液相色谱柱的粒状固定相。'可被翻译为：A granular stationary phase used to fill liquid chromatographic columns.\n\n根据上述已知信息，请将'一种液相色谱一质谱联用的接口。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The utility model relates to a liquid chromatography-mass spectrometry interface."
    },
    {
        "instruction":"已知信息：\n'<1223>替代微生物方法的验证'可被翻译为：l. <1223> Validation of alternative microbiological methods\n'在申请中包含非药典分析方法的情况下进行方法验证，以确认申请人建议的分析方法适用于监管目的。如果有，应包括与药典方法的并排比较。方法验证是在药典方法中进行的，以确认复方产品是否可以用官方方法进行令人满意的分析。'可被翻译为：Method validation is conducted where non-compendial analytical methods are included in the application to confirm that the applicants’ proposed analytical methods are suitable for regulatory purposes. A side-by-side comparison with a compendial method, if available, should be included. Method verification is conducted where the methods are compendial, to confirm whether the product as compounded can be analysed satisfactorily by the official method.\n'证明分析程序或方法适合其预期目的的形成文件的证据。'可被翻译为：The documented evidence that analytical procedures or methods are suitable for their intended purpose.\n'如果，在方法开发期间使用的样品分析方法与最终验证的样品分析方法不同，与其相关的IVRT方法研究结果不能用于支持论证IVRT方法的有效性。在IVRT方法验证报告中，应提供参考的样品分析方法验证信息，并明确表明IVRT方法验证报告中的所有相关结果均是采用经验证的样品分析方法（而不是与经验证的分析方法具有不同参数的样品分析方法）获得的。'可被翻译为：Any results from studies of the IVRT method that are performed (during method development) using a different sample analytical method than that which is ultimately validated, cannot support a demonstration of the validity of the IVRT method. Information should be provided in the IVRT method validation report referencing the (separate) sample analytical method validation, and clearly indicate that all relevant results in the IVRT method validation report were obtained using a validated sample analytical method (as opposed to an analytical method with different parameters than those which were validated).\n\n根据上述已知信息，请将'已被验证为适合目的的方法，可与替代方法进行比较。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A method which has been validated as being fit for purpose, with which an alternative method may be compared."
    },
    {
        "instruction":"已知信息：\n'附录 C 对于重复回收和产品接种方法的验证作了更深入的解释。'可被翻译为：Annex C has a more in-depth explanation of the validation of the repetitive recovery and product inoculation methods.\n'“生物负载”一词通常用于描述存在于非无菌物料或产品的微生物群。存在生物负载微生物的生物负载量和类型可以影响物料或产品的灭菌工艺。开发能够提供准确、精确和可重复测量的与物料或产品相关的生物负载量的程序非常重要。有几种方法可以从医疗器械中去除微生物。这些回收方法包括：过滤后电镀；超声\/振荡后过滤，然后放在琼脂培养基上；擦洗\/冲洗\/冲刷后过滤并涂布在琼脂培养基上；如果所有都不行，那么就直接擦拭或涂抹。'可被翻译为：The term “bioburden” is commonly used to describe the population of microorganisms present on \nunsterilized material or products. The bioburden quantity and types of bioburden organisms present can impact the sterilization process of the material or product. It is important to develop procedures which provide accurate, precise, and reproducible measurement of the bioburden population associated with the material or product. There are several approaches to remove microorganisms \nfrom a medical device. Some examples of these recovery methods include: filtration followed by plating; ultrasonic\/shaking followed by filtration then placing on an agar medium; \nstomaching\/rinsing\/flushing followed by filtration and plating on an agar medium; if all else fails perform a direct swabbing or contact plate.\n'使用生物负载回收研究中确定的校正因子，从原始的预灭菌计数中计算生物负载估测值。校正因子是在方法回收率计算中得到的。校正因子的计算见附录 C 第 C.2 节。'可被翻译为：4. Application of the correction factor(s) determined during bioburden recovery studies in order to calculate the bioburden estimate from the raw presterilization count. The correction factor is derived from the determination of the recovery efficiency of a method. The calculation of a correction factor is illustrated in Appendix C, Section C.2.\n'方法适用性（无菌）：准备测试（细菌内毒素）、生物负载和水分析方法验证'可被翻译为：3. Method Suitability (sterility), preparatory test (bacterial endotoxin), validation of method used for bioburden and water analysis\n\n根据上述已知信息，请将'附录 A 包括一个决策树“阐述基于被测产品性质设计生物负载方法，并且包括用于选择诸如搅拌技术或过滤与直接电镀之类的指南”。附录 A 还阐述了可用于确定生物负载方法验证的程序（重复回收方法、产品接种方法等）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Annex A contains a decision tree “that addresses designing a bioburden method based on the nature of the product being tested and includes guidance for choosing such things as agitation techniques or filtration versus direct plating.”2 Annex A also addresses the procedures (repetitive recovery method, product inoculation method) available for the validation of the method for determining bioburden."
    },
    {
        "instruction":"已知信息：\n'用于特定化学和物理检测的经过检定、性质均匀的物质。在检测中需要化学对照品的一个或多个性质与待测样品进行比较，化学对照品应具有满足其用途的适当纯度。'可被翻译为：A certified, homogeneous substance used for specific chemical and physical tests. One or more properties of the chemical reference required in the test to be compared with the sample to be tested, and the chemical reference should be of an appropriate purity for its purpose.\n'指定的主要化学对照物质是指在特定环境中被广泛认可具有适当质量的物质，并且其指定含量在用作测定标准时被接受，而无需与另一种化学物质进行比较。'可被翻译为：A designated primary chemical reference substance is one that is widely acknowledged to have the appropriate qualities within a specified context, and whose assigned content when used as an assay standard is accepted without requiring comparison with another chemical substance.\n'1.一个实体影响其满足明示的和隐含的需要的能力，以及符合规定要求的服务或产品的一致和可靠性能的全部特征。隐含需求包括用于治疗用途和作为进一步生产的起始材料的产品的安全和质量属性。\n2.活性药物成分或药品对其预期用途的适宜性。该术语包括特性、强度和纯度等属性。\n3.一个实体影响其满足明示和暗示的需要，并确保服务或产品符合规定要求的一致和可靠性能的能力的全部特征。'可被翻译为：1.The total set of characteristics of an entity that affect its ability to satisfy stated and implied needs, and the consistent and reliable performance of services or products in conformity with specified requirements. Implied needs include safety and quality attributes of products intended both for therapeutic use and as starting materials for further manufacturing.\n2.The suitability of either an active pharmaceutical ingredient or a pharmaceutical product for its intended use. This term includes such attributes as the identity, strength and purity.\n3.The total set of characteristics of an entity that affect its ability to satisfy stated and implied needs and to ensure the consistent and reliable performance of services or products in conformity with specified requirements.\n'用于物理或化学方法进行药品鉴别、检查、含量测定对照的标准物质。'可被翻译为：A reference substance used as a physical or chemical reference for drug identification, inspection, and content determination.\n\n根据上述已知信息，请将'1.本文所用的“化学对照物质”一词是指一种经过认证的、统一的材料，用于特定的化学和物理测试，其性能与被检查产品的性能进行比较，并具有足以满足其预期用途的纯度。\n2.一种经过认证的、统一的材料，用于特定的化学和物理测试，其性能与被检查产品的性能进行比较，并具有适合其预期用途的纯度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.The term chemical reference substances, as used in this text, refers to an authenticated, uniform material that is intended for use in specified chemical and physical tests, in which its properties are compared with those of the product under examination, and which possesses a degree of purity adequate for its intended use.\n2.An authenticated, uniform material that is intended for use in specified chemical and physical tests, in which its properties are compared with those of the product under examination, and which possesses a degree of purity adequate for its intended use."
    },
    {
        "instruction":"已知信息：\n'使排便通畅的药物。包括多种盐类，如镁盐、磷酸盐、枸椽酸盐等，如硫酸镁。'可被翻译为：Drugs that make bowel movements unimpeded. Include a variety of salts such as magnesium salts, phosphates, citrate salts, etc., such as magnesium sulfate.\n'减少尿排泄量，治疗尿崩症的药物。如垂体后叶素制剂、鞣酸加压素注射液等。'可被翻译为：Drugs that reduce urinary excretion and treat diabetes insipidus. Such as pituitrin preparations, vasopressin tannate injection, etc.\n'根据治疗需要或药物性质而选择的药物使用途径或方法。如口服、静脉注射等。'可被翻译为：The route or method of drug use chosen according to the need for treatment or the nature of the drug. Such as oral, intravenous, etc.\n'对中枢神经系统能产生不同程度的抑制作用，引起镇静和催眠的药物。常用的药物有：巴比妥类（如苯巴比妥）、苯二氮卓类（如地西泮）和其他类（如甲丙氨酯）。'可被翻译为：Drugs that can produce varying degrees of inhibition on the central nervous system, causing sedation and hypnosis. Commonly used drugs are: barbiturates (e.g. Phenobarbital), benzodiazepines (e.g. Diazepam), and others (e.g. Methalamine).\n\n根据上述已知信息，请将'治疗和防止惊厥的药物。如地西泮、镁盐注射剂等。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Drugs to treat and prevent convulsions. Such as diazepam, magnesium salt injections, etc."
    },
    {
        "instruction":"已知信息：\n'为进一步保障公众用药安全，2020年6月9日，国家药品监督管理局发布公告，决定对垂体后叶注射液说明书【不良反应】、【注意事项】等项进行修订。'可被翻译为：To further protect drug safety for the people, on June 9, 2020, NMPA issued an Announcement with decisions made to revise the [adverse reactions], [precautions], etc. in the package insert of Posterior Pituitary Injection.\n'根据药品不良反应评估结果，为进一步保障公众用药的安全性，国家药品监督管理局于2019年11月8日发布公告，决定对活血止痛胶囊等口服制剂（片剂、散剂、软胶囊剂、胶囊剂）药品说明书【警示语】【不良反应】【禁忌】和【注意事项】项进行修订。'可被翻译为：In accordance with the results of the Adverse Drug Reaction Evaluation, in order to further ensure the safety of public education, on November 8, 2019, NMPA issued an Announcement with decisions made to revise the Entries of [warnings],[adverse reactions], [contraindications]and [precautions] of oral preparations(tablets, powders, soft capsules, capsules)such as Huoxuezhitong capsules.\n'为进一步保障公众用药安全，国家药品监督管理局于2020年6月11日发布公告，决定对维生素B2注射剂说明书【不良反应】、【禁忌】等项进行修订。'可被翻译为：To further protect drug safety for the people, on June 11, 2020, NMPA issued an Announcement with decisions made to revise the [adverse reactions], [contraindications], etc. in the package insert of Vitamin B2 Injection.\n'为进一步保障公众用药安全，国家药品监督管理局于2020年6月11日发布公告，决定对硫代硫酸钠注射剂说明书【不良反应】、【注意事项】等项进行修订。'可被翻译为：To further protect drug safety for the people, on June 11, 2020, NMPA issued an Announcement with decisions made to revise the [adverse reactions], [precautions], etc. in the package insert of Sodium Thiosulfate Injection.\n\n根据上述已知信息，请将'根据药品不良反应评估结果，为进一步保障公众用药安全，国家药品监督管理局于2020年6月9日发布公告，决定对川贝枇杷制剂（包括糖浆剂、膏剂、颗粒剂、片剂、胶囊剂）说明书【不良反应】【禁忌】和【注意事项】项进行统一修订。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In accordance with the results of AD Revaluation, to further protect drug safety for the people, NMPA issued an Announcement on June 9, 2020, with decisions made to uniformly revise the [adverse reactions],[contraindications] and [precautions] in the package inserts of Chuanbei Pipa Preparations (including syrups, ointments, granules, tablets and capsules)."
    },
    {
        "instruction":"已知信息：\n'国家药监局关于发布医疗器械分类目录动态调整工作程序的公告'可被翻译为：NMPA Announcement on Issuing the Working Procedures for Dynamic Adjustment of Classification Catalogue for Medical Devices\n'第九条 国家食品药品监督管理总局可以组织医疗器械分类专家委员会制定、调整医疗器械分类目录。'可被翻译为：Article 9 The China Food and Drug Administration may organize a medical device classification experts committee to formulate and adjust the medical device classification catalogue.\n'第一条 为规范医疗器械分类，根据《医疗器械监督管理条例》，制定本规则。'可被翻译为：Article 1 The Rules is stipulated in accordance with the Regulations on Supervision and Administration of Medical Devices to standardize the classification of medical devices.\n'第一条 为加强医疗器械监督管理，保证医疗器械通用名称命名科学、规范，根据《医疗器械监督管理条例》，制定本规则。'可被翻译为：Article 1 The Rules is formulated in accordance with the Regulations on the Supervision and Administration of Medical Devices to enhance the supervision and administration of medical devices and ensure that the nomenclature of medical devices is scientific and normative.\n\n根据上述已知信息，请将'为加强医疗器械分类管理，规范《医疗器械分类目录》动态调整工作，根据《医疗器械监督管理条例》《医疗器械分类规则》，国家药监局组织制定了《医疗器械分类目录动态调整工作程序》，并于4月27日发布。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to strengthen the classification management of medical devices and standardize the dynamic adjustment of the Classification Catalogue for Medical Devices, according to the Regulations for the Supervision and Administration of Medical Devices and the Classification Rules for Medical Devices, NMPA has organized to formulate the Working Procedures for Dynamic Adjustment of Classification Catalogue for Medical Devices, which was issued on April 27."
    },
    {
        "instruction":"已知信息：\n'三、临床医师、药师应当仔细阅读甲巯咪唑制剂说明书的修订内容，在选择用药时，应当根据新修订说明书进行充分的获益\/风险分析。'可被翻译为：III. The clinicians and pharmacists shall carefully read the revised content of the package inserts for methimazole preparations. Drug options should be based on comprehensive benefit\/risk analysis as per the new revisions.\n'三、临床医师、药师应当仔细阅读妇产科用米索前列醇片说明书的修订内容，在选择用药时，应当根据新修订说明书进行充分的获益\/风险分析。'可被翻译为：III. Clinicians and pharmacists shall carefully read the revised content in the package insert of Misoprostol Tablets for obstetrical and gynecological application; in the selection of drugs, comprehensive benefit\/risk analysis shall be made based on the newly revised package insert.\n'二、临床医师、药师应当仔细阅读柳氮磺吡啶制剂说明书的修订内容，在选择用药时，应当根据新修订说明书进行充分的获益\/风险分析。'可被翻译为：2. The clinicians and pharmacists should carefully read the revised contents of the package inserts for Sulfasalazine Preparations. Drug options should be based on comprehensive benefit \/ risk analysis as per the new revisions.\n'三、患者应严格遵医嘱用药，用药前应当仔细阅读说明书。'可被翻译为：3. The patients should carefully read the newly modified package inserts before use, and strictly comply with the medication orders.\n\n根据上述已知信息，请将'三、临床医师、药师应当仔细阅读上述药品说明书的修订内容，在选择用药时，应当根据新修订说明书进行充分的获益\/风险分析。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"III. The clinicians and pharmacists shall carefully read the revised contents of the package inserts for Vitamin B6 injection. Drug options should be based on comprehensive benefit\/risk analysis a sper the new revisions."
    },
    {
        "instruction":"已知信息：\n'省级药品监管部门依职责负责辖区内持有人药品上市后生产监管事项变更的许可、登记和注册管理事项变更的备案、报告等管理工作；依法组织实施对药品上市后变更的监督管理。'可被翻译为：Provincial drug regulatory departments shall be responsible for the permit and registration of the post-approval change of supervision items for production, and the filing and reporting of the post-approval change of administrative items for registration for the drugs of MAHs within their respective administrative regions in accordance with their responsibilities; and organize the supervision and administration of post-approval changes of drugs in accordance with law.\n'第三十条 持有人和受托生产企业所在地省级药品监管部门应当按照药品生产监管的有关规定加强对药品上市后变更的监督管理，对持有人变更控制体系进行监督检查，督促其履行变更管理的责任。'可被翻译为：Article 30 The provincial drug regulatory department in the place where the MAHs and contract manufacturers are located shall strengthen the supervision and administration of post-approval changes of drugs in accordance with the relevant provisions for drug production supervision, supervise and inspect the MAHs' change control system, and urge them to fulfill their responsibilities for change management.\n'第二条 本办法所指药品上市后变更包括注册管理事项变更和生产监管事项变更。'可被翻译为：Article 2 In the Provisions, the post-approval changes of drugs include the change of registration administrative items and the change of production supervision items.\n'三是加强备案后监督管理，确保产品质量安全责任落实到位。明确备案后监督管理责任落实和工作要求，加大对备案产品违法违规行为的惩处力度；实施备案产品分级管理，合理配置监管资源。'可被翻译为：3. The enhancement of supervision and administration of post-notification to ensure that the responsibilities for product quality and safety are in place. The responsibilities and requirements for the supervision and administration of post notification are clarified, with stricter penalties for violations of laws and regulations on filed products, which are subject to classification management to rationally allocate supervision resources.\n\n根据上述已知信息，请将'各省级药品监管部门应当落实辖区内药品上市后变更监管责任，细化工作要求，制定工作文件，明确工作时限，药品注册管理和生产监管应当加强配合，互为支撑，确保药品上市后变更监管工作平稳有序开展。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Each provincial drug regulatory department shall implement the responsibility for supervision over change management of post-approval drugs at its administrative area, by specifying requirements, formulating working documents, and clarifying time limits. The cooperation between drug registration administration and production supervision should be consolidated for mutual support, to ensure the smooth and orderly implementation of change management of post-approval drugs."
    },
    {
        "instruction":"已知信息：\n'第八十条 伪造、变造、买卖、出租、出借医疗器械注册证的，按照《医疗器械监督管理条例》第六十四条第二款的规定予以处罚。'可被翻译为：Article 80 Where a medical device registration certificate is falsified, altered, bought or sold, leased or lent, punishments shall be made according to Paragraph 2, Article 64 of the Regulations on Supervision and Administration of Medical Devices.\n'第二十四条  任何单位或者个人不得伪造、变造、买卖、出租、出借医疗器械生产许可证。'可被翻译为：Article 24 No entity or individual is allowed to falsify, alter, trade in, rent or lend out the Medical Device Manufacturing License.\n'第七十九条 提供虚假资料或者采取其他欺骗手段取得医疗器械注册证的，按照《医疗器械监督管理条例》第六十四条第一款的规定予以处罚。'可被翻译为：Article 79 Where a medical device registration certificate is obtained by providing spurious documents or by other deception means, punishments shall be imposed according to Paragraph 1, Article 64 of the Regulations on Supervision and Administration of Medical Devices.\n'第二十八条  任何单位和个人不得伪造、变造、买卖、出租、出借医疗器械经营许可证。'可被翻译为：Article 28 No entity or individual is allowed to falsify, alter, trade in, rent or lend out the Medical Device Distribution License.\n\n根据上述已知信息，请将'第七十条 伪造、变造、买卖、出租、出借医疗器械注册证的，按照《医疗器械监督管理条例》第六十四条第二款的规定予以处罚。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 70 Where a medical device registration certificate is falsified, altered, bought or sold, leased or lent, punishments shall be made according to Paragraph 2, Article 64 of the Regulations on Supervision and Administration of Medical Devices."
    },
    {
        "instruction":"已知信息：\n'（五）进口单位未取得《药品经营许可证》（生产企业应当取得《药品生产许可证》）和《企业法人营业执照》的；'可被翻译为：(V) the importer has not obtained the Drug Supply License (in the case of a drug manufacturer, Drug Manufacturing Certificate shall be obtained) and the Business License for Legal Person;\n'（一）加盖本企业原印章的《药品生产许可证》或《药品经营许可证》和营业执照的复印件；'可被翻译为：(1) Copies of the Drug Manufacturing Certificate or Drug Supply Certificate, stamped with the seal of the enterprise, and the business license;\n'（一）《药品生产许可证》或者《药品经营许可证》复印件；'可被翻译为：(I) A copy of the Drug Manufacturing Certificate or Drug Distribution Certificate;\n'（二）申请人药品生产许可证或者药品经营许可证复印件，申请人为中成药上市许可持有人的，应当提供相关药品批准证明文件复印件；'可被翻译为：(II) A copy of the Drug Manufacturing Certificate or Drug Distribution Certificate, and if the applicant is the MAH of Chinese patent medicine, a copy of relevant drug approval document shall be provided;\n\n根据上述已知信息，请将'（二）报验单位的《药品经营许可证》和《企业法人营业执照》复印件；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(II) photocopies of Drug Supply Certificate and Business License for Legal Person of the applicant for testing;"
    },
    {
        "instruction":"已知信息：\n'第九十九条 纯化水、注射用水的制备、贮存和分配应当能够防止微生物的滋生。纯化水可采用循环，注射用水可采用70℃以上保温循环。'可被翻译为：Article 99: Purified water and water for injection should be produced, stored and distributed in a manner that prevents microbial growth. Purified water can be circulated, and water for injection can be circulated at a temperature above 70℃.\n'第一百条 应当对制药用水及原水的水质进行定期监测，并有相应的记录。'可被翻译为：Article 100: The quality of water for pharmaceutical use and its water sources should be monitored at defined intervals, and recorded accordingly.\n'物料和产品的处理应当按照操作规程或工艺规程执行，并有记录。'可被翻译为：All handling of materials and products should be carried out according to operation procedures and master manufacturing documents, and recorded accordingly.\n'第九十八条 纯化水、注射用水储罐和输送管道所用材料应当无毒、耐腐蚀；储罐的通气口应当安装不脱落纤维的疏水性除菌滤器；管道的设计和安装应当避免死角、盲管。'可被翻译为：Article 98: The materials of storage tanks and pipes for transport of purified water and water for injection should be non-toxical and corrosion resistant. The vent of storage tanks should be installed with non-fiber releasing hydrophobic microorganism retention filter. Dead legs should be avoided in the design and installation of pipelines.\n\n根据上述已知信息，请将'第一百零一条 应当按照操作规程对纯化水、注射用水管道进行清洗消毒，并有相关记录。发现制药用水微生物污染达到警戒限度、纠偏限度时应当按照操作规程处理。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 101: The pipes for purified water and water for injection should be cleaned and sanitized according to operation procedures and recorded accordingly. If bioburden of water for pharmaceutical use exceeds alert or action limits, actions should be taken according to operation procedures."
    },
    {
        "instruction":"已知信息：\n'1.按ISO 2859-1规定的批次检验程度。检验程度越高，检测的样品越多，因此，到达最终用户的有缺陷产品的风险越低。\n2.按ISO 2859-1规定的批次检验程度。检验程度越高，需要检测的样品越多，因此，缺陷产品到达消费者手中的风险就越低。'可被翻译为：1.The degree of examination of the lot, as specified in ISO 2859-1. The higher the inspection level, the more samples will be tested and, hence, the lower the risk of faulty products reaching the end-user.\n2.The degree of examination of the lot, as specified in ISO 2859-1. The higher the inspection level, the more samples that will be tested and, hence, the lower the risk of faulty products reaching the consumer.\n'当机体连续接受外界给予有依赖性药物达到一定程度而突然停药后出现的一系列症状。诸如痛苦，甚至威胁生命。'可被翻译为：A series of symptoms that occur when the body suddenly stops taking a dependent drug after receiving it continuously to a certain extent. Such as painful or even life threatening.\n'WFI 系统应包括连续监测系统，监测总有机碳（TOC）和电导率等指标，因为这些参数比离散取样更好地指示整体系统性能。传感器位置应基于风险。'可被翻译为：WFI systems should include continuous monitoring systems such as Total Organic Carbon (TOC) and\nconductivity, as these may give a better indication of overall system performance than discrete sampling. Sensor locations should be based on risk.\n'在可能的情况下，成品应使用经验证且受控的灭菌工艺进行最终灭菌，因为这种灭菌工艺比经验证且受控的除菌过滤工艺和\/或无菌工艺的无菌保证程度更高。当产品不能经受最终灭菌时，应考虑使用无菌工艺后终端热处理，结合无菌工艺，以提供更好的无菌保证。'可被翻译为：Where possible, finished product should be terminally sterilised, using a validated and controlled sterilisation process, as this provides a greater assurance of sterility than a validated and controlled sterile filtration process and\/or aseptic processing. Where it is not possible for a product to undergo terminal sterilisation, consideration should be given to using post-aseptic processing terminal heat treatment, combined with aseptic process to give improved sterility assurance.\n\n根据上述已知信息，请将'连续一系列批次提交接受抽样时的最差可容忍过程平均值的质量水平(ISO 2859-1)。注:制造商应始终达到比AQL更好的工艺平均水平。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The quality level that is the worst tolerable process average when a continuing series of lots is submitted for acceptance sampling (ISO 2859-1). Note: Manufacturers should be consistently achieving a process average that is better than the AQL."
    },
    {
        "instruction":"已知信息：\n'（一）质量管理部门的人员有权进入生产区和仓储区进行取样及调查。'可被翻译为：1. Personnel of quality management department should have the authority to access to production and storage areas for sampling and investigation.\n'第六十八条 休息室的设置不应当对生产区、仓储区和质量控制区造成不良影响。'可被翻译为：Article 68: Rest and refreshment rooms should not bring any hazard to production, storage and quality control areas.\n'第三十六条 生产区、仓储区应当禁止吸烟和饮食，禁止存放食品、饮料、香烟和个人用药品等非生产用物品。'可被翻译为：Article 36: In production and storage areas, smoking or eating and drinking, or the storage of food, drink, cigarettes or personal medication, as well as other goods not for manufacturing should be prohibited.\n'第三十五条 进入洁净生产区的人员不得化妆和佩带饰物。'可被翻译为：Article 35: Persons entering clean areas should not wear make-up, jewelry or similar accessories.\n\n根据上述已知信息，请将'第六十九条 更衣室和盥洗室应当方便人员进出，并与使用人数相适应。盥洗室不得与生产区和仓储区直接相通。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 69: Facilities for changing clothes and for washing and toilet purposes should be easily accessible and appropriate for the number of users. Toilets should not communicate directly with production or storage areas."
    },
    {
        "instruction":"已知信息：\n'无菌处理后采用的一种终端湿热工艺，该工艺已被证明可提供≤10-6的无菌保证水平，但不满足蒸汽灭菌的要求(例如，F0≥8分钟)。这也可能有利于破坏可能无法通过过滤去除的病毒。'可被翻译为：A terminal moist heat process employed after aseptic processing that has been demonstrated to provide a sterility assurance level of ≤ 10–6 but where the requirements of steam sterilization (for example, F0 ≥ 8 minutes) are not fulfilled. This may also be beneficial in the destruction of viruses that may not be removed through filtration.\n'在可能的情况下，成品应使用经验证且受控的灭菌工艺进行最终灭菌，因为这种灭菌工艺比经验证且受控的除菌过滤工艺和\/或无菌工艺的无菌保证程度更高。当产品不能经受最终灭菌时，应考虑使用无菌工艺后终端热处理，结合无菌工艺，以提供更好的无菌保证。'可被翻译为：Where possible, finished product should be terminally sterilised, using a validated and controlled sterilisation process, as this provides a greater assurance of sterility than a validated and controlled sterile filtration process and\/or aseptic processing. Where it is not possible for a product to undergo terminal sterilisation, consideration should be given to using post-aseptic processing terminal heat treatment, combined with aseptic process to give improved sterility assurance.\n'最终灭菌：对最终容器内的产品使用有效的灭菌剂或灭菌条件，以达到预定的 10-6 或更好的无菌保证水平（SAL）。例如已灭菌单元表面或内部存在单个活微生物的理论概率等于或小于 1×10-6（百万分之一）。'可被翻译为：Terminal Sterilisation - The application of a lethal sterilising agent or conditions to a product in its final container to achieve a predetermined sterility assurance level (SAL) of 10-6  or better (e.g. the theoretical probability of there being a single viable microorganism present on or in a sterilised unit is equal to or less than 1 x 10-6  (one in amillion)).\n'确保无菌工艺中密闭系统的所有产品接触表面的无菌性至关重要。无菌工艺中任何密闭系统的设计和选择 都应确保维持无菌性。最终除菌级过滤器之后，无菌设备（例如管道\/管道系统）与已灭菌产品通路的连接应设计成无菌连接（例如通过内在无菌连接装置）。'可被翻译为：It  is  critical  to  ensure  the  sterility  of  all  product  contact  surfaces  of closed  systems  used  for  aseptic processing. The design and selection of any closed system used for aseptic processing should ensure maintenance of sterility. Connection of sterile equipment (e.g. tubing\/pipework) to the sterilised product pathway after the final sterilising grade filter should be designed to be connected aseptically (e.g. by intrinsic sterile connection devices).\n\n根据上述已知信息，请将'无菌工艺后最终热处理：无菌工艺后采用的最终湿热工艺，已被证明可提供无菌保证水平（SAL）≤10-6 但不满足蒸汽灭菌的要求（例如 F0≥8 分钟）。这也可能有利于破坏可能无法过滤去除的病毒。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Post-aseptic  processing  terminal  heat  treatment—  A  terminal  moist  heat  process   employed  after  aseptic processing  which  has  been  demonstrated  to  provide  a  sterility  assurance  level  (SAL)  ≤10-6   but  where  the requirements of steam sterilisation (for example, Fo≥8 min) are not fulfilled. This may also be beneficial in the destruction of viruses that may not be removed through filtration."
    },
    {
        "instruction":"已知信息：\n'药品注册现场核查(药物临床试验) 的目的主要是通过对注册申报资料与临床试验的原始记录和文件的核对和\/或实地确证， 评价试验实施、数据记录和结果报告是否符合试验方案和药物临床试验相关法规， 核实相关申报资料的真实性、一致性，同时关注受试者保护。'可被翻译为：On-site inspection for drug registration (Drug Clinical Trials) is mainly aimed at evaluating whether the clinical trial execution, data recording and result reporting conform to the trial protocol and relevant regulations of drug clinical trial, verifying the authenticity and consistency of relevant application dossiers, and paying attention to subject protection, by checking and\/or on-site inspection of the original data and documents of the application dossier and clinical trials.\n'(二) 药物临床试验现场核查， 是对注册申报资料中的临床试验情况进行实地检查、核实。主要对研究者履行职责情况，包括受试者保护、执行试验方案、数据记录和结果报告等方面进行核查。基于注册需要和风险原则， 可仅对部分核查要点内容进行核查。必要时， 可对申办者、合同研究组织或试验用药品制备条件及情况等进行现场核查，对试验用药品进行抽查检验。'可被翻译为：(II) On-site inspection of drug clinical trials refers to the on-site check and verification of the clinical trials in the registration application dossiers. It mainly verifies the investigators’ performance of duties, including subject protection, the implementation of trial protocols, data records and result reports. Based on registration requirements and risk principles, the inspection may only conduct on part of the inspection points. If necessary, the sponsor, the contract research organization or the preparation conditions of investigational drug may be subject to on-site inspection, and the investigational drug may be subject to sampling inspection.\n'药品监督管理部门可以对临床试验用药物抽查检验。'可被翻译为：Drug regulatory departments may conduct sampling and testing on drugs used for clinical trials.\n'第六十四条 研究者应当保证所有临床试验参与人员充分了解临床试验方案、相关规定、试验用医疗器械特性以及与临床试验相关的职责，并确保有足够数量并符合临床试验方案入选标准的受试者进入临床试验、确保有足够的时间在协议约定的试验期内，按照相关规定安全地实施和完成临床试验。'可被翻译为：Article 64 The investigator shall ensure that all clinical trial participants are fully aware of the clinical trial protocol, relevant provisions, characteristics of the investigational medical device and the respective responsibilities in the clinical trial, that sufficient subjects who meet the selection criteria in the clinical trial protocol are involved in the clinical trial and that the time decided in the agreement is sufficient to safely implement and complete the clinical trial in accordance with relevant regulations during the trial period.\n\n根据上述已知信息，请将'药物临床试验现场核查主要是核对注册申报资料与临床试验的原始记录和文件，评价试验实施、数据记录和结果报告是否符合试验方案和药物临床试验相关法规，同时关注受试者保护。必要时可对临床试验用药物进行抽查检验。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The on-site inspection of drug clinical trials is mainly to check the registration application dossiers and the original records and documents of clinical trials, evaluate whether the implementation of the trial, data records and result reports comply with the trial protocol and relevant laws and regulations of drug clinical trials, and pay attention to the protection of subjects. If necessary, random sample and test can be conducted on drugs used in clinical trials."
    },
    {
        "instruction":"已知信息：\n'接种单位接种非免疫规划疫苗，除收取疫苗费用外，还可以收取接种服务费。接种服务费的收费标准由省、自治区、直辖市人民政府价格主管部门会同财政部门制定。'可被翻译为：When administering non-immunization program vaccines, immunization entities may charge an immunization service fee in addition to the fee for vaccines. The criteria for immunization service fee shall be formulated by the pricing departments of the people's governments of provinces, autonomous regions and municipalities directly under the Central Government jointly with the financial departments.\n'第三十二条 国家免疫规划疫苗由国务院卫生健康主管部门会同国务院财政部门等组织集中招标或者统一谈判，形成并公布中标价格或者成交价格，各省、自治区、直辖市实行统一采购。'可被翻译为：Article 32 For national immunization program vaccines, the centralized bidding or unified negotiation shall be organized by the competent health department under the State Council jointly with the financial and other departments under the State Council. The winning price or transaction price shall be established and released, and each province, autonomous region and municipality directly under the Central Government shall implement unified procurement.\n'第四十一条 国务院卫生健康主管部门制定国家免疫规划；国家免疫规划疫苗种类由国务院卫生健康主管部门会同国务院财政部门拟订，报国务院批准后公布。'可被翻译为：Article 41 The competent health department under the State Council shall formulate the national immunization program; vaccine varieties in the national immunization program shall be proposed by the competent health department under the State Council jointly with the financial department under the State Council, and released upon approval by the State Council.\n'省、自治区、直辖市人民政府在执行国家免疫规划时，可以根据本行政区域疾病预防、控制需要，增加免疫规划疫苗种类，报国务院卫生健康主管部门备案并公布。'可被翻译为：When implementing the national immunization program, people's governments of provinces, autonomous regions and municipalities directly under the Central Government may add vaccine varieties to their immunization program based on the need for disease prevention and control within their respective administrative regions, and release the adjustment after filing the record with the competent health department under the State Council.\n\n根据上述已知信息，请将'疾病预防控制机构配送非免疫规划疫苗可以收取储存、运输费用，具体办法由国务院财政部门会同国务院价格主管部门制定，收费标准由省、自治区、直辖市人民政府价格主管部门会同财政部门制定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Disease prevention and control institutions may charge storage and transportation fee for distributing non-immunization program vaccines; the specific measures shall be formulated by the financial department under the State Council in conjunction with the competent pricing department under the State Council; and the charging criteria shall be formulated by the competent pricing departments of the people's governments of provinces, autonomous regions and municipalities directly under the Central Government in conjunction with the financial departments at the same level."
    },
    {
        "instruction":"已知信息：\n'用于定量测定生物基质中待测物的分析方法。'可被翻译为：Analytical method used in the quantitative determination of analytes in biological matrices.\n'处理批（针对生物分析）'可被翻译为：batch (for bioanalysis)\n'加入已知量待测物的基质。校正标样被用于构建校正曲线。'可被翻译为：A matrix to which a known amount of analyte has been added or spiked. Calibration standards are used to construct calibration curves.\n'在基于LBA的生物分析方法中，与待测物结合的试剂。'可被翻译为：A reagent that binds to the analyte in LBA-based bioanalytical methods.\n\n根据上述已知信息，请将'加入已知量待测物的生物基质，用于监测生物分析方法的性能，并评估单个处理批或分析批中分析的未知样品结果的完整性和有效性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A biological matrix spiked with a known quantity of analyte that is used to monitor the performance of a bioanalytical method and assess the integrity and validity of the results of the unknown samples analysed in an individual batch or run."
    },
    {
        "instruction":"已知信息：\n'第一百四十七条 应当根据确认或验证的对象制定确认或验证方案，并经审核、批准。确认或验证方案应当明确职责。'可被翻译为：Article 147: The qualification or validation protocol should be prepared based on its object. The protocol should be reviewed and approved. Responsibilities should be specified in the protocol.\n'第一百四十八条 确认或验证应当按照预先确定和批准的方案实施，并有记录。确认或验证工作完成后，应当写出报告，并经审核、批准。确认或验证的结果和结论（包括评价和建议）应当有记录并存档。'可被翻译为：Article 148: Qualification or validation should be implemented in accordance with a predefined and approved protocol, and be recorded. Upon completion of qualification or validation, a report should be prepared, reviewed and approved. The qualification or validation result and conclusion (including comments and suggestions) should be recorded and archived.\n'5.确保完成各种必要的验证工作；'可被翻译为：5) To ensure that the necessary validations are done;\n'第五十五条 验证应当按照预先确定和批准的方案实施，验证报告应当经过审核和批准，验证文件应当存档。'可被翻译为：Article 55 Validation shall be carried out in accordance with the pre-determined and approved scheme; the validation report shall be reviewed and approved. Validation documents shall be archived.\n\n根据上述已知信息，请将'9.确保完成各种必要的确认或验证工作，审核和批准确认或验证方案和报告；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"9) To ensure the necessary qualifications or validations are done appropriately, and to review and approve validation protocols and reports;"
    },
    {
        "instruction":"已知信息：\n'由申办者设立一个独立的数据监查委员会，它定期对研究进展、安全性数据和关键疗效终点进行评估，向申办者建议是否继续、调整或停止试验。'可被翻译为：An independent data monitoring committee that may be established by the sponsor to assess at intervals the progress of a clinical trial, the safety data, and the critical efficacy endpoints, and to recommend to the sponsor whether to continue, modify, or stop a trial.\n'1.对试验负责并对保护试验对象的权利、健康和福利负责的人。研究者必须是法律允许执业医学\/牙科的适当合格人员。\n2.对试验和对试验对象的权利、健康和福利负责的人。研究者应具有符合当地法律法规的资格和能力，并有最新的简历和其他证书作为证明。与医疗或牙科护理相关的决定和提供必须始终由法律允许执业医学或牙科的临床胜任人员负责。'可被翻译为：1.The person responsible for the trial and for protecting the rights, health and welfare of the subjects in the trial. The investigator must be an appropriately qualified person legally allowed to practice medicine\/dentistry.\n2.A person responsible for the trial and for the rights, health and welfare of the subjects in the trial. The investigator should have qualifications and competence in accordance with local laws and regulations as evidenced by an up-to-date curriculum vitae and other credentials. Decisions relating to, and the provision of, medical or dental care must always be the responsibility of a clinically competent person legally allowed to practise medicine or dentistry.\n'第三十八条 申办者负责发起、申请、组织、监查临床试验，并对临床试验的真实性、可靠性负责。申办者通常为医疗器械生产企业。申办者为境外机构的，应当按规定在我国境内指定代理人。'可被翻译为：Article 38 The sponsor shall be responsible for initiating, applying for, organizing and supervising the clinical trial, and shall be responsible for the authenticity and reliability of the clinical trial. The sponsor is usually a medical device manufacturer. Where the sponsor is an overseas enterprise, it shall designate an agent within the territory of China in accordance with the regulations.\n'第四十五条 申办者对试验用医疗器械在临床试验中的安全性负责。当发现可能影响受试者安全或者试验实施可能改变伦理委员会对继续试验的批准情况时，申办者应当立即通知所有临床试验机构和研究者，并作出相应处理。'可被翻译为：Article 45 The sponsor shall be responsible for the safety of investigational medical device in clinical trial. When finding it may affect the safety of the subjects or the implementation of the trial may change the approval of the ethics committee for the continuation of the trial, the sponsor shall immediately notify all clinical trial institutions and investigators and make corresponding handling.\n\n根据上述已知信息，请将'1.对控制参数进行有计划的一系列观察或测量，以评估CCP是否受到控制的行为。\n2.由申办方指定并对其负责的人员，负责监测和报告试验的进展情况，并对数据进行核实。\n3.由申办者或CRO任命并对其负责的人，负责监测和报告试验的进展情况并核实数据。\n4.由申办者指定的负责监测和报告试验进展及数据核查的人员。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.The act of conducting a planned sequence of observations or measurements of control parameters to assess whether a CCP is under control.\n2.A person appointed by, and responsible to, the sponsor for monitoring and reporting the progress of the trial and for the verification of data.\n3.A person appointed by, and responsible to, the sponsor or CRO for the monitoring and reporting of progress of the trial and for verification of data.\n4.A person appointed by the sponsor who is responsible for monitoring and reporting the progress of the trial and for the verification of data."
    },
    {
        "instruction":"已知信息：\n'国家药监局关于药物临床试验数据自查核查注册申请情况的公告'可被翻译为：NMPA Issued the Announcement on Registration Application Situation and Self-Examination & Verification of Drug Clinical Trial Data\n'附件：7个药物临床试验数据自查核查注册申请清单（省略）'可被翻译为：Annex: List of Registration Applications for 7 Drugs with Self-Examination &Verification of Clinical Trial Data (Omitted)\n'2020年3月31日，国家药监局发布《关于实施<药品注册管理办法>有关事宜的公告》（2020年 第46号），公告内容如下：'可被翻译为：On March 31, 2020, NMPA issued the Announcement on Issues Pertaining to the Implementation of the Provisions for Drug Registration (No. 46 of 2020), which reads as follows:\n'国家药监局 国家卫生健康委关于发布药物临床试验机构管理规定的公告'可被翻译为：NMPA and NHC Jointly Issued the Announcement on Regulations for the Administration of Drug Clinical Trial Institutions\n\n根据上述已知信息，请将'2019年10月15日，国家药监局发布《关于药物临床试验数据自查核查注册申请情况的公告》，决定核实7份已完成临床试验并申请生产的药品的临床试验数据，现将有关事宜公告如下：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"On October 15, 2019, NMPA released the Announcement on Registration Application Situation and Self-Examination &Verification of Drug Clinical Trial Data with decision made to verify the clinical trial data of 7 newly received registration applications for drugs that have completed the clinical trials and are applying for production, the relevant issues are hereby announced:"
    },
    {
        "instruction":"已知信息：\n'（二）企业内部所用物料名称和（或）代码；'可被翻译为：2. The \"in-house\" name and\/or code of material;\n'1.企业统一指定的物料名称和内部使用的物料代码；'可被翻译为：1) Name designated by the manufacturer and internal code reference;\n'（一）产品名称和企业内部的产品代码；'可被翻译为：1. The name of the product and the internal code reference;\n'3.所用原辅料清单（包括生产过程中使用，但不在成品中出现的物料），阐明每一物料的指定名称、代码和用量；如原辅料的用量需要折算时，还应当说明计算方法。'可被翻译为：3) A list of all starting materials to be used, with the amount of each, described using the designated name and a reference that is unique to that material (mention should be made of any substance that may disappear in the course of processing); When conversion between measuring methods or units is needed, the calculation method should be specified.\n\n根据上述已知信息，请将'（一）指定的物料名称和企业内部的物料代码；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1. The designated name and the internal code reference of the material;"
    },
    {
        "instruction":"已知信息：\n'染色体数目与原来的染色体单倍体或二倍体不同；对于细胞系，其染色体数目与原型染色体不同。'可被翻译为：Chromosome numbers different from the original haploid or diploid set of chromosomes; for cell lines, chromosome numbers differe nt from the modal chromosome set.\n'细胞或生物体中染色体数目不成倍数的改变。'可被翻译为：Numerical deviation of the modal number of chromosomes in a cell or organism.\n'染色体数目从所利用细胞的正常数目特性的改变。'可被翻译为：A change in the number of chromosomes from the normal number characteristic of the utilized cell.\n'染色体数目畸变'可被翻译为：chromosome numerical aberration\n\n根据上述已知信息，请将'细胞中染色体倍数的数目变化，大致为单倍体数目的整数倍。核内复制是多倍体的一种形态类型，其为染色体对在中期相进行联合成为“双分染色体 ”。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Numerical deviation of the modal number of chromosomes in a cell, with approximately whole multiples of the haploid number. Endoreduplication is a morphological form of polyploidy in which chromosome pairs are associated at metaphase as “diplochromosomes”."
    },
    {
        "instruction":"已知信息：\n'能溶解气体、固体、液体而成为均匀混合物的一种液体。'可被翻译为：A liquid capable of dissolving a gas, solid, or liquid into a uniform mixture.\n'一种或几种物质分散到另-种物质里，形成的均一的、稳定的混合物。'可被翻译为：A uniform, stable mixture formed by the separation of one or more substances into another.\n'在处理液中加入某种试剂使某种物质从液体中析出。'可被翻译为：A reagent is added to the treatment liquid to precipitate a substance from the liquid.\n'将液态物质加热到沸腾变为蒸气，又将蒸气冷却为液体的两个联合操作过程。是提纯液体物质和分离混合物的一种常用的方法。'可被翻译为：The combined process of heating a liquid substance to boiling to vapor and of cooling the vapor to liquid. It is a common method of purifying liquid substances and separating mixtures.\n\n根据上述已知信息，请将'将某种物质溶解在一溶剂中，使该物质从一种固体或一种液体混合物中分离出来。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Dissolving a substance in a solvent separates the substance from a solid or a liquid mixture."
    },
    {
        "instruction":"已知信息：\n'分析方法应根据现行WHO技术报告系列中发布的指南进行验证。'可被翻译为：10.6. Analytical procedures should be validated according to the guidelines as published in current WHO Technical Report Series (7).\n'WHOGMP指南：验证，WHO TRS992附录3附录7无菌工艺验证，2015'可被翻译为：10. WHO guidelines on good manufacturing practices: validation. Appendix 7. Non-sterile process validation. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: forty-ninth report. Geneva: World Health Organization; 2015: Annex 3 (WHO Technical Report Series, No. 992; https:\/\/www.who.int\/medicines\/areas\/quality_safety\/quality_assurance\/Annex3 TRS992.pdf, accessed 30 November 2020).\n'对于清洁程序，应根据现行WHO技术报告系列中发布的指南进行开发和验证。在制订清洁程 序、清洁度研究和设定可接受限度时应考虑在清洁验证中使用HBEL时的考量要点。'可被翻译为：10.5. For cleaning procedures, development and validation should be done in accordance with the guidelines as published in current WHO Technical Report Series (6). Points to consider when using HBEL in cleaning validation (14) should be taken into account in establishing cleaning procedures, cleanability studies and setting acceptance limits.\n'无菌工艺验证的现行做法-2001'可被翻译为：Current Practices in the Validation of Aseptic Processing -- 2001\n\n根据上述已知信息，请将'工艺验证应依据现行WHO TRS中发布的指南执行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"10.3. Process validation should be done according to guidelines as published in current WHO Technical Report Series (3)."
    },
    {
        "instruction":"已知信息：\n'促进液体在固体表面铺展或渗透的过程。'可被翻译为：The process of promoting the spread or penetration of liquid on a solid surface.\n'能够改善疏水性微粒表面被介质(水)润湿性能的附加剂。'可被翻译为：An additive that can improve the wettability of the surface of hydrophobic particles by a medium (water).\n'物质（主要是固体物质）表面吸住周围介质（液体或气体）中的分子或离子现象。'可被翻译为：The phenomenon in which the surface of a substance (mainly a solid substance) absorbs molecules or ions in the surrounding medium (liquid or gas).\n'固体药物粉碎的程度。'可被翻译为：The degree to which the solid drug is crushed.\n\n根据上述已知信息，请将'固体表面被液体润湿的难易程度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The ease with which a solid surface can be wetted by a liquid."
    },
    {
        "instruction":"已知信息：\n'为进一步保障公众用药安全，国家药品监督管理局决定对氨酚麻美口服溶液、氨酚麻美糖浆、小儿氨酚烷胺颗粒、氨酚伪麻那敏咀嚼片、小儿复方氨酚烷胺片、小儿氨咖黄敏颗粒、氨金黄敏颗粒、氨咖愈敏溶液、儿童复方氨酚肾素片、氨咖黄敏口服溶液、氨酚伪麻那敏分散片（Ⅲ）、小儿氨酚那敏片、小儿氨酚黄那敏片、小儿氨酚黄那敏颗粒等14个品种药品说明书进行修订。'可被翻译为：In order to further protect the medication safety for the public, NMPA decided to revise the package inserts of 14 drug varieties including the Paracetamol, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, Paracetamol, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup, Pediatric Paracetamol and Amantadine Hydrochloride Granules, Paracetamol, Pseudoephedrine Hydrochloride and Chlorpheniramine Maleate Chewable Tablets, Pediatric Compound Paracetamol and Amantadine Hydrochloride Tablets, Pediatric Paracetamol, Caffein, Artificial Cow-bezoar and Chlorphenamine Maleate Granules, Paracetamol, Amantadine Hydrochloride, Artificial Cow-bezar and Chlorphenamine Mdeate Granules, Paraceramol Caffeine Guaifenfsin and Chlorphenamine Maleate Solution, Pediatric Compound Paracetamol and Phenylephrine Tablets, Paracetamol, Caffeine, Artificial Cow-Bezoar, Chlorphenamine Maleate Oral Solution, Paracetamol, Pseudoephedrine Hydrochloride and Chlorphenamine Maleate Dispersible Tablets (III), Compound Paracetamol and Chlorphenamine Tablets for Infant, Pediatric Paracetamol, Artificial Cow-bezoar and Chlorphenamine Maleate Tablets, and Pediatric Paracetamol, Artificial Cow-bezoar and Chlorphenamine Maleate Granules.\n'国家药监局关于修订活血止痛胶囊等口服制剂处方药和非处方药说明书的公告'可被翻译为：NMPA Issued the Announcement on Revising the Package Inserts of Prescription and Over-the-counter Oral Preparations such as Huoxuezhitong Capsules\n'国家药监局关于修订含吡哌酸药品说明书的公告'可被翻译为：Announcement of NMPA on Revising the Package Inserts of Drugs Containing Pipemidic Acid\n'国家药监局关于修订烟酸注射剂说明书的公告'可被翻译为：Announcement of NMPA on Revising the Package Inserts of Nicotinic Acid Injections\n\n根据上述已知信息，请将'国家药监局关于修订氨酚麻美口服溶液等14个品种药品说明书的公告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Announcement on Revising the Package Inserts of 14 Drug Varieties Including Paracetamol, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution"
    },
    {
        "instruction":"已知信息：\n'国家药监局 国家知识产权局关于发布《药品专利纠纷早期解决机制实施办法（试行）》的公告'可被翻译为：Announcement of National Medical Products Administration and National Intellectual Property Administration on the Issuance of the Measures for the Implementation of the Mechanism for Early Settlement of Drug Patent Disputes (Interim)\n'为做好《药品专利纠纷早期解决机制实施办法（试行）》（以下简称《办法》）实施工作，现于7月4日就有关事宜通告如下：'可被翻译为：In order to complete the implementation of the Measures for the Implementation of the Mechanism for Early Settlement of Drug Patent Disputes (interim) (hereinafter referred to as the Measures), relevant issues are hereby announced on July 4 as follows:\n'根据《中华人民共和国专利法》，国家药监局、国家知识产权局组织制定了《药品专利纠纷早期解决机制实施办法（试行）》，经国务院同意，于7月4日予以发布，自发布之日起施行。'可被翻译为：In accordance with the Patent Law of the People's Republic of China, the National Medical Products Administration and the China National Intellectual Property Administration formulated the Measures for the Implementation of the Mechanism for Early Settlement of Drug Patent Disputes (interim), which will be promulgated and put into effect on July 4 with the approval by the State Council.\n'药品注册过程中发生专利权纠纷的，按照有关专利的法律法规解决。'可被翻译为：Where a patent dispute occurs in the process of drug registration, it shall be settled in accordance with relevant laws and regulations on patent.\n\n根据上述已知信息，请将'国家药监局关于实施《药品专利纠纷早期解决机制实施办法（试行）》相关事宜的通告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Announcement on the Issues Related to the Implementation of the Measures for the Implementation of the Mechanism for Early Settlement of Drug Patent Disputes (interim)"
    },
    {
        "instruction":"已知信息：\n'《中华人民共和国疫苗管理法》已由中华人民共和国第十三届全国人民代表大会常务委员会第十一次会议于2019年6月29日通过，现予公布，自2019年12月1日起施行。'可被翻译为：The Vaccine Administration Law of the People's Republic of China, adopted at the 11th Meeting of the Standing Committee of the Thirteenth National People's Congress on June 29, 2019, is hereby promulgated and shall go into effect as of December 1, 2019.\n'（1984年9月20日第六届全国人民代表大会常务委员会第七次会议通过 2001年2月28日第九届全国人民代表大会常务委员会第二十次会议第一次修订 根据2013年12月28日第十二届全国人民代表大会常务委员会第六次会议《关于修改〈中华人民共和国海洋环境保护法〉等七部法律的决定》第一次修正 根据2015年4月24日第十二届全国人民代表大会常务委员会第十四次会议《关于修改〈中华人民共和国药品管理法〉的决定》第二次修正 2019年8月26日第十三届全国人民代表大会常务委员会第十二次会议第二次修订）'可被翻译为：(Adopted at the 7th Meeting of the Standing Committee of the Sixth National People's Congress on September 20, 1984; revised for the first time at the 20th Meeting of the Standing Committee of the Ninth National People's Congress on February 28, 2001; amended for the first time in accordance with the Decision on Revising Seven Laws Including the Marine Environmental Protection Law of the People's Republic of China adopted at the 6th Meeting of the Standing Committee of the Twelfth National People's Congress on December 28, 2013; amended for the second time in accordance with the Decision on Revising the Drug Administration Law of the People's Republic of China adopted at the 14th Meeting of the Standing Committee of the Twelfth National People's Congress on April 24, 2015; revised for the second time at the 12th Meeting of the Standing Committee of the Thirteenth National People's Congress on August 26, 2019)\n'2019年8月26日，经第十三届全国人大常委会第十二次会议修订通过，修订后的《中华人民共和国药品管理法》（以下称药品管理法）自2019年12月1日起施行。国家药监局正在抓紧开展配套规章、规范性文件和技术指南的制修订工作，并将按程序陆续发布。现就贯彻实施新修订的药品管理法有关事项公告如下：'可被翻译为：Revised and adopted by the Twelfth Session of the Standing Committee of the 13th National People's Congress on August 26,2019, the revised Drug Administration Law of the People's Republic of China(hereinafter referred to as DAL) shall be implemented as from December 1,2019. NMPA is stepping up work on the development, formulation and revision of supporting regulations, normative documents and technical guidelines, which will be released in accordance with procedures. We hereby announce the issues pertaining to the implementation of the newly revised DALas follows:\n'2018年10月，《药品管理法（修正草案）》提交第十三届全国人大常委会第六次会议进行初次审议，并于会后公开征求社会公众意见。审议中，有意见提出现行《药品管理法》自2001年修订以来，没有进行大的修改，建议将历年来药品领域改革成果和行之有效的做法上升为法律，将修正草案改为修订草案。2019年4月，第十三届全国人大常委会第十次会议对《药品管理法（修订草案）》进行审议。2019年8月26日，第十三届全国人大常委会第十二次会议进行第三次审议并表决通过。'可被翻译为：In October 2018, the DAL Amendment Draft was submitted to the Sixth Session of the Standing Committee of the 13thNational People's Congress for initial deliberation, and subsequent solicitation of public comments. During the deliberation,taken into account that no major revisions have been made since the DAL revision in2001, it was recommended that the results of the reform of the pharmaceutical sector and effective practices over the years be raised to the law, and the draft amendments be changed to the revised drafts. In April2019, the Tenth Session of the Standing Committee of the 13th National People'sCongress deliberated the Revised Draft of DAL, which has been passed by voting on August 26, 2019 at the third deliberation of the Twelfth Session of the Standing Committee of the 13th National People'sCongress.\n\n根据上述已知信息，请将'《中华人民共和国药品管理法》已由中华人民共和国第十三届全国人民代表大会常务委员会第十二次会议于2019年8月26日修订通过，现予公布，自2019年12月1日起施行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The Drug Administration Law of the People's Republic of China adopted at the 12th Meeting of the Standing Committee of the Thirteenth National People's Congress on August 26, 2019 is hereby promulgated and shall go into effect as of December 1, 2019."
    },
    {
        "instruction":"已知信息：\n'（一）正常使用情况下存在可能危及人体健康和生命安全的不合理风险的产品；'可被翻译为：(1) products with unreasonable risks that may cause hazards to human health and life safety under normal use;\n'器械缺陷，是指临床试验过程中医疗器械在正常使用情况下存在可能危及人体健康和生命安全的不合理风险，如标签错误、质量问题、故障等。'可被翻译为：The device defect refers to the unreasonable risk that may endanger the human health and life safety in the normal use of medical device during the clinical trial, such as label errors, quality problems and breakdowns.\n'第四十八条  持有人通过医疗器械不良事件监测，发现存在可能危及人体健康和生命安全的不合理风险的医疗器械，应当根据情况采取以下风险控制措施，并报告所在地省、自治区、直辖市药品监督管理部门：'可被翻译为：Article 48 In case of identifying the medical devices with improper risks that may endanger human health or life safety through medical device adverse event monitoring, MAHs shall take following risk control measures according to the situations and report to the drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government where they locate:\n'第四条 本办法所称存在缺陷的医疗器械产品包括：'可被翻译为：Article 4 The defective medical device products mentioned in these Provisions include:\n\n根据上述已知信息，请将'第四条 本办法所称安全隐患，是指由于研发、生产等原因可能使药品具有的危及人体健康和生命安全的不合理危险。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 4 Safety hazards mentioned in these Provisions mean unreasonable drug-related hazards to human health and life caused by problems associated with research & development, production and other factors."
    },
    {
        "instruction":"已知信息：\n'细胞的冷冻保存'可被翻译为：CRYOPRESERVATION OF CELLS\n'冷冻保存是将细胞、组织或器官在超低温环境下存储来维持其活力的过程。目的是将细胞储存起来并应用到后续的体内外实验中，因为复苏后的细胞仍可以保持冻存前的功能。冷冻保存还可以最大限度地降低由于细胞复制而导致的基因突变或亚群发育的风险。根据不同的应用，充分的冷冻保存后的功能可通过细胞分裂、增殖、分化、表达基因或产生蛋白质的能力或其他特定的功能特性来评估。'可被翻译为：Cryopreservationis the process of cooling and storing cells, tissues, or organs at very lowtemperatures to maintain their viability. The purpose of cryopreservation is tobank the cells and allow their future use in in vitro or in vivo applicationsfor which post-thaw function is sufficiently representative of the cells'prefreeze function. Cryopreservation also minimizes the risk of geneticmutation or development of subpopulations due to cell replication. Depending onthe application, sufficient postcryopreservation function may beassessed by the ability to divide, proliferate, differentiate, express genes,or to produce proteins, or by another specific functional property.\n'冷冻过程完成后，产品从控制速率或机械冷冻机转移到低温存储单元。一些微生物细胞培养物可以适当地保存在冰箱中，但应证实这一点。在将细胞产品从冷冻设备转移到存储设备的过程中，应尽量减少样品的升温。可以使用冷桌或隔热传输装置来减少传送过程中的温度升高。通常，在完成对不定因子的测试之前，应将新冷冻保存的细胞放置在隔离的低温存储单元中。在测试之后，将不定因子测试呈阴性的细胞转移到长期低温存储单元中。'可被翻译为：After the freezing process has been completed, products are transferred fromcontrolled-rate or mechanical freezers to cryogenic storage units. Some microbial cell cultures can be suitably maintained in mechanical freezers but this should be demonstrated. Sample warming should be minimized during transfer of the cell product from the freezing device to storage. Cold tables or insulated transfer devices can be used to minimize warming during transfer.Newly cryopreserved cells commonly are placed in a quarantine cryogenic storage unit before completion of testing for adventitious agents. After testing, cells that test negative for adventitious agents can be released for transfer intolong-term cryogenic storage units.\n'另一种细胞保存方式，通常称为玻璃化，即在细胞悬浮液中加入高浓度的穿透性CPA（通常是几种），诱导形成玻璃化状态，诱导细胞和细胞外水不易形成冰晶。当以这种方式制备的细胞悬液快速冷却（冷却速率为100°–1000°\/ min或更高）时，极高的粘度可防止渗透，并且水分子无法形成冰晶。这个过程已广泛用于各种复杂结构的保存过程，包括各种人类、植物和动物组织在内，并且可以帮助保存具有不同程度的细胞渗透性的细胞制剂，或者也用于在所有组织的组成细胞类型标准冷冻保护程序无法提供其生存能力的条件范围内的最佳保存方案。'可被翻译为：Analternative form of cell preservation, commonly called vitrification,wherebythe cell suspension is loaded with high levels of penetrating CPAs (oftenseveral in combination), induces a glass-like state in which cellular andextracellular water cannot readily form ice crystals. When cell suspensionsprepared in this way then are cooled very rapidly (cooling rates of100°–1000°\/min or more) the extreme viscosity prevents osmosis, and the watermolecules are unable to form ice. This procedure has been widely used forcomplex structures including a variety of human, plant, and animal tissues andmay help preserve those cell preparations that have variable degrees ofcellular permeability or when standard cryoprotection cannot deliver the rangeof conditions required to optimally preserve viability in all the tissues'component cell types.\n\n根据上述已知信息，请将'使用受控速率冷冻装置可更精确地控制冷冻环境，从而在细胞外冰晶形成时为冷却速率范围狭窄（与最大存活率相关）或敏感的细胞提供更一致（且更高）的解冻后恢复能力。将温度探针放置在要冷冻的细胞附近或同时进行低温保存的模拟细胞悬液中，用于监视冷冻过程并提供过程控制。如果融合潜热的释放被延迟或控制不当，则进行冷冻保存的细胞可能会受到破坏，并且复苏后的活力可能会降低。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The useof controlled-rate freezing provides more precise control of the freezingenvironment and therefore may provide more consistent (and higher) post-thaw recoveryfor cells that may have a narrow range of cooling rates associated with maximum survival or cells that are sensitive to the temperature at which ice forms in theextracellular solution. Temperature probes placed near the cells being frozen,or in a mock cell suspension that undergoes cryopreservation simultaneously, areused to monitor the freezing process and to provide process control. If releaseof the latent heat of fusion is delayed or poorly controlled, cells undergoing cryopreservationmay be damaged and may have diminished viability after thaw."
    },
    {
        "instruction":"已知信息：\n'导致蛋白质活性构象和信号转导变化的蛋白质之间的作用。如多肽配体与蛋白酶、多肽激素与受体之间的相互作用。'可被翻译为：Interactions between proteins that cause changes in the active conformation and signal transduction of proteins. Such as interactions between polypeptide ligands and proteases, polypeptide hormones and receptors.\n'由蛋白质的肽链和寡糖链通过共价键结合而形成的结合蛋白。'可被翻译为：A binding protein formed by covalent bonding of a protein's peptide chain and oligosaccharide chain.\n'细胞中能够识别正在合成的多肽或部分折叠的多肽并与多肽的某些部位相结合，从而帮助这些多肽转运、折叠或装配的蛋白质分子。它本身并成为被帮助折叠的蛋白质的组成部分。目前有HSP60、HSP70、HSP90、小分子HSP和泛素等。'可被翻译为：The polypeptide being synthesized or partially folded polypeptide can be recognized in the cell and combined with certain parts of the polypeptide, thereby helping these polypeptides to transport, fold or assemble protein molecules. It itself becomes a component of the protein being helped to fold. Currently, there are HSP60, HSP70, HSP90, small molecules HSP, and ubiquitin.\n'以DNA重组技术生产的活性蛋白、多肽、酶、单克隆抗体、疫苗及细胞因子类药物。如重组人生长激素等。'可被翻译为：Active proteins, peptides, enzymes, monoclonal antibodies, vaccines and cytogenic drugs produced by DNA recombination technology. Such as recombinant human growth hormone, etc.\n\n根据上述已知信息，请将'结合物是指一个活性成分(如多肽、碳水化合物等) 通过共价键或非共价键与载体(如蛋白质、多肽、无机盐等)连接，以增强制品的效力或稳定性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A conjugated product is made up of an active ingredient (for example, peptide, carbohydrate) bound covalently or noncovalently to a carrier (for example, protein, peptide, inorganic mineral) with the objective of improving the efficacy or stability of the product."
    },
    {
        "instruction":"已知信息：\n'（四）产品原液、半成品和成品的检验项目、检验方法和结果是否符合药典和药品注册标准的要求；'可被翻译为：(IV) Whether the testing items, testing methods and results of bulk, final bulk and finished products meet the requirements stipulated by the ChP and the drug registration specifications;\n'（四）产品原液、半成品和成品的检验项目、检验方法和结果是否符合国家药品标准和药品注册标准的要求；'可被翻译为：(IV)  Whether the testing items, testing methods and results of bulk, final bulk and finished products meet the requirements stipulated by national drug standards and drug registration standards;\n'（八）检验项目，如检验项目少于成品质量标准所包含的项目，应当说明理由。'可被翻译为：8. Test items, if less than the quality specifications of a finished product, it should be justified.\n'(5) 以受试者自评结果作为疗效和安全性数据结果的溯源至有受试者署名确认的原始评估记录(如受试者日记卡、受试者自评报告等)。'可被翻译为：(5) Where the results of subjects’ self-evaluation are regarded as the efficacy and safety data results, it can be traceable to the original evaluation records signed by the subjects (such as subject diary card, subject self-evaluation report and etc.)\n\n根据上述已知信息，请将'1.用于医学判断的检验项目和作为疗效和安全性指标的检验项目通过国家级室间质评或经其他方法验证以保证检测结果的可靠性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1. For relevant inspection items used for medical judgement and used as efficacy and safety index, the reliability of the test results is verified by national inter-laboratory quality assessment or other methods."
    },
    {
        "instruction":"已知信息：\n'碱基与糖相连组成的抗生素。'可被翻译为：An antibiotic consists of a base attached to a sugar.\n'脂肪链或长链脂酰基与肽相连组成的抗生素。'可被翻译为：An antibiotic consisting of a fatty chain or long chain lipid acyl group attached to a peptide.\n'由氨基糖或氨基环醇与糖组成的抗生素。'可被翻译为：An antibiotic consisting of amino sugars or aminocyclic alcohols combined with sugars.\n'与糖以共价键相连接的一种肽。'可被翻译为：A peptide that is covalently bound to a sugar.\n\n根据上述已知信息，请将'糖与肽相连组成的抗生素。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An antibiotic consisting of a sugar attached to a peptide."
    },
    {
        "instruction":"已知信息：\n'熔距'可被翻译为：melting range\n'低共熔混合物'可被翻译为：eutectic mixture\n'垂熔玻璃滤器'可被翻译为：sintered glass filter\n'将安甑颈部受热并使其熔封的操作。'可被翻译为：The operation of heating the neck of an retort and sealing it.\n\n根据上述已知信息，请将'一种物质初熔至终熔时的温度范围。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The temperature range of a substance from initial to final melting."
    },
    {
        "instruction":"已知信息：\n'第三十五条  医疗器械注册人、备案人应当建立并实施产品追溯制度，保证产品可追溯。受托生产企业应当协助注册人、备案人实施产品追溯。'可被翻译为：Article 35 The registrant or filing entity of medical devices shall establish and implement the procedures for tracing products, to guarantee the traceability of the products. The contract manufacturer shall assist with the registrant and the filing entity in tracing the products.\n'第三十三条  医疗器械注册人、备案人、受托生产企业应当建立记录管理制度，确保记录真实、准确、完整和可追溯。'可被翻译为：Article 33 The registrant, filing entity or contract manufacturer of medical devices shall establish record management procedures, to ensure the authenticity, accuracy, integrity and traceability of the records.\n'受托生产企业应当及时将变化情况告知医疗器械注册人、备案人。'可被翻译为：The contract manufacturer shall promptly inform the medical devices registrant or filing entity of the changes.\n'第五十一条  药品监督管理部门对医疗器械注册人、备案人自行生产的，开展监督检查时重点检查：'可被翻译为：Article 51 The drug regulatory department shall make key supervision and inspection on the registrant or filing entity of medical devices undertaking self-manufacturing regarding the following circumstances:\n\n根据上述已知信息，请将'第三十条  医疗器械注册人、备案人应当开展设计开发到生产的转换活动，并进行充分验证和确认，确保设计开发输出适用于生产。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 30 The registrant or filing entity of medical devices shall carry out transition activities from design and development to manufacturing, and make full verification and validation, so as to ensure that the output of design and development is applicable to the manufacturing."
    },
    {
        "instruction":"已知信息：\n'（六）国家药品监督管理局规定其他优先审评审批的情形。'可被翻译为：(6) Other circumstances of priority review and approval specified by the NMPA.\n'第五十八条  持有人主动开展医疗器械再评价的，应当制定再评价工作方案。通过再评价确定需要采取控制措施的，应当在再评价结论形成后15日内，提交再评价报告。其中，国家药品监督管理局批准注册或者备案的医疗器械，持有人应当向国家监测机构提交；其他医疗器械的持有人应当向所在地省级监测机构提交。'可被翻译为：Article 58 In case of voluntarily carrying out medical device re-evaluation, MAHs shall develop re-evaluation plan. Where control measures are required through re-evaluation, MAHs shall submit the re-evaluation report within 15 days upon the formation of re-evaluation conclusion. For medical devices approved by the NMPA to be registered or filed shall submit the report to national monitoring agencies; MAHs of other medical devices shall submit the report to the provincial monitoring agencies where MAHs locate.\n'（四）国家药品监督管理局规定的其他药品。'可被翻译为：(4) Other drugs specified by the NMPA.\n'第五十五条  有下列情形之一的，持有人应当主动开展再评价，并依据再评价结论，采取相应措施：'可被翻译为：Article 55 In case of any of following situations, MAHs shall voluntarily carry out re-evaluation and take corresponding measures based on re-evaluation conclusions:\n\n根据上述已知信息，请将'（三）国家药品监督管理局规定应当开展再评价的其他情形。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(III) Other situations under which re-evaluation shall be performed as specified by the National Medical Products Administration."
    },
    {
        "instruction":"已知信息：\n'安装完成，所有服务连接并运行，但没有生产设备，材料或人员在场的状态。'可被翻译为：Condition where the installation is complete with all services connected and functioning but with no production equipment, materials, or personnel present.\n'“静态”是指所有公用设施（包括任何正常运行的 HVAC）已安装完成、主生产设备按规定安装但未运行、并且无人员在场的状态'可被翻译为：The definition of “at rest” state is the condition whereby the installation of all the utilities is complete including any functioning HVAC, with the main manufacturing equipment installed as specified but not operating and\nwithout personnel present in the room.\n'“动态”是指洁净室安装完成、HVAC 系统全面运行、设备已安装并按照生产商规定的运行模式运行、并且有最大数量的操作人员在场执行或模拟日常操作的状态。'可被翻译为：The definition of “in operation” state is the condition where the installation of the cleanroom is complete, the HVAC system fully operational, equipment installed and functioning in the manufacturer's defined operating mode with the maximum number of personnel present performing or simulating routine operational work.\n'公用设施的设计、安装、确认、操作、维护和监测方式应确保该公用设施系统按预期运行。'可被翻译为：Utilities should be designed, installed, qualified, operated, maintained and monitored in a manner to ensure that the utility system functions as expected.\n\n根据上述已知信息，请将'设备安装完毕，设备按客户和供应商商定的方式安装和运行，但没有人员在场的状态。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Condition where the installation is complete with equipment installed and operating in a manner agreed upon by the customer and supplier, but with no personnel present."
    },
    {
        "instruction":"已知信息：\n'第二百零六条 有数条包装线同时进行包装时，应当采取隔离或其他有效防止污染、交叉污染或混淆的措施。'可被翻译为：Article 206: Appropriate segregation or other precautions to effectively prevent contamination, cross-contamination or mixups should be adopted if several packaging lines are working simultaneously.\n'第三十六条 药品包装操作应当采取降低混淆和差错风险的措施，药品包装应当确保有效期内的药品储存运输过程中不受污染。'可被翻译为：Article 36 There shall be control measures available for drug packaging to reduce the risks of mix-ups and errors. Drug packages shall be protected against any contamination during storage and transportation of drugs within shelf life.\n'第七十一条 设备的设计、选型、安装、改造和维护必须符合预定用途，应当尽可能降低产生污染、交叉污染、混淆和差错的风险，便于操作、清洁、维护，以及必要时进行的消毒或灭菌。'可被翻译为：Article 71: The design, selection, installation, adaption and maintenance of equipment should be suitable for its intended use, minimize the risk of contamination, cross-contamination, mixups or errors, and facilitate operation, cleaning, maintenance, as well as disinfection or sterilization if necessary.\n'第一百零三条 应当建立物料和产品的操作规程，确保物料和产品的正确接收、贮存、发放、使用和发运，防止污染、交叉污染、混淆和差错。'可被翻译为：Article 103: Operation procedures for handling and managing materials and products should be established to ensure the proper receiving, storage, dispensing, use and distribution of materials and products, to prevent any risk of contamination, cross-contamination, mixups and errors.\n\n根据上述已知信息，请将'第二百零二条 包装操作规程应当规定降低污染和交叉污染、混淆或差错风险的措施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 202: Packaging operation procedures should specify the measures to minimize the risk of contamination, cross-contamination, mixups or errors."
    },
    {
        "instruction":"已知信息：\n'细菌、酵母或其他微生物细胞丧失细胞壁中部分坚硬的肽聚糖时所形成的球状体。'可被翻译为：Globules formed when bacterial, yeast, or other microbial cells lose part of the hard peptidoglycan in their cell walls.\n'酶解作用'可被翻译为：zymolysis\n'高渗溶液'可被翻译为：hypertonic solution\n'机体通过消化管的运动和消化腺分泌物的酶解作用，使大块的、分子结构复杂的食物，分解为能被吸收的、分子结构简单的小分子化学物质的过程。'可被翻译为：Through the movement of the digestive tube and the enzymatic hydrolysis of the secretion of the digestive gland, the body makes the large, complex molecular structure of food decompose into small molecular chemicals that can be absorbed and the molecular structure is simple.\n\n根据上述已知信息，请将'微生物菌株通过酶解作用，脱除细胞壁，细胞在高渗溶液中释放出只含细胞膜的球状体。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process by which microbial strains remove their cell walls by enzymatic hydrolysis, and the cells release spheroids containing only the cell membrane in a hypertonic solution."
    },
    {
        "instruction":"已知信息：\n'阻滞正常生殖过程，达到避孕或终止妊娠目的的女用药物。有不同剂型,如短效口服片、长效口服片、长效注射药、埋植剂、多相片剂、阴道栓剂和胶冻剂等。'可被翻译为：A female drug used to block the normal reproductive process and to prevent or terminate pregnancy. There are different dosage forms, such as short-acting oral tablets, long-acting oral tablets, long-acting injectable drugs, implants, multiphase tablets, vaginal suppositories and gels.\n'草药剂型是由草药生产的草药产品的物理形式(液体、固体、半固体)，有或没有赋形剂，在特定配方中(如煎剂、片剂和软膏)。它们由草药原料(如干根或新鲜果汁)或草药制剂(如提取物)制成。'可被翻译为：Herbal dosage forms are the physical form (liquid, solid, semi-solid) of herbal products produced from herbs, with or without excipients, in a particular formulation (such as decoctions, tablets and ointments). They are produced either from herbal materials (such as dried roots or fresh juices) or herbal preparations (such as extracts).\n'通常是指口服的片剂、胶囊、粉剂等药品的固体剂型。'可被翻译为：Usually refers to solid dosage forms of medicinal products such as tablets, capsules and powders to be taken orally.\n'采用桨法进行溶出度测定时，用于防止片剂或胶囊漂浮的装置。'可被翻译为：A device used to prevent tablets or capsules from floating when dissolution is determined using the paddle method.\n\n根据上述已知信息，请将'1.FPP的形式，如片剂、胶囊、酏剂或栓剂。\n2.药品成品的形态，如片剂、胶囊、酏剂、注射剂、栓剂。\n3.完整的药物制剂形式，如片剂、胶囊、酏剂、栓剂。\n4.制剂的形式，如片剂、胶囊、酏剂或栓剂。\n5.制成品的形式，如片剂、胶囊、酏剂或栓剂。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.The form of the FPP, e.g. tablet, capsule, elixir or suppository.\n2.The form of the completed pharmaceutical product, e.g. tablet, capsule, elixir, injection, suppository.\n3.The form of the completed pharmaceutical preparation, e.g. tablet, capsule, elixir, suppository.\n4.The form of the completed pharmaceutical product, e.g. tablet, capsule, elixir or suppository.\n5.The form of the finished pharmaceutical product, e.g. tablet, capsule, elixir or suppository."
    },
    {
        "instruction":"已知信息：\n'初始和定期的设备检测，例如含有或生成识别码或密码信息的记号或卡，以确保其运行正常，且未遭受未经授权的修改。'可被翻译为：(e) Initial and periodic testing of devices, such as tokens or cards, that bear or generate identification code or password information to ensure that they function properly and have not been altered in an unauthorized manner.\n'利用事项处理防护避免未经授权使用密码和\/或识别码，及时发现并报告试图未经授权使用系统安全装置乃至组织管理的情况。'可被翻译为：(d) Use of transaction safeguards to prevent unauthorized use of passwords and\/or identification codes, and to detect and report in an immediate and urgent manner any attempts at their unauthorized use to the system security unit, and, as appropriate, to organizational management.\n'电子记录系指以电子形式生成、修改、维护、归档、检索或传送的文本、图标、数据、音频、图示或其他信息形式的组合。'可被翻译为：(6) Electronic record means any combination of text, graphics, data, audio, pictorial, or other information representation in digital form that is created, modified, maintained, archived, retrieved, or distributed by a computer system.\n'保证定期检查、收回或修订识别码和密码（例如，解决密码老化）。'可被翻译为：(b) Ensuring that identification code and password issuances are periodically checked, recalled, or revised (e.g., to cover such events as password aging).\n\n根据上述已知信息，请将'按照损失管理过程对丢失、失窃、遗漏或存在其他损坏可能的记号、卡及其他含有或生成识别码或密码信息装置采取电子失效，并采用适当和严格的管理发生临时或永久的代用品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(c) Following loss management procedures to electronically deauthorize lost, stolen, missing, or otherwise potentially compromised tokens, cards, and other devices that bear or generate identification code or password information, and to issue temporary or permanent replacements using suitable, rigorous controls."
    },
    {
        "instruction":"已知信息：\n'第十三条  省、自治区、直辖市药品监督管理部门应当对申请资料进行审核，按照国家药品监督管理局制定的医疗器械生产质量管理规范的要求进行核查，并自受理申请之日起20个工作日内作出决定。现场核查可以与产品注册体系核查相结合，避免重复核查。需要整改的，整改时间不计入审核时限。'可被翻译为：Article 13 The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall examine the application dossiers, and conduct inspection in compliance with the requirements of the Good Manufacturing Practice for medical devices formulated by NMPA, and make decisions within 20 working days from the date of acceptance. The on-site inspection shall be combined with inspection of the product registration system, to avoid repeated inspection. If rectification is necessary, the rectification time shall not be included in the review time.\n'第十三条 省、自治区、直辖市药品监督管理部门应当根据申请资料审核和现场核查等情况，对符合规定条件的，作出准予许可的决定，并自作出决定之日起5个工作日内向申请人颁发化妆品生产许可证；对不符合规定条件的，及时作出不予许可的书面决定并说明理由，同时告知申请人依法享有申请行政复议或者提起行政诉讼的权利。'可被翻译为：Article 13 The drug regulatory department of the province, autonomous region or municipality directly under the central government shall, according to review of the application documents and on-site inspection, grant approval for application if the specified requirements are met, and issue cosmetic manufacturing license to the applicant within 5 working days upon making the decision; if the specified requirements are not met, it shall not grant approval and shall give the reasons in writing in a timely manner, and in the meantime inform the applicant of being entitled to apply for administrative reconsideration or file an administrative litigation according to law.\n'第十一条 省、自治区、直辖市药品监督管理部门对申请人提出的化妆品生产许可申请，应当根据下列情况分别作出处理：'可被翻译为：Article 11 Regarding the application submitted by applicants for cosmetics manufacturing license, the drug regulatory department of the province, autonomous region, or municipality directly under the central government shall handle respectively according to the following circumstances:\n'第二十一条 省、自治区、直辖市药品监督管理部门应当自收到延续许可申请后5个工作日内对申请资料进行形式审查，符合要求的予以受理，并自受理之日起10个工作日内向申请人换发新的化妆品生产许可证。许可证有效期自原许可证有效期届满之日的次日起重新计算。'可被翻译为：Article 21 The drug regulatory department of the province, autonomous region or municipality directly under the central government shall conduct a format review of the application documents within 5 working days upon receiving the application for renewal of license, accept the application if it meets the requirements, and issue a new Cosmetics Manufacturing License to the applicant within 10 working days upon acceptance. The valid term of the license shall be recalculated from the day following the expiration date of the former license.\n\n根据上述已知信息，请将'第十二条 省、自治区、直辖市药品监督管理部门应当对申请人提交的申请资料进行审核，对申请人的生产场所进行现场核查，并自受理化妆品生产许可申请之日起30个工作日内作出决定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 12 The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall review the application documents submitted by the applicant, and conduct on-site inspection on manufacturing premises of the applicant, and make a decision within 30 working days beginning from the date of acceptance of the application for cosmetics manufacturing license."
    },
    {
        "instruction":"已知信息：\n'（二）有与药品生产相适应的厂房、设施、设备和卫生环境；'可被翻译为：(2) having the premises, facilities, equipment and hygienic environment required for drug manufacturing;\n'（二）有与所经营药品相适应的营业场所、设备、仓储设施和卫生环境；'可被翻译为：(2) have the premises, equipment, warehouses, and hygienic environment required for drug distribution;\n'厂房与设施'可被翻译为：buildings and facilities\n'第四章 厂房与设施'可被翻译为：Chapter4 Premises and Facilities\n\n根据上述已知信息，请将'（二）有与药品生产相适应的厂房、设施和卫生环境；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(2) have the premises, facilities, and hygienic environment required for drug manufacturing;"
    },
    {
        "instruction":"已知信息：\n'泛指各种机制导致发生的任何有害的遗传物质改变。'可被翻译为：A broad term that refers to any deleterious change in the genetic material regardless of the mechanism by which the change is induced.\n'生物化学过程发生改变的突变菌株。'可被翻译为：Mutant strains with altered biochemical processes.\n'通过化学作用使菌种发生遗传信息改变的物质。'可被翻译为：A substance that causes the genetic information of a strain to be altered by chemical action.\n'通过物理作用使菌种发生遗传信息改变的物质。'可被翻译为：A substance that changes the genetic information of a strain by physical action.\n\n根据上述已知信息，请将'对生物体的遗传物质进行人为的操作，使之发生修饰和改变的过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process of artificially manipulating the genetic material of an organism so that it is modified or altered."
    },
    {
        "instruction":"已知信息：\n'原发证部门应当结合企业遵守医疗器械管理法律法规、医疗器械生产质量管理规范情况和企业质量管理体系运行情况进行审查，必要时开展现场核查，在医疗器械生产许可证有效期届满前作出是否准予延续的决定。'可被翻译为：The former license issuing department shall make review in combination with the enterprise’s compliance with laws and regulations on administration of medical devices, the Good Manufacturing Practice for Medical Devices, and operation condition of the enterprise’s quality management system, and carry out on-site inspection if necessary, and then make a decision on whether granting renewal or not before expiration of valid term of the Medical Device Manufacturing License.\n'除有本办法第五十五条规定情形外，接到延续注册申请的食品药品监督管理部门应当在医疗器械注册证有效期届满前作出准予延续的决定。逾期未作决定的，视为准予延续。'可被翻译为：Except for the situations specified in Article 55, the food and drug regulatory department receiving the application for registration renewal shall make a decision for the renewal before the expiration of period of validity of the medical device registration certificate. If the decision is not made within the specified time, the renewal is considered approved.\n'除有本办法第六十五条规定情形外，接到延续注册申请的食品药品监督管理部门应当在医疗器械注册证有效期届满前作出准予延续的决定。逾期未作决定的，视为准予延续。'可被翻译为：Except for the situations specified in Article 65, the food and drug regulatory department receiving the application for registration renewal shall make a decision for the renewal before the expiration of period of validity of the medical device registration certificate. If the decision is not made within the specified time, the renewal is considered approved.\n'第十六条  医疗器械经营许可证有效期届满需要延续的，医疗器械经营企业应当在有效期届满前90个工作日至30个工作日期间提出延续申请。逾期未提出延续申请的，不再受理其延续申请。'可被翻译为：Article 16 If the Medical Device Distribution License needs to be renewed upon expiration of the valid term, the medical device distributor shall apply for renewal within 30 to 90 working days before expiration of the valid term. If an application for renewal fails to be made within the prescribed time limit, such application shall no longer be accepted.\n\n根据上述已知信息，请将'原发证部门应当按照本办法第十三条的规定对延续申请进行审查，必要时开展现场核查，在医疗器械经营许可证有效期届满前作出是否准予延续的决定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The former license issuing department shall review the application for renewal as stipulated in Article 13 of these Provisions, carry out on-site inspection if necessary, and make a decision on whether granting renewal or not before expiration of the valid term of the Medical Device Distribution License."
    },
    {
        "instruction":"已知信息：\n'进入 A 级和 B 级区的人员应接受无菌更衣和无菌行为的培训。应通过评估和至少每年定期再评估来确认符合无菌更衣程序，并应包括目检和微生物评估（使用戴手套的手指、前臂、胸部和头罩（口罩\/额头）等监测位置。预期限度参见 9.30 节）。对于正在或即将进行无菌操作的 A 级和 B 级区，无监督进入应仅限于经过适当资质确认、已通过更衣评估并参与过成功的 APS 的人员。'可被翻译为：The personnel accessing grade A and B areas should be trained for aseptic gowning and aseptic behaviours.\nCompliance with aseptic gowning procedures should be confirmed by assessment and periodic reassessment at\nleast annually, and should involve both visual and microbial assessment (using monitoring locations such as\ngloved fingers, forearms, chest and hood (facemask \/ forehead). See paragraph 9.30 for the expected limits). The\nunsupervised access to the grade A and grade B areas where aseptic operations are or will be conducted should be\nrestricted to appropriately qualified personnel, who have passed the gowning assessment and have participated in\na successful APS.\n'×1械注×2××××3×4××5××××6。其中：'可被翻译为：×1 XZ ×2××××3×4××5××××6. Among which,\n'人员更衣要求。'可被翻译为：Personnel gowning requirements.\n'进入无菌洁净室的任何分析员都应进行人员更衣资格确认。人员更衣资格必须包 括：'可被翻译为：Personnel gowning qualification should be performed by any analyst that enters the aseptic clean room. Personnel gowning qualification must consist of:\n\n根据上述已知信息，请将'注 3：对于人员更衣的确认，应采用表 6 中的表面微生物和五指手套的限度要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Note 3: For the qualification of personnel gowning, the limits given for contact plates and glove prints in Table 6 should apply."
    },
    {
        "instruction":"已知信息：\n'食品药品监督管理部门应当自受理复审申请之日起30个工作日内作出复审决定，并书面通知申请人。维持原决定的，食品药品监督管理部门不再受理申请人再次提出的复审申请。'可被翻译为：The food and drug regulatory department shall make a re-evaluation decision within 30 workdays after accepting the re-evaluation application and inform the applicant. Where the original decision shall be maintained, the food and drug regulatory department shall not accept further application for re-evaluation by the applicant.\n'第一百五十七条 国家食品药品监督管理局接到复审申请后，应当在50日内作出复审决定，并通知申请人。维持原决定的，国家食品药品监督管理局不再受理再次的复审申请。'可被翻译为：Article 157 The State Food and Drug Administration shall make a second review decision, and notify the applicant the decision within 50 days after receiving an application for second review. Where the original decision is affirmed, the State Food and Drug Administration shall not accept any further application for second review thereof.\n'第四十二条 申请人对食品药品监督管理部门作出的不予注册决定有异议的，可以自收到不予注册决定通知之日起20个工作日内，向作出审批决定的食品药品监督管理部门提出复审申请。复审申请的内容仅限于原申请事项和原申报资料。'可被翻译为：Article 42 Where an applicant has an objection to the disapproval decision of the food and drug regulatory department, it may submit a re-evaluation application within 20 workdays after receiving the disapproval notice to the food and drug regulatory department that made the decision. Contents of the re-evaluation application shall be limited to original application items and original application materials.\n'第五十二条 申请人对食品药品监督管理部门作出的不予注册决定有异议的，可以自收到不予注册决定通知之日起20个工作日内，向作出审批决定的食品药品监督管理部门提出复审申请。复审申请的内容仅限于原申请事项和原申报资料。'可被翻译为：Article 52 Where an applicant has an objection to the disapproval decision of the food and drug regulatory department, it may submit a re-evaluation application within 20 workdays after receiving the disapproval notice to the food and drug regulatory department that made the decision. Contents of the re-evaluation application shall be limited to original application items and original application materials.\n\n根据上述已知信息，请将'第四十三条 食品药品监督管理部门应当自受理复审申请之日起30个工作日内作出复审决定，并书面通知申请人。维持原决定的，食品药品监督管理部门不再受理申请人再次提出的复审申请。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 43 The food and drug regulatory department shall make a re-evaluation decision within 30 workdays after accepting the re-evaluation application and inform the applicant. Where the original decision shall be maintained, the food and drug regulatory department shall not accept further application for re-evaluation by the applicant."
    },
    {
        "instruction":"已知信息：\n'（六）内部审核、管理评审、变更控制、年度自查报告等情况；'可被翻译为：(6) internal audit, management review, change control, annual self-inspection report and other conditions;\n'（九）内部审核、管理评审、变更控制、年度自查报告等情况；'可被翻译为：(9) internal audit, management review, change control, annual self-inspection report and other conditions;\n'管理评审'可被翻译为：management review\n'关于发布医疗器械质量管理体系年度自查报告编写指南的通告'可被翻译为：NMPA Announcement on Issuing the Guidance for the Preparation of Annual Self-inspection Report of Medical Device Quality Management System\n\n根据上述已知信息，请将'（七）内部审核、管理评审、年度自查报告等情况；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(7) internal audit, management review, annual self-inspection report and other conditions;"
    },
    {
        "instruction":"已知信息：\n'第二百二十七条 标准品或对照品的管理应当至少符合以下要求：'可被翻译为：Article 227: The management of the standard substances or reference substances should meet at least the following requirements:\n'5.标准中涉及的标准物质（对照品或参比品）检验报告书及相关研究资料。'可被翻译为：5.Test report and related research materials of standard substance (reference substance or product) involved in the specification.\n'采用准确、可靠的方法或直接与一级标准物质相比较的方法，测量标准物质的特性量值，测量准确度满足需要的标准物质。在实验室中通常是指与一级标准物质比对后作为对照使用的工作对照品（标准品）。'可被翻译为：The characteristic quantity value of the standard substance shall be measured by accurate and reliable method or by method directly compared with the first class standard substance, and the standard substance whose measurement accuracy meets the needs shall be measured. In the laboratory, it usually refers to the working reference material (standard material) used as a control after comparison with the primary reference material.\n'5.标准中涉及的标准物质（对照品）检验报告书及相关研究资料。'可被翻译为：5.Test report and related research materials of standard substance (reference substance) involved in the specification.\n\n根据上述已知信息，请将'第二百二十条 质量控制实验室应当配备药典、标准图谱等必要的工具书，以及标准品或对照品等相关的标准物质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 220: Necessary reference books such as pharmacopeias and standards spectrum, and primary reference substances such as reference standards and reference substances, should be available in quality control laboratories."
    },
    {
        "instruction":"已知信息：\n'现场核查过程中认为有必要进行样品检验的，经报核查中心同意后，核查组按照药品抽样的有关要求，抽取样品并封样，抽样情况应当在核查报告中进行描述；样品按要求送交药品检验机构进行样品检验。'可被翻译为：If it is deemed necessary to conduct sample inspection during the on-site inspection, the inspection team shall, with the approval of CFDI, take samples and seal them in accordance with the relevant requirements on drug sampling, and the sampling situation shall be described in the inspection report. The samples shall be sent to the drug testing institution for sample testing as required.\n'第五十六条 境内生产药品的注册申请，药品注册申请受理后需要药品注册检验的，药品审评中心应当在受理后四十日内向药品检验机构和申请人发出药品注册检验通知。申请人向相关省、自治区、直辖市药品监督管理部门申请抽样，省、自治区、直辖市药品监督管理部门组织进行抽样并封签，申请人应当在规定时限内将抽样单、样品、检验所需资料及标准物质等送至相应药品检验机构。'可被翻译为：Article 56 For drugs manufactured within the territory of the People's Republic of China, where drug registration testing is necessary after the drug registration application is accepted, the CDE shall, within 40 days after the acceptance, send the notice for drug registration testing to the drug testing institutions and the applicant. The applicant can apply for sampling to the drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government, and the drug regulatory department shall organize sampling and sealing. The applicant shall send the sampling form, samples, dossiers required for testing and reference standard to the corresponding drug testing institutions within the specified timeline.\n'第三十一条 有因检查需要由核查组抽取样品进行检验的，核查组按照药品抽样的有关要求，抽取样品并封样；抽取的样品按要求送交药品检验机构进行样品检验。'可被翻译为：Article 31 If the inspection team needs to take samples for cause-related inspection, the inspection team shall take samples and seal them in accordance with the relevant requirements for drug sampling; the samples shall be sent to the drug testing institution for sample testing as required.\n'第五十五条 境内生产药品的注册申请，申请人在药品注册申请受理前提出药品注册检验的，向相关省、自治区、直辖市药品监督管理部门申请抽样，省、自治区、直辖市药品监督管理部门组织进行抽样并封签，由申请人将抽样单、样品、检验所需资料及标准物质等送至相应药品检验机构。'可被翻译为：Article 55 For drugs manufactured within the territory of the People’s Republic of China, where drug registration testing has been proposed before the drug registration application is accepted, the applicant can apply for sampling to the drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government, and the drug regulatory department shall organize to conduct the sampling and sealing. The applicant shall send the sampling form, samples, dossiers required for testing and reference standard to the corresponding drug testing institutions.\n\n根据上述已知信息，请将'第五十七条 本程序所指的抽样是指药品监督管理部门在注册核查过程中进行的取样、封样和通知检验。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 57 The sampling referred to in the Procedures refers to the sampling, sample sealing and notified inspection conducted by the drug regulatory authority during the registration inspection process."
    },
    {
        "instruction":"已知信息：\n'所有已灌装容器 100%完整性测试的方法和参数（参见第 8.22 节）。'可被翻译为：Methods and parameters for integrity testing of 100% of all filled containers (see paragraph 8.22).\n'除菌级过滤器的使用前后完整性测试的性能（参见第 8.87 节）。'可被翻译为：The performance of the pre- and post-use integrity testing for sterilising grade filters (see paragraph 8.87).\n'要求停止灌装和\/或挤出、模塑和密封，以及必要时灌装机再灭菌的干预措施，应在灌装程序中明确规定和描述，并包括在 APS 中（如相关）（参见第 9.34 、9.35 和 9.36 节）。'可被翻译为：Interventions requiring cessation of filling and\/or extrusion, moulding and sealing and, where required, re-sterilisation of the filling machine should be clearly defined and described in the filling procedure, and included in the APS as relevant (see paragraphs 9.34, 9.35 and 9.36).\n'已安装的过滤器系统的检漏和完整性测试。'可被翻译为：Installed filter system leakage and integrity testing.\n\n根据上述已知信息，请将'已灌装容器完整性测试的方法和参数（参见第 8.22 节）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Methods and parameters for integrity testing of filled containers (see paragraph 8.22)."
    },
    {
        "instruction":"已知信息：\n'血清中所含特定药物的浓度。'可被翻译为：The concentration of a particular drug contained in the serum.\n'唾液中所含特定药物的浓度。'可被翻译为：The concentration of a particular drug in saliva.\n'尿液中所含特定药物的浓度。'可被翻译为：The concentration of a particular drug in the urine.\n'血浆药物浓度'可被翻译为：plasma drug level\n\n根据上述已知信息，请将'血浆中所含特定药物的浓度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The concentration of a specific drug contained in the plasma."
    },
    {
        "instruction":"已知信息：\n'1.不被视为新活性物质的API，先前已通过严格的监管机构或WHO的成品批准，但需要提交档案。例如，这将包括新的pd和多源产品的变体。\n2.不被视为新活性物质的API，以前已通过SRA或WHO的成品批准，但需要提交档案。例如，这将包括新的pd和多源产品的变体。'可被翻译为：1.An API that is not considered a new active substance, which has been previously approved through a finished product by a stringent regulatory authority or by WHO, but requires the filing of a dossier. This would include, for example, new PDs and variations to multisource products.\n2.An API that is not considered a new active substance, that has been previously approved through a finished product by an SRA or WHO, but requires the filing of a dossier. This would include, for example, new PDs and variations to multisource products.\n'在本章中，“药物”一词更一般地指活性成分，可能包括不被视为药物的活性成分(如防晒霜活性成分)。'可被翻译为：In this chapter, the term “drug” is utilized to refer more generally to active ingredients, potentially including active ingredients that may not be considered drugs (e.g., sunscreen active ingredients).\n'新的活性药物成分'可被翻译为：new active pharmaceutical ingredient\n'1.通过在监管申请中作出的承诺在批准后启动或完成稳定性研究的活性药物成分或成品的生产批次。\n2.通过在监管申请中做出的承诺，在批准后启动或完成稳定性研究的原料药或FPP的生产批次。'可被翻译为：1.Production batches of an active pharmaceutical ingredient or finished pharmaceutical product for which the stability studies are initiated or completed post-approval through a commitment made in a regulatory application.\n2.Production batches of an API or FPP for which the stability studies are initiated or completed post-approval through a commitment made in a regulatory application.\n\n根据上述已知信息，请将'不被视为新活性物质的活性药物成分，先前已通过严格的监管机构或世界卫生组织的成品批准，但需要提交档案。这将包括，例如，新产品档案和多源产品的变体。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An active pharmaceutical ingredient that is not considered a new active substance, which has been previously approved through a finished product by a stringent regulatory authority or by the World Health Organization, but requires the filing of a dossier. This would include, for example, new product dossiers and variations to multisource products."
    },
    {
        "instruction":"已知信息：\n'在电子未占有的分子轨道中，能量最低的分子轨道。'可被翻译为：In molecular orbitals that are not occupied by electrons, the ones with the lowest energy.\n'在电子占有的分子轨道中，能量最高的分子轨道。'可被翻译为：The highest energy orbital of the electron occupied molecular orbitals.\n'原子组成分子时，原子轨道线性组合成分子轨道，组成的分子轨道的能量若高于原子轨道的能量，则该分子轨道叫做反键轨道。'可被翻译为：When atoms form a molecule, the atomic orbitals are linearly combined into molecular orbitals, and if the energy of the constituent molecular orbitals is higher than the energy of the atomic orbitals, the molecular orbitals are called antibonding orbitals.\n'原子组成分子时，原子轨道线性组合成分子轨道，组成的分子轨道的能量若低于原子轨道的能量，则该分子轨道叫做成键轨道。'可被翻译为：When atoms form molecules, the atomic orbitals are linearly combined into molecular orbitals, which are called bonding orbitals if the energy of the constituent molecular orbitals is lower than the energy of the atomic orbitals.\n\n根据上述已知信息，请将'原子或分子中电子激发前存在的低能量轨道。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A low energy orbital in an atom or molecule that exists before the electrons are excited."
    },
    {
        "instruction":"已知信息：\n'1.全国医疗器械不良事件报告数量。2019年，国家医疗器械不良事件监测信息系统共收到可疑医疗器械不良事件报告396345份，比上年减少2.61%（图1）。'可被翻译为：1. Number of Medical Device Adverse Event Report. In 2019, the National Medical Device Adverse Event Monitoring Information System has received a total of 396,345 reports of suspected medical device adverse events, a decrease of 2.61 percent YOY(See Figure 1) .\n'2020年，国家医疗器械不良事件监测信息系统收到的医疗器械不良事件报告涉及了医疗器械分类目录中的所有类别。'可被翻译为：In 2020, medical device adverse event reports received by the National Medical Device Adverse Event Monitoring Information System involved all categories in the Medical Device ClassificationCatalogue.\n'2020年，我国每百万人口平均医疗器械不良事件报告数为402份，比上年增加35.35%。'可被翻译为：In 2020, the average number of medical device adverse event reports per million population in China was 402, showing an increase of 35.35% compared with the previous year.\n'2018年，全国医疗器械不良事件监测信息系统共收到可疑医疗器械不良事件报告406974份，较2017年增长8.19%，反映出我国医疗器械不良事件报告意识不断增强、报告收集能力有效提升（图1)。'可被翻译为：In 2018, the National Medical Device Adverse Event Monitoring Information System received a total of 406,974 reports of suspected medical device adverse events,an increase of 8.19% over 2017, reflecting the increasing awareness of China's medical device adverse event reporting and the effective enhancement of report collection capabilities (Figure 1) .\n\n根据上述已知信息，请将'2020年，国家医疗器械不良事件监测信息系统共收到医疗器械不良事件报告536,055份，比上年增加35.25%。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In 2020, the National Medical Device Adverse Event Monitoring Information System has received a total of 536,055 reports of medical device adverse events, showing an increase of 35.25% compared with the previous year."
    },
    {
        "instruction":"已知信息：\n'进口疫苗类制品和血液制品应当同时提交生产企业所在国家或者地区的原产地证明以及药品管理当局出具的批签发证明文件，并提供经公证的中文译本。进口产品在本国免予批签发的，应当提供免予批签发的证明性文件。'可被翻译为：For an imported vaccine product or blood product, the certificate of origin of the country or region where the manufacturer is located and the lot release supporting documents issued by the local drug regulatory authority shall be provided at the same time, as well as their Chinese translations notarized. If an imported product is exempted from lot release in the country of origin, supporting documents for exemption of lot release shall be provided.\n'进口疫苗类制品和血液制品应当同时提交生产企业所在国家或者地区的原产地证明以及药品管理当局出具的批签发证明文件。进口产品在本国免予批签发的，应当提供免予批签发的证明性文件。相关证明性文件应当同时提供经公证的中文译本。相关证明性文件为复印件的，应当加盖企业公章。'可被翻译为：For an imported vaccine product or blood product, the certificate of origin of the country or region where the manufacturer is located and the lot release supporting documents issued by the local drug regulatory authority shall be provided at the same time. If an imported product is exempted from lot release in the country of origin, supporting documents for exemption of lot release shall be provided. A notarized Chinese translation shall be simultaneously provided for relevant supporting documents. If the relevant supporting documents are photocopies, they shall be affixed with the seal of the enterprise.\n'第十五条 批签发申请人申请批签发时，应当提供以下证明性文件、资料及样品：'可被翻译为：Article 15 In case of applying for lot release, the lot release applicant shall provide the following supporting documents, materials and samples:\n'第二十八条 批签发机构根据资料审核、样品检验或者现场检查等结果作出批签发结论。符合要求的，签发生物制品批签发证明，加盖批签发专用章，发给批签发申请人。'可被翻译为：Article 28 The lot release institution shall make decision on lot release based on dossier review, sample test or on-site inspection and other results. If the requirements are met, the institution shall issue a Certificate for Lot Release of Biological Products which is affixed with the special seal for lot release, and send it to the lot release applicant.\n\n根据上述已知信息，请将'第二十七条 申请疫苗批签发应当按照规定向批签发机构提供批生产及检验记录摘要等资料和同批号产品等样品。进口疫苗还应当提供原产地证明、批签发证明；在原产地免予批签发的，应当提供免予批签发证明。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 27 To apply for vaccine lot release, materials such as summary protocol of manufacturing and control and samples shall be provided to the lot release institutions as required. For imported vaccines, the certificate of country of origin and certificate of lot release shall also be provided; and if the imported vaccines are exempted from lot release in the country of origin, the exemption certificate of lot release shall be provided."
    },
    {
        "instruction":"已知信息：\n'使设计具备良好地接受旧版本输入信息的能力。本概念可用于整个系统、数据通信、协议、文件格式和计算机编程语言。例如，如果使用新标准设计的产品可以接收、阅读、查看或播放使用旧标准或格式设计的产品信息，那么就说该产品是向下兼容的。'可被翻译为：The ability of the design to gracefully accept input created with older versions of itself. The concept can be applied to entire systems, data \ncommunications, protocols, file formats and computer programming languages. For example, if products designed for the new standard can \nreceive, read, view or play older standards or formats, then the product is said to be Backward Compatible.\n'计算机系统设计和构建的一般术语，包括技术基础设备、信息（数据）和应用程序。'可被翻译为：A general term for the design and construction of computer systems, including technical infrastructure, information (data), and applications.\n'1.计算机系统:与计算机系统集成的过程或操作\n2.一种包括数据输入、电子处理和信息输出的系统，用于报告或自动控制。\n3.计算机化系统集中控制一个或多个自动化过程和\/或功能的性能和执行。它包括计算机硬件、软件、外围设备、网络和文件，例如手册和标准操作程序，以及与硬件和软件交互的人员。'可被翻译为：1.A process or operation integrated with a computer system.\n2.A system including the input of data, electronic processing and the output of information to be used either for reporting or for automatic control.\n3.A computerized system collectively controls the performance and execution of one or more automated processes and\/or functions. It includes computer hardware, software, peripheral devices, networks and documentation, for example, manuals and standard operating procedures, as well as personnel interacting with hardware and software.\n'这是指使用成熟的计算机系统、编程语言、应用软件或过程，而不是可用的升级版本，并且根据当前的监管要求尚未合格。'可被翻译为：This refers to a mature computer system, programming language, application software, or processes that are used instead of available upgraded versions, and that have not been qualified according to current regulatory requirements.\n\n根据上述已知信息，请将'使设计具备良好地接受新版本输入信息的能力。本概念适用于整个系统、数据通信、协议、文件格式和计算机编程语言。例如，如果按照旧标准设计的产品收、阅读、查看或播放新标准或格式（不包括新功能）下的信息，则认为该产品是具备“向上兼容性”的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The ability of the design to gracefully accept input intended for newer versions of itself. The concept can be applied to entire systems, data \ncommunications, protocols, file formats and computer programming languages. For example, if products designed for the older standard can \nreceive, read, view or play the newer standard or format (excluding new functionality), then the product is said to be Forward Compatible."
    },
    {
        "instruction":"已知信息：\n'封闭系统系指由负责系统中电子记录内容的人员管理系统访问的计算机环境。'可被翻译为：(4) Closed system means an environment in which system access is controlled by persons who are responsible for the content of electronic records that are on the system.\n'（十一）负责计算机系统操作权限的审核和质量管理基础数据的建立及更新；'可被翻译为：(XI) Being responsible for the audit of operation permission of computer system, and the establishment and update of basic data of quality management;\n'（十二）负责计算机系统操作权限的审核、控制及质量管理基础数据的维护；'可被翻译为：(XII) Being responsible for the audit and control of operation permission of computer system, and the maintenance of basic data of quality management;\n'计算机系统'可被翻译为：computer system\n\n根据上述已知信息，请将'（十）负责指导设定计算机系统质量控制功能；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(X) Guiding the setting of quality control function of the computer system;"
    },
    {
        "instruction":"已知信息：\n'第四十八条 生物制品批签发证明、生物制品不予批签发通知书、生物制品批签发复审结果通知书由批签发机构按照顺序编号，其格式为“批签X（进）检XXXXXXXX”，其中，前X符号代表批签发机构所在地省、自治区、直辖市行政区域或者机构的简称，进口生物制品使用“进”字；后8个X符号的前4位为公元年号，后4位为年内顺序号。'可被翻译为：Article 48 The Certificate for Lot Release of Biological Products, the Notice of Disapproval of Lot Release of Biological Products and the Notice of Re-review Result of Lot Release of Biological Products shall be numbered by the lot release institution in sequence with a format of “Lot Release X (Import) Test XXXXXXXX”, wherein the first X symbol represents the abbreviation of the administrative region of the province, autonomous region or municipality directly under the Central Government in the place where the lot release institution is located or abbreviation of the institution; for imported biological products, “Import” shall be used; and in the last 8 X symbols, the former 4 X symbols represent the AD year, and the latter 4 X symbols represent the sequence number within the year.\n'第四十七条 生物制品批签发申请表、生物制品批签发登记表、生物制品批签发证明、生物制品不予批签发通知书、生物制品批签发复审申请表、生物制品批签发复审结果通知书的格式由中检院统一制定并公布。'可被翻译为：Article 47 Formats of the Application Form for Lot Release of Biological Products, the Registration Form for Lot Release of Biological Products, the Certificate for Lot Release of Biological Products, the Notice of Disapproval of Lot Release of Biological Products, the Notice of Re-review of Lot Release of Biological Products and the Notice of Re-review Result of Lot Release of Biological Products shall be developed in a unified manner and publicized by the NIFDC.\n'第四十六条    国家药品监督管理局负责颁布和更新批签发机构专用章，生物制品批签发专用章命名为“国家批签发机构专用章（X）”。其中，X代表批签发机构简称。'可被翻译为：Article 46 The NMPA shall be responsible for promulgating and updating the special seal of lot release institution, which is named as \"Special Seal for National Lot Release Institution (X)\". Where, X stands for the abbreviation of lot release institution.\n'生物制品批签发申请表、生物制品批签发登记表、生物制品批签发证明、生物制品不予批签发通知书、生物制品批签发复审申请表、生物制品批签发复审结果通知书的格式由中检院统一制定并公布。'可被翻译为：Formats of the application form for lot release of biological products, the registration form for lot release of biological products, the Certificate for Lot Release of Biological Products, the Notice of Disapproval of Lot Release of Biological Products, the Notice of Re-review Result of Lot Release of Biological Products and the notice of re-review result of lot release of biological products shall be developed in a unified manner and publicized by the NIFDC.\n\n根据上述已知信息，请将'第四十七条    生物制品批签发证明、生物制品不予批签发通知书、生物制品批签发复审结果通知书由批签发机构按照国家药品监督管理局规定的顺序编号，其格式为“批签X（进）检XXXXXXXX”，其中，前X符号代表批签发机构所在地省、自治区、直辖市行政区域或者机构的简称，进口生物制品使用“进”字；后8个X符号的前4位为公元年号，后4位为年内顺序号。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 47 The Certificate for Lot Release of Biological Products, the Notice of Disapproval of Lot Release of Biological Products and the Notice of Re-review Result of Lot Release of Biological Products shall be numbered by the lot release institution in sequence specified by the NMPA, with a format of \"Lot release X (Import) Test XXXXXXXX\", wherein the first X symbol represents the abbreviation of the administrative region of provinces, autonomous regions or municipalities directly under the Central Government in the place where the lot release institution is located or abbreviation of the institution; for imported biological products, \"Import\" shall be used; and in the last 8 X symbols, the former 4 X symbols represent the AD year, and the latter 4 X symbols represent the sequence number within the year."
    },
    {
        "instruction":"已知信息：\n'（一）未按照规定建立药品不良反应报告和监测管理制度，或者无专门机构、专职人员负责本单位药品不良反应报告和监测工作的；'可被翻译为：(I) Having not established an ADR reporting and monitoring management system as required, or having no specialized department or full-time personnel in charge of ADR reporting and monitoring within the enterprise;\n'（一）违反本办法第十四条规定，未按照要求及时向社会发布产品召回信息的；'可被翻译为：(1) fail to disclose the product recall information to the society in a timely manner as required, which violates Article 14 of these Provisions;\n'第六条 医疗器械生产企业应当按照本办法的规定建立健全医疗器械召回管理制度，收集医疗器械安全相关信息，对可能的缺陷产品进行调查、评估，及时召回缺陷产品。'可被翻译为：Article 6 The medical device manufacturers shall establish and improve the medical device recall management system in accordance with these Provisions, collect the information related to medical device safety, investigate and assess possible defective products, and recall defective products in a timely manner.\n'（三）未按照本办法规定提交医疗器械召回事件报告表、调查评估报告和召回计划、医疗器械召回计划实施情况和总结评估报告的；'可被翻译为：(3) fail to submit the medical device recall event report form, investigation and assessment report and recall plan, implementation of the medical device recall plan and summary evaluation report in accordance with these Provisions;\n\n根据上述已知信息，请将'（一）未按照本办法规定建立医疗器械召回管理制度的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) fail to establish a medical device recall management system in accordance with these Provisions;"
    },
    {
        "instruction":"已知信息：\n'第三十一条 药品上市许可持有人、药品生产企业在药品生产中，应当开展风险评估、控制、验证、沟通、审核等质量管理活动，对已识别的风险及时采取有效的风险控制措施，以保证产品质量。'可被翻译为：Article 31 Drug MAHs and manufacturers shall conduct risk assessment, control, validation, communication, review and other quality management activities, and promptly take effective risk control measures for identified risks to ensure product quality.\n'药品上市许可持有人应当对受托药品生产企业、药品经营企业的质量管理体系进行定期审核，监督其持续具备质量保证和控制能力。'可被翻译为：MAHs shall conduct audits on the quality management systems of the drug contract manufacturers and drug distributors on a regular basis to supervise and ensure their continuous capability of quality assurance and control.\n'FDA 员工合规程序指导手册：药品生产检查计划 7356.002'可被翻译为：a. FDA Compliance program Guidance Manual for FDA Staff: Drug Manufacturing Inspections program 7356.002\n'第三十二条 从事药品生产活动，应当对使用的原料药、辅料、直接接触药品的包装材料和容器等相关物料供应商或者生产企业进行审核，保证购进、使用符合法规要求。'可被翻译为：Article 32 The drug manufacturers shall conduct assessment on the suppliers or manufacturers which supply the materials including active drug ingredients, excipients, primary packaging materials and container in direct contact with drug products involved in manufacturing, to ensure that the sourcing and use of such materials satisfy regulatory requirements.\n\n根据上述已知信息，请将'（四）对药品生产企业、供应商等相关方与药品生产相关的活动定期开展质量体系审核，保证持续合规；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(4) regularly carry out quality system audits of drug manufacturing related activities of related parties including drug manufacturers and suppliers to ensure continuous regulatory compliance;"
    },
    {
        "instruction":"已知信息：\n'细胞内代谢终产物的积累或某些中间产物的过量积累，阻止代谢途径中某些酶合成的现象。'可被翻译为：The accumulation of metabolic end products or excessive accumulation of certain intermediates in the cell prevents the synthesis of certain enzymes in the metabolic pathway.\n'一种特殊类型的酶的不可逆抑制剂。与酶活性中心结合前无活性,经过几步正常的酶促反应后转变为反应性极强的化合物,能与催化其反应的酶发生不可逆共价结合而抑制酶活性。'可被翻译为：An irreversible inhibitor of a particular type of enzyme. Inactive before binding to the active center of the enzyme, it is transformed after a few normal enzymatic reactions into a highly reactive compound that can irreversibly covalently bind to the enzyme that catalyzes the reaction and inhibit enzyme activity.\n'催化生成异构体反应的酶之总称。是酶分类上的主要类别之一。根据反应方式可分为：差相异构酶、消旋酶、顺反异构酶等。'可被翻译为：A general term for enzymes that catalyze reactions that produce isomers. It is one of the main classes of enzymes. According to the reaction mode can be divided into: differential isomerase, racemase, cis-trans isomerase and so on.\n'作用于或影响酶的活性中心或必需基团导致酶活性下降或丧失而降低酶促反应速率的物质。可分为可逆抑制剂和不可逆抑制剂。'可被翻译为：A substance that acts on or affects the active center or essential group of an enzyme, resulting in the decrease or loss of enzyme activity and thus reducing the rate of enzymatic reaction. Can be divided into reversible inhibitors and irreversible inhibitors.\n\n根据上述已知信息，请将'酶促系列反应中，某些中间产物或终产物对催化起始步骤反应的酶活性和酶合成进行调节的作用。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In a series of enzymatic reactions, some intermediates or end products regulate the activity and synthesis of enzymes that catalyze the initial step of the reaction."
    },
    {
        "instruction":"已知信息：\n'研究角度'可被翻译为：research perspective\n'社会角度'可被翻译为：societal perspective\n'是药物经济学评价最常用的研究角度，指一项干预措施的所有成本和产出都考虑在内，而不论这项干预应用于哪些个体或人群。'可被翻译为：This is the most commonly used research perspective for pharmacoeconomic evaluation, where all costs and outputs of an intervention are taken into account, regardless of the individual or population to which the intervention is applied.\n'从分子水平和基因表达的角度去阐释药物作用及其机制的学科。'可被翻译为：The study of drug action and its mechanisms from the perspective of molecular level and gene expression.\n\n根据上述已知信息，请将'药物经济学评价和研究的视角，主要包括社会角度、患者角度、医疗机构角度和保险方角度。不同的研究角度需要测量的成本和产出范围不同。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The perspectives of pharmacoeconomic evaluation and research mainly include the social perspective, the patient perspective, the medical institution perspective and the insurance perspective. Different research perspectives need to measure different ranges of costs and outputs."
    },
    {
        "instruction":"已知信息：\n'中国境内企业投资的境外注册人在境内生产已获进口医疗器械注册证的第二类、第三类医疗器械产品的，参照本公告执行，由投资境外注册人的中国境内企业作为注册申请人申请该产品注册。'可被翻译为：The production of Class II and Class III medical devices with imported medical device registration certificates in China by overseas registrants invested by domestic enterprises in China can be implemented with reference to this Announcement. The domestic enterprises in China that invest the overseas registrants should apply for product registration as the registration applicants.\n'（一）进口医疗器械注册人在中国境内设立的外商投资企业作为注册申请人，向药品监督管理部门提交境内医疗器械注册申请。注册申请内容，除注册人名称、住所、生产地址外，原则上应当与所对应的进口医疗器械注册证及其附件载明的相关事项保持一致。'可被翻译为：(I) The foreign-invested enterprise established by an imported medical device registrant in China shall, asthe registration applicant, submit the application for medical device registration in China to the corresponding drug regulatory authority. The content of the registration application, except the name, domicile and production address of the registrant, shall, in principle, be consistent with relevant items specified in the corresponding imported medical device registration certificate and its attachments.\n'国家药监局关于进口医疗器械产品在中国境内企业生产有关事项的公告'可被翻译为：NMPA issued the Announcement on Matters Concerning the Production of Imported Medical Devices in Domestic Enterprises in China\n'境内第三类医疗器械、进口第二类、第三类医疗器械为“国”字；'可被翻译为：The letter \"G\" shall refer to domestic class III medical devices and import class II and III medical devices.\n\n根据上述已知信息，请将'进口医疗器械注册人通过其在境内设立的外商投资企业在境内生产第二类、第三类已获进口医疗器械注册证产品的有关事项，适用本公告。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"This Announcement is applicable to the matters concerning the production of Class II and Class III medical devices with imported medical device registration certificates in China by the imported medical device registrants through their foreign invested enterprises established in China."
    },
    {
        "instruction":"已知信息：\n'第一百一十五条 应当由指定人员按照操作规程进行配料，核对物料后，精确称量或计量，并作好标识。'可被翻译为：Article 115: Dispensing should only be carried out by designated personnel according to operation procedures. After being checked, materials should be accurately weighed or measured, and well labeled.\n'第一百一十一条 一次接收数个批次的物料，应当按批取样、检验、放行。'可被翻译为：Article 111: If one material delivery is made up of different batches, each batch must be considered as separate for sampling, testing and release.\n'第一百一十二条 仓储区内的原辅料应当有适当的标识，并至少标明下述内容：'可被翻译为：Article 112: Starting materials in the storage area should be appropriately labeled. Labels should bear at least the following information:\n'第一百一十九条 中间产品和待包装产品应当有明确的标识，并至少标明下述内容：'可被翻译为：Article 119: Intermediate and bulk products should be clearly labeled, including at least the following information:\n\n根据上述已知信息，请将'第一百一十七条 用于同一批药品生产的所有配料应当集中存放，并作好标识。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 117: Materials dispensed for each batch should be kept together and conspicuously labeled as such."
    },
    {
        "instruction":"已知信息：\n'应建立适当机制，发现不符合验证参数的灭菌循环。应对任何失败的灭菌或不符合经验证工艺过程的灭菌（例如加热循环等阶段较长或较短）进行调查。'可被翻译为：There should be mechanisms in place to detect a sterilisation cycle that does not conform to the validated parameters. Any failed sterilisation or sterilisation that deviated from the validated process (e.g. have longer or shorter phases such as heating cycles) should be investigated.\n'多孔循环的验证应包括计算平衡时间、暴露时间、压力与温度的相关性以及暴露期间的最小\/最大温度范围。'可被翻译为：Validation of porous cycles should include a calculation of equilibration time, exposure time, correlation of pressure and temperature and the minimum\/maximum temperature range during exposure.\n'用于控制和\/或记录的温度探头的位置应在验证过程中确定，并根据系统设计进行选择, 以正确记录和反映常规循环条件。验证研究的设计应证明系统控制和记录探头位置的适用性，并应包括在验证过程中使用位于同一位置的独立监测探头来确认这些探头的功能和位置。'可被翻译为：The position of the temperature probes used for controlling and\/or recording should be determined during the\nvalidation and selected based on system design and in order to correctly record and represent routine cycle\nconditions. Validation studies should be designed to demonstrate the suitability of system control and recording\nprobe locations, and should include the verification of the function and location of these probes by the use of an\nindependent monitoring probe located at the same position during validation.\n'在开始计算灭菌时间之前，整个负载应达到要求的温度。对于在负载内使用参照探头控制的灭菌循环，应特别注意，负载探头温度在循环开始前应控制在规定的温度范围内。'可被翻译为：The whole of the load should reach the required temperature before measurement of the sterilising\ntime-period starts. For sterilisation cycles controlled by using a reference probe within the load, specific\nconsideration should be given to ensuring the load probe temperature is controlled within defined temperature\nrange prior to cycle commencement.\n\n根据上述已知信息，请将'液体循环的验证应包括温度，时间和\/或 F0值。关键操作参数应符合规定的限度（包括适当的公差），并作为灭菌验证和常规循环可接受标准的一部分予以确认。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":" Validation of fluid cycles should include temperature, time and\/or Fo. Critical processing parameters should be subject to defined limits (including appropriate tolerances) and be confirmed as part of the sterilisation validation and routine cycle acceptance criteria."
    }
]